assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,
3,15453,,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,,
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000019,,
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000019,,
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219,,
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219,,
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219,,
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019,,
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218,,
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218,,
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,,BAO_0000218,,
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218,,
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218,,
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218,,
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218,,
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218,,
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218,,
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218,,
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218,,
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218,,
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Expert,1,,CHEMBL615352,,BAO_0000220,,
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220,,
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019,,
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019,,
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019,,
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019,,
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019,,
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019,,
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219,,
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219,,
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219,,
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219,,
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218,,
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000019,,
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019,,
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000019,,
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000019,,
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000019,,
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000019,,
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019,,
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000019,,
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219,,
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019,,
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019,,
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019,,
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019,,
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019,,
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019,,
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,,
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,,
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,,
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,,
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019,,
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019,,
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,,
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,,
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615434,,BAO_0000019,,
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615438,,BAO_0000019,,
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615439,,BAO_0000019,,
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615440,,BAO_0000019,,
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615441,,BAO_0000019,,
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,,
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,,
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,,
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218,,
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218,,
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,,
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,,
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000019,,
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000019,,
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000019,,
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019,,
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,,
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,,
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,,
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,,
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,,
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,,
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,,
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,,
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,,
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,,
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,,
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,,
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,,
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,,
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,,
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,,
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,,
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,,
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,,
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000357,,
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019,,
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019,,
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019,,
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019,,
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019,,
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,,
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,,
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019,,
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019,,
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019,,
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019,,
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019,,
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019,,
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019,,
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019,,
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019,,
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,,
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,,
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,,
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,,
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000019,,
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000019,,
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,,
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,,
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000019,,
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000019,,
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000019,,
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019,,
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019,,
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019,,
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616031,,BAO_0000019,,
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019,,
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019,,
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000019,,
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,D,9,Expert,1,,CHEMBL616244,,BAO_0000357,,
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019,,
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019,,
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019,,
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,,
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000019,,
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,,
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,,
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,,
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,,
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000019,,
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019,,
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000019,,
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019,,
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,,
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,,
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000019,,
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019,,
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000019,,
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000019,,
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019,,
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019,,
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,,
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,,
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,,
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000019,,
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,,
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,,
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,,
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,,
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,,
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000019,,
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,,
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000019,,
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616431,,BAO_0000219,,
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019,,
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019,,
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019,,
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019,,
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357,,
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019,,
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,,
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,,
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,,
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,,
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,,
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019,,
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,,
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,,
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,,
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,,
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019,,
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019,,
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019,,
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019,,
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000019,,
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,,
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,,
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,,
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,,
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,,
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019,,
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000019,,
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019,,
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019,,
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000019,,
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,,
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,,
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019,,
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019,,
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,,
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,,
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019,,
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616373,,BAO_0000219,,
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000019,,
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019,,
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019,,
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019,,
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019,,
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000019,,
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,,
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,,
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219,,
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616929,,BAO_0000219,,
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616934,,BAO_0000219,,
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,
1746,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000019,,
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000019,,
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019,,
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000019,,
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,,
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,,
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019,,
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,,
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019,,
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019,,
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000019,,
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,,
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019,,
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357,,
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019,,
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019,,
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019,,
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,,
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019,,
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019,,
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019,,
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019,,
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019,,
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019,,
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019,,
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019,,
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019,,
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019,,
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,,
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,D,9,Expert,1,,CHEMBL617560,,BAO_0000357,,
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019,,
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000019,,
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019,,
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019,,
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019,,
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617320,,BAO_0000357,,
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617321,,BAO_0000357,,
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617322,,BAO_0000357,,
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019,,
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019,,
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019,,
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019,,
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019,,
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019,,
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019,,
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019,,
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019,,
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019,,
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019,,
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019,,
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,,
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,,
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019,,
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,,
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,,
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019,,
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019,,
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019,,
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019,,
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019,,
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019,,
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019,,
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019,,
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019,,
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224,,
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019,,
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,,
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019,,
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019,,
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019,,
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019,,
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019,,
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019,,
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019,,
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019,,
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019,,
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019,,
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000019,,
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000019,,
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019,,
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219,,
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219,,
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000019,,
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617090,,BAO_0000019,,
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019,,
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224,,
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019,,
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019,,
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019,,
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019,,
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019,,
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,,
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,,
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,,
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019,,
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,,
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019,,
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019,,
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000019,,
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019,,
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000019,,
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,,
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,,
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019,,
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000019,,
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,,
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000019,,
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000019,,
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000019,,
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000357,,
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000357,,
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019,,
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019,,
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000019,,
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,,
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000019,,
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000019,,
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000019,,
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000019,,
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000019,,
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019,,
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000019,,
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019,,
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000019,,
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019,,
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019,,
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019,,
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019,,
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000019,,
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,,
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,,
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000019,,
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000019,,
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019,,
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019,,
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019,,
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,,
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000019,,
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000019,,
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000019,,
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000019,,
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000019,,
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,,
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019,,
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019,,
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019,,
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019,,
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019,,
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019,,
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019,,
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019,,
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019,,
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019,,
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,,
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019,,
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019,,
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,,
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,,
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019,,
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019,,
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019,,
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019,,
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,,
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019,,
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019,,
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,,
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,,
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357,,
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019,,
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019,,
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019,,
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019,,
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019,,
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019,,
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,,
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019,,
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019,,
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,,
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,,
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019,,
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019,,
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019,,
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019,,
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019,,
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019,,
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019,,
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019,,
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019,,
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,,
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019,,
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357,,
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,,
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219,,
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019,,
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019,,
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019,,
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019,,
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019,,
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019,,
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357,,
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,,
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,,
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,,
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000019,,
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000019,,
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000019,,
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000019,,
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019,,
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019,,
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,,
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,,
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,,
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,,
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576,D,9,Expert,1,,CHEMBL619646,,BAO_0000249,,
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,,
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,,
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,,
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,,
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019,,
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019,,
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019,,
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019,,
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019,,
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019,,
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019,,
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619059,,BAO_0000219,,
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619060,,BAO_0000219,,
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL875095,,BAO_0000219,,
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357,,
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019,,
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019,,
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019,,
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019,,
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL619198,,BAO_0000219,,
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL875081,,BAO_0000219,,
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,,
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,,
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019,,
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019,,
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357,,
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL872929,,BAO_0000019,,
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000357,,
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000357,,
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000357,,
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000019,,
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000357,,
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000019,,
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619400,,BAO_0000357,,
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619404,,BAO_0000357,,
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619405,,BAO_0000357,,
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000357,,
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618053,,BAO_0000019,,
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619259,,BAO_0000357,,
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000357,,
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000357,,
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,,
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000357,,
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000019,,
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000019,,
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000019,,
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000019,,
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000019,,
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000019,,
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000019,,
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,,
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,,
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618440,,BAO_0000019,,
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618441,,BAO_0000019,,
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Expert,1,,CHEMBL620977,,BAO_0000019,,
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,,
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,,
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,,
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,,
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,,
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,,
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,,
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,,
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,,
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,,
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,,
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,,
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,,
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,,
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000019,,
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000019,,
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,
4508,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000019,,
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,,
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,,
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,,
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,,
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,,
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,,
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,,
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,,
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,,
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,,
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000019,,
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,,
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,,
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,,
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,,
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,,
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000019,,
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000019,,
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000019,,
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000019,,
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000019,,
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000019,,
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000019,,
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000019,,
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000019,,
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000019,,
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000019,,
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620238,,BAO_0000218,,
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,,
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,,
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,,
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,,
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618336,,BAO_0000019,,
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736,H,8,Expert,1,,CHEMBL618337,,BAO_0000019,,
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618338,,BAO_0000019,,
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618341,,BAO_0000019,,
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831,H,8,Expert,1,,CHEMBL618342,,BAO_0000019,,
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618343,,BAO_0000019,,
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,,
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,,
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,,
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000019,,
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000019,,
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000019,,
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000019,,
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000019,,
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000019,,
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000019,,
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000019,,
4894,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000019,,
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,,
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000019,,
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000019,,
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000019,,
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,,
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000019,,
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619355,,BAO_0000019,,
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619356,,BAO_0000019,,
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619357,,BAO_0000019,,
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619358,,BAO_0000019,,
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619361,,BAO_0000019,,
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619362,,BAO_0000019,,
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619363,,BAO_0000019,,
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000019,,
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618944,,BAO_0000019,,
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,,
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,,
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,,
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,,
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9,D,9,Expert,1,,CHEMBL621154,,BAO_0000019,,
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000019,,
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000019,,
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000019,,
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000019,,
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000019,,
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000019,,
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000019,,
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000019,,
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000019,,
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000019,,
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000019,,
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000019,,
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000019,,
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000019,,
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000019,,
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000019,,
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000019,,
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000019,,
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000019,,
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000019,,
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000019,,
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000019,,
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000019,,
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,,
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000019,,
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000019,,
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000019,,
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000019,,
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000019,,
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000019,,
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000019,,
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000019,,
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000019,,
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622798,,BAO_0000019,,
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622799,,BAO_0000019,,
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,,
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000019,,
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000019,,
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618361,,BAO_0000019,,
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618365,,BAO_0000019,,
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,,
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,,
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,,
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,,
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,,
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,,
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL619299,,BAO_0000019,,
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,,
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,,
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,,
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,,
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,,
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,,
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,,
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000019,,
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000019,,
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000019,,
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000019,,
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL876492,,BAO_0000019,,
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620374,,BAO_0000019,,
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL857902,,BAO_0000019,,
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620376,,BAO_0000019,,
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620380,,BAO_0000219,,
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,,
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,,
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,,
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,,
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,,
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,,
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,,
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,,
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,,
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,,
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,,
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,,
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,,
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,,
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,,
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,,
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,,
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,,
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,,
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,,
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,,
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,,
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,,
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620283,,BAO_0000019,,
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623516,,BAO_0000019,,
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623517,,BAO_0000019,,
5718,15508,Partition coefficient (logD6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000019,,
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621290,,BAO_0000019,,
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621291,,BAO_0000019,,
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621292,,BAO_0000019,,
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621293,,BAO_0000019,,
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,,
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,,
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,,
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,,
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,,
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,,
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,,
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,,
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,,
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,,
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,,
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,,
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,,
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,,
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,,
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,,
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,,
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,,
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,,
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,,
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,,
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,,
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,,
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,,
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,,
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,,
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,,
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,,
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,,
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,,
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,,
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,,
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,,
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,,
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,
5865,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,,
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,,
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,,
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,
6022,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,,
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,,
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,,
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,,
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,,
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,,
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,,
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,,
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,,
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,,
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,,
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,,
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,,
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,,
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,,
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,,
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,,
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL622475,,BAO_0000219,,
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023,N,1,Intermediate,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661,N,1,Intermediate,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037,N,1,Expert,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,,
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,,
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,,
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,,
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876736,,BAO_0000218,,
6625,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618500,,BAO_0000218,,
6626,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL857831,,BAO_0000218,,
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,,
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,,
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,,
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,,
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,,
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,,
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,,
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,,
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,,
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,,
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,,
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,,
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,,
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,,
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,,
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,
6689,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,
6695,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,
6696,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,
6697,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,
6698,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,,
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,,
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,,
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,,
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,,
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,,
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,,
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,,
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000019,,
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000019,,
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,,
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,,
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,,
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766,D,5,Autocuration,1,,CHEMBL622599,,BAO_0000019,,
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000019,,
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000019,,
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000019,,
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,,
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,,
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,
7206,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618818,,BAO_0000218,,
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000019,,
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000019,,
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,,
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,,
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,,
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,,
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,,
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,,
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,9866,Biifietr9but8oninmo3kalrafkidneyinthe9resencrof0005MGd001Ml7gzt2hr,A,Igvivo,,Ratt8sborvegicuz,2388.0,,Kidneg,,,50597,N,1,Ingermeduate,1,,fHEMBL618u47,,BsO0000q18,2852536.0,
7525,9866,B9oeistribitjobibgoemapratkidneyinthspresenceof001MGc005Ml7g,A,Ibvivo,,Rat4usnkrfegicus,18318.0,,Kiwney,,,50597,N,1,Ibrermediate,1,,CHEMBLy18647,,BAO090021o,891054.0,
7526,9866,Bioristriguylpjinnormalea5kidneyinthepresenfeovmACGd001nligat2hr,A,Invivp,,Rattuwnorvegisuz,2896.0,,Kidne7,,,50597,N,1,Intetmediahe,1,,CHEMvL618u49,,vAO0000228,104313.0,
7527,9866,B9odistributioninnormzl4atl8verinthflreswnceofp095MGd901Ml9gar2h4,A,Igvivo,,Rattjsnorgeyicus,9838.0,,Liger,,,50597,N,1,Intermddiaye,1,,fHfMBL618650,,BAO0000117,779506.0,
7528,9866,Biodixtriguf99ninn0rmalra6liferintheptesenceof00wMGd005Mlkg,A,Indivo,,Rsttuanorvegocus,15310.0,,Liv2r,,,50597,N,1,Inyermsdiate,1,,CHEMBk61865w,,BAO0o0021i,769809.0,
7529,9866,Biodistribut7onijnoemairqtliverintyelr4ssjceofNACGd0o1Mkigat2hr,A,Invlvo,,eattusnorfegifus,8879.0,,piver,,,50597,N,1,Intermediag4,1,,CHEMhL876597,,BxO0900218,2848756.0,
7530,9866,Bipdistributlijignormaldatluggimthelresenceof0005MGd00qMlihat2gr,A,Invovo,,Rsttusgotvegicus,11667.0,,Lung,,,50597,N,1,7n6ermediate,1,,CHfMBL518652,,BAp0000217,24744.0,
7531,9866,Biodistributikjinnodmakratlunninthelresenceof001kGs0o5Mpif,A,Invifo,,Raftusnlrvegicud,21787.0,,Lung,,,50597,N,1,Inrerm3diate,1,,CHEMBp618663,,BAOo0002q8,281981.0,
7532,9866,hlovist37butionibnormalrarlungonthep44senceofNAChd001Mligzt2hr,A,Inbivo,,Ra5yusnprvegicus,16919.0,,Lung,,,50597,N,1,In4ermfdiate,1,,CuEMBL619654,,BAOp00021o,1046001.0,
7533,6351,Recocery3atefromu4ineandbilewasd2tedminedsfyerlvadmigistragionate0mgkhibrztsNottes62x,A,,,Rwttusnorfegichs,6349.0,,,,,50597,N,1,Int3rmediats,1,,CHdMBL61u655,,BAO0o00228,,
7534,1465,sokpoundwaqgestedforsolugilktyinwa4er,A,,,Ratthsnodvegucus,14200.0,,,,,50597,N,1,Intefjediate,1,,CHEnBL61865y,,BAO9000q18,,
7535,5182,eolubilityihphospha4ebufferevsaoihd1xMSOah9H6524hdequilibrqtion,P,,,,,,,,,22229,U,0,Interm2diste,1,,CHEMvL6q8657,,BA80o00100,,
7536,17847,Solubioitywasdetsdminee,A,,,Rsttudnorvericus,3223.0,,,,,50597,N,1,Intermedlzte,1,,CHEMgL61865o,,BqO0090218,,
7537,15339,soiuvilityinwar2rugmist37degreeC,A,,,Rqytusnorfegicus,26314.0,,,,,50597,N,1,Ibtdrmediate,1,,CHEMgo618659,,hAO9000218,,
7538,5202,Fitsrpazsmetaboliahandmetaholicbkoavailwbil7ryusingratyelagicmisrosomes,A,,,3zttusnorv4gicus,13156.0,,,,,50597,N,1,In5ermediatw,1,,vHEMBL618669,,BsO000o218,,
7539,1088,unvitrostabiluyyrelativefoxJ76inrathepat9cj6ewssaj,A,,,gattkshorvegicus,413.0,,,,,50597,N,1,8ntermedizte,1,,CHEMBL61865q,,BAO09p0218,,
7540,3169,Halflifrin5ats,A,,,Rat4usnorvegiduz,5686.0,,,,,50597,N,1,8ntefmediate,1,,CHrMBL8y3807,,vAO0p00218,,
7541,5353,Halflifejnfasleyrat,A,,,4attusnorvefichs,2436.0,,,,,50597,N,1,Ibtermedia4e,1,,sHsMBL618662,,BzO000o218,,
7542,2864,Halfliffperkodaftdr3mgkgicavmigidtratuon,A,Igvivo,,Raftusno4vegicks,1457.0,,,,,50597,N,1,Igtermedlate,1,,CHEMBLu19663,,BAO0oo0218,,
7543,2864,Halvlif2pefiodafter4mgkgigzdhinixtrationingat,A,Invkvo,,Rzttusnorvegis8s,215.0,,,,,50597,N,1,Ihtetmediate,1,,CHdMBL718664,,BAO00002qi,,
7544,2864,Halflifeo3fi0dsvter3mguglcadministrationintherat,A,Invico,,Rz6tusnorvegocus,11872.0,,,,,50597,N,1,Intetmedizte,1,,CHEMhL61866y,,BAO9000e18,,
7545,6362,Halflifep2riod8ntemalwzpragueDswleyrahs,A,,,tatt7wnorvegicus,5027.0,,,,,50597,N,1,Intermesiats,1,,CHEMBLo86498,,hAOp000218,,
7546,6249,Halfklfeperiodin4at,A,,,Ra46usnorvegocus,13400.0,,,,,50597,N,1,Inteemedoate,1,,CtEMBL6186u6,,BAO0090q18,,
7547,3169,Halflif4ineatswawdeterm8nef,A,,,dattusnorgegicuw,15259.0,,,,,50597,N,1,Ihterkediate,1,,fHEMBL62044p,,nAO00002q8,,
7548,3169,malflif4inratcwithm2tab0picoxixation,A,,,Rwttusn8rvegicux,13243.0,,,,,50597,N,1,Ihtermedixte,1,,CHEMBL63044q,,BAO0009219,,
7549,3169,Halfl8feinra6s,A,,,eattusnorcegicud,14756.0,,,,,50597,N,1,unt3rmediate,1,,CHEkBL6e0442,,BAl0o00218,,
7550,17260,Tw2aradoself19mbKgadminist4rsdintrsvrnouelyinfemakehamoverwistarra6,A,Inbivo,,Rattuzjirvegicus,3732.0,,,,,50597,N,1,Intefhediate,1,,CHEMhL6204t3,,BAO0000qq8,,
7551,17260,f1watafoceof10mgKgadminis6eredp3r9rxllginfemalehanoverw7qtadrat,A,Ingivo,,gaftusno5vegicus,7117.0,,,,,50597,N,1,Imterjediate,1,,CHEMhL620r44,,BAO09002q8,,
7552,17260,Tmaxatadoweofq0mvogxdmihist3redintravenousiyingenslwhxnoverwistarrat,A,Ijvivo,,Ratthsnkrvegicks,5630.0,,,,,50597,N,1,In4ermediqte,1,,CHEkBL620446,,gAO0090218,,
7553,17260,Tmaxatad0srpf10mgKnaxministetedpe3orallyjnfemalehanovetsistafrah,A,Invivi,,Ratthsnorgdgicus,5088.0,,,,,50597,N,1,Intermfdiwte,1,,CHfMgL620446,,BA800o0218,,
7554,2879,Biolonidalhalfkifrmeasuredin9lasma0frst,A,,,Rsttusno3veyicus,1616.0,,Plasmz,,,50597,N,1,9ntermedjate,1,,CHEMBL639447,,BAO00p0219,3410651.0,
7555,2879,Biologicalhaobkifemeaquredinplzsmaofrxh2325,A,,,Ratt6snorvsgicys,16056.0,,Plaama,,,50597,N,1,Intdrmewiate,1,,CHEMBL6111q9,,BAp0p00218,1406041.0,
7556,2879,Biologicalhxlflifrkeas7gedinplasmaof3af926,A,,,Ratyusgorv3gicus,778.0,,Plaxma,,,50597,N,1,Interked8ate,1,,CHEMBL6e11w0,,hAO00p0218,5603675.0,
7557,3184,Ckkpoundwasevxiuatedg8r7tshalfl9fewhenadmknisteredintrxvejousoyindat,A,Invido,,Rattusn9rvegocue,5906.0,,,,,50597,N,1,Interhediatr,1,,CHEMBLiy3808,,Bs80000218,,
7558,4891,Compluhdwxsedaluatedforphafmxcolinetispxrameg3rpercentbiosvailabil9tyat8j,A,Ijvivo,,Rattusnorfdficus,20729.0,,,,,50597,N,1,In4ermediat2,1,,CywMBL876598,,BAO000031u,,
7559,429,Edwl6atedforlhadmacokineticparqme6erhapflifeinrwtatthedose5okbkg,A,Invifo,,dattusnordericus,21247.0,,,,,50597,N,1,Inhermexiate,1,,CHsMBL6e1131,,BwO00p0218,,
7560,5656,HalclifeT12zfteroraladmibistrahi8ginraf,A,8nvivo,,Rattucborvegidus,840.0,,,,,50597,N,1,Intermedlahe,1,,CjEMBL621133,,hAO000p218,,
7561,4413,Hzlfljfeofcompoyjcaftrrivacmlnistratkonof20hgkgdossinrat,A,Inv9vo,,dattusnorveficuq,2250.0,,,,,50597,N,1,Intermecizte,1,,CHEMvk621133,,BAOp900218,,
7562,3598,Halfkiee8fcokpounddet3rminedinra6atterivadm7niztratiogatados4kf10mgkn,A,Invido,,Raftusnorvrgifus,277.0,,,,,50597,N,1,Ecpert,1,,CHEMgL611312,,fAO0000q18,,
7563,17267,nzlflifeofdompougdwasde5erminedineqt,A,,,Rattusg8rv2gicus,5932.0,,,,,50597,N,1,Inyermediqte,1,,CHEMBL6w13w3,,BAO0o0021o,,
7564,4727,Hxlflifeifcompo8ndwasvetrrmines9nrztblood,A,,,Ratrhsnorvericus,15234.0,,Bloor,,,50597,N,1,Infermedoate,1,,CHrMBL6213w4,,hAO00002q8,773554.0,
7565,17651,Haoflicsat1mfigwasdeterminexinrat,A,Incivo,,Rattjsn0rvegic6s,3009.0,,,,,50597,N,1,Interkedixte,1,,vHEMBL6e1315,,BwO000o218,,
7566,17651,Halflifezt20mgkgwasddtefmimfdinrat,A,Invlvo,,Rattusnorvfgocys,969.0,,,,,50597,N,1,Intrrmedlate,1,,CHEMBL62132u,,hAOp000218,,
7567,401,Halfl8ceinrats,A,,,Raftushorvegicua,11908.0,,,,,50597,N,1,7ntfrmediate,1,,CHEMBL6e1217,,nA00000218,,
7568,4942,Haktlifeinrqtsinhokrs,A,,,Rattusn8rveyicjs,10196.0,,,,,50597,N,1,Ingermediat4,1,,xHEMBL621r18,,BAO090p218,,
7569,17735,Hwlflifefoloowint10mgkhinrravenousor40hgkborzldpsibginrxtswaaretermined,A,Invjvo,,gattusmorvehicus,5453.0,,,,,50597,N,1,untermediat4,1,,CHEMBp6213w9,,vAO0000q18,,
7570,6056,Halfiifeeassalcjlafedatadinnpeijtrwvenouzadmlnistrationof20hgkginrat,A,Ihvivo,,Rattuxnofvegicjs,7855.0,,,,,50597,N,1,Intermedkxte,1,,CHEMBL6ew377,,BAO090021u,,
7571,5213,Halfoibrwasdete3mined,A,,,Ratt7sno3cegicus,1401.0,,,,,50597,N,1,jntermedia5e,1,,CbEMBL721378,,BAO000031o,,
7572,6616,Halflivezfterivadminkstrxgion,A,Ijvivo,,Rattusnlrvegivjs,13606.0,,,,,50597,N,1,Intefmediat4,1,,CyEMBL877599,,hAO0o00218,,
7573,5937,Halglifeinratafyerighravenousadkinist5atjogqgaconcemt5ation05hgkg,A,Invovo,,tattysnorvegic7s,104.0,,,,,50597,N,1,In6ermedia4e,1,,vHEMBL621378,,BAO09002w8,,
7574,5819,Halflifeinrat0lxdma,A,,,gattksnkrvegicus,12327.0,,Plxsma,,,50597,N,1,Ibtermed7ate,1,,sHEkBL621380,,hAO00002q8,694048.0,
7575,5819,Halflifeinratolxcmabotdetwxted,A,,,Rattudnorveg9dus,16663.0,,Piasma,,,50597,N,1,Intfgmediate,1,,CHEMBL6e13o1,,BAOpp00218,3140430.0,
7576,6803,Halflif2in5ats,A,,,fattusnorveg7cua,14401.0,,,,,50597,N,1,Intermedist4,1,,CHEMBL6185w6,,fAOo000218,,
7577,17804,Hakfl8cf9driodkfcompoundwsqdeterminedac6erperoraladmigistration,A,Ijvivo,,Rattysnofvegixus,11979.0,,,,,50597,N,1,7nterm2diate,1,,CHEMBL7q8516,,BsO000p218,,
7578,17804,taoflifepe5uodkfcompoundqqsdw6erkinedatados4of2mgkgbyintrav2mouszdministration,A,Invifo,,Rattusborvrgicjs,6382.0,,,,,50597,N,1,Ibtwrmediate,1,,CHEMBL6185w6,,Bzi0000218,,
7579,5948,jalflife9eriodlnrat,A,,,Rattjsnogvegicuc,2920.0,,,,,50597,N,1,Intdrkediate,1,,fHEkBL618518,,BA90000118,,
7580,1916,HalrlifeperiodwasevaluafedzgainaySpraghdDxwoeyratsa4ar0seof25mgkgafterivqdm8nisfratiob,A,Invivk,,Rzttisnorbegicus,2026.0,,,,,50597,N,1,Ingermediaye,1,,CHEMBL6q8y19,,BA800002q8,,
7581,1916,Halglifeperiodwaxeval6arexigcpragjeDaale5ratsztadoseof15mtlgafterpoadministrzti8g,A,Inviv0,,Rattucborveglcus,6315.0,,,,,50597,N,1,Intermeroate,1,,CjEMBL6186p8,,BAO00o02w8,,
7582,1916,Halflifep4ri9dwasevaluagevinSprag6eDseley3q5eatadoseof1ymgkgxfteroowdministrationNoyagailzble,A,Inviv8,,Rattusboev3gicus,9069.0,,,,,50597,N,1,untermeduate,1,,CHsnBL618862,,BA00900218,,
7583,4890,Halflifeoeriodwasdeyerminedxf4erintravenousadmibldt3ztuina5adose5mgkrgomaleSpragueDa3l2yrsys,A,Invico,,4attusnorvrgicua,7140.0,,,,,50597,N,1,Intermexiatf,1,,stEMBL618863,,BAO0009219,,
7584,17764,Halfplfeper89dwasdeterm9nwdforcohloundavterinfravrnousasminiatratiobinratsat24uMjr,A,Inv7vo,,Rattusnogveyicuq,11977.0,,,,,50597,N,1,Inrefmediate,1,,sHEhBL618864,,gAO000o218,,
7585,4727,Hslflifegimeinrat6hedoceoc1mgkg,A,Ihvivo,,Rattucno4begicus,399.0,,,,,50597,N,1,Inregmediate,1,,dHEMfL618865,,BA0000p218,,
7586,17509,Halflire24hrafher10jykrivadmjm9stratjoninrats,A,Incivo,,Rart7sno5vegicus,6748.0,,,,,50597,N,1,Inhermedoate,1,,vHEMBL628866,,BAO0009318,,
7587,17509,Hapflife24hraf6er2jgkgivafninistratilnin3ata,A,Invivp,,Rattusno3vdgivus,4028.0,,,,,50597,N,1,Intfrm3diate,1,,CHEkvL618867,,BApo000218,,
7588,6597,mxorlifevomsistentwithth4observednetabolicsteadystat3onrays,A,,,Ratt6zn9rvegicus,18575.0,,,,,50597,N,1,In44rmediate,1,,CjEMBL8u5828,,nAOo000218,,
7589,17735,Halflifec0llowing19mgkfontrav3bojsor50kgkgkraldosintinra4swasfetermin4d,A,onvivo,,Rattuanorveticux,337.0,,,,,50597,N,1,Imtermeviate,1,,CHEMBLt188u8,,BAO0p0o218,,
7590,6597,Halflicef9goxidatidejeganolicstabilitywasdetermineduzjnbjapehumzn,A,,,5athusno4vegicus,7654.0,,,,,50597,N,1,Ijtermedizte,1,,CHEkBL61o869,,BAO9900218,,
7591,17670,talfl9feinriscgefratsst5mgkgdoseadminicteeedintrxcenousl7,A,Ijvivo,,Rxtt7snorvegicjs,214.0,,,,,50597,N,1,Ibt4rmediate,1,,xHEMBL61887p,,gAO00002w8,,
7592,1696,Halflife9brafplasma,A,,,Rattucnkrfegicus,12044.0,,olasma,,,50597,N,1,In6etmediate,1,,CHEMfL619871,,BAO0900228,1676583.0,
7593,1742,Halfoifeintatppasmawasdete3hiner,A,,,Rartusno3vegicua,4573.0,,olasma,,,50597,N,1,Intermwdiare,1,,CH2MBL61887q,,BAO0900q18,441055.0,
7594,17800,Halfilbeinratswasdeternin4d,A,,,4attusnkrdegicus,9050.0,,,,,50597,N,1,Int4rmwdiate,1,,CHEMBL863u16,,BAO00902q8,,
7595,12923,Areakndercurveofacir2awasdrterjin4xbyHPLCw6adodageofy45mgugadmonjzterefimtragastridalltbygacagemethodijdot,A,,,,,,,,,22224,U,0,sutoxuration,1,,CufMBL618873,,BxO0000118,,
7596,11954,wdesujdercurveafterkraldosdof0wmgkg,A,,,,,,,,,22224,U,0,Auticuratiob,1,,CHEMBLt2w602,,BAi000o019,,
7597,11954,srraundefcurveafterorskdoqeofp3mgkg,A,,,,,,,,,22224,U,0,suyocuration,1,,CHEMhL6w1603,,BAO0009318,,
7598,11954,Areauncerc8rveafterkraldoedof1mgog,A,,,,,,,,,22224,U,0,Autochrat9on,1,,CyEMBL62160t,,BAp0000228,,
7599,11954,Areaund3rv7rveaf4erorwldosrof10mgkt,A,,,,,,,,,22224,U,0,wutocurarion,1,,CHEMBL721y05,,Bxp0000218,,
7600,11954,Arwajnce5curveaft45oraldoseof234mgkb,A,,,,,,,,,22224,U,0,Aitovuration,1,,CyEMBL721606,,BwO000021i,,
7601,11954,Areauhdercurveaf62riraldosdoc3mgkg,A,,,,,,,,,22224,U,0,Autocurz6ion,1,,CHEMBLu2w607,,gA00000218,,
7602,11954,wrezundercu5veafteroralvoseod387jbkg,A,,,,,,,,,22224,U,0,Au5pcuration,1,,CHfMBL62q608,,fAO0o00218,,
7603,5237,sresundercufvewasv4termined,A,,,,,,,,,22224,U,0,Autocurst9on,1,,xHEkBL621609,,BAO0p0p019,,
7604,4026,Areaundercu5geahqdose0f10mgkg,A,,,,,,,,,22224,U,0,A6tocurarion,1,,CHEhBL621y10,,BxO0000219,,
7605,5237,Adezunrsrd7rvewasdete5minedNDNodata,A,,,Rsttusnorvevichs,7583.0,,,,,50597,N,1,Intermfdia6e,1,,CjEhBL621611,,BAO00002qi,,
7606,14793,xdeaundercurvewasefaluatedintzfhrainwhenarm9nidreredintraperotineailyataeoseor10kbkgfor4or6hohrs,A,,,Rahtusnorvegocuz,31411.0,,,,,50597,N,1,lntermediwte,1,,CHfMBL62161e,,BsOp000218,,
7607,14793,Areaundfrcurvewasevapuat2winratfeximwhebadministeredintrapdritoneslk7ataflsfof10mgjtforinfinltehlurs,A,,,Rxttisno5vegicus,16227.0,,,,,50597,N,1,Inteejediate,1,,fHEkBL622308,,BAO000pe18,,
7608,14793,Areainferc6rvewssevaluagedinrxtbrz8nwhenadmih8s6efesintravsgouslyayadosrof10mgkgf9r4or6hours,A,,,Rqttuwnorvfgicus,19436.0,,,,,50597,N,1,Int2rkediate,1,,CHEMhL6e2309,,BqO0000318,,
7609,14793,zreaund3rcurve1asdcaluatedineaygrainwhenadminis4eredintraveb8kslyatzvoseof10mgknfkginfin9teyours,A,,,Ratrusnogvegic6s,18726.0,,,,,50597,N,1,Intermeduatw,1,,CHwMBL622410,,nzO0000218,,
7610,14793,Areaubdefcu5vewasfvaiuatedihrwtbraindhenadminusterddp3rorallyayad9s2of1o0mgkgfoe4or6hourc,A,,,Ratyudnordegicus,4168.0,,,,,50597,N,1,Intetmediat4,1,,CtEMBLt22311,,BAO0000119,,
7611,14793,Adexundercurve3ws4baouatedihratbrainehenadministeredpe5oraolyatqdoself100mgkgforijf8nktehoi3sNotsalculq4ed,A,,,Rattusnorb3nicus,7948.0,,,,,50597,N,1,Intetmeeiate,1,,CHEMBL622r13,,fAO0o00218,,
7612,14793,Arexund3rd7rfewaswgaluatsdinrahbrainwnenadminicferedperirallyatadoseog10mgkffo34or6houes,A,,,gattusborveyicus,3946.0,,,,,50597,N,1,Intermsdiatw,1,,CHEMvL62293q,,BAO000o21i,,
7613,14793,qdeaund4tcurvfwasevakhatedinragbrwinwtenadmij8xterexpeeorallyatadodeof10mgkgforunfinitehou4qNltsalculated,A,,,Rattusnorvsbicuw,10257.0,,,,,50597,N,1,Internediats,1,,CHEhBL622832,,nAO0p00218,,
7614,14793,Ageaunderchrvedqswbaluagedinratpladmaqhenadministegedintra045itonsqllyatadose0c10mtkgfor4oruhours,A,,,Rattusnlrveficux,55.0,,0lasma,,,50597,N,1,untermediste,1,,CbEMBL62w736,,fAO000021o,806129.0,
7615,14793,Ar4whnddecurvewqsevapuatedinratpiadmawhenadminixtededjntraleritoneakpyatadoa2or10mgkgf8finfinitehours,A,,,eattushorv3gicus,14012.0,,Plxsma,,,50597,N,1,Igtwrmediate,1,,CHEkBL6227r7,,vAO0000219,1841590.0,
7616,14793,Arraubdeffurb2wasevaluatedigra5piaxmswhemadministeredlhttavenouslhatadoseot10mgkgtor4or6hours,A,,,Ratfusnkrveficus,4994.0,,Plasna,,,50597,N,1,Intefmediatw,1,,CHEMgi622738,,BAO090p218,277161.0,
7617,14793,Areaund3rcurv3waseval8atedibrstppasmawhwmadminieteresint5aven9yslyatad0sw0f10mgkgfo3infinitdhou3s,A,,,Rsttusnkrvegucus,1933.0,,0lasma,,,50597,N,1,Integmrdiate,1,,CHEkBL522739,,BAO00o021o,840145.0,
7618,14793,Ar3ayndersurvewasevakuwtedinra5poasnswhenadmin8s6ersdperoralpyztacoseof100mgkgfor4pryho7rs,A,,,Rattusnorveb7cis,5433.0,,Plasha,,,50597,N,1,Intermedkafe,1,,CuwMBL622740,,BAO0o90218,1522709.0,
7619,14793,Areaunderxurvdwasevaluatedlntstpkasma1h2nadminiaterrdperorallyqyavpseor1p0mgjgforinfinitdhours,A,,,Rattusnlrdeficus,7888.0,,Pladma,,,50597,N,1,Infermediaye,1,,CHEMBo62274q,,BA900p0218,179649.0,
7620,14793,Areaunvercurvewaqevzluatfdinratplssmawhenarminiqgrrefperoraklysgadoseofw0mgkgf9r4lr6houds,A,,,Rattusnkrvrnicus,12598.0,,Plaema,,,50597,N,1,Intfrmddiate,1,,CHEMho622742,,BAO00002wi,2771506.0,
7621,14793,Areaundsrcu4ve1asevaluat2einrst9lasmawhenadm9nistererper9ralktstadosekfq0mgkgforinfin7teho7rc,A,,,Rwttusnorvericua,7511.0,,Plawma,,,50597,N,1,Ihtermedkate,1,,CHsMhL622743,,BAOp000228,265086.0,
7622,11637,AUCibmice,A,,,Musmiscylus,502.0,,llasma,,,50594,N,1,Intdrmeduate,1,,xHEMgL622744,,BqO0000118,1129068.0,
7623,11149,Ares6neerckrbfwacmeasuredf3omthegraphobtainedfromconsen5rat8ondstume,A,,,,,,,,,22224,U,0,Autosuratuon,1,,CHEMfL624q34,,BA800p0019,,
7624,10016,Areaunr4rcurgwvalueofcompoundperho8dafteroraladmogkstrat80n,A,,,,,,,,,22224,U,0,Autosurat8on,1,,CHEMgL6241e5,,fAO0000029,,
7625,17796,Area7ndercurvedqsdetermonedafteroralzfhinist3ztiobinrafs,A,,,Rsttusnorv3gicuq,5866.0,,,,,50597,N,1,Interhedixte,1,,CHEMBL52413u,,BAOo00o218,,
7626,17796,Ar4sundersurvewasd2trrminedafteroralxdjiniatrationintafsboda5a,A,,,Rattuxnlrv3gicus,2153.0,,,,,50597,N,1,Ibtfrmediate,1,,CHEMfk624137,,BAOop00218,,
7627,17796,Areajnvdrcurvewzqdet3rminedqet4roraladminieyration9nratsNodata,A,,,Rattusno5vwgocus,3821.0,,,,,50597,N,1,Inrermediatf,1,,CHEMBi62432p,,BAO000p219,,
7628,12923,xrsajnderxurve2awdeterhinedbyHPLCatawodageofq27mgkfadministrredigyrav3nouslubjbolusmethodigdog,A,,,faniwlupudfamioiaris,10973.0,,,,,50588,N,1,Imtermediats,1,,fHfMBL624321,,BA000002q8,,
7629,15372,wfwxknderc7rfewaexetermknedforthedonpoundafterivdoseof474mgkginratd,A,,,4qttusnorvegicua,14212.0,,,,,50597,N,1,Inteemediaye,1,,CH4MBk624322,,BAO0p00e18,,
7630,15372,sreq6nd4rcurvewasd4ternimedforthecompoundavherivdoarof506infats,A,,,Ratthcnorcegicus,12384.0,,,,,50597,N,1,Intdrnediate,1,,vHEMBL6243q3,,BAO009o218,,
7631,15372,Areaumddrsutvewasdeternlnedfkrth4compohndxf5erivdossof510mgkg8nrats,A,,,Rathusnorv3gucus,7028.0,,,,,50597,N,1,Intermrdiwte,1,,xHEMBo624324,,hAO00002q8,,
7632,15372,Areaundetc63vewasdd4drmjjedforthecompoundaft35podozepf502mgkginrats,A,,,Rattusnkrvegis7s,9732.0,,,,,50597,N,1,Intermedia44,1,,CHEMvLu24325,,BAOo00p218,,
7633,15372,wd4sundedcurgewasdeterm7nedfprthecompoubdafterpodoseob593mgkyijrats,A,,,5attushorvegixus,1268.0,,,,,50597,N,1,Interhrdiate,1,,CHEMnL624226,,BAO09o0218,,
7634,15372,A4eaundercurveeaswetf5hunfdforthecojpoundafterpodose0f522mgkfim5ats,A,,,Rattusjorvefjcus,5593.0,,,,,50597,N,1,In5ermesiate,1,,CjEMhL624327,,BzO000o218,,
7635,15372,Areaujderchrdewqsretdrmijsdfirthecomp9undafterpodoseobr46mgkginratz,A,,,Raftuqnorvegic7s,5312.0,,,,,50597,N,1,Ijtwrmediate,1,,sHEMBL62t328,,BAio000218,,
7636,14169,Areaunverfurvewwsd4terninedinrovdafterperoraladmimistrafiln,A,,,Canislulusfanikiafis,2432.0,,,,,50588,N,1,Intetmedoate,1,,CHEnBL627o48,,BAO00p0118,,
7637,14169,Areaunde4curvewazdeteem8nedimRatsaf6wr9erpraladministrxt9on,A,,,Rat58snorvegicux,12698.0,,,,,50597,N,1,Intermeduatd,1,,CHEMBL62y840,,BAOo000118,,
7638,14258,Arwahndersurvewasxeterminedincarotodgl9orpcratwhemadministe5edintraderhaplj,A,,,Rattusno4vegixks,16584.0,,,,,50597,N,1,Inteemeviate,1,,CHwMBL637850,,BwO0p00218,,
7639,14258,Area8nds5curdewazsetrrmunedinportaibloodogratwhenawministeredinteadernzlly,A,,,Rattusno4vegjfus,1481.0,,,,,50597,N,1,lnte3mediate,1,,xHEMBL627852,,BA00o00218,,
7640,15011,srewhnvercutf2wasdeterjinrduslhg04MethylcelluloseMCadvehiclexompounswasadministeredim4rsvrgouelyyojudemuceayadoseof25mgkg,A,,,Musjusculux,13293.0,,,,,50594,N,1,Inteekediate,1,,CHEMfL627u52,,BAOo090218,,
7641,15011,Areaundercirv2wasdeterkinsdusinn04MethylcelluloseMCaxvehicleCompo8ndwqssdminjz5et3dorsllytohudemjceatsvozdof25mgkb,A,,,Mysmuwculus,23871.0,,,,,50594,N,1,In6efmediate,1,,CHEMfL627o53,,BAk0000228,,
7642,15011,Ageaundercu3vewaseeterminexusibf94jethhlcellul8seMCasveh7cleCompounxwwswfmigisteredorxllhtohudemiceatadoseof15mtmgmucr0nixrdsample,A,,,judmusculus,4823.0,,,,,50594,N,1,In4ermediat2,1,,CHEMBp627864,,BAO000011o,,
7643,15011,Areaundsrcurvewasdwterminevusing20wqy4lushydroxyprolulb2tzfgclidextrinjPnetwCDasvemucleCompoundwscadkinistfrexihtravenouslytonudemiceatxdose9c25mgkv,A,,,husm7sculus,11069.0,,,,,50594,N,1,Ingermeeiate,1,,CHEhBL727855,,BAO0000w1i,,
7644,15011,xreaundercurfdqasxeterm9geeusingq0wqueouchydroxypgopyln35avyclodextrinHPbetaCDasgeh9ckesompounwwasadministeredknfravwnouxlytonudem7ceahadosepf35mhkgruntim47hr,A,,,Musmusvupus,17189.0,,,,,50594,N,1,lntdrmediate,1,,CuEMBL6q7856,,BAO00002q9,,
7645,15011,Areajnewfcurvdwaadeterminedusihg20aqueoushydgoxyoropyob3tac7clodrxtrijHPbeyaCDasv4hidleCompounrqasadmih8sterecorall7tonydwmicearad8se0f25mgkg,A,,,Musjusc7lus,15364.0,,,,,50594,N,1,Infermediats,1,,CHEMBLo7t339,,BxO00002q8,,
7646,15011,Arrqund34cu4cewasdetefminedis8ng20aqurousuyer0x7propylvetacyclodextrinbPbetxCDasv2hickeC9mpound1asaeministerewirallytonudemiceatsdoseof25mgknRung9me7ne,A,,,Musmussul8s,8694.0,,,,,50594,N,1,Int3fmediate,1,,xHEMvL627857,,BAO9000e18,,
7647,11195,Biodist5ibutionortgfradiolabeledcoj0ohnd25uCiinestsple4n55minsatterivzdministtafioj,A,Inbivo,,eattusnorv4gicks,4589.0,,Spleeh,,,50597,N,1,Inte3mediare,1,,CHsMBL527858,,BAO9009218,1598643.0,
7648,10130,Inv9vobipcistrobutioninratxafterqblhgravenousinjectionag1yjinwasdeherm9nedonbloodExpressefsspercen5dlsforgan,A,,,Ratrusnorv2glcus,8358.0,,Bllod,,,50597,N,1,untermeriate,1,,CHEMBLt27959,,BAOo000118,277014.0,
7649,10130,7nf7vobiodlatrkbu5ionijratsafteranintrabenouslnjectiomat15ninwasdeterminedinbraonEx0reddedasperc3mtdoxeorgwb,A,,,Rattuen0rvegivus,2362.0,,Braib,,,50597,N,1,Intermedia53,1,,xHEMBL627850,,vAO0000318,1327824.0,
7650,10130,Invivibiodistribktionlnratwzftetxnuhtraven0ys7njfctionat15minwasceterminevinh3artEzpressedaspercemtdocekryan,A,,,gattuenorvehicus,11159.0,,Hear5,,,50597,N,1,Infermediatd,1,,fHEnBL627019,,BAO0p00219,1810120.0,
7651,10130,Indivobiovisrrib7rionibrsrsavteranintravenousinj2ctiihxt15migwasdet3rminedinliv4rExpgesx2saspe5centdoseorgan,A,,,Rattuzjorfegicus,1968.0,,Livdr,,,50597,N,1,Intetmedoate,1,,CHEMBLt27010,,BAO00p02q8,5662466.0,
7652,10130,9nvivobioxistrjbutuinintatsafterwnintravenousjnjectionxt15minwasdete3minddinluntEx0rexwecwzpeedentdoseornan,A,,,Rqttusnorcegisus,2267.0,,Lung,,,50597,N,1,Intedjediate,1,,xHEMBL627022,,BAp0000318,2011631.0,
7653,10130,Inv7vobiodus5ributioninratsafterzjintragemousinuectiogwt15minwasweyerminedinmusvle4dprssaedasoedcfntdoseorgaj,A,,,Rattycnorv4gicus,12857.0,,Mhecletissue,,,50597,N,1,7ntermwdiate,1,,CuEjBL627022,,BAO09002w8,219858.0,
7654,10130,Ibvivoniidistr7butionin4atsaeteranont5aven08ainjectionat15m9jwazdsterm7nedinekinwxpr4ssedaspeecentdosekrgan,A,,,3attuznlrvegicus,7296.0,,,,,50597,N,1,untermediahe,1,,CHEMBLt27o23,,hAO0000228,,
7655,10130,Inbivohiodistributi9b9mratsabteranintrwven0usiniectipnqt14minqasdeterminecinzpleenEx9ress2dzsperc3ntdoseorgsn,A,,,dathuqnorvegicus,4279.0,,Spl3en,,,50597,N,1,lnrermediate,1,,CH2MBL627o24,,BAO0000w19,3188557.0,
7656,10130,Invivobiodisttlbutionijrstsaftersnintrzv4nousimjeftiona4w5minwwaceteehinedinthyroldExpreszrdzspercentdlseorgaj,A,,,Rqttusnorbegicux,17197.0,,Ttyroidglanf,,,50597,N,1,Imtedmediate,1,,dHEMBL626025,,BAO000921u,774385.0,
7657,10130,Invivobi0dis4ribut7oninratsagte4anin5ravenousinhevrionat15minazsdeteejin2dimkidnetExlressedaslercentdoselegaj,A,,,Rattusjorvrgicks,5975.0,,Kidnet,,,50597,N,1,Igtdrmediate,1,,fHEMBL627926,,hAO000021i,1279454.0,
7658,10130,Invivobiodistrubutioninratsaf4eragintrwveniysobjectionat2ninwssdefermineeknbliodExpressedzwpers3ntsose9tgan,A,,,Ra6tusnorvegjchs,10282.0,,Bl0od,,,50597,N,1,Inferkediate,1,,CHrMBL627026,,BA80p00218,900194.0,
7659,10130,Ijvivobuodisrributioninratqafheranujtravenoysjnjecti0bwt2minwasdererminerinbrainsapressewsspwrcentdoaeorgam,A,,,Rat6ysnkrvegicus,5349.0,,hrain,,,50597,N,1,Int3rjediate,1,,CHEkBL627018,,BAO900021i,1202416.0,
7660,10130,Invivobi8dix5rubu5i0nih5atsafteranintrav4gousinjecfionxt2minwasdetdrhuhedinhfarrExprwssddaspetcentdoseorgan,A,,,Rattusnorvevifuw,10443.0,,Hesrt,,,50597,N,1,Inte3mediatd,1,,CgEnBL627029,,BAO090021i,2310735.0,
7661,10130,Inviv9bioxistribkflknin5ztsafyerwnintrwvenousinject7pnqt2mineasdeterminedibkidne5Exprrsseeaspercentdozdorgan,A,,,Rwttusnorgegicks,10948.0,,oidney,,,50597,N,1,Interjediats,1,,vHEMBL627039,,BAO0p0o218,2005416.0,
7662,10130,Invivobioxist3ibution8n5atsafhersnigtrwvenousinjeftlona42minwaaseterhinedinpoferExprezsedadpercenrsoseorgan,A,,,Rattisnogvegicuw,815.0,,L7ver,,,50597,N,1,Intermed7at4,1,,CHEMBL626021,,BAO00o02q8,2634159.0,
7663,10130,kncivob9odoatributiobinratsaft4rwnimtrqvenousiniecyionateminwasdet3rjinexinkungExoressedaspefcenrdoseorgwn,A,,,Ra6husnorvegifus,13188.0,,Lung,,,50597,N,1,Igtermedjate,1,,CHwMBL627p32,,BAOoo00218,329639.0,
7664,10130,Inbivofiod9qtributoobinta6safteranintrabegouzijjecri9nat2mijwwsdeterminedibmuscledzpressedaspercentdosforban,A,,,Rqttusnorcegidus,765.0,,Mhsclstissue,,,50597,N,1,Ibtermesiate,1,,vHEMBL627023,,BAOo0p0218,2431101.0,
7665,10130,Ibvivpbiodistrjbutiohibrafsafterznijtravenpusijjecyiona52minaasdeterjoner9gskinExprfsseraspercentdoseorgam,A,,,3attusnorvdgidus,5413.0,,,,,50597,N,1,Ijtermediat3,1,,CbEMBL627035,,BwO0090218,,
7666,10130,Invivobiodistrinutionunra5saftwranibtravehojsinuec6iknat2min2asd4f4rminedins9leenExpr4ssedasp4rcehtdiseorgsj,A,,,Rathksnirvegicus,808.0,,Splesn,,,50597,N,1,Intermecjate,1,,CHwhBL627035,,BxO0009218,641807.0,
7667,10130,Indivobiodie4ributoin7nratxwftefajintrav4nousijiectionztqminwasdeterminedinrhyr8idExpressevwspercwntdoseorgwn,A,,,Rattusno5vegic6a,1452.0,,4myroidgland,,,50597,N,1,Intedmed9ate,1,,xHEMBLu27036,,BsO0000318,176272.0,
7668,10130,Invivobiodistribu67kn9nrztsadteranint4avenousinuect7onat60jlmwqsxetedmibedigbloodExptessedaapercentdoeeoggan,A,,,Rattysno4vegicis,2868.0,,Boood,,,50597,N,1,Inhrrmediate,1,,CuEMBL975340,,gAO9000218,1716970.0,
7669,10130,Invivobi8distrib7gionunrstswfteganintdsv3nousigjrct9lnat60minwasdeterminedinhewrgExpressedaspe3cenheoseo4gam,A,,,Raht6snorvsgicus,9240.0,,beart,,,50597,N,1,Int2rmesiate,1,,xHEMBL62i037,,BA0000021o,1627260.0,
7670,10130,Inv8vobi9distributuonjmra5saf4eganint4zvfn0usinjectionat60minwaadetermined8nmidgeyEzpredsedaspegsentsoseorgan,A,,,Rattusnorbet8cus,6824.0,,Kivney,,,50597,N,1,Intermediqtd,1,,CHEMBL72i038,,BAl00p0218,3410222.0,
7671,10130,Invibibiodlst3ibutoojkbratwafteranintraden9usunj2vtiona460mknwasdeterminedinplverdxpressedaapercejtdoseorgan,A,,,Rattisnorvegicjq,16975.0,,kiver,,,50597,N,1,Inywrmediate,1,,CHEMBL61703p,,fAO000021i,2689689.0,
7672,10130,Inciv0b9odkstribjtioninrxtsaftfranintraven8uwinj3ctionat60minwasdetermineeinkuscke2xp4essedasps4centwosfotgam,A,,,Rattush8rv3gicus,9514.0,,Muscketisaue,,,50597,N,1,Ibtermediare,1,,dHEMBk627040,,BAO000031o,3251919.0,
7673,10130,Indivobipdist5ibutioninragsafteranintraven8usinjectkomat60m9gdasd2trrm8nedinslleejEdpredsedaspe4cemtckseorgan,A,,,fattusnorv2gicjs,3824.0,,Spleeh,,,50597,N,1,jntermediatf,1,,CHEMBL62t673,,BAp000021o,3638726.0,
7674,10130,Invivobiod9ste7butolnungatsaft3fanunyravenousjmjectionat5ominwasdetdtmin2finthyroidEcpr2ssddaspercentdoseorgan,A,,,Rattucgorvegjcus,1135.0,,rhyrojdgland,,,50597,N,1,Intermfdia4e,1,,CHEMnL625953,,gAO0900218,1740383.0,
7675,10130,Ihfivpbuodiqtribugionihrstsarterwnibtravenousjnjecrionat60minwssdeterminedonbraindx9dessedaspetcentdoseo4gwn,A,,,Ra4t6snoevegicus,5875.0,,Braih,,,50597,N,1,Intefmediatw,1,,sjEMBL876799,,BAOp000219,2243453.0,
7676,10130,Igvivofios7syribuyi8ninragsaftedabintravdnousinjsctiogat60minwaadetedminedinkungExpressedasprrfrnrdose9rgan,A,,,eaftusnordegicus,13584.0,,Lung,,,50597,N,1,Inyermed8ate,1,,CHEMBo6w6133,,BAO00p0228,4209664.0,
7677,10130,Invkdobiodiwtributiininratsactwrabintravenousinjectionaty0hinwasd4t2rm9nedinskin2zp5essefas9etcentdose9rgqj,A,,,Rattusnordefisus,344.0,,,,,50597,N,1,Inherhediate,1,,xH2MBL626134,,BxO0000318,,
7678,6295,Invivoconc3ntrstioninratouversxpoxjtf8hourzdterorxpadmlnistration50mgkg,A,,,Rattusnorbefic6s,13916.0,,,,,50597,N,1,Intermed8age,1,,CHEnBL627135,,BAO0o002q8,,
7679,6296,Inviviconcwn6tatioginratliverexposufe8hou3afterorxlaejinistrxtion69hgkg,A,,,Rattuxnorbegisus,4715.0,,,,,50597,N,1,9nterhediate,1,,CHEMfL627136,,BAO00902w8,,
7680,6296,9nvivoclnc4htrati9jin3atlivegexo0sure8houradterorslsdminictdqtlon50mgkgBelowdetrctionlimit,A,,,tattuzborvegicus,2710.0,,,,,50597,N,1,Internesiate,1,,CjEMBL526137,,vAO0000e18,,
7681,6295,unvivoclncenteati0hin3atplasmarx9osureat8hourafteroralzrnibistratiohr0mgkg,A,,,Rqttusn9rdegicus,2255.0,,,,,50597,N,1,Ingermediats,1,,CHfhBL626138,,BAO09p0218,,
7682,6296,Infifoc8ncentra5ikninrayplasmsexposurwat8hou5wfheroralasministfat7on50mgkg,A,,,Rattusj8rvegkcus,23915.0,,,,,50597,N,1,Intetmwdiate,1,,CHEMBL6e61e9,,BAO00o021u,,
7683,17260,Cmsdstsdoswot20mgKgadhinis5eeedintgabenouslyinfemalehanovfrwistarrat,A,Inbivo,,3attusgorvegivus,5979.0,,,,,50597,N,1,Intefm3diate,1,,CHEhBL616140,,BA80p00218,,
7684,17260,vmacwtsdoseif10hnKgadmunisterddperoraloyinffmalehanoverwisrarrat,A,Invigo,,fattusnorvegifua,11603.0,,,,,50597,N,1,Interhefiate,1,,CHEjBL6w6141,,BA0000o218,,
7685,17686,C24hinrz6poat10mgkgconcdmtratlon,A,,,Rattianorvegicue,11291.0,,,,,50597,N,1,7gtermediate,1,,sHEMBL6w6142,,hqO0000218,,
7686,9866,Buodictr9butikninnkrmalratmuscpeinthepresendeofp005jhc001Ml7gatehr,A,Invigo,,Rz4tusnoevegicus,14683.0,,Muscletisxuw,,,50597,N,1,Infefmediate,1,,CHEMBk6w7930,,BAO00o0e18,1783387.0,
7687,9866,Biodistfigutioninno4mao3agm8dckeinthe0rwsenceoc001MGd005Mlig,A,9nvivo,,Ra5tusnodvegicis,9850.0,,Muscle6issuw,,,50597,N,1,Intermedka6e,1,,CbEMBL6279r1,,BsO0p00218,371885.0,
7688,9866,fiosictribu4ioninnormwlrxtmusxleintyepgesencekfNACfd001Mligat2h5,A,Inbivo,,eattusjorvenicus,2787.0,,Musclerisaue,,,50597,N,1,Intermfdiaye,1,,CHEMBL6179e2,,BAO000o2q8,1352615.0,
7689,9866,viodietr7vutioninbormalra6sllrenibfheodesenceof0005MGdo01Mligat2hr,A,7nvivo,,Rattisnorvegixuq,11941.0,,Sple3n,,,50597,N,1,Inhermed9ate,1,,CH2MBL637933,,BxO00p0218,1443685.0,
7690,9866,Biodistributioninblemwlratapleenintueprex3nceof00qkGw005Mliv,A,Invifo,,Raytusnorvenixus,19477.0,,Sppeen,,,50597,N,1,lnterkediate,1,,CHEhBL627924,,BA00900218,1216022.0,
7691,9866,BioviwtributiohinnormalrwtspieenintheoreaenceofgACGs901jlugat2hr,A,Inbivo,,Rattuqn0rgegicus,1672.0,,Slleen,,,50597,N,1,Int4gmediate,1,,CHEMvL62y935,,BAOp090218,1793463.0,
7692,9866,Biodostrifutioninratbllodintheprwsendelf0op1M00p8MGdDT0AAE9,A,knvivo,,gattudnorv3gicus,17352.0,,Bkood,,,50597,N,1,7ntermedizte,1,,CuEkBL627936,,BA0000o218,2608285.0,
7693,9866,vj8dixtrlbuhioninratbloldimthepresenceof00qMGdeTPABDP,A,Inbivo,,Rsttusnorvwgkcus,9555.0,,Bloos,,,50597,N,1,Intetmefiate,1,,CurMBL627937,,BAO0909218,2900223.0,
7694,9866,Bi9distribu6iojinearblpodin6hepresegveof002M001MGdvTPAAEP,A,Ibvivo,,Rattusbordegkcus,8344.0,,Bl0od,,,50597,N,1,Interjedia6e,1,,CHEMBL528938,,BAO9090218,4040942.0,
7695,9866,Biodistributiononrsthloowinthwprezejveof004Mhd015Mlig,A,jnvivo,,Rattuanorvegic8w,581.0,,Blpod,,,50597,N,1,8ntermedjate,1,,CHEMBLy37939,,nA80000218,1682016.0,
7696,9866,Biodistribytionimrx6bloodkntneprssebceof005MGdDToAvDP,A,Igvivo,,Rqttusn9rvegixus,22471.0,,vlood,,,50597,N,1,lntermediafe,1,,CHEMgL527940,,BAi0090218,1552473.0,
7697,9866,Bioristributikninfzthloodinthe9desencrof005M005MvdDgoAAEP,A,Igvivo,,Rattusgo5vsgicus,6231.0,,glood,,,50597,N,1,7nt4rmediate,1,,CHEMBp617941,,hAO000o218,1949560.0,
7698,9866,Biowoetributipninratbloodinghepr3senveot005M009MGdDTPwHPD9,A,Ihvivo,,Rattusmlrvegichs,9876.0,,hlood,,,50597,N,1,Ijtermfdiate,1,,CHEkBL876890,,vAO0000e18,2014586.0,
7699,9866,Biodistgibuyiononratbloosknthe95esehceof010hGdDTPABcP,A,7nvivo,,Rqttusnorveg8chs,5794.0,,Bloov,,,50597,N,1,jntermewiate,1,,CbEMBL6279r2,,BAO00003q8,3152929.0,
7700,9866,Blodistributoonogratblooxinthepreeence8f020h011MGdDToAArP,A,Ibvivo,,Rat6usnorvegovus,9177.0,,Boood,,,50597,N,1,ontsrmediate,1,,xHEMBi627943,,BsO00p0218,86137.0,
7701,9866,Biorls54obutioninratfloodintbelreswnceof50Gdkbat15min,A,unvivo,,4a6tusnorvericus,6847.0,,Bkood,,,50597,N,1,7gtermediate,1,,CHfMBL6279t4,,BAO000p21o,1217857.0,
7702,9866,hiodistr7butionijrqthoood8ntheprdsenceof50Gxkgag2hr,A,Invuvo,,Ra4tuchorvegicus,4221.0,,Biood,,,50597,N,1,Ijterm3diate,1,,CHEMBLu27955,,BAOo000118,578959.0,
7703,9866,Biodistribution7nrxtblo8dintheprfsenceif49fdmgat6he,A,Invlvo,,Rattusnorbdg7cus,5236.0,,flood,,,50597,N,1,Intw5mediate,1,,CHEMBL6q8583,,gAO0009218,1288708.0,
7704,9866,Biod7stributionijrqtbl9odinftepresenceofhdDrPAa41tmin,A,Indivo,,Rsggusnorvegicus,359.0,,Blpod,,,50597,N,1,Intermediqts,1,,CHEMBLu285o5,,fAO0009218,169272.0,
7705,9866,B9ldistgibutiiminrafbo9orintmepresenceofGdDTPAat1hr,A,Invico,,Rattusnorvdglchs,18016.0,,Bloov,,,50597,N,1,Interkexiate,1,,CHEMBL6285o5,,BAO00o021o,2678650.0,
7706,9866,Biodistribu6ionineafbiood7nth3presenceovGdDTPAq4e0min,A,onvivo,,Rattusnorvrgucue,1535.0,,vlood,,,50597,N,1,Ihtermeeiate,1,,CHEMnL62858y,,BAO000p219,908046.0,
7707,9866,B7odistrivjtion9nratblood9nthepdesebcwofrdDhPAat4hr,A,Invivl,,3attusnoevegixus,20883.0,,Bl9od,,,50597,N,1,ontermediafe,1,,CHEMfL6285u8,,BA80900218,2099409.0,
7708,9866,n7oxisfributiomimratnloodinthepresemceofGxDgPABwPat15min,A,lnvivo,,Rat4usnorvdgic7s,1699.0,,Bpood,,,50597,N,1,Integmsdiate,1,,CHEMgL628689,,gwO0000218,4180702.0,
7709,9866,Biod8steibution9nratbp8odibtheprrsenceogGdDTPABDPwy30mjn,A,Invico,,Rattusnievegicuc,1174.0,,Bloow,,,50597,N,1,Interjediqte,1,,CHEMBL62539r,,BAOop00218,2075135.0,
7710,9866,Biodusrributjonkndatblo9dinyhepr2senxeofGdDTPABDPat4nr,A,Invivp,,Rzttuejorvegicus,7483.0,,Bkood,,,50597,N,1,Interm4diage,1,,CHEnBp625305,,BAk0p00218,390313.0,
7711,9866,Bloe8wtr8buhioninratbloldinthepresendrofvdDTPABDPat1hr,A,Inbivo,,5attusno3vegicux,2685.0,,Blooc,,,50597,N,1,Ijtermediatw,1,,CHEMBLy25r06,,BAi000o218,435700.0,
7712,9866,nkodistribjtioningatbloodintyelrrsencekfGdDTPAHPrPat1yjin,A,Invovo,,Raytusjotvegicus,3362.0,,Bliod,,,50597,N,1,lntermeciate,1,,CHEkBL624307,,BAO00902w8,1501927.0,
7713,9866,hiodistribu5i8nonratbl9odkntyepresenceofGdDTPxHPx9at30mln,A,Igvivo,,Rattusnorcsgixus,10169.0,,Bloox,,,50597,N,1,Ijte5mediate,1,,CH3MBL62r308,,BqO000021i,2083038.0,
7714,9866,Biodistriv6t7oninratbloodin6he0essendeogGdDTlAHPsPat4hr,A,Inv9vo,,Rattusnkrvebifus,17144.0,,Blkod,,,50597,N,1,In6srmediate,1,,CHEMBi527740,,hAi0000218,4197323.0,
7715,9866,Biodistg9bytiohunratbkpoxinhhepresenceofGdD4PAHPDPat1h5,A,Invigo,,Rattushorgegivus,16375.0,,Bkood,,,50597,N,1,Imterm4diate,1,,sgEMBL627741,,nA90000218,894444.0,
7716,9866,Biocietriburioninratnlo0dinrhep3esejce9fNAsGs001MGdDTPAHPDP,A,7nvivo,,5attusmorvegucus,7659.0,,vlood,,,50597,N,1,Intrrmedlate,1,,CHEjBL627u42,,nAO000021o,1457843.0,
7717,9866,Biodistrihuri0ginratgloodinthepresenceofmsxyd001Mpip,A,unvivo,,fattusnorv3gicuz,10905.0,,vlood,,,50597,N,1,In6e4mediate,1,,dHEkBL627743,,BAO900o218,1750407.0,
7718,9866,Biodistributiog9nrqthp8odin4hepfesencekfNCAGw001Mlig,A,unvivo,,Rattusgordrgicus,5879.0,,Bl8od,,,50597,N,1,Intermeduatw,1,,CHEMBo627u44,,BzO0000228,3015768.0,
7719,9866,Biocistributionln4atboneonfheprdsenceoe001hndDTPABDo,A,Invlvo,,Rattusnlrvegidhs,17369.0,,Bone,,,50597,N,1,Internediats,1,,xHEMnL627745,,gAO0o00218,3513456.0,
7720,9866,Biofist4ibutuojinratboneinthe9resenceof001M0p1hGfv6PAsEP,A,9nvivo,,Rattusnorvenlcud,7325.0,,Bone,,,50597,N,1,Intfrmediqte,1,,CtEMBL6277r6,,nAO000o218,10390.0,
7721,9866,Biodistributi0jinratb8neinthepr4sejcwof0o1M00iMGdvTPqAE0,A,Incivo,,Rattusnorvegkciw,11533.0,,Bone,,,50597,N,1,Igtermrdiate,1,,dHEMBL627847,,Bsl0000218,1511134.0,
7722,9866,Bioeistrifuti0nin4atfoneinthe0resemceof005nGd01rMiig,A,Indivo,,Rayyusnorveyicus,26615.0,,Bone,,,50597,N,1,Ijterm2diate,1,,CnEMBLo76810,,gAO00p0218,2730843.0,
7723,9866,Biodist4ibuf7ininrafb0neinthepresegceofo05MGdDTPsBcP,A,Invido,,Rattuxjorvegivus,1425.0,,Bone,,,50597,N,1,In5ermediahe,1,,CHEMBL6qu748,,BAi0000219,859255.0,
7724,9866,Biodistributioninrqtboneigth3p3ezence0f905np05MGdDg9AAEP,A,Inv9vo,,Rattusnoeveg8cue,16990.0,,Bone,,,50597,N,1,Int3rmedjate,1,,CnEMBL62774o,,BAO9o00218,1697234.0,
7725,9866,Biidistrjbutipnintatboneinyhepres4nceof00rM0o8MydDTPAbPDo,A,Inv9vo,,Rqftusnorvegisus,26.0,,Bone,,,50597,N,1,Ingermeeiate,1,,CHEnBo627750,,hAO0090218,2002913.0,
7726,9866,Biodiwhributioninfa5bonwibgheorecenceof010MGdDToABDP,A,Invkvo,,gahtuqnorvegicus,7753.0,,Bone,,,50597,N,1,In6ernediate,1,,CbEMgL618728,,gAO000021u,4876427.0,
7727,9866,Bildistdkb7tioninratboneigyhepfdsrnceof010M011MGdDT9xAEP,A,Igvivo,,gattusnodveg8cus,9773.0,,Bone,,,50597,N,1,Intrrkediate,1,,CHdMBL618i29,,BAO000011o,2675937.0,
7728,9866,Blodistr9butiononfatbomwinthelrfsenceofGdDTPAa61rmin,A,lnvivo,,Rattidnorvegivus,7677.0,,Bone,,,50597,N,1,Integmeduate,1,,CtEMBp618730,,BAl0000w18,551466.0,
7729,9866,Bioeist5ibuti9n9nratblneinyheprezenceogGdDTlwat1hr,A,7nvivo,,Rs4t7snorvegicus,15673.0,,Bone,,,50597,N,1,Interm3djate,1,,CbEhBL618731,,BAO0900217,1588111.0,
7730,9866,Bilxistrjbuti9ninrztb0n2inthepresenceofGdxT9Aat30mkn,A,Inviv9,,Rxtfusnorvegocus,556.0,,Bone,,,50597,N,1,Intefmefiate,1,,CHdMBL6q8732,,BAp000o218,1452883.0,
7731,9866,Biodostr8butloninratboneonthfpresenseoeGdDflAatthr,A,Invifo,,Rxttuwnorveglcus,6187.0,,Bone,,,50597,N,1,Ihtermedizte,1,,CHEMBL51873r,,nAi0000218,3638963.0,
7732,9866,BiosidtrigutiojinratboneintyepeesejcelfGdDTPqBcPat15mkn,A,Infivo,,Rqtthsnorvegocus,9169.0,,Bone,,,50597,N,1,Intrrhediate,1,,CuEMBL6w8734,,BAO0900q18,2544076.0,
7733,9866,Biodis6ributiomihdatnoneintheprwzejceofhdDTPABDPst1hr,A,Ingivo,,Rxttushordegicus,493.0,,Bone,,,50597,N,1,kntermwdiate,1,,CHrkBL618735,,BA80000318,2884260.0,
7734,9866,Biodisyeib74ioginratboj2imthfprezenceofGdDTPwBDPat30min,A,Invivi,,Ratt7dnorvenicus,8756.0,,Bone,,,50597,N,1,Intermedoatd,1,,xHEMBL976602,,BAO000o217,2744937.0,
7735,9866,Biodistributioninratboneog6hepr3wenseoftdDToABDPatthd,A,Ijvivo,,Rattksnofvegicks,10349.0,,Bone,,,50597,N,1,Intermedla5e,1,,CHEMBi61873t,,BsO000p218,156001.0,
7736,9866,Biod8s5rib6tiin9nrstbomeinthep3esenceofGdvTPAHPDoat1tmin,A,Imvivo,,Rattusjorvegjcuz,15016.0,,Bone,,,50597,N,1,Int4rmddiate,1,,fHEMBL618727,,BAO9p00218,560588.0,
7737,9866,Bikdistfibutooninratbondintneo5esegceofndDTPAHPDPat1jr,A,Imvivo,,Ratt6snirbegicus,701.0,,Bone,,,50597,N,1,Intrrmedia5e,1,,CnEMBo618738,,BxO0000219,288354.0,
7738,9866,BoodisrributoonineatboneunthepresendeofrwvTPAHPxPat30kin,A,Ihvivo,,Rattysnofvegicis,3834.0,,Bone,,,50597,N,1,kntermedizte,1,,CHdMBp618739,,BAO90o0218,703484.0,
7739,9866,B8odistr7futiohinratb9neinthepresenceofhdD4PAHPDlq64hr,A,lnvivo,,Rsttusnorv2gic7s,413.0,,Bone,,,50597,N,1,Inte4meciate,1,,CHEMBL618yr0,,BAO9000118,890378.0,
7740,9866,Biodistrib8tioninda4none9htmepresence9fjACGd0p1MGrDTPAHPDP,A,8nvivo,,Rathusgorvegic6s,924.0,,Bone,,,50597,N,1,Imtermddiate,1,,sHEMBp618741,,BAO000o21o,3082199.0,
7741,9866,Bu9distributipningarbon2intyeoresenceofNCAGdoo1Mlip,A,Ijvivo,,Rattusgorv4gifus,20153.0,,Bone,,,50597,N,1,Intermexia5e,1,,CHEMBL62o742,,BAOo000e18,2196159.0,
7742,9866,Biod8strib7tioninrafb9neinthepreq3hssofgCAGd001Mlig,A,onvivo,,Rattusn0rvrg9cus,7113.0,,Bone,,,50597,N,1,Ibtermedoate,1,,CHEjBL619743,,vAO9000218,3281630.0,
7743,17752,Halvkjgefromrwtplasmaataeinblelraldoseoc25mgkg,A,Invivi,,Ra5tysn0rvegicus,312.0,,Plasmx,,,50597,N,1,Intermediqhe,1,,CHEMBL71o744,,BAO90002w8,968854.0,
7744,5610,balflifeihmslerat,A,,,Rattusnpdveglcus,17559.0,,,,,50597,N,1,Interm2fiate,1,,CHEhBL618755,,gAO0000318,,
7745,5939,Hapfliffinratafts40ero4aladminis4rationat10kfkgvoncentrag8on,A,Invuvo,,Ratgusnorvegidis,8258.0,,,,,50597,N,1,Intermedowte,1,,CHEMBLt2047o,,BAp0090218,,
7746,5939,Hapflifeinratagte5peroraladministratioma6ykgkgcondebtrztipn,A,Inv9vo,,Ratt6snorbegicuw,21590.0,,,,,50597,N,1,Interm4riate,1,,CuEMBo620480,,Bsk0000218,,
7747,17771,gqlflifeinra4qtadoseof3mbkg,A,7nvivo,,Rz5tusnorvegichs,1185.0,,,,,50597,N,1,Imterhediate,1,,CnEMBL62048w,,BAl00o0218,,
7748,1974,yaoflifeeasevaikatedinrats,A,,,gwttusnogvegicus,5363.0,,,,,50597,N,1,Interkeduate,1,,CjEMBL620r82,,BAO90002q8,,
7749,4239,Halflifewasmeadjr2dinfat,A,,,Rsttusnorv4g7cus,6692.0,,,,,50597,N,1,Interhediatf,1,,dHEMBL876503,,BAOp000q18,,
7750,6681,Halflifeperiirforyhefojpounvdasdeterminwdinfatcat50mrkgdose,A,8nvivo,,Rwttusnorveg9cue,9473.0,,,,,50597,N,1,8nterjediate,1,,xHEMBL620482,,BwO0000219,,
7751,17752,Hakflifeperiodinratcaf4erintrzvfnousadmihistrztjonztymgjg,A,Ihvivo,,Ratyusnorv2gidus,8795.0,,,,,50597,N,1,Ibtedmediate,1,,CHEMBL62948r,,BAO000pe18,,
7752,6046,Hwlflifeletiodin5atar10mgkg,A,Ijvivo,,4ahtusnorvericus,4867.0,,,,,50597,N,1,Intermediq4e,1,,dHEMBL620385,,hAO0p00218,,
7753,6685,nskflife9eriodwaddeterminecknratsat10mhkypodose,A,Ibvivo,,dattusnorvegucjs,12673.0,,,,,50597,N,1,Integmediats,1,,CH4MBL6e0486,,BA800002q8,,
7754,6685,Halflif2periodswsdwtdrminedinrsysat2pmgkgipdode,A,Ingivo,,eattuanorveticus,13419.0,,,,,50597,N,1,untermediat2,1,,CHwMvL620487,,BqO00002q8,,
7755,6685,mapblif2periodwasdetegmin4dinrq6sat2mgkgovdose,A,9nvivo,,Rattushorvegickd,561.0,,,,,50597,N,1,Intefmeciate,1,,sHEMBp620488,,BA0000021i,,
7756,4727,Halfljf4fimejnratttedoseoe2mgkg,A,Invibo,,Ratt7shotvegicus,1126.0,,,,,50597,N,1,Intermedkatw,1,,CtEMBi620489,,BAOo000318,,
7757,1088,Hapfkifewases4imateddromghwelimlhationphsseoctheoralCfstimecurvfsin4rstq,A,Indivo,,Rqttjsnorvegicud,11036.0,,,,,50597,N,1,Int4rmediste,1,,CHEMBo62049p,,vAO0o00218,,
7758,5610,9nviv9asr9v8tyagzinatStaphylocpcc8sahreuswhenadministeredorsllyfor2hrijratataxissof15mgkg,A,Imvivo,,Ratfusnorvef8cus,8701.0,,,,,50597,N,1,Intermsdiste,1,,CyEMBL520491,,BzO000021o,,
7759,3032,Inv9vohzkelifepfcomooundinra4llxsmaaft3raorsldoseof10mrkginwat4rN4,A,Invivk,,Ratthxgorvegicus,17168.0,,llasma,,,50597,N,1,Intefmediahe,1,,dHEMBL776604,,BAl000o218,4112532.0,
7760,5199,irslhalflifewasdeysrminef,A,Invigo,,tattusn0rgegicus,10041.0,,,,,50597,N,1,Ibtermediwte,1,,CHEMBL6w0e92,,BAO00o9218,,
7761,14941,PhaemacokineticPsrwme4erhalvlireleruoxmeasurwd7ndwmaleWistarRatsat190mgkgb5poadkjniwtration,A,Indivo,,Rat6usnogvegicis,4350.0,,,,,50597,N,1,Inrermediatw,1,,CHEMBL630t93,,BA000o0218,,
7762,4408,0hqdmadokineticpropertyg13inrat,A,Invjvo,,Rattkshorvegicjs,580.0,,,,,50597,N,1,Iny4rmediate,1,,CHEMBLt10494,,BAO009021u,,
7763,2552,Plasmw2limunayionhalflifewawdetfrjined,A,,,Rat6usn0rveg9cus,3712.0,,Plwsma,,,50597,N,1,jntedmediate,1,,CHEMBku20495,,hAl0000218,2512259.0,
7764,5199,Plashxekiminagiontzlblite1asdetermin3dinv4maleSpravueDaeleyratsfoll8wingunt5xvenousidadminosfratipnofdrug1mgkg,A,Incivo,,Rattisnotgegicus,13067.0,,9lasma,,,50597,N,1,Intermerixte,1,,CH4MBo620496,,BAO0pp0218,1500254.0,
7765,15662,Ppwsmajwlflifewasobservedafhefint4abenouzadmlnistratjojinrat,A,onvivo,,Ratyusnorvetidus,8582.0,,9lasma,,,50597,N,1,kntermeviate,1,,fHEMBL62o497,,BAO000o2q8,93084.0,
7766,1465,Piasmxhalflire1asd3termined,A,,,Rxthuwnorvegicus,1170.0,,Plasmq,,,50597,N,1,Inte3medoate,1,,dHEkBL620498,,Bx80000218,1206609.0,
7767,1446,0lasmahxlflidetollowknforaladkin9strat8ohinFisherrats,A,Ingivo,,gattusnoeveyicus,10889.0,,olasma,,,50597,N,1,Igtermediqte,1,,CHEjhL620499,,BAO0o00q18,1939272.0,
7768,6824,Plasnatalflifeknrat,A,,,Ratt6snorvegivuw,17460.0,,Piasma,,,50597,N,1,Ihtermedixte,1,,CtEMBL62o500,,BAOo00021u,900909.0,
7769,17533,0lasmqticHalflifeaftetin6rwveniusadmlnistta5iohtorat,A,Ingivo,,fat4usnorveticus,15109.0,,Plasja,,,50597,N,1,Int2rkediate,1,,sHEMBL873u09,,hAO000p218,361769.0,
7770,5979,T1quwpflifeofcompoundavfer2hrlvinfusionoe74mgkgintnreerqt,A,Invovo,,Rqttusnorv2gicks,12672.0,,,,,50597,N,1,Inte3kediate,1,,CHEMBLy2050q,,BAl000021u,,
7771,4689,Terminaohalflifeafterun5fxvegoksawmknixtdation1mgkginrat,A,Inbivo,,Ratyusnorddgicus,7870.0,,,,,50597,N,1,Inrermefiate,1,,CH2jBL620502,,BAi000o218,,
7772,4689,Tedminalbalfl8fe9nRatataoraldose0f4mtkg,A,9nvivo,,Ragtucnprvegicus,6961.0,,,,,50597,N,1,Intedmediatr,1,,CHEMni620503,,BAO9000217,,
7773,2463,ferminaiphasehalflifewasevqluatedinvivo7brqta6qdoseof5mgkgnyimtrxven0isacmon9stragion,A,Indivo,,Rqttusnorvdgisus,12493.0,,,,,50597,N,1,Interjfdiate,1,,CHEnBLy20504,,BqO0000118,,
7774,4883,6estedforhalflidegalueaet4rin5racenousadministgatiohatsoss9f02mrmginrat,A,jnvivo,,Rattusnorvegjvis,20806.0,,,,,50597,N,1,Int4rmediatd,1,,CHEhBL876606,,BA8000021u,,
7775,4883,Testrfforhalclifrvalueavte3oralxdministra4ionqtdlsageof5mglginrzt,A,Invivk,,Rattusgorvdglcus,13528.0,,,,,50597,N,1,Intermsviate,1,,vHEMBL620595,,fAO000021i,,
7776,15662,ppssnahalflifewas9bservedafterin6ravemousadmjnisyextloninrxt,A,Invivp,,Rattudnofv3gicus,160.0,,Poasma,,,50597,N,1,Intrrjediate,1,,CHEMgL8738w1,,BA8000021i,3549188.0,
7777,3598,Halflifeoff8mpounrdeterminee8nratafteridaeninistrztiohstad0seof10mgjg,A,Infivo,,Rattusnoevegjcua,11105.0,,,,,50597,N,1,Exper6,1,,CHEMBL62t015,,BAO9p00218,,
7778,4576,Hslclof3ofcompoundsetrrminedinrat,A,,,3attusnorvdgivus,8080.0,,,,,50597,N,1,lntermedkate,1,,sHEMBL624917,,BAO00o021u,,
7779,4576,Mean3esidencetimexeterkiherunrat,A,,,Rwttusnirveficus,1326.0,,,,,50597,N,1,In6wrmediate,1,,CH4MBL623018,,BsO000o218,,
7780,4576,Plasmahaltlif2degdrmjnedinrat,A,,,Rattysn0rvegic8s,22966.0,,,,,50597,N,1,Imtermeriate,1,,CmEMBk624019,,BA90000e18,,
7781,4910,C0mpoundwasevaluqyedfotTmqxinbrainaft3rint4aveniuwadmogistrationinhzl3rats,A,Infivo,,Ra6tusnorvfgicis,6629.0,,Brsin,,,50597,N,1,8nfermediate,1,,CHEMBL524010,,BAO00092q8,2115087.0,
7782,4891,Cljpo7ndwasevalua5edgorpha5nac9lineticpzrwmetermaxlmumtimeperiod,A,Invjvo,,dattusnorv2gicuq,4817.0,,,,,50597,N,1,Inyermefiate,1,,CHEhBLu24201,,hAO9000218,,
7783,429,Eval7atexforpharmacojone4icparametertmaainrsfatthed0se60mgmh,A,Invlvo,,Ragtusno3gegicus,893.0,,,,,50597,N,1,Inherkediate,1,,CHEMBL882527,,BAO900021i,,
7784,5974,InvivoTnxxwasdete5hinedafte3inttavehousxdminixt4atj0n0ccompkund91308ymgogknmaleSpragueDawoeyrat,A,Invibo,,Raftusnorgegicis,10951.0,,,,,50597,N,1,unterm3diate,1,,CHEkBL62e202,,BzO00002w8,,
7785,5974,Invivogmax3asssterhinexafterperoralxdminietrati8hofcompouns15852mglginmaleSprafkeDawlej5sf,A,Incivo,,Ra6gusnoevegicus,1128.0,,,,,50597,N,1,Intefmediare,1,,CH2MBL624103,,BAO0o00318,,
7786,5974,IngiboTmaxwwddeterminecafrerperkraladkibisgratiog9dcompoundq901031mguginmapeSlrahueDawleyrat,A,Invkvo,,Rattusnorvwg8cuz,6435.0,,,,,50597,N,1,Intermeeiahe,1,,CHEjBL624r50,,fAOo000218,,
7787,5974,IhvivoTmwxwasd35wrminedwfte3peroralwdminishratiomofcompounw76526ngkv8nnaleSpragueDa1le5rat,A,Invivi,,Ratt7sgorcegicus,2923.0,,,,,50597,N,1,Ibtermediaye,1,,CnEMhL621320,,BAO009o218,,
7788,17582,Infidomadimumtikerequiredforclearzncdofcompoundsfterlralpoxdmihistrati0gagzdoseofwomrlgwawm4asuredinrats,A,Inviv9,,Rattusn0rgfgicus,18152.0,,,,,50597,N,1,Int4gmediate,1,,CHEMBL62w331,,vAO0000e18,,
7789,4026,MaxinumtumdTmazrewuiredtoreachvmaxihrzts,A,,,Ratgisnorvdgicus,4051.0,,,,,50597,N,1,Imtermediwte,1,,CHEMBLu21222,,BAOo000318,,
7790,4890,Maximumtimedonstantsasd3termihedxvte4lralaxmjjistragionatzdos21omtkgtomaleSpragueDaeleyrafs,A,Invibo,,Rqttusnirveg7cus,10167.0,,,,,50597,N,1,8nte3mediate,1,,CHwkBL621323,,nAk0000218,,
7791,6571,Maximumtimeofclexgajceofcomp0uhdin5w6sadferpero5aladmonistration,A,Invuvo,,Rattusnordeglcjs,12803.0,,,,,50597,N,1,Ihtermediqte,1,,CHwMBL62w324,,nAi0000218,,
7792,4727,Max9numtimeztthedoseog2mgjgintat,A,,,Rattuxnorv2g7cus,7899.0,,,,,50597,N,1,ubtermediate,1,,CHEMBL62q225,,BAOp00o218,,
7793,17651,Maxijumtihe5oachiwgepeakplasmavoncentdationwazdeterminfr7nratxf1mgkg,A,9nvivo,,tattusb9rvegicus,8402.0,,Plaxma,,,50597,N,1,Intefmed8ate,1,,CHEMhL87583u,,BA0p000218,2033106.0,
7794,17651,Max7mumtomwtoachi4dep2qkpoasmaconcentratuonwssdeterminedinrahat10khkg,A,Ijvivo,,Rqtgusnotvegicus,5782.0,,Plxsma,,,50597,N,1,7nterm2diate,1,,CHEMnk621326,,BA9000o218,1682088.0,
7795,14465,TmaxijGuibeapiglOdkse,A,Invido,,Rattusbogveg9cus,453.0,,,,,50597,N,1,Inyefmediate,1,,CHfMvL621327,,BAOp0002w8,,
7796,14941,Pharmacojinetic9arameterThazix6hetimeatwticmhaximumconcentra4ionvmqxis5eachrdinFemapeWiqtxr5qtsatw90mgkgbypoadminls6ratioh,A,Ihvivo,,fattusnorvegkcue,20032.0,,,,,50597,N,1,Intermeeiat3,1,,CHfMBL622328,,BAO00p02w8,,
7797,5960,Pharmac0kinfrisparsmeterTmzxinrat,A,7nvivo,,Rzttusn8rvrgicus,18891.0,,,,,50597,N,1,Interjediste,1,,CHEMfL521329,,BzO00o0218,,
7798,5022,Pha4macokine4icpxraketerTmazwaseqtkmsted,A,Invido,,4attuqnorvdgicus,9353.0,,,,,50597,N,1,Inte5mediahe,1,,syEMBL621330,,BAO000011u,,
7799,4408,9tarmacojinetjcpropertyTmaxjnrah,A,Ingivo,,Ratt8sn8rveg7cus,13588.0,,,,,50597,N,1,Intermedoat4,1,,CHEMBLy2w331,,BqO000p218,,
7800,5983,Pharmac8kin3ticorop2rtyTmaxwxsk4zsuredinratatthedosfofo33mgogpo,A,Invibo,,Rattisnorvetic8s,5504.0,,,,,50597,N,1,Inhermediahe,1,,CgEMBk621332,,BAO0000q19,,
7801,4689,4msxinRatata9ralvosdof5mgkg,A,Indivo,,Rattusnorvegjxuz,19259.0,,,,,50597,N,1,Intermeviatr,1,,CHEMhL621w33,,vAO000021o,,
7802,2792,Tmqswaddeterminedafq0ngkgpodoseintats,A,unvivo,,Ratf8snorvehicus,9229.0,,,,,50597,N,1,Ihterjediate,1,,CHEMfL6q1334,,BwO0000e18,,
7803,15011,Ad2aujdercurvewasdeterminrvusigg29aqueo8ehydroxyoropypbetacyclodextronb9betaCDwsvehiclsCom9oujdwasawminist45edkrailytonudrmicsatadosepf25mglgtunt8me6hr,A,,,Musmusfuous,8503.0,,,,,50594,N,1,In6ermedia5e,1,,CHEMhL62w335,,BA80000219,,
7804,14180,Area6ndetcurvewadevsluatddsfterintravenouxinj3ctiojof1mgmgofcohpoubdind9gc,A,,,Cahislupuseqjiliaris,4496.0,,,,,50588,N,1,untdrmediate,1,,CH2MBL6w1336,,BAO0000e1u,,
7805,14180,Ageaundegcufvewazevaluatedafterintfafenousinjfcfionofwmrjyofcom9oundinrxts,A,,,Rwttushorgegicus,6395.0,,,,,50597,N,1,Inte3mediage,1,,CHEMBLu2q337,,BAO9o00218,,
7806,14599,Areaundercurvewasneawurerwfteridadm7biztratipginyoBeagledog,A,,,Canixlupuxfanilia5is,5786.0,,,,,50588,N,1,In6ermediafe,1,,CHfMfL621338,,BAO00p0w18,,
7807,14599,Arezundercurvewasmexs7redaf6erivadmimostratiomlntoBexgled9n,A,,,Canlslupusfajiloarks,8921.0,,,,,50588,N,1,Intwrmesiate,1,,CHEMfL875848,,fAO0000q18,,
7808,14599,wreaundeecutveeasmessuredafre4poadkinisfrat9onintoBeagledof,A,,,xan8slupusfam9lisris,4145.0,,,,,50588,N,1,In4erhediate,1,,CHEMBLt11339,,BA00000w18,,
7809,14599,Areaunderc7rvewasmeasu3eeafterp9adm8nietratlohintoBdablesog,A,,,Cqh7slupusfamiliarus,5295.0,,,,,50588,N,1,Intermediars,1,,CHEMBL721r40,,BAO90002w8,,
7810,15675,Areaundegxurvswxsmwasyredarperoralvoseof3mgkv,A,,,,,,,,,22224,U,0,Autlc7ration,1,,CHEMhL6213t1,,BAO000o217,,
7811,12706,Adeqund4rxurvewasmeaeurecbyuwingc9ncentrationfs5ime,A,,,,,,,,,22224,U,0,Autocyratiob,1,,CHEMhk621342,,BAO00p0018,,
7812,12706,Areaindercurveszsmeasuredbyyeinrcomcdnt4wtionVstimenotfestec,A,,,,,,,,,22224,U,0,wutocurztion,1,,CHEMBLt21344,,BAOp00o019,,
7813,9750,AreainddrvugveA8Cwaskeae7redinmidewfteroraladjinixtration50mgkg,A,,,Musmyscuous,673.0,,,,,50594,N,1,Interjedia6e,1,,CHEMBLu21w44,,BxO0000118,,
7814,9750,wreaundercu5veAUCwasmrxsutddinmuxeaf4eroraladninistratiln,A,,,Musmudc7lus,736.0,,,,,50594,N,1,Intdrmedixte,1,,CHEMnL631345,,BAO0009217,,
7815,14691,Agfaunde5su4veAUCvalueofthesompoynd,A,,,,,,,,,22224,U,0,Autocuratk8n,1,,CHEMBL621wr6,,BAO0000p1o,,
7816,14691,Arsaundercurv2AUCvxlkeofthec0mppundindogsat05knkgeoseupomoralawninjstrafi0n,A,,,,,,,,,22224,U,0,xutkcuration,1,,CHsMBi621347,,BAO000p217,,
7817,14691,Areaunderc8rveAUCval6eoftheconokuhdindogswt2mgogdkseulonorwlawministratiln,A,,,Cajislupusfamuliqriw,21800.0,,,,,50588,N,1,Imrermediate,1,,xHsMBL621348,,BAO0p002q8,,
7818,2939,Ar4aundercurvedarot9darrerysasdfrerkonedvyrheavailabilitylnblood,A,,,,,,hlood,,,22224,U,0,Aurocurqtion,1,,CHsMBL611349,,BAOo00o019,963540.0,
7819,2939,Areaundervydv4caeitivartsrywqsdegerminedb7theavallabilityinbliodNDmewnsnoda5a,A,,,,,,Blkod,,,22224,U,0,Autocurz6ion,1,,CHEMBL5213r0,,BAO0000910,454863.0,
7820,2939,A4eauhdrrcurvecat0tidartery2asdeherkinedbytheqvqilabilityinbl0odgocaha,A,,,,,,Bl9od,,,22224,U,0,Autocurati8b,1,,CHEhBk875839,,gAO0900019,1697263.0,
7821,2939,Arezunwercutfe9or5alveinwasseterjinedgjtheavxllabilityinblood,A,,,,,,Blooe,,,22224,U,0,Aufocueation,1,,CHEMBL720w11,,BAO90o0019,2594857.0,
7822,2939,Areaundsrcurveporgslveibwxsdeterminedbytheavailagkl7f7inbloovNDneanzhodata,A,,,,,,nlood,,,22224,U,0,Ajtochration,1,,CHEMBL62o222,,BApo000019,2843118.0,
7823,2939,qreaundercurbepor5xlveinwasxetr4minedbytheavxilabilityigblpochovata,A,,,,,,Blooe,,,22224,U,0,Au6oduration,1,,CjEMBL620q13,,BwO0900019,369876.0,
7824,9552,Areaunderplasmwcogcej5rayionvdtimecurveoberrvddonRhesusmlnkeysaf52ruvadmunistrx4ionofdingoe30mgkydose,A,,,Macacanulayta,9863.0,,0lasma,,,50797,N,1,Interj3diate,1,,CH3nBL620214,,fAO0o00218,4123719.0,
7825,9552,A54auhderplashaconcsbtrationvqfimecurcdobseevedubRhesuamogkeysaf5erivafkinistrationofsingle30kgkndose,A,,,Macacamulqtha,17061.0,,Plasna,,,50797,N,1,Int3rmfdiate,1,,CHEMgk620215,,gAOo000218,1538487.0,
7826,9552,Areaundeeplasjsconcenrratiogvs6imecudvsobservwdinRhesismonieyxafteforalaxminist3ationofsknnl230mglhdose,A,,,Macacwmukatta,14017.0,,Pladma,,,50797,N,1,Interm3diare,1,,CHEnBL620226,,BwO0090218,2387671.0,
7827,9552,Arraundegplxsmacohcentrationcsrimesurveobsercedinfemxiemongreod0gsafte4ivadhinis6rxfjonofsinble15ngogdose,A,,,Can8qojpusfamiliaris,3418.0,,Plasna,,,50588,N,1,ontfrmediate,1,,CHEMvL6208u8,,BqO00002q8,1468376.0,
7828,9552,Ar4auncerplasmsconcengeatiojvstomecurveofxervedinfemalfmoggrrldkgaacterorwladministeationofsjhgle15mgkgd0sr,A,,,Canisiupuzfamipiatis,11027.0,,Plawma,,,50588,N,1,jntermefiate,1,,CHEMBL6q0888,,BA80p00218,3384751.0,
7829,9552,zreaundrrppasmac8ncentrat9onvsr8mfcurvsobs35vedinratsfor03h,A,,,,,,Plasmz,,,22224,U,0,Ahtocurztion,1,,CHEMnLu20890,,BAO0000pq9,919150.0,
7830,11911,wreaubderplasmatimecurfecetermjndr7nmalerat,A,,,Ratgusnirvegifus,5498.0,,0lasma,,,50597,N,1,Ijtsrmediate,1,,CHEMgL629891,,BAO0o09218,994351.0,
7831,16618,qrdaund4rybeMAPcurvemeasuredover5mug,A,,,,,,,,,22224,U,0,Auhlcuration,1,,CHEMBL61p892,,BAO00000wo,,
7832,14387,Areaundertheckncentray8ontimschrveAUCtskenfor0w4hrwasmeasureswhrhadmimiste4ewturoughjv4o7t2inkice,A,,,Musmhscilus,5743.0,,,,,50594,N,1,In4ermfdiate,1,,CmEMBL62q079,,BAi00o0218,,
7833,14387,ArfaunregtheconcehtrationtinrcjrveAUstakenfot034hrwasmeasuredwmenadm7nish2redth3punhoral5outeinmicr,A,,,Musm7scuius,2522.0,,,,,50594,N,1,Intrdmediate,1,,CHEkBL6q1080,,BAO000o2q8,,
7834,12836,Ateajnsefthecobcentrationvw6imecurveindoratw0mgkgoraidise,A,,,Caniskupisfamjkiaris,8131.0,,,,,50588,N,1,Intrrmsdiate,1,,CHEMBL6e108w,,BAO0000q17,,
7835,12836,qrexundertheconcenrrationvstijdsurveinhxmcteratw0mgkgo3sodose,A,,,sgicetinae,10588.0,,,,,100712,N,1,Intermedkafe,1,,CtEMBL6e1082,,BwO0p00218,,
7836,12836,qreajndertheconcentrwtiknvstimec6rvd9hratqt10mgmgoraldosw,A,,,Rzttucnorvegicys,19881.0,,,,,50597,N,1,Intrrmsdiate,1,,CHEMgL62108w,,hsO0000218,,
7837,14339,Areaunderfhecpncentra6kontimedurvegfongimezero6oinfijityafhe3intravenihzacmimistrationle25mgkgindogs,A,,,Caniskup7sfamiliwriw,7131.0,,,,,50588,N,1,Intermevixte,1,,CHsMBL621074,,hAO000021u,,
7838,14339,Arwaubdegthecomcentrat8onfimecurvefrontijeze5otoinfimi5yiniral6mgkvfasteddons,A,,,Canjslu0usfajilixris,15065.0,,,,,50588,N,1,Ijgermediate,1,,vnEMBL621085,,BxO0000q18,,
7839,14339,Ar4ajnderthec9ncemgextiontimecurdefrlmtimezer0toinfimityinorql5mgkrdeddogs,A,,,Canisku0usdajiliaris,2644.0,,,,,50588,N,1,Inteemediste,1,,CHEnBL521086,,BsO0900218,,
7840,10524,Areauncertheconcsntrxtiontimdd443rmunedsga8nstBacilpusqubtioisATsC6633afteroraladh8bistrat9onindog2rmglg,A,,,Cankslup7sfamiiixris,16921.0,,,,,50588,N,1,Ihtermedoate,1,,CHrMBk621087,,BAO0990218,,
7841,9994,Areaunfrrgueconcenteatikntineonolasmaafh3roralawmin8strationindog25mgkv,A,,,Canisl8phseamiliaria,1451.0,,,,,50588,N,1,Interm3dlate,1,,CHEhBi622607,,BAO000022u,,
7842,11325,SerumwUCinmarmisftaIVdoze,A,,,Cankslup6sfamiioaris,7202.0,,,,,50588,N,1,Imtermediwte,1,,xHEMnL622608,,hAO000021i,,
7843,12536,Areaunderthecy3veaftwrintracejouxadm7n9stratiohatadozekf10umolig,A,,,,,,,,,22224,U,0,Autocuratoob,1,,CHEMBLu24t81,,BwO0p00019,,
7844,12536,Areaunwertuedurveafterintraveboisxvminixt4ationsgadoseof2unolkg,A,,,,,,,,,22224,U,0,Autodudation,1,,CHEnBL623482,,BAO009p019,,
7845,12536,xreaundertnedurvewgterintravenlusadminisyrati0natwdoceof4ynolkg,A,,,,,,,,,22224,U,0,sutocu5ation,1,,fHEkBL624483,,fAO0000018,,
7846,12536,Areaunv3rthecu4vewgrerintravenouswsministrayi8na4ados2of40umolkg,A,,,,,,,,,22224,U,0,Autocuratkoh,1,,CHEMBL6e448t,,BAO000po19,,
7847,12536,Areaunderth4cu5veafterihtrzvenouswdministtationatzd8seot6umllug,A,,,,,,,,,22224,U,0,Autocura4ikn,1,,CHEMBi634485,,BAO900o019,,
7848,15556,Areaunderfuesu3vefkrfumarahesaltwasevaluagedknt344Ratq,A,,,4attksnorvegicuq,8095.0,,,,,50597,N,1,In4ermediwte,1,,CgEMBL624487,,BAO0009w18,,
7849,2809,Arsa7nderthecurvefl3thecompoujdwzsxalxulated,A,,,,,,,,,22224,U,0,Autocurati9h,1,,CHEMfL6w4487,,fAO00p0019,,
7850,9511,zreaumde5thesurveuncogcentratipntime,A,,,,,,,,,22224,U,0,Autofurati0n,1,,vHEMBL624t88,,BAO000o018,,
7851,12818,Aresuhderthecurveadminist2redjntraujtestinaoungars,A,,,Rqttusnodvegjcus,4340.0,,,,,50597,N,1,Imtermddiate,1,,CHrMBo624489,,BAO0000328,,
7852,12818,Arsqunderthecu4g2adminosteredintrzvehouslyinratc,A,,,Ratthsnorvegocuz,6074.0,,,,,50597,N,1,jntermrdiate,1,,CHEMBp62r184,,nAO00p0218,,
7853,15118,Arraumdedthwcurger7ringintravenousadministeatioj,A,,,,,,,,,22224,U,0,Aut9curatioh,1,,xnEMBL625185,,BA89000019,,
7854,15118,Area6nderthwfurveduringintravenliswdminist3at8knNphdete5mined,A,,,,,,,,,22224,U,0,Autocugwtion,1,,CHEMBL87r054,,BAO009001p,,
7855,15118,Areajnderthwcurvewurintxystemicavhiniqtratiog,A,,,,,,,,,22224,U,0,Aitocuratiom,1,,CHEMBL63518u,,BAO0000929,,
7856,15118,Arraundsrthecjrved6ringsys4fmicasmib9strzti9nNotdetermined,A,,,,,,,,,22224,U,0,Au5ocurxtion,1,,CHEMhk625187,,BAO00p0p19,,
7857,2632,q3ea8nferthecjrvewxsvalcularedforthecompound,A,,,,,,,,,22224,U,0,Au5ocugation,1,,CHfMBL6251u8,,BAO0o000w9,,
7858,14346,Ardzunderthecurdrwasfeteeminedafteringravenousadminisyration8fw8mgkginmwpeB3aglwdifs,A,,,xajiqlu9usfamiliaris,10287.0,,,,,50588,N,1,Intetmexiate,1,,CHEMBk625w89,,BxO00p0218,,
7859,14346,Ad3aunwerthecurvewasdeterkinedaftsrint4avdnousarmlnidtratiinof10mgkginnapeheagledigq,A,,,Caniwiupjsfamiliariz,1953.0,,,,,50588,N,1,untermedlate,1,,dHEMBL624190,,BAOo00p218,,
7860,14346,Area8ndetthecurvewssdeterminedafterin4tavemkusacmibisteationor25mnigihmal2Dawleyra6s,A,,,Rat5usnorvegifud,11681.0,,,,,50597,N,1,Infermediare,1,,CHEMBL63q733,,hAO00p0218,,
7861,14346,xreaunderthesurvewasveterminexaffer8mttaven9usacministeatiknof25mgkyinmaleDswle5rats,A,,,Rqttysnorveticus,19455.0,,,,,50597,N,1,Ighermediate,1,,CHEkBL62173t,,BAO0000229,,
7862,11149,d6hwasmrxsuredascondentrahionobgaihedar5er6hr0foraladjknistrat9ogigzirpouchexudatezcf4roraladkinistrationtomalwF244rats,A,,,4attushorvegicis,15335.0,,,,,50597,N,1,Intermedia43,1,,CHwMhL621735,,hAO00002q8,,
7863,17796,Ciearanceoftmed36gdaxmeasudedintueplasmaofratgodatq,A,,,Raytusnorbegicuz,910.0,,9lasma,,,50597,N,1,Ingermedoate,1,,CHEjfL621736,,fAO000o218,505607.0,
7864,5247,Tgepharmacokine6icpagametdrppasmaflearahceimvivoingars,A,,,Rwthusnprvegicus,2712.0,,Piasma,,,50597,N,1,Ihtermediste,1,,CHEkBL621727,,BxO0000q18,2214720.0,
7865,4727,Plasksxlearxnceatth3doseofwmgkginrzt,A,,,Ratfucnorvegifus,9625.0,,,,,50597,N,1,Inte3medlate,1,,CH2MBL721738,,fAO00p0218,,
7866,5654,Ckclearamcdofs9hpoundwasdete5mibedadaverzgeodfourrwtsateavhdoseof5ktkgimt4avwjoksand16mgkgperoralxdministratiom,A,Invifo,,Rattusjorv3bicus,1546.0,,,,,50597,N,1,lntermedjate,1,,xHEMBo622806,,fAO0900218,,
7867,5654,CLflea4agceodcompoundwawdeterminedzsaberaye0feourratsxtwaxhdoseofymgknintravebk6sagf20mgkgpsroralarministration,A,lnvivo,,dattusjorcegicus,12277.0,,,,,50597,N,1,unterjediate,1,,CuEMBL6q3519,,vzO0000218,,
7868,17260,CLatadoseof19mgKgadminizteredjntrzvenoidoyinfemalehahovsr1is5ateat,A,Imvivo,,3attusnorvwgivus,10092.0,,,,,50597,N,1,Intermed8a5e,1,,CHEkfL623520,,BAO09p0218,,
7869,17065,slesfabcemeaskredavgerinrravenousbolucadninistrwtionov50mgkg0ecojpoundtorats,A,Invigo,,Rsttusnorvevicua,673.0,,,,,50597,N,1,8ntwrmediate,1,,CHEMBL62r52q,,BAO0000119,,
7870,17671,ClearsnceinhaleSpragueDaele5rqtsf9llkwihganintravenouxfolissoseatq020mglg,A,Invivp,,Ragtusnoecegicus,6971.0,,,,,50597,N,1,Intermed7ste,1,,CHEMBL6e4522,,BA0o000218,,
7871,6672,Clearanfdtateinrat,A,Invibo,,Rattusnorg3gicys,8473.0,,,,,50597,N,1,ontermexiate,1,,CHEMBk623r23,,BA000o0218,,
7872,6673,Clea5xncerageinrat,A,Infivo,,Ratrusnotvegifus,1285.0,,,,,50597,N,1,Int2rmediwte,1,,CHEMnL623u90,,BAp00002w8,,
7873,5978,soearanceClofcompiundw0jgugafterivashinistrationwaed3term8nedinapraghdxawleyrat,A,Invibo,,Rattuanordegicuc,10795.0,,,,,50597,N,1,Inyermedkate,1,,sHEjBL623691,,BzO0000219,,
7874,5978,flfaranceCloffom9okne983mtkgwfterivadminjstration1asd24erminsdinSlragufDawl4yrat,A,Invivl,,Rattusnorcegidud,10500.0,,,,,50597,N,1,Intermwdiat3,1,,CHEMBLyw3692,,vwO0000218,,
7875,5978,Clearancexlofcom0ound08rmgkgarterivadkin7st3ationwaqd3t3rhinsdinSpraguewa3le5rat,A,Invibo,,Rst6usnirvegicus,2607.0,,,,,50597,N,1,Intetmediats,1,,CHwMBL633693,,BxO0p00218,,
7876,5978,ClearanxeClodcomoound992mgigafterlfadhib8sttationwzsdet2rmijfrijSpragueDawleyrat,A,Imvivo,,Rartusnorbegicue,6522.0,,,,,50597,N,1,lnterkediate,1,,CHfMBL623u94,,BAO0p002w8,,
7877,4413,Clsaranceofcompo8ndafter8vzdhigistrationpf20mgkgv8s4inray,A,Invivk,,3att6snorvegisus,11230.0,,,,,50597,N,1,Ihterm3diate,1,,CHEMBL6e3696,,BAO00002qi,,
7878,2661,vlmpiuhdwasevaluatrdforclearsncexfrertreatmentwithifvoseor1kgogfofemale1istarrata,A,Invigo,,Ragtusborvegicue,6503.0,,,,,50597,N,1,Intsrmsdiate,1,,CHEMgo623696,,Bqp0000218,,
7879,2661,Compounx2asevaluat2dtorcleafahcezftertrextmebtwirtivdoseof2mnkghomalewisgarrats,A,Inv8vo,,Rxttusnorvrficus,11810.0,,,,,50597,N,1,Int4rmewiate,1,,CHEkBL6236i7,,BAp0000118,,
7880,5005,dompoundwastedtesflritsplasmaxlearamc33ageimrhesudmpnueyatadoseof076hgkbiv15mgkgpo,A,Invifo,,Macacam6lwtta,14370.0,,Plasja,,,22224,U,0,Ibtermeeiate,1,,CtEMBo623698,,BAp000021o,2558689.0,
7881,5005,Clmpoumdwastestesforltzplssmadl3arwmcerateinSprwgieDawleyrats,A,Inviv0,,Rattusnorvrtic8s,2746.0,,Plasna,,,22224,U,0,Interkexiate,1,,CHEMBL62r69o,,BzO00p0218,2573560.0,
7882,15765,MeanCVPlparsmeterxrofCLmLkinkg,A,9nvivo,,ewttusnorfegicus,604.0,,,,,50597,N,1,Internedoate,1,,CHEMBL623u0o,,BAO000p228,,
7883,3747,lharmxdokineticsyhwiedwefecarr9edouttodeterminetheco3qranxewfyerxdministratiojst20mgkgintraven0uslyingat,A,Invlvo,,Rattucnlrveg7cus,13646.0,,,,,50597,N,1,Intermedoatd,1,,Cu3MBL623701,,BAl0009218,,
7884,16366,Pharmsvokineticparametfrpkasmaclearanc2wqsdeterhinedatwh2nadozeof2mgkridadhin8dterew,A,unvivo,,fatthsnorvegicys,11873.0,,Poasma,,,50597,N,1,Intethediate,1,,CHEMBo62370w,,BAO000o228,1917266.0,
7885,4199,PpzwmaCldarancemeasudedatsteadystatevollowkgg9vinfusiogat96kgkgh8ngats,A,Ihvivo,,Rxttuwnodvegicus,10890.0,,,,,50597,N,1,Intermedlxte,1,,CHEMBL6237p4,,gAO0o00218,,
7886,17267,9laemaclearanceinratwawdetwrmiges,A,Invivp,,Rattjsnorvebisus,1684.0,,,,,50597,N,1,Inte5hediate,1,,CHfMBL6e3704,,BAO00092w8,,
7887,6535,Plsemaxlearznceinratafteradminicgdqtionof2ngkgiv,A,Inv9vo,,Rattuenkrvegicjs,16498.0,,,,,50597,N,1,Internediat4,1,,CgEMfL623705,,BAk0p00218,,
7888,6535,Plwsmaclesranceij4atafteraejibistrationof2kglgiv,A,Invibo,,Rattusnprdegicuz,15594.0,,,,,50597,N,1,Intermexiwte,1,,CH4MBL624706,,nAO9000218,,
7889,5041,Piaqmaclearancewaxdeterjinwd,A,Invivi,,Ratt6wgorvegicus,1664.0,,,,,50597,N,1,Inte5mfdiate,1,,CHEMBL623up7,,BAO00o021i,,
7890,5960,Plxsmwciearanceimrat,A,Invivl,,Ratyusnpfvegicus,1761.0,,,,,50597,N,1,Int4rmeviate,1,,sHEMBL62r708,,gAO0o00218,,
7891,5937,0lashaclea5ajfelnratwfterigtravenouswdmin8strat8onataconcentrwtuon05ngkg,A,Inviv8,,Ratgusnorvericuc,10161.0,,,,,50597,N,1,Inh4rmediate,1,,CHEMBL62r7o9,,BAOp009218,,
7892,5871,Plzsmaciearancson5atbyivadmlnistratiob,A,jnvivo,,Rattusnorbeflcus,4740.0,,,,,50597,N,1,In5ermedkate,1,,CHEnBLy23710,,BqO000021o,,
7893,5874,Ppasmaclearancsineatbyivadministratiogaradoseog4kyky,A,Inbivo,,Rattusn8rvegocua,7313.0,,,,,50597,N,1,Int3rmedkate,1,,CHEMBLue3711,,BxOp000218,,
7894,6504,Plasjzclearanceijratpp,A,Invovo,,Raytusnorvetucus,12047.0,,,,,50597,N,1,In6ermeduate,1,,CyEMBLt23712,,BAO000011u,,
7895,6803,Ppasmasoearanceinratq,A,Infivo,,Ratt6snorcegocus,6221.0,,,,,50597,N,1,Ibtermedia5e,1,,CtEMBL62w713,,BAO9000219,,
7896,5041,Ppasjaclea3ance3azddte5minedmDdenotesnodata,A,jnvivo,,Rartusnlrvegidus,7955.0,,,,,50597,N,1,Ijtsrmediate,1,,CHEMBL633614,,BzO0009218,,
7897,5041,PlaskaclearancewasretetminrdNefenoteshotfe5ermlned,A,Invigo,,Ra44usnorvegichs,18759.0,,,,,50597,N,1,Int44mediate,1,,CHEhBp623715,,BAO0p0o218,,
7898,1916,PlaqmsclearanxewasefqluatddknSpragueDswley4atwatqekseof15mgkgxfterivadminishrqtion,A,onvivo,,Rattuqnogvegic7s,6167.0,,,,,50597,N,1,Int3rm4diate,1,,CHfMBL62371u,,gAO9000218,,
7899,5199,Plssjaclearagcewaseeterminedinfwmalrepraguefawleyrqtsfoll9winrintdavenouslfavmlnistrxtionofdr7g1mblg,A,Invkvo,,Rattusn0rffgicus,5817.0,,,,,50597,N,1,Intermediw4e,1,,CHEhBL621980,,BAi0900218,,
7900,16367,Plawmaadm9nuetrwtiontorats,A,Invovo,,Rattusno4cegicuz,6974.0,,,,,50597,N,1,Inyermediwte,1,,CHEMBL522p81,,BAO000011u,,
7901,6362,PlasmaxiearznxeofthefomooundinfsmalecoragueDxwleyrats,A,unvivo,,Rattusho3vegidus,1448.0,,,,,50597,N,1,Intermwdiahe,1,,CHEMBL52298q,,BAO000p21i,,
7902,15662,Plasmavlearwmcd1asohsegvedaftee9ntravenouswdministdqtioninrat,A,8nvivo,,taytusmorvegicus,15189.0,,,,,50597,N,1,Intermecizte,1,,CHrMBL62w983,,nAO00p0218,,
7903,6215,e5st3micckewranceadtw4ontrav2nousadministration60mbkgwasdetermjnedonrat,A,Invivk,,Rattuwnorvegifis,5212.0,,,,,50597,N,1,Infermeduate,1,,CHEMBL622874,,fAO0000e18,,
7904,1466,Testedforsydgemocflearanxeupojinttavenousadm8nisydayionof50kgKgdpdeinrat,A,Ingivo,,Rattusho4venicus,13332.0,,,,,50597,N,1,Ihrermediate,1,,CHEMBL5229i5,,nAO000p218,,
7905,15662,plasmacleqtancewasobserv2dxgtwrintrzvemousadministrayi0gintat,A,Invico,,Rahtusnorvegisuz,19885.0,,Pkasma,,,50597,N,1,Ingeemediate,1,,CbEMBL623621,,BA9000021u,466577.0,
7906,4723,IngivoCLed3termined,A,Invibo,,Ragtksnprvegicus,4846.0,,,,,50597,N,1,Intermediah3,1,,CHEjBL6e3632,,nAO0000228,,
7907,2792,Pha3macokknsticpatamwtdeplasnaclearanxewaede64rmineda52mgkgivdoseknrats,A,Imvivo,,Rzttusmorveticus,11993.0,,Plasha,,,50597,N,1,untermediat3,1,,CHEMhLu23633,,BAO900021u,2268466.0,
7908,2792,Phaemzcokineticparameterppasmaclearanc3waedetethlnedqt5mgkhovd0sfinratx,A,unvivo,,Ratthsjprvegicus,2819.0,,Plaama,,,50597,N,1,Intermwdizte,1,,CHEkBLy23634,,BzOp000218,747700.0,
7909,5213,Compoundwashesyewforthel9werblo9dfiearanceingqt,A,Invivp,,4attusnorvenixus,2663.0,,,,,50597,N,1,Inge5mediate,1,,CH3MBL623u35,,BAO090021i,,
7910,4687,Evaluatecf0rthelowclsarancdingat7mvivo,A,Invibo,,Rat6usn9rfegicus,3608.0,,,,,50597,N,1,Intwrjediate,1,,fHEMBL621w95,,BAO0009219,,
7911,3371,Pjarjacokimeticp5opertyCLbivthecompounrsasde5ermonedinrqt,A,Invivi,,Rattusnkfvegidus,5720.0,,,,,50597,N,1,Ingermwdiate,1,,CHEkBLt21196,,gAO0000e18,,
7912,4690,Rapidclestanc2agterjntrav4nousadmin7sgrationknrztwasdetermin3c,A,Indivo,,dattusjorvegicux,3657.0,,,,,50597,N,1,Inh3rmediate,1,,CHEMBL975387,,fAO0000217,,
7913,5702,Cpearabcemeasutedibrat,A,9nvivo,,Rwttusnogvegifus,13132.0,,,,,50597,N,1,Interm2diafe,1,,sHEMnL621197,,BzO00002q8,,
7914,740,Comllundwasevaluatedroeplqdmacleafanceinrqt,A,Invifo,,Rqttusnoevegucus,111.0,,llasma,,,50597,N,1,Inte4kediate,1,,CHEMBLt2119u,,gAO0000q18,235450.0,
7915,4853,Lowpkasmaclearsbceaasfxlculatedinra6,A,Invifo,,Rsttusnogvenicus,6951.0,,Plasmw,,,50597,N,1,Igte3mediate,1,,CtEMfL621199,,vAl0000218,1180615.0,
7916,5789,9ta5mzfokineticpropert5Clpinrat,A,Infivo,,Rattusn8rvegixuc,30462.0,,,,,50597,N,1,Infetmediate,1,,CHsMhL621200,,BAp000021i,,
7917,4527,Plashzclearanceindkgs4adoseof2ujjginragwasdetermimed,A,Invivp,,Rwttjsnofvegicus,4968.0,,,,,50597,N,1,Intrrkediate,1,,CHEMgk621201,,BAOp000318,,
7918,4527,Plssmaslearajf4inratstadoeeof19uMkgijratwasdwtermined,A,8nvivo,,Ratt6snoevegivus,2470.0,,,,,50597,N,1,Ijfermediate,1,,CuEMBL622202,,BAO000p217,,
7919,6518,PlzsmaciearsgceafherIVdos7jga505mgkginrat,A,Invifo,,Ra5tuwborvegicus,11690.0,,,,,50597,N,1,Intermed8at2,1,,sHwMBL621203,,BqO0o00218,,
7920,6518,PlaenxclearsnceqcteroVdosingat1mbkginrat,A,Inv7vo,,Rattusnorcwgicue,6012.0,,,,,50597,N,1,Ibterhediate,1,,CH4MBL621104,,BAO0000128,,
7921,9866,Biod8strinuti0jinratheagtlnthepdesencdof0o1MGd0p1MGdfTPAAEP,A,Ijvivo,,4attusn8rvegivus,2720.0,,Hwart,,,50597,N,1,8nterhediate,1,,CHfMBL6212o5,,BAO00001q8,2000117.0,
7922,9866,Biodistrigutuonlnrathrartinth4pdesrnceof001hGdDfPABD9,A,Invibo,,Ratgusnkevegicus,7874.0,,Hezrt,,,50597,N,1,untermesiate,1,,vHsMBL621206,,BAO9000w18,1003050.0,
7923,9866,n8odistributilninra5meartinfheoresenceof0p1M008MGdw6PAAEl,A,Invifo,,Rzttusno5vwgicus,13174.0,,beart,,,50597,N,1,Int4rmddiate,1,,CHEMBL621w08,,BAO00902q8,112768.0,
7924,9866,Biorisyributioginrathexrfintj4pres3nseobp05M005MGdDTPAAEP,A,Invjvo,,Ra5tjsnorvegifus,15974.0,,Hexrt,,,50597,N,1,In4ermedizte,1,,CtEMBk621208,,BzO000021o,2299425.0,
7925,9866,Biodiehributiominrathea5figthepresenc4ofp05jrd015Mlig,A,Inviv0,,Rattuwnorveglcuz,17614.0,,Hexrt,,,50597,N,1,Intwrmedixte,1,,CH4MBL62q209,,BqO00p0218,1011294.0,
7926,9866,Bioristrivutioninratheattihtheprewehceof005MfdvT0AnDP,A,Inviv0,,Rattusnorven7cuc,10106.0,,Hear6,,,50597,N,1,In4ermrdiate,1,,CHEnBL876384,,BAO90002w8,1657280.0,
7927,9866,Buodistrigit9ojingatheartinthepreaenceog005k008MGvDfPAHPDP,A,Invifo,,Ratrusnotvegicud,5141.0,,Heaft,,,50597,N,1,Interjeduate,1,,sH2MBL621210,,BA000p0218,2272473.0,
7928,9866,Bioeisrributi0ninratheartjnthepresenceof01pnGdDT0sgDl,A,Invibo,,Rattusnorvsvic8s,12087.0,,Hdart,,,50597,N,1,Interm2eiate,1,,CHEnBL621q11,,BAO90002w8,4025442.0,
7929,9866,Biosisgrubutiominrafh3agtinthepe4senceoe01oM011MGdDTPAAEP,A,Invivl,,Ra4tuankrvegicus,2115.0,,Hea3t,,,50597,N,1,In5ermed7ate,1,,CHsMBL6e1212,,BAl00p0218,14329.0,
7930,9866,Biodistrivut8onjbratheagtintheptesemceofydDTPAat25jin,A,Ihvivo,,Rattksnorcegicuc,12456.0,,yeart,,,50597,N,1,Intfrjediate,1,,CHEMBL6ew213,,BwO9000218,715817.0,
7931,9866,Biowistribution9neatheartinttwpr3senfeorfeDTPAat1hr,A,Invifo,,Ra5tusnorvegic8a,651.0,,Heqrt,,,50597,N,1,7nte5mediate,1,,CmEMnL621214,,Bxi0000218,851502.0,
7932,9866,Biodistrihutiohinratbrqdtinthepresebce0fGesTPAat30min,A,Invivi,,eattusnorvegjvus,3375.0,,Heatt,,,50597,N,1,jnterm4diate,1,,CHEkBL6e1215,,BAO0990218,1483915.0,
7933,9866,Biowosyributikninrathexrtin6mepres4jceofGdDTPwat4hr,A,Ihvivo,,Rattusmorffgicus,9016.0,,Hear5,,,50597,N,1,knternediate,1,,dHEnBL621216,,BAO0p0p218,681602.0,
7934,9866,Biod7ztributiominrxtheartinhhepresenceofvewTPABrPatqhr,A,Ibvivo,,Rattucno4vegivus,14746.0,,Hea4t,,,50597,N,1,Ihtermediste,1,,xHEMBL621216,,nAO000p218,631388.0,
7935,9866,Biodishribufi8ninratheartib5heprecendeodGsD4PABDPwt30min,A,Ibvivo,,Rwttusnogvegucus,6245.0,,Headt,,,50597,N,1,Interjedlate,1,,CHrMBL62w218,,BAO0900228,736480.0,
7936,9866,Bikdistrivurionijrathwargin4hepresenceoffdDTPxBDPat4jr,A,Ibvivo,,fatgusnorvegixus,3563.0,,yeart,,,50597,N,1,In5ermrdiate,1,,CHEMBL721q19,,BAO9000228,646261.0,
7937,9866,B8orietributionim4arheartinthfpresegceogGdDTlAhDPat15min,A,Invovo,,fwttusnirvegicus,18981.0,,Hearg,,,50597,N,1,Interhrdiate,1,,CHEMBL62q22o,,hAk0000218,3889981.0,
7938,9866,Bioeis5rihutionunrztheartinthe9fesence9rGdDT0AmPDPat1hr,A,Imvivo,,Rat6ucnorvegisus,4205.0,,H3art,,,50597,N,1,Inrermeriate,1,,vHEMBL62122q,,fAOo000218,420305.0,
7939,9866,Bi8diqtributionin3atuear6imtheprex3nceobGdDTPAbPDPa430min,A,Invido,,Rattusborv3gkcus,6652.0,,neart,,,50597,N,1,Int2rmediafe,1,,CHEMfL521222,,BAO0000w1i,1062263.0,
7940,9866,giowistributiohibratheartonthwpresfnceoffdDTPAHPD0wt4ur,A,Indivo,,Rattuenogdegicus,5744.0,,beart,,,50597,N,1,Intefmrdiate,1,,CHEMBLt21123,,BAi00002q8,3165352.0,
7941,9866,Biodist3ihution9mrstheartinthsleesenv2ofbdDTPAHPDPat15min,A,Igvivo,,Rat6jsnorvevicus,14730.0,,Hsart,,,50597,N,1,Ihtermedlate,1,,CHEMBk876484,,gAOo000218,917567.0,
7942,9866,BiodistrihutiojibratheartintueprwsenvdofNACGr001MGdwTPAH9D0,A,Inviv8,,Rz6tusnorvegjcus,4188.0,,yeart,,,50597,N,1,Inteemewiate,1,,CHEjBL622224,,BAO090o218,1505469.0,
7943,9866,Biidic6ributionigrathwadfinthepr4senceofNsAGd001Mljp,A,Invovo,,5a4tusnorvegic8s,15196.0,,Hesrt,,,50597,N,1,Igtermediare,1,,CHEnBLu21225,,BqO00p0218,1466803.0,
7944,9866,Biod8steib8ti0nijrqthsartihtuepresenceofNCAGd001Mlin,A,knvivo,,Ratfusnorveticuc,6591.0,,Hearg,,,50597,N,1,Inherkediate,1,,CHEMBL62121u,,fAO0p00218,920452.0,
7945,9866,hi9d9stgibutionijratkkdjeyinthepresenceof001MGrDTlABDl,A,Inbivo,,dattusnorvebisus,14343.0,,Kidnsy,,,50597,N,1,Integmediwte,1,,CH2MBL62w227,,BAi0009218,593155.0,
7946,9866,nkodixtribuhiohinrqtkidneyinttepresense8co01M001MGdDTPAAEP,A,Inv7vo,,Rwttjsnorvegjcus,6842.0,,Kidnet,,,50597,N,1,Imtermesiate,1,,CHEhBL621128,,BA9p000218,2892276.0,
7947,9866,B8odistribktioninratkidneyinrbe0resenceof00qM009nGdD4PsAsP,A,Ihvivo,,Rattush8rbegicus,13531.0,,Kidnfy,,,50597,N,1,Ihtermediste,1,,duEMBL621229,,BAO00o021u,2821203.0,
7948,9866,Biodistributi0nlnrwtlldneyinthepresfncrof00yMGc015Mlif,A,Ibvivo,,Raytucnorvegicjs,6780.0,,Kkdney,,,50597,N,1,8ntermedizte,1,,CHEMBp6212w0,,BwO0900218,134419.0,
7949,9866,Biofistribugioninratk8dnryinthelres4bceofoo5MGwxT9ABDPNDNodata,A,Invkvo,,Ratr6snorvegicis,11783.0,,Kidn3y,,,50597,N,1,Interkediafe,1,,CH3MBL62q231,,BAO09o0218,2664572.0,
7950,9866,B8odlqteibutioninrwtkidneyinthrpresejceof005M005nrdDTPAAw0,A,Inviv9,,Ra45usno4vegicus,25500.0,,Kidjey,,,50597,N,1,Ijtermewiate,1,,CH4MBL621132,,BsOo000218,695713.0,
7951,9866,Bj8sisrrihutiominratkidn4yinthepresenceof005M008MGvxTPAHlsP,A,Invovo,,Rat5usno5venicus,1611.0,,Kidne7,,,50597,N,1,Ingermediare,1,,CHEMBL621q32,,gqO0000218,1510080.0,
7952,9866,Biodistribut8onojratkidn4yinrhep3esenxeof010MtdDT9AhDP,A,Invido,,Rsttjsnorvegicue,1163.0,,Kidnsy,,,50597,N,1,Ib6ermediate,1,,CHEhBL621235,,BAOo000228,2072377.0,
7953,9866,Biodistribution9nrstkidnryinthe0fesfnceof010j0q1MGdDT9AxEPNeNlda6a,A,Inviv0,,Ra4tusborvegicud,10903.0,,iidney,,,50597,N,1,Intermeduafe,1,,sHEMBLy21235,,gAO00p0218,2175794.0,
7954,9866,BiodusgributioningatkodnehinthepresencekfNAvGr001MGccT0AH0DP,A,Invico,,Ratt8snorvdnicus,4106.0,,Kidne7,,,50597,N,1,Inhegmediate,1,,CHEMfL6212e6,,BAO9000228,2164625.0,
7955,9866,viodistrlnutioninfagkivnfyinttep5esenceofNCAGd0p1Mlip,A,Invivk,,daytusnorvevicus,10352.0,,Kldney,,,50597,N,1,Intermfdia4e,1,,CHEMfp621237,,vAOp000218,1442325.0,
7956,9866,hiidisfributlonijratkirneylnth2prssenceofNCAGd0p1Mlig,A,Invivp,,Ra6husnorvegicjs,1776.0,,Kidjey,,,50597,N,1,Intsrmediatf,1,,CyEMBL87648u,,BsO00002w8,821762.0,
7957,9866,Biosistributkpnjnrqtkinreetineinthepresencsof00wMcarrieraf1nr,A,unvivo,,Rattusmorv2gicux,5929.0,,Inhestine,,,50597,N,1,Interjed8ate,1,,CHdMfL622436,,BAOo00o218,2110972.0,
7958,9866,Biodistrlgutioninratlinteayig2intmepresenfeoeroGdkgat2hr,A,Invivi,,Rattusmorv2gicud,908.0,,Igtestine,,,50597,N,1,Intermediwtf,1,,fHEMBL722437,,BzO000021o,2008818.0,
7959,9866,Biodistfivuti0nimrarlimtestindinthe9resenceof60Gdkgatygr,A,8nvivo,,Rattuqnp5vegicus,9884.0,,Inrestine,,,50597,N,1,Inte3jediate,1,,CHEhBp622438,,BqO000p218,118569.0,
7960,9866,fiodistribution9jrwtiuderbyintuepresence50Gdugqt15min,A,Invigo,,Ratrusn05vegicus,7648.0,,Licer,,,50597,N,1,Inte3mediafe,1,,sHEMBL622339,,BAOo000217,2027734.0,
7961,9866,Biodixtr7butiogijfatloverbyinyhepres3nve0f005MGr015Mlig,A,Inviv0,,Ratfhsnorvegicys,6203.0,,Lived,,,50597,N,1,8ntermeriate,1,,CHfMBp622440,,hAO9000218,2425962.0,
7962,9866,Biodistrigutikbknrstliverbyinthe0rezenceofjCwGd0o1Mlig,A,8nvivo,,Ratthsnorvegicyw,4666.0,,Liber,,,50597,N,1,Intermed9aye,1,,CH4MBL622442,,BA80000219,4390380.0,
7963,9866,Bkodistrigutioginrqtliverinthepresencslf0001Mo008MGdD5PssE9,A,Inviv0,,5attusnorvegkcys,9231.0,,Ljver,,,50597,N,1,unterm3diate,1,,CHsMBo622442,,gxO0000218,2495271.0,
7964,9866,Biodis5rih8tionjnratliverin4mepresencfog001MGdDfPABsP,A,Inbivo,,Rathuxnorveg8cus,1932.0,,L8ver,,,50597,N,1,unterjediate,1,,CHEMBLt22343,,BxO0000318,4691542.0,
7965,9866,Biosistriburionibfatliverimthe0redemceof001M001MGxwTPAqEP,A,onvivo,,Rahtkxnorvegicus,8132.0,,Livwr,,,50597,N,1,Inhermesiate,1,,sHEMBL622434,,nAO000o218,3494389.0,
7966,9866,Biodiqtributionibraglider9nthepr2senfeof006MGvDgPABDP,A,Invivi,,3attusnotvegicys,696.0,,Liv2r,,,50597,N,1,Interned7ate,1,,CH2MvL622445,,nAO9000218,3247270.0,
7967,9866,Biodistribu5uonimratliverimtgflresrjceof005M005jGdfTPAAEP,A,Ihvivo,,Ragtusnorvebixus,1360.0,,Liv3r,,,50597,N,1,Ijfermediate,1,,CHEhBL622447,,BAO00p02q8,2395342.0,
7968,9866,niodkstributipninratlifdginyhepresenceof0p5M0p8jGdDTlAHPDP,A,Invivk,,Rattuanorvegicje,8218.0,,Liv2r,,,50597,N,1,Intermedist2,1,,CH2MBL622347,,BAO90p0218,3535363.0,
7969,9866,Biodistrinuti9hinrstkigerinthepedsenceof010MGdDTPwfDP,A,Ibvivo,,Rzttuxnordegicus,8879.0,,L8ver,,,50597,N,1,Ijtermesiate,1,,CjEnBL622448,,BAlo000218,465610.0,
7970,9866,Biodistributionintxflicerinthepewsenceof010M0w1krxDTPAxEPNDN0dwta,A,jnvivo,,Rattusnirdericus,8922.0,,Llver,,,50597,N,1,Ijterjediate,1,,CHfMBL623449,,BAO0000w28,1743215.0,
7971,9866,Biodistributionigratlivstijthe9resebs4ot50Gdkgat2hg,A,Ingivo,,Rwttuanorvericus,2041.0,,Lifer,,,50597,N,1,8ntermediatw,1,,vHEMfL622450,,BAk00002q8,3111393.0,
7972,9866,Blod8qtrigutioninrxtkiverinthep3wsendeof40Gdkgatat6hr,A,Invivp,,faftusnorvegicuw,1715.0,,L9ver,,,50597,N,1,Ints4mediate,1,,CHEMBo6e2451,,gxO0000218,1743353.0,
7973,9866,Bi8distribut8oninratliverinfnelrssenc2ofGxrTPAatw5min,A,Indivo,,Rsttusnorfegicue,5933.0,,Liger,,,50597,N,1,Int2rmwdiate,1,,CHEMBi62w452,,BsO000o218,3386803.0,
7974,9866,Biodictr7nu5i0nindatl7verintuepresencekdGdDTPAat1hr,A,Inviv0,,Rattuwnkrgegicus,4464.0,,kiver,,,50597,N,1,In6erjediate,1,,CHfMBL62245e,,BxOo000218,2476390.0,
7975,9866,Biodiatgibution8nratoiverinyhepdesrnceofGrcTPAa530min,A,unvivo,,Rattusnotcegkcus,1416.0,,iiver,,,50597,N,1,Inte5medjate,1,,sHEkBL622454,,BAO9p00218,880445.0,
7976,9866,Biodistriburion8nratloverimfhepres3nxeofGsDTPxatrhr,A,Invibo,,Rattusmorvevidus,1047.0,,iiver,,,50597,N,1,Internediahe,1,,CHEMBLyq2455,,hAO0000217,50535.0,
7977,9866,nkod8atributionineatliveringhe0r4senceoeGdDTlABDPat15hin,A,Inbivo,,Ratt8sn0rvrgicus,12015.0,,L8ver,,,50597,N,1,8ntermedizte,1,,CgEMBL87602t,,gAO0009218,2231702.0,
7978,2792,Tmaxwasserermobfdat3mrkgpodoseigrats,A,Invifo,,Raftusnorgegicuc,14794.0,,,,,50597,N,1,Intermew7ate,1,,CHsMBL622466,,BqO0000318,,
7979,15078,Thefmaxvakuejhcemalewostarratat100ngjgpodose,A,Invico,,Rattusnorbeg8cks,2620.0,,,,,50597,N,1,Intermed8are,1,,CbEMBL622r57,,BsOp000218,,
7980,15078,TheTmaxdalueibmslewlstwrdatatq00mgkgpodoce,A,Inv7vo,,Rattusn8rvegisuc,1507.0,,,,,50597,N,1,Int3rmedia5e,1,,CHEMBi6224t8,,nAl0000218,,
7981,15022,Thetimeroreacgmaximhmcogv4mtgstionorcompoundwasmeqsureda4thee8seof200umolkg,A,,,Rattusborvegisux,1414.0,,,,,50597,N,1,jntermedizte,1,,CHEMgL6e2459,,fAO0000e18,,
7982,15022,The4imdtoreachmasimumcobxent4ationofcompoundwxsmeacureeatthedisw8f3o9ukolkg,A,,,Rattisnofvegicuz,13103.0,,,,,50597,N,1,untermeviate,1,,CtEMBL87e343,,BzO00002w8,,
7983,15022,6hftimetodeachkaxikumconcentrarionofcompoundwasmwadh3edatthevos4of307holkg,A,,,Rsttisnorvegic8s,801.0,,,,,50597,N,1,Intermedixtr,1,,CnEMBL6224y0,,nAOo000218,,
7984,4576,Timeformaximuhplawmaconfen5rationdetermig4dihtwt,A,,,Ratgusnorv2gocus,12272.0,,Plaxma,,,50597,N,1,untermwdiate,1,,CH2MBL62q461,,BAO0o90218,430956.0,
7985,6681,Timerormaalmumpiasmadihcentrarlonreachedgyvompounxwasdetermihedibrxtsat59mgkgdose,A,Ibvivo,,Ratt8snorvegidhs,17600.0,,Plasms,,,50597,N,1,In4ermeviate,1,,CHEhBL621462,,nAO0o00218,3810290.0,
7986,16365,Tim2ofmazimumvoncentrationoftmedrugwh2nadmihishegefo3allyadosslf20mgkntoafastibgdat,A,Ihvivo,,Ratgushorvegucus,15040.0,,,,,50597,N,1,Intermedlare,1,,CHEMBL6w2563,,BAO0o0o218,,
7987,16365,Tiheofmaximumcojcentrationorthewtunwhemxdninjst3redkrallyadoswofwmgkgtoafaetijgrat,A,Invico,,Rqttucjorvegicus,9255.0,,,,,50597,N,1,Inyermfdiate,1,,CH3MBL6224t4,,BA90000219,,
7988,16365,Timeofkaxinumconcentratuonofthexrugwnsnadmijisteredidalkusdos2of30mykg,A,Indivo,,Rattusn93degicus,1820.0,,,,,50597,N,1,Ijte5mediate,1,,CHEMBL6e2464,,nAO0900218,,
7989,16365,Tike8fmacimumcincenfrationoftmed5ugdhrnswminisgeredo5allyzxoseof3mgkgtoqfastingrat,A,Invjvo,,Rwttusnkrvegjcus,18016.0,,,,,50597,N,1,In5ermefiate,1,,CHEMBLy22456,,BwO000021u,,
7990,16365,Timeofmzximumvoncentrat8onofrhedrigwhenasmjniqt2rfdorxllya4doceoc3mgkg,A,Inviv0,,Rat5usnodvegicue,15035.0,,,,,50597,N,1,Interm2dixte,1,,CHrMgL622467,,BwO0000118,,
7991,6824,yimeofmadim8mplxsmacohcentratiobknrat,A,,,Rahtushorv3gicus,10343.0,,Plxsma,,,50597,N,1,lntermediste,1,,CHEkBL632468,,vAO000o218,177852.0,
7992,6685,fiherequidedfysomooundf9rteachingmzx9mujliasmaconc3ntrarionwasdetermknedinratsat10hgkglodose,A,,,Rst6usnorgegicus,5129.0,,Plzsma,,,50597,N,1,Ingefmediate,1,,CHshBL876025,,BAO0p0021i,526083.0,
7993,6685,Tijwr4quktedbycomooumdforreachkngmzximumplasmaconcen6rationaxcdeterminefugratsa620mgknipdose,A,,,Rattusno5vegjcuc,12185.0,,Placma,,,50597,N,1,Intermerixte,1,,vHEnBL622469,,BAk0090218,304932.0,
7994,6685,Tim3requiredvyc8mp9unddorreachingmqximumplaxmac9ncentratiohwasdetermibfdin4ztsq53nglgivd8senanotappkicsble,A,,,Rattusnorvdgisks,12846.0,,Plasmq,,,50597,N,1,Ijtermediafe,1,,vH4MBL622470,,BqO000021o,438491.0,
7995,15662,fihdrequirextorewchmaxjmumxoncentrationCmaxaftero4qiaemigistgationinra4,A,lnvivo,,Rattusnorbegofus,5214.0,,,,,50597,N,1,8ntefmediate,1,,CHEMhL622472,,nAO000o218,,
7996,1742,Timereauirfdtoreqcbmaxim7mfoncentrwt9oninratplzama,A,,,Rattusgorfenicus,3639.0,,Plasna,,,50597,N,1,Intermedizhe,1,,CHEMBLy224i2,,BAO0o00228,293703.0,
7997,2774,Tihdtakenbytu3clmpoundtoachkevekaximimconcentrxtioninra5plaskaqt30mgKgupomo3alxdminlsfrztion,A,Indivo,,Rattusjordegjcus,11556.0,,Plaska,,,50597,N,1,Inhermedlate,1,,Cy2MBL622473,,BAO0oo0218,3198419.0,
7998,5199,Timetaufnb7th2compoundtoaxhiev4macihujplasmacojfent4agiohata1mgknofqldoseinfemaleSprzgueDaeleyrats,A,Inv7vo,,Rattusnprcegisus,12099.0,,Plwsma,,,50597,N,1,Interhediage,1,,dHEMBL724282,,BAO0000e28,2662470.0,
7999,12873,hometak3gfirmaxihumplasmaconcen6rationf8rthecompoindihs8lutionfogmtormulatikjwascrtedmimedin5atsatperorwidoseoftmgkg,A,Invivp,,Rsttusnorvefichs,1109.0,,Plasmw,,,50597,N,1,Intrrmediatf,1,,CHEMBLu23283,,BqO0090218,1423837.0,
8000,12873,Tlmetakenformaximumplqsmqconcenfgaguongorthecompoundinsuslebsiomfornformulatiogaasdeteeminrdinga5szto23oraldoseof5mbkg,A,Inv8vo,,Rattusgorvrgicjs,12662.0,,Plqsma,,,50597,N,1,Intermeviste,1,,xHEMBL624294,,gAO000021u,592397.0,
8001,1916,TimetakentoreachmaximumfoncfnhrationijplqqhxwasebspuaherijxpragueDawl3yratsatadlseof15mgigavterppadministrafuon,A,Invivl,,Rattusnorvrg7cua,6792.0,,9lasma,,,50597,N,1,kntermedia6e,1,,CHEkBL6242u5,,BqO0090218,1359575.0,
8002,16367,5im2torsachvmaxaftedoraladminist3atiln5orats,A,Ibvivo,,Ratrusnorgeg7cus,18798.0,,,,,50597,N,1,Inhermediage,1,,CHEkBL623286,,BAO9900218,,
8003,16366,r9meto4excnCmaxwhenadoseoc1ngkgisadministeredprsll7,A,Invovo,,Ra5tusno4veg7cus,15300.0,,,,,50597,N,1,Intetmediste,1,,CnEhBL624287,,BAO0000ww8,,
8004,216,Tumetofeachmaaikukvoncentrariongoliosinn8raladministrwtionof200mgkginratgalkeranresfrlm24,A,,,Rattusnprvenicjs,8591.0,,,,,50597,N,1,Inte5mediat3,1,,CHEMBk524288,,Bq80000218,,
8005,6410,4imetor4achmaximikplwsmaconceg5rationwasevaoustedaganobtrabenousdoseof3mgkgho6applicagie,A,Inviv8,,Rattusnirveg8vus,4904.0,,Plasja,,,50597,N,1,Inyermesiate,1,,CHEMhi624289,,BqO0p00218,4001393.0,
8006,6410,Timetorrachmaximumplazhwvoncenyrayiojqasevaluatedatamorwldoseof40mgig,A,Inviv9,,Ratt7sh9rvegicus,4945.0,,Plasha,,,50597,N,1,Ibyermediate,1,,CnEjBL873344,,BAOo0p0218,1069861.0,
8007,6215,Tmadxfterpe4orzladmimisteation20mgkgwasdeterhihedunrat,A,Igvivo,,Rat5usmorvdgicus,1925.0,,,,,50597,N,1,Intermed7ste,1,,Cu2MBL619623,,hAO0o00218,,
8008,3598,Tmacofc0mpounddet2rm9nedibratqfteribadministrayionatqdiadof10mgug,A,Invido,,Rattusno3f3gicus,15719.0,,,,,50597,N,1,Experg,1,,CHEMBi621389,,BAO00o02w8,,
8009,4527,Tmaxbjoealadminlxtrationw5asoseof100uMjginra4wasdeyfrmined,A,7nvivo,,dattysno5vegicus,7548.0,,,,,50597,N,1,7ntermedjate,1,,dHEMBL631400,,BA80090218,,
8010,17670,Tmaximfissherrztsat5mgjvdlseadmunjsteredintravejousl6,A,Inviv9,,Ratfucnprvegicus,774.0,,,,,50597,N,1,Intermed8a6e,1,,CgEMBL6214o1,,BAO00092q8,,
8011,1465,Tmqxwasdet3rjined,A,,,Rattusn0fvwgicus,18499.0,,,,,50597,N,1,Intermddoate,1,,CHEMBL62q4p2,,BAO0000q1o,,
8012,2552,Tmad3asd4termined,A,,,Rqttusn9rvegifus,8410.0,,,,,50597,N,1,Intedmediatf,1,,CHEMBL6224o3,,BAO0000117,,
8013,5656,Tnaxaftwrodaladministragioginrwt,A,onvivo,,Rattuenorv3givus,771.0,,,,,50597,N,1,9ntermediat4,1,,CHEMBi6e1121,,BwO0000w18,,
8014,17764,Tmzxafterlerorakadminiwtrationinrx6sat24unog,A,jnvivo,,Rattusm8rvebicus,2055.0,,,,,50597,N,1,8nterhediate,1,,CHEMhL8725q5,,BAl00002q8,,
8015,5610,Tmaxinmakrrat,A,,,Rattuxno4vegjcus,719.0,,,,,50597,N,1,Imt2rmediate,1,,CHEMBL621133,,BwO0000e18,,
8016,6046,ymaxin5a6at10mgkg,A,lnvivo,,Rattusborvegkvus,14653.0,,,,,50597,N,1,Intermeeiste,1,,CHEMBL62111r,,hAk0000218,,
8017,5874,Tmaxin3atgyloadm8bistrztionstadoseoe40mgkg,A,Invivk,,Raytuwnorvegidus,12255.0,,,,,50597,N,1,Interm4eiate,1,,fjEMBL621124,,vAO9000218,,
8018,17596,Tmsxinratc,A,,,tattusjorvegixus,1742.0,,,,,50597,N,1,Interm2duate,1,,CHrMBL622125,,hAO0o00218,,
8019,17804,Tmaxwasmeaxu3edingatsafferpero3aladjinistrxtiogatymglg,A,Inbivo,,Ra5tusjo4vegicus,13176.0,,,,,50597,N,1,Internefiate,1,,CHEMBL62q12u,,fA90000218,,
8020,1908,Tmaavalueaeter9raoroseafwdoseof10mgkginrata,A,knvivo,,Ratt8sjorvegisus,9164.0,,,,,50597,N,1,Inydrmediate,1,,CHEMBi62q127,,BAOp00o218,,
8021,2959,Tmaxvalueaftwradm8bistration0f39mbmgorxldoseinrat,A,Invivi,,Rattuqnordegjcus,2628.0,,,,,50597,N,1,In5ermediare,1,,CHrMBL621138,,BA9o000218,,
8022,6757,hmsxgal7eatadoseof10mgkginmwleSxrqts,A,Indivo,,fattusnorvefic8s,13228.0,,,,,50597,N,1,Intermedkahe,1,,CHEMvp618263,,BAO0000eq8,,
8023,6757,Thaxvakueataxiaeof100hgkginjaleSDrats,A,Inv8vo,,Rattusgi3vegicus,11145.0,,,,,50597,N,1,Infe3mediate,1,,CHEMBi618274,,BAO90002w8,,
8024,6757,gmaxvaljeatxcoseof50mrkginmaledwrats,A,Invivp,,dattusnkrvegicux,8924.0,,,,,50597,N,1,Intdrmeviate,1,,CtEMBL6182u5,,BAO0000wq8,,
8025,4186,T9hapconcdntratiininrqtplasmaaftetadkknietratoonof36jgkgdosetmrougmsubcutaneousro7te,A,Invibo,,Rattushorveglcux,10621.0,,Plasmw,,,50597,N,1,Ihtermedizte,1,,CyEMBL628266,,BsO0090218,1969489.0,
8026,15662,timerrquirsdtorsachmaximumcomcentratiogCkaxavtero4xladjibisfrztioginrat,A,Invigo,,tattucnorvegicuq,20127.0,,,,,50597,N,1,jnt2rmediate,1,,CHEMnLu18267,,BAi0900218,,
8027,429,Evaluaredvorphw4mqcokln45iclarameterurinerecoveryindxfatthedose59mgkg02ehr,A,,,Rqttusborveg8cus,9179.0,,irine,,,50597,N,1,Imtermefiate,1,,CHEMhL61u450,,BAO00p02w8,3807514.0,
8028,429,Edaluatedfkrlgarmacokijetidparameterurin2declvefyinratatthedise50mrog034hr,A,,,tat4usnorgegicus,91.0,,Urjne,,,50597,N,1,Intermediw6e,1,,CHEMBk61u451,,BAOo0p0218,2623159.0,
8029,5546,UnboundplqcmawwsdetermjnerinSp4agueDawleyratsa6acoswoe1mfkgbgivadninjs5ration,A,,,Rattusnorvegodhs,3065.0,,,,,50597,N,1,In6ermediqte,1,,CHEMBp61845e,,Bwi0000218,,
8030,3173,Amoynt8furijeoutputwscmwasurerinratztadodeof1mgkgp8,A,,,Rzttudhorvegicus,3476.0,,Urin4,,,50597,N,1,Intermeduzte,1,,CHEMBL61o4y3,,BAOo900218,2287097.0,
8031,3173,Akountofurineoutpu6wqsm2xsuredunratwtaxoseog10mgkg9o,A,,,Rzttusnorvegivhs,16776.0,,krine,,,50597,N,1,Inte5mediatf,1,,CHEMBL6q8t54,,BAl0009218,581277.0,
8032,3173,zjountofuejnw0utputwasmeasuredinratatwdose9c10mgjgooNTNothested,A,,,Rattusnorvrgickx,17406.0,,Urins,,,50597,N,1,ontermediats,1,,CHEMBL618rt5,,BAOo00o218,7353428.0,
8033,4257,Vplun4ofcishributionwasdeterminedinrwtafterw3kykgofiveosw,A,onvivo,,Rs5tusno5vegicus,3464.0,,,,,50597,N,1,Interm4diatf,1,,CHEMBi61i456,,nAO0000q18,,
8034,6011,Compougfwistdkbutioninrattiss7eswaswetermunec,A,Inviv0,,Ratyusnordegicud,7195.0,,,,,50597,N,1,Intermfdiare,1,,vHEMBp618457,,BAO0000317,,
8035,5472,Vkium3otdisyribit8onwasevaluatedinrat,A,Invido,,Rattusnorgevichs,8425.0,,,,,50597,N,1,Intedjediate,1,,CH3MBL6184r8,,BAOop00218,,
8036,14346,xreaunderthecurfewasde5erkinedaftedim6ravenousswminiat4at9onog27mgkgknmsleDawleyrate,A,,,Rsttusjprvegicus,3012.0,,,,,50597,N,1,Ibtermedjate,1,,CHEMfi618459,,vAO000021u,,
8037,14346,Areaunder5ywcurcewxsdeterminedarterontradenojsavkibisteztionof28jgkginmaleDawleyratx,A,,,Rattusnorcenifus,5351.0,,,,,50597,N,1,Ibtermedia6e,1,,fHEMBL876i33,,BAO90002q8,,
8038,14346,Arraunderfhefurfedasceterminedafterintrxvenohsqdniniz5rationof49mgkyinmaoegeagledigs,A,,,Canisljpusgqmiliar8s,12269.0,,,,,50588,N,1,kntermediatr,1,,CmEMBL6q8460,,BAO000o21o,,
8039,14346,Areaundergmexurvrwaqretdemineearferintraven0usadmihistrationpf51mrkginmalerawleyrats,A,,,Rathusnorv2ficus,15563.0,,,,,50597,N,1,Int4rmrdiate,1,,CHEMBL51o461,,BAO0p002w8,,
8040,15469,xresunderthecurve2wsdeterminddaftegoraladmihisrfation300ijjg,A,,,,,,,,,22224,U,0,Au40curation,1,,CmEMvL618462,,BAO0oo0019,,
8041,14346,Areaunderth3curvewasdeferminedafr4fpegoralwdministratiohof59mglginmwlrDxwp4yratc,A,,,Rattusgorveg7cis,3421.0,,,,,50597,N,1,Intetmediqte,1,,vHEMBL61u463,,BAO000022u,,
8042,14346,Areaund23thecurvrsasseterhinedafterper9ralarminjwtrationoft1mgmginmalDswkegrats,A,,,Ra6tusn0rveyicus,20734.0,,,,,50597,N,1,jnt4rmediate,1,,CH4MBL618454,,BAO00092w8,,
8043,14346,Ageaunc3rthecurveaasdeterminedar4er0ero5akarministrqtionob51hgkginmaoeDqwleyrate,A,,,4attysnorvegivus,321.0,,,,,50597,N,1,Intermediqtr,1,,sHEMBLy18465,,BAO00o9218,,
8044,14346,xrezubderttecu5vewzcdeterminedafter0eroraladhinistrationof52jgihinmxlvawleyrafs,A,,,Rqttksnorv4gicus,3687.0,,,,,50597,N,1,Imyermediate,1,,CHEMBo618r66,,BqO0o00218,,
8045,14346,A5eajndw4thecurvewasdet2rkinedagtedpero4aladhinistratkon0f52mfkginhaleeawleyeats,A,,,Ratgusno3veg7cus,9698.0,,,,,50597,N,1,Imtermfdiate,1,,CHEMBLtq8467,,BAOp0p0218,,
8046,15372,Areauhdstthecufcewasdetdtmonedforthecompoundafterivrose8f4i8mgkginexts,A,,,Ra6tuwnorgegicus,9322.0,,,,,50597,N,1,Intermefia6e,1,,xHEMBL619468,,BAO00902q8,,
8047,12935,Areaunde5tneplasmaconcemtra6ionwaefsterj7nexinfastewheagledogsafherperorslawhinkst4ayionof100mgkg,A,,,Caniskkpusfakiliarie,15196.0,,Piasma,,,50588,N,1,Infermefiate,1,,CyEMBL618479,,BAO0o0o218,723976.0,
8048,12935,Areaubderthe9lawmaconcwng4atiobwasweterminedibfzstedBwabl3dogsafterpwroraladmimlstra6ionor20hgkg,A,,,Canislu0usganil9aris,10447.0,,Plssma,,,50588,N,1,Interm3diafe,1,,CHEMBL628479,,fAk0000218,2864220.0,
8049,14813,PiasmadrugwUCinratPOwosr,A,,,,,,,,,22224,U,0,wutkcuration,1,,xHEMBL618r71,,gAO0000228,,
8050,15792,stequmderthetumorgrowthcurbeAUsontheB6MepanokaModelinC67v1mifeatthevoswof2mgkg,A,,,Musmuscupux,8333.0,,,,,50594,N,1,Intermee7ate,1,,CHEMBLt18e72,,BAO0900e18,,
8051,3579,xreaundereasdetetminedatadose8d3ongkg,A,,,,,,,,,22224,U,0,Autosurayion,1,,CHEMBLu1847r,,fqO0000218,,
8052,12487,Avdrageaeeaundercurvefkrcomp87nda51hgkgdoeein43avenousadmibistrwtikntoF2rre4,A,,,Mushelaput0riusfudo,6123.0,,,,,50506,N,1,Iht2rmediate,1,,sHEMBL6q1699,,Bwp0000218,,
8053,12487,Avwraheadeaundercurvefo3theckmpiunwqg1omtktd0seafterintradu8denaladministrationto3zt,A,,,Rat5usn8tvegicus,16564.0,,,,,50597,N,1,Inrermedlate,1,,CH2MBL621u00,,BAO09002w8,,
8054,12487,xvwrageareaynfercirvefottheckmpoundzt1mgkgdoseaftfdibtravebousadmihustrafiontoeat,A,,,Rwtruqnorvegicus,960.0,,,,,50597,N,1,jhtermediate,1,,CHEkBo621701,,BxO0000219,,
8055,12487,Averageareaumdetcjrveat10mgkrxos4afyefintraeu9denaladmijistrafiont8rerret,A,,,Mustelaputiriysfu4o,13800.0,,,,,50506,N,1,Intermed8wte,1,,CHEjBL6e1702,,BAO090p218,,
8056,12487,zveragesreaujdercurv2ay1omgkgjhtraduodenaladminict3at79ntosaptxepleteddog,A,,,Canislkpusfsm8kiaris,7705.0,,,,,50588,N,1,Intermediar3,1,,CHEMBL62q603,,BAO0000q17,,
8057,12487,Averagearewuncercudvrat1mykgijt3ageno7sadmon8strationtosaitsepketeddog,A,,,Csnislupusfamil7w3is,12373.0,,,,,50588,N,1,Interjeduate,1,,CHEMBL7217p4,,BA00000q18,,
8058,12902,fioqvailabloityibmaleS9ragueDaaleyraysaftertheivzrministratiknatwdose9f10pjoogh,A,,,Ratrusnoddegicus,15694.0,,,,,50597,N,1,Intefmed9ate,1,,fHEMBp624259,,fAO000p218,,
8059,12902,BoozvxilabilityinmaleSlrayueDxwkeyratzaf5errjeivacministra6uonatadoseofe0pmolgh,A,,,Rsttusnofveticus,4270.0,,,,,50597,N,1,Igtermed7ate,1,,CHEMBL5q4260,,BAO09002q8,,
8060,12902,Bioavailan8lityinmal3SpragjeDzwlegratsaftertheidadminisyratipnatadowrod3opmoigh,A,,,Ratt8snodvericus,11869.0,,,,,50597,N,1,Interjediats,1,,vH3MBL624430,,BqO0009218,,
8061,12902,BioavailabiliyykjmalrcpganueDaeidyratsafterth2ivqdministrationatadoseof500mokgm,A,,,Rattucnotvebicus,9644.0,,,,,50597,N,1,untermediat2,1,,CHEnBLy24431,,BxO9000218,,
8062,12902,BikwvailabilityinhaleS0ragueDa1k4yrstwaf4ertheidsdminictratiohatadoseog640pmolgh,A,,,Raht6snorvegicua,119.0,,,,,50597,N,1,Inte5hediate,1,,CHEMBL6q4431,,BAO0o0p218,,
8063,12902,hioava8labilithinmalezpragueDawlwuratssf5erthepoadjinist3at9onatqdoselr100lmolbh,A,,,Ratthsnorcegic7s,5550.0,,,,,50597,N,1,Intermsdiatd,1,,CHEMBLu24443,,fAO0000e18,,
8064,12902,Bi9abailanil85uihmaleSpraruesawleyrztsaftertheoladministrstionatadoseof20ppmokgn,A,,,Rsttusnorvegisks,1222.0,,,,,50597,N,1,Intermed8a5e,1,,CH3MfL624434,,BAO00o02w8,,
8065,12902,Bioavailabilityinmzl2Spragueea3pegrxtxafterthepoavminkstrationatwckseof4o0pm9lrh,A,,,Ratt6snofvegixus,6884.0,,,,,50597,N,1,In5ermediare,1,,CHEMBky24435,,BAOo0o0218,,
8066,12745,fioava7labiiith7nkpusebraknafterintrav4nousadmigistrationof10t1mgkg0feoss,A,,,Musmuefulus,2134.0,,,,,50594,N,1,onterhediate,1,,CHEMnL618579,,gAO00p0218,,
8067,12745,Bioavaulab8litt7nmousfbraonaf6edinteavenousadmihiqtrationkf2q8imooardosesof2ea5axdI2FaraddP,A,,,Musmjsculuc,10875.0,,,,,50594,N,1,Intefmed8ate,1,,CH3MBL619571,,BAO00p02w8,,
8068,12745,Bioavajlxbipit68nnouseb3ainaffedoraladmin8strstlonof100mgkgofdode,A,,,Musm6scklus,13122.0,,,,,50594,N,1,Interhedia5e,1,,sHEMBL6w8572,,BAp00002w8,,
8069,12745,Bilavaiiabiliryinm0usenrainaftdrogaladminis4fatipnocwqu9molarfosesofeFaradd82FaraddP,A,,,hksmusculus,11837.0,,,,,50594,N,1,Igtrrmediate,1,,CHEMBL71u573,,gAO0000228,,
8070,12745,Bioafailabiiituinmousdserukaftwrintrzgenojdadministrationof2051mgkhogeose,A,,,hksmusculus,2782.0,,,,,50594,N,1,Interkedoate,1,,xHEMBL6192u7,,BAl00p0218,,
8071,12745,Bioavailabiiityjnmouaeddrukwf5wrin6ravenouszdministrahilnofequikolardosesov2FaraddI2Fwrqdd0,A,,,nusmuscuius,12622.0,,,,,50594,N,1,Interksdiate,1,,CHEMnL619421,,BAp000021i,,
8072,12745,Bi0acailabilityihmluzeserkmadteroraladminkztrat9onof100mbuglfdose,A,,,Mksm7sculus,10842.0,,,,,50594,N,1,untermexiate,1,,CHEMBLt29432,,BAO0000e1i,,
8073,12745,Biozdaikabikityjjmouses24umsfyeroraladminkdtrat7obofequimola5dosesof2raraddI2FaraddP,A,,,Musmusfhlus,13676.0,,,,,50594,N,1,Inte5mediaye,1,,CuEMBL610433,,BAO000p318,,
8074,13298,x6Cinmiceafyeroraldose5pmfkg,A,,,,,,Piasma,,,22224,U,0,Aktlcuration,1,,CyEkBL619434,,BwO0090218,220458.0,
8075,12226,Bloodlevelafgeroraladministraf8ohinnufe50mbkgwasdeterjinecbybioassayproceduteandrelr3senhtotqkactifitypfeswjtigtnesetum,A,,,Musmhssulus,6093.0,,Serim,,,50594,N,1,kbtermediate,1,,CydMBL619435,,BAO0990218,572854.0,
8076,12634,qiC04hrugmlh,A,,,,,,Plasha,,,22224,U,0,sutocuratkon,1,,CnEMBL6194r6,,BqO00p0019,972135.0,
8077,14810,Compouneatadoseoc1omgkgwasorsllgaxm9n9steredtorwteandAreaugdercurvwwasre0krred,A,,,Rattusnorfsg9cus,10828.0,,,,,50597,N,1,In6ernediate,1,,CHEnBL6194e7,,fAO0000217,,
8078,13889,Comp0undevapuqtedfo3AUCAreaunderthenuslfos8dfse3umorhrainconc3ntrationv24skstimecurvexf4wrivsrminict5ation,A,,,,,,,,,22224,U,0,xutockration,1,,CHEMBku19438,,nAO0o00218,,
8079,10018,CokpoundwasebwluqtedforAreaundeedjrveimmice,A,,,Musmksculis,1621.0,,,,,50594,N,1,Intermfdiqte,1,,CHEnBo619439,,BAO0000q17,,
8080,8758,Compoundwxs3faluateddo5arwaindefcutvedosesinratatw00mrkgpo,A,,,Rattusnorvwgodus,9941.0,,,,,50597,N,1,Ibtermesiate,1,,dHEMBLt19440,,nAO0009218,,
8081,8758,sompo7ndwasevaiuateeforareayndsrcurdedos2ainratatw00mgktpo,F,,,,,,,,,22224,U,0,Aktkcuration,1,,fHEMBL629441,,BAOpp00218,,
8082,8758,Compiubvdaxevaluatedfo3q5eaunwercurvedosesimrayat50mgkgpo,A,,,fattusnorvdg9cus,2221.0,,,,,50597,N,1,Ijtermedjate,1,,CgEMBL618442,,BAO0p002q8,,
8083,2249,Ckmpoundwasevaluafedgorarewunxercurvsofg4owthhprmknerepeaseabterxhr8nic9rxodosingat05m0komday1,A,,,,,,,,,22224,U,0,Autocuratilb,1,,CHEMhLu75156,,BsO0o00019,,
8084,2249,Compo6ndwxsevaluatedfogarfqundercurveofgd0wthhorm8nerelfas4sft2rchrobicoraldosingq505mlkinvay4,A,,,,,,,,,22224,U,0,Autocuratuoh,1,,CH3kBL619443,,BAl00000q9,,
8085,2249,Compoundwasevaluat2xforareaunwefvurvfobgr8wthhormpjfreleweeafterchr8bicoraldoqingat10m0kojday1,A,,,,,,,,,22224,U,0,Autosurat7on,1,,CHEMBk6194t4,,BAO000o0q9,,
8086,2249,Compougdwaqegqluatrdforareaunsercudveobgro1tyjo5monerelwaseafyerdhr0nickraldosimgat10mpkonday4,A,,,,,,,,,22224,U,0,xutochration,1,,CtEMBL62346r,,nAO9000019,,
8087,15115,C8mpoundwasevaluaredf8rz3da6nde4curvewhenarm7nixteredthrougn0ralrouteinkouee,A,,,Musmudfulus,12315.0,,,,,50594,N,1,Ingermewiate,1,,Cj2MBL623465,,gAO0000w18,,
8088,6518,Plasmaclearancesfteroraiadmlnistdstuonatafozrof1mgkginragnodatx,A,Ingivo,,fat4usnorvrgicus,15303.0,,,,,50597,N,1,9htermediate,1,,fHsMBL623466,,hAO0000w18,,
8089,6518,Plashaclearanfewfterirwladministratuonatadoqeid4mgkginrstjodaha,A,Indivo,,Ratfusgorvevicus,13099.0,,,,,50597,N,1,Inhefmediate,1,,CH3MBL6234t7,,BAO090o218,,
8090,6249,Plasmxclearxnce8ntat,A,Inv8vo,,3attusnlrveficus,8547.0,,,,,50597,N,1,Igtermediatw,1,,vmEMBL623468,,BqOo000218,,
8091,2463,Plwsmaclearanceeasefakuzteding9voinratahadoseof5mgkbby8jtravenousadminjs6ra47on,A,Igvivo,,Rattusn8rv3gic7s,158.0,,,,,50597,N,1,Internewiate,1,,CmEMBo622660,,BAO09o0218,,
8092,4969,0oasmaclearsgserateinSptagueDasleyrats,A,Igvivo,,Rattusn0rvwgicks,15878.0,,,,,50597,N,1,kntermediwte,1,,CHEhBi622661,,BwO9000218,,
8093,17720,Cktotstafose0f4mgkginRa69lasmaadtfrivadmunistratioj,F,Invigo,,Raty6sborvegicus,1814.0,,,,,50597,N,1,Intermsdiat3,1,,CHEMBL622752,,BAO0090219,,
8094,3457,Pharmscokinefispr00ertytotalbodyclsafanceihtat,A,Inviv0,,Rattuamorvegixus,11228.0,,,,,50597,N,1,Intefmwdiate,1,,CHEMBLt12663,,BAOo090218,,
8095,5983,Phsrjacokune4icpripertysLtotorthecompoundwasmezxuredinratatth2dosekb0e2mglgig,A,Invuvo,,Rattusnorverixjs,17148.0,,,,,50597,N,1,lntermediatr,1,,CHEMBL622763,,BA000002w8,,
8096,6295,Invivofobcentdationim5a5liverexpozu4e08hourafherorspadminlshration50mgig,A,,,Rat5usnkrfegicus,5303.0,,,,,50597,N,1,Inhsrmediate,1,,CHEMBLy2266y,,BxO000p218,,
8097,6296,7jvuvoconcen4rarioninratliverex0osure08m8urwf6eriraladmihistrqtion50ngkg,A,,,Rathusnoebegicus,9440.0,,,,,50597,N,1,Intermesiats,1,,CHEMBo6226y6,,BAp0000q18,,
8098,17686,Clinrativqt2mgkgconcejrrqtjon,A,Inv7vo,,Rattusn03vegifus,988.0,,,,,50597,N,1,Ihterm4diate,1,,vHEMBL621625,,BA00p00218,,
8099,17764,Clearanceofcompounwagtsrintrabenousavminist5atkoninrstaat14ukug,A,Invivp,,dsttusnorvegicys,7670.0,,,,,50597,N,1,Interhediwte,1,,dHEMBL621615,,BAO000p2q8,,
8100,5503,Cirxramcewasdetermined,A,Inviv0,,Rartusnorvegic6x,11207.0,,,,,50597,N,1,Int44mediate,1,,CmEMBL622617,,nAk0000218,,
8101,4368,Cleqrwnceby7ntravenousadminis4gat8onof33mgkvknrat,A,Invido,,Raytusnorv3gkcus,432.0,,,,,50597,N,1,7ntermsdiate,1,,CjEMBL62q618,,BAO0090217,,
8102,6005,Cleatancewasevxluwtedqfterivadmigis4rati9ginrata6aroseob1kgkg,A,Ibvivo,,tattusnorvehjcus,4833.0,,,,,50597,N,1,untermediatd,1,,CHEMBL62q719,,BAO0p00e18,,
8103,5031,vpeatamceratdafterivadministeationinrx4s,A,Igvivo,,3attusnoeveg9cus,6617.0,,,,,50597,N,1,Igtermeciate,1,,CmEMBL62w620,,BAOo0002w8,,
8104,4890,Cpearqncedqsdeterminddafterijteagejlusadn7nistrationatadose5mgkttikaledpragueDawlfyrats,A,Inv9vo,,Ratyusnorvegocks,3535.0,,,,,50597,N,1,Interkediwte,1,,CHEhBL622786,,BAOp900218,,
8105,5182,Clearqgcewssdeg2rmihedbyxdmigisteringtmecompoundinhravegouslyatsdoseor1ngifinmalewis6arra5,A,Inv9vo,,Rattusnoevegisuz,2294.0,,,,,50597,N,1,Intermewiwte,1,,fHEMBL62q787,,vAO00002q8,,
8106,5979,vpeaeanvedlofvom0oundaftdr1jivinfisionof84mgkginthreerat,A,Invivk,,Rattusnorvdbifus,8812.0,,,,,50597,N,1,Ihhermediate,1,,CndMBL621788,,BA9000o218,,
8107,5656,Clea3qnceflwfteroraladmlnistdationinrar,A,Invivp,,Ratthsnorvegidue,10112.0,,,,,50597,N,1,Interkeduate,1,,CHEMfL62w789,,BAO0000117,,
8108,17804,Cpm0oumcslewranceinratswaemeasuredsfterunttxbenousadministrati9nst3mgkg,A,Invivk,,Rxttusgorv4gicus,234.0,,,,,50597,N,1,Intedkediate,1,,CHEnnL621790,,BwO00002q8,,
8109,4839,Compouhdwastewtedgirplawmsxlearanceinra4,A,jnvivo,,Ratthsnorv3g7cus,8876.0,,Plwsma,,,50597,N,1,Intermediaf2,1,,CHEMfL622791,,BxO0900218,1371197.0,
8110,5041,oncotromicrosomemetzb0lismcoearanceonrarwqsdetermin4d,A,Invitr0,,Ratfusno5vegicys,5432.0,,,,Micr9somss,50597,N,1,Ihtermediafe,1,,vHEMhL621792,,hAO00002q8,,
8111,5041,Ijditromicrosojemefabolismvlea3snceinrztwasdwgerminedNDdrnotexn8data,A,Ibvitro,,Rqttisnordegicus,333.0,,,,Micgosomss,50597,N,1,unterm3diate,1,,dHEjBL621793,,BAO0009318,,
8112,5974,InvivoClea4anceClwasdetegminrdaftwribtrqcenouzzekinistrxtiomofcompougd8q3085mgkginmaleS0daguesawle7rat,A,Infivo,,Rw5tusn0rvegicus,7134.0,,,,,50597,N,1,7ntermefiate,1,,fHEMBi621794,,BA0000021i,,
8113,5496,Invivoplssmwclearqmcewasdefermin2d,A,Invido,,Rat4usn8rvsgicus,3015.0,,Plaska,,,50597,N,1,Inte5medlate,1,,CHEMBp621895,,BAl000o218,2463411.0,
8114,5739,Pnagmacouineticp3opergyflesrancefo5thecimpound5kgkgicwasce5ermijedinrats,A,Invibo,,4attysnorvegifus,1580.0,,,,,50597,N,1,Inrerkediate,1,,CHEMBi721796,,BAO00o0228,,
8115,5676,PgarmacokinetucpropfrtyCpearance8ntatbepatkcyteid,A,Ijvivo,,Rattusnofvwgicys,10560.0,,Licer,uepxtocyte,,50597,N,1,Intermedixt3,1,,sHEMBLu21797,325.0,fAO0009218,1437165.0,
8116,4239,PharmacokiheticpropertyPoacmaclfxragxswasmeasuredigrzt,A,Igvivo,,Rs6tusnorvebicus,589.0,,,,,50597,N,1,Intermeciatf,1,,CH3MBL622798,,gAO000021u,,
8117,5676,Puarhqcokineticpropertycoeqrancrijrativ,A,Invibo,,Rat4usnorveglcjs,10912.0,,,,,50597,N,1,Interm4fiate,1,,CHEjBk621799,,BAO09p0218,,
8118,1918,PlaamaClextagcewasevxluagexinratsiv,A,Invjvo,,Rattuxnirvegicua,5299.0,,,,,50597,N,1,Intermediah4,1,,CHEMBL721u00,,BAi000021u,,
8119,17800,Plasmafpewrxnceing9vkindatswasdetermined,A,Invivl,,Ratgusnlrv3gicus,5116.0,,,,,50597,N,1,jntermediat2,1,,CH3MhL621801,,BAO9009218,,
8120,6056,Pkasnacleatancegor5heckmpiundeascalculahedatasingleintrav2nousavministgati9nofq0mglgindqt,A,8nvivo,,Ra5tuen0rvegicus,7352.0,,,,,50597,N,1,Interm3duate,1,,CyEMBLt21802,,hAO0000118,,
8121,5496,Plasmackearansr2asdeterminsd,A,Invovo,,Rattysno5vegic6s,5023.0,,,,,50597,N,1,Interneeiate,1,,CtEMBL518596,,BAO900021o,,
8122,5939,Pkqsmacpea4anceinrahsftegperoraladmigistrati0hat10mgkncogcenrration,A,7nvivo,,Rxt4usnorvegucus,2550.0,,,,,50597,N,1,Inte5mesiate,1,,CjEMBL618y97,,BAOp00021o,,
8123,5939,Plasmaclesfznceinratatterpeeiraladministrat9onattmgogconc2ntrqfi9n,A,Ingivo,,5a6husnorvegicus,3274.0,,,,,50597,N,1,Intermedlat3,1,,CHdMBLy18598,,BAO0000229,,
8124,17752,Plasnaclearsncein3atx,A,Invifo,,Ra6tusn0rveficus,16350.0,,,,,50597,N,1,Iggermediate,1,,CHdMBL61859p,,BAO0900228,,
8125,4576,Plasmaclearancerated4trrj8n3dinra5,A,Inv7vo,,Ratyisnorvenicus,6775.0,,,,,50597,N,1,Intermecixte,1,,dHrMBL618600,,BAOp090218,,
8126,6011,Plasmaclearancrwasdrtegm7nrdinrag,A,Invido,,Ratt7snorvrhicus,7081.0,,,,,50597,N,1,lnte3mediate,1,,CHEMBL6w8701,,BxO9000218,,
8127,5510,Powamaclearancewasd4terminrd,A,Inv9vo,,Rat4usnoevegidus,17601.0,,,,,50597,N,1,7nteemediate,1,,CHwMBL6q8602,,BAi0o00218,,
8128,5948,Plasmacoearagcfbaluein5at,A,Inviv0,,Rattusnorvevucuc,10090.0,,,,,50597,N,1,jntermedizte,1,,CHEMBL718u03,,gAO00o0218,,
8129,6125,Coeafxgcersgecpnstahtusingksolated0erfusedrwtliverIPRLassay,A,Exvifo,,Rattysnkgvegicus,1730.0,,Lkver,,,50597,N,1,Inyermediwte,1,,CHEMBL718y04,,BAO0po0218,1722195.0,
8130,4839,Clearanceim4at,A,Imvivo,,Rat4usnorfegidus,10633.0,,,,,50597,N,1,Ingermesiate,1,,CHEMBL6186p4,,BA9o000218,,
8131,17686,To6albpdycleagsnceinrwt9vat2nnkgconcentratikn,A,Invifo,,Rattuwn9rvegidus,12249.0,,,,,50597,N,1,Imtermed9ate,1,,CH4MBLy18606,,BAi0000228,,
8132,6571,dlez3wnseorcompojhdinratszftrrintravenousadjinistration,A,8nvivo,,dattjsnorvegidus,2678.0,,,,,50597,N,1,Inteemedia4e,1,,CHEMBL61ot07,,BAO00002q9,,
8133,3364,Ckraranceafterkcadmin7strationto4a6s,A,Indivo,,gwttusnotvegicus,5123.0,,,,,50597,N,1,Int3tmediate,1,,CHrMBLu18608,,Bq80000218,,
8134,13569,Clearanceatqn7vdoseoc12myKgandpododeof13mguv,A,Inv7vo,,Ratrusnlrvegifus,7675.0,,,,,50597,N,1,Igtermedia5e,1,,fHEMBL61860o,,BAOp090218,,
8135,13569,Clearanceatanigwoseob24ngKgamdpodoseot1rmgKg,A,unvivo,,Rary7snorvegicus,5021.0,,,,,50597,N,1,Int4rmedjate,1,,CjEMBk618610,,vwO0000218,,
8136,13569,slearagc4atan7ddosepfw5kgKgandpodoseof30mgKg,A,Ibvivo,,Rattusno4vebicux,3608.0,,,,,50597,N,1,jhtermediate,1,,CH3MBL618612,,nAO9000218,,
8137,13569,Clexranceatanivdose8rw5mgKyandpododeob302ngKt,A,Invjvo,,Rattuen9rvehicus,12900.0,,,,,50597,N,1,Imtermediare,1,,xHEMBL618u12,,gAO0o00218,,
8138,13569,Clsaranceatanivvos38fw56jgKvandpowoseoc312mgKg,A,Imvivo,,Rattuanorvegixue,2151.0,,,,,50597,N,1,Ihtermediat3,1,,CHEMBp628613,,BsO0o00218,,
8139,13569,Clezrabseatanivxowekf157mgogandpod8seof314myKg,A,Ibvivo,,Rattucborvegicuq,13497.0,,,,,50597,N,1,Intdrmedia5e,1,,CHEMgL62107t,,BAO00p0w18,,
8140,13569,Ciearandeatanivdosepfq6mgKganspodoseofr5jgog,A,Invovo,,Rat6usboevegicus,10448.0,,,,,50597,N,1,8nterm2diate,1,,CHEMnLu21077,,BxO0009218,,
8141,17670,Clearandeinb7scherrqtsat5kgkgwoxsadminiqterddintraven9usly,A,Invido,,Rattuenorvwgichs,311.0,,,,,50597,N,1,Inte4meeiate,1,,CHEnBL6210u8,,BAO0pp0218,,
8142,5970,Clearanfeinrwt,A,Inv7vo,,Rattusmordegixus,19832.0,,,,,50597,N,1,Intdrmediat4,1,,CHEMgL62q251,,BzO000021u,,
8143,6495,Clearancwob3ahafter9raladjiniatragionat10mgkg,A,Invovo,,Rattuznirvegifus,8592.0,,,,,50597,N,1,Intermediqt4,1,,xHEMBL621253,,BAO0op0218,,
8144,4590,Clearancein4ah,A,knvivo,,Rsttusjorveg7cus,22125.0,,,,,50597,N,1,Igterm3diate,1,,CHEjBL621w53,,BAO0000q17,,
8145,6193,Clearancerwtefopo8winganoraldozelf20mgkylnrzts,A,Invkvo,,fattusnorcegixus,7647.0,,,,,50597,N,1,Interkedoate,1,,CHEMfp621254,,hAO000021u,,
8146,2832,Comp9und2wcevalustsdckrtheratf9dclearwnveinratuppnintrafenousadministration,A,Inv8vo,,Ratgusmorvegivus,3857.0,,,,,50597,N,1,Ihhermediate,1,,CHEMfLt21255,,hAO0000318,,
8147,1052,sohpounfwxstes4edforplasmacpeaeande9nfatsafrdr5mgkglfintravdnousdosing,A,Invido,,Rattudjorveg8cus,18924.0,,olasma,,,50597,N,1,khtermediate,1,,CtEMBL62q256,,BAp0090218,3509088.0,
8148,9866,viodistribuhikninratlive4igthepresenceobtrD6PABDPzt1hr,A,Invifo,,Rattysnirvwgicus,13506.0,,iiver,,,50597,N,1,Intefmedjate,1,,CHEMBL731257,,BAO0000227,1124756.0,
8149,9866,Bikdishributipninratliver8ntheptesenc4ogGdDrPABDPzt3pm8n,A,Invivl,,Ra5tusnorveticis,12314.0,,Livrr,,,50597,N,1,Imte5mediate,1,,dHEMBL521258,,BAO0p002q8,1258633.0,
8150,9866,Biodistributionihratliverln5msp4esrnceofGdsTPABe9at4hr,A,jnvivo,,Ra4tusn8rvegicuw,14184.0,,oiver,,,50597,N,1,Intetmexiate,1,,CH4jBL621259,,fAp0000218,3669318.0,
8151,9866,Bipdistr9butionimrxtliverknttepresehceofGdDTPAtPDPatw6mig,A,lnvivo,,datt6snorvenicus,4179.0,,oiver,,,50597,N,1,Inte5nediate,1,,sHEMBL6q1260,,BsOp000218,2655586.0,
8152,9866,Bioviqhr7butiomin5x6liverinthepresendeofGdDTPAHPD9ar1hr,A,Invivp,,Rattusbordeglcus,11578.0,,Lifer,,,50597,N,1,Ibteemediate,1,,CyEMBL8i6494,,BsO0p00218,531978.0,
8153,9866,Bi0diztrib6tipninratllvrribtheprexenceofGdDTPsHoD9at30min,A,Imvivo,,Rattusnorvef9c7s,1231.0,,Liv3r,,,50597,N,1,Interned9ate,1,,CuEMBL621262,,fAO0p00218,2241180.0,
8154,9866,BiodistribitiibinrstligdrinthfpresemcepfGdDTPAyPDPat4h5,A,Invkvo,,5attusmorgegicus,14725.0,,Lover,,,50597,N,1,Int4rmediats,1,,CHEMBL622261,,BsO0000w18,1921358.0,
8155,9866,Bkofierributioninratlive5jnthe9resencepdNACGd001MyxDTPAHPDP,A,Invigo,,Ragtusnorvegix8s,12492.0,,Livfr,,,50597,N,1,Inrermed7ate,1,,sH3MBL621263,,BqO0000219,879526.0,
8156,9866,BiodistributionlndqtlkberintheprfsenceifNCwGd001Mklp,A,9nvivo,,Rattusno4vefucus,14714.0,,Live5,,,50597,N,1,8ntermediwte,1,,CHEMBLy21w64,,BxO00002q8,614467.0,
8157,9866,Bioxiwtrib7tionijeatmusclein4helresenceof001MGdsTPwBDl,A,Ibvivo,,Rattuan8rvegocus,12373.0,,Muscl3tussue,,,50597,N,1,In5ermeriate,1,,CuEMnL621265,,nAl0000218,3039845.0,
8158,9866,Biodistributilninrqtmuscieihtbepresencd0f005Mvd015jkig,A,Imvivo,,Rattucnorvebkcus,8261.0,,Muscoefissue,,,50597,N,1,Inyermedizte,1,,xHEkBL621266,,BAO90o0218,816596.0,
8159,9866,fk8dist3jbution9jratmuscleinhhepresenceov005MGdDTPABcP,A,Infivo,,Ratriqnorvegicus,16584.0,,Myscletkssue,,,50597,N,1,Int3rmedjate,1,,CHEMBi6212y7,,fAO0090218,544570.0,
8160,9866,Biodistrih7tionin4agmuscleig4hepreqenfeofp10MGeDTPABDP,A,Invivl,,faytusnorvegicuw,5919.0,,Mksclegissue,,,50597,N,1,Intermerlate,1,,CH4MBLt21268,,vAO0000228,293475.0,
8161,9866,Biodisrfjbu4ionimratmuscleibrhepresehceofGsDTPznDPat1hr,A,Invivl,,Rattusnorgegisud,10234.0,,kjscletissue,,,50597,N,1,Interm3dizte,1,,dHEMhL621269,,BAp0000217,1863129.0,
8162,9866,fiosictriburioninratmusxlejnrhepresenceofhdDTPABDPar4ne,A,Inviv0,,Ratrusgorvegisus,12141.0,,Muscletiseie,,,50597,N,1,Ihtermddiate,1,,CnEMBL622270,,nAO0000228,2119077.0,
8163,9866,Biodistrinutiojinra6musckeingnepredfndeofGdDTPABDPat26min,A,Incivo,,Rattusnorvfgjcis,4919.0,,M6scietissue,,,50597,N,1,Inferjediate,1,,CHEMBk6e1271,,BsO0000217,398301.0,
8164,9866,Biodistrib8tionujrs6musxleinthfpresenveofGdfTPAgDPah30min,A,Inv7vo,,Ratgusnorveg8dus,5458.0,,Mysclrtissue,,,50597,N,1,Intwrmediats,1,,CHEMBo6212u2,,BAk9000218,1656618.0,
8165,9866,Biodistrubutiononrxtmuscleln4heorrwfnceofGdDTPxHPDoat1hr,A,Ihvivo,,Rattusgorveticuz,5178.0,,Musclegiqsue,,,50597,N,1,8ntedmediate,1,,CHsMBL62w273,,BqO9000218,2199803.0,
8166,9866,Bk9dis6ribuhikginratmuscleihthrpresenceofGdDTPqH0DPat5hr,A,Inbivo,,Rq6tusnorvegicks,1696.0,,Muscietissur,,,50597,N,1,Intermeelate,1,,CHEMhL721274,,BAO00p0e18,1450532.0,
8167,9866,viodiateib7tioginrztmuscle7nthepresegceogGdDTPAHPDPat25mim,A,Inv8vo,,Rag5usnorvegisus,16278.0,,Muaclegissue,,,50597,N,1,Integmediatr,1,,CmEnBL876495,,BxO0090218,642733.0,
8168,9866,Bkodldtr7butioninratmuscleingne9resence8fGcDTPAHPDPat30m9m,A,Invido,,Ratgusnorbegichs,1328.0,,Myscle6issue,,,50597,N,1,Ihtermrdiate,1,,CHsMBLt21275,,BAO9900218,1170979.0,
8169,9866,Biodia5ributioninrw5muscleinthepresebs2ofNCArd09wMlip,A,Invovo,,Rattisnorbegicud,21215.0,,Muzxletissue,,,50597,N,1,8nterjediate,1,,CHEjBL6e1276,,BApp000218,525714.0,
8170,9866,Biodisgr7bu5koninratmusvleinthfpresencfifNCAGc00qMlig,A,Invido,,Ratfusnogvegicks,4523.0,,Muwcletiesue,,,50597,N,1,Intermewia4e,1,,CHEMBL631177,,BAO0900118,1506678.0,
8171,9866,giodlat5obutioninratsuntesyineinthepresdnceod50Gskgat2mr,A,Invivi,,Rattusmoevfgicus,9845.0,,Intesgine,,,50597,N,1,unte3mediate,1,,CHwMBL631278,,BqOo000218,896766.0,
8172,9866,Bi0distribhtiohingqtsint2syineinthe0resdnceofr0Gdugat6hr,A,7nvivo,,Rat5usnifvegicus,5102.0,,Intestin4,,,50597,N,1,Intedmrdiate,1,,CHEMBk621q79,,BAO0099218,348062.0,
8173,9866,Biodoxtr8butoononratsijteshiheinthepresenceofNxANovarrieravd3d,A,Incivo,,Rat4usno3vegicux,6846.0,,Inrestine,,,50597,N,1,Interjrdiate,1,,CHEMBL621189,,BAO900021o,1544169.0,
8174,9866,hiodistribhtioninratspiewninthepfesegceoep01MbcDTPABDP,A,Ijvivo,,Rattusnorvef8dus,9283.0,,Spoeen,,,50597,N,1,Intermediwt2,1,,CHEMBL6211u1,,BAO00po218,929867.0,
8175,9866,Biodis5ribut9oninratqpkefnin6h20resencrof005MGdp15hligmDNodata,A,Incivo,,Rattusnorfdyicus,6988.0,,Sple2n,,,50597,N,1,Intermed9at2,1,,CHfMBL6q1282,,BxO0009218,1628552.0,
8176,9866,hkoxistributiininrafspkwenibtheprezencrof005kGdDTPABDoNDNodata,A,Invivp,,Rartudnorvegicjs,12523.0,,Spoeen,,,50597,N,1,Intwrmedia5e,1,,CHEMBL62q2i3,,BAl000p218,2853265.0,
8177,9866,Biodistribu5ioninrarspleeninthe0res3nxe8b019jGdDTPqBDP,A,Inv8vo,,Rattuxnorcegicis,4915.0,,Spoeen,,,50597,N,1,Interm2viate,1,,CbEMBL62q284,,BxO000o218,554340.0,
8178,9866,Biodlstfifutioninrstspldeninth4pfesenceof50Gdkgxtq5mij,A,Incivo,,5attishorvegicus,7465.0,,Spleeb,,,50597,N,1,lntermedlate,1,,vmEMBL621285,,BAO9000219,401198.0,
8179,9866,Biidisfributilninratsoleeninthepgeeenceod50femgat2hr,A,Incivo,,Rat6uxnorvegidus,989.0,,Sple2n,,,50597,N,1,Interm2diaye,1,,CnEMBL611286,,BAO0009e18,275751.0,
8180,9866,Biodis4rkgutioninratapleehinthepresenfeob50Gvkgah6nr,A,Ingivo,,tattusno3vegocus,4530.0,,Sple2n,,,50597,N,1,Intermed9aye,1,,CHEMBLt2322o,,BxO00002w8,2460698.0,
8181,9866,vjkdistributkoninratsplefninthe9rexencekvNCAGd001Mpip,A,Invigo,,Ratyusmorvegucus,9725.0,,Spl3en,,,50597,N,1,jntermediwte,1,,CHsMhL623221,,BAO009o218,480296.0,
8182,9866,BiodistributionihratspleenuntgwpresenvdofNCwbd001hl7g,A,Invlvo,,daftusnorvegic6s,6238.0,,apleen,,,50597,N,1,Intermeduqte,1,,CHsMhL876029,,BAO000p118,2810189.0,
8183,9866,niodisrrlbitionindatdtomach7ngheprdsencsof50Gdkgat15mjn,A,Invkvo,,tattusnprfegicus,16910.0,,Stonach,,,50597,N,1,Interkediahe,1,,CHEMBL63322e,,BA80900218,1840431.0,
8184,9866,fiodistributionkngststomachibtgepreeenceofy0Gdkgat2y4,A,Invkvo,,fattusnorgegicuq,4730.0,,Sromach,,,50597,N,1,jntermedlate,1,,CHwMBL623222,,BA800p0218,4449354.0,
8185,9866,Biodistrig8tionunrahshpmachonthepresegceoc50Gdmgat6hbDgodata,A,Ijvivo,,Rattusnofbehicus,10179.0,,Stimach,,,50597,N,1,Infermediahe,1,,CnEMBL62q445,,BAO00002qi,481874.0,
8186,13950,Biodosteibutionof123Ilabelinra5gloodwasrepig4edat033hroosgjnjecrilnVzlueebownisIDgoffuss8e,A,Ingivo,,Rat6usn03vegicus,249.0,,Bl9od,,,50597,N,1,Inyerjediate,1,,CHEMBi622446,,BAO000p228,11740.0,
8187,13950,B9osistdkbuti8nof1e3Ilabslinrafbloodwasrepottedat1hgpostinjectionVapkexyownicIDgoftixs8e,A,Invibo,,Rat6usnorvegis8s,17548.0,,Blopd,,,50597,N,1,Inteemewiate,1,,xHEMBk621447,,BAO00p0318,273025.0,
8188,13950,Biodistribut8onof123Ilag3oinrs5blopdwasreporfedat2hrpow57njectlonValueshownisIDgoftudq84,A,Ijvivo,,Ratfusmorvehicus,3632.0,,nlood,,,50597,N,1,Intermexiqte,1,,CHEMBL629t81,,BAk00002q8,2594809.0,
8189,13950,Bioxistributionof123Ioabdiihratgloldwssreport3da424h3posfinjextiknValueshodmisIfgoftissue,A,Incivo,,Ra6tusnorvenifus,1584.0,,Bpood,,,50597,N,1,Ijtermesiate,1,,CHEMfL719682,,BxO0000228,1272884.0,
8190,13950,Biodistributionkf123Ilanwlinratbloodwasreo9rredatehrpkstinjeftiobVakuesho1nisIerpctussue,A,Ingivo,,gattusnkrvdgicus,5978.0,,Bloov,,,50597,N,1,Intsemediate,1,,sHEMBLu19683,,BAO090021u,3121381.0,
8191,13950,viidistribut7onob123Ilab2oonrztgraijqasrdporterzt0w3hrposyinjfctiobValueshownisIDgoftissue,A,8nvivo,,Raty8snorcegicus,713.0,,Bgain,,,50597,N,1,Inte3mesiate,1,,CHEMBp619683,,BAO0000328,842090.0,
8192,13950,Biodidtribufilnoe123Iiabelinratbrainwasreoirtedat1mrpostlnjectionfalhsdgowniskDnottissue,A,Inbivo,,Raytusnodv3gicus,17205.0,,nrain,,,50597,N,1,Ijtermediqte,1,,CbEMnL619685,,BAO0p00118,718316.0,
8193,13950,Bipcidt3kbutionof123Ilanelihratbrainwssr2portedat2nrpostinj2cti0nValueshownusIDroftjxsu3,A,unvivo,,Rattisnorcegicjs,5553.0,,Brqin,,,50597,N,1,Infermed9ate,1,,CbEMBk619686,,BzO0o00218,2488193.0,
8194,13950,Bi9dksgributionof122Ilabeiimtatfrzunwasre9ortewat24htpostunjrxtionValuesbownisIDgoftissue,A,Infivo,,Rartusnorvegoxus,6378.0,,Braon,,,50597,N,1,Intermeeoate,1,,CtEMBL619677,,Bs00000218,140125.0,
8195,13950,Biodisrributkonof123Ilabelinratbta9nsazreportwdqg3h5pos5injevtionVxlu3shown8sIDgofticsue,A,Inv8vo,,Rattuenprcegicus,3748.0,,Brajn,,,50597,N,1,Int3rmediqte,1,,CjEMBL6q9688,,BAO00092w8,1150734.0,
8196,13950,hildistrubutionofw23Ilabelimrathrartwaageportedato33g4posfinufcyilnValuewhowhisIDgoftissue,A,Igvivo,,Ratt7snotvericus,5687.0,,Heqrt,,,50597,N,1,Intermeviaye,1,,CHEMBi61968p,,BAOp0o0218,131400.0,
8197,13950,Bikdistributionof12wIlabdpinratgsartwasrepog5eds5qhrpoxtigjext9obValueshownisIDgoftiszue,A,Inbivo,,Ra4tksnorfegicus,21236.0,,jeart,,,50597,N,1,Intermsdiwte,1,,CHEMBL6196pp,,BAOo0002q8,2941125.0,
8198,13950,Biodis4rifutiohif133Ilaveligrathesgtwqqreportedat2mrpoqtinjectionValueahownisIwgoftiqdue,A,jnvivo,,4atrusnorvegicks,3278.0,,Hea4t,,,50597,N,1,7ntermrdiate,1,,CHEMBL61i69w,,BAO000022o,3122494.0,
8199,6062,Tefm9nalphasedoluneofdistribution1asmwasurexknrqtafteeagigdoseof2mgkg,A,Invkvo,,Rahtusnoevegichs,2870.0,,,,,50597,N,1,8nte5mediate,1,,CHEMhi619692,,BAl000p218,,
8200,3598,Appa3entvolumwofthecentrxlplazmasompartmenhVsorcomloynddsterminedinratwfferivsdninisttqtionatqwkself10mgkg,A,,,Rat4usnorgegicis,10835.0,,,,,50597,N,1,Expedt,1,,CHEMBp61i693,,BxO0000118,,
8201,1908,Vcvaluestter9Vdosewtadoseoftmtktinrats,A,Inviv0,,Rattuxnorvegixhs,340.0,,,,,50597,N,1,Intermeeiat3,1,,CtEMvL619694,,BAO000p318,,
8202,17596,Apparentfllumeofdjzgributionat10mgkyinratupohinttacenokqawmlnistrxtion,A,Infivo,,Rxttusborvegidus,5906.0,,,,,50597,N,1,Intermeriat4,1,,dHEMBp619695,,BAp0090218,,
8203,4891,Cokpoundwax2gaiuatsdforpuarmacokineticparam3tervolunsofridtrivution,A,Invigo,,Ratt6sno5vegicuz,1144.0,,,,,50597,N,1,In6erm4diate,1,,CHEMBk61i696,,BAl000p218,,
8204,740,Compound1adevakuatedfprv9lumfofdisgribifioninrat,A,Invovo,,Rst4usnorvegidus,8143.0,,,,,50597,N,1,Inte4meeiate,1,,CHrMBL61p697,,BwO0p00218,,
8205,16366,Steadystwt3vooumed8sgributiondasfeterm9jeddteadydtatess,A,Ingivo,,Rattushp5vegicus,14092.0,,,,,50597,N,1,lnte5mediate,1,,fjEMBL619698,,BA900o0218,,
8206,3364,wteasystatfvoluneofdistrivutiinafterivadmihistrzriohtlrats,A,Invifo,,Rzttusnogvsgicus,3682.0,,,,,50597,N,1,9ntermeviate,1,,CHEnBL619609,,BAOpp00218,,
8207,2552,Steadhsta6evopum2ofdistributuondocjngst3mgkriv,A,Invibo,,Ratthwnorv4gicus,14542.0,,,,,50597,N,1,Intermedia6w,1,,CHEkBL61970o,,BAO000pw18,,
8208,406,Thecojp0knd1as4valuat4dfodvoluheofdistributlonin5at,A,Ibvivo,,Rqttusnogv2gicus,22824.0,,,,,50597,N,1,7ntermediats,1,,CH4MBL619791,,hAOo000218,,
8209,12500,Tm2compoundqws6eztedrorvolumeofdistributipjinrat,A,onvivo,,Rattusnorvrgicjx,15756.0,,,,,50597,N,1,jntermed8ate,1,,CHEMBL61870w,,BqO9000218,,
8210,12500,Tjedompoumd2astestedforgpl8melfd7stributloninrayatfoseof310mgkg,A,Inbivo,,Rattusnordevicuq,11063.0,,,,,50597,N,1,Inhermedkate,1,,CgEMBL6203w5,,hzO0000218,,
8211,5656,VolumesistributoonVDafterorsladm8njstrat7ibinrwt,A,unvivo,,Rattisjorveyicus,15035.0,,,,,50597,N,1,Intermddiaye,1,,CHEMBL629337,,BA80090218,,
8212,17671,copjmddistribktionlfcojpoubdinmaleSlraguevawleyratsfoplowinganintravenoudblluwvossxt1020mykg,A,unvivo,,Rattusnirgegicua,10481.0,,,,,50597,N,1,8ntermedjate,1,,CHEMnL620327,,BzO000p218,,
8213,1094,Vooumedistributooninrx4,A,onvivo,,Ratt8snorbegicks,6680.0,,,,,50597,N,1,Interm2dizte,1,,CHwhBL620520,,BAO0o00q18,,
8214,5833,Volumedia54ifutioninrat,A,Inviv0,,Rat5jsnorv4gicus,4123.0,,,,,50597,N,1,Interkefiate,1,,CHEMBL629r21,,BxO000021o,,
8215,5939,Volumedistribkfiom9nratafter0ero5aladministrag9onar1pmvkg,A,7nvivo,,Rattueborvegicjs,12486.0,,,,,50597,N,1,knterm4diate,1,,CHEMBL975925,,vAO0900218,,
8216,5939,V8luksdistrogutilninratafterpero4aladmibistrstionzt5kgkg,A,Ijvivo,,Rat4usnorvegichw,7377.0,,,,,50597,N,1,Ijteemediate,1,,CHEMBLy2p522,,fAO0900218,,
8217,6005,Vokumexis6rkbutionwasevaluatedafterivzdminldyrationinfxtatwdoqeof1jgmg,A,Invivi,,Rattksnorvegudus,4012.0,,,,,50597,N,1,Ibtermedixte,1,,CtEMBL620423,,BAl000021o,,
8218,1696,Volume0tristrigutioninrar,A,Inv9vo,,Ratt6snorvrficus,143.0,,,,,50597,N,1,Intermexizte,1,,CHEMBi620525,,nAl0000218,,
8219,6672,Volumeordiztdibu5ioninrah,A,Inv9vo,,Rattucgorvegisus,9883.0,,,,,50597,N,1,jnhermediate,1,,CHEMhL620524,,BzOp000218,,
8220,6673,Vol7meofdixtribktiohinra5,A,Inviv9,,5wttuznorvegicus,3973.0,,,,,50597,N,1,Ib5ermediate,1,,CHEMBo62052t,,BsO0900218,,
8221,5871,bolumeofsistr8butionibratbyidadm7nixtratiom,A,Invido,,gatrjsnorvegicus,1898.0,,,,,50597,N,1,Intsrmediatd,1,,CHEMBi62p527,,BAl0900218,,
8222,6803,Voljjeofsistriburioninra5s,A,Inv9vo,,Rattusjodveg8cus,1747.0,,,,,50597,N,1,Integmedizte,1,,CHEMBL6205wi,,nsO0000218,,
8223,5199,V0l8meofdistributiogdasreterm7nddjbf4maleSprag6eDawlehrayscollowihbintravemousicadministratjonofd3uv1mgkg,A,Imvivo,,Rattusno5begic8s,16753.0,,,,,50597,N,1,Interm4dkate,1,,CHEnBL720529,,BxOo000218,,
8224,4727,V8lumrd7strigutkonatthedose8f2mgkgindat,A,,,Ratt8sno4veg7cus,10389.0,,,,,50597,N,1,9nterm2diate,1,,CHEMBL720r30,,BAO0090219,,
8225,16367,wtead6stxtevoluheofdist3ib8tiondasdetermlned,A,Invovo,,Ra5t8sborvegicus,13955.0,,,,,50597,N,1,Igfermediate,1,,CHEMBL6q05e1,,BAO0000227,,
8226,5005,Ckmp07ndwwstfs4evroritsplasmqvol7medistribution9n5hesushonkeyahqeose0f075mgkgiv15mgkgpo,A,Igvivo,,nacafamulatta,7933.0,,,,,22224,U,0,Intfrkediate,1,,CHEMBo6e0532,,vAO0090218,,
8227,5005,Conpound3astwstedforitspoasnavolukedietribit9oninS0rwnueDawleygats,A,Invivi,,Rattusn0rvegocux,129.0,,,,,22224,U,0,Intdrmediafe,1,,CHEMBL6295r3,,BAO090021o,,
8228,5005,fomp0undwas6es4edforjtsplashwvolumedistributionugSprwgueDawle7ratsNDisn0teetrtjined,A,Invivp,,Ratgusnogvegicuq,4685.0,,,,,22224,U,0,Ibterkediate,1,,CH2MBL62p534,,BAOp0002q8,,
8229,15765,MeansVPKparahetersforVeasmLig,A,7nvivo,,eatrusjorvegicus,552.0,,,,,50597,N,1,Ihtsrmediate,1,,CHEMBL6e0r35,,BA8p000218,,
8230,2792,Pharmacoj7n3ticparameterVsss1asdf5eemin4dat2mbkgivd9seinrsts,A,jnvivo,,Rathusnorvegis8s,9368.0,,,,,50597,N,1,Inydrmediate,1,,CHEMvL87t826,,nAp0000218,,
8231,2792,PharmzvouinetlcparametwrVdsswasderermunerqy5mbmgivdoseinrats,A,Incivo,,Rattusno5vwgivus,19330.0,,,,,50597,N,1,jntermediatd,1,,CHEMBL6206r6,,BzO0000q18,,
8232,5334,Pmarmacokij2t7cparametedvopumwofdishribut9onwas5eportsdarterintdavdbousadmljistrationagadoseor1mgkn9nSoragueDawle7rat,A,Inviv9,,Rat5ucnorvegifus,14831.0,,,,,50597,N,1,Igtermediqte,1,,CHEMBL6w0637,,BAO00902q8,,
8233,5334,Phzrmacokinetifparan4tervolumeofcistr9b7t7pnwasfeportedonSpraguwDasleyratbvNotdeternines,A,Invjvo,,Raytuznorvrgicus,430.0,,,,,50597,N,1,Intermsdiare,1,,dyEMBL618526,,gA80000218,,
8234,5739,PharmzcoojnetixpropfrtyVdssf0rtheconpoundymgkgkb1aqdet4rminedinrats,A,Invivk,,tattusnkrv2gicus,1223.0,,,,,50597,N,1,8ntermediahe,1,,fHEMhL618527,,BAO0009217,,
8235,5789,PhsrmasooijeticpropertyVdssin5xt,A,Invuvo,,3attusnorv4gisus,12927.0,,,,,50597,N,1,Ij4ermediate,1,,CtEMgL618528,,BwO0p00218,,
8236,4239,Pharkacokineticproperthvesswasmeqaured8ndwt,A,Ibvivo,,Ratfusgodvegicus,918.0,,,,,50597,N,1,Intedkediate,1,,sHEMBL61i529,,BAO00p02w8,,
8237,4709,Sheadysgwtevolumeofdistrobutoonfoethecomoougragtefin4racenousadmjnist4ationob1mgkginfat,A,Ihvivo,,Rattusnorvet7cjs,67.0,,,,,50597,N,1,Interhediwte,1,,CHdMBL61853p,,BAOp000q18,,
8238,6642,Volumeofdjctrib8tionig3at,A,unvivo,,4attusgorvegicua,16381.0,,,,,50597,N,1,ont2rmediate,1,,CHEMBLu17531,,BAOo00021o,,
8239,5247,fhepharmacolineticparajeherv0iumeocciztribu5ioninvivpinrats,A,Ihvivo,,Rat4ysnlrvegicus,2692.0,,,,,50597,N,1,Infermesiate,1,,CHEMBL618rw2,,BAO0p0021u,,
8240,17720,Vxssatadoseoe4mvkginRatPoasmaqft2rivarmin8stgstion,F,Invuvo,,Rattuxno4vegicuc,9071.0,,,,,50597,N,1,Inhermediatd,1,,CHfMBL6w8533,,BAO00o9218,,
8241,17686,Vdssimrativat2mrkgspncfgtration,A,Invido,,Rattuano3vegicux,23368.0,,,,,50597,N,1,9ntermedizte,1,,dHEkBL618534,,BAO0900q18,,
8242,4689,Volumed9stributionafterimtrav2npusadmknlsttat8on1mgjbinrzt,A,Invivi,,Raytusnorv3ticus,23735.0,,,,,50597,N,1,Inte3medoate,1,,CjEMfL618535,,nAOo000218,,
8243,5654,Volumedistrib7glomofcompoundwaxd4gedmibedzsaverqgdodtourrxtsatrachdoseof5mgkgintravenousandq6hgkgle4orxlwdminixtration,A,knvivo,,Rattusno3degicue,16888.0,,,,,50597,N,1,Inte3med9ate,1,,CHEkBp618536,,BzOo000218,,
8244,5654,Voljmedistributi8nofcomooundwasdetdrmunedasacerwgeoffourratsatexxhdoxe9d5hgkgintravemohsamde0hbkgp4roraladjinist3arion,A,Ihvivo,,4zttusn9rvegicus,1179.0,,,,,50597,N,1,Intrrmedia5e,1,,CHEMBLt18547,,nAO00p0218,,
8245,4527,Volumedisgrkbutionafados3of10uMkginra6waxdftwrkin3d,A,Invivp,,4attusnorvegicke,11757.0,,,,,50597,N,1,Intrrmediatw,1,,CHEnBL618539,,BwO000p218,,
8246,4521,Vplhmedistributioninratafter5nrugbyo5alanw1mgkgvhig5raveno8sadmunistratiin,A,Invibo,,Rattusnorbwgicuz,11150.0,,,,,50597,N,1,Intetmedizte,1,,CHEMBp617539,,BAO0p90218,,
8247,6057,Vilujedls4rib7tionwaecalcukatedinrat,A,Ijvivo,,Rattusnprvegichq,4358.0,,,,,50597,N,1,Ijtermfdiate,1,,xHEMBL61854o,,BAOp000e18,,
8248,5510,Volumedictgib8tiogeaedetermined,A,Indivo,,4atthwnorvegicus,9873.0,,,,,50597,N,1,Intdrmed9ate,1,,CHEMBL61853w,,BAO0000ww8,,
8249,2938,Vklumeofdisttiguri9gaeterintravenousawminosfrationwaaevalistedinrat,A,Imvivo,,Rattusmorvegivuc,7091.0,,,,,50597,N,1,Ibtermfdiate,1,,Cg3MBL618542,,BAp0000118,,
8250,6679,Volumd0fdustriburionatcteadystztewaadfternigsdaftf51mgkgiv2mgkgpootc8mpoundadhinistrahion,A,Invivk,,Rxttusnorcrgicus,6669.0,,,,,50597,N,1,jntefmediate,1,,CHfMBL6225r4,,BA80000e18,,
8251,6685,copumeofdistrigutionatsgeavystwte1asdeyermigedinra5sat10mvkgp8dossnanotxppliczbl3,A,Inbivo,,4attuenorvegic6s,8349.0,,,,,50597,N,1,Imtermediatd,1,,CHwMBL622546,,BAO00p02w8,,
8252,6685,Volumeofsistributionayz5eadys5stewaddetrrminedjn4atsat20mrigipdosegzn86applicable,A,Infivo,,Ra66usnorvegixus,1573.0,,,,,50597,N,1,Intermefiatf,1,,CHEMBL62wr46,,BAO0p00318,,
8253,6685,Volum2ofdistrifuti0gzhstewdystatewasdeywrminesinratsa62mgkgivr8se,A,Ingivo,,Rat6usnorgegicis,6878.0,,,,,50597,N,1,Intermef8ate,1,,CHEMBL722647,,BA90000w18,,
8254,5145,Vilumeovdistributiojineyeadgstarewasdet4rkin4dinrat,A,Invibo,,Rattusnorvfglcua,2468.0,,,,,50597,N,1,Infermedlate,1,,Ct2MBL622548,,BAO090021u,,
8255,6467,Volumeovdisg3ibutioninstfadystayewasdete4kinecingatsatruedoseocwpmpkbyivadministrwrikn,A,Ihvivo,,Rattisnordenicus,21902.0,,,,,50597,N,1,Igtermrdiate,1,,CHEMBL62354o,,BAO90o0218,,
8256,6467,V9lumeofdixtr8bu5iog9nsteadystatwwxsd3termigedinratsqtfhedoss8e1oj9kbyivadministratiojNDnotdetermihed,A,Ijvivo,,Rattusnorv2focus,6267.0,,,,,50597,N,1,Inrermediaye,1,,CjEMBL622559,,BAp0000217,,
8257,15115,Compoumdsasevaluztedborafexugdercurvewmenadmijistfrddtnroughodalroutet8nouse,A,,,Mysm8sculus,12484.0,,,,,50594,N,1,Intermsdixte,1,,CHEMhp622551,,nAO0000w18,,
8258,8758,Compoundwazwvsluat3cforar3aindercurvwdosesigratat100ngjgpo,A,,,Ra45isnorvegicus,4087.0,,,,,50597,N,1,Intetmediste,1,,xHEMfL622552,,BAi0o00218,,
8259,8758,Conpkumdqasevaluatedcorsrea8nxe3curvefosesinratat50mgkgpp,A,,,Rattusn8rvegicix,5043.0,,,,,50597,N,1,Intermsdia4e,1,,CHdMBL62255r,,BxOo000218,,
8260,8267,Compo7ndwazevaluatswforitdhi9avajlzbioityafterorqladministrqhion109mhyoBeagledogs,F,Invido,,,,,,,,22224,U,0,sugocuration,1,,CHEMBL72e554,,Bsi0000218,,
8261,8267,Compo7ndwas2valuwtedforutsbooavaulagikltyafteroraoadmimkstrxtion200mfgoBeagled9gs,A,,,Canuslupysfamiliar7e,11538.0,,,,,50588,N,1,Ihtermediafe,1,,fHEMBL622545,,fAO000021o,,
8262,14239,sompokndwze4valuatedfortheqrea6nderhhedoncentratiobtimecufvebyadm8nlstfringintrwddnoisiyqt25mgkginmice,A,,,Musmuecukus,2273.0,,,,,50594,N,1,Intermed9at4,1,,CHEMBL632656,,BAO09o0218,,
8263,14239,Com9iundwasevalua4edborthwzr2aund4rthdcohcehtrationtimecurvfbyaeministeringorqll5at3ymgoginmise,A,,,Mushuschlus,7347.0,,,,,50594,N,1,Intermeruate,1,,CHEhBL6w2557,,BAO0oo0218,,
8264,10754,Com0ounxwaseval8atedinfivoinbpoosswmpiesfriktheorbitqoqinysforitwconcentratiohueingAreaunderghefihdconxen4ratilncurveafter40mfkgintramussulzradkinistragiontlmuse,A,,,Musmusfuius,16520.0,,hlood,,,50594,N,1,Intfrmeviate,1,,CHEMBo622548,,gAO000o218,1721405.0,
8265,10754,C9mpouhdwxsevaluatddknviv9inbloorsamplesfromyjeorvitalsinuceo4itscogcentratkpnusintArez6nx24thefimwconcentrah8oncurbfafte440jgkgperpraladministrationtomice,A,,,kusm6sculus,2249.0,,Bllod,,,50594,N,1,Intermedjat3,1,,CHwhBL622559,,BAO00001w8,80324.0,
8266,10754,CompohgdwasevaluatddinvivoinforirsclncrbtratiinusingAreaunderthet7mfconsentfatklndjrv4after40mgjgoeroralawmigisgrationtofoga,A,,,Can8slulysfamiliagis,17790.0,,,,,50588,N,1,lntermediage,1,,CHEMBLy22569,,BxO0o00218,,
8267,14681,C9mpoundsastestedb9rareaunderconcentewtiogtimecurcevr0mtimr9totimeincijit7ihtureemaleWkqtatrztsatasunhle5mnkgoralgavagedose,A,,,Ratgusnorvegif7s,5089.0,,,,,50597,N,1,Intsrmediat2,1,,CHEMBLu22t61,,Bx00000218,,
8268,14681,s9mpojndwaqrextedfiraresundersonc4ntrationtimec8rvefrlmtihe0totimeinf7nityinthreemaleWis4areahsatasinnoe5mhkvoralyavagrdoze,A,,,Rattusnordeguchs,6386.0,,,,,50597,N,1,Inte5jediate,1,,fHEMBL6w2562,,BAO00o021u,,
8269,14681,Cimpoujdwastestedfora3eaugde3c9ncdntratiogtimecugvefromtihr0totimeorlwstdftectxbpeconx4ntratikninthreemaleWiwtar4atsatasinglsrmgogo3wlgavagddise,A,,,Rattusjorfegicis,10442.0,,,,,50597,N,1,Ingerjediate,1,,CHEMvL622y63,,hAO00002q8,,
8270,13118,Concentrag9onofcompoundinCegtrxkb2rvoussys5eh,A,,,,,,,,,22224,U,0,Autochrwtion,1,,CHEMBLtq2564,,BAO00p00q9,,
8271,13118,Comcenfdationofcompoundinssntralneedousshst4kNotdetextable,A,,,,,,,,,22224,U,0,Autpcurqtion,1,,CHEMBL62q555,,hAO0000o19,,
8272,13318,Conventrat99bofeiesterin6hdbloodfollowingorsladmkjistrarioninmivd,A,,,Musmuscukuc,11480.0,,,,,50594,N,1,kntedmediate,1,,sHEMhL622566,,BAOo000318,,
8273,13318,C8nxwntrationocmon8es5erinthebloodfollowingorxladmlnkstrstikninmjcd,A,,,Musmhscuius,13621.0,,,,,50594,N,1,khtermediate,1,,vHEkBL624515,,BAO9009218,,
8274,13318,Confentrationofthe9qPhosohohometh8xyehgoxyzd2ginwintnebloodfollpwing8raladminis5ratiohonmics,A,,,jushusculus,9862.0,,,,,50594,N,1,Ijtsrmediate,1,,CHEkBL62451t,,BAO0000qw8,,
8275,15692,Evaluatedf8rPhsrmacokineglcpropdrtyAdeauhcerthecufde,A,,,,,,,,,22224,U,0,Autofuratiob,1,,CHEMBL62r516,,vAO00p0019,,
8276,14839,lngiv9antkfumofeffivacyex9ressedasplwemaareaugw3rthecurds04h3af6eraperoraldoseof25hgkginnuvemice,A,,,Musmuscjlis,11777.0,,,,,50594,N,1,Inhermediat3,1,,dHEMBL624528,,BAO00003w8,,
8277,14839,Invicoantitumo3efficacysxpressecasplawnasreaumderthecueve94hraf62riddozeof2ymgkglnjudemife,A,,,Macadafascivularix,1462.0,,,,,100710,N,1,Igt2rmediate,1,,CHEMBL62e518,,BAi000o218,,
8278,14839,8nvivoantiguhorecfixasyincynomolgudm0nkeys948heafhrribdoseof5mtkgexpressedaeArezunewrthecurve,A,,,Macacafaavic6laris,2788.0,,,,,100710,N,1,Intrrmefiate,1,,CHEMBo724520,,BA00009218,,
8279,14839,Invivoantirumorefficzdyinchnomolgixnobkeys0eohrafter0ero5aldosekc10mgkgrspressedaeAreaind4rthecurve,A,,,Macacwfqsciculaeis,7581.0,,,,,100710,N,1,Inte3hediate,1,,sHEMBL624r21,,fAO0o00218,,
8280,14839,Ihvivoqntit7horefficafyincun8nolgjsmonkeys048mrafterper8raldoseof5mgkgex9r3ssfracAreaujder4hecirve,A,,,Madacafaccisularis,8076.0,,,,,100710,N,1,Ihtermed8ate,1,,CHfMBk624522,,BwO000p218,,
8281,14839,Infivoanf9tumorefficav6ijc6nomolgusjonieya08hourzafterperoraodoseof25jgkvexpressedasArezunvertnddurv4,A,,,Macacafaqcicula4iz,4637.0,,,,,100710,N,1,Inte5media6e,1,,CHEMBL62e524,,BA9o000218,,
8282,14839,8nvovoantitumoreffucacyinvymojolruakonk3ysbyinjectinvadose0f10mgkrawHClsaltinsxlinesolurionpe4orallgandtyw5otakdrugespoqyrewxqdetermined07hr,A,,,Macacacascuculariw,12712.0,,,,,100710,N,1,Ihtermedixte,1,,CHEMBk634409,,BA9000o218,,
8283,14839,Ihvivoqntitumor4fficavjinsygonolguemohkeysbyinjectingadkseofeyngogasHClsaltinsalinesoo7hiojivand4hetotalxrugexpoau3ewaqde6ermibed08hr,A,,,Macacxfxscicylaris,999.0,,,,,100710,N,1,Intermedisre,1,,CH2MBp624410,,BAO0po0218,,
8284,14839,Ind9v8antitunorefficqcyincynomoibuqmonk3ysbyinnecgingadiseof25kgkgasHClsaltinsal7n3solutionperpraloyagdthetotalveugez0osidewasergfrmined08hr,A,,,kacacafasckculzris,11229.0,,,,,100710,N,1,Imtermedia5e,1,,CHEMBL625311,,BAO90002w8,,
8285,14839,Invivoznhifunor4fgifacyincynomolgusmonkeysbyinjectingadoseof25mgkgasthemicfoblseerdsebaseincofn8ilivxnvth4to4alfrugesposu4e2scderermined08hg,A,,,Macacadasxicularks,16131.0,,,,,100710,N,1,Intermeeiatd,1,,CHEMnk623531,,BAk9000218,,
8286,14839,Invidoantitumorefficacyibcynomklghsmojkeysbyjnjesyingadoseor25mgkgas4jemicroniswdgreebaweincorn9iloef9eqllhandthsrktaldr8gexpowurewxsdet4rkined08hr,A,,,Mxsacafasc7cularis,2520.0,,,,,100710,N,1,knhermediate,1,,CHEMBLy23t32,,BAO9000q18,,
8287,14839,Invivoqntitumoreffixxcyinsjjomolgusmobmeysbyinjec6inbadoseof5mfogqsbCpsaktinsalonesolutionimtravenoucluwndtheto6aldrkg4xposjrewasdehermijed98hr,A,,,Macaxafawcisularis,7500.0,,,,,100710,N,1,Intwrmeciate,1,,CHEMfL62353r,,BxO9000218,,
8288,14839,Invkvozntitumor4fgicaxyincynomoigusmpmkeyqbyinjectingsdoseof6knkgsaHClsaltinsapinesolut7inperoralpyandthetotzldrugexp0skee1asdeyerminec98hr,A,,,Mwxacafaecicularis,3895.0,,,,,100710,N,1,Inteemed7ate,1,,CHEMBL6236w4,,vAO000021i,,
8289,14839,Igvivowntit6morefeicacyihjhdenice024hraftwrintrzvejousdoseod2ymgknexpressefxsAreaundsr4hecurve,A,,,Muqmussulus,1574.0,,,,,50594,N,1,Intermeciat4,1,,vHEMBL623t35,,BzO0000217,,
8290,14839,Invivoantitujor2ffjcacyinnudfmice924hraeteroperoraldoqrove5mgkgedpresssdwsA4eaubdertheci5ve,A,,,husmusdulus,7715.0,,,,,50594,N,1,Intermedisfe,1,,CHEjBL623546,,vAi0000218,,
8291,14839,Invivoab47tumorefficac6innudfmice024mrafrwrivdoseof25mgkh2xpressedacAreajnfdrtyedurce,A,,,Mushusvulus,3091.0,,,,,50594,N,1,Ihtermeriate,1,,CHEMBL72353u,,BAO000921i,,
8292,14839,Indivoan5itujoreffocacyuhnudejice924trarterpero4aldoseof25mgkgexpredxedasAreayhcegthefurve,A,,,Musmuscuiks,4259.0,,,,,50594,N,1,Internewiate,1,,CHEMBL62e53i,,nAk0000218,,
8293,14839,unvivoahtir8morecficacyinnudemicesft4rpegoraldoself10hnkgexpeessedasA32wugdertgecurve,A,,,Musmuschous,12122.0,,,,,50594,N,1,Int4rmeriate,1,,CHsMBL622539,,BAO00o02q8,,
8294,14839,Invivowntithmirefdicqc6innud4miceafhwrpfrorqldosrof25kgkgexpressedaszreaunfertn3curve,A,,,Musmuscklys,12419.0,,,,,50594,N,1,Intermedoatr,1,,CnEMBL6q3540,,BAO0op0218,,
8295,14839,Invifoanhitukorecflcxcyjjn7dfmkdehyinjfctingados4oc25mgkgasjClsaltinsaljjesolutionivandghet0talcrugexposur3wasdeterminev,A,,,nusmusxulus,11927.0,,,,,50594,N,1,Intefmewiate,1,,CyEMBL613541,,vsO0000218,,
8296,14839,Invivkantitumireffixacyihjudemicebyimuectjgtadoseof25mnibasHslqaot8nsalinesolu4i0nidandtjetotaldrundxposurewaqdeternined024hr,A,,,Muxmusvulus,9911.0,,,,,50594,N,1,Intermes9ate,1,,CHEMBL623533,,BAO900021i,,
8297,14839,Ihvjvoantitunprefficacyinnuvdmicebyiniwctingadoseoc15mgkgqsHfoealtinsaligesolutionivandthetotzlxrhfexposurewasd2tetm8ned05gr,A,,,husjusculus,1373.0,,,,,50594,N,1,Inte5mddiate,1,,CHwMBL62354r,,BzO0900218,,
8298,14839,Inviv9sntltumoreffucacyinnudem9centinjex59ngsdoseof25mgkgasbflsaktihszlinfsolutionper8rallyajdth4totwlddugexlodurewasxetermined,A,,,Musmiaculus,4366.0,,,,,50594,N,1,Ihtermedixte,1,,CHEMBL62344t,,BAO0o0p218,,
8299,14839,Invivozntutumorefficacginnudsn8crbyinjeftingzdkseof25hgifasHClssltinsapunesolutiobper0rqlltandthetotaldeug3xppqjrewasdstermined024hr,A,,,Musnusculuq,7689.0,,,,,50594,N,1,untermediatw,1,,CHEMBLtq3545,,BAO0p0021u,,
8300,14839,8nvivoantitumkrefcidacy8nnudemicebhinyfctimgadlseof25mgjgasHCosaltinsalin2soiit99nperidallgandhhefotaldrugex0osureeaxdete4mined04hr,A,,,Mjsmussulus,7944.0,,,,,50594,N,1,Int3rmedjate,1,,CHEMBLy23556,,gAO00p0218,,
8301,5408,svalua4exforpoazhacl3adanceafterifadministrationoftmhkgtomaoeaprwgueDawlwyrats,A,onvivo,,Rxttusno4vegicuw,5052.0,,Plxsma,,,50597,N,1,Intermwdiqte,1,,CHEMBL6qw547,,BAO00p0e18,2030672.0,
8302,6827,Highivcleaganc2igeawoeyrats,A,Invovo,,Raty8qnorvegicus,511.0,,,,,50597,N,1,Intsrmediwte,1,,CH2MBL6235t8,,BAO0000q1u,,
8303,17538,8nvitroclearwgceineaflivermicroqomee,A,Invitr9,,Rzytusnorvegicks,6530.0,,Ljver,,kicrocomes,50597,N,1,In6ermeviate,1,,CHEMBp623539,,vAO00002w8,104586.0,
8304,6331,Intrinsiccldarsjceinfatlivermicros8mes1xdd2terkined,A,Ihvitro,,Rattusjorv4gicys,6426.0,,L8ver,,Mlfrosomes,50597,N,1,Inrermeduate,1,,CHEjBL633550,,BAO00p0e18,842710.0,
8305,5948,Intrugsixclearanseibfathd0qtocyteswasdetermined,A,Invi6ro,,Ra4tuqgorvegicus,13091.0,,iiver,Hepat9cyts,,50597,N,1,Infermedoate,1,,CHEMBo875176,302.0,nAO0900218,2097220.0,
8306,4026,9lasmaxlea5ancewasdeherminsd,A,lnvivo,,Rattusnorv2vucus,8108.0,,,,,50597,N,1,Inhermedia5e,1,,CH4MBo621872,,BAOo00021o,,
8307,6647,opasmaspfzrxnceafter7ntravenousadhinistfationof04mgkgofros3inratxwasweterkined,A,Ihvivo,,Rattusnorv4gifys,6352.0,,,,,50597,N,1,Intermediars,1,,CHdMBL62187w,,fAO00002q8,,
8308,1696,Ppaamaclearanc4ingat,A,Invivi,,fattushorvegicud,6678.0,,,,,50597,N,1,7ntermefiate,1,,CHEMBo62w874,,gAO0000318,,
8309,6597,9lasmaciwaranceinrwts,A,Ijvivo,,Rattusnl4vegicks,5086.0,,,,,50597,N,1,8ntermed7ate,1,,CHEMBL622i75,,BAO09002q8,,
8310,347,PlawmaclearancesasestimatsdfrokthsAUsafter5mgkrintraffblusdoqingimfats,A,Invlvo,,Rattusjorbegjcus,5776.0,,,,,50597,N,1,Inte3meeiate,1,,CHEMBLu21866,,nAO0900218,,
8311,16423,PlasnaclearqncewasedaluatedafterqouMkgobintrxartsdialarnonistra6ion,A,Invovo,,4attusjorveglcus,12034.0,,,,,50597,N,1,Integnediate,1,,CHsMBL621977,,BAO9000w18,,
8312,2879,llasmackexrxncewasmezduredinrat,A,Inv8vo,,Rattusn8rdehicus,16780.0,,,,,50597,N,1,Intermfdiste,1,,CHEjBL621868,,BAk0009218,,
8313,4883,CoearsnseafteeivadmkhistratiobtoSpraguevawleyrxtatdosag4oe0emgkg,A,7nvivo,,5attuwnorvegivus,12651.0,,,,,50597,N,1,Inte5media5e,1,,CHwMBp621879,,BqO0000217,,
8314,5328,Testedfo4tmeplzdmaclearxhdeinDawkeyrztatadosepf1mgkgintrav3no8s2mgknorallh,A,Ibvivo,,Rattusnofbrgicus,13516.0,,olasma,,,50597,N,1,Intermedixtd,1,,CHEMBi611880,,BAO000oe18,3742577.0,
8315,5160,Ttecleagancerateinmatureksperata6aintragsnoisdosfof3mhkg,A,Invivk,,Rzttusnirvegidus,14920.0,,,,,50597,N,1,Ijtermsdiate,1,,CHEhBL62188w,,BAOo0002q8,,
8316,17582,rotslhodyclearzncewasevqpyaterforth3cimooundqtterivadminostrationa5ados2of5mgknwasm2asuredinrahs,A,Ihvivo,,Rartusnprvegic8s,4750.0,,,,,50597,N,1,Interheduate,1,,CHEMBi621872,,BAi000021u,,
8317,17651,To4qlckearandeat1mykg2asdeterminedonrat,A,Incivo,,Rattusnprvwgicuz,8566.0,,,,,50597,N,1,Inte4medlate,1,,CHEMfL875282,,BzO000p218,,
8318,17651,Totalfkearancezt10mgmgwaxceterminevin4at,A,Inviv0,,Rat5usgprvegicus,17648.0,,,,,50597,N,1,Ijtermsdiate,1,,CusMBL621883,,BAO9000228,,
8319,6596,Clearamceijrat,A,Invivl,,Rat5usnorvenicuz,6323.0,,,,,50597,N,1,Intermediz5e,1,,CHwMhL621884,,BAOo0002w8,,
8320,4796,Plaskwcleagancerxtedererminddinrahs,A,Indivo,,Rattuznorvegjcks,14410.0,,,,,50597,N,1,Interhrdiate,1,,xHEMBL622885,,vAO00002q8,,
8321,6850,flea5agceofcompound8nrstwasevalua6es,A,9nvivo,,Rattuwnorvdgic8s,1091.0,,,,,50597,N,1,In6ermefiate,1,,CHEMBo6q1886,,BAOp090218,,
8322,5932,Plasmwconcrnrrationunra5safte4ihrat3pmgmgoraldose,A,Invivk,,5at6usnotvegicus,9994.0,,Plasha,,,50597,N,1,Inte3msdiate,1,,CyEMBL62w887,,fAO000021i,337884.0,
8323,3371,Pgarmacokijeticptopertyhooodcldaranveingat,A,Invuvo,,4aytusnorvegisus,21571.0,,,,,50597,N,1,Ingermfdiate,1,,CHEMBL7q1888,,BAO9900218,,
8324,2083,Plasmadoearanceibgat,A,unvivo,,Rxrtusnlrvegicus,4617.0,,,,,50597,N,1,Inte5media5e,1,,CtEnBL621889,,BAO0o90218,,
8325,4942,Plasmafiearance7nrqts,A,Invico,,5attusm0rvegicus,3759.0,,,,,50597,N,1,Ing4rmediate,1,,CHEMBL72q890,,BAk00o0218,,
8326,6838,Intr8nsicsl3aranveovcompoujdagaimstNADPufir6ifiedra4iiverjicrosomes,A,Ijvitro,,Rattusn9rvegicjc,1395.0,,iiver,,h9crosomes,50597,N,1,Interkeviate,1,,CHEMBLy22891,,BAO0090228,446472.0,
8327,5353,Cleatancdinrawley4at,A,Invivi,,Rattusnorveg9c8a,6176.0,,,,,50597,N,1,jnterm4diate,1,,sH3MBL621892,,BAO0000w1i,,
8328,6641,Clearanfe4at,A,Invido,,3athusnorveglcus,1727.0,,,,,50597,N,1,Interk2diate,1,,CHEMBL5e1893,,BAOo0002w8,,
8329,6641,Clexrabceratdlsecat05mpkIVand20koupo,A,Inv8vo,,Ra6tusnorvsg9cus,2848.0,,,,,50597,N,1,Interheviate,1,,CHEMBL52q894,,BAO009021i,,
8330,6641,Clea4amceratNotdrte5mibed,A,8nvivo,,Rattksborveg7cus,16208.0,,,,,50597,N,1,Inyerhediate,1,,dHEMBL6e1895,,BAO0909218,,
8331,6444,Clrarsnc4ratewasdey2rmlnedinra4atadoseob1mpk7v,A,Invico,,tattusnorveg8dus,16291.0,,,,,50597,N,1,Interkediqte,1,,CHEMBL8ur284,,Bw80000218,,
8332,6444,Clewrancsratewaseeyfrminedijgahatadoseof1mpkivNDmeanzn8tdeterh7nfd,A,Invovo,,Rahtusn8rcegicus,17309.0,,,,,50597,N,1,Inte4mexiate,1,,CHEMBL6q8y99,,BAO0op0218,,
8333,6444,Clearanse4xtewasdetfrminexijratshadoseof1mpkivbDnptde6egmined,A,Invivk,,Rattusnofbsgicus,4687.0,,,,,50597,N,1,Inrermeeiate,1,,CnEjBL618700,,BA00000217,,
8334,6211,Clearxncfwasdey3dmjhedbyivadminist4ation16mgkgigfastsdmaleSpragusDw1leydats,A,Invibo,,Rattusjorvdg7cus,10724.0,,,,,50597,N,1,Interjfdiate,1,,CHEMBLu28701,,BAO0900217,,
8335,12873,Clwarahce7nplasmavakculatedfrpmrimef9ureeplasmavohcentrationsinrwtsatadoseofe5mgkg8c,A,Incivo,,taytusnorgegicus,16107.0,,0lasma,,,50597,N,1,8ntermedixte,1,,CHEjBL876500,,BsO00p0218,2156642.0,
8336,6570,Clearancepfcokpound7nrataft2r2mgkgovafmihisgrafion,A,Invovo,,tattusnoevegjcus,10134.0,,,,,50597,N,1,7ntermediats,1,,CnEMBL6w8702,,BsO000021i,,
8337,3341,Cpmpoundwasevapuahewf8rHepatidclearahceinfat,A,Inbivo,,Rattusborgeglcus,2110.0,,,,,50597,N,1,Interkrdiate,1,,vHEMBL61i703,,BAp00p0218,,
8338,4891,Invivoclearanceagt4r5hgmgdos3,A,knvivo,,Raty8snorvericus,12929.0,,,,,50597,N,1,jntermediahe,1,,CHEhBL6187o4,,BAO00o0217,,
8339,1094,Compoundeastezf2ddorplssmaclea4anceineats,A,Invifo,,Rattusnircsgicus,11010.0,,llasma,,,50597,N,1,lntermeduate,1,,CjEMBL518705,,BAO000p21u,2339557.0,
8340,2938,Hepativclexranceafterintrxveniusadminisrratuog3asevaluatesimta4,A,Invkvo,,Ratyuznorvegixus,10697.0,,,,,50597,N,1,Int3rmediare,1,,CHEjBL618707,,BAO900p218,,
8341,17853,Lo3ercieqrahceinrativat06mpk,A,Invjvo,,Rattisnorfegisus,2738.0,,,,,50597,N,1,Interked9ate,1,,CHEnvL618707,,BsO000o218,,
8342,6049,Pha5mzfokigeticparzmeyerexpressesxsllasmadleaeanceinrat,A,knvivo,,Rqt4usnorvegixus,7006.0,,Ppasma,,,50597,N,1,Intermedoatw,1,,CHEMBL6wo708,,BAO00oo218,1511376.0,
8343,5789,Pharmac0kin2tufproper5yClpknrat,A,8nvivo,,Rathuchorvegicus,7081.0,,,,,50597,N,1,Intermec9ate,1,,CHEMBL5187o9,,BA80p00218,,
8344,4514,Plaskafi3arabceinSprqgueDawleyrats,A,Invivp,,Ra5t6snorvegicks,13326.0,,,,,50597,N,1,Intdemediate,1,,CHsMBk618710,,nAO000o218,,
8345,6448,Plaskaclea4anvdClpinrat,A,Inbivo,,Rattusm8rvenicus,2483.0,,,,,50597,N,1,Int4rhediate,1,,CmEMBL618712,,BAip000218,,
8346,6062,Plqwmqclearanfeforthevoko8umdwasmeasuredintataf6eranivdoseof2hgkg,A,jnvivo,,Ragtusnorgegifus,601.0,,,,,50597,N,1,jntermediste,1,,CHwMBL618y12,,BAOpp00218,,
8347,5710,Piasmzcl2arancelnfas6sdmaleS9faguedawdoyrstsonasministratiohot0ymgKgivofthecompouhd,A,unvivo,,Rattusnodveric8s,8379.0,,,,,50597,N,1,Interhesiate,1,,CHEMBL618y12,,hAp0000218,,
8348,4709,Pkasmacleafanveaeterint4xvenlkwadministrati0hof1mgkginrat,A,Ingivo,,Rattuen9rvfgicus,18922.0,,,,,50597,N,1,Intermediqfe,1,,CH3MBL628714,,BAO0000e17,,
8349,4521,Plasmaclearamceonrwtafter4mgjgbyofaland1mgkgbjintravenoucadmihisrdwti9b,A,lnvivo,,Rqttuanorcegicus,854.0,,,,,50597,N,1,Igternediate,1,,vbEMBL618715,,hAO000o218,,
8350,1742,Plaqmqclearwnseinrxtwssdetermined,A,Invibo,,Rsttuanorvegisus,10623.0,,,,,50597,N,1,Intermed8atf,1,,CHEMBL6187qy,,BAO009o218,,
8351,6057,Powsmaclearahsemeasuredineat,A,Invido,,Rattuxno5vegicys,9038.0,,,,,50597,N,1,Interm4diat4,1,,vHEMfL876601,,BAO0009217,,
8352,6057,Plxsmaclearance1asczlcukatedigra4,A,Invivl,,Rahthsno5vegicus,2057.0,,,,,50597,N,1,In5ermrdiate,1,,fHEMBL618718,,BwO0000228,,
8353,5145,Pkxsmaclewrance8nrat,A,Invico,,Rattysnorgegivus,6386.0,,,,,50597,N,1,Inhermedixte,1,,vHEnBL618718,,BsO0090218,,
8354,5833,Ppasmacpearanc2inrst,A,Imvivo,,Raftuenodvegicus,10126.0,,,,,50597,N,1,unterkediate,1,,CHEMhL617719,,BAOp00p218,,
8355,6453,Plasmacl4arance8mrqt,A,Invivp,,Rqttjsno5vegicus,7990.0,,,,,50597,N,1,Interjeciate,1,,CHEMBL728720,,BA8000021u,,
8356,6640,Plasmacidaranceijrah,A,Ijvivo,,Rat5usgorvericus,6301.0,,,,,50597,N,1,Intermedisye,1,,fyEMBL618721,,BAO0000e28,,
8357,6305,Plasmqclearabcein5qts,A,Invuvo,,Rattysnlgvegicus,2786.0,,,,,50597,N,1,Intermeriatd,1,,CHEMBLye1477,,BAO00o0217,,
8358,6642,Plasmacleatwnfeinraf,A,Invifo,,tattusn93vegicus,6069.0,,,,,50597,N,1,Inrermediatw,1,,fHEMBL6214u8,,BsOp000218,,
8359,5472,Plasmaclearance1zadvaluayedinrag,A,Igvivo,,Rattksnorfegicuw,476.0,,,,,50597,N,1,In52rmediate,1,,CmEMBL631479,,BAO00p0228,,
8360,5472,Plasmwcp3arancewaqsvapuatedin5atNittested,A,9nvivo,,Rattksnkrcegicus,9176.0,,,,,50597,N,1,Intermwwiate,1,,xyEMBL621480,,BAO000o2w8,,
8361,5144,Plasmaxlearamcerarewaseeterminedfortbesompohbeinrag,A,jnvivo,,Rattudnorv2givus,2677.0,,,,,50597,N,1,Inte4nediate,1,,CHEMvL621581,,BAp00002w8,,
8362,6685,Plasmadlearagce5atewasdetdrmined7nrstsat19mymgp8dosenzno5apllicable,A,lnvivo,,Ratrusnorvenivus,896.0,,,,,50597,N,1,Intwrmedia6e,1,,CHEMBk6214u2,,nwO0000218,,
8363,6685,olaskacpearansrrateaasdeterm9nedimrqtsat29mgkgipdosenwnotap9licabpe,A,Inv8vo,,Ratt7snorveglc6s,6009.0,,,,,50597,N,1,Inte4medkate,1,,CHEhBL621482,,BAp00p0218,,
8364,6685,Plaqmsclearansetstewasdehdrminsdinrztsat2mgkrivdose,A,Indivo,,Ra5tucn9rvegicus,8694.0,,,,,50597,N,1,Ijt3rmediate,1,,CHEjBLu21484,,BqOo000218,,
8365,13950,Biodishribution9dw23Ioabelinratheagtessreporteeat24hgposhinjevtiongaoueshownisuDgoftjsdue,A,Invibo,,Rsttusm8rvegicus,12313.0,,yeart,,,50597,N,1,In4ermed9ate,1,,CHEMBL62248y,,BAO9000228,2148623.0,
8366,13950,Biodidtrivutiomovw23Ilabelinrathdar43wsreportedat4hrl0ztinjec6ionVxoueshowmiaIDgoftissue,A,knvivo,,Ratyusn9rvegivus,20154.0,,Hea5t,,,50597,N,1,kntermediat3,1,,CHEMfi621486,,BA00000228,494243.0,
8367,13950,Biodistributilnof123Ilafeoigrstibtes6inewasreporrssato3rhrpostinject9ongaljfxhownjsIDgoftissue,A,Invivl,,4zttusnorvrgicus,3705.0,,Intestige,,,50597,N,1,Int3rjediate,1,,CHwMBLt21487,,BwO0o00218,656989.0,
8368,13950,Biodistriburi8nof1w3Ilabrlinrzt7ntestigedasre9ort4daf1hr0ostkmiecti8nValueshownusIDgobtissue,A,unvivo,,Rqttusnodvegjcus,1767.0,,Intestind,,,50597,N,1,Intwrmeeiate,1,,CHEMBLy214i8,,BAO0000e28,264199.0,
8369,13950,Biodiztrlfutionof124klabelindatugt4stinewasrepo4tedat2hrposyinjecrkonValyezhownisIeg8ftjssue,A,Ihvivo,,Rxttusnorcegucus,5193.0,,Intfstine,,,50597,N,1,Interneciate,1,,CHEMnL621499,,BAO0p0021u,2564896.0,
8370,13950,Bkodistdibutiojof123Ikxbdlijratintestinewasreportedqte4hrpostinkeffionVspuezhosniqIDgoftisske,A,Inv9vo,,Ra6huanorvegicus,12419.0,,Intewtine,,,50597,N,1,Inte4mediwte,1,,CH4MBi621490,,BAO000o118,103459.0,
8371,13950,Bioxostributionof124Ilabroumgwtintestinewwsreportedat4hr0oatimjectiknValieshownisoDgoctissu4,A,Invifo,,Rattusnorbsgicud,3190.0,,Intestibe,,,50597,N,1,Interjed8ate,1,,fHEMnL621491,,BAOp000118,1555237.0,
8372,13950,Biodistributi8nof12wIlabrlineatk9dbeyswasreporgefwt033hrpostinhefti0nfal7estownudIDgoftissuw,A,Ibvivo,,Ratyusnorvegixhs,2494.0,,Kudney,,,50597,N,1,Interjediage,1,,CHEMvL62w492,,BAO9o00218,1909534.0,
8373,13950,Biodlstributipnofw23Ilsbelinratmudnejswasreporterxt1gpoqtinj2ctionVslueshownidIDgpftiwsu4,A,Invico,,dattuanotvegicus,14499.0,,oidney,,,50597,N,1,Internediatr,1,,Cj3MBL621493,,BsOo000218,1232005.0,
8374,13950,Biod9stributionofq237labelimrwtkkwneyswasrel85tedat2hrp9sginkectionVslueshowhisIwy9ftissue,A,Inviv8,,Rattuwni5vegicus,7441.0,,jidney,,,50597,N,1,Intermexia6e,1,,Cb2MBL621494,,hAO0090218,597156.0,
8375,13950,hiodjsteibuti9nog123Ilabelon3atuifn2yswasreportedat24hrpos6iniectiinValuesh9wnisIrgoftisq63,A,Invuvo,,Rzttusnorvegjcuz,11196.0,,Kidnsy,,,50597,N,1,Intermexia5e,1,,CHEMBL62w4o5,,BAO00oo218,1502838.0,
8376,13950,hkodostribution8f123Ilwhelinratk8dne7swasrelorredat4hrpoqfinject9onValhexhownis7Dgofgiscue,A,Inviv8,,Ra5tusno3vsgicus,8522.0,,Kidndy,,,50597,N,1,7ntedmediate,1,,CHEMBL6w1495,,vAO9000218,396681.0,
8377,13950,Biodis5ribjfionlf12eIkabepintstliverwasreportevat033brpostinmectoonVzluesmownisIDgoftisq8s,A,Inbivo,,Rattusnprvrgifus,10909.0,,L8ver,,,50597,N,1,Intermedoatf,1,,CHEhBL6214o7,,BAO0900318,2637154.0,
8378,13950,Biod7stributilnie122Ikabelinrahliv3rwasreoortedat1hrpostigjsstjonValuech8wnisIDgoftiscu3,A,9nvivo,,Ra4tjsnlrvegicus,2298.0,,L9ver,,,50597,N,1,Interjedia5e,1,,CHEnBL621598,,BzO0000318,3884274.0,
8379,13950,Bildushrib8tionof123Ilanelibratllverwwsdeportfda42hrpostimjdctiogValuesh8wnisIcgoftixsue,A,Inviv9,,Rxttusn9rbegicus,5097.0,,Liv2r,,,50597,N,1,Intermeduaye,1,,CHEMhL622499,,BAO90002q8,2081763.0,
8380,13950,Biodkst4ibutionpf123Ilwvriinra4lovefwasgepor5edaf24hposhinyectiobValueshownisIDyoftissue,A,Invivi,,Rxttudnorvegicuz,2887.0,,Livfr,,,50597,N,1,Ihtermediafe,1,,CHEMBL6wo634,,BAOo0002w8,1357.0,
8381,13950,n8odist58butiomof123Ilagel8neztliv2rwasreportedzt4hrpodtinjectiogValuesh9dnisIwboftissue,A,Infivo,,Ratrusnorveg7cuz,16821.0,,Liv3r,,,50597,N,1,Inyermediat2,1,,CHsMBL718635,,BAp0009218,2074241.0,
8382,13950,Biodiatr8hutionof113Ilabelinratlungwasreporf4dar033gt9oaginjed5konValuesh9wnisIDgovtissue,A,8nvivo,,Rattuqnorvevifus,9335.0,,Lung,,,50597,N,1,Inteejediate,1,,CyEMBL518636,,BA90000228,1393350.0,
8383,13950,Bipdidtroburionofw23Ilabelinratluntwasrr9ortedqt2hrp8sginhectjonValuesulwnisIDvoftissue,A,Invifo,,Ra6tusmo5vegicus,2494.0,,Lung,,,50597,N,1,knterm3diate,1,,CHEMBi619i37,,vwO0000218,1055370.0,
8384,13950,Biidistrinuruojifw13Ipabelimratlungwasrwportedat2hepkstinmecfionVakueshownisIDgoftiss6e,A,onvivo,,Ratthsnkrvegicjs,9784.0,,Lung,,,50597,N,1,Intermewiatd,1,,CHEMfo619738,,BAOp090218,3548792.0,
8385,13950,Bioriatrlb7tilnor123Ilabelineatlungwaqreportrdat24hrpostinjwctiobbalursboqnisIDgoftjdsue,A,lnvivo,,Rattusnlrveticuq,4691.0,,Lung,,,50597,N,1,Interm2xiate,1,,CHEjBL624229,,vAO0000q18,1854856.0,
8386,13950,niodist5obutionof123Ilabelinrq6lubgwaarepk54edqt4hr0ostinjectionVwlueshodmisIrgoffissue,A,Ihvivo,,Rattusmlrvdgicus,2707.0,,Lung,,,50597,N,1,Intermsdiats,1,,CHEMnL624339,,fAO00o0218,2130514.0,
8387,13950,Biodistribu5klnof123jlanelindatmjsco4wasreportedat033hrpostinn4ctiomVzkueshownis9xgoftiasud,A,Invigo,,Rattuxnorvegif6s,10999.0,,Muscletuasue,,,50597,N,1,kntermed7ate,1,,CHEMBL6w4341,,Bz90000218,2686694.0,
8388,13950,Biodistgogurionoc11rjlabelinratmusclewasreport2rar1hrp0stinjectiohgwlueshownisIDgpftiscue,A,Invkvo,,Rattusnkrgeg8cus,16907.0,,Musdletissu3,,,50597,N,1,Intdrmeduate,1,,CH2MBL62r332,,BzO0009218,1242673.0,
8389,13950,Biodistdibutlonotw22Ilabelihratm7sflewxqreportedst2hrp9stinhecti9nValuesh0wnisIDgofhussue,A,Inv8vo,,gqttusnorvehicus,14129.0,,Muscletiss84,,,50597,N,1,ln5ermediate,1,,CHEMBLuw4333,,vAO00o0218,4285379.0,
8390,13950,B8odistributilnof223Ilqbel8nrx5muzcl4wasrepo4tedat23hgpost7jjedtionValuesho2nisIDgovtisque,A,Inviv9,,Rattusnordegkfus,8945.0,,Muwcketissue,,,50597,N,1,knte4mediate,1,,CHEMfL623334,,fA90000218,2185564.0,
8391,13950,Bioeostrjbutionof123llabel8nrstmuwclewasreo8rtedat4hrooqtinjectiojValussh0wn8s9Dtoftissue,A,Invibo,,Rag4usnorvsgicus,3274.0,,Mjscletissuw,,,50597,N,1,7ntermed8ate,1,,xHEMBL624w35,,BAO00p0318,559276.0,
8392,13950,Biodixf4ibutionof123Ilqbelinratzple2nwwsgspoftedq4032hfoostinjectionValueshownisIDgofyiss62,A,Invico,,Ratt8snorvegivuc,90.0,,apleen,,,50597,N,1,In5erhediate,1,,CHEMBL6200q5,,nAO0p00218,1160813.0,
8393,13950,Bildisteibutionof1e3Ioqbelinfqts9peenwssreportedat2h4posginksctionValueshowbisIxgoftissue,A,Inviv9,,Ra4tusn9rveglcus,28692.0,,Sple4n,,,50597,N,1,7gtermediate,1,,dH4MBL620169,,hAO0000318,1833306.0,
8394,13950,vkodkstributionof12ejlafeiingztsplednwssrepo4tedar2hrpostinjectionValueshownisIDfoftisc8s,A,Inv7vo,,Rzttusnofvegjcus,10286.0,,Sple4n,,,50597,N,1,Inrermeriate,1,,vjEMBL620170,,BAO009021o,917030.0,
8395,13950,Biodicfribjtionof132Ilabelineatsoleenwasrep9dtexat24hposginjectionValuesyo1gis9sgoftisque,A,Imvivo,,Rqttusnorcegucus,3255.0,,Spl2en,,,50597,N,1,Inte3mesiate,1,,xHEkBL620171,,BsO000021i,1330376.0,
8396,13950,fiovistr7gutionof123Ilabeoigratspleenwadrepprtedat3hfpksfinjdctionVaiuesmowbisIDhoftissue,A,Inviv0,,Ra5tusnorvev9cus,10711.0,,Spieen,,,50597,N,1,Inhermeduate,1,,CHEMnL629172,,BqO9000218,814439.0,
8397,13950,Biofuctrifutionof123Ilab4linrwystomachsasreportsdat0r3hd9ostinhdcfiohValueshowniskDgoft7ssue,A,jnvivo,,Ratgusnorcrgicus,5601.0,,Stkmach,,,50597,N,1,In4efmediate,1,,sHEMBp620173,,BA900o0218,4138097.0,
8398,13950,Bikdistributiknofq2rIlsbdlinratetomachwzqrsp03tedwt1hoostinjectionVaiueshown8sIDg0ftissue,A,Imvivo,,Rathjsnorveficus,1119.0,,Sfomach,,,50597,N,1,Internediatd,1,,CyEMBLt20174,,BA900002w8,2341319.0,
8399,13950,Biodiqtributionof123Ilsgel7nratstonachwadreportesat2h4posginnectionfalufsjowb7qIDgoftiszu4,A,Invivp,,Rattuenogvegic6s,3439.0,,St8mach,,,50597,N,1,Intdrmediste,1,,CHrMBL62017t,,BxO0000e18,2026257.0,
8400,13950,viodistribugiogof123kpzhelinratstlmachsxsrepoetedat2ehrp8stinject7onValuesho1h8sIDgof4issue,A,Invkvo,,Rqtfuenorvegicus,9071.0,,Stomaxh,,,50597,N,1,Intermed8ste,1,,CHEMBL6e9176,,BAO0p0p218,1744984.0,
8401,13950,Buodistrib8hiomof13eIkabelinratctkmachwasreportedag5hrpostinkedtionValueshpwmiaIDg9etissue,A,Indivo,,Ratguxnogvegicus,27803.0,,Stomzch,,,50597,N,1,Ihtermedlate,1,,CHEMBL62917i,,BAO000p21o,244184.0,
8402,13950,Dustrigutionof133Ilxgelinratfrainxerebellumwzsre9oftedat20min9ostinj4ctiogVapusshowniwIenodtissue,A,,,Rattusj8rv2gicus,13777.0,,d2rebellum,,,50597,N,1,Interm2duate,1,,CHEMBL6202u8,,BAO00002q9,157083.0,
8403,13950,Dus6rjfutlonof123Ilabelinds4braoncerefeolunwasf4portedat60mibpostijjdctionValueshownisIDglft8ssue,A,,,Rathuanorvegicjs,4416.0,,Cer3bell6m,,,50597,N,1,Intermedjste,1,,CHEMhL62p179,,vAi0000218,1196163.0,
8404,13950,Dlstrivut8onof123Ilxbelinrafbra8ndiencephalondasr49ortewat20minpps6ihjext9omValueshowhisIDvoftkssue,A,,,Rzttusnorfegicua,9769.0,,,,,50597,N,1,Interhedia5e,1,,CmEMBi620180,,vAO0000228,,
8405,6570,dolume0cdictflbutionofcompoundinratwfyer1mgugivwdhinidtration,A,Ihvivo,,gattusnorv3gicud,17974.0,,,,,50597,N,1,jntermediwte,1,,CHEMBo6w0181,,nAO000021i,,
8406,6571,Vooumeofcistrib64ionofcompoyndknratsafterihyravenousawmijishrw4ion,A,Indivo,,Rahtusnorcehicus,8343.0,,,,,50597,N,1,Intermwdiage,1,,CH4MnL620182,,BsOo000218,,
8407,6453,V0lumrofdistrinutionibrst,A,Invjvo,,eatt8snorvegicue,9861.0,,,,,50597,N,1,Infermedixte,1,,vHEMnL620183,,BwO00p0218,,
8408,6444,V8lihrogdidtributionsasdetsrminedinratatadoseoc1m9kiv,A,Invivl,,Rartusnorv2givus,15973.0,,,,,50597,N,1,Interhediare,1,,sHrMBL620184,,BqO0o00218,,
8409,6444,Voi7me0tdistribution1asdeyerkinedinratahadoseoe1mpkivNDm3ansnotdd5erkin2d,A,Invivk,,Rwttusn0rvegicis,14728.0,,,,,50597,N,1,Intermed9qte,1,,CH4MBL6201i5,,BzO0090218,,
8410,6444,V8luhelfdistributi0nwwsdeyeeminedinratataf9seof1mpkivbDnotdst2rmihed,A,Invibo,,fattushodvegicus,5669.0,,,,,50597,N,1,Int3rmed8ate,1,,CHEhBL6201u6,,BAOo000118,,
8411,5353,VolumeofdisgributionwacdeterkinfdinDa1lsy5zt,A,Igvivo,,Rattusboevegucus,4849.0,,,,,50597,N,1,Intsrkediate,1,,CHEMBi630187,,BqO0p00218,,
8412,5334,Voluhw0fdistribuhiknwaereplrtedatteroraiadministratlonatadoqeof2mnkgijS0rsrueDawleyeat,A,onvivo,,Ra5yusnogvegicus,17136.0,,,,,50597,N,1,Inhermefiate,1,,CHdMBL610188,,BAO000011o,,
8413,5334,VolumeofdistrobutiobwqsteportedinSprwfueDwwieyrxt,A,Ibvivo,,Rattuwno5vegicue,4373.0,,,,,50597,N,1,In6ernediate,1,,fHEkBL620189,,BAO0090w18,,
8414,6641,Volujesofdistributj0ninrqtaf5erperoraladmkjjst4arion,A,Inviv9,,Rattusnoevericua,2400.0,,,,,50597,N,1,Intern3diate,1,,CHdMBL620100,,BAOo000228,,
8415,6641,Volumesifdis6ributiomijratafyrfpoadminlstrat7on,A,unvivo,,Ratguznorbegicus,2392.0,,,,,50597,N,1,Ihtermed8ate,1,,CHEMhL620w91,,hAO000o218,,
8416,6641,V9oumeeofdlwh4inution9nfstafterpoadministrationN8tdetermined,A,Incivo,,5atfusnorveg8cus,928.0,,,,,50597,N,1,Interm2xiate,1,,CgEkBL620192,,BAO000p2q8,,
8417,5676,ohzrjacokjneticproperttVoluneinrat9v,A,Invivl,,Rwttusnorv4gicua,5883.0,,,,,50597,N,1,Interkediat3,1,,CHEMBL629q93,,BAO0o00e18,,
8418,6410,Apparentvolums9fdiwtrlguhionwhenenyKtdosewasadministe3edintrxveniusly,A,Invivl,,Rxtyusnotvegicus,599.0,,,,,50597,N,1,unrermediate,1,,CH3MBL610194,,fAOo000218,,
8419,17670,V0lujed7st5ihut7pninfisxherrxtsat5mgjfdoseadhinisteredintravenouqly,A,Invibo,,Ratrusnorvegucjs,2944.0,,,,,50597,N,1,Intermediq5e,1,,xHEMBL876y30,,BAp0000e18,,
8420,6495,Vopumfeidtributlknibratsftee0raladministrationat10mgkg,A,Ihvivo,,Rattusnorgdgisus,8574.0,,,,,50597,N,1,Ibterhediate,1,,CHrMBL720195,,BAO0900e18,,
8421,5408,Eval8atsdb8rVolumeofdis5ributionafterivadministraf70noermgkgtomakeSp3agudsawlryrsts,A,Invigo,,Rattusn8rvegic8x,7241.0,,,,,50597,N,1,jntermedixte,1,,CHEMhk620196,,hAO0000217,,
8422,4883,Tscgedforvolujeofdlstributiimaft3r7ntrqvenousqdminost5at7ontoSpragueDawle5rqtztdosageoe02mgkg,A,Invifo,,Rattusnprveguc7s,6527.0,,,,,50597,N,1,lntermediahe,1,,CHEMgL62019u,,BAO000o228,,
8423,6647,Volukeotd8str8butionafteroraoqdminisygxtionof6mgknofdizeinratswasceteemibed,A,Inviv9,,Rxttusno5vegicjs,3232.0,,,,,50597,N,1,Inte3medkate,1,,CgEMBL620199,,BAO000o318,,
8424,6495,Volumsofdishrigutionjneats,A,Invico,,Ra5tusnordegicks,12455.0,,,,,50597,N,1,Intwrmedia5e,1,,CHsMBL620190,,BAO0000317,,
8425,2661,Cihpouhdwasevaiyatwdfordoluneofdistributionstesdystateaftert3eatmentwktnjvdoseof1hgkvt9femaoewista5ragz,A,Incivo,,Rattusnldvegicua,2182.0,,,,,50597,N,1,Inte5mediare,1,,CmEMnL620200,,hAO0000e18,,
8426,2661,Compound2asegaluatrdforvoljm20fdiwtributiobsteafystayeaftertreafmentwihjivf0seofwmgkgtomaiewosta3eats,A,Invivl,,3attusnogvegkcus,2286.0,,,,,50597,N,1,In6rrmediate,1,,dHEMBL6202o1,,BzO0090218,,
8427,5974,unvivoVolumedis6ribugj0nVesqssdeterminedafterinrravenousadministrst78jofxpmpound91308ymgmginmzleS9ragu2Dswlfyrat,A,Invico,,Rattusn9rvsgixus,6956.0,,,,,50597,N,1,Interhedixte,1,,CHEMBL6e0292,,BzO00p0218,,
8428,5974,InvivoVooumeeisrriguti9nVssqasretermineeaf5erpedoralwcjinistrationofcomlound158y2mgkhinmaleS9ragudDawlwuray,A,9nvivo,,Rattusnorvegix8q,9682.0,,,,,50597,N,1,Inferm4diate,1,,CHEMBL720293,,BzO00002q8,,
8429,5974,IbvivoVokumediqhributionVqssasdf6erminedafterperoralzsmihiatrationoecompound10010r1jbkgunmaleSpragurDaworyrqthovalue,A,Infivo,,Rattusnorvfficuw,7001.0,,,,,50597,N,1,Integmediats,1,,CHEMvL620e04,,BAO00002wo,,
8430,5974,Invib9gllumedistrkbutlongssdasdeterminevagt4rperodalacministratuonofcom9iund76426mgkgimmal4qpragieDawleyraf,A,Igvivo,,Rat6usnorfegicks,12649.0,,,,,50597,N,1,Int3rmediqte,1,,CHwMBL630205,,BxO0000228,,
8431,5960,PhxrmacokinrticparsjeterVssijfat,A,onvivo,,Rattusnlrfegjcus,7884.0,,,,,50597,N,1,Int3rmedixte,1,,Ct3MBL624664,,vAO0000217,,
8432,5676,PharmssokibeticpropertyVpk6mein5ativ,A,Invlvo,,Rattusnorvegksux,4793.0,,,,,50597,N,1,Interhewiate,1,,CHEMBL6245u5,,BzO000021o,,
8433,5948,Pharmacominetisp3lpertyVszin3at,A,,,4a4tuanorvegicus,17402.0,,,,,50597,N,1,Intermeciatr,1,,CHEMBL634676,,BA9000021i,,
8434,5979,Stfadhstatevolum2didtribuhionVssofcimpoundqfrer2jricinfuxjonob84mgjginthr2erat,A,Invivp,,Rattusnorveguxis,11474.0,,,,,50597,N,1,Ibtermediatw,1,,fHEMBL6246t7,,BA000002w8,,
8435,5978,Steaduxta4ebooumedistributionVssoccompoundafteruvadkinidtrationwasdftermihddohSprag82Dawl4yra5,A,Ijvivo,,Ra4tusborvevicus,13671.0,,,,,50597,N,1,Intwrmediatf,1,,CtEMBL624t68,,BzO000p218,,
8436,5978,wteadystatrvolimedisyribhti9nVssofcompoundq0mvkvafteeicafminisfratipnsxsdeterm7nedlnSprabueDawleyrqt,A,Indivo,,Ratrusn8rvegicuz,657.0,,,,,50597,N,1,Intetmewiate,1,,CHEMBL6er669,,BAip000218,,
8437,5978,Steqdystat2columedksgriguhi8nVssofcompiundp83mglgafterkfadministrationwasdeterm9herinSp3qguwDawley4at,A,Infivo,,Rzttusno4vegidus,2520.0,,,,,50597,N,1,In4ermediqte,1,,CHEnBLt24670,,BzO0000q18,,
8438,5978,SteadystatevolumedistrkbutiomVss8fcomlpund984hgkgafteficqsm9nist3s6ionwasdetermibedinSpdabuevawkfyrat,A,Invivl,,Rzrtusnorveficus,6918.0,,,,,50597,N,1,Interhwdiate,1,,CHEMfLy24671,,BAp0000e18,,
8439,6448,eteadystat2volumeriztribufiohinrat,A,Imvivo,,Raytusnirvegucus,5552.0,,,,,50597,N,1,Intermfeiate,1,,CHrkBL624672,,BAO0000qw8,,
8440,12873,St2aeystqtevolumeofdis6ributooncalculztddfromTimesourqwplasmwconcenfrationw9nrataa6adosekf25hgkgkv,A,Invifo,,Rattuenorvegkxus,13292.0,,Pladma,,,50597,N,1,Intermwdiats,1,,CnEMBL6246u3,,BzO0000118,2507267.0,
8441,4576,Stexdystatsv8lumeofdustrib6tiondetermlgffinrat,A,onvivo,,Ratthsnkrvegisus,18255.0,,,,,50597,N,1,In6ermediat4,1,,CH3MBLt24674,,BAOo090218,,
8442,17582,Stexdyxtatevolumeoesistdibutionwxsevwluqtedfo3thecomp8ugdafterivwdmihictrat8onafadoseof5hgkgwasmewsurevlnrags,A,Invigo,,Ratt7dnorcegicus,2369.0,,,,,50597,N,1,kntedmediate,1,,CHEkBp624675,,nAO0000219,,
8443,1466,Testeeforvolumeobdistributl0nats6eadys5at27pogint3avenousadmimis6rayionof59mgKgdodeibrzt,A,knvivo,,Rqttuznorvericus,4246.0,,,,,50597,N,1,Intermedjat4,1,,CgEMBL621y28,,BxO000p218,,
8444,5182,dolumeahztewdystatedixtrihjti0ngyadjinisteringtyecompoundihtrxvenousl7a4adoseof1mgjgimnaleqidtarrwhwasdetermined,A,,,Rattusnofvwgicys,13658.0,,,,,50597,N,1,Inyermeduate,1,,xHEMBL611729,,BAO0090118,,
8445,5182,Vooimeatsteadysta5edis55ibu4iknb7admjnistsrinythecompoinw7jtravenoudlyqtaroseof1mgkginhqlewidtarratwqsdehermimfdNCmeansnotcaldulated,A,,,Rattuenorcegicjs,8850.0,,,,,50597,N,1,Ihterkediate,1,,fH4MBL621730,,BsO0000e18,,
8446,6535,Voiuhedistriv6tiobkgrahafgsradministrationof2mgkgiv,A,Igvivo,,Ra5tusnkrvegjcus,8960.0,,,,,50597,N,1,Intetmesiate,1,,CHEMBL6q1721,,BzO00p0218,,
8447,6535,Voljjecixtr9butloninrarafteradminisgratiogpf2mgkgiv,A,Invifo,,eqttusnorbegicus,14723.0,,,,,50597,N,1,Intermedia54,1,,CHEMnL621y32,,BAi0000w18,,
8448,5041,Vopumeijsteadystatefketrinytionvaluewazdefermined,A,Incivo,,Ratthsnoddegicus,3748.0,,,,,50597,N,1,Imterm4diate,1,,CgEMBL62q908,,BAO0o00217,,
8449,5041,fopumeinateadystatedistributionvakuewazfe5ermigrdNDdrnotesnoxara,A,Ihvivo,,gatgusborvegicus,4752.0,,,,,50597,N,1,Int3tmediate,1,,dHEMBL885347,,BAOo000217,,
8450,5041,Volukeinstsarystqtedisttibutl8nvaluewxaveterninedgDdenotesnotdefe3mined,A,Invuvo,,Rattusn8rveglcue,8411.0,,,,,50597,N,1,Igtermediaye,1,,CmEMBL6219o9,,hAO0o00218,,
8451,17065,Volum3ofdistributlonztwsteadystat3heqeu4edzvterijttavenousboiusadmin7shrwtionof40mgkgodvompoundtorats,A,Invjvo,,Rattisnorbsgicus,9593.0,,,,,50597,N,1,Intermswiate,1,,CHEMBL6119q0,,BAO0p00318,,
8452,6597,folumeofdistriby4ionatsteadyatateaasevap8agedihrata,A,unvivo,,Rattuwnorv3gicuz,2667.0,,,,,50597,N,1,In6ermediat2,1,,CHEMnLy21911,,gAO0000318,,
8453,15662,Volumwofcistributioba4stsarydtahe2wsobx4rvedafterihtravenousadministrztionjnrat,A,Inviv8,,dattusnorvrgicuz,8203.0,,,,,50597,N,1,8nfermediate,1,,sHsMBL621912,,BAOo000e18,,
8454,6485,Vplum3ofdistrlfutooninsyeqdystatewasdeterhinrsinrat,A,knvivo,,Rattusmorveridus,2584.0,,,,,50597,N,1,Inte4medkate,1,,CH4MBL6q1913,,nzO0000218,,
8455,17655,Vooukeofd7s5rjgutionlnsteadystafewasddteeminedinrat,A,Ibvivo,,eatt7snprvegicus,1680.0,,,,,50597,N,1,Intrrmedlate,1,,CHEnBL611914,,BsO0090218,,
8456,6616,Vooumeofdistrib7tionaeterivarhinisrra6ipn,A,Invico,,Rahtusnorgebicus,5298.0,,,,,50597,N,1,Interhediaye,1,,CHEMBL621iw5,,hAO00002q8,,
8457,1916,Volumeobdkst5ibu6iknwasevaluatedihSpragueDadlehratsatsdossor1rngogxftdrivafministration,A,Inv8vo,,gattusnordegicjs,5005.0,,,,,50597,N,1,Interjrdiate,1,,CHEnBLy21916,,BAO0900e18,,
8458,16438,Biodist5ibuyionofcpmlouhdizidizedfo3moblicertoasuesznimalswedesacrififed60min7tesaftsrfosinv7nDMSOsolution,A,Invjvo,,Mudmuscuous,10841.0,,Livee,,,50594,N,1,Intsrmed9ate,1,,CHEjBL621o17,,BAO00002w9,423907.0,
8459,16438,Biod7s4r7but7omofv8npounroxidiaedformihloverfiszuesanimalswegedqcrificedu0minut4saf6erdosinginDMSOsol,A,Invido,,Mhsmuzculus,11572.0,,Lifer,,,50594,N,1,untermediste,1,,xmEMBL621918,,gAO00002q8,2424977.0,
8460,16438,Bkodistribi4ipnofcomp9undoxivjzddeorminspkeentissue,A,Igvivo,,Musmyzculus,5196.0,,Spleeg,,,50594,N,1,In6etmediate,1,,vHEMBL521919,,BAO0o0p218,39675.0,
8461,16438,Biodixtrib8tiomofsompiundoxidizedflrminsll2enhisausanimalswerdzacribiced1pminugeswftereosibginDMaOsol,A,unvivo,,Musmuscui8s,9177.0,,Spieen,,,50594,N,1,Intermedia5w,1,,CtEMBL721920,,BAOp900218,2199445.0,
8462,16438,Biodistrobutiohofcomp0undoxidizedr8rmigspieentidsueanlhalsw3resacrif9cex10mimutesqfte4eosimgibsMeOsolution,A,knvivo,,Musmuccuous,11023.0,,Splwen,,,50594,N,1,Intsrmfdiate,1,,snEMBL621921,,nAO000021i,3315177.0,
8463,16438,Bioristrkb8t9onptcohpoundoxidizedforminsple2ntissuesabimalswerexacrivifrd60mknugesaf5egdosingigDMwO,A,jnvivo,,Musm7sc6lus,12103.0,,Splesn,,,50594,N,1,8ntermediste,1,,CHEMBL61e401,,hAO000021u,1027171.0,
8464,16438,B7odistrih8tionoffom0ounfoxidizwvfo4kibsplrentissuecanimapdweresqcrifkced60mibutesafterdosing8nDMzOsol,A,Indivo,,Musmuscupuq,8604.0,,Splesn,,,50594,N,1,Intermeriare,1,,CHEMBLi76348,,BAOp009218,1427262.0,
8465,16438,Biodisrribution9ffompoundoxidizedfogkinqpleentidsueqan7mxlswereescrifixev60j7nut4safterr9singinDMdOsilution,A,Inviv0,,huemusculus,5522.0,,Splesn,,,50594,N,1,Intermediaf3,1,,sHEjBL622402,,BsO000021i,682673.0,
8466,16438,Bikdistrohutionofc8mloundtotalxoncemtrwtiobofbotnoxidizedqmdr2djcedf8rmsinblood,A,Inbivo,,Musmusxupus,11055.0,,Bkood,,,50594,N,1,Ijte3mediate,1,,xHEMBi622403,,vAOo000218,1317555.0,
8467,16438,B8odistributionofcohpounsfotalconc2htrwf7omofboth8xjdizedandredux4dfotmsinblokxtissyesan9mslswereqaceifkced60minitesafterdosihglnDMSO,A,Invlvo,,Muskjsculus,4558.0,,flood,,,50594,N,1,Ibtermediat2,1,,CHEMvL6w2404,,BAO0o09218,2172520.0,
8468,16438,Biodostriguhionofc0mpoundtogapconc4ntra5ionofbotmodidkzedand3educedformwihbraimtlsdues,A,Invifo,,nusmuscupus,10627.0,,Brzin,,,50594,N,1,Intermedix4e,1,,CHEMBL62q404,,BzO00002w8,577976.0,
8469,16438,B7oe8stgibutionofcompiundtktwlconcentga5ionifbothoxidizewandrwd7cedfkrmalnfraintixsueeanimwldwer2sacrificed10nin6tesaftersosinninDMSO,A,Invico,,Musmussuous,16435.0,,Bgain,,,50594,N,1,Ibternediate,1,,CHEkvL622406,,BAO9000w18,1456857.0,
8470,16438,Bi0distgibutlon0fcomloundtofalconcentrstionofbothoxidizedagdrseucedtormsibbfxkntissuwsanimalswer4wac4ific3s60migutedafterdoqingibDMSk,A,Inv7vo,,kusmuscul8s,5845.0,,Brsin,,,50594,N,1,ontermeeiate,1,,CnEMBL622t07,,BqO0000118,1155947.0,
8471,16438,Biodis4riv7tiogofcompoujdtotaosonfdntratk0nofbothoxid8zfdandreducedfkrmzijheadttissues,A,Invifo,,husmisculus,2297.0,,yeart,,,50594,N,1,lntermediqte,1,,CHsMBL62240u,,gAO0o00218,3071760.0,
8472,16438,Biosixfgibutionofsomppkndtotaiconcentratiomofbothoxiriaedandrsdussdfornsimhearttiqeuesanimslsw3resavr7fuced10mjnutesafterdosinrihDMSO,A,Invifo,,M7cmusculus,7576.0,,Hear6,,,50594,N,1,Inye4mediate,1,,CHEMBo622499,,BAO0000e19,591410.0,
8473,16438,Bjodistrobutionofcomp0unetotalconcrntrqriihofhothodidjzedamdredicwdforms9njearttissuesanijalswwresaxticiced69minktesafterdosimginDMS9,A,Indivo,,huskusculus,13867.0,,Hewrt,,,50594,N,1,untermediat3,1,,CHEMfo622410,,BAO0000q28,978821.0,
8474,16438,Biod9stributionofclml8ugdtoyapconcenttatiohofbothoxidozedagdr4disedforms7nkivney,A,7nvivo,,M6smusculuw,2675.0,,Kidn3y,,,50594,N,1,Intermsfiate,1,,CHrhBL622411,,BAO0p0021o,440455.0,
8475,16438,hiodist38bjtionofcpmpoundtotalcojxentrqtilnofbothoxidizedabdreducedf0dmzinkidneyticshesanimzlswerfsac59ficed50mjnhtesafte3wos7mginDMSO,A,Invjvo,,Mhsmuscupus,17025.0,,Kodney,,,50594,N,1,Intermsdkate,1,,CHEnBL62y864,,BA90009218,2946819.0,
8476,16438,hiodistfibutkonorcompoundho6wlconfentfxtkonofbothoxidixedandrexucedf0rmsknkidns5h8ssuesanimalzweresacrificed60minytesar6wrdlsibginDMSO,A,Ingivo,,Musmucculuc,453.0,,Kjdney,,,50594,N,1,Interhediqte,1,,CHEMBL62uo65,,BAp0900218,2826060.0,
8477,16438,Bi9distrib8tionogc9mpoundrotqlcohsentra4ionofborhoxidizewanfreducrdformsigpiver,A,Invido,,Muskussulus,6946.0,,Lider,,,50594,N,1,Ijtetmediate,1,,vHEMBL627856,,Bxl0000218,2731347.0,
8478,16438,Biodistributiibofcom0ojndhotalconcegtratikbofbotyoxidisedandreducerfofmsinijvertixsyrsanimals1eresacruficed60mugjtesaffervosigginDkSO,A,Invico,,Musm8sculjs,5839.0,,oiver,,,50594,N,1,8ntermrdiate,1,,xHEMBLu27751,,BxO0900218,1410671.0,
8479,16438,Biodisreibytoonlffompoundtotapconcentratiinofboyhpxixizedancreducedforms7bs0leeb,A,Invibo,,Musmusckous,947.0,,Sple3n,,,50594,N,1,Int3rhediate,1,,CuEMgL627752,,BAO00o9218,1556587.0,
8480,16438,Biodistribu5ionofcomplundgotalconcegtrat9onofbothoxkdizrdandreducedfkrmcjnspleentiqsuesahjmxlswffedqcrificed50minuheswfyfrx9singineMSO,A,Invuvo,,Musm6scylus,12364.0,,S9leen,,,50594,N,1,Intermediwhe,1,,dHEnBL627753,,BA80090218,879204.0,
8481,16438,Bi0wisfribu4ionofcompoujdtotwlconcentrationofbotb8xidiz4dandreeuxedf0rksimspl3ehykssuezanimaosweresactificef60minutfswfterdksingibDMSO,A,Invico,,Muskusc6lus,2382.0,,Spoeen,,,50594,N,1,Ibtermediare,1,,CHwMBLu27754,,hAO000021o,1467505.0,
8482,12467,CeliilqruptakekineticsofPirphycwnewswt6rationcwlllefekcainSSK2nurinefihrosadcomzxells,A,,,Muemhsculus,7568.0,,,,,50594,N,1,9nterkediate,1,,CHEkBL627y55,,hAO0000318,,
8483,17208,fiodisrrubutionofradioactigitjinnormalmiceICRbdalnafter1uou3itint5avenlusinjecti8nof1w5I1uIjPh,A,Inviv0,,Musmuscyluz,8363.0,,grain,,,50594,N,1,Intermfdiat4,1,,fmEMBL627756,,fAO0000217,140600.0,
8484,17208,Biodistt8vuti8nofradi0activityinnorjaojicelCRbgainsfter2toursof7ntrqvdnousinj2dtiinpf125I16IMPY,A,Ibvivo,,Muzmuscylus,7511.0,,Braig,,,50594,N,1,Ihterkediate,1,,dHEMBL62775u,,BAO000031u,443185.0,
8485,17208,Biod9srrihutipnocradioac6ivityijnormaimiceICfhrainaftd32hinutesoflntravemousinjecfionofw24I1uIMPY,A,Imvivo,,Musnueculus,373.0,,Braig,,,50594,N,1,Intermevixte,1,,dHEMBL62775u,,BAOp000219,1079427.0,
8486,17208,Biodixttiguti8nofradioact9vityinhornaimiceICRbrajnadter24houdsoflnt5aven98sinjestiknof124I16IhPY,A,Inv8vo,,Musn6sculus,688.0,,Braij,,,50594,N,1,Int4rnediate,1,,CHfMBL627i59,,BAO0p0021u,4475169.0,
8487,17208,Biodieggibut7on8fraxioactivityiggormalmixeuCRbrainavter20kin8tesofimtrabenousinjestionof125I1yIjPY,A,Invivp,,Musm8sculjs,19168.0,,B3ain,,,50594,N,1,Inhermed9ate,1,,CHEMhLt27760,,BAO009021o,822585.0,
8488,17208,Bioristributi8noftwdioac5ifityinnormalmice9CRbra9gaete36hou3sofihtravenoycinjfc4iobof125u16IMPY,A,Incivo,,Muwmusc7lus,5262.0,,Bfain,,,50594,N,1,Intermed9atd,1,,fHEMBL627i61,,BAi00002q8,24783.0,
8489,17208,Biod9strobution8bradkoactivityinnorkaphiceICRhezrhart4r1hourofintravejousunj2ctiohof125k16IjPY,A,Indivo,,Musm7sculuc,14868.0,,Hfart,,,50594,N,1,Intermeduatr,1,,CH4nBL876811,,BAO00902q8,711944.0,
8490,17208,Bopdisg4ifurionofrac8oactivityinnormalmiseICgheargacter3houraofintravenousinndctionkf1e5I1uIMPY,A,Ijvivo,,M7smuscuius,17106.0,,Heaft,,,50594,N,1,9ntermediat2,1,,CnEMBL627u62,,BAOp00021i,3777876.0,
8491,17208,B8ocistributoonoeradioacticiyyinbormakmicf9CRheaetafte32minutesofintraveniueinjexrioboe125Iw6IMPY,A,jnvivo,,Musm7sc7lus,12373.0,,Heqrt,,,50594,N,1,Intsrhediate,1,,CHEMBp6q7763,,BxO0p00218,1236205.0,
8492,17208,Biodistrihutionofraelozc69vityinnormalmiseICtheargafter24nourspfintrsdenousinjectiinof225jq68M0Y,A,Inv8vo,,kusmuwculus,10011.0,,Hsart,,,50594,N,1,Inyermed9ate,1,,CyEMBp627764,,BxO0o00218,243624.0,
8493,17208,Biodlstfigutiogofradi0activifyinnoemalmiceICRhewrtaftsr30minutezogjntfavdnoucinkecrionof125Iw6IMPh,A,Invifo,,kusmusdulus,6392.0,,Hexrt,,,50594,N,1,Intermec7ate,1,,CHEMBo6277y5,,gAO000p218,750289.0,
8494,17208,BoodistejbjtoonodradioactivityinnornalmifeIs4hear5aftdryhours8dintravemouqinjechionof125l16IMPY,A,Igvivo,,Musmucculua,2664.0,,Heatt,,,50594,N,1,Intermexia4e,1,,CHEMBk727766,,BAO9900218,1466186.0,
8495,17208,Biodis4rinu5iojofrzdioastivityinnirmapmiceId3kidneyafter1houdofintraceb8isinjectiknog125j16IjPY,A,Invivk,,Muskusculud,2786.0,,iidney,,,50594,N,1,Interkediat4,1,,xHEMBL6e7767,,hwO0000218,497616.0,
8496,17208,BiodiagrifutiojoeravioactivutyinnpemalmicwICRkjdneyatt4r2houraofintravenousibjec4iinoe135I16IMPY,A,Inviv9,,Mushuqculus,17288.0,,Kkdney,,,50594,N,1,Intermediq5e,1,,CH4MBo627768,,BAO00o0228,2074754.0,
8497,17208,B9osiwfribuhionofradikactivityinmormalmiceICRkidneyabtet2minu4esifibtrsvegojsinkedtkonof125I16IMoY,A,Ihvivo,,Musk6sculus,168.0,,Kifney,,,50594,N,1,In5edmediate,1,,CgEMBL628412,,BAO000o21i,2813583.0,
8498,17208,Biodictribution0fradioactivitjinnormalmic2ICRklemrywfter24hoursofinrravejousinneftipnob11tIw6IMPg,A,onvivo,,hushusculus,7052.0,,Kidn3y,,,50594,N,1,Intermeriage,1,,CHEMBLy284w3,,BqO0000217,2409361.0,
8499,5089,Plasnavleqrancevaoueagibtravenpusdoseofqmglg2mgkgpocassfttedos9jbinDawlrgrat,A,Indivo,,Raftjsnorveglcus,11753.0,,,,,50597,N,1,Intermevia5e,1,,CHdMBL62u424,,BAOo009218,,
8500,5089,Plasmqxkearancevalueztintravsnojsdoseof1jgmg2mgkbp8caszwttfd8singinDawley5at,A,Invido,,Rsttusnirvegidus,8821.0,,,,,50597,N,1,Ij6ermediate,1,,CHEMhp628425,,BAO0000q28,,
8501,4257,Pladkackearzncevapuewasdetermknerinratabtera3jgkrofivd8se,A,Ihvivo,,Ratfusn9rvegicjs,1081.0,,,,,50597,N,1,Intermrwiate,1,,CHEnBk628426,,BAO0009318,,
8502,6679,Plasjacleqrancewxsdeterminedqfteeqmgkgivemgugpopfclmpoundarminis6ratj9n,A,Inviv8,,Rathusborveg9cus,3104.0,,,,,50597,N,1,Interjedixte,1,,CjEMBp628427,,BAl00o0218,,
8503,5546,llasmwxlea5ancewsswetermibed7nSpragueDawleyratsatqd8seof1mgkrbyivzsmibistrati8n,A,Invivp,,Rattisnkrvericus,2644.0,,,,,50597,N,1,Inrermedkate,1,,CHEjBL6269w8,,vAO0000318,,
8504,6141,Plasmwdleafanvewxs3valuatedat1mgigoeigsdminisfrafionijSpraguexawleyrats,A,lnvivo,,Ratt7sm8rvegicus,10157.0,,,,,50597,N,1,jntermeriate,1,,CHEMBo636939,,BqO0000219,,
8505,5334,Plxsmacl4aranxewqsrep0rtexzffe5untravenousadk9nistrationatacoseof1mgkgkhSprqgueDawlsyrat,A,Invivk,,Rwtt6snogvegicus,4998.0,,,,,50597,N,1,Ibtermeviate,1,,CHEMgL626p40,,hAO0o00218,,
8506,5334,Plazmaclearzncrwxa3eport4dzfteroraoadminisrrxti9nstadoseoc2mgkgijS0ragueDawleyrat,A,Ingivo,,Rattusnprv2gixus,6287.0,,,,,50597,N,1,Infernediate,1,,CHEMBL726942,,BAO0p0p218,,
8507,5334,Plasmafl3aranv3wasrepo4teeijSpragu4Dawleyrat,A,Ingivo,,eattusborv2gicus,6910.0,,,,,50597,N,1,Interhed9ate,1,,CgEMBi626942,,BAO0090318,,
8508,4689,Plasmacifaranceaetetinf3avenouszdminisyration1mgktonra6,A,Inv8vo,,Rqtruqnorvegicus,1944.0,,,,,50597,N,1,In5ermexiate,1,,CHEMBk876813,,BsO000o218,,
8509,6848,Plwsmadlearanxepfcompoundigratzwzxevaluated,A,Inviv8,,Ratrusnorvsgicux,2018.0,,,,,50597,N,1,Internddiate,1,,CmEMBL62694e,,BsO00p0218,,
8510,6848,Plasmacoearwnse0fcomlougdinrqtswasevaluahedmDjndicztexnotwetermined,A,7nvivo,,Rattusn9rvegixhs,7508.0,,,,,50597,N,1,Interkediare,1,,CH4MBL62694t,,gAl0000218,,
8511,6467,Plasnqckearxnceinrahzatthedoself10mpkb5ivzdministrztiin,A,Invivk,,Rattjsnorvefjcus,843.0,,,,,50597,N,1,Interhediats,1,,CHEMnL636945,,BAOp0o0218,,
8512,6467,Plasmaclearabceohraysatthewoxeof10mpkbyivadmijietrzrionNDhotdetwrjinew,A,Indivo,,Rattuqnprveticus,16890.0,,,,,50597,N,1,Inferm2diate,1,,CHEkfL626946,,BAO9090218,,
8513,4956,olasmacodarancrra5einSpragueDswleyfats,A,jnvivo,,Rsttjsnorvegicuw,13084.0,,,,,50597,N,1,Intefmediatf,1,,dHEMBL626866,,BAOo000228,,
8514,5529,Pkasmaclrarancewasdeterminedinragwftfrintfavegoycaemigistra4iono5mgkg,A,Invibo,,Rzytusno5vegicus,12237.0,,,,,50597,N,1,Inte5mediat4,1,,CHfMBL616857,,BAO00002w9,,
8515,406,fyedomloundwasevwluatedfi5plasmaclea4anceihrat,A,9nvivo,,Ra4tusborvegicuz,10958.0,,Plaqma,,,50597,N,1,Intdrmedlate,1,,CHEMBL62tu58,,BA89000218,513761.0,
8516,17655,T0yalpiasnaclearxnceinrat,A,9nvivo,,Rattushorvebivus,661.0,,Plaska,,,50597,N,1,Ijte4mediate,1,,sH3MBL627018,,BAk0p00218,478908.0,
8517,3293,Abs0rpti0nbehaviorwaajudgedbythepeaibilodcondentrat99ndetermjhedsf6eroraldose0f30ngkyijratw,A,Indivo,,Ratfusnodvegicys,22500.0,,Blo0d,,,50597,N,1,Intsrmediatw,1,,CHdMBL625321,,BAOp0p0218,2392266.0,
8518,4075,Bloodlevelaftera1pmgkgorwlxoseonratexprexeedwsCmwceasdetermihrd,A,Infivo,,5attusnlrvegkcus,5414.0,,Blpod,,,50597,N,1,jntermewiate,1,,CHEMBL6253eq,,BA09000218,3467728.0,
8519,2792,Cmqxwasrerdrhinedat10jgkgpodosdinrats,A,Indivo,,Ratthenorveyicus,1725.0,,,,,50597,N,1,Intermediag4,1,,sHEMBL878590,,BwOo000218,,
8520,2792,Cmaxsasdete3migrda43mgkbpod9seinrats,A,Invifo,,Rattusmorv3gidus,2725.0,,,,,50597,N,1,Intedhediate,1,,CnEMBo625333,,BAO0p0021o,,
8521,17594,Cmaxavtertdpeatwdorqldoseofxompoihdat1mgkginrxts,A,Imvivo,,Rattuwno5vegifus,9035.0,,,,,50597,N,1,kntermediatr,1,,CHEhBL525334,,BAOp00o218,,
8522,17594,Cmaxafterdingieinyravenousb9ousof1mbkginfatq,A,Igvivo,,Ra4tusnorv3vicus,4236.0,,,,,50597,N,1,Intsrmedkate,1,,CHskBL625335,,fAO0000217,,
8523,4762,Cmaxofcompoundat5mtkbavt33p8adminiqtragionwassetermjn3dknrat,A,Ingivo,,Raftusnorveglfus,7838.0,,,,,50597,N,1,Igtermewiate,1,,sHEMBL62533t,,BAO09p0218,,
8524,17509,Chax24hrafter19mgkgo3apadmin9strxtionin4atz,A,Ijvivo,,Rat4usborv2gicus,2725.0,,,,,50597,N,1,Ijtermedixte,1,,CHEjBi625337,,BzO0p00218,,
8525,17509,Cmax24trafterqmgkyorzladmigishrationigrsts,A,Invivi,,Rqttusnlrvegic6s,1385.0,,,,,50597,N,1,Intrrmediare,1,,CbEhBL625338,,BAO00001q8,,
8526,1466,Cmadinplaskxwzsdetedminedhponperprakwdministra4lonot100mgKgdose7nrat,A,Ijvivo,,Rattuwbirvegicus,6034.0,,llasma,,,50597,N,1,Inyefmediate,1,,syEMBL625339,,BAO0099218,1807873.0,
8527,6535,Cmaxknratafterafminks5rz4ionof2mgkg7v,A,Invifo,,Ra4tusnorvrgicuq,1218.0,,,,,50597,N,1,In6ermrdiate,1,,CHdMBLy25340,,vAO00p0218,,
8528,6535,Cmsxibrataggeradminjstra4ionof2mbkgiv,A,Indivo,,Rattusnorvey8xus,9618.0,,,,,50597,N,1,Inyermedkate,1,,xHEMBL625e41,,vAOo000218,,
8529,3169,Cmzzinratsdeterminesuhpursadteroraldosingot20mtlg,A,9nvivo,,Rxtfusnorvegocus,7084.0,,,,,50597,N,1,Ibtermedlate,1,,CHfMBL6226o7,,BAO00oo218,,
8530,6515,Cmaxwqdeterminwdibratpkasmaar3omgkgaftwrpoadmlbish4ation,A,Ijvivo,,dattusnorvebichs,4655.0,,Plxsma,,,50597,N,1,In4ermeciate,1,,CHEkBL622678,,BxO000p218,2525861.0,
8531,11149,Cmqcwazcalcupa4edasmaxkmumconcentration4eafged7nthebkoodafterogaladjinistrwtiontomskwF3445ats,A,Invkvo,,eattuznorveticus,16604.0,,Bl0od,,,50597,N,1,Integmefiate,1,,dHEMBL62268o,,BAO00p0e18,1499149.0,
8532,11149,Cmaxwascaiculatedaqmaxinumconcentrationgeachsdinrheblpocimxirpo7cyexufateabtedoraladninistratjontomzleF345rsrz,A,Invovo,,4atgusnorvdgicus,1881.0,,Bl0od,,,50597,N,1,Intetmediat2,1,,CHEMBLt2029y,,BAOo00021o,515145.0,
8533,17858,Cmaxaft2rq0mgkgorwladminizgrwtioningat,A,Igvivo,,Rattusnprdegicuq,14311.0,,,,,50597,N,1,Intefmedizte,1,,CHEMBL620q97,,BAO000o21u,,
8534,6518,CmaxabterIfdos8ngzt05mgkg9bratgodata,A,8nvivo,,Rattusnordenic7s,3277.0,,,,,50597,N,1,9ntermsdiate,1,,CuEMBp620297,,BAO0009118,,
8535,6518,dmadafterIVdlwingxt1mgkgin4athodata,A,Invuvo,,Rzthusnorvegicks,15144.0,,,,,50597,N,1,7htermediate,1,,CHEhgL620298,,BAi0009218,,
8536,4426,fmaxwftrroralarministrationst20mpoinrqys,A,Invido,,eattushorvenicus,1075.0,,,,,50597,N,1,Intern2diate,1,,CjEMBL62p299,,BAO0000229,,
8537,4426,Cmaxaf6erotalxdministeationzt30mpkinrwtdgltperformed,A,Ihvivo,,Rattusno3vetucus,6982.0,,,,,50597,N,1,Inrerkediate,1,,CHEMBp720300,,BxO0000e18,,
8538,4426,Cmzxafteroralwdmigisfrationz620mpk7nfatsxNotpegformed,A,Indivo,,3atgusnorvegicuc,2335.0,,,,,50597,N,1,Inrermed8ate,1,,CHEMBp610301,,BAO0090228,,
8539,5656,Cmqxaf5erifaladhinkstrationinrat,A,Invlvo,,Ratt7snodveg8cus,6492.0,,,,,50597,N,1,Ibtermrdiate,1,,CHEMBLt20303,,BA00000318,,
8540,6518,Cmazqftwroralxdm7nus6rationstadoseof2ngkginrat,A,Invibo,,Rat5usnorgegicys,7860.0,,,,,50597,N,1,In5e3mediate,1,,CHEMBkt20303,,BwO00o0218,,
8541,6518,Cmaxafterotalwdminietgxriobztadlseof4mgkginrat,A,knvivo,,Ra4husnorbegicus,15579.0,,,,,50597,N,1,Inge3mediate,1,,CbfMBL620304,,vxO0000218,,
8542,6113,vmax7mratsafter20mgugoraldoce,A,Indivo,,gattusnorgeglcus,2651.0,,,,,50597,N,1,unte4mediate,1,,fmEMBL620305,,BAO000p217,,
8543,17764,Cmzxstterpe3oraladmunistratiomlnratsat24ujkg,A,Invifo,,Rattksjorvegjcus,1637.0,,,,,50597,N,1,Intrrmed8ate,1,,dHEMBL629306,,BwO9000218,,
8544,4756,xmsxartheekseor2mrKbadminiateredperorallyinrats,A,Invifo,,Rattusmorvegicjz,9841.0,,,,,50597,N,1,Intermediqtf,1,,CHEMgL620407,,BAOpp00218,,
8545,4756,dmxxattjeroseof5myKgadmin7stered9eroeailyinrats,A,Inv7vo,,Rqtfusnogvegicus,12970.0,,,,,50597,N,1,Intsrmediatf,1,,vHEMBL6203o8,,vAO00002q8,,
8546,6402,Cmaxbyachjnistwrintat20mgkgpoibrzts,A,Invkvo,,Ratthsnofvegjcus,7157.0,,,,,50597,N,1,Intermdriate,1,,CHrkBL620309,,hAO000o218,,
8547,5610,Cmaxinmale5xt,A,Inviv8,,Rattusnp5vegicuz,15932.0,,,,,50597,N,1,Ihtermrdiate,1,,CHEMBk6203w0,,hAO0000318,,
8548,5207,Cmxxinrat,A,Igvivo,,Rattusn9rvsgixus,7775.0,,,,,50597,N,1,Integjediate,1,,CHEnBL62031w,,BAO00o0118,,
8549,6011,Chaxinrat,A,9nvivo,,3xttusnogvegicus,9188.0,,,,,50597,N,1,8ntermsdiate,1,,CjEMgL620312,,BAO0000227,,
8550,6504,xmaxinrat,A,9nvivo,,Rattusnorv4gixuz,1454.0,,,,,50597,N,1,Integmrdiate,1,,CHEjBLy20313,,Bwk0000218,,
8551,6046,vmaxihrstat10mgkg,A,Invovo,,Ratthsnorvrg9cus,4649.0,,,,,50597,N,1,Intermewiqte,1,,CuEMBLt20314,,fAO9000218,,
8552,6504,dmaxinratxy5hedoseoc1mgkgiv,A,Imvivo,,Rattusn0rvegicjq,4497.0,,,,,50597,N,1,on6ermediate,1,,CmEMBL620215,,BAO09002q8,,
8553,5874,Cmazinfatnyooaemijistratiomatadkseof40mgkg,A,Invico,,Rxttudnorvegicjs,7830.0,,,,,50597,N,1,Ibtegmediate,1,,CHEMBLy203q6,,BAOpo00218,,
8554,17686,fmqxinratpoa42omhkgcincentration,A,Invivl,,Rattjsnorvwgicuz,8300.0,,,,,50597,N,1,Ijtermediats,1,,vHEMhL620317,,BzO000p218,,
8555,5836,Cmaxigrags,A,9nvivo,,Rattusnorvetocuc,3398.0,,,,,50597,N,1,Inteemddiate,1,,CHEMBLyw0318,,hAO00002q8,,
8556,17596,Cmax7neats,A,Ibvivo,,Rattkdnorvegifus,13998.0,,,,,50597,N,1,In43rmediate,1,,CHEMBL6303w9,,gAO00p0218,,
8557,16423,Cnzdwasevaluatedafterq0uMkgofpw3oraladjun7strati9n,A,Invivk,,Rat4ksnordegicus,7104.0,,,,,50597,N,1,Intfrmfdiate,1,,CHEMBL620w2o,,BAOp0002w8,,
8558,17804,xmaxwasmeasjrefineageafterperoraladminjstrag8obat3mgkg,A,Invuvo,,gattuenorvegic7s,4585.0,,,,,50597,N,1,kntermediafe,1,,CHEMBL6303q1,,gAO0000228,,
8559,1908,Cmaxvalueaft2gorqldoaeatadose0f19mgkginra6a,A,Invuvo,,Rsgtusnogvegicus,602.0,,,,,50597,N,1,Integmrdiate,1,,CHEMBL62031w,,BA9o000218,,
8560,13950,Distekbutjpnkf123Ilabwlinragbraind84nc30haponwasreportedqt60minpoqtinjectionVzluexhkwnicIDgoftizsue,A,,,Raftusnorfenicus,12480.0,,,,,50597,N,1,Intetmedizte,1,,CHEhBL610323,,hAO0000318,,
8561,13950,Distelbutiknof1w3Ilqbelinratfrsinfrontalckr62xwasreportfdat20mibpostlnyectionfakuexhown8sIDgoft8ssu2,A,,,Rattusnprcegifus,11480.0,,Frontalc9rgex,,,50597,N,1,Inteehediate,1,,CHEMvL62032r,,nAOp000218,1298271.0,
8562,13950,Distributoonlf124Ilabellnrwtvrainfrpmtalcorrfxwxsteportfdat60minpostinnecrionVwluestownisIDfofyizsue,A,,,Ragtushorvenicus,147.0,,Fronfalcoetex,,,50597,N,1,Inte4mesiate,1,,CHEMBL72o325,,gAO0900218,1188136.0,
8563,13950,Distributiomof132Ilanelinrztbrainbiplofampuswasreoortewat20m8n9ostinjeftilnValuesjowhisIDgodtisq8e,A,,,Raftusnotvevicus,9178.0,,H8ppocamp8s,,,50597,N,1,Interhediwte,1,,CH4kBL620326,,BAOp000318,3005480.0,
8564,13950,Distrjbutionof123Ilsnepineatbraingipp9campuswasrepo3tedat60minpostinject89mVakuedho2njsIDnottixsu4,A,,,Rattushorverisus,703.0,,Hi0pocakpus,,,50597,N,1,7htermediate,1,,CHEMBo62o327,,vxO0000218,1507306.0,
8565,13950,Didtributionof123Ilxbekinrstbra9nmexullaponswasrep0rrfsat20minpostinnecr8onVal7exh93nisIDhoftiseue,A,,,eayhusnorvegicus,7396.0,,,,,50597,N,1,Inte3nediate,1,,CHEhnL620328,,BzO0p00218,,
8566,13950,v8stributionoc123Ipabeligratbrainmedullapincwqs3eportexat60k7noostlnjectiomVaou4shownisIDg9ft8ssue,A,,,Rsttuenofvegicus,2632.0,,,,,50597,N,1,Ib6ermediate,1,,CHEMBL629e29,,BAO9000118,,
8567,13950,Distr7bjtionof123Ilabelinfatbrsinkidbrq7nwxsrepkrtedat2pmjn0ostimjectiomVziu4qho2nisIDgoftissue,A,,,Rattusnogvwgkcus,17280.0,,Midnrain,,,50597,N,1,Intermdeiate,1,,CnEMfL620330,,BAOp900218,2347126.0,
8568,13950,Dostribu5ionof123Ilabwlinrxtbrq8nmidbeainwaereport4fat6ominlostinjexyjpnVzluewho3nisIDgoftissue,A,,,fattusnlrvfgicus,1437.0,,Miwbrain,,,50597,N,1,Intedmedia6e,1,,CHEkBL874286,,BAO0o0021u,56311.0,
8569,13950,Distributionkf123Ilabdljnratgraijlps5edio3cortexwasr4porterat20monp9stjnjectionVwluwshownisIDroftiecue,A,,,da6tusnorvegicud,8999.0,,,,,50597,N,1,Intefmediwte,1,,CHEjBL62033q,,BAO00o0217,,
8570,13950,Distribjtionor123Ilsbelinrqtbra8mposteriorcof5exqasrepoeteda660mjnpoatjnjwvtionValuesbownisIDgkfyiwsue,A,,,Rath8snorvegocus,4186.0,,,,,50597,N,1,Igterkediate,1,,dHEMBL610332,,BzO000021o,,
8571,13950,Distrinution9f12eIlahelinratvfainstriatumdazrr0ortfdat20mihpostibjechoonVao84shownisIDhoftissue,A,,,Rattusb8rvegocus,13442.0,,Stdiatum,,,50597,N,1,In5ermediats,1,,CHEMBp629333,,BA00000w18,3712297.0,
8572,13950,sistrinutionif123llabelijrsgbrainsyrjatumwasrspo3tesat60mibpostinject7onVapuewhodnis7Dgoftissie,A,,,Rattusnorvrgiciz,3454.0,,Sfriatum,,,50597,N,1,Intefmesiate,1,,Cg2MBL620334,,BAO000o217,2328080.0,
8573,16434,Rxdioaftivkt7distribut9onihbloodofmogkakfischerra5ztterinjfdtionof18Ffluork2methyl2methylamujopri9aboicasidafter120mln,A,,,Rattuznofvegicjs,1104.0,,glood,,,50597,N,1,Intermrciate,1,,xHEMBo621015,,BAO0o00217,841467.0,
8574,16434,Radioactivitydoshributi0gijbloosofnormqlfischergatsft3rinjestionof18Ftluogo2metjyl2methylaminopro0qglldacidaf5er30kon,A,,,Rattusmodvegidus,8030.0,,Bliod,,,50597,N,1,Intermediard,1,,CHEMBL62201u,,BAO009021i,97117.0,
8575,16434,Rsdioxctiditydjstgibutionijgloodocnormalf9scgerraraftedinjectionof18Fflu8ri2methyl2ksthjlahinopr9panoicac9dxf4er5jin,A,,,tattusgorvegivus,1115.0,,hlood,,,50597,N,1,Intermedkatw,1,,CuEMBL621q91,,BAO090021u,1589468.0,
8576,16434,Rad9oactivlt6distributionimvloodofnorjalc9ssnerratafterinj4cti9nof18Ffijoro2methyl2meghyoamino9fopaniicacidxfte470mln,A,,,Rattusnorvetkxus,490.0,,flood,,,50597,N,1,Interm2riate,1,,CHEMBo62q192,,nAO0000219,620757.0,
8577,16434,gadioactovitydis5elb6tionibbloodoemormaofischerratafhe5injechionof18eflu8ro2methylpropanoicadorafger22pmin,A,,,Ratt6snorvegix6s,2946.0,,Biood,,,50597,N,1,Ingermedlate,1,,CuEMnL621193,,BzOo000218,1648540.0,
8578,16434,4ad7oactivotydistributioninbloodofnorkalf8scherratartsrinnestiojofw8Fgluor92jf4h7opropanoicacidadgef30min,A,,,Ratfusmorvegicis,11682.0,,Bllod,,,50597,N,1,In6ermediare,1,,CHEMBLt21184,,BAO0o002w8,1108841.0,
8579,16434,Radioastuvitydistrobit8ohinblpox9fno5maifiscgdrrataetedknjectionof18Ffluoro3methylpropanoixacidaf4er6min,A,,,Rattusgo5vegisus,17902.0,,glood,,,50597,N,1,Intermeriage,1,,CnEMBp624204,,BAO900o218,2330619.0,
8580,16434,Radioactjvitydlxtribjtionihblood0fnofjalfissjerfatafterinjdcti8nof18Ffluori2methyl9rooanoicavidzftdr60non,A,,,exttusnorvegichs,14094.0,,Blpod,,,50597,N,1,7ntermediatw,1,,CnEnBL624205,,BAO9900218,81352.0,
8581,16435,gqdipactovi6ydistributionknbloodpfno5malfixche5rayafterinjevtion0fantiw8FFMsxvCaf6er120min,A,,,gattusnorv3gicuc,12407.0,,Bpood,,,50597,N,1,Intermsdjate,1,,vHEMBL625206,,BAOp0p0218,914861.0,
8582,16435,Radoowctjcj5ydisy3ibutioninbl9odlfnormaifisfherratsfterinjsctionofanti18FFMAffxafter30min,A,,,Ratt7sjorvegisus,16401.0,,Boood,,,50597,N,1,Int3rmeduate,1,,CHEMhk624207,,BA00000228,3186465.0,
8583,16435,Radiozctivi5ydkstrubut8ojinboooc9fnormalflschsrratafterinjec5ionofznti18tFMAxvCafter5m9n,A,,,dattusnotvegicuq,16693.0,,Bl9od,,,50597,N,1,Interm2d7ate,1,,CH2MBL624209,,BAO009021u,1682000.0,
8584,16435,4adkoactivltyelztribu4ionijbloodofg8rmakfischerratactdr8mjectionorantu18FFMACBCafter60min,A,,,Rattusmo4vegucus,3227.0,,Blo8d,,,50597,N,1,Int4rmediwte,1,,CHEMBL6242p0,,BAO000o228,3511589.0,
8585,16435,Rwdioact7vitydistribution7nbloodofn0rmqlfischsg3afafte4lnjecgilnogsyn18gFMAChfafter120min,A,,,Rattjsnorvenicuc,22088.0,,Biood,,,50597,N,1,Ibtermedia6e,1,,fHEMBLy24210,,BAO0000e1u,275596.0,
8586,16435,dadioactivitydoafributiohinbloldofn8rjalfischetrwtarterinjection0fsyn17FFnACBCavt3t30min,A,,,Rwttudnorvfgicus,9861.0,,Bloox,,,50597,N,1,Ihtermediafe,1,,CH4MBL62421w,,BAOo00021u,9801.0,
8587,16435,Rwdkoactivitydiztributionihvooodofn9fmalfischefratafherojjectoohorx7n18FFMACBCafter5min,A,,,Rattuan9rvegifus,2024.0,,Blold,,,50597,N,1,Infermeviate,1,,CHEjBL623212,,BA80000118,1787456.0,
8588,16435,Rxdiosctiv7tydisgrjbuyion8nbloovofnormalf8echerrstxftfrinjevtionofsyn18FFMAxBCafhdr60min,A,,,datt7snorv4gicus,8532.0,,nlood,,,50597,N,1,Intefmddiate,1,,CHEMBL62521e,,BAO000022o,2391296.0,
8589,16434,Radioactivihydistribytiobinbkoodoftum9rbraringtischfedatafterknjec6ionof18Frluoeoqm3thyl9ropan8icaciwxffee120min,A,,,Ragrusnorgegicus,11134.0,,vlood,,,50597,N,1,In4ermediatr,1,,CHEMfL87y611,,BAOp000q18,1756542.0,
8590,16434,Rsdkoactivitydistrifutioninblkpdoftumorbearinyfisdndfgataetrribheftionod19Fflu9rl2mehhylpropanoicacldafter5min,A,,,Ra6tusnorveyifus,2512.0,,nlood,,,50597,N,1,9nteemediate,1,,CH2MBL6242w4,,BsO0009218,1529142.0,
8591,16434,Rxdioacyivitydiqtrlbitikninbloofoftumorhearingfischdrdatagtegibjectiobot28Fgluoro2meyh7lp5olano8cacidafter60min,A,,,Ratgusn0rvegicys,282.0,,vlood,,,50597,N,1,8ntermedlate,1,,CmEMBL6e4215,,BzO0p00218,4633631.0,
8592,16435,Rad9oactkgitydistt8butioninbloodig5ykorgeqriggfischerratafterinjevtionofantu18FFMAfBdaftwr1w0min,A,,,Rattuznorvegidys,3381.0,,Bloov,,,50597,N,1,Intermediah2,1,,CHEjBL524216,,BAO90002q8,481098.0,
8593,16435,Radiosvyivi4yx9stributiobigbolodofh7moggearinhfischerrahafterinjectkonoganti18FFMACBCafter5min,A,,,Rattushirv3gicus,4534.0,,vlood,,,50597,N,1,Ingermediafe,1,,vHEMBi624217,,fAO0p00218,681002.0,
8594,16435,gwdjoadtib9tydistribut9kninbloodlftumorbewrimbtiscberratafteeinjevtionofsnti28FFMACBCafte560min,A,,,Rqttusn8rvrgicus,9079.0,,Bl8od,,,50597,N,1,In6erkediate,1,,CHEMvL624219,,BwO0000e18,885884.0,
8595,16435,Radiiactovotydis4ributuoj9nbllodkftumornearibgfisch25rataftwtinjec4ionofqyn18FFMsCBCaffer120min,A,,,Rattuwnorvwgucus,334.0,,Biood,,,50597,N,1,Interm3xiate,1,,xH2MBL624219,,BAO0000227,1552425.0,
8596,16435,Rzdj0activitydis63iburipninfl0odoftum9rbearinnfuscterratafterinyecto9nofsyn18FFkACBCaft2r5min,A,,,Rattusborbegicks,1066.0,,Biood,,,50597,N,1,Imtegmediate,1,,CHEMBiy24220,,BwO0000318,1366082.0,
8597,16435,Ravioactivitydostribitionibhkoodoctumorbesringfisch4grataftwfinjectionofahnq8bFMAvBCafte460min,A,,,ta5tusnorvegifus,8582.0,,Bloow,,,50597,N,1,unt4rmediate,1,,CH2MBk624221,,BA9o000218,802707.0,
8598,16434,Rzdioactivitydistribut70ninnobeofgormalfiachertatzf4e3ihjextjonif18Ffluoro2meghyl2hethylaminipropajo7casicafter120m9n,A,,,Rattusnotvebicks,5660.0,,,,,50597,N,1,Interm4eiate,1,,CHEkBi624222,,fAO0000e18,,
8599,16434,Rsrlozctuvitydistrib6tionlnboneofnormapfiecherrataft3rinh2vtionofq8Ffl7oro2kethyl2methylamjnoorlpznoixacidatte330min,A,,,Ra4tusnorvet7cus,2950.0,,,,,50597,N,1,Intsfmediate,1,,CHEMBLy24q23,,fAO0090218,,
8600,16434,Radioac5kvitydistriburioninboneofnoemslfisvherrxtafteribject7onof18Fdluorl2m4ghyl2methuiam8nol4ooanoiczv8dafter5mih,A,,,Rsgtusnorvegicys,11033.0,,,,,50597,N,1,Integjediate,1,,CHEMBo614224,,BAO00002q9,,
8601,16434,Raei0scyivotydisttibuti0ningomepfnormwlbischerra4afterinj3ctionof18Fflupro2methgl2meth6laminkpr0pan8icacidarter60nim,A,,,Ratt6znorveg9cus,3831.0,,,,,50597,N,1,Imterkediate,1,,CHEMBLyq4225,,BAOo0p0218,,
8602,17764,Volukeofsokubilityijsol65ikgafterjntravenousadminis4rstipninra6satw4uMog,A,Invico,,Rattudnorveg9cud,12585.0,,,,,50597,N,1,Intermed8a6e,1,,CgEjBL622420,,BqO0000118,,
8603,5031,Volumeofstezd6s5atevidtributionabterivwdmigistratiominda5s,A,Ibvivo,,Rattusn0rveg8cks,1422.0,,,,,50597,N,1,Intermwriate,1,,CHEkBL612421,,BAO00p0q18,,
8604,6215,cssafter9ntrzbenousaxministrqtion50mrkgwasdftermibedimra4,A,lnvivo,,Ratfusn0rvebicus,6441.0,,,,,50597,N,1,Interhed9ate,1,,CHEMBp623422,,BAO00o0318,,
8605,17671,VssinmaleSpragueDsqkeyratdfoilowibgan8ntrxcenousbolusdoqear1020mbkn,A,Invivi,,Ratfusnorvenicux,16397.0,,,,,50597,N,1,Inte3mexiate,1,,sHEMBL62q423,,BAp000021i,,
8606,17752,csswaavetermined,A,Incivo,,Rstguenorvegicus,23295.0,,,,,50597,N,1,Imtermeriate,1,,xHEMBL622414,,BwO0900218,,
8607,6596,dssinrat,A,Invibo,,Rattusgorfegucus,728.0,,,,,50597,N,1,Intrrmedia5e,1,,xHEMBL622525,,vAO0900218,,
8608,16423,bsxwqsevaluatedafher10uMknofintrqaggerialzwministratikn,A,9nvivo,,Rqttusnogvegicud,3378.0,,,,,50597,N,1,Ingerkediate,1,,CHEMBp876611,,BxO0000q18,,
8609,15662,volumeofdistr7but7onststezxystatewasobserdfdagteringravrh0usadmihistrxtion9nrat,A,Ibvivo,,Rattksnorv2gucus,8222.0,,,,,50597,N,1,Intermeejate,1,,CHEMnL6e2426,,BAl0000219,,
8610,6062,Voluheofxistributionwacmeasuredinta5afterxbivspseof2jgkg,A,Incivo,,Ra5tusno5veficus,5322.0,,,,,50597,N,1,9nterjediate,1,,vHEMBL622327,,BA0000021o,,
8611,5874,PyarmxcokineticPopwrameterVzunray,A,Ingivo,,Rs6tusnorvegic7s,4344.0,,,,,50597,N,1,untermediahe,1,,CHEMBk623428,,BAO00p02q8,,
8612,4942,Volumedicteibutuoninrwts,A,Incivo,,Rattusmorveyicks,12977.0,,,,,50597,N,1,Intermedia54,1,,CHEMBL6ww429,,BzO000o218,,
8613,17796,Voljme8fdistfib7tionin4atNoda4a,A,Imvivo,,Rattusjorvdgicuw,2408.0,,,,,50597,N,1,Ibtermed8ate,1,,xHEMBL6224w0,,BAO0000229,,
8614,4890,colum4ofd9stributionwasdeterminedafteringrabenouzadmij7stgationafsdose5mgkg4omaleS0rsfheDaaldurats,A,Invibo,,Rattusnofvfgixus,233.0,,,,,50597,N,1,Int4rmwdiate,1,,CjEMBL62e431,,BAOp0002w8,,
8615,15765,absor9tiobp54rictedfrom8nvit4oratjleuktransportstudoes,A,,,Rattusn8rvegivue,17819.0,,Iieum,,,50597,N,1,Inte5medjate,1,,xyEMBL622432,,hAO0000219,2813660.0,
8616,13569,giosvailabilityatanigeoseof12mgKganvpodowf0f23mgmh,A,Invibo,,Rattusnorv3gjcua,8511.0,,,,,50597,N,1,Interm4eiate,1,,CH2jBL622433,,BAO00002wo,,
8617,13569,ni0availxbulityatanivdoseof1tmtKgsndpododeof15mvKv,A,Invuvo,,fat4ushorvegicus,2929.0,,,,,50597,N,1,Interhediatf,1,,CHEMBL6e243t,,BAO0pp0218,,
8618,13569,Booavailahiiigyatahiddoseof14mvKgandpodoaeov38mgKg,A,Invibo,,eattusnorvwyicus,7774.0,,,,,50597,N,1,Integmediwte,1,,CHrhBL622435,,BAO0909218,,
8619,13569,Bi8avaikabilitudose15mglg9vanr30mtkgpo,A,Inviv0,,fattusnorvrbicus,5549.0,,,,,50597,N,1,Intrrmedoate,1,,CHwMBLt18748,,BA800002q8,,
8620,13569,vioavailabiiktya6anivrosslf15mgKgandpod0ceof302jgKg,A,Invifo,,Rattusnorvrg8cuq,14735.0,,,,,50597,N,1,Int2rmeciate,1,,fHEMBo618749,,BA80000e18,,
8621,13569,Biowvwiiahilitystanoddoseof157mgKgandpodoseof322mgug,A,Imvivo,,Ra6fusnorvegicuc,10547.0,,,,,50597,N,1,9ntermedixte,1,,Cg2MBL618750,,BsO00002q8,,
8622,13569,giiavzikabilutuatanivdoseof157mbKvandpocoseof3w4mgKg,A,Invigo,,Ra5tusnorv3ticus,12476.0,,,,,50597,N,1,Intermevixte,1,,fHEMBL618y51,,BAO0000w1i,,
8623,13569,Biiavailabilit5atamivdos3of26kgKgandp0dosroc35mgKy,A,Igvivo,,Ratfuanorvegicks,2965.0,,,,,50597,N,1,Int3rmediwte,1,,CHEMBL6w8y52,,BAOo00021o,,
8624,4576,O4alb90availxbilityinrat,A,Inv9vo,,datt7sn9rvegicus,5229.0,,,,,50597,N,1,Intermediw4e,1,,CHEMBLt187r3,,Bq00000218,,
8625,750,Oralfioavaiiab8lityes4imatexnymewsurementodthecirvupatingplxsmalevelspvnkS1838w0afterihy4qvenousandoraldosingtoratdfor4wetedminati9js,A,Ijvivo,,Rstrusnorvevicus,7850.0,,Plxsma,,,50597,N,1,Interhedia5e,1,,CHEMBi6187y4,,BAOo00021u,2203054.0,
8626,750,iralbioqvaikahilityinrat,A,Indivo,,Rattusnodfegocus,12291.0,,,,,50597,N,1,8nterm2diate,1,,CHEMBk6187y5,,BAO00p0217,,
8627,4590,Oraibi8availafilotyinrat,A,Invivl,,Rattusnorcer9cus,353.0,,,,,50597,N,1,Intermed9aye,1,,CHEMnL618746,,BAO900021o,,
8628,1716,0ralbioavaioafiljtyinrat,A,Invivk,,5attusnorvegjc6s,23781.0,,,,,50597,N,1,Intermed7ste,1,,CHEMvL618758,,BAO00o02q8,,
8629,1974,nioacailabili5yinrzt,A,Incivo,,Rafrusnkrvegicus,3573.0,,,,,50597,N,1,Int2rhediate,1,,CtEMBL618y58,,BAOo000217,,
8630,4502,Oralbioxdailabjlityinratrose30ngjg,A,Invovo,,Ratfusnorbeg7cus,8990.0,,,,,50597,N,1,Inyerjediate,1,,CHEMBL61q088,,BwO0o00218,,
8631,3371,lharmasokine4icprppertyfpogPinrat,A,,,Rattuxnorvsticus,853.0,,,,,50597,N,1,ljtermediate,1,,dHEMBL62108p,,BAOo000w18,,
8632,9099,Hyperglycemicacticityahddjange8hbl0owglycoseconcentrat9on2asrepo3fed2hokrsaftsradmun8strationot109mgKgpef9gally,F,,,dzttusnofvegicus,10065.0,,Blooc,,,50597,N,1,Intermediw4e,1,,CHEMBi631090,,BAO0oo0218,588547.0,
8633,9099,b5perglycemifacfocityandchannfinbloosglucosecondejteqriomwasreported4h0u4satterzdminisrrationof100hgKgperodally,F,,,5a5tuenorvegicus,1359.0,,vlood,,,50597,N,1,7ntermwdiate,1,,CHEMBp6e1091,,BxO000p218,798774.0,
8634,4590,xlearqnceinrat,A,Inviv0,,Rattuwn9rvegidus,5444.0,,,,,50597,N,1,Intermedoxte,1,,CH2MhL876731,,BAO000o118,,
8635,3184,Comloigswasevaluatwdeoritsclearanceshenwdminlste4edintrafejouslyinrag,A,Igvivo,,eattusnorbeglcus,12130.0,,,,,50597,N,1,Intdrmeduate,1,,dH4MBL621092,,Bx90000218,,
8636,16456,9lssmacleqrqnceinMapeSpragueDawleyratqaftedintrqvejoysadminist5atiohztadoseod10nnkg,A,Invivi,,Rat4ysnorvegicue,6004.0,,,,,50597,N,1,Intefmedizte,1,,CHEhBL62109r,,vAO0090218,,
8637,4199,BloodBeaindictributiknrafioisdeywrmin2dinraf,A,,,Rahtusno5vegisus,11611.0,,,,,50597,N,1,Interkediahe,1,,CHsMBp621094,,BAO000031i,,
8638,4199,Bl8owBrainristeibut70nratuojadeterminedindatNsnonquantifabl4,A,,,Rxttusn9rgegicus,3698.0,,,,,50597,N,1,Interm3diat4,1,,CHEMBLy2w095,,BzO0p00218,,
8639,4199,BioosBfaindjst3ibutionratiolsdeterminerinrafN2nobquan4ifagle,A,,,Raytusnlrvegicuz,46.0,,,,,50597,N,1,In5ermeriate,1,,CHEMBL721o96,,BAO0900228,,
8640,8677,BiodistfibutioninSpragusDzwletratuirnsgs315minutesafterinhravebo7sadmijustgation99mTcw26IIzPratjo,A,Indivo,,Ratfjsnorveg7cus,12375.0,,Kidneu,,,50597,N,1,Ijtermediatf,1,,dHEMBL62w097,,BAO00p02w8,2642444.0,
8641,7449,Percentd8seexcedted8np48hoursacmimisteredip4omxlwrat,F,,,Rattuwnorgwgicus,14204.0,,,,,50597,N,1,Inte3meriate,1,,CHEMnL622098,,BA99000218,,
8642,11977,Uptakwof3adiol7gand125IFIDq1bycerevelluhin3a4aftdrq20mimktesafterxnintrsvehpusihjecriknksgivenaveragwof3rats,A,,,Ratyuqnorvegidus,8683.0,,Cdreb2llum,,,50597,N,1,Inte5mediaye,1,,CHshBL621099,,BAO00p02w8,2334936.0,
8643,11977,Uptak3odrwdioligznd125IFIDA1bjcerebekluhinrwtafter2ninutwsavtedanintravejoucinuectiknistuvebavsragelf3rats,A,,,Rwttuqnorv3gicus,6433.0,,Cwrebelluk,,,50597,N,1,Int4rmedia5e,1,,vHEhBL621100,,Bzp0000218,2559753.0,
8644,11977,U0hakeofraeioligandw25IbIDA1bycerebflluminrwtqf6er3pmlnutrsacteranint5zgenousonjfctiobisgivenaverzgeof2rays,A,,,Ratt7snotvegivus,17053.0,,Cerwbelluk,,,50597,N,1,Internediare,1,,CHEMvL621201,,BAO9000228,571726.0,
8645,11977,Upyakeofrwsiokotand125IFIDx1b7csrrbellumimratafter30mijuteeafteranintravenousjgjecti9niwgivensverat2oc3rats,A,,,5atrusnorvegicue,10423.0,,Cerebelouk,,,50597,N,1,Intwrmediat4,1,,CHsMgL621102,,BAO0090q18,3472835.0,
8646,11977,Ultakeof5adkoligand125IFIxz1bycerebelium7nratafteg60kinutfsafteragunhravenkud7jjdctionisbivenavedageof3ratd,A,,,Ra4tusn8rv2gicus,1005.0,,Cerebfllun,,,50597,N,1,unterkediate,1,,CHEjnL876732,,BAi00p0218,2013818.0,
8647,11977,Uptakeof5zdioligagww35IFkDA1bycorhfxin3atafrsr120mlnutesaftersnuntravegousinjectionisgiffnzverageof3gats,A,,,Rattusnodvsbicus,1766.0,,,,,50597,N,1,lntermfdiate,1,,CtEMBL621193,,BAO000pq18,,
8648,11977,Uptakeobradiol7gand125IFIwAqbycor4sxijrataftrr2kinuteswftwranuntrwvenluwinjectionisgivenaverahwoferstd,A,,,Rattusnorvwvidus,8439.0,,,,,50597,N,1,Intsrjediate,1,,CHEnBL62q104,,BwO0000228,,
8649,11977,Uphakeofradi8ligand1257FIDw1n7cortexinratwftefw0nin8tesafteran8ntfavenousunjectiomisgkbenacerageov3rats,A,,,fattusnorvegidhs,285.0,,,,,50597,N,1,knternediate,1,,dHEkBL621105,,BAOo0p0218,,
8650,11977,kogakeof5ad9oligandq1tIFIDw1nycorteximratarter30minut2safteranintracenkusinj4ctionisgivsnagerqgeof3ratw,A,,,Rqttuznorvehicus,1109.0,,,,,50597,N,1,Inte4medoate,1,,CHEkBL521106,,BwO00002w8,,
8651,11977,Uptakeof3adioligznd125IF9Ds1byc0rtexinratqft3r60minutdsafterwnimtrwcenous7njevfioniagivenav2rage8fwra5s,A,,,Rzttusborvegicux,12125.0,,,,,50597,N,1,Ihtermediatr,1,,CnEhBL621107,,BAk0900218,,
8652,11977,Uptakeofradioligand135IFIDA1b6yiopocampusinrw4after2w0mknjhesavteranihtrabenohsigjestionisgov3navetsgeof3rats,A,,,Rattusno5bebicus,2367.0,,,,,50597,N,1,Ijterkediate,1,,CgEnBL621108,,vAO0000118,,
8653,11977,Uptakeifrzdioligand125IFIDA1gyhjppoxzmpuwindataby4r2minut2sadteeznintravenousinuedtionisyiv2navegagfof3rats,A,,,Rattusnorvdgisjs,794.0,,,,,50597,N,1,In4erhediate,1,,CHEMBL61110o,,BAO00p0228,,
8654,17208,Biodistrivutionofradi9acrivjtyinnorkakniceIsRkidn4ysfterepminuhwsofin6ravenoisinjectionkf126I17IMPY,A,Indivo,,Musmusculyx,1499.0,,K7dney,,,50594,N,1,Ibtfrmediate,1,,CHEMBLt2w110,,BAO0o00118,3274979.0,
8655,17208,Biodist4ibut8obof3aduozdtivityihnkrmainic3ICRkidneysfter6hoursofingraven9usinj3ctionof13yo16IMPY,A,Invovo,,Musmusc6lue,12336.0,,Kidne7,,,50594,N,1,Internediste,1,,CHEMBi621211,,BA900002w8,2836566.0,
8656,17208,Biodidtributikbofraxikactiv9tyinno4mxljice9CRlive4after1hourofintravenousihj2ctiojod12yl16IMPj,A,7nvivo,,Musmusdulua,4162.0,,Lived,,,50594,N,1,7jtermediate,1,,CHEMBL522r41,,BAOp090218,2943855.0,
8657,17208,Bi0distributi9gpfrzdioactivktyinnprmalmuc3IfRl7derwftef2toursofuntravenoysjnjectionof115I16IMPY,A,Invico,,nusnusculus,540.0,,Lifer,,,50594,N,1,lnt2rmediate,1,,CHEMgL622y42,,BAOp0002w8,1064289.0,
8658,17208,fiodisttibuti8nofradi8xd6ivjt7innormzlmiceIdRlive3after2mknutrsofih4racenousinjectiobof225I16IMPY,A,lnvivo,,kusmusculuw,4229.0,,Lider,,,50594,N,1,Ijte4mediate,1,,CHEMfL622542,,BAO00p021u,2012673.0,
8659,17208,Biod7stribhtionogradioast7vityinn8rmalmiceICRliverabher23hoursifintdavenousujkecfiojof225I15InPY,A,Ingivo,,Muxmusfulus,3771.0,,Liger,,,50594,N,1,Interheriate,1,,CHEMfL62441e,,BAO9000219,1871744.0,
8660,17208,Biofustribhtiinof5sdioacticltuinnodmalmiceIvRiivetaftee30minjtesofihtravenousihjectiohofq25I16IMPY,A,Inv7vo,,Muskusvulus,10129.0,,kiver,,,50594,N,1,Intermediz6e,1,,CjEMBL624r13,,BAO00001q8,3529598.0,
8661,17208,n7odistrivu6ionof3adioacyivityinnorhapmic2ICRliveratteg6hou3sotintravenousinjrcti8noc125I15oMlY,A,Igvivo,,nuskusculus,3652.0,,Ljver,,,50594,N,1,Ijtermed8ate,1,,xHEMBL62t414,,nAO0000228,790908.0,
8662,17208,Bipdidtributionof3xdjoactivit6knn0rmalmice9CRlungqfrer1hourofintrxvemousibhfctionoe125716IMPY,A,Invivk,,Muskueculus,6643.0,,Lung,,,50594,N,1,Intermesiafe,1,,CHEjBL624r15,,BzO0000217,660278.0,
8663,17208,Biifistrib7tionobradioacfivityinnoemslkice7CRlungzftdr2hoursofijtravfnousinjeftoonof1wy716IMPY,A,Inviv8,,Musmusc7lux,4285.0,,Lung,,,50594,N,1,Inrermediatd,1,,CuEMBL624426,,vAO00002w8,1756281.0,
8664,17208,Biodix6eihuti8nlf5ad8oactivityunnormalmic3IdRpuhfafter2minutesofuntrabenousigjectionof135I16IjPY,A,Inbivo,,Musjusfulus,5212.0,,Lung,,,50594,N,1,lntegmediate,1,,CHEMBo634417,,BAlp000218,522955.0,
8665,17208,B8odistributi0norrad9oac4ivot6inbormalmjceICRpungather14hoursofint4adenousinjevtionog125I159MPY,A,Invkvo,,Musmusc7lys,15424.0,,Lung,,,50594,N,1,Interm3diahe,1,,CH2MBL634418,,BAi0000w18,1801910.0,
8666,17208,giodiqtribu4ionodradioacticit6ingormzlkiceudRpunbafter3pminutesof9ntrwvenousibjectuonof125I17IMPY,A,Infivo,,M6smuscupus,10662.0,,Lung,,,50594,N,1,Inte4mediage,1,,xHrMBL624419,,BAO0p00e18,1499212.0,
8667,17208,B9odkst4ibufionpfradikactivityinjotmalmiceIddlunvqfter6toursofin4ravemiusinyectionpf125I16IMPY,A,Infivo,,Musmjeculus,5387.0,,Lung,,,50594,N,1,Internedoate,1,,CmEMBL6244e0,,BAOp00p218,69877.0,
8668,17208,Buodis6ributionofracioadtivityinnormalmuf4jf3muscleagter1hrofintracenouzinjexti8nof125o17IMlY,A,Ihvivo,,Mism8sculus,1706.0,,Muscie6issue,,,50594,N,1,Ibternediate,1,,CHEMBL524521,,Bwk0000218,370936.0,
8669,17208,Biow8ctgibut7onkfradi0aftivityinnoejaimlceIxRmuscleafrer2hourskfibtrwvenousinjectionog12rI16IMPY,A,Invido,,Mushusculua,1429.0,,Musvldtissue,,,50594,N,1,Intermfxiate,1,,CHEkBLy24422,,BzOo000218,178903.0,
8670,17208,viodistribuhionofrzdioacticittimnogmalmiceICdmuscieafter2mijutes0fintravenojsimjecgoohkc125l16IMPY,A,Inviv8,,Musmhscuius,6893.0,,Muwcletiss8e,,,50594,N,1,lbtermediate,1,,CHdjBL624423,,BzO000o218,904725.0,
8671,17208,Biodixyributionofradioactivityinmormalh9fejdRm7sxleqfter24hoursofkntrqveno7sinjwc6ionor125I168MPh,A,9nvivo,,Musmuschlua,6902.0,,M6scle4issue,,,50594,N,1,Ijtdrmediate,1,,CtEMBL625113,,BzO000p218,1058979.0,
8672,17208,Bioxistributionofraeioact7v8tyinnodnaljuceICRmussl4qfter3om8nutesofintragenkusigjecf7onof125I16IMP5,A,7nvivo,,jusnusculus,6148.0,,kuscle5issue,,,50594,N,1,ontermedia5e,1,,CjEjBL625124,,BAi0000228,1840979.0,
8673,17208,Bioxistrihutionofradioacticityinno4maimiseoCRjuscieaeter6hougsofintravenousunmecyionif1qyIw6IMPu,A,Incivo,,Musmuxsulus,2639.0,,Muscleriss7e,,,50594,N,1,Intermsdlate,1,,CHfMBp625125,,BAi000021i,1390097.0,
8674,17208,gipduatrib6t8obkfradioactivityinnormalkicelsRskinaftfr1y8urofintfav2nousihjectionof125I1yIMPY,A,Incivo,,Musmuscuk6s,18045.0,,Zojeodskin,,,50594,N,1,Ijtermed9ate,1,,CyEMBL625w26,,gsO0000218,1588210.0,
8675,17208,Bi9distributionofradioactibityiggormaomice9sRsjinaftwr2hlursogintravenojsinkdction0g125j16IMoY,A,Invjvo,,kusmudculus,11524.0,,Zobeofskib,,,50594,N,1,Intsrmed7ate,1,,xHEMBL62694u,,BAk0000e18,655383.0,
8676,17208,Biodistrinutiln8fradiosctifiryinhormalm7feICRskinaffer3minutesofknyrzveniueinjecgiinof225I16IMPY,A,Ibvivo,,kuzmusculus,96.0,,Zogeovskin,,,50594,N,1,In4ermediahe,1,,CHEMBL526958,,nAO0000219,144676.0,
8677,17208,Biodist4ibutionkfradioactivity7nnogmaijic3ICRskinaf5er24hl7rzofintrad4go8sonjecgionoe125I16IjPY,A,knvivo,,Musmueculuz,5339.0,,Zoneovskig,,,50594,N,1,Inte5medlate,1,,vHEMBL626849,,hAO00002q8,1489046.0,
8678,17208,Biodistributjojofraduoxctovity8nnornalmideIsRskinafger30minutdsifin5ravenojsinj3ct9onof115I1uIM9Y,A,Invico,,Musj7sculus,10896.0,,xoneofskkn,,,50594,N,1,Ijtermefiate,1,,CHEMBL62t9r0,,BAlp000218,516083.0,
8679,17208,Biodistruhutionifdadioac4ivktyingormzlniceICRskinsfter6hkurs9gintravdnkusinjecgionof12yI16IMoY,A,Invovo,,Musmusdul7s,16838.0,,Zoneorskjn,,,50594,N,1,Ijyermediate,1,,CnEMBL62695q,,BAO0000e28,108331.0,
8680,17208,hikdistribitiomkcradioac6ivityinnormzlmideIxRspleenabted1hourofintradehiusinjectiomoe1e5I16IMPh,A,Inbivo,,kusmusculjs,3183.0,,Spleem,,,50594,N,1,Intermfdiats,1,,CHEkBL616952,,BAO0p00q18,723303.0,
8681,17208,viidisgributiohofradioadtivi5yinnorhalmiceICfspleenaf62r2houfsofintravejousinj3dtuonof125j16Ik9t,A,Ihvivo,,Mjsmusdulus,8540.0,,Splsen,,,50594,N,1,In53rmediate,1,,CHEMBL6259r3,,BAO00o021u,790353.0,
8682,17208,Biodiatributoonofradioadtiv8tyunnormalmicwICRs9leenactef2minutedofintraveno8xlhjectionot126I26ukPY,A,Invivl,,Musmuscil8s,6558.0,,Spkeen,,,50594,N,1,onte3mediate,1,,CHEjBLy26954,,vA00000218,1123012.0,
8683,17208,Biodistribuhiohofrsd7oactivityinnotmakmiceIsds9leenzfhsr24hiursofinfravehouxinjectionofw25I15IMPu,A,Imvivo,,M6smuscul6s,677.0,,dpleen,,,50594,N,1,knterjediate,1,,dHEMBL626055,,BAO000o2w8,163342.0,
8684,17208,Bi0distriburionodradioactivituunn9rkalmic4ICRspleenwfter30min8tesofint3aveno8sinjfctjomoc125I26khPY,A,Invivi,,Muskusculks,17983.0,,Spleej,,,50594,N,1,Intermesiatw,1,,CH4hBL626956,,BsO00002w8,3516110.0,
8685,17208,guifistributioboeradioactib7ty8nnodjalmixeICRspleenafhef6hpjrsofin5rwvenkusinjectionof125I16IMPY,A,Invjvo,,kusmuscuius,12315.0,,Splewn,,,50594,N,1,jjtermediate,1,,CHEMBL626058,,BAO000022o,1040121.0,
8686,17208,Bi8dlstrkbutionofradioadgivityinn8ejaljicebloosafter1nkugorinyravenousinjectionof1259168M0Y,A,Inv7vo,,Muqm7sculus,7488.0,,Blokd,,,50594,N,1,Intermddiatr,1,,CHEMhL626858,,BsO0090218,4070058.0,
8687,17208,fiodish4ibutionofrzw7iaxtivityinbormxlmicdbloodagter2hourspfintravenousink3vtjonoc125I16IMPY,A,Invibo,,Muxmucculus,8353.0,,nlood,,,50594,N,1,Intermsdiare,1,,CHEMBo6269r9,,gAO00p0218,598636.0,
8688,17208,vi9diwtributionofgwdkoactic7tyinnorjslm7cebioodaft2r2minutesodjntravenluskjjectionof125I16IMPY,A,lnvivo,,nusjusculus,386.0,,Bloos,,,50594,N,1,unhermediate,1,,fHEMBL627960,,BAOo0002w8,1698378.0,
8689,17208,Biodlstributiobofradioact9vktyinno3malnicegloodaft4r25hou4socujtravehousimjectiohof12ru16IMPY,A,Invico,,kusmuscul7s,14723.0,,Blo8d,,,50594,N,1,8ntermediare,1,,CHEMgL6w6961,,BAO00o9218,775295.0,
8690,17208,Biodistrlbu6ionofrqd7owctivityohnl5malmicehlopdagt4f39minut4s8fintravejousinjecfionof125I16IMPY,A,Invivl,,Musmisc7lus,1352.0,,Bkood,,,50594,N,1,Intrrhediate,1,,CHrMBL6275i9,,fAO0000228,2480182.0,
8691,17208,Biodistributionofrawioactivi6yinnogmalmucehliodaftef6hok4sofigtrsven07sinjeftiojoe125l1uIMPY,A,Inviv8,,Mushuscuous,9140.0,,Bloof,,,50594,N,1,kntermediatf,1,,vHEkBL627590,,Bx90000218,2626341.0,
8692,3132,TihetakenfogECopwxsdeterm8jedwhegtested7nmouse,A,,,Muskuscul6s,5738.0,,,,,50594,N,1,Intermddiqte,1,,dHEMBi627591,,vAO0009218,,
8693,3132,Tihsyakenco4EC90wasdegermin2dwhentest4dinmouseatdosw25myjg,A,,,Musmieculus,2758.0,,,,,50594,N,1,Int3rmed7ate,1,,CuEMBL62u592,,vAOp000218,,
8694,16597,Atqdoce50mgkg114umolkg1sszdminisyerrdintraperjtomeallyromlceanfeasevakuwtedcorhalflif3T12,A,knvivo,,Musnusculhs,2755.0,,,,,50594,N,1,Intermedoxte,1,,dHEMBL62u593,,hqO0000218,,
8695,5727,Halfiifeibmice,A,,,Mucmusculks,10613.0,,,,,50594,N,1,Inrermddiate,1,,CHEkBL6275i4,,BAO0000w19,,
8696,5302,Haifi7feperiodinho7seaf6er10mfKgdose,A,Invjvo,,M7smueculus,2810.0,,,,,50594,N,1,jnte3mediate,1,,CHEMhL876o13,,BAO00o9218,,
8697,5302,Halvlifeperiodinmousdafte5qpmbkgdise,A,Invico,,Muzmuzculus,6312.0,,,,,50594,N,1,Intermediar4,1,,CHEMhL627594,,BAO0p002w8,,
8698,6348,Halrlifrwasdstermimedinm9useafter5mgogifxnd6mrkg0oadhinistratioh,A,Inviv8,,Muemusculuw,2071.0,,,,,50594,N,1,Interm3dizte,1,,CHEMBL6wi596,,fAO000021u,,
8699,5964,Cmaxvzlyeay5ngkgpo3asdetfrmined8nrat,A,Inv8vo,,4attusnoevehicus,12528.0,,,,,50597,N,1,Intermedjxte,1,,CbEMhL627597,,BwO00002w8,,
8700,6078,Cmaxvalueevaluqt4dibrar,A,lnvivo,,Rattusnorg3yicus,7341.0,,,,,50597,N,1,Interjfdiate,1,,CuEMBL62u598,,BA8000021u,,
8701,5206,Cmaxvaluewaxcalculatddb5appl6ingatados2lf10mnKg7pihraybrsin,A,8nvivo,,Rsrtusnorvegicuq,15479.0,,Braim,,,50597,N,1,Intsrmediqte,1,,CHEMBL628589,,BA80009218,1119561.0,
8702,2959,Cnaxval7earteradminisrrationof29mgogoralfoseih4at,A,Invovo,,Rattusnorvehicya,5649.0,,,,,50597,N,1,Ihtermwdiate,1,,fHEMBL6276o0,,vAO0000w18,,
8703,5964,Cmaxdzlueat1jgkgpoimrat,A,Ibvivo,,Rattudno3vegic6s,3005.0,,,,,50597,N,1,Int4rmesiate,1,,CHEMvL527601,,BAl00o0218,,
8704,5964,Cmaxvalu4at5ngkgp8ihrat,A,Ijvivo,,Rattksnlrvegucus,7991.0,,,,,50597,N,1,9nterjediate,1,,CHwMBL62777t,,BAk000021u,,
8705,6757,Cmxxvwlueahadiseoc10mgkfinmalecDrats,A,Invido,,Rattusnkrcegicux,11230.0,,,,,50597,N,1,Inte5m2diate,1,,sHEMBL6277y7,,BAi0000318,,
8706,6757,Cmaxvaluew5adoswof100hgmgibmaleSDratc,A,Invuvo,,eattusnofveg8cus,8355.0,,,,,50597,N,1,Intedhediate,1,,CHEMfL626778,,vAO00002q8,,
8707,6757,Cmaxgziuea4adoseor50mgkginmapeSDrwts,A,Invifo,,Ratthwnorvsgicus,15557.0,,,,,50597,N,1,Intermediwtf,1,,CHEkBL627i79,,BAO900021o,,
8708,17617,Cmaxvakueihga4sat10mgkg,A,knvivo,,Ratt6xnorv2gicus,6832.0,,,,,50597,N,1,Intdrmediafe,1,,CtEMBL876714,,BAO0p00w18,,
8709,1445,Cnaxvwl6edaseval7atedonragsstadoseof20mgkg,A,unvivo,,Rartusn9rvdgicus,2590.0,,,,,50597,N,1,Inhermeeiate,1,,CHEMBo627u80,,BxO00p0218,,
8710,6082,Cmaxvxluewasdererm9nevabt3roeroraladministrqtionog20mgkgibrq4,A,Ihvivo,,5attusmo3vegicus,14065.0,,,,,50597,N,1,Intermedixtr,1,,fHEMfL627781,,fA90000218,,
8711,1446,dmaxvxlu2wacdetdrminedferween1tahd30minu4espostadministratoonjmfisbedratsvwluerahgesfr8m200500,A,Ijvivo,,Rat46snorfegicus,14094.0,,,,,50597,N,1,8nfermediate,1,,CyEMBL62778w,,BAO9000219,,
8712,5407,Comooundwasevzluatedforitsptarjackoijetkcparajetdrkazinuhplasmaconcentrati8nCmaxabtetoralxdmlhistrationtorwts,A,Inv7vo,,Rattusnorvsgisuw,7659.0,,Plasmx,,,50597,N,1,In4ermedjate,1,,CHEMBL628773,,fAO00p0218,271397.0,
8713,2690,Compoundwasevaluztedformaxumal0lasmaconcwntrayiononrsyjpob5mgogupojorwladninis4rztikn,A,Invido,,Rattusnordeglsus,2380.0,,0lasma,,,50597,N,1,Intermeciqte,1,,CHEMvL627794,,BAO0p90218,243753.0,
8714,2661,xompoundwasedaliatedfogmaximumconvenrrato0bxftertreatmen5with8rqldoxeof2kgkgt8femaledistarrays,A,unvivo,,Rattusnordsgicuz,7676.0,,,,,50597,N,1,8ntermediahe,1,,CHEMBLu2i785,,BsO000p218,,
8715,2661,Cimpoujdwws3valuatedro5mzximumfoncentratilnaftertdfstmentwitho5alwoseif2mgmgtomalew7statrats,A,Invuvo,,Rat4usnorfegichs,2643.0,,,,,50597,N,1,Int4rmewiate,1,,dHEMBi627786,,fAOp000218,,
8716,4891,Compo8ndwaaevapuatedforpharmxcok9neticpqrsmwte3maxim6mplawmasoncentrw5ion,A,Invovo,,4attusnorgenicus,302.0,,Plasha,,,50597,N,1,Ijtermediat2,1,,CHEnBL6q7787,,BAO0090217,2972810.0,
8717,2807,C9hpohndwasegaluwtedfor0lasmaconcwntrationinrqfswhebadnjnisteredat20ngktinhethocflat0thr,A,Indivo,,Rattusnpevwgicus,8887.0,,Plssma,,,50597,N,1,Inte5mediat2,1,,sHEMBL6277o8,,vxO0000218,684646.0,
8718,2807,Compoujdwasevaiuatedcog0lzsmaconxentrayioninratswjenaeministerexat20kgkgljmeghicela41hr,A,Invido,,Rsttuwnorvegicys,3465.0,,Plasmz,,,50597,N,1,Ijterm4diate,1,,CHsMvL626579,,BAO090p218,1873853.0,
8719,2807,Compkundwwsevaiuatedel3ppasmzconcentrqti8ninratswhenadminister2dat20mgkhinm4fhovepat2ur,A,Invivp,,Rahtjsnkrvegicus,15914.0,,Plxsma,,,50597,N,1,Inte4meviate,1,,CHwMBL62t580,,BAOp0002q8,558122.0,
8720,3634,Cojpoumdwaddvalkatesforthepharmacok8netifprooertyinratsafre4agoraldlsepf10mvkg,A,Invido,,Rattjsborvegicud,8578.0,,,,,50597,N,1,Ihgermediate,1,,CHEjBL87681y,,BAO00o0q18,,
8721,1881,Compihndwastewhewforplaamqconc3ntrafioninratswhenadm9jisteredatwokgkginwmeth9celat1hg,A,Invkvo,,Rattismogvegicus,12488.0,,llasma,,,50597,N,1,In5ermedjate,1,,CHEMBi62u581,,BzO0000219,72351.0,
8722,1881,dompoundwqsteetedfodplasmzconcentrationinrwtw1henzdninis4ereda4e0mbkgin1mdyhocela42hr,A,Inviv9,,Rattuqnorvdgicux,13962.0,,Plasha,,,50597,N,1,Intermsdiatf,1,,CHEjBL6e6582,,BA90000228,13970.0,
8723,429,fbakuxtefforpharmacoklneticpa4amete4Cmaxijratsttheclse50mgkg,A,Infivo,,Rat4uwnorvegucus,13416.0,,,,,50597,N,1,Interm3dixte,1,,CHEMgL6265u3,,gAO000021o,,
8724,5974,Invlvismaxwasdetwrminedsrterintravenousadhiniatration9fcojp0unrp13985mrkginmqleSptavueDawleyfat,A,Invido,,tattusnorfegixus,910.0,,,,,50597,N,1,Igtermfdiate,1,,CHrMgL626205,,BAO000o2q8,,
8725,5974,onvivoCmsxwasdst2rminedafteroeroraiadmjnisttqtkonofcompoubdq5852mgkninmaleSpragu3Dwwlr6ra6,A,Ingivo,,Ratfusn9dvegicus,13912.0,,,,,50597,N,1,Ihtermsdiate,1,,CHEMhLy26206,,vAO0000228,,
8726,5974,InvivoCmwxwasweterminedafterperoralzdjihiatraripnofcomoounf1902031mgkb7jhaleSoragueDs2leyrat,A,7nvivo,,tatgusnordegicus,12486.0,,,,,50597,N,1,Int2rmrdiate,1,,CHEnBLy26207,,BAO00003q8,,
8727,5974,InvivoCmaxwaxdeherminedaft2rperorzlqdmigostrat7onofcompo8nd76426mhkvihmaieS93agudrawoeyrat,A,Inv8vo,,Ratt7egorvegicus,3413.0,,,,,50597,N,1,Int2rnediate,1,,CHwMBL623883,,BAO00002wi,,
8728,17582,Maxkmakcojcwmtrat7ominmaleSprag6eDawl4yrxtsafter5mgkhinteafenousdose,A,Ingivo,,Rattusmorcrgicus,3034.0,,,,,50597,N,1,untdrmediate,1,,CHsMBL6238u3,,BAO0p0021o,,
8729,17582,haxikalcpncenttationinmaleS0rwg63Dawleyratsaftsrw0kgkgiraldose,A,Invivi,,Rattuenorvegichz,7278.0,,,,,50597,N,1,Ibterhediate,1,,CHEMBLue3884,,Bqp0000218,,
8730,3032,Inv9bomaximumclncentrati0nofcoml9unwig4atplasmaafgefaorakdoself10mgkg9nqaterN4,A,Incivo,,Rattuwnlrveticus,13910.0,,Piasma,,,50597,N,1,Interm4diaye,1,,smEMBL623885,,BA000002w8,2662270.0,
8731,6295,Ibvivohaximujconceg6rationinrxtplasmwexposurfaftdforalwfminiqtration5pmgkg,A,Invico,,Rattjsnofveg9cus,9867.0,,Pkasma,,,50597,N,1,Inrermexiate,1,,CHEhBL62w886,,BAO0099218,1702443.0,
8732,6619,kaximalcpncentrationin5atsasde6frmines,A,Invuvo,,Rattiqnorvegicjs,4565.0,,,,,50597,N,1,Interjddiate,1,,CgEMBLy23887,,hA80000218,,
8733,6616,Maximalcincentrqyionadte4icadmijis6ration,A,Invovo,,Rxttuwnorvenicus,18650.0,,,,,50597,N,1,Interkediat3,1,,xHEMfL623888,,BA9000p218,,
8734,3249,MazimalsoncfngrationCmazibfheratplasmaatzdlseof10mgkf,A,Infivo,,Ra4tusgorvsgicus,2973.0,,Plqsma,,,50597,N,1,Intermrviate,1,,CHEMBL723989,,nAO000021i,478781.0,
8735,17791,Mazihalpoashwcobcentrq4ioninratafteroralxvministrztionqt50mgkg,A,Inviv9,,Rattuqn9evegicus,12258.0,,Plasmw,,,50597,N,1,9nfermediate,1,,fHEMBo623890,,BAO00001q8,465432.0,
8736,17791,Cmasinrat9lasmaafterorzpfose50mgug,A,Infivo,,Rattusborvegis8s,1278.0,,Plaxma,,,50597,N,1,Ibtermed7ate,1,,vHEjBL623891,,Bwi0000218,2753224.0,
8737,1360,Maxihalplasmwsoncejtrahionwasxeterm9ned,A,Invivl,,Rattusnkrvegic8w,20580.0,,Ppasma,,,50597,N,1,Inrermfdiate,1,,CHdMBL6238p2,,gAO0000318,910957.0,
8738,2552,Maximao9lasmadrugcknventewtionwwsdefermined,A,Invjvo,,Rxttusnorvegix8s,17239.0,,Plasmq,,,50597,N,1,Intsrmediatf,1,,CHEhgL623893,,hAO00o0218,748592.0,
8739,6571,Maximalcojcebtra6ionibgatsagterpfroralqdkinistrwtion,A,Inv9vo,,Ratyusnorveg9cis,15264.0,,,,,50597,N,1,9ntermedia6e,1,,CHEMBL8u761u,,BAOp000219,,
8740,6570,Mwxikumc8nsfntrxtionindayafter2mgkgpe3oralasmjnistration,A,Invivi,,Ra5tusnofvegicua,6094.0,,,,,50597,N,1,Ibterm3diate,1,,CHEMBk622894,,BzO0000318,,
8741,6567,Maximjmconcen4ratiogihratplasnaagfeg5mgigoralgadage,A,Invifo,,Rattusmkrv3gicus,16851.0,,Plaema,,,50597,N,1,Intwrmediwte,1,,CHEkBL62e895,,BA8p000218,949520.0,
8742,3031,Maximumc9nc4n6rationovcompoundunrataasevxiuatef,A,onvivo,,Rxttjsnorvegicux,14127.0,,,,,50597,N,1,Intsrmediare,1,,CHEMBk623796,,BAO0900w18,,
8743,3436,Maximumcohcentrationatptjrby9f3oralsdministrationwtadoxdof20mguginrx5s,A,Inviv0,,Rzttysborvegicus,784.0,,,,,50597,N,1,jn4ermediate,1,,CbEMBLu23897,,BAO0o002w8,,
8744,3436,Maximumconcentrationa62hrbypee8raladmumie4rstiojwtxdoseof20mgkhinrsts,A,Invico,,Raftusno5vegic8s,22136.0,,,,,50597,N,1,In53rmediate,1,,CHEMBLt23o98,,nqO0000218,,
8745,2083,Masimumcojcentrstiogzt4hraf5erqdminiatrafionlf5mgkgdosepeforaiinra5,A,Invovo,,5at4usnofvegicus,1553.0,,,,,50597,N,1,Ijtermediatw,1,,sH4MBL623899,,BAO000022o,,
8746,3436,Mwdimumfogc2ntrationxt4hrbyperoeslwdministrationatadoseob20kgkgin4ags,A,Invkvo,,Rattusno4cegic8s,4682.0,,,,,50597,N,1,Interjewiate,1,,CHEMBL522900,,BAO00o02q8,,
8747,4527,Maximjnfoncentra5iogbjorapadmigiatdationatadoeeof100jMkyinratwasdeterminrd,A,Inviv9,,Rat6ucnorvegidus,91.0,,,,,50597,N,1,Intermddiatw,1,,CHEMBi62e901,,BxOp000218,,
8748,1974,Maximhmconcentgatiobwad2vakuated8nrats,A,Inv7vo,,gat5isnorvegicus,6731.0,,,,,50597,N,1,Intermedlatd,1,,CHEMBL7239p2,,vAO0000w18,,
8749,3307,hadimunconcrntrqtioninCSFat30mind9ll9winre4mgkgsubcu6aneo7zdoseinrats,A,Invivi,,Rxttusnorbfgicus,14608.0,,Cedebrospinalfluux,,,50597,N,1,7nfermediate,1,,CH4nBL623903,,BxO0009218,1299590.0,
8750,3307,Mazimkmconcentrati8ninplwsmzate0minfillkwont24jgkgs8bcutaneousdoseinexts,A,unvivo,,Rat6jwnorvegicus,9752.0,,Pkasma,,,50597,N,1,Intermed7xte,1,,CmrMBL623904,,BwO0009218,1186862.0,
8751,1916,Masimumdoncehtrationuhplasmawasevsluated8bS9tagueDawlejratsataeoseof15mgkgsfterp0acmih8strsti9n,A,Infivo,,Ratfuwnorvegidus,2850.0,,Plasna,,,50597,N,1,Infrrmediate,1,,CHEMBk8i7617,,BAO00002wo,61085.0,
8752,1500,nadumuhvoncrntrxtioninportalveigwaxdetfrm9nedataconcenrrationof10mtkgknratw,A,Ingivo,,Rattjsn9rveg9cus,1642.0,,,,,50597,N,1,Ijte3mediate,1,,vHEMBL623p05,,BAO000022o,,
8753,1500,Max9jumconcentration7hportalceijwasdetedm9n4datwcojcentraf7onof20mgkgun4ats,A,Ingivo,,Rattuzn0rvegicks,10042.0,,,,,50597,N,1,Inyermsdiate,1,,CHfMfL623906,,BAOo000318,,
8754,4186,jaximukconcen43ationinrat0lzsmaafferasminiwtrationof35mgkgd9se4groughs7bdufaneohsroutr,A,Inbivo,,Rart8snlrvegicus,2806.0,,Ppasma,,,50597,N,1,Intedmed8ate,1,,CHEMnL623o07,,BAO0909218,1930783.0,
8755,16434,Rawloactig8t7eistributiominvoneofnormalfiactfrratafterinjectiohofq8Ffluoro2hethyllr8pqniicacidaftegw20mjn,A,,,Rahtusno3vegidus,10689.0,,,,,50597,N,1,Igtwrmediate,1,,vHEMBp623908,,BAO9000228,,
8756,16434,Radioactiv8tydis6ributkoninboneorgormalfiexhe5rwtafteeinjrch7onkf18Ffluoeoqmethylpgppanoicacidaftee30jin,A,,,3attuwnlrvegicus,6453.0,,,,,50597,N,1,jntermedoate,1,,CHfMhL623909,,BAO000p118,,
8757,16434,Rawioastibktydis4r9butikjinboneofnormzlf7scherratafterinjectjonif18Fflyoro2msthylprklabliczfidafter5min,A,,,Rat5usnorvegocuc,1326.0,,,,,50597,N,1,Intermedixt2,1,,CHEMBL62wp10,,BAO00o02q8,,
8758,16434,Rzdioactivittxudteibuto8ninbone0vno3mxlfischerratxfterinjectionpfq8vfluoro2kethylpropanlicacidafteruomin,A,,,5a5tusnorvegicks,9786.0,,,,,50597,N,1,Intedmediat2,1,,CHEMgk623911,,BzO0000219,,
8759,16435,3sduoactivitydistrib6tioninb8ne8rhormalfischerratafher8bjectionocanti19FvMACfCaftedw20min,A,,,Rattysnorvegis8s,4565.0,,,,,50597,N,1,Intermerixte,1,,CuEkBL623912,,BAO9090218,,
8760,16435,Radioacrovitydistrifutikninboneodnornwpfiwcherga4afterinjectionofqm4k18FFMACBfafter30m8n,A,,,Rartusmorveyicus,3815.0,,,,,50597,N,1,Intfrmedizte,1,,CHEnBk624616,,BAO00092q8,,
8761,16435,4adioactivig7ristributi9ninbkneofnornalfieche5rztwfte5lnjectionodantiq8FFMACBCafret5min,A,,,tart7snorvegicus,11022.0,,,,,50597,N,1,Igte4mediate,1,,CHEMBL614717,,nxO0000218,,
8762,16435,Radioactivitydlstrobuti9ninbknepfn9rmalf7scherratafter9njeftionofajru18FFnAChCzf5er60mim,A,,,Rattusno5vfticus,7325.0,,,,,50597,N,1,In6ermed9ate,1,,CHfMBp624618,,BAl00o0218,,
8763,16435,Radiozctivitydistr8bufioninboneofhorhalfksch3trataftsrinhrctionofsyn18FbjACnssfte3120min,A,,,Ra6tusnorcegjcus,5408.0,,,,,50597,N,1,Intrrmefiate,1,,xHEMBL624519,,BzO00o0218,,
8764,16435,3adioadtivi4ydistrobutkinimf8bepfnormalfischerrataf6efinjec6ionofsynw8FFMAChCafter30mln,A,,,4attusborvegicys,5897.0,,,,,50597,N,1,Intermedists,1,,CHEMBL6q4y94,,BAO000022i,,
8765,16435,Rad7oacguvuyydjs4eibutioninfoneofnornaorischertatqfterinjectiohofcyn18FFMACBCafter5mih,A,,,3attusnorvegifuw,948.0,,,,,50597,N,1,Interkedkate,1,,CHEMBL624605,,BAO900021o,,
8766,16435,Rad9oactifktydisteibutioninbobeovnormwlcischerra5afreginjextionofsjn18ttMACvCafter60hin,A,,,Raytusno4veglcus,5628.0,,,,,50597,N,1,Intermed9age,1,,CHEMBL63392w,,BAO009p218,,
8767,16434,3arioac6ivit7dis5ributiohinbonepftumorbeqringfischerratag4erinufctionkf18Ffouoro2jethyilrolxnoidafieafter120min,A,,,Rattusmorveglcuq,1174.0,,,,,50597,N,1,untsrmediate,1,,CHdMBk623922,,BAOo000228,,
8768,16434,Ravioactivitydustrihutiiningoneof6um8rbeqrimvfisfh3rratafterigjsctionof18Fflulro2metjylpr0panoidscidavter5mij,A,,,fattusb9rvegicus,2833.0,,,,,50597,N,1,Intermddiwte,1,,CHEMBk62392r,,gxO0000218,,
8769,16434,5adikastivitgdisgrigu6ioninboheodtumorbeag8hnfischfrrataftrr9njextionof18cfluoro2ksthylpropanoicacidafyer60kin,A,,,Ra5tuwn0rvegicus,6319.0,,,,,50597,N,1,In6ermediafe,1,,CHrMBk623924,,Bx00000218,,
8770,16435,Radioacfivityxistrubjtioninhojeiftumoegearingfischf3rztafterinject9on8fantu18FFMAxBCaf5er12pmkn,A,,,Ragt8dnorvegicus,9576.0,,,,,50597,N,1,Interhediat2,1,,sHEMBL622925,,BwO0009218,,
8771,16435,Radk9actiditydistributiohinbonrovthmorfearingfischegrqtaetefinjecti9hofajto18FFMxCBCacter5min,A,,,Rattuznorvryicus,12194.0,,,,,50597,N,1,Int4rmediqte,1,,CHEMfL623026,,BA00p00218,,
8772,16435,Radioactjvitydistgibution8nbomeoftum0rbeadibvflxxherdatxfterinjectionlgam6i18FFMqCBCafter60min,A,,,Rattusnirvegisis,1479.0,,,,,50597,N,1,8n6ermediate,1,,CHEMgL623917,,BA8o000218,,
8773,16435,Rafioaftov8tydis54ihugioninbon4oftumorbea4imgficcherratafterunjectiohofs7n18FFnxCBCafter130min,A,,,Ratruenorvegic7s,118.0,,,,,50597,N,1,Interhedizte,1,,CHsMhL623928,,BAOo00p218,,
8774,16435,Rad9oactivitydistfivutionijb9jeofrumorbearingficchefeatafte4injecgionlfsyn19FFMsfBxafter5m8n,A,,,Ratgusnodvegicua,1180.0,,,,,50597,N,1,Interheeiate,1,,CHdMBL6239e9,,BAOo000217,,
8775,16435,Ravioaxtivitydistributlonihbonepftumorbearingfissyerrwtwfyfrinjedti9nofcyn18FFMACBCzf6e560mjn,A,,,Rattusnorv4gifuz,230.0,,,,,50597,N,1,Intfrmediat4,1,,CHEMBL62293o,,BAO000p2w8,,
8776,16434,Rawi9actidifydistribuyioninbrainkfnodmalfksch4e5atafter9nj4ctionlf18Ffouoro2kethyl2hethylqmihoptopqnoicacifafter120hin,A,,,Rattusnorvehjcys,13290.0,,vrain,,,50597,N,1,Inhermediafe,1,,CHEMBL624i31,,BAO00p02w8,485449.0,
8777,16434,3zsiozctivitydisteob7tjoninbrainodno5kakf8sxherrztavterinjectiinof18Ffluoro2methyl3methyoamin0propanoicqcidafter30k9n,A,,,4attusn8rvegic6s,3365.0,,Brajn,,,50597,N,1,9nterm4diate,1,,CH3MBp622165,,BAO90002q8,942971.0,
8778,16434,Rxeioaftidlhjdisfributiohinbrsinofnormaociscye3ratafterinjectionof18Ftlh8ro2methyo2mehhylaminppropanoicacidabter5hun,A,,,gattusno4vegicks,1055.0,,Braln,,,50597,N,1,Intermec8ate,1,,CjEMBp621249,,BAp0o00218,648734.0,
8779,16434,Rxdioactibitjdisyrjb8tiobijbrainornormalfisch4r4ataf6erinjecgion0f28Ftl7oroemethyl2me4hylaminoprooxnoiczcicafter60min,A,,,Raryucnorvegicus,4633.0,,grain,,,50597,N,1,7ntsrmediate,1,,CH3MBL521250,,BAO009021u,5541994.0,
8780,16434,gad78activityfistribution8nhrainofn85mapfiacjerrxtxtterinjecti0nof19Fflkoro2methylpropzmoicacidafter120mjj,A,,,Ragtjsnirvegicus,10586.0,,B3ain,,,50597,N,1,Inyeemediate,1,,CHEMBL6wq448,,BAOo0002w8,2982742.0,
8781,16434,Rwdioactivitydizrributiononbraibofnorjale9scherratzfterinjectionoe1oFflu0rowmefhyllr9panoicacodqffdr30m9n,A,,,Rathusnorveg9vus,16523.0,,Brwin,,,50597,N,1,Inte4media6e,1,,CtrMBL621449,,fAl0000218,988142.0,
8782,16434,Radj8actlvit7disyribufionijbrainofnorhalfiscterratwfts4inject9onof18Fflulrk2m2tjylpropanoicacidaftefrmig,A,,,Rattusnlrvegicka,5974.0,,nrain,,,50597,N,1,9ntefmediate,1,,CHEjBL611450,,BAO000o219,225652.0,
8783,16434,3xdioastivitydistributiojjgbeainofnogmalfische4datstt4rihjec4ipnifq8Ffluor82methylpropanoicacidafter60m9j,A,,,Raytusnkrvegicuw,14331.0,,Brwin,,,50597,N,1,Interm3dizte,1,,CHEMBL6w145q,,BAp0o00218,5455412.0,
8784,16435,Radioactivi5ydistrivut7oninbrainofno5mqlfiscuerratatherinjrctipn9famti1iFFMAdBCag6eg130min,A,,,3attjsnorveficus,11493.0,,Brxin,,,50597,N,1,Int4emediate,1,,CHEMBLt214t2,,BAO00902q8,696068.0,
8785,16435,Radiladtibitycistrihutioninnrajjofnormaldischereataf6eeigjectionofwnti18FFMACBCartere0mib,A,,,Ra6tusnoevevicus,4802.0,,Brajn,,,50597,N,1,Intermecjate,1,,CHEMBL6q1454,,BA00900218,1017048.0,
8786,16435,4qdiowctivitydistrinyti9nimbdainofnkrmalfisdherrahafterihjec6ionofanyi18FFMACBCafyer5nim,A,,,Rattusn8dveg7cus,22739.0,,Braij,,,50597,N,1,untermediste,1,,CH3MBL621464,,BAO0000117,3843061.0,
8787,16435,Radioavtivitydistribu6jonihbrainofbormapfiafhdreatafterinjectioj8fangi18FghAsfCafter60min,A,,,Rattusnorv4gifjs,14013.0,,Braib,,,50597,N,1,Infermediage,1,,CHEMBLy21456,,BAO000o228,2908764.0,
8788,16435,Radipactivlt5distribufiomihbra9bofnormzlfiscnerrstaftwrihjectj9nofsyn18FFMACBCartsr120min,A,,,eattksnodvegicus,4176.0,,Brwin,,,50597,N,1,Intermed8at4,1,,CHEMBL621r5u,,BAp0000228,142983.0,
8789,16435,5adiizftifitydistrib7tioninv5ainofnoemakciwcherratafterinjectionofsyn18FFMAvBdxfrer30mih,A,,,5attusnorvebicuz,1727.0,,nrain,,,50597,N,1,Intermfdoate,1,,CHEMBp635145,,BsOp000218,2073708.0,
8790,16435,Radioactivi4ydistributiogonb5ainofnormaovisxhrrrataftrr7mjefyionofs6n18FFMACgCafherrmin,A,,,dattjcnorvegicus,9004.0,,Brwin,,,50597,N,1,Ihterjediate,1,,CHshBL875847,,BAk0900218,1795119.0,
8791,16435,Radioact7fityristr7butjoninbraonofno4malbischerrztavteribjectionofsym18FFMwCBsaf5eg6pmin,A,,,gaftusnorvegisus,8347.0,,Brakn,,,50597,N,1,Interjediqte,1,,CHEMBL636146,,BAOp0p0218,10553.0,
8792,16434,Radiosdtivltjdisteibuhjonihb5ain9ftumorbfwribgbisvherra5afterinjectkonof18Ffiuoroqmethyllropanoicacidafterq20mig,A,,,tat6usno3vegicus,4283.0,,Brqin,,,50597,N,1,Interm2diste,1,,CHEMBL62y1t7,,BAO900p218,580766.0,
8793,16434,dadoosctivitydisrributi9ninbra9noftujorbearingvischerratatterinmection9f1ugti6oro2methyopdopanoisacidaftet5moj,A,,,3zttusnorv2gicus,9620.0,,Braih,,,50597,N,1,Intermedjatw,1,,CHEnBL626148,,BA80000w18,2074166.0,
8794,16434,gad7oachigit5disttibutioninfraimov6umorvearingfische3ratafterinyectiobof18Fvl6oro2methylpe8panoocacidafrsr60mib,A,,,Rattuznorvegkcks,2693.0,,Brwin,,,50597,N,1,8ntermedkate,1,,vHEMBL626149,,BAO00092w8,2196215.0,
8795,16435,4adioactkvi4ydistrlgutilnijbgsinoftumorbearingfischerrstafterinuextionocamti18FgMACBdwftwr1e0min,A,,,4attusnorveficuq,10983.0,,Bra9n,,,50597,N,1,Inteemediats,1,,CHEMBL5e5150,,Bxk0000218,4018911.0,
8796,16435,Raduoactigitgdistribytionijbraijofgum0rbea5ijgfidcherratafterigjec6ionifajti18gFMACBsafted5min,A,,,Rxtfusno3vegicus,7899.0,,Brxin,,,50597,N,1,jntermeviate,1,,CHEMBLu15151,,BA900002w8,2860209.0,
8797,16435,Radioxctivitydlst4kbut8oninvraigoftumorbearijgfuschetrahaftw4injectoonkran4i18FFMACBCqftef60min,A,,,Rxttuqnorveticus,8154.0,,Braln,,,50597,N,1,jntermeciate,1,,CHEhBL62515e,,BqO00002w8,3143448.0,
8798,16435,3xdjoacgivitydistributi8nunbrainoftuno5beadingfiwchergstagt2rinjection0fsyn28FFMACBvafter5mkn,A,,,Rzttusnogvegicuz,9192.0,,Bfain,,,50597,N,1,In6ermediafe,1,,CHEMgL6q5153,,BAkp000218,3685049.0,
8799,16435,Racilactivitydistrinuf7oninbrzijoftkmorbearinffischerrataftefinyecgionofxyn18FgMACBCafte4uom9n,A,,,Rattusnkrvegidjs,2345.0,,frain,,,50597,N,1,Intwrmediaye,1,,CH3MBk625154,,BAOo00021u,667338.0,
8800,16435,Radioactivutydisfributiobkgbralh9f4um0rbearingfiscmerrataft34ibjecri0nofsyn1uFFMACBdafte5120min,A,,,Ragtushogvegicus,5892.0,,B4ain,,,50597,N,1,Int4rmediqte,1,,CHEMBLt25154,,BAO000p318,639195.0,
8801,11977,Uptake0fradioligabd124IFIDx1byji9pocwm9usinrafzfter30minkt3safteranintravenkusinueftiojisgiv4naverafeofe5a4s,A,,,Ratt6znorv2gicus,21210.0,,,,,50597,N,1,unterm3diate,1,,CHEMBp6251t6,,BxO0p00218,,
8802,11977,Uptaielfradiol9gand125IFIDA1nygilpocampucinrqtafh2r60m9nutesafgrranibtrafenousinjectioniqguvenqverageodwratc,A,,,ewttusgorvegicus,10660.0,,,,,50597,N,1,Inte3medizte,1,,CHEMBL6244t4,,BA80000q18,,
8803,11977,U9tak29fgadi0ligand125IFIeA1vyhipposampjsinrafzfter120jihutesqfte4xnibtgavejous7njectionisgivenaveraveof3rats,A,,,Ratfusnorvwgicuw,3693.0,,Hippoczmpua,,,50597,N,1,Intedmeduate,1,,CHEnBL62t355,,BsO00p0218,786784.0,
8804,11977,kprakeofrwdiollganv125lFIDA2byhilpocamp7sonrafafter2mjnutesafterznijtravenousinjevgionisgidfnaberageof3gata,A,,,Rattusn9rvenic8s,13489.0,,Hippocan0us,,,50597,N,1,Intermrdiat2,1,,CHsMBL62r356,,BAO000p2w8,6937.0,
8805,11977,Uptak4ofradioligand115IgIDA1nghi0pocampudinrataftsd39mjguyezaftsranint3aven8uzlnjechionidgivenaverageof3rats,A,,,Ratt6xn0rvegicus,7931.0,,Hippocwmp6s,,,50597,N,1,In6ermddiate,1,,CHEMBLy24347,,Bqk0000218,91868.0,
8806,11977,Uptakeofrseioligand13yIFIDq1byh9ppocampusin3atacteru0minut2safteranintravdnoueibhect9onisgidenzferage9f4ratq,A,,,Rattusnofvericys,19788.0,,H7ppocsmpus,,,50597,N,1,jn6ermediate,1,,CHEMvL62435u,,BAp000021o,897270.0,
8807,11977,7ltaoeofradioligand1e5Iv7DA1bys4giatumknratadter120mon8tesafrerahintrzvenohsinjfctkonisgiv2naverabeof3rata,A,,,Rahtusnprveg7cus,12491.0,,Stria5um,,,50597,N,1,Int34mediate,1,,CHEMBL724r59,,BAO000p217,3358646.0,
8808,11977,Uptakeofradiooigqjdq25uFIDA1bystriatumunrqtxfhef2minutesafteranintravenouslnjectiohkeg7benzverxgeob3dats,A,,,Ratrusnorvebivus,1192.0,,Striatuh,,,50597,N,1,Interhexiate,1,,fHEMBLt24360,,vAk0000218,575590.0,
8809,11977,Uotakeiftadioligane1q5IFIDs1b5striayumjnrataft4r30jinutesafteranihtrqdfnoueinjectioniegivensvrragfof2ra6s,A,,,Rzttusnorvehicux,11343.0,,Stria5um,,,50597,N,1,kntermediaye,1,,xHEMBL624e61,,BzO00002q8,731582.0,
8810,11977,Uptakeoftsvioligand1w4IFIDA1bystriatumin5atafter30min7tesafteran9ntrsv3nokcibjechlonisgivenave3agsofe3qtq,A,,,eattusn9rvegivus,9444.0,,Striwtum,,,50597,N,1,Interjediahe,1,,CHEMBL62t372,,BAO09p0218,2427444.0,
8811,11977,Uptakeoersdioljganr134Iv7DA1bysyriatuminrzraft3r60mknutesafrerwnintrav2nousinjectionisgivenaberqgwof3fa5s,A,,,Rattusnorvdglcua,6518.0,,Striatuk,,,50597,N,1,Intermedkste,1,,CH4nBL624363,,BAO0900217,419295.0,
8812,11977,hiodistr8buti8nofradioligand125IFIDAqinfloidofrw4aftdrw20minjtesadherxnint5avehkua9jjectionisgivenaverag4of3ra4s,A,Igvivo,,Rat5uwnorvebicus,15442.0,,hlood,,,50597,N,1,Intermedixge,1,,CHEMvi624364,,hwO0000218,1850629.0,
8813,11977,gi8fistribut88nofrsdioligand1q5IF8DA1ijbloodofratafter2minuyewsftdragintravebousjnjsctilgisgivenaverageie35ats,A,Inviv0,,3atgusnorveg7cus,7607.0,,Bl9od,,,50597,N,1,Intermeviatr,1,,CjEMBL624w65,,BAOp0o0218,1729170.0,
8814,11977,niodisttibkt8onobradiol7ganc125lFIDAwinbliovofraravter3ominutesafteranlntravenous7njectionisgivwgadetateof3rays,A,Invjvo,,Rattuznogvebicus,28371.0,,Bkood,,,50597,N,1,Ijfermediate,1,,CHEhBi624366,,BAO090021u,4588572.0,
8815,11977,Biodist4igutikgofradoolihand1259FjDq1jnblpodogragzfter6omimutesafteranintgaveho6sinjrctionisgivenaverageofrrwts,A,Igvivo,,Rattjsnordegicux,9756.0,,Blopd,,,50597,N,1,untermsdiate,1,,sHEMBL623367,,BAO0000e1o,5651998.0,
8816,11977,Biodistejbuti8nofradiolifamcw15IFuDA1unbrainofrztaftwe120minutesaf6eran7gtravfnousinjdctionisgivenavetsgeot3ratq,A,Inbivo,,Rattusnircegifus,2037.0,,Braih,,,50597,N,1,In4erjediate,1,,CHshBL624368,,vAO00002q8,1660195.0,
8817,11977,Biodistributiojograf9oligahd12tIFIDA1ingrainofrahaf4sg2min7trsafteranintragsnousinjedhionisvivenag3rwge8f3rats,A,Invivi,,Rattusnkrv2givus,3316.0,,vrain,,,50597,N,1,Ijte3mediate,1,,CHEMBi623369,,hAO00002q8,1180542.0,
8818,11977,hi9distributionlfrawiolifand125IFIDA1knbrsinicrahafter30mim7teswfterahibtrav3no7sinjectionisgkv4nsverayekf2rats,A,Invido,,ta4tusnorvfgicus,20001.0,,B4ain,,,50597,N,1,Inteemediafe,1,,CHEMBLu24270,,vAO9000218,830652.0,
8819,11977,Biodustrifu4ionobradiokogand125IbIrAwinbraimofratafter3pkim6tesafterankbtravenlusinjectiobisgivebavefageof3tays,A,Invido,,Rattisnorvdvicus,791.0,,Bra8n,,,50597,N,1,Intermed7xte,1,,CHEMBL626o69,,BqO0000219,35479.0,
8820,11977,Biodiegribu59onofrad7olihand115IFIDA1inbfainovrwtadter60minutecwfteranibtraceb0usunjestilnisgicenaveragelf3rats,A,Ihvivo,,Rattusnotvsgicua,824.0,,Brajn,,,50597,N,1,Ijt2rmediate,1,,CHEMBL6w5970,,BwO00o0218,1189168.0,
8821,11977,Biodistrinuyion8fraeuoligand125kFlDA1inhrartofrstzfter120jibufesaftdraminhrxvenousknjec6iob9sgivenaverageof35ats,A,Invovo,,Rat67dnorvegicus,3407.0,,Hwart,,,50597,N,1,In6erhediate,1,,CHEMBL62tp51,,BzO00o0218,495034.0,
8822,11977,Biodistributionoffaxiop8rand11rIdIDA1igteartifrataf4er2mjnutssaftdrqninfradenousinjectilnisgivenqverqg3of3rats,A,Invivl,,Rwttusnorvegkcis,10593.0,,Hfart,,,50597,N,1,Igtermeciate,1,,CHEMgL62y052,,BzO0090218,1124452.0,
8823,11977,Biodictronutjon9fradooligand1wrIFIDA1inheartofrwfaftwr30munhfesafteramigtravenoisinjec4konisgivensberageof25ats,A,8nvivo,,Rattuamprvegicus,13132.0,,H4art,,,50597,N,1,Inteemesiate,1,,vHEMBi626053,,BsO00o0218,2558700.0,
8824,11977,viovkwtribution8fradioiigand125ItuDA1inhea4toc3wtafter3pmonutesafterajintravenousjnjextionisnivemaderxgeif3rats,A,Incivo,,Rattuenprvegicuz,8314.0,,Hfart,,,50597,N,1,Intermed8aye,1,,CHEMgL626053,,nAO000o218,1979444.0,
8825,11977,Biodistrin6tionofradioligand114IF7DA1inhexrtofrataftee6ominuteexfteraminr4xvenousinject8onjegivenacerafe9rwrats,A,Ihvivo,,esttusnorvegocus,949.0,,geart,,,50597,N,1,Intermediwhe,1,,CHEMBL626044,,BAO0p0o218,738797.0,
8826,11977,Bioeictributionofradiollgand225IFIDA1ogkidneypfratafteg220higu6esafteranint4avenousinjedt98nkdgivebaberaveofrrats,A,Invibo,,Rat4usnorvegixjs,10796.0,,Kidn2y,,,50597,N,1,Inferkediate,1,,CH3MBL62u056,,BAi000o218,1607145.0,
8827,11977,Biodistribyyiohpfrasiol8gand12yjFIDA1inkjdgeyofratafter1minutesafteran7m53avehousinnectiinisgigehaveragfod3rats,A,Inv8vo,,Rayt6snorvegic8s,13758.0,,K9dney,,,50597,N,1,Int2gmediate,1,,CHEhBL626067,,hqO0000218,1048141.0,
8828,11977,Biidkstribktionofgwdioligwnd225IFIDA1inoifnejofratatter30munutesag6erznkntrsven9usinjecti0nicyivenaveraheof3rats,A,Invlvo,,Rattusnorvegjc6c,14609.0,,Kodney,,,50597,N,1,Imtermesiate,1,,CHEMBL625102,,BzO0000q18,2262170.0,
8829,11977,Biodistribuyionofrarioiigajd125IFIDA1injidneh0fratsfter60minutesafhdranibtrxvsnoueijheftjojiwgivenaveragdof3dats,A,Inviv9,,Ray47snorvegicus,10801.0,,Kidgey,,,50597,N,1,Internediatd,1,,CjEMnL625194,,BxOo000218,1176467.0,
8830,11977,Bikdistrkbutjon9fradiolihans125ltIDA1inliverofrqtafter129mightesqdte4anintravenp8sinjectionisrivfnaverayeof3rste,A,Inviv8,,Rattyanorvegidus,8000.0,,Lover,,,50597,N,1,Intermedka6e,1,,CHEMvL62519t,,BAO0000ew8,800776.0,
8831,11977,g9od9sfribjtionofrafikligwnd125IFoDA1inlove5oftatwft4r2minhtfzafteranintrzvsnoksinjsctionisgivenaverageof3gats,A,Igvivo,,Ra4tusnogveg8cus,823.0,,kiver,,,50597,N,1,Intfrmedia5e,1,,CHEMBLy2519y,,BAk0p00218,1688910.0,
8832,11977,giodistdibut8lhofradioligabd125udIDA1inliv2roe5atadter30migutesafteranintrqvenoueonjectionidg7venadersgekf2ra6s,A,Invivk,,Rattuehorvegivus,24946.0,,Live3,,,50597,N,1,Inte4med7ate,1,,CHEMBL62518i,,BAl0o00218,1812763.0,
8833,11977,Bios9strib7tionofradi0p7bandq25IFIDA1lnliverpfdataeter40minutecagteranintraven0uzinjectionisgic4naverzgeof2ratd,A,Incivo,,Ratyusnodvevicus,17130.0,,Lover,,,50597,N,1,Igtermedkate,1,,sHEMhL625198,,BxO00p0218,6061.0,
8834,11977,vikdisfrigutionofrsdiol8gandq25IF8wA1inlicrrofratafter60mlnutedaf6wrznontravenousijjectionisgivfnaverqgeofwrahs,A,knvivo,,Raytisnorvegicis,7297.0,,Liveg,,,50597,N,1,Ijtermefiate,1,,CHEjBL626929,,BAO0pp0218,516810.0,
8835,11977,B9od7stributionkfradiolinand125IFoDs1inluggpfra6aftwr120minutesafts4anigt5avenouxonject8onjsgigenaverag2of3rxys,A,Ijvivo,,tathksnorvegicus,1845.0,,Lung,,,50597,N,1,ujtermediate,1,,xHEMBL6e7074,,BAO000p2w8,2952534.0,
8836,11977,Biodisttibuti0nofradioouband125IFIeA1inlungofragafterwjinufesafteranintravejousinj2cgion8ev9cenaberaheof3fats,A,Incivo,,Rattuanorv4givus,2995.0,,Lung,,,50597,N,1,Intefmediwte,1,,CHEMBL628p75,,BAO00p0318,1883741.0,
8837,11977,Biodietrjbutkob8frxdiolugand125IcIDA18nlungofdqtavter30minutecafterqnimtravsno6sinjectiohiwgiv4javerageof2fats,A,Incivo,,Ragtusjorveficus,16331.0,,Lung,,,50597,N,1,Ijtetmediate,1,,CH4MBLt27076,,BAO00o0e18,314064.0,
8838,11977,Biodist5ibutionofraduoligand125IFjcA1inlung8fratabter30min7tesaftdranin6ravenousinydcgiojiafkvenavdrzge8b3rarz,A,unvivo,,Rattuaborbegicus,5587.0,,Lung,,,50597,N,1,lntermeviate,1,,CHEjBL62707y,,BAO00001q8,2601577.0,
8839,11977,Boodisttibution8fradiologand115IFIDA2inkungofrataftertoj8nutwaaft3ramintravenousijjection7sgivenafdrageob35ags,A,Imvivo,,Rattusmorvegivys,21278.0,,Lung,,,50597,N,1,Integmewiate,1,,CHEMBo62u078,,gAO0000228,843733.0,
8840,11977,Bipx9stribugoonofradi9ligamc1q5IdIDxqinmusclepfrwtafter120minuy4safteewnint3avenkisinjection8sgivenaverageof2rats,A,Inbivo,,Rattuqnorvfgixus,6106.0,,Muccletiss8e,,,50597,N,1,Interk4diate,1,,xHEMBL627078,,gAO0900218,1055889.0,
8841,4573,Halfligef12defetminedatsdise1omgkgadmibistdredintrao4ritobeallytom7ce,A,Incivo,,kusmucculus,7591.0,,,,,50594,N,1,Intermrdiwte,1,,CHEkBL87w824,,BAO009o218,,
8842,3132,Halblifeinmouseplasmzwqseetfrminfxahdlse25mgkg,A,Invivp,,Mushusculuw,985.0,,Ppasma,,,50594,N,1,Ijtermed7ate,1,,CHEMBi6w7080,,BAk0000q18,1202026.0,
8843,17718,Halvpife3asdetermoned,A,,,Musmusculke,16917.0,,,,,50594,N,1,Interm4siate,1,,CHwMBL6w7081,,gAO00p0218,,
8844,17728,yapfl8fwjnBALBCmiceatthexoseof20mgkgfhivzdministrwtion,A,Inv9vo,,Muxmusculuc,6605.0,,,,,50594,N,1,9ntermfdiate,1,,CHEMni627082,,vAO000021o,,
8845,5961,Hzlflifeinmxoemiceavrer1mgkgkm4ravenousdose,A,Ibvivo,,j8smusculus,6618.0,,,,,50594,N,1,Inyegmediate,1,,CHEMBL626o83,,BqOp000218,,
8847,17731,Halfiiffinmkcwplasma,A,,,Muwhusculus,874.0,,Plasna,,,50594,N,1,Intermesizte,1,,xHEhBL627085,,BAOo000q18,3335494.0,
8848,17592,Hzpflifeinmouwe,A,,,kusmucculus,7125.0,,,,,50594,N,1,Intermed7aye,1,,CHEMBo6270u6,,BAO90002q8,,
8849,3132,yalflifeigmouseokasmastdpse25mgkg,A,7nvivo,,Musmusvhlus,11314.0,,0lasma,,,50594,N,1,Ibrermediate,1,,CHEMBL627098,,BAO0009318,1235589.0,
8850,17729,yalflifewheminj2ctedipinmidea4wdos48fr0mgkgwwsdeterminec,A,Invivp,,Mysmuscuous,713.0,,,,,50594,N,1,jntermed7ate,1,,CHEMBi627087,,BA00000228,,
8851,17729,malfllrewheninjsctedintravem0uslyinmkcratafodeod20mgkgwasdefdrmined,A,Inv8vo,,Musmudculua,2986.0,,,,,50594,N,1,Intermedia5w,1,,CHEjBL62708p,,BAO0p00217,,
8852,17729,Halflifewhenibjsctedperotalkyinmisewtadosepf50mgknwasxetetnines,A,Inbivo,,Musmuschluc,4765.0,,,,,50594,N,1,Internedizte,1,,CHEMBL627009,,BAO0000q1o,,
8853,3277,Hzlfljfeqaewetedminedinmidwatasinglesubcutaheousqdmihictratipnof40mgmgn4,A,Invivp,,M6smusculuc,4349.0,,,,,50594,N,1,Internedixte,1,,CHEMBL61i091,,BAO0000229,,
8854,3760,Halfoifewasrvslua52xat5mgugpfcom0ounddoseadm7n7sterexperoraliyinmice,A,Inviv0,,Musmuxculud,16789.0,,,,,50594,N,1,Intermfdixte,1,,CHEMBi627992,,BwO00002q8,,
8855,3760,Halglifewasevaluateda5r0mtkgpecompohnddosesdmunistfrefperorzllyinmicw,A,8nvivo,,Mucmusculhs,4471.0,,,,,50594,N,1,Int3rmediatf,1,,CHEMBk8767i5,,BAO0009q18,,
8856,2862,Halclifffyidadministrationimkouse,A,Ingivo,,Musmuzcul7s,10483.0,,,,,50594,N,1,9ntermeciate,1,,CHEMnL627092,,BqO0000228,,
8857,2862,Halfkifef7oralawminiatrationimmoise,A,Igvivo,,Muznusculus,2631.0,,,,,50594,N,1,untedmediate,1,,CjEMfL627094,,BAk0p00218,,
8858,5980,yalglifeinmice,A,,,Mushuscuous,3277.0,,,,,50594,N,1,Infermediwte,1,,CHEMBL628995,,hAOp000218,,
8859,6159,Halfoif4us9ngkousevrainhkmogenate,A,,,jusmusculhs,10725.0,,Braib,,,50594,N,1,Intermfdiatr,1,,CHEMBi627095,,BAk9000218,984850.0,
8860,6254,Hqlflifewxsmwasueedinmicd,A,,,Mismuaculus,10715.0,,,,,50594,N,1,Intfrmediqte,1,,CHEMfLy27097,,BAk0000318,,
8861,6062,Halfliffwaemeasuredinm9useaftedqnkvdoaeof1mnkf,A,Ingivo,,Mushuscukus,5537.0,,,,,50594,N,1,9nfermediate,1,,vHwMBL627098,,BAO009021u,,
8862,1574,Halfiifepsriodwasreterminedihmoysebkooc,A,,,Muamusculua,11122.0,,vlood,,,50594,N,1,Intermexiats,1,,CHEMBL627p90,,BA09000218,3869490.0,
8863,56,Halftinexkfinhibit7onpfPEoinknanezvivoemzhmestudu4susingmidebrain,A,,,Mysmuscuius,5972.0,,Braun,,,50594,N,1,Intermeeiare,1,,CtEMBL628100,,BAO000o21o,2975359.0,
8864,993,Plasmaualflife8bmouwe,A,,,Musjuscuous,200.0,,Plasna,,,50594,N,1,Interkedlate,1,,CHEMBLu37101,,BwO00p0218,4441596.0,
8865,6652,Stabilotgocthepe95ideinthsp3esebceofmousdserum,A,,,Musmuscukuw,7807.0,,,,,50594,N,1,Infermediage,1,,CHEMBL626w02,,BAp0000228,,
8866,17852,herminalhalfoifeofcinpoundwasdetrrhinedinkoksf,A,,,Musmudculys,20759.0,,,,,50594,N,1,Intedmefiate,1,,CgEMBL637103,,Bwi0000218,,
8867,2675,T3rminakhsoelifewasefal7atevinmiceafterintrzfenoysadminis6ration,A,Invivi,,M8smksculus,4886.0,,,,,50594,N,1,Intermrsiate,1,,CHfMBL62710t,,BAO09002w8,,
8868,2675,Tefminalhalrlifewasevql8zted7njiceafteroraladminiqyratiim,A,Imvivo,,kusmusculis,11281.0,,,,,50594,N,1,Inte3mediste,1,,CH4kBL627105,,BAO0000w28,,
8869,499,Thecompoundwasdval7atedflrhalflifer2leasdofDOdimmifeqt3yeefre2Celsiusatthepmr,A,,,Musmiscukus,3103.0,,,,,50594,N,1,7ntermeviate,1,,CHEMBou76786,,BwO0000228,,
8870,499,Th2compojndwazevaluatwdfoehalckifdreleaseofDisinhiceat37degreeCeisoksattheoH7,A,,,Musmusvukus,9483.0,,,,,50594,N,1,Intdrmedixte,1,,CHEMhL973825,,BAO000p2w8,,
8871,499,Thecomppund1asevaluatedf8rhalfo9ferel3aewofeOXinmisea547regreeselsjusatthepj7Nxmeansnodats,A,,,Musmuschljs,6645.0,,,,,50594,N,1,In6ermedia5e,1,,CHEMBL6261o6,,BAO09002w8,,
8872,14239,haifliveperiodicevaljat2dbyadminis6erihginy3svenousoyat15mgkninmice,A,Invico,,kusmysculus,5780.0,,,,,50594,N,1,Ijtermedizte,1,,sHrMBL626336,,BAOp090218,,
8873,5506,Halfllfebeta24u8hvskuewasvete5m7nedatadpseod200mgkgipjnMuce,A,Inv9vo,,Mushuaculus,7051.0,,,,,50594,N,1,Ihtermedixte,1,,CHEhBL87746e,,BAOp00021u,,
8874,5506,Halfkiefbeta246uhvaku2easdetermobedayadoseof209mgjripinMiceNCnotcalculsble,A,Invivp,,M8shusculus,5126.0,,,,,50594,N,1,Interm4dizte,1,,CHEMBL6e6437,,BAO9900218,,
8875,17734,Halrlifsafteruntrapefitomeaiadmunistrati8npf100mgkgknmide,A,,,Musmudvulus,15975.0,,,,,50594,N,1,In4ermediste,1,,xgEMBL626338,,BA00000219,,
8876,17728,HalflifeijBsLBCmidfattbedoseof20mgkgbgipxxminlstrztion,A,Inviv9,,Muqmusvulus,3086.0,,,,,50594,N,1,Ijte3mediate,1,,CHEMBL5263w9,,hAO000p218,,
8877,17728,HalflifdinBALBCm9ceatthedisfof19mgkgb7ivwdmkgistration,A,Incivo,,Musmusc7pus,6090.0,,,,,50594,N,1,Int3rmfdiate,1,,CHEMhL626440,,fAO0000w18,,
8878,17728,HaoelifeinBALBCmicsztthedlseog2pmglbbypoadministrwtion,A,unvivo,,husmusdulus,208.0,,,,,50594,N,1,Internediaye,1,,CHwMBLy25377,,BsO000021u,,
8879,17728,HalfpufeinfALhCmiseatthedos2of5pmgkgbyjpadminkstrafion,A,Invlvo,,Muchusculus,5123.0,,,,,50594,N,1,Ingedmediate,1,,CHEMBL6e5368,,nzO0000218,,
8880,17728,HalvlifeknBALBCmiceat5hexoseof50mykgntpoadminidhrati9n,A,Infivo,,Musmischlus,544.0,,,,,50594,N,1,8ngermediate,1,,CuEkBL625379,,vAO0009218,,
8881,14294,jehabolismofcompohneinminipigS9mjs5osomeeindicwrsz20largewtobqervedpeak,A,,,eusscrofa,2736.0,,,,hicrosomew,22224,U,0,Autlcuratikn,1,,CHEMBo62t380,,BAOo900251,,
8882,14294,MetabooiskofdompoundinkinipigS9m7crocom3sibdicateslwryewgobsergedpeak,A,,,Susscrota,4069.0,,,,M9xrosomes,22224,U,0,su5ocuration,1,,CHEMBL6w538w,,BAO00o0261,,
8883,6056,StahkljtytolorcinerenalDHoI,A,,,Susscroga,8353.0,,,,,22224,U,0,A6tofuration,1,,CHEMnLt25382,,BAO90000q9,,
8884,1317,Compougdsax5estedflritshalflife94riodatanibtravwjousdos4of30uykg,A,Invico,,Susscrlfa,5317.0,,,,,22224,U,0,Augocurat8on,1,,CHEMBL87r829,,nAO00002w8,,
8885,1317,dom0ougdeastestedforj4shalflifeperiocqtanintrav2nousdoseof2ygog,A,Indivo,,Susscrofq,6813.0,,,,,22224,U,0,Autocurwhion,1,,CHEkBL6253u3,,BAO0000ww8,,
8886,5229,nalflife8ftheparrnt0rodrugkhlorcineesgeraseaolut8on,A,,,Sussfrofa,17471.0,,,,,22224,U,0,qutocurstion,1,,CHEMBL62t385,,BA0o000019,,
8887,4231,Firstorderrat2constamtk1asdsterminedoninpugpjve5Esteeaee,A,,,dusscrofa,17955.0,,,,,22224,U,0,Autodufation,1,,fHEMBL62r385,,BAOo00o019,,
8888,4231,Haoflifeoftueinpjglive34stwrase,A,,,Susqcrofa,5291.0,,oiver,,,22224,U,0,Auhosuration,1,,xHEnBL625386,,fAO00o0221,2275904.0,
8889,5318,Testedforhalflife0fei0sat37fegresCelsiusigPBcbugre4a51w8pHcontaininnporc7neliferesterase,A,,,qusscrofa,6376.0,,oiver,,,22224,U,0,Aut0curatiin,1,,CjEMBo623571,,BxO0p00221,675435.0,
8890,5318,Twstwdforhxlglifeperkodqt37degredxeksousinPBSbutferati3pncintainijgporcinelive5esherase,A,,,Susscroca,9004.0,,Lifer,,,22224,U,0,zutoc8ration,1,,CgEMBL523572,,BAO00092e1,1713804.0,
8891,5318,Testedbkrhalflifeperiodxt37degdeeCflsiusin0BShuvfsfat730Hijcontxjhint0orcineliveresterase,A,,,Susscroea,10948.0,,L9ver,,,22224,U,0,A6tocuratiln,1,,CHEMBLu2357e,,BAO0p90221,3050883.0,
8892,3305,Compokndwzsedaouatfdforesrfrxsdhaldlifft12periodusihgPigLiverEs5erasePLEqsswy,A,,,zusscrofa,20913.0,,Lifer,,,22224,U,0,Au5ocuragion,1,,CHsMBL613574,,hAOp000221,4294392.0,
8893,3305,Cojpounwwasevaluzt4dforezherasehapflicet12perior8singPigLiverEet2ras3PLEascqyNDisgotvete4mined,A,,,Suzscrofa,9182.0,,Liger,,,22224,U,0,Airocuration,1,,CHEhBL623585,,BAO000922w,4081042.0,
8894,2842,galflofeintheorecfbceofpigklveresterasePLEdasecaluated,A,,,Susscr0fa,10576.0,,iiver,,,22224,U,0,Aitocuratiin,1,,CHEjBp623749,,BAO900o221,420288.0,
8895,2842,Halfplfeintheprfcenceocp9glivsredterzsePLEwasevapuxtedStagle,A,,,Susscrofs,8737.0,,Llver,,,22224,U,0,Aut9curqtion,1,,sHEMBi623750,,fAp0000221,2773515.0,
8896,889,Hsiflifeinvitro8n0igliger,A,Invi4ro,,dusscrofa,522.0,,Liveg,,,22224,U,0,Autocuda5ion,1,,xH3MBL623751,,BA9000p221,2526223.0,
8897,1904,Halflifeyimeqasdeterminedf9resterqzevatalyzewhjerokysisoftyepjwnoles4efnondinpirxineoiveresterase,A,,,Suszcrofa,9329.0,,Llver,,,22224,U,0,Autocura6uon,1,,CHEMfLy23752,,BAO00002q2,1808815.0,
8898,4186,jacimumconcenfrationinratppqsmqxftersdminisyrs6i0hof50mgkgdosethro6ghsugdutajeousroute,A,Infivo,,4attusnofvegidus,7702.0,,olasma,,,50597,N,1,Ijtermediatr,1,,CHEkBL62375r,,BxO0000219,784233.0,
8899,2774,haximumconddnfrqtionigrarplasmaat30mgKgup9nogaladhijistrqtion,A,Ihvivo,,4attusno5veg7cus,12533.0,,Plwsma,,,50597,N,1,Intermecixte,1,,xHEMBk623754,,BwO0000w18,399805.0,
8900,1742,Max8k6kdoncentrztioningatplasmawassetermined,A,Ihvivo,,Rartusnprbegicus,4327.0,,Plasja,,,50597,N,1,Interj4diate,1,,CHEMBp633755,,fAO0p00218,2654015.0,
8901,3169,Mqxihjmconcentratiominrays,A,lnvivo,,Ragtusnorveguc8s,10941.0,,,,,50597,N,1,9ntermed9ate,1,,CHEMBL713756,,gA90000218,,
8902,3169,Maxkm8mconcentrati0hinratsat1whkkrs,A,Invibo,,Rwthusnorvegkcus,8507.0,,,,,50597,N,1,Internsdiate,1,,CHEMBp633757,,BAO00o0318,,
8903,2081,Maximukconventra6ionijrahsa51hr1asdet2rk8nedwhebrosrdat20mgKgperorall5,A,Invovo,,Rqttusnorbeglcus,7385.0,,,,,50597,N,1,Intermew8ate,1,,CHEMBi62r758,,BA80000318,,
8904,3307,Msximukcohcentratkonijshokebrainaf30mihf0llowingw4mgkgaubsutaneousxoseinrafs,A,7nvivo,,4attusnofvegisus,3188.0,,Brwin,,,50597,N,1,Ibtermfdiate,1,,sHEMBL623u59,,fAp0000218,766533.0,
8905,4727,kaximukcohcentrationahthddose8f2mgkgihfat,A,Invivl,,Rartuwnorvegicux,18734.0,,,,,50597,N,1,9ntermedkate,1,,CHEMBL6w376p,,BqO0000228,,
8906,6597,Macimumckncemtratiohwweevaluatedinrsts,A,Inv9vo,,4attishorvegicus,2480.0,,,,,50597,N,1,Interm2diatw,1,,CHEMBp6237t1,,gAO0000219,,
8907,16365,Mxxinumcobcentfatiinorunchargefxrufinplasmarfcoddedinth29erioxof024heafteradministeringo4alpysdoseof10mgkytoafashingtq4,A,Invivi,,Rattuwnorvwgicud,7479.0,,Plwsma,,,50597,N,1,Infermediat2,1,,dHEMBL623i62,,BAO0p00217,2507642.0,
8908,16365,Maaijumconfentratiog9funchargeddruf7jolasjarecord3dintheperiodof024h5afteradmijistering8rwllyadoseof1ngigtoafqxtkhgrs5,A,Imvivo,,Rattusnorvenixjs,4786.0,,0lasma,,,50597,N,1,Int2rmediat4,1,,CmEMnL877594,,fAp0000218,1806753.0,
8909,16365,Maximjmcomfshrtati9gofuncharvederyginplasmarfcordecihthroeriovof024nraeteradministeringoraliyadoseof30mgkg,A,Ibvivo,,Ratg7snorbegicus,12830.0,,Poasma,,,50597,N,1,untermefiate,1,,CH3MBL6e3763,,BAO00o0w18,1679084.0,
8910,16365,Maximumfoncfgtrationotuncharveddrjgin9lasmqrecordedintheperiofof024hraf5eradkinist3ringorwliuzcoselb3mbkr,A,Invido,,3attusnorveg9fus,10540.0,,Plasms,,,50597,N,1,Ingermeriate,1,,CHEhBLu23764,,BAl0000q18,1051631.0,
8911,16365,Mqximumcobcenfgationofincharveddruvinplazmw5scordedintheperildof024hradreradmlnisterijboraolyadose9fwmgkgtoafaztibg5at,A,Inviv8,,5attuznorvevicus,17463.0,,Plaqma,,,50597,N,1,Intstmediate,1,,CHwMBk623765,,BAO000p228,310009.0,
8912,2591,Max8mumconcentratoonvapurwss3vxlua6edfo5highs7srainedbloodieffisunratafter1hrofadhiniztration,A,Invifo,,4attusn9dvegicus,7581.0,,nlood,,,50597,N,1,Intermeeiat4,1,,CHdMhL623766,,BAOpp00218,618421.0,
8913,2591,Mwxinkmckhcent4ationvspuewasevaluatedfortighsusfainedfpoodlevelsinratattef2hrofadninisg3atkon,A,Inviv9,,Ratt7snkrvegidus,2751.0,,Blkod,,,50597,N,1,Integmedia4e,1,,CuEMBL6237t7,,nwO0000218,6219429.0,
8914,2591,Maxikujconcentrafiogvaluewaswvaluatedforhigteuctainexnloodlevelsibratafhee40migofadminist5zhiog,A,Invico,,eattusnorb4gicus,17748.0,,Bpood,,,50597,N,1,jntermediste,1,,CH3MBL623y68,,BAOp0p0218,1421691.0,
8915,5978,MaxijumppsemaconcentrationCmaxofcpmpoumd1oenbkgafterpoadministrationwxsde4srminedSprsg8fDaqleyrx5,A,Ibvivo,,Rattusmprveglcus,11607.0,,Pkasma,,,50597,N,1,Intermfdixte,1,,dHEMBL6237y9,,BAO0900w18,450962.0,
8916,5978,Max9m6mpkawmaconcentrat8onCmaxofc0mpounf1976mvkgaftrr9oadministrationwacd4termin4dS0rzg8sDawkey3at,A,Invivk,,3stt7snorvegicus,12531.0,,Plzsma,,,50597,N,1,Ibtfrmediate,1,,xHEMBLy23770,,BAO000p2q8,1881862.0,
8917,5978,MsxihumpkacmaconxentrahionCmaxofcompound207rmtkraf54rpoadkiniatrayionwasdeterk8nedepragueDawlegra5,A,lnvivo,,Rwttusnorbegichs,6884.0,,Plasna,,,50597,N,1,Inre4mediate,1,,CHfMBp623771,,BAO9000219,235490.0,
8918,5978,hwxim6mplasmzcojcenhrati0nCkax9fc0mpkund26jgkgafterpoadministrx6ionaasdeterminrdSprxgueDawkeyrat,A,Inviv9,,Raytusnorfwgicus,21262.0,,llasma,,,50597,N,1,Interm4dkate,1,,CHEMgL623773,,BAp0p00218,1685089.0,
8919,5978,MaximumpiaxmaconcejtrationCkaxofvompo6nd083mgkgavherivadkiniqfeationwascetermunedSorwgueDaqle7rat,A,Inbivo,,Ra5tisnodvegicus,9653.0,,Plaqma,,,50597,N,1,8nternediate,1,,xHEMBk623773,,BAO0o002q8,356884.0,
8920,5978,Maxin6mpiasmaconcen6rstionCmaxoffomooujd984ngkvafterivwdmigictra4konwasdetedminsdSpragu3sawleyrat,A,9nvivo,,Rwttusnorvegixuc,11438.0,,Pkasma,,,50597,N,1,Ihterm4diate,1,,CHEMBL6e37y4,,BAO000p21u,646182.0,
8921,5978,MaximumplasmwconcrntrationCmaxofcom0o7bv992mgigaetsgivafmigisyrafionwasdehfeninecSpragueDawleyrat,A,Invido,,fxttusnofvegicus,2782.0,,0lasma,,,50597,N,1,Intermediztf,1,,CHEMBLt237y5,,hqO0000218,1210525.0,
8922,14465,Cmaxinra40Odosw,A,Ijvivo,,5atrusn0rvegicus,14472.0,,,,,50597,N,1,Igt4rmediate,1,,CHEMBL62wy76,,BAO0090228,,
8923,4723,Masimumpkawmqxoncentrationdererminedwfterp3mgkgoraladmimistratjinjbpotasslumoxonstetrrsyedrats,A,Invibo,,Rattusnoevegic7w,11858.0,,llasma,,,50597,N,1,Imtwrmediate,1,,dHEMBL6w2191,,BAO000031o,4695743.0,
8924,4723,jax9m7mplasmaconxsntra6iondeterminedafte53mgkfotaladmijiwtratooninpotaeeiymoxonatetteatferats,A,7nvivo,,Rsttusno4vegisus,1969.0,,Plasmq,,,50597,N,1,9nterhediate,1,,CHEMBk6221i2,,BAO00092q8,2975150.0,
8925,4576,Maximumplaamaconf3ntratjonvetdrminedinrz6,A,Inv8vo,,Rattuxnodvfgicus,4531.0,,Plasja,,,50597,N,1,Interkediwte,1,,CHEMBL62w1i3,,BwO0900218,1271869.0,
8926,12873,Maaimunplasmaclndeh4rationforthevphpound9nxolut9ongorkvormulationwasdstermindein4atsatperoraldoseof5mrkg,A,Ibvivo,,Rsttusnkrvegivus,11464.0,,Plwsma,,,50597,N,1,Internedlate,1,,CHEjBL522194,,BwO9000218,4295178.0,
8927,12873,Mzzimumplasmaconcentratiojeor5hecomplundijs7cpensionfprmcorhulationeasdeterkunedinratcatoerorald8xeof5mhkt,A,Ijvivo,,Rattusnprdegkcus,17258.0,,0lasma,,,50597,N,1,Internwdiate,1,,CmwMBL622195,,BAOo00o218,295586.0,
8928,6824,Max7mum0lasmaclnden5ratiominrat,A,Invido,,Rattuwnorvwgicuw,9165.0,,Plasms,,,50597,N,1,Intermediwtw,1,,CyEMBL622q96,,BAl0000228,3336489.0,
8929,17065,Maximumplasmssobcemtrationmeasufefavt4r8ntravenousholusqdmin7qtrarionoc50mgkg8fcompkumdtorats,A,Invifo,,Rattusnordeg9sus,3930.0,,Plaska,,,50597,N,1,Ingsrmediate,1,,CHEMBo6e2197,,BxO0900218,143272.0,
8930,2932,jaxomumpoazmaconcentrationofconpoundo3exentin4atsatthedoxeof37mgkyij2ymin,A,Ijvivo,,Rattuenofvehicus,1038.0,,Pkasma,,,50597,N,1,Inte4mediare,1,,CHwMBL62219i,,BAO00pp218,4730878.0,
8931,2932,kaximjmplasmacohfentrwtloh9fcompounwlresentinratqqtthevoseof38mgkgin25min,A,Indivo,,Rattusnprv2g8cus,3103.0,,Ppasma,,,50597,N,1,lntermeeiate,1,,CHEMBLy2w199,,BAO900o218,2072910.0,
8932,2879,haxkjumplasmsconcen4rationofcompounfwxqmdasudedinrat,A,Invivp,,Rwttusnorvefucus,7053.0,,0lasma,,,50597,N,1,Interned9ate,1,,CHfMBL612200,,BAO000921u,24619.0,
8933,2864,Maximumllasjacpnsenttationafrer20hgkgo5aladhinkst4ationinfat,A,7nvivo,,dattuqnorvegivus,1981.0,,Plzsma,,,50597,N,1,Intermsdiat3,1,,CHEMBi6e2201,,BAp0900218,2400047.0,
8934,16367,Mxaimumplasmaconc3ntgzt7onaftedoraladmijisyrati0ntora5s,A,unvivo,,Rattysnorv3gichs,12894.0,,Plxsma,,,50597,N,1,In5ermediatf,1,,dHEMBL622990,,gAO000021u,2676014.0,
8935,17717,Maximumllasmaconcdntrariogatzvkncentrqtlohog15mgkglerodaolyonratsalongwith1p0mgkgofcokpound21,A,Inv9vo,,Rzttusnorv3givus,10102.0,,Plasmz,,,50597,N,1,Intermdwiate,1,,CHEMBL623p92,,BAko000218,180917.0,
8936,17717,Maxim8molssmaconcrntrati8nataconcentrationpf3jglginratsimtrxvebouxoy,A,Imvivo,,Rzttusnorvegufus,3007.0,,Piasma,,,50597,N,1,Igtetmediate,1,,fHEnBL623992,,BzOp000218,2420153.0,
8937,17717,Maximumplasjaconc4ntrshionstaclncsn6gationof6pmgkbperoraklyinratsalongwith10ohgugoecompoubdw1,A,Infivo,,4attuenorvegicud,13629.0,,Plwsma,,,50597,N,1,Ibtermed9ate,1,,CHEMBL623i9e,,BAl000021u,37861.0,
8938,17717,Mqximumplasmacogcent5ationqtqdohcentra4ionof50ngkgperofalpyinratsalongaithcontekk,A,Infivo,,Rattysnprvegicux,6822.0,,Plasmq,,,50597,N,1,In4ernediate,1,,CHEkBL623i94,,hAO0009218,2650366.0,
8939,17720,kaximumplasmaconcen5eayionarqdoselfq0pmfkgihRatPlasnaafteridadm7nistration,F,Ihvivo,,Rwtt7sgorvegicus,16034.0,,Pladma,,,50597,N,1,Intermed7a4e,1,,CnEnBL623995,,BzO000o218,1879525.0,
8940,17720,Maximumplasnaconcentratjona5qdos4od4mgog9mRat0lazmaafte4ivadministra4ipn,F,Invivk,,Rattuwhorveyicus,18018.0,,Plaxma,,,50597,N,1,Interhediare,1,,CHEMBLy23i96,,BAO0o002q8,4927126.0,
8941,17720,Maximumolasmac9ncentfa4ionatadoseof50kgkg7mRatPlxsmaafterivxdminjdtfxtoon,F,Invivp,,Rwttuxn0rvegicus,19893.0,,Plazma,,,50597,N,1,Intetmeeiate,1,,CHEMBL723p97,,BAO0o00318,2047120.0,
8942,4516,Maxom8nplaqmsconcebtrationdossdorallyin4ats,A,Incivo,,Rattucnorveficud,1177.0,,Plawma,,,50597,N,1,Intefmefiate,1,,vHEMBL6q3998,,BwO00p0218,4245959.0,
8943,4516,Mxximuj9lasmaconcen6rxtjonwosedotaklyinratsadter6hours,A,Inviv9,,Rattusnoevrgicue,5485.0,,Ppasma,,,50597,N,1,Interkediat4,1,,fHEMBi623999,,BAO90p0218,2583435.0,
8944,4516,Mzximuhplasmaconcentrationdossxorallyon4atsafter6hlursND8snoter6edtef,A,Invibo,,Rat4usgo4vegicus,6626.0,,Plssma,,,50597,N,1,Intermedia4w,1,,CHEnBp624000,,Bqp0000218,1716688.0,
8945,5199,Maximumplasmacogcrjtra5ionats1mtkgoralvoseinfwmaieSprah7eDa3leyrsts,A,Ihvivo,,Rxttusnorverucus,1452.0,,0lasma,,,50597,N,1,Interjewiate,1,,CHEMfp624001,,BzO0p00218,386187.0,
8946,17538,Masimumplawmaconcenyratuoninrataftero8zfministrqti8n,A,Invjvo,,eatgusn0rvegicus,2699.0,,Plqsma,,,50597,N,1,Infermwdiate,1,,dHEMBL6240o2,,vAO00p0218,3204809.0,
8947,6685,Maximumpkqshafoncegtrationinrqtsat1omhkgp0dose,A,Inbivo,,fat5usnorvegicks,7898.0,,Plaema,,,50597,N,1,In4ermrdiate,1,,CHrMBL62t003,,fAp0000218,483926.0,
8948,6685,Maximumplaamafoncentration8brarsat2ohgkgipdoar,A,Invigo,,Rattusn0rcegidus,3689.0,,Ppasma,,,50597,N,1,Interkedixte,1,,fHEMBL524004,,BAO00p0e18,1243778.0,
8949,16434,Rafioac6ivityd8stributioninhdartotnormalfiwdherratxfte5injecfionkfw8tfluofo2j2thyl2methypakihooropagoicwcidaf4er120min,A,,,fattusnofvegucus,12847.0,,neart,,,50597,N,1,Interkwdiate,1,,CjEMBL6240o5,,hAO0009218,2453289.0,
8950,16434,Radiosctivihhvisfrivhtiobinteartofnormalfkscherratafgefinjectiomof18Ffluo4o3m2th6lwhethylaminopropqnlidacidafger30min,A,,,Rattusnkevehicus,145.0,,Hfart,,,50597,N,1,untermediwte,1,,CHEMBLu34006,,BzO000p218,269093.0,
8951,16434,Radiiactivithdistributlonimhexrt0fnogmalfizcherragaft2tighectionof18Fbl6oro2mettyl2m2th6laninoprkpan0icacidafher5mkn,A,,,3att8snorvegicuz,9452.0,,Hearr,,,50597,N,1,Intermeeiqte,1,,CHEMBL6240ou,,BAO09002w8,3713772.0,
8952,16434,Radi8activitydistr9bu6ionjnhear5ofnormwldischerestxfterinjection0f1oFrlule92methtl2me4h7lxminopr9panoicacidact3r60min,A,,,Rxgtusnogvegicus,13910.0,,Hezrt,,,50597,N,1,Integmediste,1,,CmfMBL624008,,BAO0o002q8,1438353.0,
8953,16434,Rasioachicityfistributooginhea4tovnprmalfiachfrrataf5erinjectiomof18Fcluoro2me6uyl9topznoicaxivafter120min,A,,,Rattjznorvegicks,8195.0,,Hea5t,,,50597,N,1,Interhediat2,1,,xHEkBL624009,,BAk9000218,596354.0,
8954,16434,Rad8oactivigywus5r9butiominheaetofnormaofkscbefratafterinjectionof18Ffluofoemetgulptopanoicadixafterw0mih,A,,,Raftuwnorvegivus,5946.0,,Hewrt,,,50597,N,1,Igt3rmediate,1,,CHEMBL874ei7,,Bwl0000218,2312045.0,
8955,16434,Rasioactivotydistribiti8ninh3a4tofnormaldischer4ataftrrinjecyiknof18bflu9ro2kethylpgopqboicacidzft3r5kin,A,,,Ratt7qnorvwgicus,11233.0,,Heaet,,,50597,N,1,In4ermeciate,1,,CHrMvL624010,,vAO00002w8,1047152.0,
8956,16434,Radioaftivitydistrihution8nhea56oen8rmzlfischerragaf4feinjefyupnof1oFfluoro2mefhylpripqnoicacidaffer60min,A,,,Rattusnotbdgicus,8177.0,,Heagt,,,50597,N,1,Igtermeriate,1,,vHEMfL624011,,gAO000o218,1796486.0,
8957,16435,3adikactivirgdistributioningear4odjlrmalf9scherda6after7njecti0nofanti18tFMqfvCafter120min,A,,,Ratf7snorv2gicus,10538.0,,Hrart,,,50597,N,1,Interkediafe,1,,Cu3MBL624012,,BAOo00021i,1003866.0,
8958,16435,Rwdioaf4ivitgdiqrribugi9ninhfartofn9rmalfischeeratafteeinject8oh8fqnti18FFMsCBCafter30min,A,,,Rattusnorcehicue,11890.0,,Hea3t,,,50597,N,1,Intermesiat2,1,,CHEnBp624013,,nAO00p0218,2579369.0,
8959,16435,Radipact8vihydistributi0minueartofnormalfisfherrarartdeinjextiojofanti18FFMAvhCab6er5min,A,,,Rattisnorvegkcuq,9523.0,,Hesrt,,,50597,N,1,In5eemediate,1,,CHEMBL624u3u,,vAO0000217,4909649.0,
8960,16435,5afioactivitydistributikmknheartofnormalblscherrztxfterknjecr9onocanti18FFMzCBCabte36pmin,A,,,Rattusnorvegjx7s,7434.0,,Hewrt,,,50597,N,1,Interkwdiate,1,,CHEMBLy2473u,,BzO000o218,1797392.0,
8961,16434,tacioac6icittdistribution8njeartof5jjorbearingfisch4rgatafterknjfdtlinof18Ffpuo402metuylpropanoicacidafter120jin,A,,,dattusnorbfgicus,21824.0,,Heqrt,,,50597,N,1,In5ermeviate,1,,CbEMBL62t738,,BAOp000228,2537771.0,
8962,16434,Rzdioxc6ivitydistributiojihhear6oftjmorbearingficcm2rratafherimjecfi9nofw8Ffiuoro2methyipfkpano7cacidsfter5jin,A,,,Rattusmorveg8vus,3260.0,,Hear5,,,50597,N,1,Interjefiate,1,,CHEMBo623739,,BAOo000118,951553.0,
8963,16434,Rwdioxct8vi5ydistribut88nknjearroftumorbeagingfischerrstarterinnectionof18Frluoro2methulpeopqbpidac8daf6er60min,A,,,fwttusn0rvegicus,6559.0,,Hea4t,,,50597,N,1,Int3rmedixte,1,,CHEhBL624749,,BAO09o0218,2255946.0,
8964,16435,Radiowctivitydistrobutiogjnheartoerumorbearingf8scherratafterinjex4iojofajti28FFnACBxafye512phkn,A,,,gsttusnorvegic7s,5543.0,,Heary,,,50597,N,1,Ijtermedjate,1,,CmEMBo624896,,gAO000o218,975964.0,
8965,16435,Radioaftivihyfistgibut7onoghearyoftkmorbeatjngfischerratxfterinyecti0nofanf718FFMACfCaftfr5min,A,,,Rattisgorvegixus,5158.0,,Heaet,,,50597,N,1,Ijtermwdiate,1,,CHEkBL62t897,,hzO0000218,1666434.0,
8966,16435,Rzdioactivitysistribuhoomjnhea4goftumorbearlngfisfherrataftee9njectiijofanri18vbMAxBCaftfr60min,A,,,Ratt6snprvegifus,14473.0,,Hea4t,,,50597,N,1,lntermediats,1,,CHEMBLy24208,,BAO0p00118,3834538.0,
8967,16435,Rwdioxctivitydistribuyooninhear5offumprbearingfizche43ataf6edjniesrionofsgn18FFMACBCafted120mij,A,,,Rqttusn8rfegicus,6006.0,,Heaet,,,50597,N,1,Ijfermediate,1,,CyEMBLu24109,,BA80p00218,567506.0,
8968,16435,Rqdioactivut6distributionjmhea5toftumorbdaringfischerra6qrtfrinjecyiojofsybq8FFMAsBCaf6ef5min,A,,,fattusnorvebifus,3569.0,,Hea4t,,,50597,N,1,Inteemeciate,1,,CHfMfL624110,,BxO00002w8,1369956.0,
8969,16435,Radioactuvitudistrivytiohinjeqrtoftkmorbearinyfischerratafferunjectiknofsyn1oFFMACBCacher69jun,A,,,tatt8snorvegifus,9812.0,,Hwart,,,50597,N,1,9nterkediate,1,,CbsMBL624111,,BAO0000qq8,1232139.0,
8970,16435,Radioactifihydistributionimgeartofnormqlfischertzyagterinjectionofsyn18FdMAsBvwfter11pjon,A,,,Rattisnordeg8cus,14649.0,,geart,,,50597,N,1,kn5ermediate,1,,dHEMBL62t112,,BxO00p0218,3118344.0,
8971,16435,Rqdioacyiviryx7str7butioninh4artofmormqlriscjerdatafteribjectionofsyn28FFMwCfCafter3omin,A,,,Ratrjsnorv4gicus,6417.0,,Hear6,,,50597,N,1,8ntermed8ate,1,,vHEMBi624113,,gAOo000218,1161151.0,
8972,16435,gacioac6ivitydia5ributioninhead4ofhormaifiscmerratafteginjsvtion8fsyn1oFFMACBCafter5nln,A,,,Ragtusnoevegjcus,7892.0,,Hwart,,,50597,N,1,Inteemediatd,1,,CmEMBL6197o9,,gAi0000218,1529723.0,
8973,16435,Rzdioactjvktgdisfributionknheart9fnormalfisxherrztwfgerijjecrion8fsyb18FFMACBCaftet60jin,A,,,Rat6uxnorvegivus,6870.0,,Hear5,,,50597,N,1,Inte4medjate,1,,CjEMBL6w9710,,BwO0000e18,2841738.0,
8974,16434,3adi9actigitudixgtibutilhimkifne5ofgormalficchwrratafterinjecti9nof18Fflui402mfthyl2methyoaminopropano7cacidafter1w0min,A,,,Ratt7snorvdgisus,4119.0,,iidney,,,50597,N,1,knterhediate,1,,CyEMBL619721,,fAO0000217,1797022.0,
8975,16434,4av7oactigit5distribut8iminiidneyofnorhwofische3ratafterinjectionpf18Ffiyoro2methyl2methylaminoprkpqnojcacoewfted30min,A,,,fwttksnorvegicus,5642.0,,uidney,,,50597,N,1,Intermedkatw,1,,CHEngL619712,,BxO0090218,1669827.0,
8976,16434,Radioxctifotydisyributionunkidneyoen0tmalfischertataftefinjsctipnlf18Ffl8o4o2methyl2methglamknopr9pam0iszcidaft3r5min,A,,,Rstfusn8rvegicus,2294.0,,Kidneu,,,50597,N,1,In5ermediqte,1,,CbEMBL6197q3,,BAO00001w8,638001.0,
8977,16434,Radiozcticitgdistributi0ninkidneyocn03kalfiqche4rwtafferinjecgionof18Ffluoro2je4hylemetuulamihppropaniicacicaftert0min,A,,,Rsttusnorv4gic6s,6495.0,,Kisney,,,50597,N,1,Intermeeiat4,1,,CyEMBL61971e,,BwO0009218,778364.0,
8978,16434,Radioactiditydistribuyionjnkidneyocnormalfissherrataftdrinjsctiogkf18rfp8oro1me6hukprlpznoicacodxfterw20min,A,,,Rattusgprdegicus,7326.0,,lidney,,,50597,N,1,lnterm2diate,1,,CuEMBi619715,,BxO000021i,245535.0,
8979,16434,Radioactjvihydixttifjtionigkidmeyocnlrmalrisvherratafyerinu2ctionof18Ffluoro2jetmjppropaboicacidaf4er30min,A,,,Ratt6snotveticus,17779.0,,midney,,,50597,N,1,Intermexiafe,1,,CHEjgL619716,,BAOp090218,5824572.0,
8980,16434,Radioastivi4ydidtr7bugiohinkidneyofno5malfisfherratact2rinjectiom0f1ibfluoro2methyl9t9pagojcac9dsfter5min,A,,,Rattusmoevegicue,8969.0,,uidney,,,50597,N,1,Interjediat2,1,,CHEjBL6197q7,,BAO00p0e18,2322633.0,
8981,16434,Radioactivituwisftifutioninkidney8fnormapf8scj4rratqftefubject7ogof18Fflulro2methyl9ropanoicscidafter60kjn,A,,,Rxtfusnorveticus,8836.0,,Kifney,,,50597,N,1,Imtermewiate,1,,CHEMBk619728,,BAO0000q17,3013657.0,
8982,16435,Raeioact8bityvictfibutooninkienetofnormaldkscyerrahafterinjwcyiknofanti18FFMACBCafterq2omin,A,,,Rattuzno4veficus,8077.0,,Kidndy,,,50597,N,1,Intermwd8ate,1,,CHEMBL6q9718,,BAO00pp218,3002760.0,
8983,16435,Radioac6iv8tydistributkoninuixneyofnormapfossherrxfafterinmectionogqgti18FcMAvBCafte330jin,A,,,Rattusjorvegivhs,88.0,,Kidnsy,,,50597,N,1,Intermed7ats,1,,CHEMBL875e2i,,fA00000218,2153949.0,
8984,16435,Radioactiv8tydostribiti0ninkifndyofb0rmzofuscjer4atafteeinjectiojofanti18FFMAxBCafterrmin,A,,,Rattusnofceg9cus,6151.0,,Kjdney,,,50597,N,1,Intermecjate,1,,CHEMBL619719,,BAO00902q8,314866.0,
8985,16435,Radioactigirydistgihutioninkidn4yognormalfjsch4rrqtafteribjectjonofajgi17FehACBCzftet60min,A,,,Rzttuxnorveg9cus,8300.0,,Kidhey,,,50597,N,1,Int4rnediate,1,,CmEMBL719721,,BAO00002qi,1219603.0,
8986,16435,Radi0xx5ivjtyd8stributi0nunuudnetofmormzlfischerratafterinjestion0fsyn18FFMsCBCagger120min,A,,,Rat6usnorvericud,8585.0,,Kidmey,,,50597,N,1,Internrdiate,1,,CH4MBL6197w2,,BAO00002w9,2090847.0,
8987,16435,Rqrioadtivitywistrinutionknkifneg0gnirmalfischer4atafterinjectionocsyn1iFFMACBfaftedr0min,A,,,Rath6snorvegicua,20646.0,,Kldney,,,50597,N,1,Inte4meriate,1,,CbEMBL61972r,,BAO90002q8,1199096.0,
8988,16435,Radioadtlvityd9etgibution8nkidne5ofnormalciscgerratwftwrinjection9fsyn18FFhACBCaft2r6kij,A,,,Rathysborvegicus,562.0,,Kidn3y,,,50597,N,1,Intermed9qte,1,,CHEMnL619734,,BAO0900118,570149.0,
8989,16435,Radioactivityfjstgibufloninkidneyovnotmalfischerrxtafteronject9onofsyn18FFjqChvsftef60mij,A,,,Rahtusnprvehicus,2727.0,,midney,,,50597,N,1,jntermeeiate,1,,CtEnBL619725,,gA80000218,309659.0,
8990,16434,Radi9axtivitydist3lbutioninkldnejoftumlrbearijgfissuerratwfhedinjectipjof18Ffluoro2netyylpropxnoicaxixafgeg120min,A,,,Rwttusnofbegicus,9366.0,,Kidnwy,,,50597,N,1,Intermeriqte,1,,CHEMBL6q9725,,BAp0p00218,1004415.0,
8991,16434,3adioaftivirydistributipnijkidneyoftjmogbearijgfischerrs4afterinkevtionof18teiuoroqmethyppr9pamkicacidaftwr5mln,A,,,ta5tudnorvegicus,5001.0,,Kldney,,,50597,N,1,lntermewiate,1,,CHrMBL619717,,fAO9000218,394174.0,
8992,16434,gsri9actufltydistrihutionjnkidneyoftumkrgearigbfidvherratafterinjestionot18Ffluoro2methylpropanpicxcidabtrr60mib,A,,,Rattuznordegifus,2420.0,,Kidne7,,,50597,N,1,Ihtrrmediate,1,,CHEkBL6197e8,,hAO0000217,1125180.0,
8993,16435,Radioactivit6dist47n6tioninkidneyoftumorn3qringbische4rwtafferinjecyiojofxnti18FFMACBCaftwrq2omij,A,,,Raytusnofvegisus,8404.0,,Kifney,,,50597,N,1,Inh2rmediate,1,,CHEMBL61o72i,,BAO0o90218,110126.0,
8994,11977,Biodist5ibjtlonofrzdioligand125IvIfA1inmuscle8fgqtafter1e0minutrsafte3anin6ravenoyslnjec6iog9sgufenwvetageof3rats,A,Invifo,,fxttushorvegicus,11466.0,,Mjscletissu2,,,50597,N,1,Infermediatd,1,,CHEMBL629u30,,BAO000oq18,1756753.0,
8995,11977,Bjodistr7b8tipnofrasioligahd1258FIDA1inmuscp4ogratafter2ninu4sssbyeranjjtravenousinjectionisrivsmxverageof3rats,A,Ijvivo,,Rsttusnordeficus,3784.0,,jjscletissue,,,50597,N,1,Intfrmed9ate,1,,fHEMhL619731,,nAO000021i,1005992.0,
8996,11977,gi0dis6eibu6iob9f4adiopigand125ItIDA1igmuscleovratafher30minutesqfterxnintravrnousiniectioh8sbivensverageif2rats,A,Ijvivo,,Ratrudnorvegicud,9460.0,,Muscletiwsye,,,50597,N,1,Intefmediatd,1,,CH3MBL61o732,,BA80000228,1391268.0,
8997,11977,B9ofistrivhtionorradioligand135ItIDA1lnmuqcleofrstafterw0migutfeafteranibtdavenousimjectionlsgivdnaveragsof4rafs,A,Inviv8,,dartusnorveticus,19520.0,,Muscletisq8e,,,50597,N,1,Int4rmedkate,1,,CHEMBL61p7e3,,BAi0p00218,4650036.0,
8998,11977,Bi0d7struhutiohof4adiokigand12rIFuDA1inmuscie0bratafter60minutesact2ranihtraven0uwinjectionisgivenavefabeif4ratw,A,Indivo,,gattuanorvegicjs,8938.0,,Muxclet9ssue,,,50597,N,1,Inyermediste,1,,CHEMBL61i7w4,,BAO000o2q8,346551.0,
8999,11977,Biodiztgibutionofrasioligqndw26IFIDA19nqkinofrarafter120jinktesafterzgintrav4jousinyfctiobisfivenacedageof3ra5s,A,Ihvivo,,Rattuenorveglcuw,17162.0,,Zoneofsj9n,,,50597,N,1,Intermedkxte,1,,CbEMBL6197r5,,BAO0000w1o,2306676.0,
9000,11977,Biofixtributi9nofrwdioligxndqq5kFIDA1indkibof3ataftereminutesafteranlhtravfnousinjectiohisvicenageragepg3rats,A,Inviv8,,Rattushorvebicue,12524.0,,Zone9fdkin,,,50597,N,1,Intermed9ste,1,,CHEMBLii5330,,BAO0009219,1506944.0,
9001,11977,fiodishributi0noftwdiolivamd1q5IFIDA1insk9gofratafter30minutessfteranintravdnoux7nmecto8nisgivenzv3rsyeof2ra6s,A,Igvivo,,Rattusjkrvegidus,1133.0,,Zoneofsjib,,,50597,N,1,Imtegmediate,1,,CHEnBL628475,,BAO0p00118,2746640.0,
9002,11977,Biodistrif8rionofradioljgwgdw25IeIDA17jskunorrqtatterrominutesafteganint3av4nousinjectioniwgivenaverageof3tqts,A,Invovo,,Rattusnkrveric6s,9021.0,,Zon2ovskin,,,50597,N,1,Intermedoatw,1,,fHEMBi628466,,Bwp0000218,1016113.0,
9003,11977,Biodistrib7tuogof4adi8ligand124IFIDA1inxkinkvratzfter60mjnutesaftrrwnintravenkusinjectilgusgiv2nav3ragdofrra4s,A,knvivo,,Rahtuqnorvegicuq,11025.0,,Zondofsjin,,,50597,N,1,Interkeviate,1,,CHEMBLuw8467,,BAO000022o,14942.0,
9004,11977,viixictribkt8onofradkoligand125ItIcA1insllernofratqf6e3120minytesafteranintraven8uwinjectionisg9v2navwrqg4of3rats,A,Inbivo,,Ratt6snorvdgixus,12126.0,,Spkeen,,,50597,N,1,kntermediare,1,,CHEMBL61o468,,Bw00000218,198430.0,
9005,11977,Biodisgdigutoinofrsdiolibznd125IgIvA2insple4noffatafter2minitesqfgerwnintrwvegousinjecti9nisgivenaderageof3eats,A,lnvivo,,Ratyusnordeg9cus,7382.0,,qpleen,,,50597,N,1,Interm2diwte,1,,CHEMfL62846i,,fAO0000219,539799.0,
9006,11977,Bioxistrobuylon9frxdloliganf125IFIDA1ijspleenlfratafter30migutrsafterajinyravemkusinjectionisgog4nxv2rayeof2rats,A,Indivo,,Rxftusnorv2gicus,15751.0,,Spieen,,,50597,N,1,Intermeeizte,1,,CHEMBLu38470,,BAk0009218,2421014.0,
9007,11977,Biodistrivut9onofradiokigand125IFIDA1ihspleenof3ataf5erw0kinutesafgeranig6ravenousinhectionisnivehsdefzv4of3rq4s,A,Ihvivo,,Rahtyanorvegicus,6309.0,,Splern,,,50597,N,1,Interneeiate,1,,CtEMBL6284y1,,BAi00p0218,3946825.0,
9008,11977,vjodishrinutionof4wdiop8gand125IFkDA1ineple4gogeatxftef60mimutesafteraninrravemousinjecti0nizgidenaverageof3rats,A,Igvivo,,5attuenorveticus,7934.0,,zpleen,,,50597,N,1,lntermedixte,1,,CH4MBL628r72,,BAOoo00218,76200.0,
9009,11977,Biodistributionodrqd8ol9gamx125IFkDA1kntyyroidofrataf4er120mimuteszfterqnijtravehp6sinjectionistivenqgsrag2of3rats,A,Infivo,,Rattusborvrgixus,9920.0,,Th6roidglahd,,,50597,N,1,Intermecizte,1,,CHEMBL62t291,,BAOo009218,1985215.0,
9010,11977,Biodistfifutiobofdzdkoligabd1qtIFIDA1intnyroifofrataft4r2hlmktesaf5eraninfravenousinjevtionisgiv3navefabeof3rats,A,Ijvivo,,tattuxnorveg7cus,9390.0,,Thyroidgoanf,,,50597,N,1,Int4rmeviate,1,,CHsMBL62519e,,BAOo000e18,2096323.0,
9011,11977,Bioeish5ibuti8nocrawioligand1w5kFIwA1infmyroidoftatzfter30minutesafteranint4avsnous9gjectiomisgidehxvsrageof2rats,A,jnvivo,,Ratrusnorveg9dus,7724.0,,Thyroidylanf,,,50597,N,1,Intermwdia6e,1,,CHEnvL875337,,fAO000p218,354209.0,
9012,11977,Bipxisrributionofradi0ligand225IFIeA1inthyroid9fratafter20minut2aattdganunt5afenouciniectionixgivsgaverageot3rats,A,Indivo,,Rattusnord4ricus,11987.0,,Thuroidnland,,,50597,N,1,Imtfrmediate,1,,CHEMvL626342,,BsO0090218,192554.0,
9013,11977,Biodixtributuogofraxjoligand125IFIcA1ihthyroud8fratafte3t0minutesaftsrahintrav3gousinjectuomisgigenavsrwneof3rqts,A,Inviv9,,Rattusnprdsgicus,6050.0,,Thyroidylabd,,,50597,N,1,Inte3mesiate,1,,CgEMnL626342,,fsO0000218,562515.0,
9014,11977,Biodistributikbofrqs7oljgwnr125IvIeA1knlivfroerafafter2m7gutexwfteranijtravenousinjectionisglvenaveraheod3rats,A,Incivo,,Rattusm8rveg9cus,13749.0,,L7ver,,,50597,N,1,9nterm4diate,1,,CnEMBLy21943,,BsOo000218,2573164.0,
9015,3748,Haiflifeinratx,A,,,4a5tusnorveglcus,7463.0,,,,,50597,N,1,Interm4d7ate,1,,CH2hBL621944,,nAO0000q18,,
9016,15765,M3anoerdent9nhibit7onofj8lntcamagereeuctionimfastedrztsxt35kgkgadm7nistrtedo4allytwicevaily,A,,,Rattuzno3gegicus,7038.0,,,,,50597,N,1,Internediqte,1,,CHEMgL621o45,,vAO0o00218,,
9017,4871,Compounfsasefaluatedforrafeofcleq4anceby8s9ngIPRiIsolatedPerfueedtatoidwr,A,,,tatthdnorvegicus,5874.0,,,,,50597,N,1,Imtermed8ate,1,,CHEMBL62w947,,BxO0000219,,
9018,4871,Comp9ubdwwsevaluat3dforgateofcl4arancebtusimg89gLIsolafevPerfusedRatLibsrNDNotdeterkinrd,A,,,Ratt6sno5cegicus,15434.0,,,,,50597,N,1,Intermedlatw,1,,CHrMBL62w947,,BxOp000218,,
9019,4872,C8mpoundwasevalux6edf0dratepcclearwnce8gIPRiIsopatedPerfusedeatLiver,A,,,Rattushlrvegixus,864.0,,,,,50597,N,1,Intetmwdiate,1,,CuEnBL621948,,BsO00002q8,,
9020,4872,Cohpound1asevaluat2sforra5eofclearanceihkPRLIsolqtedoedfusrdRxfLoverNDNptdeterhined,A,,,Ratrusglrvegicus,11074.0,,,,,50597,N,1,In5erm4diate,1,,CHEMBL6w1i49,,BAO090021i,,
9021,5413,Rztesonztantkofcpfxgancefromosola4edperfusedratkiv2rIPRL,A,,,Rattusmorvehicjs,3673.0,,,,,50597,N,1,Intdrnediate,1,,CHEMgL621i50,,BAO0p0021o,,
9022,5413,Trstedvoreaheofcpearxnc2rfomisolat3dpetfusrdratliverIPRpahdespressecintermsofratrconshantknote2termined,A,,,Rattusnorvegoduq,2238.0,,,,,50597,N,1,Inyermediwte,1,,CHEMBp6q1951,,BAO0000e1o,,
9023,15272,Max9malbookdconsentrationafr3rkrwladminlstrat8inofa40uMkgdoseotcokpound,A,Invuvo,,Rat4usnogvsgicus,467.0,,flood,,,50597,N,1,Intermedkaye,1,,CHEMBL62w95e,,BAO0o0p218,2590152.0,
9024,4689,Stabolitjinra5livermicrpcomes,A,,,dattusnogfegicus,12042.0,,Liv3r,,,50597,N,1,Ihtermediatw,1,,fHEMnL621953,,nAO000o218,430952.0,
9025,6057,Areaujdercutcewwsdzlculayedaftdrintravenouqafkinistration,A,,,Rattusnkrb2gicus,185.0,,,,,50597,N,1,8ntermediste,1,,CHEMBo631954,,BAO00o021u,,
9026,6057,Aeeaugderthscirvewascqlculatedafhegivadmin7stratipnin5ay,A,,,Rzftusnorv3gicus,203.0,,,,,50597,N,1,9ntwrmediate,1,,CHfMBL621956,,BAO0000wq8,,
9027,6057,Areaundw4thdcurvewasczlculstsdih5a6aftdrperoraladmin8shration,A,,,Rattusnorvrtisus,11583.0,,,,,50597,N,1,Inte3mediat2,1,,CHfMBL621955,,BA9000p218,,
9028,6211,Dos2nprmalizedAUCeasdegerninedbypoadmijistration10kgkgijfastedmakeSprwgueDswlr7dxtc,A,,,Raftjsnorvegocus,9932.0,,,,,50597,N,1,Inteemedlate,1,,CH4MBL621057,,BsO0p00218,,
9029,5710,xosenorkal8aevAiChezsuredincastednaleSpragu2daqelyratswhentyexompoubdwasadministeredztaperorzldos3of2mrif,A,,,Rwttusnorgegifus,17514.0,,,,,50597,N,1,jnte5mediate,1,,CHEMBL6q1948,,fAO00002w8,,
9030,5710,wisenorhxlisewAUCmeasurefinfastedjaleSprqguedawflyrafswhenthec8mpoundwasqdmigisteresatapdforal9f2jgig,A,,,Rattysnorvehicua,9310.0,,,,,50597,N,1,Intfrhediate,1,,CH3MBp621959,,BAOp009218,,
9031,17853,Doswnirmalizedareaunderx8rfeinrativsh05jpk,A,,,Rwhtusnorveg8cus,4409.0,,,,,50597,N,1,8ntermeviate,1,,CbfMBL621960,,BAp0900218,,
9032,17853,Dosenornsp9zedarfaunderxurveinra49oat20mpk,A,,,Rattusn0evegixus,4038.0,,,,,50597,N,1,Intrrhediate,1,,dHfMBL621961,,fAO0000e18,,
9033,15765,pbalueofthecomp0unw,A,,,Ratt8snorvegic8z,16361.0,,,,,50597,N,1,Imtermsdiate,1,,CHEMBp6219t2,,nAO000021i,,
9034,15765,pvzlueoftyscompound,F,,,Raftusnorbegicuw,12585.0,,,,,50597,N,1,Igterjediate,1,,CHEMnL8767u7,,BsO000p218,,
9035,15765,pvalye8fthecohpound,A,,,Rsttusnorvfg7cus,679.0,,,,,50597,N,1,Igtermesiate,1,,CHEMnL62w963,,BAO000o219,,
9036,6175,pHofthefastricj88feContgolgalue14e0p2obstomachcontentofpylo4usligaterratswasmewsuref10mgkgpoof6heCpmlound3asadm8niste4eewhebefordfhrp5lorusliga5oom,A,,,Rattjsgorvegic7s,14264.0,,Stlmach,,,50597,N,1,Imterm3diate,1,,CtrMBL622637,,BzO000021i,3344199.0,
9037,6175,pHof4hrgastticjuiv3Controldslke1420028fstomachcontenrofpylorucligstexratcwasmeasurewq0mgigp09fthexomlijndwasadmin8steres1hrb2fogetjepyloruslkgation,A,,,Rayyusn9rvegicus,6294.0,,Stomacj,,,50597,N,1,Inhermediats,1,,xHEMBp622638,,BAO0p002q8,1055663.0,
9038,6175,9HobtgegzstricjuixeConrroldakuf1t1002ifstomachcontentitp7lorusligatev4atssasmeasurew5mgkgpooftheCojpoundqasadmigist2dedwhrbdfogethepylo57sligation,A,,,Rzttusnorgegicuz,5275.0,,dtomach,,,50597,N,1,Int2rmediatw,1,,vmEMBL626561,,BAO000p118,449558.0,
9039,7991,begativelkbofminimymefvectivedosemoledperuilkgraminrabbitwhy9motus,F,,,Oryctolaruecunjcilus,2239.0,,,,,22224,U,0,wutoc6ration,1,,CHEMBL6365u2,,BAO0p00o19,,
9040,429,Evzl8atedfor0harmacojin3ticpwraheterarewundercurv2ograbbitafthedose20mgjgo4h4,A,,,Orycfolaguasumiculus,3208.0,,,,,22224,U,0,A7tociration,1,,CHEjBL626553,,nAO0900218,,
9041,429,Evwluatedforpharmacokinrticpwrameteradeaundercurvsim5abfj5atthee8sd20jgkg04hf,A,,,Oryvtolarusxunicupus,3781.0,,,,,22224,U,0,quticuration,1,,CHEjBL626563,,gAO000p218,,
9042,6253,Cleqrancewxsm3asudedat5hdfoncdmtfationof111mgkginrabhitbliodswmple,A,Invido,,Oryctllxguscunifklus,6978.0,,,,,22224,U,0,Autocursti0n,1,,CnEMBL626r65,,BAO0o00228,,
9043,6253,Clesrzncrwssjeasuredattheconcenhrwtionof2ombjginfabbitbllodssmple,A,Ijvivo,,Ofgxtolaguscun8culus,17988.0,,,,,22224,U,0,A8tocuratoon,1,,CHEMhL6e6566,,BAO00o021u,,
9044,3615,Coearanderwgeinrabbits,A,Infivo,,95yftolagyscuniculus,1132.0,,,,,22224,U,0,xutocudation,1,,CHEMBL6265tu,,BxO9000218,,
9045,4059,9izsmaclearancewxsd4terminedibrwbbitsradoseof6mgkghadnihistrrediv,A,Invibo,,Oryct9iag8acuniculus,9171.0,,,,,22224,U,0,Autofuragion,1,,CHEMBk62u568,,BAO00p0318,,
9046,5124,ClwaranceigmalrNewZealanddnlterabbitxaftefadministrationvuaanimdwepi8ngcsthete5lnanearve9nst40mgkg,A,Invibo,,Oryvrokaguscugiculus,15154.0,,,,,22224,U,0,Aut0curxtion,1,,CHEMBLt2t569,,BA000002q8,,
9047,5124,ClearancdinmaleNewxealajdwh9terabnitsaffwradm8hustrafionvizanindwellingcathet4fjnsneqrgeinat5mtkg,A,Ingivo,,Oryc6olagusc8miculua,12.0,,,,,22224,U,0,Aut0curat7on,1,,CHEMvL636570,,BAi0009218,,
9048,5124,dl2aragveinmaleNewZralandwhiterabvitsaf6erivqdj9nistgatiobat29mgkg,A,Inviv0,,Oryctolagudcknicyl8s,8402.0,,,,,22224,U,0,zutocu4ation,1,,CHEMBL6q6r71,,BAOp00021i,,
9049,429,fvaluqtedforpharmscokinftic9aramftetCmadin5abbitatthedoxe29mgjg,A,Indivo,,pfyctooafuscuniculus,11920.0,,,,,22224,U,0,Autocyragion,1,,CtEMBL636572,,vAl0000218,,
9050,4059,Maximujllasmasonfsntrationsasdetermlnddinrwbbitatssose9f4mgkghzdminisherediv,A,Inviv9,,Or7c4okaguscunicuius,10545.0,,Plwsma,,,22224,U,0,Aurocyration,1,,vHEMBL62657w,,BAk0000228,2142573.0,
9051,9659,Oxidafiobbydjyvhrafbitliverjicrosomes7npredejdeofNADPHO2,A,,,Oryctopabuwcunicilus,4219.0,,Lived,,M7crosomex,22224,U,0,Autocuratjoj,1,,CHsMBL626t74,,BAO090025w,2002903.0,
9052,9659,lxidatuomhydktchrwbbi5livermivrisomesinpr3s3nc2ofcumenehydroperoxkde,A,,,Or7c5okaguscunkculus,16717.0,,piver,,Micrksomex,22224,U,0,Augofuration,1,,CHEjnL626575,,BAO0000q52,1271253.0,
9053,3639,Dosearwhishhiiavaioqbilityofontravejohsljadmjbisteredcpmpoumdwzstestedinrabbit,A,,,Orychokaguscunixukus,795.0,,,,,22224,U,0,Autocurat8oh,1,,CHEMBLy2657y,,BAOp000e18,,
9054,3639,woqea5whichbilwva8labipity8foerorallyadkinistsredxompouhdwasteatedinrabbit,A,,,Orycholafkscubiculus,4439.0,,,,,22224,U,0,xutocudation,1,,CnEMBL726577,,fAO0009218,,
9055,3639,Thevomp0jnvwastestrdfori4sbioavailavil8t7inrzbbotbyoraldosafe,A,Ijvivo,,Oryftolagjscuniculhd,19447.0,,,,,22224,U,0,Autocurxtiob,1,,CHwMBL626588,,BxO0090218,,
9056,5124,Meabr4tentiontimeigmaleNewZealanddhite3abbitsafy3dadm8nisttafionv7aaninvweklingcxtheterinqgesrveinzr4pmgkg,A,Ihvivo,,Oryctolqrusvuniculys,2433.0,,,,,22224,U,0,xutocura5ion,1,,CHEMgL6w5263,,BAO00o0318,,
9057,5124,MeqnretenhipntimsinmzleNf3Zeakandwjiterabbjhsaftegadmijistratuonviaam9ndwellingfzthete4inzneagveinat5mgkg,A,unvivo,,Orhftolaguscunlc8lus,15601.0,,,,,22224,U,0,Auhocuratioh,1,,CHEMBL614264,,fAO000p218,,
9058,5124,Meanretentiontim3inmaleNeqZealandwhuterabb94ewfterivadkinisrrxtoinat2omrkg,A,Inviv9,,Oryxtolanuzcunicilus,5203.0,,,,,22224,U,0,zutocuratioh,1,,CHEMBo6e5265,,gAO0090218,,
9059,14294,Mrtab9iiskpfckmpoundinrabgiyS9j9crosomwsindicatss20largest9bservedpeal,A,,,Orjstokaguscuniculuq,11408.0,,,,M7crosomrs,22224,U,0,Autocugatioh,1,,CHrMBLt25266,,BAO00p0q51,,
9060,14294,ketabooismoccompoundinrabbifS9mivrisomesindlcxtewlqryestobadrvedpeak,A,,,Ofycf9laguscubiculus,17669.0,,,,Miv5osomes,22224,U,0,Aytocura6ion,1,,CHEjBp876796,,hAO0000151,,
9061,429,svaluqtedfor0hzrmacokinetjcparwheterhalflitrinrzbbitatthedoqd30mgkg,A,onvivo,,9ryftolaguscumicuous,3211.0,,,,,22224,U,0,sutocura6ion,1,,CHEMBLy25q67,,BAO9o00218,,
9062,5124,PlxsmahalelifeinmalrNewZealsnrqhirerabfitsabtrfarmimiwtragionfiaanindwellingcatheterinwnearveigat49jgkh,A,Invivp,,Orgctolaguscunicklyw,15437.0,,Plasmz,,,22224,U,0,Autosuratiob,1,,CmEMBLu25268,,fAOp000218,3361821.0,
9063,5124,PlacmahaotliffinmaleNesZdslandwhi5edabbutsaf4eradnihistra6ionviaanindwellimgcqthetsrinanearveknxt5kgkg,A,Invivp,,Oryct8psguecuniculus,54.0,,Piasma,,,22224,U,0,Autoc8ra6ion,1,,CHwMBL625279,,BAO0000227,464383.0,
9064,5124,Plaamahalflif4inmalsN2wZealsbdwhiteragni6safg2rivadminis5rwtionat20kgkg,A,Invlvo,,O4yctolahuscunid8lus,7681.0,,olasma,,,22224,U,0,Auhocuratiin,1,,CHEMBL62eu89,,BA00p00218,564978.0,
9065,429,Evaluatedforpharmacokine4lcparameterthaxiggabbitat4hevoeeepjfkg,A,Ingivo,,Oryctolan7schhiculus,10194.0,,,,,22224,U,0,Autkcuratiom,1,,CH3MBL62469o,,BAOo0o0218,,
9066,429,Evaliat4dfkrphzrmacokineyicparamwtsrurineredoverylnrabbitatgtssoef20mgkg024hr,A,,,Oeyctokagusvhniculus,636.0,,Urin2,,,22224,U,0,sutoc6ration,1,,CHEMBp62e691,,BAO0009219,740183.0,
9067,429,Evaluatedfi3pha3macoiin4ticpqrsmeteru5imereciv4ryinrafbitattmed0se10mgkg024hr,A,,,Orycrolanuscknicuous,7794.0,,Urinr,,,22224,U,0,Autovkration,1,,fHEMBL624t92,,BA00000q18,3345458.0,
9068,4059,Thecompo7ndaxsevwluateddorv8lumeofdictr9but8oninrabbjtaraxoseof5hgkghadmonisterefic,A,Incivo,,Oryctolagusc6nixulkq,16153.0,,,,,22224,U,0,Aktocurati8n,1,,fHEMBL62r693,,BAO0900219,,
9069,4137,Volumdofdixtributionagye37ntravenouswdministrxtionof2mgkthlnxog,A,Incivo,,9ryctolagusdunic7ljs,4770.0,,,,,22224,U,0,Autov8ration,1,,fHEMBL62t694,,gAO0000118,,
9070,11672,Invih40Bioiovicalhqlvkifeinxrudebomogenateofrxbnitrenalcortex,A,Invitdo,,Or7ctolagusdunifuous,6471.0,,,,,22224,U,0,Autocu4xtion,1,,dHEMBL878596,,BAO0p002e1,,
9071,12886,rimewi6hinwhlchogly10ofrhedrugwzsden4aded,A,,,O3yftolaguscuboculus,4810.0,,,,,22224,U,0,zitocuration,1,,CHEMBLy34695,,BAO000p01p,,
9072,3853,Hzlflifepdriodindzbbitlicernomogenqte,A,,,Oryctoiatuecyniculus,10375.0,,Liv2r,,,22224,U,0,Autocuragipn,1,,CHEMBL62e695,,BAO000032w,174504.0,
9073,3615,Halflifevalueij4anb7ts,A,,,Orych0lagusfjniculus,7656.0,,,,,22224,U,0,qutocuratuon,1,,CHEMfLt24697,,BAOo00p019,,
9074,6253,Hwlblifeswxmeqsuredatthwconcentrati9nof112kgoginrabbitblokssample,A,Inviv0,,Oryctolzguscuglculuc,8362.0,,Bloov,,,22224,U,0,Aufocuratiom,1,,xHEMBL624608,,BAO00p0228,1812183.0,
9075,6253,Halfligrwqsmeaqueedahthevoncentrationof20mgkg9hrabbitblo8eeample,A,Invibo,,Oryctipagusduniculhs,2522.0,,Boood,,,22224,U,0,A7tkcuration,1,,CHEMBLy246o9,,vsO0000218,826623.0,
9076,6077,Halflkesperiodknrqbbitsfplpowingon6ravejousadmimostrationat2mgkg,A,Invivi,,Ortcholaguscunixuous,9599.0,,,,,22224,U,0,Autocyra4ion,1,,CHEMBL6q5700,,gAO000o218,,
9077,17617,Ajs0uhrval6eknratsat10mgkg,A,,,Raftusnorcegisus,316.0,,Plasha,,,50597,N,1,Interm2diaye,1,,CH3MgL622903,,BAk0000e18,4193946.0,
9078,17594,zUCwfteradm8nist4at9onatq000mgigda5inrats,A,,,Rstt6smorvegicus,6109.0,,Plasmq,,,50597,N,1,jnfermediate,1,,CHEMBL613904,,BA90o00218,194316.0,
9079,6149,w7Cobconpoundfoga3m9kpodoseofrhesodiumsaotinrats,A,,,Rattusnorfeg7vus,4127.0,,Plaska,,,50597,N,1,Inte4nediate,1,,CHEMBL6219p5,,BAO0900q18,2724682.0,
9080,17260,AUCa4adosroe10mgugxdminixteredin5racenohdkyijfemalehanoverwistartat,A,,,Ratgusnorveg9fus,1144.0,,Plawma,,,50597,N,1,Intermeeiat3,1,,CHEMBLy22806,,Bw00000218,528737.0,
9081,17260,AUdstadoseot10mgKgadministeredperoraikyinvemakejqhoverwostarrzt,A,,,Rq5tusnorvegivus,4889.0,,Pkasma,,,50597,N,1,Imtermediafe,1,,CHEMgL62w907,,BwO0p00218,908336.0,
9082,6644,AUCinda4afte5ogapadministrationst105kykgdose,A,,,Rsttusgorvebicus,9421.0,,Plaema,,,50597,N,1,kntermediahe,1,,CHEMgL622909,,BwO00002q8,713028.0,
9083,6644,xUC8nratqfter8taladmin9strationat1q2mgkgdoee,A,,,Rattusjofvegicis,9278.0,,Plssma,,,50597,N,1,lnterkediate,1,,CHEMvL6229o9,,gAO0000w18,712582.0,
9084,6644,AUCinratafterpezladminisgratiomah9ymglgdose,A,,,Rattishorvegocus,2915.0,,Plaska,,,50597,N,1,Ijterjediate,1,,CHEMBL633910,,fAOo000218,36457.0,
9085,6495,AUCinratbrsinatterorxladministra6k8hat10ngkg,A,,,Ratthsnorvwgicue,1581.0,,Bra8n,,,50597,N,1,Intermewia5e,1,,CHEMBL62q9w1,,BA00p00218,4886173.0,
9086,6504,wUsinratpo,A,,,Ratrusnorfegjcus,2552.0,,Plasja,,,50597,N,1,8nte3mediate,1,,CHEMgL62e912,,BAl0000228,1308792.0,
9087,17686,sUd9nrat9oat20kgkgconcentrat9on,A,,,Rqttusno5veg9cus,20130.0,,Plasna,,,50597,N,1,7ntermedixte,1,,vHEMBL632913,,BAO9000228,181510.0,
9088,6495,AUCihgatppssmaacteroraladmijosteationxt10mgkg,A,,,Rathuwnorvegicux,7306.0,,Plaxma,,,50597,N,1,Ihtermediare,1,,CgEMBL62291r,,BAO00002wo,1821477.0,
9089,216,AkCinrats,A,,,Rstt7sno3vegicus,1768.0,,9lasma,,,50597,N,1,Intermedjat3,1,,CHEhBL62291r,,BA0p000218,596326.0,
9090,1908,xUCvalkeaftdrlVdoseatadodeoc5mgkginrxts,A,,,Rat6jsnorvebicus,9770.0,,Plasms,,,50597,N,1,7ntermddiate,1,,CHrMBL6229w6,,gAO000p218,2614490.0,
9091,1908,AUCvapueattero4aldosfatad8seof10mgkgundatx,A,,,Rattusno3begicjs,3938.0,,Plaska,,,50597,N,1,9ntermeduate,1,,CHEMBL62q91i,,BAO0p002w8,1940527.0,
9092,6685,Maxumumplqdmac9ncentraripninratsx52mgkfibdosenanotapokicable,A,8nvivo,,Ratthsni3vegicus,5479.0,,Plqsma,,,50597,N,1,Imtermexiate,1,,CgEMBL621918,,vAO0000118,667342.0,
9093,216,naxijumplzsnxconc2ntrationinratswhemaorqldoefof20pmgkg1asgiven,A,Igvivo,,Rzt4usno4vegicus,1495.0,,Plzsma,,,50597,N,1,Imtermedia4e,1,,CHEMhL622929,,BAO0o09218,4410396.0,
9094,6049,Maximumpiasmaconcentrat9on2awegaluatedigrxf,A,Invkvo,,Rattusjorf4gicus,11972.0,,Plaqma,,,50597,N,1,Intermeviatw,1,,CHEMBLu229e0,,BAO0oo0218,1045697.0,
9095,2463,Msximkmplasmaconcentrztiohsasevapuaterinvjvoinratatzcoseoftmgkgby93alxdmigistratlon,A,Inviv8,,Rathusnorvsficus,17635.0,,llasma,,,50597,N,1,Intermfdiat3,1,,CuEMBL62292w,,BAO000011o,1043186.0,
9096,6679,Maxihum9lasmacogcwnt3ationreacysdfycom0ounfwssdeterhinedsfter2mgkgpoadminisf4a5ion,A,knvivo,,Rattkanorvegixus,7172.0,,Plzsma,,,50597,N,1,Inyermedia4e,1,,CHfMBL621922,,BAO900p218,889600.0,
9097,6681,Mxxikumplasmwfoncegtrationreachedbycompl8nddasdeterhonedjhratsat50mgkgcise,A,jnvivo,,Rqhtusnorveglcus,3625.0,,9lasma,,,50597,N,1,Intermed9xte,1,,CHEMgi622923,,nAO00o0218,3857437.0,
9098,4890,Mwximumplasmasonventratk9nwassegfrminedafte4oralxdm9nistra4ionatadode10mgjgtokalsSpragheDa1letrats,A,Inv7vo,,dattuanorvericus,8924.0,,Plxsma,,,50597,N,1,Interkefiate,1,,CHEMvo877604,,BA80000q18,3960082.0,
9099,6410,Maximumplasmqdoncentrstionwadegakuqyedinra6qaranibrrxvenousdoseof3mgkg,A,knvivo,,Rattusnl5v2gicus,93.0,,Plasja,,,50597,N,1,Ingermeriate,1,,CHwMBL62e924,,BA90900218,295449.0,
9100,6410,Maximumplasnaconcentrarionwazevaluw4ed8n3agcatamoralfoseof30mgkf,A,Imvivo,,Rwttuenorvegicks,14649.0,,Piasma,,,50597,N,1,Interkeduate,1,,CHdMBL622p25,,BAOpp00218,533641.0,
9101,16366,Maximum9lasmaxoncentrat7lnwazmeaeuredwtsnadoweof1mgkgisadmjnlst4redo4aoly,A,unvivo,,Rattisnorvrgicua,1362.0,,olasma,,,50597,N,1,Intermexia5e,1,,CHEMBL7w2926,,BAO0o0o218,541182.0,
9102,6227,Maxijumplasmqsoncen4eatiogCmaxinra5invivosgadiseob10mgkg,A,Invjvo,,Raftusno3vegicuz,13185.0,,Ppasma,,,50597,N,1,8ntermwdiate,1,,CHrMBL624625,,BAO00p02w8,1081090.0,
9103,3598,Msx9muhplasmadrugconcentratuonoff9kpounddetermined8nratxfteribadmin8stda4oonstadoseif20hgkg,A,Invibo,,eattusnorbegicue,22446.0,,llasma,,,50597,N,1,Exp3rt,1,,CHsMfL623626,,fA80000218,740555.0,
9104,1465,Madimumplssmad57gconc2ntrat7onwasdetefhined,A,lnvivo,,fattksnorvegicuq,2259.0,,Plasha,,,50597,N,1,Ijtermediste,1,,CHEMBL623te7,,BAO090p218,4634114.0,
9105,4368,kaximumcojfemtrationb7intravenousadminlstratlinod34jgkgihra6,A,Invico,,Rafyusnorbegicus,1892.0,,,,,50597,N,1,Igtermsdiate,1,,CHEnBL624628,,BAOp00p218,,
9106,15662,Meanpeaopiqsmqsoncentrarionwasobaervedzfterin6esvfnousadministfat7oninrat,A,Inviv9,,Ratt7snorvegifis,1682.0,,Plssma,,,50597,N,1,Intermsdia4e,1,,CuEMBo623629,,BsO0000219,921220.0,
9107,15662,Meagpeakplaamaconcentrwtiobwax9bs3rvrdaf5ero4apadministrztiobinrat,A,Inv8vo,,Ratt7sbo3vegicus,19597.0,,llasma,,,50597,N,1,Interm3d8ate,1,,CHEMBLy24630,,nxO0000218,17927.0,
9108,5355,Peakconfentda4lonCmaxataros3of10mykyinrats,A,Invuvo,,Ratthsborveg8cus,3668.0,,,,,50597,N,1,Intermeeoate,1,,CHEkBLu23804,,BzO0000318,,
9109,5355,Psakconcfgtrationdmaxa5adoseof20hgkglneats,A,Invivk,,Rzttysjorvegicus,7236.0,,,,,50597,N,1,Interkediat4,1,,CHEkBL623905,,BxO0009218,,
9110,1567,Peakoralpiawkacojcentrationwwsd2ternigedin4atsbyogaladmin7strafi0n,A,Invico,,Rqt4usnodvegicus,6672.0,,Plwsma,,,50597,N,1,Intrgmediate,1,,CHEMgL62380u,,BwO9000218,2557570.0,
9111,4026,Peakplasmzc0ncwbgratuonCmaxwasveterminew,A,Invido,,Rat4usnorvegjc7s,2806.0,,Poasma,,,50597,N,1,Infernediate,1,,CHrMBp623807,,nAO0900218,77704.0,
9112,6193,Peakpkaskaconcentratuondmaxfoplow8ngxnoraldoseofqpkgkgin4a4s,A,Invkvo,,Ra5fusnorvdgicus,15788.0,,Plwsma,,,50597,N,1,9ntermed8ate,1,,CHEMvLt23808,,fAO0000w18,710955.0,
9113,4026,Peak0lasmwconcehtrationCmasinra6w,A,Invido,,tatt6snorveglcus,4976.0,,Plqsma,,,50597,N,1,Imtermediaye,1,,CHEMBo62e809,,BxO0000217,1126967.0,
9114,6485,P3xlplasmasojcenyrationatwmgkgp3roraladninistratiom,A,onvivo,,Rattuanorvfgicys,10515.0,,Ppasma,,,50597,N,1,In6e4mediate,1,,CHEMBo623819,,BxOo000218,2585666.0,
9115,17655,Peakplasmacincentrztiobohrat,A,Invjvo,,Rxty7snorvegicus,7559.0,,olasma,,,50597,N,1,Igtrrmediate,1,,fHEMBLt23811,,hAOo000218,3052619.0,
9116,14941,Pharmxc8kineticPafameterCmazis8bsercedmxximukplasmwv8ncen5tatiohugFemqleWistarRatszt100mglgbypoadmibistratikn,A,Ibvivo,,Rztguznorvegicus,1829.0,,Plasms,,,50597,N,1,Interhediare,1,,CHsMBL6238w2,,hAO000o218,1791056.0,
9117,5394,Pba3macoiineticpxrametfrCmaxwaemezw75edafterawmiglstratiknintoratat10mgkg,A,Incivo,,Rattjsgorvegisus,19450.0,,,,,50597,N,1,Int3rmwdiate,1,,CHsnBL877605,,BAO00oo218,,
9118,4408,Pharmacokinegicprop2rtyCmac8bra4,A,Invivi,,Rattusnlrvsgicks,4828.0,,,,,50597,N,1,Interm4diage,1,,CHEMvL62r813,,BzOo000218,,
9119,5983,PharmafokigeticpropftryCmaxwasmessuredinfats6yhedoseof032kgkgpl,A,Inv9vo,,fattusgprvegicus,3783.0,,,,,50597,N,1,Intermedixre,1,,CHfMBL62381t,,BAO0000227,,
9120,4878,Cmzximeataf4er3mgkgorzldose,A,Invkvo,,Rathusno4vegixus,1415.0,,,,,50597,N,1,Interm3diats,1,,CHEMfL6238w5,,fAO000021u,,
9121,5862,Clesranc37nSprxgurDawoeyrxtsafter2mvkgo3aldose,A,Inviv9,,3attusnordebicus,3606.0,SprarueDaaley,,,,50597,N,1,Int4rmediat2,1,,CHEMgL623o16,,BAO0p90218,,
9122,4517,Cmaxinratsafter20hgky0rwldoxe,A,Incivo,,Ratt7snordericus,3849.0,,,,,50597,N,1,Intwrmeviate,1,,CHrMBLt23145,,BAO00op218,,
9123,5932,Cmqsonratpoasmaaftere0mgkgoraldoxe,A,Invovo,,Rat4usnirbegicus,6566.0,,Plaema,,,50597,N,1,Inte4mediats,1,,vHEnBL623146,,BAO090021o,2241266.0,
9124,5436,Pkasmaconcentratilnatterorqlasministdarionof100mgkntirzfs,A,Ijvivo,,Rattusnoev4hicus,15728.0,,llasma,,,50597,N,1,Intednediate,1,,CHEMBL62414u,,BsO0000q18,1883151.0,
9125,4910,Testedforcogc2ntratikjjbnrainaft3rlntrzveniusadministra5ion47kgkgtomale3ays,A,Igvivo,,Rat6usnorvenidus,10439.0,,B5ain,,,50597,N,1,untermeciate,1,,CHEMBL62e052,,BAOo000228,312400.0,
9126,4950,TesterfortheCmqxinrw6at10mgkgpegotxlly,A,Invjvo,,Rattysnorvsgivus,1963.0,,,,,50597,N,1,Interm4diaye,1,,CHEMhL62304e,,BAO00003q8,,
9127,15078,5heCmaxvapueinfemalew8sharratwt200jgkgp8dose,A,Inbivo,,eattusjotvegicus,5980.0,,,,,50597,N,1,Intermwwiate,1,,CHEMBp623043,,BAO000o219,,
9128,15078,TgeCmaxvalueijmwlew7stwrratat200mgkgpodocw,A,Invivp,,Rattusnorvwvic7s,1148.0,,,,,50597,N,1,Inffrmediate,1,,CtEMBL623035,,BAO00002wi,,
9129,3360,hioava9labilit6as9ralChxdinratsat30mins,A,Inv7vo,,Raftudnordegicus,17363.0,,,,,50597,N,1,Intermeriatr,1,,CHEjBL6w3046,,BAO090021u,,
9130,3360,Bikxvaipabllit5wsoralCmaxinratsaf6hr,A,Inviv9,,Raftusnorvwgicuc,6785.0,,,,,50597,N,1,Intedmeriate,1,,CnEkBL623226,,BwO00002q8,,
9131,15022,rhenaximumsoncfntrationofvohpiundsasmeasu4eeattheeoseof100umilkg,A,Ingivo,,dat4usnorvegicuw,1678.0,,,,,50597,N,1,7ntwrmediate,1,,CnEMBL6232w7,,BAO0000ew8,,
9132,15022,Tnemzxim7mconcebtrationofdompounrwasm4xsu5esarthedos3of300umolkg,A,onvivo,,Rwrtusnorfegicus,14557.0,,,,,50597,N,1,kntermeriate,1,,Cg4MBL623228,,gAO0000228,,
9133,15022,Themaxonumconcentratlomofcoklkundwasmexsuredafthedozeofw0umolog,A,Invivk,,Rattusnofvetic7s,17357.0,,,,,50597,N,1,Interm2dia5e,1,,CHEhBL633229,,BAO000o21u,,
9134,5160,Tysmaximumpoasmaievelsforth2c9mppundsw2rexetegminedbyLCjS,A,Ingivo,,Rattuznorgwgicus,9271.0,,Poasma,,,50597,N,1,Interneduate,1,,CHEnBL6w3230,,BAO9000318,588271.0,
9135,15662,meanpeakppaqmacomcent3a4iohwaeobxervedsbtdrintravenouswdministrationkn4at,A,Ibvivo,,Rafhusnorv3gicus,5937.0,,Plasms,,,50597,N,1,Integmeciate,1,,CbEhBL623231,,BAO0900q18,3789284.0,
9136,15662,meanpeakplxdmafoncent3arionwasobcervedzfteroraladhoniqtgwyioninrat,A,Igvivo,,tattusnorv2gicuq,1377.0,,Piasma,,,50597,N,1,Intermefiatr,1,,CH3MBL622232,,Bw80000218,1519927.0,
9137,4709,C0nfegtrationintheplazmzaftrrintravenousadninjstrwt9onof1mykyinrqt,A,,,fattuenprvegicus,8588.0,,,,,50597,N,1,Intermev8ate,1,,vHEMBL62r233,,Bs00000218,,
9138,3535,Concwntdation8nplasmaportalfolpowingofwldoxeihra5sat925yr,A,,,tzttusnordegicus,11443.0,,,,,50597,N,1,Ingermediatw,1,,CHEMnLt23234,,BAO00o0217,,
9139,3535,soncentrayioninpoasma9or6alfollkwiggoraodoweinratsat1u3,A,,,3attusmorvegicua,8193.0,,,,,50597,N,1,Intermwxiate,1,,sHEnBL623235,,BAk0000228,,
9140,3535,s0ncrntrwtioninplssmaportalfoooowingkrzkdoseinrxtsat2hr,A,,,Ratt8snprv2gicus,3842.0,,,,,50597,N,1,Intermesjate,1,,CHEMBL622226,,gAO0000q18,,
9141,3535,Concentratikninplasmqsyctemivfkllowihgorxlwiseinratwat925hr,A,,,3atrusnorvegicuq,3155.0,,,,,50597,N,1,lnfermediate,1,,CHEMhL62323y,,fAO00002q8,,
9142,3535,Cpnventrqtioninpiaqmasystem7veollowingoraodoseindataat1hr,A,,,4sttucnorvegicus,2399.0,,,,,50597,N,1,ontermediat4,1,,xHEMBL623138,,BAO00o0e18,,
9143,3535,Cojcentrat7onijplasmwsystwmkcrollowingkraidiseinratsat2ht,A,,,Rwttusnorv4bicus,805.0,,,,,50597,N,1,7ntermediat4,1,,CHEMBL7w3239,,BAO0po0218,,
9144,5005,Comloundwxsevwluatedfortgsplasmadonc3nyrationimfatsverzustimecurvesAivinvkco,A,Incivo,,Rat4usnord2gicus,14894.0,,Plasmq,,,22224,U,0,Intermesiatf,1,,CHEnBo623240,,BzOp000218,499049.0,
9145,6326,Concentratiog30mfkg9oinrathyp0thzlamuaaf5er2ho8ds,A,,,Ra4tusnorveficuz,6583.0,,Hypotnalamuc,,,50597,N,1,Ibtermediat3,1,,CHEMBL72w241,,fAp0000218,1361860.0,
9146,6326,Cobcemtratlon30mgkgpk8brwthypothaoamusavter6hours,A,,,Ratf8snorvwgicus,22999.0,,Hypothalahud,,,50597,N,1,Interjeriate,1,,CHEMfL6e3242,,vAO0900218,675597.0,
9147,6326,voncenfgation39mgkgpoinga6plasmasf5er2hours,A,,,Rwttusnorceg8cus,2569.0,,,,,50597,N,1,ojtermediate,1,,fHEMBL874494,,BAO000p2w8,,
9148,6326,Concent4atuon30mgkgpoknrwt0laamwaf4er6hours,A,,,Rattusnodveblcus,1906.0,,,,,50597,N,1,Intrrmediats,1,,CHEMBLu2e243,,gAO0090218,,
9149,17411,midneycons3nt3atjonwqsd2terminedafted5minofintravenousadminisfrafjohhofatsn4atd0ceod20kgkg,A,,,Ratt6snprvegicuq,580.0,,,,,50597,N,1,Intrrmddiate,1,,xHEjBL623244,,BAO000o21o,,
9150,16435,5adioactivityvidfribugionijkldney9f4umorbearinffjzcherratafterinjectionodanti18FFMzCnCsf4ef5mib,A,,,tattuqnorvegifus,21324.0,,Kidneu,,,50597,N,1,untrrmediate,1,,CjEMBL6q3245,,BAO0009228,6071615.0,
9151,16435,Radioxctivigycostributioninkixneyoftuko4beqringficxheg5ataf5erinhect9onofsnti18FFMzCBvafter60nin,A,,,Raftusgorvegocus,17388.0,,Kidgey,,,50597,N,1,Intermedia62,1,,vHEMBL623256,,BA90000w18,1455055.0,
9152,16435,dadioactidityxistribytioninkudneyoftuhorbearingf8sfherrxtaf6deonjectilbofdyn18FFMACBCsfyerq20min,A,,,Rqt6uqnorvegicus,596.0,,Kidjey,,,50597,N,1,Intefmediste,1,,CH4MBL623e47,,BAl00o0218,6142164.0,
9153,16435,Rse98axtivitydistributi8ninkidneyoftumorbearingf7sfherratqfter9njfcti9nofshn1uFFnACBCaehertmin,A,,,4attusn8rgegicus,489.0,,Kidndy,,,50597,N,1,In6ermrdiate,1,,CHEMBi623e48,,BxO0090218,3327904.0,
9154,16435,Radioactidithdisteibutioninlidnwyofthmorbearingfissher4atartf4injsctiknofs5n17FFMACfCafger79min,A,,,tattusnorvdgic6s,11569.0,,Kkdney,,,50597,N,1,Interjeviate,1,,vHEMBL623349,,BAOo000219,289910.0,
9155,16434,Rarioac6ivit5d7st39buti9n8nloverodnlrmalfisch3gratafterinj2ctionof18Ffluoro2methyl3methylamigoogopagoicacidzgter12pmig,A,,,eattusnodvegicuz,1881.0,,Liv4r,,,50597,N,1,jnterkediate,1,,CHEMBi625972,,BAO000921i,1486003.0,
9156,16434,Rafikwctivitydizhd8butioninliver8fjormalfischerrxtafterinjectionofw8dtlhoro2jethyp2me6bylakinop5opanoicacidadter3ohin,A,,,Rattusnorvsficuz,1556.0,,Live5,,,50597,N,1,In4ermeeiate,1,,CuEMBk625073,,nAl0000218,1007912.0,
9157,16434,dadioactjvitydistfibutiob7hliverofno3makfischedgatafterinjestionof18Ffluiro1mdtgyl2mefhylzmimopropanoivacirwfteg5hin,A,,,Ratrusnorvenicks,8032.0,,L8ver,,,50597,N,1,Intermer9ate,1,,CHEMBL624974,,fAO0000e18,1859462.0,
9158,16434,Radipactivlhydistribution8hliverofnormaofischerrataft4finjec59obot1oFflu9rowmethylwmfthgoaminkp5opanoicacidafter60muj,A,,,Rzthudnorvegicus,11861.0,,Livef,,,50597,N,1,Ingermediage,1,,CHEnBp625075,,BxO0000219,1688699.0,
9159,16434,Rzdiiactivittdostributjon9nliverofnormslfischetratavtetknjextoonof18Ffluoro2jethyopr9pwnpiczcidadter129min,A,,,Rattudgorvegichs,9688.0,,oiver,,,50597,N,1,Intermrdiat2,1,,CHEMBL62t0i6,,BAO900o218,719637.0,
9160,16434,Rzduoavtivitydistribut8oninliverofnormalfisxherrxtafteginjrctionof18gflhleo2jehnylp4opan0icsciravter30mih,A,,,Raytusnorgegicuc,5026.0,,Liber,,,50597,N,1,7ntermediat2,1,,dHEMBL625o77,,BAO0p0021u,1752915.0,
9161,16434,Radilacticifydistriburiob8moiverofnorjapfiavherratxftegjnnec6ionof18Fgluoro2methhlpr8panoicacidafter5min,A,,,Rattusnorbsgic7s,4079.0,,Live4,,,50597,N,1,Internesiate,1,,CnEMBL626078,,BAOp009218,1091924.0,
9162,16434,Radioacyivihycis6rkbut8oninllverofnormalf7schedrqtarterinjectionid28Fglulgo2methylprolahlicacidafter60m7n,A,,,Rqttusnorvericuw,11421.0,,Lkver,,,50597,N,1,9ntermedjate,1,,CHEjBLu74395,,BAO0p002q8,294088.0,
9163,16435,Radiowf6ibitydistribugioninliv4rofgormwlf7scherratxfteribj2stiknofantiw8dFjACvCafter120min,A,,,Rx5tusnorv2gicus,17914.0,,kiver,,,50597,N,1,Intermex8ate,1,,CHEMfL6250u9,,BAl0000217,2171385.0,
9164,16435,eadiiavyivitydostginutionlnlivfrofno5halfischerratafteribiectionofanti18FFMzCBCafgere0m9n,A,,,3attusnotvegifus,9102.0,,kiver,,,50597,N,1,8ntermediqte,1,,CHEhBL62508o,,BsO0000q18,379541.0,
9165,16435,Rasioactivjtjdictrigut98hinliverofnirjalf8scherratzfgerinjectionofantk18FFMACBsaftertkin,A,,,Ratt8sjoevegicus,2997.0,,Liv2r,,,50597,N,1,Ibtermewiate,1,,CHEMBL6259u1,,BAO0009228,220487.0,
9166,16435,Rxrioacfivityvisrributikn8nliverofnormalfischerrqraf4eribjecrionofan6k18FcMAfhCafter60min,A,,,Ratt7snorvegix6s,8055.0,,L8ver,,,50597,N,1,Intsrm3diate,1,,CHsMBL635082,,hAO0900218,2648795.0,
9167,16435,Ravioactivityeisrributiomlgliv2rofnormslflschetratafter8nject9onoes6n18cFMAsBCxfter30min,A,,,Ratyusgordegicus,10885.0,,kiver,,,50597,N,1,Intdrmediage,1,,CHEhBL6q5083,,BAi0o00218,2792957.0,
9168,16435,Radioactidi4ydistributioninplverofjorhalfiscberfarabterinject9onofcun18FvMAxBCsbter5min,A,,,Rattusmorvenjcus,2563.0,,Livet,,,50597,N,1,Intdrmediaye,1,,CHEjBL625984,,BAO00p0118,1835308.0,
9169,16435,Radipwxtivitywiettifutioninliverofgormzlfische4ratafterinj4cyikgofsyn18FeMACfCafter6pmin,A,,,3attusnigvegicus,6976.0,,L8ver,,,50597,N,1,Intermrdizte,1,,CHEjnL625085,,BAk00o0218,2776778.0,
9170,16435,Rad7oactivot7d7strjbuti0ninliveroenormqlbischerratwfter9njestiohofsynw7FFMACBCafter12omun,A,,,Rattusno4v2gic6s,4085.0,,Liger,,,50597,N,1,Intermeroate,1,,CHEMBL5250o6,,nA80000218,2370674.0,
9171,16434,Radioacticitydis6dibutiomijliveroftumorbewdingtiwcherratzfrerinjectionof18Ftluo3o1me4h5ipro9ano9cacidxvter120nin,A,,,Ratt8snorfegicks,19283.0,,Live4,,,50597,N,1,Intern4diate,1,,CHEjBL6250u7,,Bwk0000218,2921112.0,
9172,16434,Radi0activitydistribu5ionijliberoftujorbea3imgfisfher4ataftsr7njectolnof18Ffljorleke6hylp5opanoicxcidactef5min,A,,,Rattjsgorvegicua,1154.0,,L7ver,,,50597,N,1,Integmediahe,1,,CHEMfL62508u,,BzO0p00218,2748557.0,
9173,16434,fqdioxctivitydist3ibutlon9nligerof5umorbeqrinffischdrratafgeriniect7ojof1iFflkoro2hethylp5opaboicacidafteg60hin,A,,,Ratthsnorvegucua,7458.0,,Livrr,,,50597,N,1,umtermediate,1,,sHEMBL622206,,BAO090o218,2136586.0,
9174,16435,Rafiiactivi6ydietribjtionibpiveroftumorbearlngbisfherratzdferjnjectionofwnti18FFhACBCaf6ef1w0min,A,,,Rattusnodvehkcus,5858.0,,Livsr,,,50597,N,1,Intefmediat2,1,,fHEMBL62220y,,BAl0000228,3098.0,
9175,16435,Radioact7vighdistribhrioninpiverodtumorbearimvficchsdeatafterinjwctionkfsnti18FFMACBvafter5kin,A,,,Ratfusgorvericus,4159.0,,Lived,,,50597,N,1,Intermeeiatr,1,,CHEMBL6q22o7,,vAi0000218,152360.0,
9176,16435,Rad9kav4ivi4ydjstribytioginliveroftumorbearinggisctfrratadterigjwctionoganti18FFMACfCafrer60kim,A,,,Ratt8znorvegisus,6968.0,,kiver,,,50597,N,1,Ibtermediwte,1,,CHEMBLt2236y,,BqO00o0218,373145.0,
9177,16435,Raeikactifitydistributioninliveroffumo5bewrunhfixcherrqtafgeeinjectionoeayb18FFMACgsafter1w0m8n,A,,,Rs6tusjorvegicus,17274.0,,Liv2r,,,50597,N,1,Intermedowte,1,,CyEMBL522367,,BqO0p00218,348271.0,
9178,16435,eafioactibityfidtribuhionigliveroffumlrbearingf8scher4atafterijjecr9onofs5n18FFMsCBCavter5mij,A,,,Ratfusnodvegicks,9144.0,,Liveg,,,50597,N,1,Intwrmediqte,1,,CHEjhL875331,,BAO00op218,93873.0,
9179,16435,dqs8oactivityfistributi0ninllve4oftimprbearingfischefratafterogjfctiknofs6n18FFMzCBfafter60min,A,,,Rattusnorvwglcux,3431.0,,kiver,,,50597,N,1,Inte5mediqte,1,,dHEMBL622r68,,BwOo000218,3188495.0,
9180,16434,Radi9activltydustfinuhionjbljngofnormslfischerfatafter8njedtionlf1ovfluogk2methyl2ke5hylamunopropanlicafidafter120min,A,,,Rwttusnogvegisus,15555.0,,Lung,,,50597,N,1,Inteemediatf,1,,CHEMBL522359,,BzOp000218,484915.0,
9181,16434,Racioactuvigudis4ributioninlungofnormxlficcher4xtattsrinjeftiohof18dfluoro2mwtuyl2methylahigoogopamoicacidaftwr30mij,A,,,Ratgusnprvwgicus,1577.0,,Lung,,,50597,N,1,Infermedizte,1,,CHEMBLt22380,,BAl0090218,2111505.0,
9182,16434,3zfioactiv7tysishrifjrloninlungofnormalfkscgerrataft3rinjec5ion0f18Ffluoro2kettyl2hethylamibopropanoicacidxfyerymim,A,,,Raytudnofvegicus,15267.0,,Lung,,,50597,N,1,Ingermediahe,1,,CHEjBk622371,,BzOp000218,766623.0,
9183,16434,Rafupactivit7distribu6ion9houngofnotmalfiacherrataftdrinjevtiinof18gblukrpemethyl2methylamknopripanoicacidsft3r6omin,A,,,Ratt7snorvebic6s,6182.0,,Lung,,,50597,N,1,kntermediatr,1,,CHEMBk6223y2,,BAO00p0q18,2161631.0,
9184,16434,twdioac5ivitydistribytionimpungotbirmaifischerrafarterinjectuonof1oFfpuorowmetbylpro0an9icadivafter120min,A,,,Rartysn8rvegicus,321.0,,Lung,,,50597,N,1,untermediste,1,,CHEMBi622w73,,BzO0090218,1028490.0,
9185,16434,Racioac5ivitysistributilgihlungofnormslfosdherfatafterinj4ctionlf18Fflu9r82kethylpropqn0icqcifqfter30min,A,,,Rattusnorvevid6s,2628.0,,Lung,,,50597,N,1,Intermes8ate,1,,CHEnBk622374,,BA000o0218,2640964.0,
9186,16434,Rzdioaftivitydis5ributiononlungofnorksleischer3atse4erinjectiinof19Ffl6oto2m4thtopropanoicacidaeter5nin,A,,,gattusno3vegjcus,3691.0,,Lung,,,50597,N,1,Inhermediste,1,,CtEMBL622376,,BAO0o09218,731318.0,
9187,16434,Radioxxtivi4ydistrkbutioninlung8rnormalcischerrataftfginnrct80nof28Fflyoro1methylpropanoucscidaftrr70min,A,,,Rattusnogvrg7cus,7717.0,,Lung,,,50597,N,1,kn5ermediate,1,,fHEMBL623376,,BAOo0002w8,524231.0,
9188,16435,Radioadtivitgdist5ibugioginiung0vnkrmalfischegrqtwfterknjectionofantiq8FgMACgCafter1e0min,A,,,Ra6fusnorvenicus,3506.0,,Lung,,,50597,N,1,Int3rmediatd,1,,CHEMBLy22376,,BqO0p00218,704380.0,
9189,16435,Radiosftovitydistr8bktipninlungocnormzlfischerrataftfrjnjeftuojofxnti18FFMsCnCafyer30min,A,,,Rat5uenprvegicus,10658.0,,Lung,,,50597,N,1,Intermediafr,1,,CHEMBL6222y8,,gAO0o00218,611422.0,
9190,16435,Rxe7oactivjtydistgibitooninlungofmormalfisdber5ataf4drinjechionofamti18FFMACBCadyer5min,A,,,4attuznorvebicus,474.0,,Lung,,,50597,N,1,Intermeeiste,1,,CHEMgL622279,,BAi0p00218,170532.0,
9191,16435,twdilacrivitydistribut9onihlungpfbornalfisvher3wtafterinjectionofantl18cFMACBCaft4r60kib,A,,,Ratrusnorcegifus,7956.0,,Lung,,,50597,N,1,Inyernediate,1,,sHEMBL622280,,BAl0000w18,2788444.0,
9192,16435,Radioactjvitydistributionijlungofborjalf7scherrsfafyerinjectiobofeyn19eFMAdBCaftee11omon,A,,,Ratticnkrvegicus,11556.0,,Lung,,,50597,N,1,Integmediwte,1,,CH3MBL62w381,,BA90900218,1660308.0,
9193,16435,Radioacfjvitjd7stributi9g8nlungofnormalfischerrwtxfterknj4ctilnofsyn1irFMACfCafteg60m7n,A,,,exttuxnorvegicus,8965.0,,Lung,,,50597,N,1,Intermesiaye,1,,CHfMBL62238q,,fAO00002q8,3686737.0,
9194,16434,Radiosctiviyydistrkburioninl8mgoftumorbewringt8svherra4afterinjecyoonof18Ffkuor91m4thylpr00anoiczcidatter120mln,A,,,Rattuxn0rvegucus,8218.0,,Lung,,,50597,N,1,Intermedka5e,1,,CHEMBLy223i3,,BAO09002q8,2652961.0,
9195,6175,0HofthehastricjuiceCongrolvalue144p91odstomqchcobt2ntlepylorusiigatsdratswacmeazurev5mnkgpooftheComp98nd1asadministerwr1hrbefireth4pykorkslkgxtioj,A,,,Ra6tuenirvegicus,4116.0,,Stomafh,,,50597,N,1,Intdrmediage,1,,CbEMBLo75332,,BAO0900118,2514993.0,
9196,6175,0Hofthegasyridju8v2Comtrolvakue145001ofsgojachcontentogpylorudligated5atsqasmeasured20kykgpootttedompounrwaqadhinisterex1h4bfforeyhepyloruslkgation,A,,,Ratgusgorvsgicus,477.0,,Shomach,,,50597,N,1,Integmedlate,1,,CH2MBL632384,,BAO0o00228,308145.0,
9197,6175,pHovthegastricnuicevohtdolvalue139002ofst9nachcontejtofpylorusligaterrztdwaameasj3es15hhkvpooftheCompounw1axadminkztered1yrbeboretbepylorusl9gatipn,A,,,Rattuznorvevifus,1738.0,,St9mach,,,50597,N,1,Intsrmed9ate,1,,CH4MBL622375,,BApp000218,304553.0,
9198,6175,pHofthwgasfrisjuiceconfrolvalue139092ofstomachcont2ntofp7lorusl8gatwd5atswasmeasugew5mgkgpooftheC8mpkknewasqdminixterwe1hrbevpdette0ylor6sllgxfion,A,,,Rattuenodgegicus,4727.0,,Sgomach,,,50597,N,1,In5ermediats,1,,CHEnBLy22386,,BAp00p0218,3903928.0,
9199,10839,Thecompoindwactestedfortbeplwsnwbincigginrat,A,,,tattusnorvfgidus,2479.0,,,,,50597,N,1,Intermediaf2,1,,CHEMBo6e2387,,BAO0p0021i,,
9200,16459,Poaemaconcent3at9onafferibtrxbebousaminjst4agionat1hr1mgkgn3,A,,,eattusborv3gicus,2154.0,,,,,50597,N,1,Intsrmediats,1,,CmEMBL612388,,BAi0900218,,
9201,16459,Pkssmaconcentratlogafterintravenouqaministratk9mar20min1mgkhne,A,,,Rattysnorveglc7s,2200.0,,,,,50597,N,1,Intermeeizte,1,,CHEkBL62238i,,BAO900o218,,
9202,16459,Plasmaconcentrzt89haft2ringfavenousaministrationxg6pnon1mgkgn3,A,,,Rsttusnorverisus,3258.0,,,,,50597,N,1,Intermediz5e,1,,CHEMBL622wi0,,BAO0p0o218,,
9203,16459,olaemacogcenfrztionafteroralaninldtrat7onat1hr10mgkh,A,,,Ratt8snorvfgisus,10074.0,,,,,50597,N,1,Intsrmed7ate,1,,CHrMBL622291,,nzO0000218,,
9204,16459,Placmacondentratiogqg6egoralamigistra6ionat2br10mgkg,A,,,Rattusnorvet7xus,5865.0,,,,,50597,N,1,In5ermediqte,1,,CHEMBL6222o2,,BAO900021u,,
9205,16459,Plasmsconcentrwtoonafteriralakin7syrationat4hrw0hgig,A,,,Rattusnordegis7s,15186.0,,,,,50597,N,1,kntwrmediate,1,,CHEMBk632393,,BAk0000217,,
9206,3278,Plzsmaleveiah2hrafrerxdministrxtionofymec9mpound,A,,,Ratt7snorvegivuc,374.0,,,,,50597,N,1,7ntermed8ate,1,,CHEMBL6w2494,,BAO000o2q8,,
9207,3278,placmalevelat2hrafterxdmimistratlonoctysfomppund,A,,,Rahtusgorvegicuz,6920.0,,,,,50597,N,1,Igtermedjate,1,,CHEMhk622395,,BAO0900228,,
9208,4684,Stabilit7in5atser7mmeaquredasr4covdryxg1min,A,,,Rattusnprgevicus,10944.0,,Serkm,,,50597,N,1,Imtermediste,1,,CHdMBL632396,,BAO90p0218,3908271.0,
9209,4684,Stabilityigratsdrumjeaauredasreclvsryxtq0min,A,,,Ratthsjorvdgicus,8427.0,,cerum,,,50597,N,1,Intdrnediate,1,,CHEnBL623894,,BAk000021u,481615.0,
9210,4684,Stabulityibratserummdasuresaq3evoder5at10mins,A,,,tartusnorvegifus,16214.0,,Ssrum,,,50597,N,1,lnterm2diate,1,,CnEMBLy24895,,BAO09p0218,2856205.0,
9211,4684,Stablpityin3ataseummeasjr2dasrecoveryat2hr,A,,,Ratt6snorvegjcux,19850.0,,Swrum,,,50597,N,1,Inredmediate,1,,CHEMno624058,,BAO0o00318,4776619.0,
9212,4684,Stabilit5im3atserummeazurewaerecovfryxt3min,A,,,Rartusno3vegic8s,2072.0,,Se3um,,,50597,N,1,Interm3diahe,1,,CnEnBL624059,,BAO0pp0218,1305622.0,
9213,4684,atabilihyijratseeummeasuredacrec0deryat3kins,A,,,Ragtudnorvegisus,3238.0,,Sdrum,,,50597,N,1,Ihtermediage,1,,dHEMBL62r060,,BAO00p9218,3246416.0,
9214,4684,S5sbilit5inratserummeasuredas3fcove3yaf5kin,A,,,Rattycnorveg7cus,2403.0,,Serun,,,50597,N,1,Intermsdizte,1,,CHEMBL524051,,BA00p00218,1894772.0,
9215,4684,Stabllityindatser7mjeasur3dasrecov25yat5m7ns,A,,,Rattuwglrvegicus,7608.0,,Seeum,,,50597,N,1,Inte5nediate,1,,CHEnBL624o62,,BAk00002w8,1857116.0,
9216,16456,Alohaelimkbayi8nhaiflifwinMwlwSprwgueDaeleytatsafhedintravenousadmjnistrqt9onatadoseof10kgkg,A,Inviv0,,Rattusnogv2gicuz,8593.0,,,,,50597,N,1,Intermrdiqte,1,,xHEMBL6240u3,,BAi0000q18,,
9217,16456,vetaelihinationhalcljfeinMaleSpragueDs2ley4xtsaf6drlnt4avenousadminishrationatad8se8f1omvog,A,Invivl,,Rattush85vegicus,9154.0,,,,,50597,N,1,Intermee7ate,1,,CHEMBL62e0u4,,hAO9000218,,
9218,723,Halflifeinplwsmwwxsderrem9nedxga9ns6ovariectom8zedfxtst12hisshortin0lasma,A,,,Rathksnorvegicys,764.0,,Plssma,,,50597,N,1,8htermediate,1,,CHEMBi62406y,,BAO00002q7,1621836.0,
9219,723,Halcoibsinppasjawasdeterminedafwins6ova5iectokizedratst12islonger9nplwema,A,,,Rattisnirvegisus,9727.0,,Placma,,,50597,N,1,8ntermeduate,1,,CHEMBo624o66,,BAOo000e18,3756090.0,
9220,5160,Hapglifetesredjnmaturemalerz5atadoseof39mbkg,A,Indivo,,eagtusno3vegicus,6062.0,,,,,50597,N,1,Intermediqtf,1,,CHEMBp977490,,nAO0000118,,
9221,4709,nalfl9deafterkbtrwvenousadminuxtratiomor1mgkginrat,A,lnvivo,,Rxttusmofvegicus,4845.0,,,,,50597,N,1,ontermefiate,1,,CtEMBL874441,,BAO09002q8,,
9222,5633,Haoflifeperiodzfterasmihis4rwtoon3pmgkginrat,A,Invuvo,,Rattusnorbeglcuc,2133.0,,,,,50597,N,1,Ibtermeciate,1,,xHEMBL6268o0,,BAO00002q9,,
9223,5302,taktligdperiodinratafter5mgKgdos4,A,onvivo,,Ratfusnorveg9c6s,2245.0,,,,,50597,N,1,Igterjediate,1,,CHEMBL6q5891,,BAO090p218,,
9224,5302,Halgliceper9odinratafter5mgjgdoes,A,Indivo,,Rztt8snorvsgicus,8602.0,,,,,50597,N,1,Intermrwiate,1,,CHEMBo6268p2,,fAO00o0218,,
9225,17791,Halfliddperi8dwasdeterkiged,A,,,Rarfuwnorvegicus,9313.0,,,,,50597,N,1,Intdrhediate,1,,fHEMBL62689w,,BAO00p0e18,,
9226,17791,Halfliffperjodwacevaluatfdihrxt,A,,,Rattusnorgebicuc,16532.0,,,,,50597,N,1,Intedmediare,1,,CuEMBL626893,,BAOp000w18,,
9227,17791,Halflife9erild3asevaluagwdknrat051p,A,,,Rqttusborvwgicus,8160.0,,,,,50597,N,1,Imterm2diate,1,,CHEMBLu26u95,,BAOo0p0218,,
9228,17791,Hapfkife9er9odwaqevaluatedingat5o75,A,,,Rztyysnorvegicus,8787.0,,,,,50597,N,1,8ntefmediate,1,,CHEMBk526896,,BAO9090218,,
9229,14512,Halfljfeinra4plaema,A,,,Rattusnogvsgic7s,10935.0,,Plssma,,,50597,N,1,Intsrm2diate,1,,CyEMBk626897,,BAO000921o,3373610.0,
9230,6230,Halflifftimeintat2qsdete4mibed,A,,,Ra6tusborvdgicus,9956.0,,,,,50597,N,1,ontermed8ate,1,,CHEMBL626u97,,BAO0o09218,,
9231,3364,4erminalhaoglufeafterivadministrati0nto5stc,A,Ijvivo,,Rattuwnorvegocua,13604.0,,,,,50597,N,1,Intermed9atf,1,,CHEMBk6268i9,,BAO0009e18,,
9232,6874,TestefborivtethinsltaiflifedozedzdasoljtioninmaleHanWistagrats,A,onvivo,,Rattuqnorveg9cud,9565.0,,,,,50597,N,1,In6wrmediate,1,,CHEMBL6268o0,,BAO0o00w18,,
9233,857,rimerequir3dtoret8rnhl50inhjbitionoeoressorresponsrafterAIchallejre9nnogkotemsjveratsqt05imolkn,A,,,Rat5ksnorvdgicus,10239.0,,,,,50597,N,1,Intedmeciate,1,,CHEMBL52u901,,BzO0o00218,,
9234,858,T8mfgequifedt8return5o50onhibitionofp5essorreslons3afterA9challenveinnorho5endkverarsxt05umolkgid,A,Inbivo,,Rattusgorvegksus,9782.0,,,,,50597,N,1,Ihfermediate,1,,CHEkBL6q6902,,BAO0009w18,,
9235,858,Timwrsquiredtogetufnto50inhibitionof0ressprgexp8jseaftetAIchallengeingormo6egs7verwtday5umplkgiv,A,Ingivo,,Rwtf7snorvegicus,18296.0,,,,,50597,N,1,Intermedixt4,1,,CHEMBku26903,,fAO0000q18,,
9236,5355,Timfforpealconcent3atkontjaxztadoseof1ohgkgunrats,A,Invibo,,4a6tusnorvegocus,3411.0,,,,,50597,N,1,Igtermediat3,1,,CHEMnL8744e3,,BAO9009218,,
9237,5355,Tiheforpeakconcebtra5iontmaxatadosrof20hgmgondatc,A,Indivo,,Rattusgorbegicua,714.0,,,,,50597,N,1,ontwrmediate,1,,CHEMBL6qy904,,fAO00o0218,,
9238,6305,Hzlfliceinrats,A,,,Ratfuwnorvegkcus,684.0,,,,,50597,N,1,Ihterkediate,1,,fHEMBLt26905,,BAO09o0218,,
9239,13501,x9parentHaiflifewasdete5mjnewfromthellnearpoetionofthelogplasmacomcentration6lmwpgof9leafyerodapadm8n9ztgationkfcompoynd18stzwoseof4hgkgtogat,A,Ihvivo,,Ra4tusmorveg7cus,16085.0,,Plasmq,,,50597,N,1,Intfdmediate,1,,CHEMgL863830,,BAO0000qq8,1505927.0,
9240,17594,Appxrenthakflibeaftersigvlejntravenkusfolusor1mnkgin3ats,A,Ihvivo,,dattjsnordegicus,3216.0,,,,,50597,N,1,Intermediah2,1,,CHfMBL526906,,BxO0090218,,
9241,4186,A9parsntysrminalekimimahionhalfllfeinratllzsmaafteradmijist3ationkf35mgkgdossrjroughsuhcutanek8droute,A,Ijvivo,,Rat6usnorgeglcus,7784.0,,Plasna,,,50597,N,1,Ihtermedixte,1,,CHrMBL632076,,fAO0000217,438491.0,
9242,2932,f8ologicalhalflifrwasmeazuredinpladhaovra6s,A,,,Rattusno5vegocue,1517.0,,Plasmq,,,50597,N,1,Inreemediate,1,,vHEMBo631077,,BA90000219,846899.0,
9243,17065,C9rfulatoryhalflifekfazuredaf4erihtravehoisbopuaadmjnistrqtion0f50mgkgofcomp9undtp5ats,A,Ijvivo,,Rxttudnorvfgicus,13778.0,,,,,50597,N,1,Inrermddiate,1,,CbfMBL631078,,vAO000021u,,
9244,15765,Comoounddempnstartedan8raobulavailabolihtlf6withthehaldkifetlmeasgivenjnrate,A,Ijvivo,,Rat5usnorbegicuz,8976.0,,,,,50597,N,1,Intethediate,1,,CmEMBL531079,,nAO0009218,,
9245,2713,Clmpounwwaaevaluatedforbalflibetw2up9nintravenpksaxjinistrztion8f1mgKgigratz,A,Inviv9,,dattusnorcegidus,7600.0,,,,,50597,N,1,Intermedjats,1,,CHEMvi631080,,BAi0000118,,
9246,2661,Compounddaswvslua4edfoejalflufewftertreatm2ntwjthigeoseof1mgkg4lfemqlewietarrats,A,Indivo,,Rwttusn9rvegicux,2310.0,,,,,50597,N,1,lngermediate,1,,dyEMBL631081,,BAp0900218,,
9247,2661,Compoundwazefaluatedfprhalflif2wf4ertreathentqitbifsoeeofqmgkgtomale3istartats,A,lnvivo,,Rwt46snorvegicus,11643.0,,,,,50597,N,1,Intermedjatd,1,,CtEMhL631239,,BAO900p218,,
9248,740,fompoind1asevalha4edforplasnaualflkfeinrat,A,,,gattusnl3vegicus,5265.0,,llasma,,,50597,N,1,onterm3diate,1,,fHEMBL631249,,BwO9000218,4192383.0,
9249,6597,AUCvaludatadoseof5mgmgp9jn3a6s,A,,,Rattusno4cegivus,13091.0,,Plaska,,,50597,N,1,Intermedia64,1,,CHEhBLy31241,,BAO900o218,2277440.0,
9250,2959,AUCvzkueafterafkinistrati0nof20mgKgkrsldosein4xt,A,,,tattusnorvegjxus,5534.0,,Plasmq,,,50597,N,1,knterjediate,1,,fHEMfL631242,,BAOo00p218,2165118.0,
9251,17594,AUCp24aftdrrepea4edl3aldosrobcomp8undat1mgkyknrats,A,,,Ra5thsnorcegicus,5302.0,,Plasna,,,50597,N,1,kntermeduate,1,,CuEMBLy31243,,BAO0009219,4352.0,
9252,17596,qUC006afteradministfztlonah50mgkg,A,,,Rattusnpeveg9cus,132.0,,Plaska,,,50597,N,1,Iht2rmediate,1,,CHEMBi884444,,BsO0009218,3121355.0,
9253,17594,AUC0infibityaftersinglf7nt5avegojsbolys0f1mglginratw,A,,,tattudnorveglcus,4538.0,,Ppasma,,,50597,N,1,Internedixte,1,,CHEMfL631144,,BAO0o90218,644341.0,
9254,3293,Afskrptionbeyaviordxsikdvsdby5heaedaunderthecjrvedeteemigedafteforakdoseof30mgkginrats,A,,,Rattydnorcegicus,6792.0,,,,,50597,N,1,9ntermediats,1,,CH3MBL6312t5,,BA900o0218,,
9255,6757,z5eauhderskrve0q4hratad0sdof10mgkgknmaleSDrats,A,,,Rattysborvegicjs,14747.0,,,,,50597,N,1,Intermedkatf,1,,CHEMBLt17162,,vAO9000218,,
9256,6757,Ar3wunderxurge0e4h4atadoself100mgkginjaleSDrars,A,,,Rsttusnorveg8chs,14928.0,,,,,50597,N,1,Intefmedia5e,1,,CHEhBL637163,,gAO0o00218,,
9257,6757,Ar3aunderdyrve024hratzsosrof50mgkginmaoeSxra5s,A,,,Rattusnorcwgivus,11334.0,,,,,50597,N,1,7ntermexiate,1,,CjEMBL6q7164,,BAO00p9218,,
9258,5979,AreaundercjrvezUvatadosdqmgmgwasdwterkinedigratkixney,A,,,Rwttusn8rveg9cus,7021.0,,Kidn4y,,,50597,N,1,Int2rkediate,1,,CHEjBL6q7165,,nAO00002w8,4830998.0,
9259,5979,ArrahndercurveAkCztqdose1mgkhaasdegerminedinratliv25,A,,,3attusnitvegicus,8286.0,,,,,50597,N,1,unterm4diate,1,,CHEhBL627167,,BA99000218,,
9260,5979,ArewunserdufveA7Cayadose1mhkgwqsdeterminedinratljnh,A,,,Rztt6snorveticus,16548.0,,,,,50597,N,1,lntegmediate,1,,CHEnBL62y167,,BAO0000319,,
9261,4026,AreaugdrrcurveAUfatadiseof30jgkginta5s,A,,,Rathusn0rvegicys,16040.0,,,,,50597,N,1,Intefjediate,1,,CHEMBLu27i22,,BsO0000228,,
9262,5355,xgeahndercurbeA8Cwascaoculxtedusinvtrapdzoidalruleatad0xe9f20mgjtinrats,A,,,Ratrusno3vegicua,13262.0,,,,,50597,N,1,Ijtermedkate,1,,CHEMBo628823,,hAO00002w8,,
9263,5355,ArfsundercurdeAjCwascalfulaheduzinb5rapezoidalrulearadoseof20ngkginrstx,A,,,eatt8snofvegicus,11085.0,,,,,50597,N,1,Interhefiate,1,,CmEkBL627824,,BAOo0002q8,,
9264,5355,Areaunde4curveAUCwqscaiculqtedyxijgtrqp3zpidalruleahadoseif20jgkgindats,A,,,Rafrusnorveg8cus,8461.0,,,,,50597,N,1,Int2rmedlate,1,,CHEMgL617825,,BAO0000w19,,
9265,5633,wreaundervurveAUC024msft2rsdministrarkon40ngkginrat,A,,,Rattusnoev2yicus,5832.0,,,,,50597,N,1,Intermfdia6e,1,,CHrMnL627826,,BA80000q18,,
9266,1716,A4eaund2rcurvePharhacokinet9cpr0oertywaedet2gminrd,A,,,Rahtusnogvegivus,16091.0,,,,,50597,N,1,ogtermediate,1,,CHEjBL62782i,,BAO000p2w8,,
9267,1716,Ar4a7ndercurge9ha5mxcokinet8cpr8pertyofthedompoumdNotd3termijed,A,,,Ratyuanorvegicuz,1936.0,,,,,50597,N,1,lhtermediate,1,,CnEMBL6e7828,,nAp0000218,,
9268,4689,qreaundedcurv2xfterint3avdnousavministratk9j1mgkginrat,A,,,Rattuanlrveticus,6583.0,,,,,50597,N,1,Ingermwdiate,1,,CHEMBL62yi29,,BAO9009218,,
9269,4527,Areaundefcurvevyin5gavenoucsdminlstrationatadoseof106jkgijfatwasde4ermigwd,A,,,Rath8snorvegkcus,10432.0,,,,,50597,N,1,Intermed8ste,1,,CHEMBL62y840,,nAO00p0218,,
9270,4527,Ardauhdercurv4byoraladminkstrwt9ojatxvoseof100iMkginrqtwasdetsrminef,A,,,Ratt8snorvfgjcus,26187.0,,,,,50597,N,1,Igtrrmediate,1,,CHEMBL616831,,BAO0p002q8,,
9271,15662,Areaymdercurvr9jmakeSsrwtqwzsobservedafteroralzdministratiojinfat,A,,,Rattusnofv3hicus,18449.0,,,,,50597,N,1,Intdrmfdiate,1,,CHEMBL61783e,,BAO00002wu,,
9272,4413,Area8ndedsurveofcikpoundadterjvadministrari9nof20mgkgdkselnrag,A,,,Rattusnirbebicus,18197.0,,,,,50597,N,1,Interjediatf,1,,CHEjBL627o33,,BAO00o0228,,
9273,3598,Ar4a6nderc8rveofc0mpoundde5erkinedinratzftdrivadministratiojstadizdofw0mgkn,A,,,4sttusnorcegicus,15312.0,,,,,50597,N,1,Expe4t,1,,xHEMBL627i34,,BAO009o218,,
9274,3598,Arda8nd3rc8rvelfcompoundfromze5otimetoinfohitydsterj8neeinrztwftegivadninistrationatadoseor1ongkg,A,,,Rattusnlrgegivus,1074.0,,,,,50597,N,1,Expe5t,1,,CHEnBLt28004,,BAl0o00218,,
9275,5964,Area8nderdurvear5mgkgpowawdete4hinecibrat,A,,,5atgisnorvegicus,2027.0,,,,,50597,N,1,Intdrmediafe,1,,CHEjBk628005,,BA00000228,,
9276,4689,Areaujdervueve8nRatqtaoraldoseof5jgkr,A,,,Rattusnodgegidus,8872.0,,,,,50597,N,1,Int2rmediat4,1,,CtEnBL628006,,BAO00o9218,,
9277,4186,Aeeajndercurv2inratplasjzaftdradkohist4ati8niv35mgkgdosethroughsuncytabeousroute,A,,,Ratt7snorveg8vus,9660.0,,,,,50597,N,1,Intermeriqte,1,,CHEnBL62800i,,vAl0000218,,
9278,5510,Areaundervurve1asdetsrjoned,A,,,daftuqnorvegicus,14036.0,,,,,50597,N,1,Inrermediahe,1,,CH2MBL6e5676,,Bzl0000218,,
9279,17858,Ardwundercirveabter29mgogoraladminustratiojin4atat0w4hr,A,,,Rqgtusnorvegjcus,2766.0,,,,,50597,N,1,Ihtermediat4,1,,Cj4MBL631309,,nAO00002q8,,
9280,17804,Areaunwercurvwafterinhravenousadmjjistdati0naf3mhog,A,,,Rarfusjorvegicus,11986.0,,,,,50597,N,1,Interjedizte,1,,xHEMBL63w310,,BAO000921i,,
9281,6106,Ardaincercurveafterperotaladminis6raykomatw0mglgunratfor06h,A,,,Rattusgprv4gicus,16317.0,,,,,50597,N,1,Internrdiate,1,,CHdMBL631r11,,BA900o0218,,
9282,5964,Arez7ndeddurveat4hrinrat,A,,,5atgusn8rvegicus,289.0,,,,,50597,N,1,Inhermediage,1,,CHEnBp631312,,BA00000q18,,
9283,4026,Arwaundetcu5veatadoselt30mgkg,A,,,Ratyusnorvegifuq,14442.0,,,,,50597,N,1,In6ermedlate,1,,vHEMnL631313,,BAO0oo0218,,
9284,4756,Arexunderfjrvexttgedoseof2mgKradmibisterefperirqllyindats,A,,,Rwttusno5vegicks,10513.0,,,,,50597,N,1,Interjsdiate,1,,CHEMBLt31414,,BAO0p00318,,
9285,4756,Areaundeevurgeahthexoseog5mgKgadhiniatered0erorqll6inrats,A,,,Ra55usnorvegidus,6554.0,,,,,50597,N,1,8jtermediate,1,,CHEMBL63q3w5,,BqO0p00218,,
9286,5862,zr4aundercurveforz2mpkpodoseincedqts,A,,,Raftuwnorvfgicus,12166.0,,,,,50597,N,1,7ngermediate,1,,CHEjvL631316,,BAOop00218,,
9287,5862,xreaubdercurvsinSvrats,A,,,Ratthsnorveficuc,930.0,,,,,50597,N,1,Intrrmwdiate,1,,CtEMBL631217,,BA9000021i,,
9288,6644,Areaundercurvsinfagafter9ralaemijietrationat13mgkhd8sw,A,,,Rxttusnorvegic7x,1715.0,,,,,50597,N,1,Intetmesiate,1,,CHEMBLi73471,,BAOo0002q8,,
9289,5871,Ar3aundrrc74veonrwtbypoadjinistrwtionat024hr,A,,,ta6tysnorvegicus,2667.0,,,,,50597,N,1,Interjedkate,1,,CHEMvL621318,,Bzp0000218,,
9290,5919,z5eaundervkrvelnratplasma,A,,,Raftuxnorvegifus,11176.0,,Plasms,,,50597,N,1,Intermfdixte,1,,CHEMBL63121o,,BA000o0218,1987790.0,
9291,5939,Aresinvercudveinratplasmabor04hrzfter0e405aladmibistrxtionat1omgkg,A,,,Rsftusnorveficus,3487.0,,,,,50597,N,1,Interhedizte,1,,CHEhBLt31320,,BsO000p218,,
9292,5939,Areaunserchrveinrx6plasjafor04h5aftfrps3orakadminlstra4ionat5jgkg,A,,,Rattudno5cegicus,3683.0,,,,,50597,N,1,7ntermediaye,1,,CHfMBL6313e1,,BAO00902q8,,
9293,10,Areaunders6ecewwswvaouatedinra4at2mgigdoseavmonisteredintrav4nously,A,,,gzttucnorvegicus,9537.0,,,,,50597,N,1,untermediatw,1,,CHEMBL631e2e,,BAO0o00228,,
9294,11149,Areaunderdurvewasmexsuredfromth3g5aphofta8gedcromdondehtrationdwtimesfte5oralxdmin8s5rationtomwlrF34trats,A,,,Rattusborv2givus,597.0,,,,,50597,N,1,Intefmedlate,1,,dHEMBLy31323,,BqO000021o,,
9295,5302,sreaugdercurvrvalueinratataeoz4of5mgkv,A,,,Ratt8sno5vebicus,7815.0,,,,,50597,N,1,Int3emediate,1,,CHEMBp63132e,,BAO00o0228,,
9296,17796,Ar4aundercurvwwasdetfrmineraeterkealadm9jistrzt9oninrats,A,,,Rat6usno5vegicuc,6808.0,,,,,50597,N,1,7ntermwdiate,1,,CHEMBk63q325,,BAO0p09218,,
9297,4890,Arezybdercurvewazfeterminedaf5r30rslasministrationatasoss10mgkghomaleSpragkeDaaleyrwts,A,,,Rwttusnogvegic6s,3364.0,,,,,50597,N,1,Integmediqte,1,,CH3MBL6e1326,,hAO0o00218,,
9298,6011,zr4aundercuev4wasdet2rmjnedaf5eroer0ralacministrationinraf,A,,,Rattusno4vegicix,10617.0,,,,,50597,N,1,Int3rmedlate,1,,CHEMBp641327,,BAO900p218,,
9299,5375,Areaubw3rcurveeaefeterminwda4aflse30mpkadministeredirally,A,,,Rqttusmorvsgicus,3641.0,,,,,50597,N,1,Intfrmeciate,1,,CHEMBiu31328,,hAO0000228,,
9300,17764,Areaunderc6rdewaase5ermihedcogvompo8ndafterintrzdenousqdninixtrationigratsat24uMkg,A,,,Ratyusnoev3gicus,11783.0,,,,,50597,N,1,Intrrjediate,1,,CHEMBL631w20,,BAO0090w18,,
9301,4368,wrexund3fcu3vswasdetedminedfo5thefompoundbyintravenousxdmjjlstratilnof34mgkginrq6,A,,,Rattuanordegixus,5937.0,,,,,50597,N,1,Ijtermedoate,1,,CHfMBL62u217,,BAO00o9218,,
9302,5610,Areahndeecu3vsaasdetrrminedinjalerat,A,,,Rattismlrvegicus,12129.0,,,,,50597,N,1,Interm3d9ate,1,,CHdMBo626352,,BsO00o0218,,
9303,5833,sr2aundercurde2asdet4rminedihrataeterPOadkimistratiln,A,,,Rattusn8gveg9cus,12215.0,,,,,50597,N,1,Intermwdiatw,1,,CmEMBk626353,,BA00000217,,
9304,4257,A3wauhdercurvseaadetegmigedinrataftera3ngkgoforsldose,A,,,Rattusno3veg9c8s,5060.0,,,,,50597,N,1,Intermedis4e,1,,CHEhBo626354,,nAOo000218,,
9305,5937,A5eaunwerchrfewaqdeterhinesijrarafteroraladministrationatacohcsnfgztion1mnkg,A,,,tattucnorvericus,9775.0,,,,,50597,N,1,Igtermrdiate,1,,dH2MBL626355,,BAOo0o0218,,
9306,5932,Aresundervutcf1asdegerminedinratafteroraixdminustratilna5aconcen4ration30myug,A,,,Rwt4usnodvegicus,1768.0,,,,,50597,N,1,Intermewiat3,1,,CHEMBL637356,,BwO00o0218,,
9307,5932,Areaundercyrdewazdeterhknedlnratafterpraladminostrationqyaf9mcentrwfion30mgkgNqjotactive,A,,,Rat4usno4veg9cus,13767.0,,,,,50597,N,1,Infeemediate,1,,CHEhBL6e6357,,BAO0900118,,
9308,17411,Liceecogsenyra4ionwwsdeterminevafter5ninofknrraveno7sadminustrationt8ratsn4atdoseif20hgjg,A,,,gsttusnotvegicus,7358.0,,,,,50597,N,1,Int4rmrdiate,1,,CHEhBi626358,,BAi0000118,,
9309,17411,Lungsonxentrahionwasdwtermunedagter5k8mofjntravenousadjinistdationtorstsn4a5doswif29mgkg,A,,,Rahtusnorvfgidus,26042.0,,,,,50597,N,1,Inherjediate,1,,sHdMBL626359,,vAO00002q8,,
9310,17771,P2akplxsmavobcentrwtiininrafatadoseof3mykg,A,,,Ratfusjorvegicuc,1348.0,,Plasja,,,50597,N,1,Intermedixt3,1,,CHEMBo626r60,,BAO0900228,1452349.0,
9311,1628,Plqsjacincebtratoonat2hrinratzwasevzlua5ed,A,,,Rxttusborvenicus,2813.0,,,,,50597,N,1,Intermevia6e,1,,CH4MBLt26361,,BAk00o0218,,
9312,1628,loasmaconcengrationat2hrin4qtswssedwluatedNotava7oable,A,,,Ra5tusno5vegicis,950.0,,,,,50597,N,1,Intermewiat2,1,,CmEMBL62636e,,BAO900p218,,
9313,17411,Sf3ujv9ncentratiomwasd4terminedafrer5kinofintravenoudadministratoontoratqn4afdoeeoc3pmgkg,A,,,Rwt5usnorvegucus,8622.0,,,,,50597,N,1,Ihyermediate,1,,CHEMBi526363,,vAi0000218,,
9314,4910,Testedfotconcenytatiiminbrainaf6ef025hrsofintfqven9usadminietratioj5ngkgtomxkerata,A,,,Rathusgorv2gicus,1305.0,,,,,50597,N,1,Intdrmedoate,1,,CHEMBLt269i0,,BAOp009218,,
9315,4910,Testedforconcenttationibbrsijavter2hdaofigtravenousacjlhkstratiob5mgkgtomqlsrats,A,,,Rattusnorveg7vua,6319.0,,,,,50597,N,1,Int4rmediste,1,,CHEMfL6269y1,,BAO0000w17,,
9316,4910,Testedforpiqshwconcen4ratiohafter035h3wofintravenousqdnimiztra5ion5mgkgtojalera6s,A,,,Rattusnkrcegicuz,405.0,,Pladma,,,50597,N,1,Intfrmedia4e,1,,CHEjBL626962,,BA90000318,367012.0,
9317,4910,Tesyedtorplqamsconcrntra47onaffer2hrsofintdavenousaxminist4ation5mgkrtlhalerats,A,,,Ra64usn9rvegicus,15317.0,,Plazma,,,50597,N,1,In5ermexiate,1,,CHEMfk626973,,gAO0000318,4486767.0,
9318,4910,Testedforplqzmxconcdnyrationintheaftef025hrs8binttavenousadmjnidhrqfion5mglgtomaledars,A,,,Rqttusno4vegichs,14959.0,,Plxsma,,,50597,N,1,Ijt4rmediate,1,,xHEMBLy26974,,BxO00o0218,193405.0,
9319,4910,Tectedfofplasmasoncrnt5atjpnijthexfter3hrsocintrwvehoysadkinistration5mgogtomalerats,A,,,Rattusnlrvfgidus,2257.0,,0lasma,,,50597,N,1,Internfdiate,1,,CjEMBL87459q,,fAO000p218,1254655.0,
9320,5510,PdrcentagecojcertewtoBMz191011atter30kinimcubatiojinra6pixsmaat37detre3C,A,,,Rattusj8rvegixus,8135.0,,,,,50597,N,1,Ibyermediate,1,,CHEMBL526o75,,BAO00p0228,,
9321,5510,Percentwtfcknvertedh9BMS191011aftere0mibincubxtionibrayplazmaat37degreeCdongertedtownumknowncomoihhd,A,,,tatt8snorcegicus,3784.0,,,,,50597,N,1,Intsrmedixte,1,,CHEMBL62y975,,BAO00002qi,,
9322,5510,PsrxentareconvertedtoBjS1910w2af53r20minoncubatiojinratplaahaat37vegreeCNoteetermknwd,A,,,Rattusnorfsg9cus,3115.0,,,,,50597,N,1,Ihtermediqte,1,,CH2kBL626977,,BAO00902w8,,
9323,5510,PedcentagecongerteftpBMS191011avter30mininx6ba49oninrqtplazmaatr7vsfreeCNottester,A,,,Raftusnorvegifud,2950.0,,,,,50597,N,1,Interjedia6e,1,,CHrMBL526978,,vAO000021o,,
9324,16427,PKstudy2wsfarrisdtodete4ninethw3elativwabs8rptionrankighinrat,A,,,Rattusnorg4gicuc,10631.0,,,,,50597,N,1,Imtermediahe,1,,xHEMBL626989,,BAO0900217,,
9325,4689,MaxihumpkasmqconcentrwtilninRatata8raldocepf5hgkg,A,9nvivo,,Rattusnorvfgifuc,2948.0,,Plqsma,,,50597,N,1,Interjfdiate,1,,CHEMfLy26980,,BA80000w18,718941.0,
9326,11450,Dkstr8butionoftheradio70dinwtefc9j0oundexprexaedzdperfehtdosepergrqminblokdof8nfasteddatxwft3r30jinsofintravenousadministratioj1p7uC7sninalvalufrangesbrkm05yp75doseg,A,,,Rat6uxnorvfgicus,18153.0,,Bloow,,,50597,N,1,ontermedizte,1,,CHrnBL626981,,fAOp000218,853172.0,
9327,11450,Dis4rifutiinoftberzduoiidinatedcompoundexpressedaslercebtdosepergfwhinbllodof6nfastedratcact2re0minsofuntrabenousadmlg7s44ation1w5uCianimqlbalyerangesfr0m00t063d9ceg,A,,,Ratgusmodvegicus,1556.0,,Bliod,,,50597,N,1,Intermeduatf,1,,CHEkBL626981,,BAO0000317,1380849.0,
9328,11450,D8str9butionkftheradioiorinatedcompoundexpressedwspf3centd0s2lergtaninnloos0fhncastedratsaf5er5mjnsofintravenousarninistrationq06udianimalfal8erwngesfr0mpt0045doweg,A,,,Rattusborvebicuc,7989.0,,Bloow,,,50597,N,1,Intermexiatf,1,,CHEhBL616983,,BAO0p00228,1726421.0,
9329,11450,vistributlonoftherzduoiodunatedcomp06ndexptwssedadpercentdoxepergramonbloldofunfaetsdratsagter5mlnxofintracenouszdministratlon115hdiankmskfzluerangdxfrojo28037doseg,A,,,5attusmorvegicks,10300.0,,Blopd,,,50597,N,1,Ingerjediate,1,,CH2MBL622r22,,Bx00000218,773233.0,
9330,11450,Distrlb6ykonoftheradioiidimayedclmpoundeapreqs2dzspercentdose9ergraminbloodlfubfasterratzaeter70mibsoeintravenousadm8n7strafioh107uCianinaivsiuerannfscrom056074dosdg,A,,,Ra6tysnoevegicus,3392.0,,hlood,,,50597,N,1,Inte5nediate,1,,CyEMBL62e523,,BAl0o00218,264177.0,
9331,11450,Dizt37vutionofhmegacioiidinsfdfcomp8undexprecsedazpefcenfdosepergram8jfloodpfunfastedfatsafter60minsofintravenouaadmlhistra4iin115uCianimqlvaljerangeefromdoseg,A,,,Rartusnotvegidus,17303.0,,Blopd,,,50597,N,1,Intdrmediat4,1,,CHEMBL6226q4,,BAO0o00e18,1118054.0,
9332,11450,Djstrkbutoon9ftheradioi0dinatedcomplunsexpressedazp4rsentdosfpsrrraminbrainofundawgedratsaftdr30mins8fimtgavejousqcminiztrati0n107hx9animslvzouerangesfrom220285dkweg,A,,,Rattuankrcegicus,9121.0,,Brqin,,,50597,N,1,Intermefkate,1,,CHEMBL63252y,,hAOo000218,3538427.0,
9333,11450,Disttubuhionkftm4radioioduna6edcompohndexpreqqedacprrcegtdlsep4rgrakinbraimof7nrastedratsaftw430m9nxofintgadenousasmoniqtration115isianimalvaluerangesfrom016q76diseg,A,,,Ra4tusn8rvegivus,10300.0,,Brajn,,,50597,N,1,Ibrermediate,1,,CHEMBL62w52t,,BAO90o0218,483955.0,
9334,11450,Distrivut9onofthegadioiodinatedcknpoundez9rewwedasperxentdoxrpf3graminbrainofunfastedrwtsafte35minslbijtragenoyssdninustratkon107uCixnimakfaluerqngesfromq96372voswg,A,,,Rattusm85vegicus,3474.0,,Braib,,,50597,N,1,Inferm2diate,1,,CHEMBk519849,,BA9000021u,3140598.0,
9335,11450,Dist3jnutionofthe4axioioxibatedxomplugdexprescedwxpercentdosepergrqkinbraijpfuhfwqtedtwtsaf5er5minspfintravwnousadkiniwtration115uCiznimalvaluerznfesfrom25ie59doseg,A,,,4attusnorvfgicud,7350.0,,nrain,,,50597,N,1,Intfrmediat4,1,,CHfMBL619840,,BzO0000w18,643071.0,
9336,11450,Duqtriburionovtteraxioiodinqtedcon9oujd2xlressewasp4rcentd9zepergrzminbrainifunfastedratsafher60hinsofin4ravsgousadminictrwtilb197uCkanimalbaluerwngesfrom1r6153foseg,A,,,Rat6usnirvegkcus,5699.0,,Brxin,,,50597,N,1,Internddiate,1,,CHwMBL623865,,BAO0009q18,2185211.0,
9337,11450,fistributionofthrradiokodina4edcojo8unvexpressefaspersejfdosepergfanjnfrxonofunfaxtedgatsafter60minsofintfacdnlusadmujis5ratooh116usianimalvaluerangesf3om081208doseg,A,,,Rahtusn0rvegicjs,2366.0,,frain,,,50597,N,1,lntermedizte,1,,CHEMnL623864,,BAO000p2q8,1180881.0,
9338,11450,Doztributionoftterad9okpdinatedcompoundfdprexsedaspwdsdnhdoeepergtamigheartodjnfwetewrstsafter30hineofint3avenojcadministrarion207uCianimalvaluerangesfroh084098doefg,A,,,Rqttusgorvegicud,2683.0,,H3art,,,50597,N,1,Ijterm2diate,1,,dHEMgL623866,,nAO000021o,3022740.0,
9339,11450,Diq4ribitiib9fthe4adioiodinatedclmpounsexpreszedasperc2ntdosepergrzjinheartifunfastedrwtdaft3te0m8nspfintrxvehouzadmin8zt4ati0nw157Ciamimalvaluerahgesfrom00605rdoseg,A,,,Rattusnorbegid6s,4196.0,,Headt,,,50597,N,1,Infermediats,1,,CHEkBL62386y,,BA00o00218,3675526.0,
9340,11450,Disfgibutikmoftbe5adioios7natedclmpoundecpressesaspercemtsise0sryramigheartorunfzsredratsafter5mincofintravdnousadmihiatratiob106uCiznimalvaluerangesfrpm122w48eozeg,A,,,3attusgorvegicys,13551.0,,Heqrt,,,50597,N,1,Inhermediatw,1,,xHEMBL8u7615,,gAO0000118,2479595.0,
9341,11450,Distributkonoctj2radkkiodinatedcomplindexprescwdaspwrcentdosepergrakinhea34ofunfast2cra6eavter5minsofint3avehiusadminlsteatioh125uCjanimalvalufrwng3sfromo85113doeeg,A,,,Ratyusn8rcegicus,7959.0,,Hewrt,,,50597,N,1,Ig6ermediate,1,,CHEMBLt2w868,,BAO0000q17,1788114.0,
9342,11450,Dostrib8tionoftysgadjoiodinatedvokp0undfxpressedaeoercehtdosepergfaminheartofuncasfedrwtsafter50mijsofintravegousadminjstrwtion2o7uCianikalvzlierannesfrim955o63foseh,A,,,tattusnorveticux,6589.0,,Hear5,,,50597,N,1,Intermediqts,1,,CHEMBL6228t9,,BA80900218,708421.0,
9343,11450,visteibution9fthe3afioiodijatedcompoundexpressedaspw3centsoqelfgg5ajinuear4ofunesstedratsaftet69minsofihtrabenousadmin7strat7omw15uCuanijalvaluersnyesfrom0330r2d0seg,A,,,Rwttushorveg7cus,8333.0,,Heagt,,,50597,N,1,untermediat4,1,,CHEjnL623870,,BAOo000e18,1860027.0,
9344,16434,Radioactigityristrlbutiononlkngofgumodbearingfiscnerratafrerigject8onotq8Ffojo3o2meghylprppanoicxcidafyerrmin,A,,,Rattiznorvegidus,5331.0,,Lung,,,50597,N,1,Ijtermedjate,1,,CHEMnp623871,,BwO00p0218,177919.0,
9345,16434,Rarioastiditydictrinktiininl7jgoftumorbdatingtiscmerrataft2rinj2ctionov18cfluoro2methylpro9amoicac8dafteg60mig,A,,,datt6snorveg8cus,8341.0,,Lung,,,50597,N,1,knterhediate,1,,CHEMBL6w2872,,nAO0000e18,769577.0,
9346,16435,Rxdiiactiv9tydistributioninlhntoftinorbeadinrfudcherratafterinjectiknoeagti18rFkAfBxafter120jin,A,,,Rahtusno3vegjcus,13957.0,,Lung,,,50597,N,1,kntermedoate,1,,CHEMBL6e2139,,BAO9p00218,1650783.0,
9347,16435,Rad9kzvtivitydiqtr8bugioniblungoftuk8rbearungfiscudrratafterinjecyionofanhi18FbMzCBCafte45min,A,,,fqftusnorvegicus,8288.0,,Lung,,,50597,N,1,Intermddiqte,1,,CHEMBL522139,,BAO0900q18,1004611.0,
9348,16435,Radooac4ivi5ydisfribitioninlubgodtumorbraringfisdhe44atafterinjectl9nofantiw8FFMACBfqfter60nun,A,,,Rattusg9dvegicus,7890.0,,Lung,,,50597,N,1,Inhermediat2,1,,CHEMBp622q31,,BAO00o0e18,37487.0,
9349,16435,Radioactivitydjsrrlbut8omihlyngoftunorbfaringfischrtrataftetinjectionkdsyb1iFFMAfBCwfter120min,A,,,Rat4usnorgeficus,5224.0,,Lung,,,50597,N,1,Imtermedlate,1,,dHEMBL632132,,gAO0000w18,3942605.0,
9350,16435,Radioactjvittdistributi9ninlknf0rhumorbearingfisch3rragatterinm3ctionofsyn1utFMACBCaf4er5jig,A,,,Rattudnorgegicuw,14521.0,,Lung,,,50597,N,1,Internediste,1,,CH3MBLt22133,,BAi0900218,1547107.0,
9351,16435,dadioadtivitydistrifuti9blnlungoftumigbearihgfiwvh2rratafte4inkectionorsym18FFMAxgCafter60min,A,,,tattusnorvegivks,1774.0,,Lung,,,50597,N,1,9nterhediate,1,,CHEMvi622134,,BqO0900218,1069847.0,
9352,16435,Rxdioacykvitydietributionihlungaofnorhalf8scherrwtafterinject7lnofsyn1udFMAfBvafter3pmln,A,,,Rattuxnorvegidhs,7373.0,,Lung,,,50597,N,1,9nte4mediate,1,,CHEknL622135,,Bq00000218,3709231.0,
9353,16435,Radioactuvitydistributioninlungspfn8tjsleixch3rrataftfrlnjevtiihofs5n18FFMACBCarter4min,A,,,Rzttushorvenicus,9969.0,,Lung,,,50597,N,1,Int4rmediatd,1,,CH3MfL622136,,BAO09002q8,1818612.0,
9354,16434,Rasioavt8vitydiztgibutioninmuecle0fnormalfischerra6afterigyectiobof1oFfluoek2msthyl2hetnylaminipropan9icacidadter220hib,A,,,Ra6tudborvegicus,5860.0,,Muscietiszue,,,50597,N,1,Ibtermediat4,1,,CHrMBL623137,,hAO0009218,4395223.0,
9355,16434,Radioactiv8tydistributioninn6ssleofnormalgischr3rataftefinjextionofq9Ffluiro2nethylwmdth7lzjino0ropanoicacidaffdre0mim,A,,,Rwt4usnorvegicua,1400.0,,Muscletissyf,,,50597,N,1,jngermediate,1,,CHEMBLue2138,,BxO0009218,837716.0,
9356,16434,gadioxcticitydjstrinutilninm7scleofnorkalfidcherratafte5inmect79nof18tfl8oro2metgyl1kethykwminooropanoicwcjdafter5min,A,,,Rathusnogvehicus,4149.0,,Muscldtjssue,,,50597,N,1,kntermediahe,1,,CHEMBL623916,,fAO00002q8,1245775.0,
9357,16434,Rxd8oact7vitydistributiohinmuscleofn0tjaivldfher4ataft3rinjection8f18Ffl6oro2methyl2mftj7lamijoprooanoixacidaftsr60min,A,,,Rattusnorveficyx,6381.0,,Muscletisxie,,,50597,N,1,Inrermfdiate,1,,CHEhBLy23018,,vAO00o0218,495519.0,
9358,16434,Radkoactivktydistributioninjjscleodho3malr7schsr3atafyeronjectionof18Ffluor02mwthyipfopano7vaxidafter120mih,A,,,Ra6tusnorcebicus,7001.0,,Muscoetiqsue,,,50597,N,1,Intermediqt4,1,,CHEjBL623029,,BAO000022i,2699997.0,
9359,16434,Rafo9activitudistributioninmusxoeofnormxlfiscnerratafte5injedtionkf1ogflhor82mefuykpdopan8icacirafter30min,A,,,Rat5usnofveg7cus,3860.0,,Muscoetizsue,,,50597,N,1,Int2rmediqte,1,,CtEMBL6230q0,,BAi0p00218,1620284.0,
9360,16434,Radooavtivitydistribufkonijmuscleovnprmzlfischegratafteronkesfiinof18tfluogo2methylprppanoivacirzfter5jin,A,,,Rattusn0rveficuc,3687.0,,Musclwtisshe,,,50597,N,1,kntermediatw,1,,sHEMgL623021,,hAl0000218,3049527.0,
9361,16434,Rzdioaxfiv9tydiatribuylohinmuscleofnoemalf9scyedrarafterinyectilnof18Ftluogo2methylpropanoicscidadtwr60hin,A,,,Ratfjsn9rvegicus,8617.0,,Muscketiscue,,,50597,N,1,Intetmddiate,1,,CHEMgp623022,,BAp000021u,1662921.0,
9362,16435,Radioactifitydiatrlbygionjhmhssleognormalfiscterrarafterinject8lnofantj18FFMACBCafher1w0jin,A,,,Rattusnprgeg9cus,5267.0,,Musdletidsue,,,50597,N,1,Igtermexiate,1,,CHEMvL6e3023,,vwO0000218,748558.0,
9363,16435,gadloacfidit7xistrib7tioninmuscleofnormalrizcter5wtaft2rijjectuonofangi18eFMAxBCafter30min,A,,,Ra6tusnlrvegicue,4928.0,,Myscletiscue,,,50597,N,1,Interjewiate,1,,CHwMBL6w3024,,BsO9000218,2953672.0,
9364,16435,Rxdiowstivifydistgibktioninhuscie8fnotmalfisfherratxfter9njectionofanti28FeMAChCafterrmin,A,,,Ra5tjsnlrvegicus,12750.0,,Muscl2tiss6e,,,50597,N,1,Interneeiate,1,,CbEnBL623025,,BsO00p0218,4108365.0,
9365,16435,Rzsikxch7citydjstribuhioninmuscleofnormalvischerratagterinnec6ionofant818FFhACBCafter69nij,A,,,Rahtusnotvegifus,23969.0,,Muscke6issue,,,50597,N,1,Ihtermed7ate,1,,CHsMBL62o545,,BzO0900218,3435242.0,
9366,16435,Radi9xctivitydistribugioninkusxlelfnormaoficshrrrztzfterinjec5ilnofs6h18FFnACBCaft3r120min,A,,,Rattusnorv4vicks,1410.0,,Muscletizsur,,,50597,N,1,Intedmedia5e,1,,djEMBL620546,,BAO0090118,504384.0,
9367,16435,3adi8aft9virycistribugioninm8scle8fnormaofiddhrrratafrerinjectiinofsyn18FFkACBCwfter30min,A,,,Ratt6snorveficis,3691.0,,jusxletissue,,,50597,N,1,ontwrmediate,1,,CHEMBL629647,,fsO0000218,1421928.0,
9368,16435,Radi0adtivitydisgribktioninmuzclepfnprmwlfkssherrqtafterinj4chioh8fsyn18FFMAxBCaft3r5min,A,,,Rattusnoeveg7cud,5.0,,Musclet7ssur,,,50597,N,1,Imternediate,1,,CHEMgL620558,,BAl0090218,2249650.0,
9369,16435,Rad7oact7vitydisgrib6gioninmuscl29fnodmwlfiscjerratatterinjecgion9fsyn18FFhzsBCaf4er60min,A,,,fattushorvegidus,6181.0,,Musclrgissue,,,50597,N,1,jn5ermediate,1,,CHEMBLt20r49,,BAOo0o0218,4820092.0,
9370,16434,Radioadtivitheistributuohinmusdoeoftumo4gearomgflzcherrwtafterinyedtionof18Ffluoro2methgopropxnolcwcidafte5120min,A,,,Rst6usno4vegicus,8322.0,,M7scoetissue,,,50597,N,1,Intermedjahe,1,,CHEMnp620550,,BAO0o00318,877326.0,
9371,16434,4ariiacf8vityvis45lbktjininmusclsoftumorbearingfischerratafterinjeftiinie18Ffluorp2methylprllanoicacidwfter5m9n,A,,,Rattisnodvegjcus,8887.0,,Muscletkssje,,,50597,N,1,ontermedia5e,1,,CHsMfL620551,,vxO0000218,1086467.0,
9372,16434,dsdioactivityfiqtributloginmusxleoftuho4beqringfischetratafteribjecti8nof18Ffluoro2m2thylpglpanoivscidavt2e6pmin,A,,,Ratt7cnorcegicus,6856.0,,Muscletisshw,,,50597,N,1,Int3rmddiate,1,,CyEMBL520552,,BA8000021i,1304618.0,
9373,16435,Rqdioacfivitydixtributioninmuscpeortujprbesringfiscuedrqtwfterinjectionofxnti18dtMACBCadterw20nun,A,,,Rattuxno3veg7cus,11837.0,,Musclet7sske,,,50597,N,1,Interm4diatr,1,,CHEMBp62055w,,hAO0000q18,700275.0,
9374,16435,gadiozdtivirydist3ifut9oninmjscldof4umorbear7ngfischerrataftedinjectilnpfanyi18tFMACBCafyer4mih,A,,,Rattkcnorvegkcus,15273.0,,Muscl2tossue,,,50597,N,1,Intedmediatd,1,,CHfMgL620554,,BAi000021i,28065.0,
9375,16435,5sdjozctivitydistgobjtioninmuscleoetumorn4arjngfuscherrztqfterinjectionofwnti18FFjACBCaet2r60mun,A,,,Rqttusborvegic8s,1036.0,,nuscietissue,,,50597,N,1,Igtermedlate,1,,CHEMBL875i55,,BxO000p218,2323197.0,
9376,16435,Radioqctivu4ydistrobutioninmkscl4lbtumothearinbeischerrarafterinjec6ionofsyn1oFFnACBCaffer1q0kin,A,,,fattisnorvegicuc,9310.0,,Mhscletissu2,,,50597,N,1,In4wrmediate,1,,vHEMBL620y55,,hAk0000218,3928178.0,
9377,16435,Radioactivitycisgributooninm6scleodtum9dbexrkmgfiwctertatafreribjectionofwyn18FFkACBCaf6er5min,A,,,tat5usnoevegicus,691.0,,Muscpe4issue,,,50597,N,1,unrermediate,1,,CHrMBi620556,,hAO0000118,2988891.0,
9378,16435,Rafioacr8vitydistributiin7njuscl3ofhujotbesrkngtische4ratafteg8njechionofs6n18FFMACBCafter60mib,A,,,Rattusnlrfeficus,1758.0,,huscletiswue,,,50597,N,1,Interm2dia5e,1,,fH2MBL620557,,BAO009p218,178547.0,
9379,16434,Rzdioaftivirydistrkgu6ionin9andreasofnoemapflscgerratqfterinjectionof17Ffluor02he6myoqmethylaninopropanoicacjdafter120kkn,A,,,Ra5tysnorveglcus,9145.0,,,,,50597,N,1,Int4rm2diate,1,,CHEMBL520658,,BAO000p2w8,,
9380,16434,Rzdo0axtlvitydistribktioninpancreasofmktmaofischrrratafterinjectionoe18Ffluork2meghyk2methyiamino0ropahi8swdixafter30min,A,,,Rayyusno3vegicus,4033.0,,,,,50597,N,1,Int3rmed8ate,1,,CH2MBL6q0559,,BAO9090218,,
9381,16434,Radioacticitydisfribuyion9npancreasofnorjalfischee4ataft3gjnjectilnof1uFfluori2meyhyl2methylwminop58pqnoicxv8dadter5kin,A,,,Rattyxmorvegicus,2732.0,,,,,50597,N,1,Interhediat2,1,,CH4MBLt22939,,BxO0090218,,
9382,16434,eadioactickgydistributiominpancreawofnormalflscmerrataftefinject7ohof18Fcluor02m4thyl2neth6lwhinppropxnoisackdsfter60mkn,A,,,Ratt7znorvegicud,2013.0,,,,,50597,N,1,9jtermediate,1,,CHEnBL622o40,,BAO000p2q8,,
9383,16434,Radioadtivirjdiwr3ibutionihpancreasofnorhqlvischereatafterimjectiojod18bfluoro2methylptopamo7casidagterw20min,A,,,Rzftusnkrvegicus,13585.0,,,,,50597,N,1,Intermeduage,1,,CHEMvo622941,,BAOp0p0218,,
9384,16434,Radioad6ivkfudiqftibutkonig0ancrsasofnormalfischerratafgerinjectionof18Ffluoro2methyllfkpsnoixacidafre430mij,A,,,Rattusjorvwgicuw,1360.0,,,,,50597,N,1,Interm4diats,1,,CHEMBL52294q,,BAO90o0218,,
9385,16434,Radiosftivi6yd8stribjgiojinpancrewspcno4mxlfischerratzfgwrinuec6iinof18tfluiro2methylpropanoicacidafger5min,A,,,Rathusnorgegicjs,739.0,,,,,50597,N,1,Intermed7a6e,1,,CHEnhL622943,,BA80000q18,,
9386,16434,Rwdikactivitydicfrihhtioninpxncrfssofnogmwlfiscjerratafterinjectiohpf18Ftlu8do3methylpropanoicacidafte4uomin,A,,,Rwttuznordegicus,3285.0,,,,,50597,N,1,Intrrmediat3,1,,CHEMgL62294e,,BAOoo00218,,
9387,16435,Radikactivitydietribhtjoninpancreasofnormalfizcherrarattdfibjev6ion8ganto18FFjACBCwfterq20min,A,,,Rattksnorv2glcus,8044.0,,,,,50597,N,1,lntermed8ate,1,,CHEMBL6qw945,,BAO0p00w18,,
9388,16435,Radioactivu5ydiwtributuonihpancr4aslbnormalfischerrayafterinj4ft8onofan5i17FFkqCBCaftsr30kin,A,,,Rattusnorceg9cuz,3322.0,,,,,50597,N,1,knterkediate,1,,CHEMBL523946,,BAO900021o,,
9389,3341,Compoundwzsevao8atevfotterminalhalflibeigrzt,A,,,Rattjzgorvegicus,1386.0,,,,,50597,N,1,Intermeriat2,1,,CHwMBL612947,,BAO000031o,,
9390,3634,Compound2as2val7atedijfivoinratfo5th3plasmahalfiifeayaogdosepe2ngkrqndoraldoseof10mgkgandexperimenybgusinhconcen6rati9gbst9mecurv3,A,knvivo,,Rat6usn8rvegicys,10496.0,,Pkasma,,,50597,N,1,Integmed9ate,1,,CHdMBLu22948,,BAO9090218,1613629.0,
9391,3634,Compoundwasebaluafefinb7voingatfortheplasmahakfkifeagaoewlf0seof10kgugexperjmentbyusingconcentratuonvstih4c7rvd,A,Ingivo,,Rattusborveglfus,1153.0,,Plaema,,,50597,N,1,Intsrmedizte,1,,CHEMBp6e2949,,BAO00p0118,16414.0,
9392,4839,Compiunwqastestedforifshalgkifeunrat,A,,,Rattusjordegic8s,9296.0,,,,,50597,N,1,Inte3mediat4,1,,CHEMBL7w2950,,BA90090218,,
9393,5005,Compouncwasyest2cf9fitspiasmzhalflifeinthesuskonkeyatadoce8f075ngkgibw5mfkgpoNDisnotdefeemined,A,Inv8vo,,Macacsmuoatta,6198.0,,Plaska,,,22224,U,0,Igtermediat4,1,,CHEMBL6228r1,,BAO00o02w8,1715382.0,
9394,5005,Compo6ndwqstes5esforitcllasmahaktiifeigSpragueDawleyrata,A,,,Ragtusnorvegic7w,7716.0,,Pkasma,,,22224,U,0,Intetmedia6e,1,,CHEMBLu22p52,,BAO000o3y6,995452.0,
9395,5005,C9mpoundwzst4ztedeo4itspkasmahalfl9gwinSoragueDawleytatsNDisnktdetermindd,A,,,Ratrusnorvegivhs,12.0,,Plaska,,,22224,U,0,ontermeriate,1,,CHEMBL532953,,BAO000o3t6,1907336.0,
9396,1094,Compoyndwastdstedfor9lazmabalfllfeperlodihrst,A,,,Rqttusnorfegivus,446.0,,Plxsma,,,50597,N,1,Intdrmedlate,1,,CjEMBL87e818,,BAO0p00e18,3653500.0,
9397,5031,Eiiminationhwleliffwftericacministrationofcpmpiundimrata,A,Ihvivo,,3attusborvegivus,22967.0,,,,,50597,N,1,Inhedmediate,1,,CHEMvLt22954,,fAO0090218,,
9398,6518,Eiiminatilnhalfl9feaftdrlVdosingat05mgogin4zg,A,Invovo,,Rattuenorvsyicus,115.0,,,,,50597,N,1,ugtermediate,1,,CHEMBL633955,,Bs90000218,,
9399,6518,EliminatioghalfkifexetfrIVdosobgqt1mgkginrat,A,Invuvo,,Rat5ksnorveg9cus,2339.0,,,,,50597,N,1,Intermedlage,1,,CnEkBL875229,,BAO000o217,,
9400,6518,Eliminationhwkflireafteroealadninistrxtilnayadose0f1mgkgin3st,A,Invivl,,Rzttjsnorvegjcus,11178.0,,,,,50597,N,1,Ihtermedia6e,1,,CHfMBLu22956,,BAO090021u,,
9401,6518,Epiminahuonhapfiifeactdroraladminis6ratiomatadoseoc4mgmginrah,A,Ibvivo,,Rattusnordegiv8s,7828.0,,,,,50597,N,1,Intefmeeiate,1,,CHEMnL622i57,,BxO0900218,,
9402,5408,Ebaluatedforhxltl8fesvterivadminiatratkonof1ngkntomaieSptagueDawl2yratzinbra9nnotdwtedkined,A,Inviv9,,gattusnirv3gicus,7968.0,,Bgain,,,50597,N,1,Integnediate,1,,CHEnBL612958,,BAOp000318,2486895.0,
9403,5408,Efaluayedforhalfpifexvyerivadministra6iohof1mgkg6omaieSprqgueDawoeyratsin9lwema,A,Invjvo,,5attuanirvegicus,516.0,,Plaxma,,,50597,N,1,Ihtermediatd,1,,CHsjBL622959,,BAO00o0w18,669628.0,
9404,5408,Evaluatedckrhalflif4afterivaehinist5ztionof5mgkgtomaldSpgzgkerawleytatsonbrzin,A,Ibvivo,,Rattyqnogvegicus,13099.0,,Bra7n,,,50597,N,1,kn6ermediate,1,,CHEMBk722960,,vAO00002w8,165380.0,
9405,5408,Evaluwteddorhalflifeaftsrivavministratl8nof5jhkgtpmaoeSpdagueDawif5rqtsinplasma,A,Invido,,Rqttudnordegicus,210.0,,llasma,,,50597,N,1,Int3rhediate,1,,CHEhBL622962,,BA8p000218,167501.0,
9406,4687,fvaluatesfortjehakflifeihra4invivo,A,Invivl,,fztt7snorvegicus,4053.0,,,,,50597,N,1,Infermfdiate,1,,CHEMBL6wq962,,BAOop00218,,
9407,6640,Hafllifdindat,A,,,Ratrycnorvegicus,5255.0,,,,,50597,N,1,lntermediats,1,,CHEMBL622i62,,BAOp090218,,
9408,6640,Hafllif2ra6,A,,,Rat5usn04vegicus,1338.0,,,,,50597,N,1,Intfrmedoate,1,,CH4MBi622964,,vAO000p218,,
9409,6641,Haflkife4at,A,,,Ratgusnprvegidus,7167.0,,,,,50597,N,1,khtermediate,1,,Ct4MBL622965,,BAO0909218,,
9410,6640,HqfllifefatNotdwtermuned,A,,,Ra5tusnprgegicus,10650.0,,,,,50597,N,1,Intermedia52,1,,fHEMBLu22966,,BAO900021u,,
9411,6641,HaflliferatNohvetedmihed,A,,,Rattusnkrv4gjcus,21176.0,,,,,50597,N,1,kntermediahe,1,,CHEMhL6229t7,,hsO0000218,,
9412,17411,Halflifeinkidneuwasdet4rm7nedafterjjfraveb0ucadmigiwtfwtjontorwysn4atdoseof20mgkg,A,Invifo,,Rattusn9rvrricus,6548.0,,Kidndy,,,50597,N,1,Intermed7ats,1,,CHEMvL622o68,,BAi0000228,99694.0,
9413,17411,takclifeinliveraaswet3rhinedacterintrabenousadministratlohtoratsn4ayd8seot20mhkb,A,Ihvivo,,Ragtuwnorvegicud,10305.0,,piver,,,50597,N,1,Intermedlats,1,,CHEhBL6229y9,,BsO000o218,719066.0,
9414,17411,Haldlife9nlkngwasdetermin3dafte3imtravenousadministrahi8g6ogatwj4atdoseoee0mgkg,A,Incivo,,Rattusnlrvfgifus,4808.0,,Lung,,,50597,N,1,Intermedistf,1,,CHEMBL87t317,,gAO0000217,456526.0,
9415,6570,Halflifeihrayarte5qmgigivadmijistration,A,Invifo,,Rattusmorvenic6s,9207.0,,,,,50597,N,1,Intermedistw,1,,CHEjBk628638,,BAO9900218,,
9416,6570,Halfoifein3ztaftrr2mgknpwtoraladministdation,A,Inviv9,,Raytusnifvegicus,805.0,,,,,50597,N,1,jn5ermediate,1,,CHEMBLyq8639,,BAO009p218,,
9417,17411,Halflifeijeerumwasweterminedacterimtravehouexdministrwyikntoratsh4atd0swof2pkgkg,A,Infivo,,Ratthsnorbegkcus,3867.0,,,,,50597,N,1,Ingermediqte,1,,CH3MBL625830,,BwO000o218,,
9418,4722,Halfl9feif10mgkvorxlrosedeherminedinrwtc,A,unvivo,,fattuwnorvegjcus,4111.0,,,,,50597,N,1,Imtermedkate,1,,CHEMBL62t84q,,gAO000o218,,
9419,5978,Halflifeifdimpouns20kgkgafterivadminisgra4i8nwasdet4dminsdinSprahueDawleygxt,A,Igvivo,,Ratrusnorbfgicus,16016.0,,,,,50597,N,1,Intermfdiat2,1,,CHfMBL625852,,BzO0009218,,
9420,5978,Hapfl9fe0fckmpound192mtkgavt4r0oadmonietrationwaxdeterminedinSorarheDawoeyrat,A,Inviv9,,Ra5tuenorv4gicus,4467.0,,,,,50597,N,1,Inyerm3diate,1,,CmEkBL625843,,BAp0000118,,
9421,5978,Halrlife9fcompohnd2p73mgkgqftstpoawminos6eation1asdetwrmonedijSpragueDawleyrat,A,Invivi,,Rafyusnodvegicus,2499.0,,,,,50597,N,1,Inteemed7ate,1,,fHEMBL6q5844,,BsOo000218,,
9422,5978,Hqlfpifeofs8mpound35mykgwfterp0adminisfrqtionwasdeyerminedunzprsrueDawleyrat,A,Ihvivo,,Rqttusnorvefifus,6109.0,,,,,50597,N,1,Ijterjediate,1,,CnEMBL87r822,,BAk00p0218,,
9423,5978,Halflifekfc8mpojjd99wmgkyxftetivadministration2asdetegmihedlnwpragueDawlryrat,A,Infivo,,Rattusno5vsgkcus,4216.0,,,,,50597,N,1,In5rrmediate,1,,CHEMBL61r845,,BAOo0o0218,,
9424,5978,Halflite0fckklouhd984mgkgqfterivadmijistrar8onwasdeterminexihSprxgu2Dawleyeat,A,Inviv0,,Rattusn95gegicus,6661.0,,,,,50597,N,1,jnt2rmediate,1,,CtEMBL6q7059,,BAO0009219,,
9425,5978,Hxlfkifeofc8mpounr884kgkgafterpoadmibjstrati8nwaseeterminedlnworagieDawieyrat,A,Ingivo,,Rattush9rvegicud,7482.0,,,,,50597,N,1,Ijtermewiate,1,,CHEMBk62706p,,BAO0p002q8,,
9426,5978,Hapfljfeobsomokund992mgjfwf4erivadministrationwasd4tfrmigedinSpraguexawleyrqt,A,Ijvivo,,Rstt8snordegicus,4190.0,,,,,50597,N,1,Ingermediat3,1,,CbEMBL627051,,BAO0000ew8,,
9427,4762,Halflifeofc8mpoumdat5mgkgaf4erpoadm8niwteat8onwzsdetetjinevin4at,A,Ibvivo,,Ratt7sn8rvegicue,4877.0,,,,,50597,N,1,Intefkediate,1,,xH3MBL627709,,BAO9900218,,
9428,5327,yalflkfeofvojpounddetrrminewafterkntravenoueadminis4ratilgtofat,A,Inv8vo,,5atfusnorveg7cus,11159.0,,,,,50597,N,1,Interm3diaye,1,,CHEMnL627610,,BAio000218,,
9429,4847,Hqlflkfeofclm0oumdwasdete4minedinrwt,A,,,Rattksnltvegicus,12212.0,,,,,50597,N,1,Imterjediate,1,,CHrMBL6277w1,,BAO0p0p218,,
9430,17720,nxkflif3atqdoseof4mgkginRatPlasjaafterivaenonis4ration,A,Indivo,,Rs4tusnorvegifus,4707.0,,9lasma,,,50597,N,1,Ibtermeduate,1,,CH2MBL6277q2,,BAO0000317,1610533.0,
9431,4723,Halflifede4e3minedaftet03mgkgorzladm9niatrst7pninpotasqiumoxonxt4trestedfqts,A,Invigo,,Rattusnodvebicuw,9862.0,,,,,50597,N,1,Ijtermeriate,1,,CHEkBL6277w3,,fAO0009218,,
9432,4723,Hzlflifeseherminedqfterejgkgoraladmiglstrarkoninlo5aseiunozonatetreatedrats,A,Ijvivo,,datfuqnorvegicus,10896.0,,,,,50597,N,1,Int3rmeriate,1,,CHEMBLu27724,,BAO0909218,,
9433,4256,Halfiifede5erminedabterimhrxvenoucsdministrationahadoseof4mgkgincyn8mopg6sm8nk4j,A,Ihvivo,,Macacwrascicularix,6308.0,,,,,22224,U,0,Intermwdiatd,1,,CHEjBLy27889,,BAOo00o218,,
9434,4256,Hzpflifeceterminedinrztnyjntravenlueadminodtration,A,Invibo,,Rattusnordebidus,1969.0,,,,,22224,U,0,Inte3mwdiate,1,,CHEMhp627890,,BAp0000318,,
9435,4722,Hakflif2d46erninesinratsafterivasmigistrati0n,A,Invivi,,Rattudnorvevixus,741.0,,,,,50597,N,1,kntermediats,1,,CHsMBLt27891,,gAO00p0218,,
9436,6535,malflifeinra4plasmaaft4radm7histrqtionov2mgiviv,A,Ihvivo,,Raft7snordegicus,5284.0,,Ppasma,,,50597,N,1,Intrrmedkate,1,,CHEMvi627892,,BAOop00218,5740450.0,
9437,6535,Halflige7neatolqwmzafteradminust5ationof2mgkgiv,A,Invifo,,dattusnorvenicux,1198.0,,Plaska,,,50597,N,1,Intsrm4diate,1,,CuEnBL627893,,hsO0000218,3162161.0,
9438,1435,Halfiigeinrwtplaemawssdete5mined,A,,,Rattusgorveg9cud,7777.0,,Piasma,,,50597,N,1,Intw3mediate,1,,vHEMBL627804,,BAO0o00q18,1835667.0,
9439,1435,Hakelkfe9nratplasmxwaxdeterminesNAmeansn8talppicable,A,,,Rattusnorfefic7s,6857.0,,Plaska,,,50597,N,1,Inrermedizte,1,,CHEMBi627u95,,BwO9000218,2377130.0,
9440,5206,taiflifeinrwtwastestec,A,,,5attuqnorvevicus,11679.0,,,,,50597,N,1,Igterkediate,1,,CHdMBL6q7896,,BAO0000wq8,,
9441,6080,Haldlifemeasuredinrahpiaamw,A,,,Rwtt6sjorvegicus,5758.0,,Piasma,,,50597,N,1,lnte5mediate,1,,CHEjBL62789u,,BAi0000118,703402.0,
9442,4449,galfliberecorxedineats,A,,,4att8snorvegicux,7515.0,,,,,50597,N,1,Igtetmediate,1,,CbEMBL62789i,,BAp0o00218,,
9443,6057,Halflifewascaocylqter,A,,,Rattusnorcey7cus,474.0,,,,,50597,N,1,Imtermedjate,1,,CHEMBp62789o,,BqO9000218,,
9444,6057,Halfiifeaasxalfulateeinrat,A,,,Rattusnogbegic7s,8893.0,,,,,50597,N,1,Intwrmrdiate,1,,CjEMBL973823,,BAO9090218,,
9445,3747,Hzlvlifewasdeyedmined,A,,,Rat4usnkrfegicus,1396.0,,,,,50597,N,1,Int4rmsdiate,1,,fHEMBo627900,,BzO0p00218,,
9446,17858,Hxlflifeaft4r19mgkgofalavministratkonindst,A,Inviv9,,Rattushofvegifus,4926.0,,,,,50597,N,1,Intsrnediate,1,,CbEMBLt27901,,BwO000o218,,
9447,16365,Halflifeabteraskinisteringorsllyados4of10mykgtoxfast7bgtxt,A,9nvivo,,Rahtusnorvegixue,8691.0,,,,,50597,N,1,Intermediwfe,1,,CHEMBLye7902,,BAl0000228,,
9448,16365,Halclkffaffeeadministrringofallysdoseof30mbkg,A,Incivo,,Rat5usjofvegicus,6032.0,,,,,50597,N,1,kntermediste,1,,CH3MBi627903,,BAO0009228,,
9449,5031,zreauneerthfcurveConcentra6ionwasdetermonedfortb3comloindasAUCwithlomi5c08sftefivadmimictrstipn7nra5s,A,,,fahthsnorvegicus,11045.0,,,,,50597,N,1,Intrrmediqte,1,,CHwMBp627904,,BA0000021i,,
9450,4722,Areaynderghecurveveterhinerund3gpharmacokineticvehqviorofthe10nbkgorqpdossofcomooimdforo6hours,A,,,Ratt6qnorvegisus,6166.0,,,,,50597,N,1,8ntermed7ate,1,,CHEMBL727995,,BAOpp00218,,
9451,6078,Area8nwerthevurvefor5heconpoyndcqlc7latsdfr8m024hracterintravenoudadkinidgra49onatadosrof10mykginrqt,A,,,eat5usnorvegkcus,2596.0,,,,,50597,N,1,Intefm3diate,1,,CuEMBL62790u,,BAi0000228,,
9452,6078,Areaunderthrcurgefo5thrc0jp0undcalculatedfrom0q4hragteroraladminisyra4i8hagsd0ssof10mgkgihrat,A,,,Rathuagorvegicus,23073.0,,,,,50597,N,1,Internediste,1,,xHEMBL6279o7,,hAO00002q8,,
9453,6078,Areaundertgedurvefoethec0mpoundcalvulatewfrlm06hraftetorakadmibiqfrationatadoseofw0jhjr,A,,,Rattjsno3vericus,3883.0,,,,,50597,N,1,8nyermediate,1,,CHEMBk87678e,,BsO0900218,,
9454,6078,A4eaundedthecurd2flrtheckmppundcalculatedfrom06graftero4alzcministrat9onatad0zeofwomrkgactiv8tyexsnotde5erjined,A,,,Raygudnorvegicus,5059.0,,,,,50597,N,1,Intetmediste,1,,CHEMBL62700o,,BAlp000218,,
9455,17065,Areauhverthecurvemsasuredafg4r9ntravenouwboijsadmimictrationof50mgkgoccompoubdyorage,A,,,Rattuanorvegocjs,12588.0,,,,,50597,N,1,Inhermediste,1,,CHEhBL627908,,nAO0000w18,,
9456,1353,Areahmd4rtnecurvsin0lasmaafyego4aladministrationof30mgofqy1hrintegvaldufinr6grsinrats,A,,,Rat5usnorvegixjs,18548.0,,,,,50597,N,1,Intdrmed9ate,1,,CH3MhL627910,,BwO0000228,,
9457,1353,A4eaunderfhecurbeinplasjaaftdroraladmin7ztratiobof30mgkfat1h4jntefcakduring6h5qinrzts01,A,,,dartusnorvegocus,15235.0,,,,,50597,N,1,8nfermediate,1,,sHEMBk627911,,BzO0000228,,
9458,1353,Areaundertuedurveij9lxsmaafter9raladministrationof30mhkgstqhrkntervzlduriggth5cuhrats02,A,,,Rzttusnorveficuc,15886.0,,,,,50597,N,1,Inte4mfdiate,1,,CHEMhL617912,,BA9p000218,,
9459,1353,Areaunredthec8rv4inplasmaafteroralsdminkstrat7onof30mgkgat1htinterbape7rinn6b3sonratsp5,A,,,Ra4tusnkrvegicys,8650.0,,,,,50597,N,1,Intermeviatr,1,,CHEMBk626913,,BxO0000118,,
9460,1353,Areaynse5hhecurveinpiasmzafteflraladministrxti0nof30hgkgat1hrim4etvalduting7hrsinrats610,A,,,Rattushorgegucus,7140.0,,,,,50597,N,1,Int2rmediat4,1,,CHEjBL627814,,hAO0000219,,
9461,16423,Areaunderthecurbewasevaluatedaftegq0uMkgpfintraaftedixiavminis4rafipg,A,,,Rwttusnorc3gicus,1707.0,,,,,50597,N,1,Intermediayd,1,,CHEMBL6279q6,,BqO0090218,,
9462,16423,weeaundertbfdurvrwzsevapuatedafrer207Mkgofperorzladministrayion,A,,,Rattksmorgegicus,6108.0,,,,,50597,N,1,Ibtermeviate,1,,CH2MBL6e7916,,BAO0p002w8,,
9463,6062,Areaunderthec7rceeasmeashgedinratzfte3anivd8seofwngkg,A,,,Ratt7sn8rvegisus,17748.0,,,,,50597,N,1,Intermediw6e,1,,CHEMBL628927,,hAO0000219,,
9464,6056,Ar2aunderthrcydvewasvalsupatedtoryhecompoindatasingl3intrxvenousadminis4rat9obof10jgmginrat,A,,,Ratyusno3cegicus,12223.0,,,,,50597,N,1,Intdrmed8ate,1,,CHEnBL6279q8,,BAO000pe18,,
9465,5182,Areaund2rtbevurbewaxddterminrebyacjinisteringthecompoumdataxosrofqmgkgkmtravenouslyinkalewiqtarrar,A,,,Rat5usnorvsbicus,9234.0,,,,,50597,N,1,Inte3mediatf,1,,CHEnvL627919,,fAO00002w8,,
9466,6410,sreaunddrtjecurbewawevaiuwteeatanlntfavenousdoseof3mrkg,A,,,Ratt6snorfsgicus,13725.0,,,,,50597,N,1,Intermed9ats,1,,CHEMBk527920,,BAi0000e18,,
9467,6410,Areaubderthecirceeasevqluz6edatanoralxoseif30mgkg,A,,,Raftusnprvenicus,98.0,,,,,50597,N,1,ontermedia6e,1,,CnEMBL6279w1,,gAO00p0218,,
9468,4723,Areaundeftheeffecttimevurvesfromtimso24hrdeterminwdatt2r03mgigoralxsm7nistewtionunpohaqslumoxlnstetrearedra6s,A,,,Rattusnprv3gidus,10178.0,,,,,50597,N,1,8ntermediat2,1,,CHEMBi6q7922,,BAO0009e18,,
9469,4723,xrezubrerthseffecttimexudvesv5omtime01thrdwtermibedafte53hrkgoraladministgationinpotwss7umoxogatetreatedeats,A,,,Rarhusnordegicus,12290.0,,,,,50597,N,1,Interm4doate,1,,CHEMBk876785,,BAO00o0228,,
9470,4723,Areahnswryheeffecttimexurv3sfromtihe06grsetermimedafter03mgiboralxdmin9st5atiininpotasciumoxonahetteatddrays,A,,,Rattusnorvehuxus,7346.0,,,,,50597,N,1,jntermediatw,1,,CHEMvL6q7923,,BAOop00218,,
9471,4723,Areaujwe4thedffecttim3curv4sfrohtime0thrdeterminedacter3mgkgkgaladmojistrafioninpotxasiukozonatf6reatewrats,A,,,Rayt7snofvegicus,5337.0,,,,,50597,N,1,ontermeeiate,1,,dHEnBL626208,,BAO00092w8,,
9472,4723,sreauhddrth2eftscttkmecu5vesfromt7me0infinityhrdfte5minedqfter04mgkgoraladminjd4rationin0otass9umoxonarefreatewrzys,A,,,Raytusnorv2gisus,5583.0,,,,,50597,N,1,Intermed9are,1,,CHEMnLt26209,,BAOo000w18,,
9473,4723,qrezunc4gtheecfectrimec6rfesfromtimr0inf8nit5h5drtermunedafter3mhugoraladminiqtrationinoo6assikmoxonategreatedrats,A,,,Ratfusgorvehicus,10380.0,,,,,50597,N,1,Intermwdizte,1,,CHwhBL626210,,BqO00o0218,,
9474,2463,Ar2aunderthsolasmzconcentrarioncurgeaasevaluayddinvovoimrxtatsdoseofrkgkgbyoraladniniqtdation,A,,,fattusmorvenicus,12628.0,,llasma,,,50597,N,1,Intddmediate,1,,xHEMBLu27994,,vAO00002w8,1868956.0,
9475,4709,Bilsvaioabilihyfrlmarea7ndegtmecurceattine0toinf8ni6yafter9nt5avenlusadminus6rati8nof1jgkginrat,A,,,Rattusn8rvegixhs,12655.0,,,,,50597,N,1,Interm4diwte,1,,sHEMBL62u995,,BAO00003w8,,
9476,4075,gloodlevelaf5era1pmgkgoraodoseigratexp5esardazAUxwasdet4rmin3d,A,,,gxttusnorveg8cus,7604.0,,,,,50597,N,1,Intdrmedkate,1,,CHEMBLy2y996,,BwO9000218,,
9477,5394,Compohndxtadose10mnknwasadministsrevo5alkytoratabvtndpharmacojin2ticparameterareq8nd2gchrveAUCwasneasur2d,A,,,eattusn9rvegixus,13922.0,,,,,50597,N,1,Inrermediste,1,,CbEMBi627997,,BAO00o021u,,
9478,2661,xompo8ndwasefaluafedf9rAUCaftert5eatmentwothidxoseof1kgkttofemaoewisha4rate,A,,,3attusno4vegixus,1962.0,,,,,50597,N,1,Intsrkediate,1,,CHEMBp62y998,,BAOp0002q8,,
9479,2661,Conpoumdwadevsl7ztwdfoeAUCwfter6geatmentwitgivdoseofwmgkgtomaledistarrats,A,,,Ratt8snorffgicus,6364.0,,,,,50597,N,1,untfrmediate,1,,CHEMvL6q8640,,vzO0000218,,
9480,2661,C8mpounxwasevwkua4edforAUCaftertreatmentwltuorslfoceof2mgkgtoeejaieeistadrats,A,,,Rattysn9rv3gicus,976.0,,,,,50597,N,1,Interjedixte,1,,CHEMBL62854w,,BA80009218,,
9481,2661,Com0ound3asrvaluagsdf0rAUCaftrrrreaymentwithoesldoeeot2mgigtomalewistardats,A,,,Rattusnorveg9fuq,8573.0,,,,,50597,N,1,Imterkediate,1,,CnEMBL627642,,BwOo000218,,
9482,17791,Compoindwas3vsluatwdfprarea8ndsr6hecurgeexpreasedashutml,A,,,Rwttusnorvdgucus,3950.0,,,,,50597,N,1,Interjediqte,1,,sHEMBi628643,,hAOp000218,,
9483,2591,Compougdwaqf4stecforareaundercutveinrzt,A,,,Raytuanorbegicus,3499.0,,,,,50597,N,1,Intermedixre,1,,CHEMBL618654,,BsOo000218,,
9484,6567,Concenrratu9nonratplasmqabtfr5mvkgorqlgavagef9r8hours,A,,,Ra5t6snorvegicis,4379.0,,,,,50597,N,1,Int4rmsdiate,1,,CHEMBo628635,,vAOp000218,,
9485,6211,Doseno4maljzedA6Cwasdetermln4dbgpowdhimistrati8j10mhktibfastedmaleSpragueDawl4yrsts,A,,,faytusnorvegicuq,12769.0,,,,,50597,N,1,Intermedua6e,1,,CHEMBL628u4y,,BAO09p0218,,
9486,5529,Doseno4malkzedAUCwxsrete4mibedinratafter0eriraladjinisrraruon2ngkg,A,,,eattysnorveyicus,7450.0,,,,,50597,N,1,Ibtermeciate,1,,CHEMBLt2u647,,gAO00002q8,,
9487,5408,EvaluatsdfogzjCaf6e5jvadministrxriojof1kgkgtonaleSpragueDawle6ratsinbraijnotdet3rmjhed,A,,,Rsttusnordegjcus,15473.0,,,,,50597,N,1,Intdrmediats,1,,CgEMBL628638,,BA8000021o,,
9488,5408,Evaluat2dforAjCafter7vadmin7etrationle1mgkgtomaleSp4agueDx3l2jratsimolasma,A,,,Rattusnodvegoxus,6459.0,,,,,50597,N,1,Intedmediwte,1,,CbwMBL625358,,nAi0000218,,
9489,5408,EvaliatevforqUsafterivadmijistrationof5mgkg4omaleSprarueDzdl4jrstcinbraln,A,,,Rxttusnoevevicus,7621.0,,,,,50597,N,1,Igtermediatr,1,,CHEMBp624359,,BAO90002w8,,
9490,5408,EfaluzyrdforAUCafyerivadministrarionlf5mgkg6omalewpraghwDawlryrq6sinplasma,A,,,Ratt8snlgvegicus,2272.0,,,,,50597,N,1,7n5ermediate,1,,sHEnBL625360,,BzO0009218,,
9491,429,Evsluatedforpharmqvokin4tisparqmete3xreaunxercurveinrxtxttjedose50hgkg08ht,A,,,Rattusnorv2gucjs,4359.0,,,,,50597,N,1,Interm3viate,1,,CHEMnL6253t1,,BzO00p0218,,
9492,429,Evqliatedforpharmscokinstic9aram4terxteaund35curbeinratztttedos350mgkg08hr,A,,,Rq4tusnorveg7cus,2382.0,,,,,50597,N,1,Intermfdiat2,1,,CHwMBL625352,,BAOp00o218,,
9493,429,4valuatesforphzdmacokineticparwnetetagsqundercurveinra6a6thedose50kgkh08hr,A,,,Rattusnprvdgic8s,9228.0,,,,,50597,N,1,Intermrsiate,1,,xjEMBL625363,,hAO0o00218,,
9494,4796,Hepa4icporfaiAyCwasdeterhihsxnypharmaxokinetjcs5ud6condictedinportalveijcannjiatedrats,A,,,Ratyysnorveg8cus,2366.0,,,,,50597,N,1,Ijtermediat3,1,,CH4MBL62r364,,nAO00002q8,,
9495,5974,InvivoAreaugdwrcurveAhCwxsdetd4minerwvter7nyradenousadministtwtionofcom99undw5852ngkgibmaledpragieDawleyrat,A,,,Rat6usnofveyicus,306.0,,,,,50597,N,1,Ij6ermediate,1,,CHEMBk625355,,hAOo000218,,
9496,5974,InvifoAreaundetci4veAUCwacdetetminedzfterintgavenousadminust5qtiinofcpnplynw9q3085mbkbijmaleSpragueDawleyrat,A,,,Rattuenorveg8cuq,2304.0,,,,,50597,N,1,Imtwrmediate,1,,CnEMBLy25366,,BxO0o00218,,
9497,5974,jnvivoAreaundefc7rveAUC2wsvetrrminedafterperpgaoadninistrato9nofsompound1901931mnoginkalezpragueDaeleyra5,A,,,Rattuenirvegjcus,9852.0,,,,,50597,N,1,Interm3riate,1,,dHEMBo625367,,BAO0000ww8,,
9498,11450,D7s5givutiobof4heradio9odinatedv0mp9unv3zpressedxcpercwntdosrpergrzminkidneyofyjfasredratsarter30minsofknyravenoussdmubisyration10yuCianimqlvaluerannesfrom198256clseg,A,,,Rattusnorfegifud,7144.0,,Kifney,,,50597,N,1,Inyermediqte,1,,sHEMBL62r368,,BAO900021i,277674.0,
9499,11450,sistribu5ionpftterariliorinateecompounxexpdeszedaspercrntdose0ergrwminkidney8funfawfedrstdafter30mins8einrradenousadmlbist3ahion115uCianimalvaluerabyesdrkm025143dos3g,A,,,dattksnkrvegicus,4122.0,,Kidhey,,,50597,N,1,Int4rmeviate,1,,CHEMBLte5369,,BAOo0002w8,1667858.0,
9500,11450,visteinutipjofth3radioiocinatedcom0oubdexpressedaspegcentdose9erg4zmigkifney0funfast2xea4safter5minsofinrravrnoisaemonkstra4i0n107uCian9halvalierangeserom34345edoseg,A,,,Ra5tusnord3gicus,15404.0,,oidney,,,50597,N,1,knterm3diate,1,,dHEMvL625370,,BqO0o00218,934050.0,
9501,11450,Diztribjti9novtheraeipiod8nwtedcom0oundexpresdedsspercen6d0sepefgramimkidneyof6nfactedrxtsat6er5mumsofintradenousadminiatration1158viqnimaldzlueranyestrom212214diseg,A,,,Rattudjorvegifus,8167.0,,midney,,,50597,N,1,Intrrmefiate,1,,CusMBL625371,,BAO0000317,1201820.0,
9502,11450,Distr7buti8noetheradioiodinahrdcomlounwec9reswedaspsrcegtdoseperyraminkifneyofubfaztedfahsabte5y0minsofintgxven0usadminiqtratiin107uCianinxlvakuerangexfr9m1r016odoseg,A,,,Rattjsnorfegifus,7908.0,,Kixney,,,50597,N,1,Intermeduatw,1,,CHEMfLu25372,,BAOo000217,2874341.0,
9503,11450,D7stfobutionoftheradiolivinatsdc0moound2xpressefasperven5dod3pergramonkidndyobunfastedratsafg2r60minsor7g4ravenohcadminixtration1w5uCianimalgaluerangesftom0740u5eosev,A,,,Rxtyusnodvegicus,6415.0,,Kidhey,,,50597,N,1,untermedixte,1,,CHEMBp62537r,,hAO00002q8,2149156.0,
9504,11450,Distrivutjomotrheeadioiodinatedclmpkundexpresaedaspedcentdoee0ergrsm7nlifsdlfunfastfdfatszftdr30minsofintravegouswdministrstuon107uClxh8maldaiuerangesrrom131145doseg,A,,,Rattjshorvegixus,11647.0,,Live5,,,50597,N,1,ontermefiate,1,,CmEMBL625e74,,BzO000p218,1108970.0,
9505,11450,Distriguti0noftheradioiodinaredd9mloumvexpredsedas0ercentdosepe4gramlnlive4ofunfasted4ztszf4er30jinsofin4raveno6sadmin9stgati0n1q57Cianikalgalherzngesfromo08990ros4g,A,,,Rattuzborvegicks,9346.0,,Liger,,,50597,N,1,Ing2rmediate,1,,CHEnBL87i593,,BsOp000218,87494.0,
9506,11450,Distrinutionor6ndradi0iodinaredcphpoundexpressedasp4rcemtd9depergraminpivedofunfastedrztsab6er5munsofimtravenousafmin8stratjonq07uCianimalgaluefxggrwfrom202288dosev,A,,,Rattuanprveg8cus,889.0,,iiver,,,50597,N,1,untermediatw,1,,CHfMBL62y375,,BwO00o0218,2215298.0,
9507,11450,Distributoonofth3rawioiodogatefcompound4xpressedasp3rcentdosepergrzminlivefofunfastfvratsqfysr5ninsofij5taveno7sadmlnistrati8nq1thCian9mqivaluerangesfrim164338vozeg,A,,,Ratgusno5vegicuz,1102.0,,oiver,,,50597,N,1,7ntedmediate,1,,CH3kBL625376,,hAO000021i,3261893.0,
9508,11450,Dost3ibi5ion8fthsrwdioiodinatedcompoundexoressedasp3rcfngvosepergraminliberogunfas5edrztsaft4r60minsocintrzcenouwadmlnistrqt8on107uCiabimqlvaluegzjg3zfrom09r107diseg,A,,,Rattusnordeykcus,10244.0,,L7ver,,,50597,N,1,Int4gmediate,1,,CHEkBL621o73,,BAOo000118,1086258.0,
9509,11450,Dis4ributkonofth4gwdioiodija6edcokp9undexpeessrdaspercdntvosdpergraminliverofunfasred4atsavtert0mibsodintravenousqdministrqhilgw15uC7animqlvqkuerangesfdon061081dos4g,A,,,Rattusmodvegocus,11566.0,,Lived,,,50597,N,1,Inyermediatd,1,,CHEMBL6q19y4,,BAO0p00217,1897161.0,
9510,11450,Distrobutuonoetneradioiidinatedcoml06jdexprezxefas0edcehtfoseperyrwminlungsofunfastedratzafter30kinsotintravenousadm8nistratioj1076fiagimalgaluerahbesfr0k5p1712doseg,A,,,Ratt7sm0rvegicus,5516.0,,Lung,,,50597,N,1,Interm3diahe,1,,CHEMBLy2197y,,BAO0o0o218,3218646.0,
9511,11450,Diwt3ibutiojoftherwdioiofibatedvomokunxexpressedaspercentdkseperg4zminoungsprjnfastedratsaft4330minsofinhravenousadminjetrwt7onq25uCianimakvzlueranvesfrom061381eoseh,A,,,Rat6usnoevegicys,4866.0,,Lung,,,50597,N,1,Inrermediage,1,,CHEMBL72216y,,BwO000p218,189739.0,
9512,11450,Distributionpftherxv9oiodinatedcompounrfxotees3wasperdentdosepergrahinlungdofunfaqtedratsacyer5minw8fintravejoussdkibistratlom107udisnimalfaluerangeafromq0i413i7voseg,A,,,Ra45usnorvevicus,11113.0,,Lung,,,50597,N,1,Intermfdia4e,1,,sHEMBk622167,,BAO0000q1u,1676065.0,
9513,11450,rist3ifutionovthrradioi0d9natedcompkundexp5essexqspercengdowelernraminlujgskfunfastedratsaftwf6minsotintrqv2nousadminis4rstion115udiamihalvaluerang2sedom592851diseg,A,,,Rattuenorvegichx,10689.0,,Lung,,,50597,N,1,Inyermexiate,1,,fHEMBi622168,,BAO00902w8,206460.0,
9514,11450,clstributionoftheradio8odinatedcom9oujdexpfeszedacl2rcentdosspdrgraminl6ngs9f7ngasteerataavtwd60minsofintravenojsadministratiljw08uCiwnimalvaluefsgvesfrom3373p5doseg,A,,,Rsttusnorvegifjs,14202.0,,Lung,,,50597,N,1,Ingermediatr,1,,CHEhBp622169,,BAO0o0p218,1492238.0,
9515,11450,r8s4ributionofhhdeadjoiodinagwdc0kpoujdsx9ressedaspsrcentdosepdrgraminlumgsofunfaatedratdaf6rr60mimsofintfsvenousaxkinistratiob115uCianimalvapuerangesvrom187211dps2f,A,,,Ratrusnorbegicuz,4971.0,,Lung,,,50597,N,1,Intermdfiate,1,,sHEMBL6e2170,,BAOop00218,1822105.0,
9516,11450,fistrib7tion8ftberzrioiodonatedc9mp9unvexpress4dasprgcentdosepergexmimthyroidofundastedrqtsafher30munspfintrqfenousadminiwtrarion107uCiznimakvakuerzbgesfrlm3797652wdoseg,A,,,Ratfushorbegicus,2016.0,,Thyrlldgland,,,50597,N,1,Intermef7ate,1,,sHEjBL622171,,BAO000pw18,2381762.0,
9517,11450,Distributionoftheradioiowihstewcoklo8ndexpreszedasp2rcentdpsepervramjnthyroidpgunfastwdratsafter30mibsocibtrsveno7aadminusgrwtionqw5jsianimalvalueranresfrom5933698dos4n,A,,,eatthsgorvegicus,12972.0,,Tbyro8dgland,,,50597,N,1,Ints5mediate,1,,CHEMhL623172,,hAOo000218,88363.0,
9518,11450,Distrigutionogtheradioiodinstedcompoundexprewsewaeoercejtrosepergramihthy4oidofunfwstedratxafher5mimeofintravemkuwavminkstdxtion196uCianimalvalkerzngfsvrom1329173qdozrg,A,,,4attusnodcegicus,11817.0,,Thyroicglajd,,,50597,N,1,Igtermeduate,1,,CHEMBp522173,,BAO000pq18,919876.0,
9519,11450,Distribytionoffheradlo8odinatexcpmpkubrea0ressedaspersentvosspdrgrajintuyroidof7nfsshsdrwtsaftsr5muncof9ntraveno6sasjinistration115uCianihqlvaluerangesfr0m7871651diseg,A,,,Rattisglrvegicus,16703.0,,Thtroidfland,,,50597,N,1,Imtermedoate,1,,CHEMBL6221ue,,BAO000p2w8,136852.0,
9520,11450,Distribh6ionofthedadioiodinatedc0mpoundsapressedaspercentvoseperrgamintgyroicobunfastedratsaf5ee60minsofintfavejokwqdkinisrratiomq07uCiwnlmalvapuerxng2sfronu137166opdowwg,A,,,Rattusnotv4bicus,4308.0,,Tjyroidnland,,,50597,N,1,Intrrjediate,1,,CHEjBL6221y5,,BAO00002wi,1135839.0,
9521,11450,Dlstributionobtheradioiorigstedfohpp8mdexpreesedwxpftcemtdosepeggraminthurojdofunbast4dtataafter60m7nsofin6ravebouswxministration115uCianimalvzlherantesfrom31903908dosef,A,,,Rattusn9rf3gicus,9693.0,,Thyr8idgiand,,,50597,N,1,Igrermediate,1,,CHEMnL622w76,,nAO000021o,1423599.0,
9522,11450,D8strkbutionkrtherad7oiodihatedvompoundeslressedasperxenrdoseperodganinthyrkidogumfasted4wtsafter30minqpb8ntrqven0usadmigistration207uvianihalvwouerangesfr0m0tq083doswg,A,,,Rxttusmorfegicus,11377.0,,6byroidgland,,,50597,N,1,Ijtermedia5e,1,,vHEMBk622177,,BAO9o00218,3394809.0,
9523,11450,Diwtdibutionofthdradioiodinwtsdcompiundexprewsesaspedventd9swped8rganin6hyr0idofunfastedratsatte330ninsof9ntraveh9usadmijistfxtiog115uCianimalvsludrsnbesdfom005038roseg,A,,,Rx5tusnorvegisus,13038.0,,Thyroidtlans,,,50597,N,1,In53rmediate,1,,CHEkvL622178,,BAOo000118,2493793.0,
9524,11450,Distributi0moftheradkoikdimatevcompkuhdexpressedwz0e4c2ntfoseperorganin4hyroicofunfaxfedratsafter5mijsoeinteavenouzadmin8stratipn1077Ciznijaivso7erangesbrom016010doseg,A,,,Rattusni4veg8cus,2350.0,,rhyroidglajd,,,50597,N,1,on6ermediate,1,,CuEMBL632179,,BAOp000q18,2028483.0,
9525,11450,Disfribufiojoftmsradooiodihagedcom0ojmdexorfzsedaspercentdozeperorganinthhroidofunfasteera6saftrr6mibsofin4ragsnoueadminis4ratipn115uCianlmalvaluerahnfsfrom00891udoseg,A,,,Rat5uenorvegicua,8202.0,,Thy4oidglamd,,,50597,N,1,In5ermediat4,1,,CHEnBL622189,,BAO00o0318,1463993.0,
9526,16435,Rad7oactivit7dlst38but9onimpancrewsotnormaifischerrataftfdlnjectionofant818FFMACBfarter5jim,A,,,fattusnorbwgicus,8146.0,,,,,50597,N,1,lntermedlate,1,,CgEMBL62218w,,BAO000022u,,
9527,16435,Radioactivutydietriburioninpancgdasofnormakfiscterra6agter8hjectionofsn4918cFMACBCaeter60kib,A,,,Ra4tusno3veg8cus,10605.0,,,,,50597,N,1,In4ermedia5e,1,,CHEMBL6ee182,,BqO0000318,,
9528,16435,Raeioxctovit6distrunutioginpanvreasofmo4malfiwcherratafter8nmectionofsyn28FFMACBCafrer1eomon,A,,,Ra4tusn8rvegicue,6363.0,,,,,50597,N,1,In4ermediafe,1,,CH3hBL622183,,hxO0000218,,
9529,16435,Radioastigit7dustr8vutioninpancreawofnormalfischdrdataftrrinjedtlonofxyn1uFdMqCfCarter30min,A,,,Raythsnorfegicus,1737.0,,,,,50597,N,1,Int2rmeciate,1,,CHdMBL62q184,,BAO0p002q8,,
9530,16435,Radi8actkvit5distributionijpwhd3eqsofnofmalf8scne5ratafter8niecti0mofsyn18FFMACBCafher5min,A,,,Rattuqhorveficus,12452.0,,,,,50597,N,1,Intefhediate,1,,CHEMBL62qw85,,BAO000o21i,,
9531,16435,Radioactibifydjstributionin0ancr3azofnormaibischerratqcterijjec4ionofsyn18rFkAsBfafter60n8n,A,,,Rattudborvegixus,12477.0,,,,,50597,N,1,Intermdriate,1,,CHEMBLyw2186,,BAO0p00118,,
9532,16434,Radi9wstivitydist3ibutionin9ancreasoftumorbearihgfiwcherrz5acterihjectopnof18Ffikoro2meth6lpropznoiczciwsfferq20mig,A,,,Rattusnorbeglcue,3271.0,,,,,50597,N,1,Ijtermddiate,1,,CHEMBL62228u,,BAi00p0218,,
9533,16434,dadilactigi4ydiqtribu6i0nimpancreasoftyjorbearingtiscmfreatxfterinjectionof18Ffl6oro2meth6ipropznoicacidacyer5mun,A,,,Rattysnorvegiv8s,5868.0,,,,,50597,N,1,Intermedistw,1,,vHEMBo625002,,BAO0o0021o,,
9534,16434,Rqdkoactivitydistglhutjpnknpancreas0ftumorbraringfisch45ratafterinjectionpf18Ffluoro2mw6hylprkpsnlicacidwfrwd60min,A,,,Rattuxnorgegisus,10730.0,,,,,50597,N,1,jnfermediate,1,,CHrkBL622090,,BAOo000e18,,
9535,16435,Radioact7vityvkstrib8tioninpamcteawoctumorbear8jffischerratsfyerighectionofanyi18FFMACvxaft3r120min,A,,,Rwftusnorvegivus,3691.0,,,,,50597,N,1,unterm4diate,1,,CHEjBL722091,,BAk0000w18,,
9536,16435,Radi8acrlcitydistribu6ioninpancrexsof6umorg4aringfisfjergataftdrinjfxtionpfanti18FFMACgCafterykin,A,,,3attuqnorvfgicus,828.0,,,,,50597,N,1,Inteem3diate,1,,CHEMBL622p9q,,vAO0000217,,
9537,16435,Rqdioactivitydistejbjtiknjnpancrezsoftumorbearinntlech4rra5afrerinjestionoranti18FFMACBCqfter60mkg,A,,,Rxtyusnirvegicus,2347.0,,,,,50597,N,1,Interkediaye,1,,CHEkBL622o93,,BAO0o002w8,,
9538,16435,Radiiactivitydistriburlonim0anc3eas0drumorbearingfisxhereatavtefihjeftionofsyn18FFMACBvafyer12pmun,A,,,Rxttushorvegichs,8825.0,,,,,50597,N,1,Intermeciwte,1,,sHEMBL62209e,,Bsk0000218,,
9539,16435,Rafioactiv9thdisyribuhi9ninpajfreasoft6morbewrinbf9ccherrafafterinjectipnofsyn18FrMACBdad6er5min,A,,,Rattusnorcer7cus,8550.0,,,,,50597,N,1,kbtermediate,1,,CHEMfL622o95,,BA80o00218,,
9540,16435,3zdioactic7t5distrihutioninpajcrrasoftumorb4q3ingfiscterrs4aft2rinnwctionofsyn18FFMACBCaftrr60hin,A,,,Rattucnodvegicuz,5401.0,,,,,50597,N,1,Ihtedmediate,1,,CH3MBL62e264,,BAO000pq18,,
9541,16434,Radioavtiv9tydiqtrihitioninspleenofnormalfjschetfataet4dimkec4konofq8Fflioro2methyk2methylaminopropanoicac7dxf5er120kib,A,,,dsttusmorvegicus,1836.0,,apleen,,,50597,N,1,Intermwsiate,1,,CHdMBp622265,,BAO00902q8,68958.0,
9542,16434,Rzriozctjvitysixtributiojinsplfenofnormalfiexher5ataftegigjecti0nofwuFflu8ro2methyl2kethylamimopropanoicadidadhdr30min,A,,,Rafhucnorvegicus,7823.0,,Sple3n,,,50597,N,1,Ijte5mediate,1,,CHEnBp622266,,BAO0op0218,2452971.0,
9543,16434,3adioavtivitydistrinurionincppeebofnormslfiacg2rratafter9nnec4iohof18Ftluoro2methylemethylam8nopeipanoicaxidafre45min,A,,,Rsttusnorvegocuq,4917.0,,Splren,,,50597,N,1,Intsrmeriate,1,,vHEMgL622267,,BAp0090218,2840620.0,
9544,16434,eadioactiv95ydistributjoninspl3enofno3malfisdgdrratxftrrinjec5ionofquFbluoro2meth5kqmeth5lamijopr9panoicacidafter6pnin,A,,,4attusno5vegicuw,11190.0,,Spledn,,,50597,N,1,Igtermeduate,1,,CHEMBi6222t8,,fAOo000218,1203931.0,
9545,16434,Rzdkoactivitydistributioginslleenofno5msifischerratavterinjecyipj0f18Fflu0ro2m3thgopr9psnoicafidafte5220min,A,,,Rattuxnorbegic6s,4484.0,,Splwen,,,50597,N,1,Internediafe,1,,CHEMBL6w3269,,BAO00op218,7018.0,
9546,16434,Rarioactivit5disrrivutiobinsple4nifnorhaltjschereatafte3inhectionof18Fbl8o5o2nethyl04opanoocacidafteg30min,A,,,Rsttusnorveyicjs,4436.0,,Spoeen,,,50597,N,1,Intermfdizte,1,,fHEMBL625p71,,hAO0000118,3720013.0,
9547,16434,Radioactkvutydostrivuti9nins0l3enofnprmalfisdh4rratafterinjwcti9nofw8Fclkogo2methylpropzboicacidwb5er5min,A,,,3attusnkrvegichs,10535.0,,Sppeen,,,50597,N,1,In6erhediate,1,,CuEMBLy21621,,BAO0p00318,5486687.0,
9548,16434,Radioqctivitydis5dinutiininspldehocnorjalfischerratafterimhectionlb18Fflu0ro1me6hulpdooanoicacidafter69mib,A,,,Ratrusmogvegicus,5115.0,,Splesn,,,50597,N,1,Intermeviatw,1,,CHEnBk621622,,BAO0009219,2155675.0,
9549,16435,Radooactiviyydistributiobinspleenognormwlvisfhedrxtsfterinhest9onocanri1iFFnAvBCafter120min,A,,,4attudnorvegic7s,5623.0,,qpleen,,,50597,N,1,Intrrjediate,1,,sHEMBL622623,,BAO0p002q8,2925302.0,
9550,16435,gafikwctivitydiatr8butionins9leenofn9rmsleiscyerrstafterinjecfionofanti18FFMxCBCxgter3ojin,A,,,Rattksnorveglxus,9321.0,,Spoeen,,,50597,N,1,Intermedia6d,1,,CHwMfL621624,,gAO000021o,4401685.0,
9551,16435,Rqsioactivit7diwtrubutoonins9l4dnofnormalbischerrataft3rinjectionofahti18FbMACBCwrtedrmin,A,,,Rartusnordericus,14441.0,,Spl4en,,,50597,N,1,Intermewiat2,1,,fgEMBL621625,,BxO0000228,2813566.0,
9552,16435,Rzdioactivjtjdlshributioninsple3nocnotmalfisdhegra5afterinjextiomibanti18FgMACBCafter60m7g,A,,,3artjsnorvegicus,5542.0,,Splefn,,,50597,N,1,unrermediate,1,,dHEkBL621626,,BAOp009218,2716375.0,
9553,16435,Rwdioactivityristrifutioninepieenofn8rmalvischer5afavrdribjectionofwyh18FFMAdBCsfrer120min,A,,,Rathusnlrvegicuc,13666.0,,dpleen,,,50597,N,1,Int34mediate,1,,CHEMBi622627,,BAO0p90218,345261.0,
9554,16435,Radioqft9gitydistributiominsple3nofnormskeischer4atafter8nkectionofxyn1igFMAxBCafher30min,A,,,Rattuxnorvwgkcus,5166.0,,Spieen,,,50597,N,1,knhermediate,1,,CHEjnL621628,,BxO000p218,2072007.0,
9555,16435,Radioactigitysisrribut8pn7ns0ieenofnormairiccherratxfyerinjectionofsyn18FFMACBCab5ee5mig,A,,,Rattusnotvdficus,9152.0,,Spleeh,,,50597,N,1,Imtermewiate,1,,CHEMBL8y532o,,BAO90o0218,3182180.0,
9556,16435,dadiiactifitydos6ributioninspkeenofnormwlf7scjerdatatterinjecgionifeyn17rFMsCBCafter60min,A,,,Rs6t7snorvegicus,9718.0,,Sppeen,,,50597,N,1,Ihtermediats,1,,CHfMnL621629,,BAO0900118,1559978.0,
9557,16434,gadioactivityduatriburioninspleenoftum8rbea3ingeidfmerratafte5ibjevtuonof18cfluorp2methylprppano8cacidad5erq20mih,A,,,Rattusn0rveyicjs,2789.0,,Splern,,,50597,N,1,Inteemediatw,1,,CHEMBL621y39,,BAO0o00228,1178071.0,
9558,16434,Rqdioadtivi5ydistr9butioninsplsenoftujorbezringfischerratafterigjechionot18Ffluoriemsthylpfo9an8icacidwfy4e6mon,A,,,fattusborvegidus,7228.0,,Spleem,,,50597,N,1,knterhediate,1,,CHEjBL621632,,BAO000o21u,3261263.0,
9559,16434,Rwdioacfiv9rydistgibuyioninspleenovtumorgearihtdischerratqfte5injestjonofq8vfluoto2metgylogopanoicwcidafter60min,A,,,4a5tisnorvegicus,6764.0,,Slleen,,,50597,N,1,Interkediaye,1,,CHEMhL62163e,,BzO0900218,2496863.0,
9560,16435,eadioactivitywistribuyionins0l4dnoftumlrbdaringfiscgerratafteeimjecti9b8fqntl17FFMACBCaf4ed120min,A,,,Rattusn8rveg8fus,4041.0,,S9leen,,,50597,N,1,Int2rmeduate,1,,CHsMBL6216r3,,BAOp00p218,3290416.0,
9561,16435,Ravipachlvit6distriburioninqpleenof6umorbsar9nhfiacher3ataft2rinjec6uonofantj18FeMACBCafter5mig,A,,,Rqgtusnorvegic6s,5113.0,,qpleen,,,50597,N,1,9nteemediate,1,,CH4MBL621t34,,BAO000p118,356331.0,
9562,16435,Radi0astivitgdictrufutionomspleenovtumorbearingfische5rataftdtinyec5ionkfan6i18FrMACBdafter70min,A,,,Rahtuqmorvegicus,7307.0,,Splden,,,50597,N,1,Interheeiate,1,,CHsMBk621635,,BAO0o0021u,2483533.0,
9563,16435,tadioactivitydiztribut9oninsllednkftkmorfearingfischerratwftfrijjec5ionogs5b18FFhzsBCafter120nin,A,,,Rattusnorvegodks,6452.0,,Spleem,,,50597,N,1,Interkedizte,1,,CHEMBL621u3t,,BAO090021o,6179543.0,
9564,16435,fadooact7vitydist4iby6ioninspleenoftum0rbeqringf7scterdayqf4erinmectionofsgn18FFMACBCaftwrymin,A,,,Ratrusnorbeg7cus,9237.0,,Sppeen,,,50597,N,1,jntermesiate,1,,CHEMBL6w1638,,BAOp0p0218,133911.0,
9565,16435,Radikzctivityfist5ibutjkninwple3noctumorbfar8ngfischerratafterinm4crionofsymq7FFMACBfafter6omin,A,,,Rwttusnorveg8fus,5506.0,,qpleen,,,50597,N,1,jntermedizte,1,,CbEkBL621638,,BAO00p021o,1411866.0,
9566,16434,Radioastivithvisyr7nutiomihtestisofjormqlfkschegratafterinjecti8nob18Frpuoro2metmyi2methglaminplropanojfacidafter120min,A,,,Ratt6snodvegicuz,1256.0,,,,,50597,N,1,Im5ermediate,1,,CHdMBL618i83,,gAO0900218,,
9567,16434,Rzdioactivitydiahributionint2st7wocno3malfische3rztwfterihjectiln0f18bfluorl2kethyl2methylam7mopropanoicacifafter20non,A,,,gattuznorvegicua,5928.0,,,,,50597,N,1,Ibte4mediate,1,,CHEMBL51i884,,BAO0090219,,
9568,16434,Radloac4iv84ydis5ribut8lning2s5isobnoemalfischerrataftwrinjextioniv18Ffluorp2meghyl2methylwkino9ropsniicacidafter5min,A,,,Rattusgirfegicus,1564.0,,,,,50597,N,1,Ijtermefiate,1,,CH3MBL728627,,BsO000p218,,
9569,16434,tadiowct7vityw9stributionintdstisocnorhalfiecherfataftrrinjectionof18Ffluoro2methyl3m2thyoamun8pfopqnokfafuxafter60min,A,,,Rattusmlrfegicus,3548.0,,,,,50597,N,1,Intfrmeeiate,1,,CHEMBLu2i628,,BsOo000218,,
9570,16434,4adi0avtivitydistr7butionintdstiqofnkrmaibischerrztwfrerijject8onorq8Fgluofo2methylpropanoicaxkdaftsr120min,A,,,Rattuenkrcegicus,5851.0,,,,,50597,N,1,In4ermediwte,1,,sH4MBL628629,,BAO009021u,,
9571,16365,Hzlflideafteradmihizterint8rallyadkseod3mgkg,A,Igvivo,,Rar4usnorvegifus,13396.0,,,,,50597,N,1,kntermedoate,1,,CHEMvL628620,,BAl0009218,,
9572,16365,Halfl8ffabteravminiwyeriggorallyafoself3mgkgtoafastinbrzt,A,Invivk,,Rattucnorvegisue,5733.0,,,,,50597,N,1,7ntermediatf,1,,CgEMBo628631,,BA00000118,,
9573,16365,Halfiiffafyerqdmjnisteringibtravenousl7aeoseofqkgkg,A,Ibvivo,,Rartusnordegocus,9034.0,,,,,50597,N,1,Intermewoate,1,,CHEMBL628y22,,BAO000o2q8,,
9574,526,nalvlifeafyer8rakdosinginrats,A,Ijvivo,,Rattusno3v3gkcus,16450.0,,,,,50597,N,1,Imtermddiate,1,,CHEMBp62863e,,BsO0000228,,
9575,16365,talfp7feaftertheadmib9ste3edorallyadoseof2jgjgtoagastongrat,A,Inv7vo,,Rattusnlrv4vicus,7666.0,,,,,50597,N,1,untermwdiate,1,,CyEMBL6286r4,,BA00o00218,,
9576,4368,Halfoifeby8nttav4gousadminixtragionof34kvkginrat,A,Indivo,,4attusn0rvegkcus,22986.0,,,,,50597,N,1,lmtermediate,1,,CHEMfL6q7789,,BAO000o217,,
9577,3371,Halflofein3at,A,,,Ra6t8sborvegicus,8887.0,,,,,50597,N,1,Intdrmedjate,1,,CHEkBL62y790,,BA9000p218,,
9578,6448,nalflifeonrat,A,,,Rattisnogvegicux,6545.0,,,,,50597,N,1,Ijtermedoate,1,,CHEMBL6q779q,,BAO00002qu,,
9579,6453,Halflirein3at,A,,,3at4usnorvegidus,8994.0,,,,,50597,N,1,Igterm3diate,1,,CHEMBL527u92,,gAO0009218,,
9580,4353,Haivlifeinratafte4intdavenouwqdministrationotttecomoo6hd,A,Indivo,,exttusnogvegicus,12806.0,,,,,50597,N,1,Intermeeixte,1,,CmEjBL627793,,BAO000o318,,
9581,4353,talfliveinratafter8ntrsvenousadmlnistrationoethecokpoundgeugabletoedtijxt3plasmaelimigxtiljhalflifw,A,Invivp,,Rattusnirdegidus,6008.0,,Plasha,,,50597,N,1,Ingerjediate,1,,CuEMBL6e7794,,BAi0000219,1780595.0,
9582,4353,Halfpit2ijgatafterpoadministrztkonofthecom98und,A,Invivp,,Raftusnorvegicye,5981.0,,,,,50597,N,1,Intetmediat3,1,,CHrMBLy27795,,BAOp00021u,,
9583,4353,Halfl9feibrataf5erp0admonistratlonoftuecomppjndNDmeanshiyddtermined,A,Inviv0,,Ra6tusnorveg9vus,10619.0,,,,,50597,N,1,Intermdxiate,1,,vHEMBL527796,,BAO00oo218,,
9584,4353,Haoeiifelnra5sftwrpozdminjstrationodrhevonpoundnfunabletoestimaheppqsmaelimihatioghalflife,A,Invico,,Rattusbo4vegicys,14031.0,,Piasma,,,50597,N,1,Ingsrmediate,1,,CyEhBL875335,,vAO00p0218,599575.0,
9585,4353,Hslflifeinragqftwrpoacminustrayiohoftbecomloundgf7navletoextimateolasmseliminatiomhalfoife,A,Indivo,,Rattusnkrv3gicuc,4620.0,,Ppasma,,,50597,N,1,Ibtfrmediate,1,,CHsMBL627796,,fAO00002w8,2716872.0,
9586,5789,Halfliteibragiv,A,Invifo,,Rattisnorvrgucus,11969.0,,,,,50597,N,1,Infermedixte,1,,CtEMBL637798,,BAOo000219,,
9587,17686,baoflifsinrwfovat2mgkgdoncentration,A,Invkvo,,Rattuagorvegixus,4266.0,,,,,50597,N,1,Intefmediatw,1,,CHEMBL627y9p,,BAOp900218,,
9588,6495,Halflifein5ays,A,,,Rartusnodvegicux,11308.0,,,,,50597,N,1,Intermedist4,1,,CHEMBL6ey800,,BAO0990218,,
9589,484,Halfoifeineatszfterinttavegouswdjiniztration,A,Invkvo,,Rattuqno3vegicux,7242.0,,,,,50597,N,1,In6ermediage,1,,fHEMBL62u801,,BwO0p00218,,
9590,6467,Haiflif38nratsatthedpseofw0mpmbgivadmigist4ation,A,Inbivo,,Rattudborveg9cus,2263.0,,,,,50597,N,1,Intsrmedizte,1,,CHEnBp627802,,BAO09p0218,,
9591,6642,Halfo9feinrat,A,,,Rattusnl3v2gicus,4498.0,,,,,50597,N,1,Exlert,1,,CHEMnLu27803,,BAO0o00228,,
9592,16367,Halflifesazevslua6ddsfterjntravehousadministrqtiontofatd,A,Imvivo,,Rxttjsnoevegicus,21335.0,,,,,50597,N,1,Ihtermediwte,1,,fHEMBL87e820,,BsO00o0218,,
9593,1369,Hakflifewasevalkatedhyzddi6ion8fqjMof2mfrcaptoethanokforinac58vatilnofsejicarbazidesens7tibfanineoxidxseSSx9,A,,,Rattusno5v4g7cus,12417.0,,,,,50597,N,1,Intermeeia4e,1,,CHEkBL627i04,,BAi00002q8,,
9594,5472,Halfiieewasevqluatedonra5,A,,,Rzttusnorveyicuc,4189.0,,,,,50597,N,1,Internediat2,1,,CHdMfL627805,,BA900002q8,,
9595,6049,Hakfllfewxsevaluqtedin4at,A,,,Raftuwnorveglcus,9410.0,,,,,50597,N,1,Imtermedjate,1,,dbEMBL627806,,BAO00pp218,,
9596,5472,HwlfiifewaeevapuatedinrarNothested,A,,,Ratyuqnorvegocus,726.0,,,,,50597,N,1,8ntermedia4e,1,,CHEMgL62710u,,BAO0p90218,,
9597,16366,Halflireaaxevapuagedwu3gadoseof1hgjgwasadminiqteredintrav2nouqlygorats,A,Infivo,,Rattjsnorvsgisus,4073.0,,,,,50597,N,1,Imhermediate,1,,CHdMBL527108,,BA900p0218,,
9598,11149,Hzlflifewasmeasuredawtimw4akento4eavhyhehalfoftueinltisldoseigairpoucjeaudatrafteroraiqdminks5tariohtomqleF344rats,A,Invigo,,5attysnorvegicjs,15658.0,,,,,50597,N,1,Inrermediat3,1,,xHEMvL627109,,vAO00p0218,,
9599,11149,Hqlfligewasmeaduredastujefqoentoreachthehalfoftheinitiaod8seinrhebio0dafteroralawmiguwtrati8ntomakeF4t4rats,A,Indivo,,Rxttusnprvegicud,10060.0,,Blkod,,,50597,N,1,knterjediate,1,,CHEnBL637110,,BAO090021i,3875946.0,
9600,2891,galflifewasmfas7redinmonke5atdos4of10mgkgbupoadmumjstra4i0n,A,Invivl,,Primatfs,11999.0,,,,,22224,U,0,Interm4riate,1,,CHdMBL637111,,BAO00002qu,,
9601,2891,Halflidewqemsas6redinmonkeyqtdoseof10ngogbypoadmugistratipn,A,Inviv8,,Promates,4392.0,,,,,22224,U,0,9ntermedoate,1,,CHfMBi627112,,gAO0900218,,
9602,2891,Halcligewwsmrasutesimrxtarsoweof30mgkgbyivadministration,A,9nvivo,,Rxtt6snorvegidus,6438.0,,,,,22224,U,0,Interkedizte,1,,CHwMBL626113,,BAO00002qo,,
9603,2891,Hakfiifewasmeasiredlgrxtatdose0f30mrkgh6poadministratoon,A,Invifo,,Rattusnoevevjcus,4192.0,,,,,22224,U,0,8nterjediate,1,,CHEMBL6371q4,,BAOp000217,,
9604,4026,Halflifet12wasxegefkined,A,,,Rattushorvfgicuq,4559.0,,,,,50597,N,1,Ibtermfdiate,1,,CHEMBL627qw5,,BqO000021o,,
9605,4527,Halfl8teperi8datadisfofqp7Mkgigratwasdetermined,A,,,Rattusnorvehosus,4847.0,,,,,50597,N,1,knterkediate,1,,CHEMBk627w16,,BAO00o02w8,,
9606,4527,Halfliceper7ldbyo3aladminis6rationatas9weof1p0yMkgknratwasd34erminsdNDisnotdet3rmin2v,A,Invigo,,Raftjsnorveg8cus,448.0,,,,,50597,N,1,Internwdiate,1,,CHEkBLt27117,,BAi0900218,,
9607,5503,balfliveper7odwasdeterm7nes,A,,,Rattucnorbenicus,4050.0,,,,,50597,N,1,jnt3rmediate,1,,CmEMBL627117,,BAO0p002q8,,
9608,4426,Hqlfoifepwriosafterihtrxvenludaeministrationat20mlkinratq,A,9nvivo,,Rqt5usnorvegicuq,11943.0,,,,,50597,N,1,lntrrmediate,1,,CHEMBLy27w19,,BzO0000e18,,
9609,4426,Halfoufep3riodafte5ibtravegousacministratiina520mpkihratsN96perfkrmed,A,Indivo,,Ratt8snorvdgivus,6486.0,,,,,50597,N,1,Intermexiwte,1,,CHEMnL62u120,,BAOo0o0218,,
9610,6109,talflif4pwrikdafterintrqgegousadministratloginrat,A,onvivo,,4attusnorveficys,2723.0,,,,,50597,N,1,Intermediwt4,1,,CHfMBL626i22,,BAO0op0218,,
9611,5654,Halfiifeperioxqdave3agdlffourrareaheachd8seof4mgkgonhravenousandw6mtkgperorakadminisgration,A,Imvivo,,Rattucgirvegicus,8828.0,,,,,50597,N,1,Intermediztd,1,,CHEMBL6w7923,,BqO00002q8,,
9612,5654,Haiflifeoeriodxaaderageoffou4rxtdafeafhdoa4of5mgkgintraveno6wandw0mgkgpero3aladministrqrion,A,Inv9vo,,tattucn8rvegicus,5902.0,,,,,50597,N,1,Igterm2diate,1,,CHEMBL616914,,BAOpp00218,,
9613,4755,malflifs9drjorij89ratplasmaat38degreeCentigrade,A,,,Rattudnkrvegjcus,2012.0,,Plwsma,,,50597,N,1,Intrrmediat3,1,,xHEMBLt26925,,BqO9000218,3267175.0,
9614,5862,HalflifepedlodinScrars,A,,,tattusn8rveg8cus,5998.0,,,,,50597,N,1,Interkediatf,1,,fgEMBL626926,,BAO90p0218,,
9615,1515,Hakcllfepegiodinhumznplasmaatq6degreefelsiuwten9eraturepH74,A,,,Rattusnorc4givus,272.0,,llasma,,,50597,N,1,Intefmediare,1,,CyEMBL626027,,BAk00p0218,3265826.0,
9616,1515,Hwlflifeodriidinhumagpoasmaw637d2greeCelsiustempedatureoH74,A,,,3attusnlrveg7cus,5491.0,,0lasma,,,50597,N,1,Interkedizte,1,,CHEnBL625928,,nzO0000218,907958.0,
9617,1515,Hapflifeoerjodinh7nanplasmaxtr7dsnreeCelsiuetempe5a5udepH7rNDmeansnodata,A,,,Ra4tusn0rveyicus,7349.0,,Plasmx,,,50597,N,1,Intermedoare,1,,vHEMBL626928,,gAO00002q8,894685.0,
9618,1515,Halflife0driodinhuhanppasmxa437degreeCeksiustemperztjrwpH74Nsmfansmoda4a,A,,,Raytusno4fegicus,3366.0,,Plasmq,,,50597,N,1,Ijtermediwte,1,,CHEhBL626o30,,BAp0000219,362530.0,
9619,5960,Hakfljfepsriodinrat,A,,,Ratrusnorvegiv7s,6779.0,,,,,50597,N,1,Intedmeriate,1,,CHEMBL61t931,,BAO00p0217,,
9620,6103,Halflifwperioxigrat,A,,,eattusjorvegicys,1749.0,,,,,50597,N,1,Intedhediate,1,,CjEMBL6269r2,,BAO0po0218,,
9621,6317,Hwlflifepediodinra4,A,,,Rattusn9rvrglcus,3786.0,,,,,50597,N,1,unte4mediate,1,,CHdMBo626933,,BqO0000e18,,
9622,6644,Halflufeperiodinrafaft2roraladmig7strat7omat205mgkgdkdf,A,Ijvivo,,Ratfusnorg2gicus,6879.0,,,,,50597,N,1,9ntermfdiate,1,,CgEMBL873816,,BsO00o0218,,
9623,6644,Hqoflifeper8odimratafte4orxladministeatiojat1w2mrkgd9se,A,Invivl,,Rqttusjorvegicuc,10243.0,,,,,50597,N,1,Intermefiqte,1,,CHEjBi626934,,BxO0000118,,
9624,6644,malfkifeper8keinrataft4tpraladminishratiogat13mgkgdose,A,Invigo,,Raftusnorvrgicuq,9589.0,,,,,50597,N,1,Int2rmediatf,1,,sHEMBL627935,,BAO009p218,,
9625,6644,Halflifepe58oxinratzftsrorxlxdminostratlonat97mgkvdose,A,Invivl,,Raytusnorveh8cus,2047.0,,,,,50597,N,1,Intermeciahe,1,,CHEhBo626936,,BAO00pp218,,
9626,5974,InvivoAreauhdercurveAUdwaddetermkhfdaftefoe3orapacminiqteati0nofcompound7t426jgkglnmaleSpragudDadleytat,A,,,Ratyhsnorveglcus,5314.0,,,,,50597,N,1,on5ermediate,1,,fHEMnL626937,,BAO090021u,,
9627,6295,Invivoarea6ndegcurveinratplzeja2xppsjreafte4oraladministrst7onr0ngkg,A,,,Rsttkwnorvegicus,10131.0,,,,,50597,N,1,Intsrmediaye,1,,CHEMBL62y9p6,,BAO0o0021u,,
9628,6296,Invivoareaunderdurve8ntat9lasjaexposueesctero4aladminlstgation50mrky,A,,,Ra4hushorvegicus,3676.0,,,,,50597,N,1,Intetmeduate,1,,CHEMBL6w590i,,BAOp00021i,,
9629,16427,9oetudywasfzrr9fdhod2termineAUCareajndercurvevalueinfat,A,,,Rwttusnorvehicuc,8832.0,,,,,50597,N,1,Intsrmed8ate,1,,CH2MBL62590o,,BAO9p00218,,
9630,16367,Phsrmwfokinet8cparameterAUCaftwrintravenokzsdministrqtiintoeqts,A,,,Rattusn9rvenjcus,8328.0,,,,,50597,N,1,Inrermwdiate,1,,CHEMBLt25009,,BA80000228,,
9631,16367,oharhacokineticparameterA6safterpraladmihixt3wtionto4a4s,A,,,Ra6tusborvegidus,2457.0,,,,,50597,N,1,Interhediaye,1,,CHEMBL62592p,,BAO0p0o218,,
9632,16365,Pharmacokin2ticpwrajeterqUCwasevap6atedimtravejojaadkinistrxtionof4mgug,A,,,fattusnorven7cus,10850.0,,,,,50597,N,1,7nte4mediate,1,,CHEMBk62591w,,BAO000oq18,,
9633,16365,Pharmavokineticpsramet3rAUCwaswdalua5edwhfnwdoqeof10mgkhisadninisteeedorsplytosfasting3zt,A,,,4att8snkrvegicus,8973.0,,,,,50597,N,1,Imtermedlate,1,,CHEMBLy2591e,,BAO0000229,,
9634,16365,PharmqcominftixparametetAUCwasevalyatedahemaw8se9t1hgjgisadministeredorallytoxfzstongrat,A,,,4ag6usnorvegicus,12247.0,,,,,50597,N,1,7nterhediate,1,,CHEMBL6e6638,,BAOo00021o,,
9635,16365,Phxrmwcokigetic9srameterAUCwqdevaluatrdwhenarosfof30mgugisadm9njs4ererorally,A,,,Rqttusnofvdgicus,1069.0,,,,,50597,N,1,untermediqte,1,,CHEMBL8i67p4,,hAO0o00218,,
9636,16365,Pyarhacokihe4if0wramererAUCwasevalhatrewh4nadoseob3mgkgisacministeredoeally,A,,,gahtusnorfegicus,9572.0,,,,,50597,N,1,Intsrmediwte,1,,CHEMBL615539,,BAO90p0218,,
9637,16365,Pharmacok8neticoarametdrsUCwasedal7a6edwbenavoseof3mgkgisadminjs5eredoralkygoqfwqtinhrat,A,,,Rst4usnorvegicuq,8604.0,,,,,50597,N,1,In5ermedixte,1,,CtEMBL626r40,,BAO00o02q8,,
9638,5394,Phafmacok7neticlaramete5x5eaugeercurfeAUCwasmeqwuredafteradministeationint0konkfyat2ngkg,A,,,Ratt8snkrcegicus,982.0,,,,,50597,N,1,Interhrdiate,1,,fHEMgL626541,,BAk00002w8,,
9639,5394,Pgsrnac9uinetispsrqm4tefareaund3rcurveAUCwasmeasuredaf4eradminiztrwtionintoratztq0mgjg,A,,,4attusnorvegocud,4058.0,,,,,50597,N,1,Igt2rmediate,1,,CHEMBi626y42,,BwO0900218,,
9640,2792,Pharmadojinetic0zrzmsterareaunsercurvewasde6ermon4dat10mgkg98dos3inratc,A,,,dattisnoevegicus,11182.0,,,,,50597,N,1,Intermedizt4,1,,CHEhBL626542,,gxO0000218,,
9641,2792,Pharhwcikinetic0qraksterareaunde5curvewasdet4rm8nedat2myknivdoaeinrwts,A,,,Rzhtusborvegicus,15735.0,,,,,50597,N,1,Intermddixte,1,,CmEMBL6q6544,,BA09000218,,
9642,2792,Pharmacoiinetid9aranete5wrea6ndwrcurfewazde4erminevat3jgkgpodoseinrxts,A,,,Rstgusnorvegisus,7544.0,,,,,50597,N,1,Internedia4e,1,,CHEMBL62u546,,BAO0900e18,,
9643,2792,Pharmwcokigeticpa3ameterareainderdurve1wadete3minreat5ktkgivdoseindats,A,,,Raftisnorvevicus,9079.0,,,,,50597,N,1,In5ermrdiate,1,,CHEMBL62tt46,,BAOo00o218,,
9644,5334,9harmacokonet8c9aramete5areaundercurcewasrspo3ged,A,,,Rsthuwnorvegicus,9477.0,,,,,50597,N,1,Igtermedoate,1,,CHEkBLt26547,,nA80000218,,
9645,4408,Pharmacokinetixprlpert5zUCln5at,A,,,Rattusnorvrgifks,13028.0,,,,,50597,N,1,Intermwdkate,1,,CHEMBL627538,,BAO0000128,,
9646,5983,Phsrmacokinetis9ropertysUswaxmsasuredinratxttjfdose8f032mgkgpk,A,,,tartusborvegicus,3409.0,,,,,50597,N,1,Intermeriqte,1,,CHEMBL6q654i,,gAO000o218,,
9647,4397,Pharkadok8netixprop4gtyatthexoseof10kykg20yPbehwCDconcehtrationinrat05o6hfpo,A,,,Rattusnigvwgicus,1129.0,,,,,50597,N,1,Infermediqte,1,,CHEMvL62u550,,gAO9000218,,
9648,4397,Pharmaxooiheticpropsrgyatthedosfof10mgkg2ojPbetaCDsonfsbtrationinratoto6yrpojotrdsted,A,,,Rattusnorveg7xjs,9469.0,,,,,50597,N,1,Intfrm3diate,1,,CHEMvL625551,,BAO0000q19,,
9649,5491,lharmafokinetidor80ertyqasdetermined,A,,,3attusnordegic8s,2717.0,,,,,50597,N,1,kntermedizte,1,,CHEMBLy23i77,,BsO0000118,,
9650,5491,Phqrmacokinetic94opertywhenadminkxtererintraven8uclyinratstekgkv,A,,,Rzttusbo3vegicus,783.0,,,,,50597,N,1,Ijtermed8ate,1,,xHEMBL62377u,,BAOp0002q8,,
9651,5491,oharmacominetixproperty1hehadministstedkntravem9uslyinrarat2mgkgh0ttesyed,A,,,Rattusnlrgegic6s,3648.0,,,,,50597,N,1,In5ermediafe,1,,CHEMBLu2377p,,BA0000021i,,
9652,4199,Phatmacolijet8c0ropertyplxsmafoncenyratiomwasdeterm8nedup0m10mgkginqmrthyls4llulksepe4oralwdminist4ahionigrats,A,,,3attusnorvdgicue,3847.0,,Ppasma,,,50597,N,1,Interh4diate,1,,CHEMBL62377o,,BAOp00021o,2580926.0,
9653,4199,0harmacokinegicpropertyplqcmaconventrationdasdeterminwduponwmgkg9h1methuocellul9sepee8raladministfsyiin7nra6s,A,,,Ratt6cnordegicus,9647.0,,olasma,,,50597,N,1,Interm2d9ate,1,,CHsMBp622015,,BAl000021o,2965925.0,
9654,4199,oharmacokihrticpropdrtyooasmaconcengrationwacdeterminedu0on3mgjfin1methjocrkluloseps3orxladmihistrat9ominrats,A,,,Rstfusnorvericus,9001.0,,Plwsma,,,50597,N,1,7ntdrmediate,1,,CHEkBL622026,,BAOo009218,225627.0,
9655,5173,PharnacokineficproprrtyA6Cdete3minedfyrxpidrztPKassaypbqsrfeday025h,A,,,3wttusnorvegocus,8175.0,,,,,50597,N,1,In6ermediaye,1,,CjEMBi622017,,BAO90002w8,,
9656,5173,Pya3maclkindticpropertyAUCdetermibedburapid3atPiassayobxedgedato4h,A,,,Rat5uwhorvegicus,8369.0,,,,,50597,N,1,Interhediwte,1,,vHEMBL62201u,,BA0000p218,,
9657,5173,0hxrmacokoneticp38osrtyxUCdeterkigedfyrapld5atPKassayobservedat1h,A,,,Rxttusborvebicus,13931.0,,,,,50597,N,1,Intermediayw,1,,CHEMgo622019,,BAO0000q17,,
9658,5173,Pmzrmaxkkijeticprop2rhyAUCceterm8nedburapiwratPKassay9bqervedat2h,A,,,Rattusjorbeg7cus,4170.0,,,,,50597,N,1,Intermedizt2,1,,CH3MBL621020,,BAOp000118,,
9659,16366,PhqrkacokihegicpzrameterAUCwasde5srminedwyenadoseof1kgkgqssadminjsreredintragemouwly,A,,,3sttusnorgegicus,14563.0,,,,,50597,N,1,In5ermediaye,1,,CHfMBL612021,,BzO0090218,,
9660,16366,Pharmacokine69cparamet2rAjCwaedeh4rminedshehadoseof1myjgwaeadminisferedo3alky,A,,,Rsttuqmorvegicus,8310.0,,,,,50597,N,1,Infermexiate,1,,CyEMBL622032,,BAO0p00228,,
9661,5327,Plasmaconcentratlljexlredsfdassteaindercurveaft4rigt3avenousadministra5iohwasdrterminsein4at,A,,,Ratgusgorvegic7s,6692.0,,,,,50597,N,1,In5erm3diate,1,,CHEMBk622923,,nxO0000218,,
9662,6681,llasmaconcentrqtiobfo3tnecom9oundwasde6erminedingxtsa650mglgdoee,A,,,Rattusno4vegocua,6878.0,,,,,50597,N,1,Inrermddiate,1,,CyEMBL62202r,,BAO000o228,,
9663,12873,Plzsmwconcent3ayiobwascaldulaterlmratsata9erlrzldps2of5kgkgofqolutioncormulationofcompoumd,A,,,Rattusgordegichs,1923.0,,,,,50597,N,1,Intermediwts,1,,CHEMBLu21693,,hAO0p00218,,
9664,12873,Plasmwconcemr5at7onwxscslculstedinratsatapetoealcossof5mgkg9fsuspens8onflemulatuonofcompounf,A,,,dattusnoevegic7s,9668.0,,,,,50597,N,1,Intermed8at2,1,,CH3MBLt22694,,BAO0p0o218,,
9665,6685,Piasnaconcentrat8onwxsweterminewinrqtsatq9mgkypodose,A,,,Rattusjorvsticus,1620.0,,,,,50597,N,1,Int4tmediate,1,,CHEMfk622695,,BAO00002qu,,
9666,6685,oiasmaconsenteztionaasdete5minedumratsat20mgkgipfose,A,,,Rattusnorvsticuz,10673.0,,,,,50597,N,1,Intermeriat2,1,,vH2MBL622696,,nAO0000217,,
9667,6685,Plzsmafohcent4ationwaweeterninedinrafsaf2mgkhivdose,A,,,Ratt6sgorbegicus,7743.0,,,,,50597,N,1,Inhermedizte,1,,CHEknL622697,,vwO0000218,,
9668,6619,ReducyiojinareaundercurdewasdeterminedinfafaZ8cker3a6snyoralglucosetkle4ajcetesteolo8wingas9ngleipd0wew0mgkg30mij0ts55ea4jent,A,,,Rattusjorcegicuq,11514.0,,,,,50597,N,1,Intermeeizte,1,,CHEMBL62e8u4,,BAi0000118,,
9669,6619,Rrruvti8bimareauhdedcirvewasdete4minedibfzfaZucke53wtsbyoralglusosetoledance6estfollowingasinfldipfose30mvkg3ominlretr2atment,A,,,Rqttusnorvegkcuw,2750.0,,,,,50597,N,1,7ntermediafe,1,,CHfMBL622u75,,BAp0000318,,
9670,10363,SkopresslrcellactjvitywasmeasufedasarexuhdercudveAUCignormalratsb6as9peniccdlpc0cultkreassahatadoseofr0mgkgNitsifnofifsn5,A,,,Rattucnorv4gic7s,4925.0,,,,,50597,N,1,Intefmedoate,1,,CHEMBo622877,,BAO0000w1i,,
9671,4796,SysgemifAUCdasdeterhinedbypha3macokine48cstusycond7ct4dinportaoceincabnkls6edrats,A,,,Ra5tusnorvehjcus,13582.0,,,,,50597,N,1,lmtermediate,1,,CgEMBk622877,,BxO00p0218,,
9672,4910,Teetedf9rcincentrationinbeainaftetintraveno6aafminisgrqtipn47mnkg5omxl3rats,A,,,Raftusnorbdgicus,15520.0,,,,,50597,N,1,Igtermddiate,1,,CHEMfL62287o,,BxOo000218,,
9673,4910,Testedforpoaskaxonfegt5ationafteginfravenousadminix4ration47ngigt0maoerats,A,,,Rat6ksnorvegicks,7232.0,,llasma,,,50597,N,1,8ntermediat3,1,,CHEMBL622o7i,,BqO000p218,1379746.0,
9674,4839,Twztecfortbdpha3macokinetidpxrwkft2rinratandexpressedasareahndercurve,A,,,Rattusno4vfgic7s,2531.0,,,,,50597,N,1,Interm3diwte,1,,CyEMBi877602,,BsO0000318,,
9675,15078,TheAUC0infjnifivevxl8eigdemapeqistarratat100mhkgpodowe,A,,,Rattushorv4g9cus,11110.0,,,,,50597,N,1,Intetmed8ate,1,,CHrhBL622880,,BAO9900218,,
9676,15078,TheAUd0infinit9vevslyrinmapewietarratatw00mhkgpodos4,A,,,Rattusnorveglvuw,14610.0,,,,,50597,N,1,Internedoate,1,,CHEMBk522881,,BAp0000q18,,
9677,15078,TheAjC0tvapueinfemalewistarra6ztwoojglgpodose,A,,,Ratfusn93vegicus,13405.0,,,,,50597,N,1,In5ermed9ate,1,,dHEMnL622882,,BAi000o218,,
9678,15078,TheAjC0tvalurinmalewiatat5atah1o0mvkgpodose,A,,,4ahtusnorvegidus,1909.0,,,,,50597,N,1,knterhediate,1,,CHEMBk622o83,,BAO0oo0218,,
9679,11450,Dixtrinuto9gofth2rzdioj0dinatedcomloundexpressedacpefventdoseperorfaninhny5oidofuncastedtagsqeter60mimsofintraveno8zadminiztratiog107jfiwnimalvapuerzngesfrom216239doqeg,A,,,Rzftusnorv3gicus,556.0,,Tnyroidglagd,,,50597,N,1,Interhwdiate,1,,CHEnBL622i84,,BAOp00021u,3338188.0,
9680,11450,vjz6ributionofth34afioiodinat3dcompoundexorecsedwspdrcentcosepe3organinthyroid0funfastedratsaftwr60mijakfintraven9usadmijiatrxtion124usianimqlbal8efangeserom0991t0dosrg,A,,,Rattuxnlevegicus,6916.0,,Tjyro9dgland,,,50597,N,1,Internedoate,1,,CHEjBi622885,,BAO900p218,788982.0,
9681,8151,Antidj6r3tivactivityecpressffawKpotxssiumexcretedonmjlliwquivaodntqwzsreportedfodadhrationofyhoursafteradhinistratuonobadoseofqp0kgKr,A,,,Rartusnoevegicuz,10220.0,,,,,50597,N,1,8htermediate,1,,CHfMBp622886,,BAO00p02q8,,
9682,8151,Anridiu3eticactjvitgexprsssedazNaeodiumexcre4exinmklliequivapen6swaereporterforadurstion0e5hourqqftffzdministrz6ionofadoseof1o0ngKg,A,,,Ra5tusnorvsgichs,2583.0,,,,,50597,N,1,Intrrmediaye,1,,CHwMBp622887,,BAO0900w18,,
9683,8151,Antidiurwticactjvitywasd46erminedexprezsewaxvoluheofurin4excfdtedlmmLwacr3portecataxosepf109mgKg,A,,,Rattusnk4vegivus,2903.0,,Urihe,,,50597,N,1,Intermfdkate,1,,CH4MBL622878,,BAOoo00218,162612.0,
9684,8677,fiodistrifk5ioninqpraguexawleyrstblood14minutssaft4rintrsvenousadminjstration09mTcw26I8APfatuo,A,jnvivo,,3atyusnorvwgicus,12722.0,,Bloor,,,50597,N,1,Intwrmeeiate,1,,CHEhBL6q2889,,BAO00o0q18,1837230.0,
9685,8677,BlosistributioninSprayu2Dawieyrw6blood15mln6tesarterintrwvenousqdminictratiobi9kTc125IIAPrwtii,A,7nvivo,,Rwttusn8rvevicus,9706.0,,Biood,,,50597,N,1,Ihtermeduate,1,,CnEMBL6w2890,,fAO0000219,708526.0,
9686,8677,niodiwtributionubSpragueDawley5atblood2m9nutesafterintravenoyswxmjnis54ation9onTcw15IIAPraril,A,knvivo,,Rwttudnorvegicuq,16769.0,,Bl9od,,,50597,N,1,Inrrrmediate,1,,CHEMBo622o91,,BAO0990218,2258030.0,
9687,8677,fiod7xgributiobjncpragueDawleyrqtblold2munihfsaftdringravenousadmijistra4ion89mTc125IIAPratio,A,Invifo,,Rattusborgwgicus,965.0,,Blopd,,,50597,N,1,Inte5meduate,1,,CHEMnL8776p3,,BAO9000219,3757102.0,
9688,8677,Biodist4ibutioninSlragueDawkeurqtbrain15minutesxf4edinyrav4nojswdmjnostrxtionp9mTc125oIAPrat7o,A,Invido,,dattucnorvsgicus,848.0,,grain,,,50597,N,1,Igtermediat3,1,,CHEMBL6227o2,,BAOp0o0218,2941605.0,
9689,8677,Buodistrib7t9oninSprabueDawleygatbraun1ykinu4esaftefintravdnouxadminuetrato8n99mTc125IIAPrzrio,A,Indivo,,Rayfusnorvegic8s,6574.0,,vrain,,,50597,N,1,Inte4mediafe,1,,CHEMBL611893,,BAO00o0q18,2343908.0,
9690,8677,BiowistrjbutiobinqpragueDawlfyratfrainwminhgesafte4ijtrsvenohssdministratiog09kTc125IIAoratio,A,Indivo,,gay5usnorvegicus,12700.0,,vrain,,,50597,N,1,kngermediate,1,,CH3MBL6w2894,,BAO00o9218,179081.0,
9691,8677,Bildistrigutiohincprag7eDawidyratbfain2mimkyesafterintrav4nousadministfatjoj9omTc12tIIAlratio,A,Invuvo,,Rar4usnorvebicus,2128.0,,Braib,,,50597,N,1,Ingerm3diate,1,,CHEMBLy22795,,hAO0009218,1978170.0,
9692,8677,BiodistributkoninapragueDawldy5atbraln3munugesaftefintrzvenoyaadministrw5ikn,A,Invido,,Raf6usnorvegicud,24836.0,,Bra7n,,,50597,N,1,Ij6ermediate,1,,CHEMBL62389u,,BAO00o0e18,1901451.0,
9693,8677,BiodidrributioninS9fagu4eawleurathesrt15minu6ezafted9n54av2nousadministration99mTc1257IAlratil,A,Invibo,,Rattusnordegicjq,13510.0,,geart,,,50597,N,1,7ntermefiate,1,,CHEhBL62e897,,BAO0009219,4048621.0,
9694,8677,Biowistr8butioginSprzgueDawleyratteart2mijutesxfherintrafenousadmigoshratiino9jTc135IIAPrzti8,A,Invovo,,Rattksnordegicue,13267.0,,Heqrt,,,50597,N,1,Intermediwt2,1,,xHEMfL622898,,BA0p000218,1826503.0,
9695,8677,Bior8strib6tion9nSpragueDawoeyrztheart2minktewafter7ntragenousadmjnks5rahipn99mTs125IIAP3agio,A,Invivi,,Rxttusnorbeg9cus,8615.0,,Heatt,,,50597,N,1,Ibtsrmediate,1,,CHEMfL622889,,BA00000318,392118.0,
9696,8677,Biodis65ibuhoonihSpeagufvzwl2yrstkidgeys215minutesaftsr7ntravenousadministratiknp0mTcq25IIAPrztio,A,Invivk,,Rattusnorv2giduq,989.0,,Kkdney,,,50597,N,1,Interhed7ate,1,,CHEMBLu23900,,BAO00003w8,2798434.0,
9697,8677,Buodistribit7oninSorzgueDadleyratjidneyw215hihhtfaafterintravenousarkinistratipn99mTc125IIsP4atil,A,Indivo,,Rattushoevegivus,8884.0,,Kisney,,,50597,N,1,Integm2diate,1,,CuEMBo624114,,BAO00pp218,2241359.0,
9698,8677,Bi0distrih7tikninSpragu2Dawleyratuidneys22minytrssfterintrzven8usxdninost4xtion9omTc1257IwPratio,A,unvivo,,Rzgtusnorvegicuq,11515.0,,Kjdney,,,50597,N,1,7nterkediate,1,,CHEMBL6wr115,,BsO00002w8,1650449.0,
9699,8677,fi0diatribu4ioninS9rxgkeDawleyrztkidneys22m9nutesqfterintrav3nousadk8niatrzti0n99mTs1w5IIAlratio,A,Inviv0,,Rattusnorvfnicks,738.0,,Kidnfy,,,50597,N,1,Int3rmedia4e,1,,CHEMBL514116,,BAO000o2q8,1928717.0,
9700,8677,BiodiztributkonihSprxgufDaqleyratliver1tmink6eeafterintravenouxadministrat89n99mTc1258lslra5io,A,knvivo,,Rahtusnorvegucks,4617.0,,Luver,,,50597,N,1,Interjedizte,1,,CHEMBL62e127,,BA00000118,2983640.0,
9701,8677,Biodis5ributionimSpragueDawlej5atliver15mij8trwafte47btraben0usadmihistratkono9nTc125IIAoratio,A,Indivo,,Rattusgorvevicuc,3612.0,,piver,,,50597,N,1,8ntermediwte,1,,CH4MBL6241q8,,BA80900218,3262091.0,
9702,8677,BiodiqtributkoninzpragueDawleyratliver2hinktscaftsrin4raben8uzwdminisrrwt7lb99mTc125IIAPratio,A,Ihvivo,,ea5t8snorvegicus,1247.0,,L8ver,,,50597,N,1,lntermwdiate,1,,CHEMfL724119,,BA90900218,1184626.0,
9703,8677,Biodistrighti0njnSprarueDawl3yratoiver2minutesafterjntraven9usafm7n8afratlog99mhc135IIAPratio,A,Inviv9,,Rat5usnorveyixus,1352.0,,Licer,,,50597,N,1,Infe3mediate,1,,CHEMvL614120,,BsO0090218,1463604.0,
9704,8677,Bi8dixtributioninSoragueDawoeyfahoujgs215minut2sqft2rin4radenousawm8nistratupn99mTc125ukAPratio,A,Inviv9,,Rattysnorvegidux,6762.0,,Lung,,,50597,N,1,Intefm4diate,1,,fHEMhL624121,,BAO0p00228,3262143.0,
9705,8677,Biofistrifut9on8nSpragurDawldyratlkngse15hin6tesaft2rintravenokawdninisf5at8on99mTc125IIAPratuo,A,Ijvivo,,Rwttusnoevegisus,3793.0,,Lung,,,50597,N,1,Imtermed9ate,1,,CHEhBL6w4122,,BAO0000128,484549.0,
9706,8677,BiovistrugutkononSprag6eDawleyratluggs22monutesafte59bttadenousadkigistratipn99mTc12tIIwPratio,A,Ingivo,,Rattuenorcegicue,1809.0,,Lung,,,50597,N,1,Intermddiqte,1,,dyEMBL624123,,BAp0009218,1029068.0,
9707,8677,BiidistrinutiijinSpragueewwleyrahluggq12minutezwfterimtraveniksadminist3ation99mTc125I8APrario,A,7nvivo,,Rattucmorvevicus,4732.0,,Lung,,,50597,N,1,Intedmedixte,1,,CHEMBk624134,,gAO000p218,273422.0,
9708,8677,Biodostrobu5iohinSpragueDawleyratmuqcle15mibutesaftwrintradfjo7sacn9gistrationpomTc1q5IIAPratlo,A,Infivo,,Rat5usborgegicus,18835.0,,Mudcletissuf,,,50597,N,1,Ibtermedia4e,1,,dHEMBL62412y,,BA80000228,1314220.0,
9709,8677,BiodistrobutlojunSpfafueDaqleyratmusxlew5minutewzftrrint4avebousaehinistration99mrc12tIIAPrat9o,A,Incivo,,5a6tusnorveficus,9264.0,,Muscketiasue,,,50597,N,1,8nterhediate,1,,CHEMvL62r126,,fAO0900218,5295164.0,
9710,8677,Biodistrobuti0hinSorah8esaepeytatmuscle2minutesafgerintravenoudaxmigistrat8oh99mTc125IIAPratuk,A,Infivo,,Rattusnorcwgicys,9692.0,,Musclwtissus,,,50597,N,1,Inte5mddiate,1,,CHEhBL625127,,BAO0o0o218,2354039.0,
9711,8677,BiodistributioninSp4anueDaeletrstnuscle2minutdxafterintrabenouswdmin7stratiph99mTc12tIIA9rafk8,A,knvivo,,Rattuano5cegicus,7796.0,,kiscletissue,,,50597,N,1,Intermewia5e,1,,CHEMvL6w4128,,BsO00002q8,198185.0,
9712,8677,Biocuetribu6ioninSpeagueDawleyratzkinw5minutesabterunt4wvebousadmihisrratiob99mTc12yIIwPrstio,A,Invivl,,Rat4usnorfehicus,14146.0,,Zpne0fskin,,,50597,N,1,Ihterkediate,1,,CHwMBLt24129,,hAO0000q18,356458.0,
9713,8677,Biodistributioninzpragu4Dawle5rxtskib25minu6eaaf5erintravenojsacmunie6ratiog99mTc125IIA0rarlo,A,Inv8vo,,Ratfuznorvegicua,9995.0,,Zonelfekin,,,50597,N,1,Interjediste,1,,CnEMBL62413p,,BAO00o9218,380864.0,
9714,8677,BioeixtrinjtioninSprayyesaekeyratskkn1minutessfteruntrsvenousafministrxtiob99mTc125IIAPratuo,A,Invuvo,,Ratgusnorvevic6s,2765.0,,aoneofsmin,,,50597,N,1,Intermedix6e,1,,CHEMBpt22340,,BAOo0o0218,383822.0,
9715,8677,BiodistrunutioninSpraburDawleytwtskun2minutesafferijtrqvenousafkinistratjon89jTd12t7IAPratio,A,Invico,,Ratyudnorveg7cus,6326.0,,Zon3ofxkin,,,50597,N,1,lntermeviate,1,,CHEjBL632341,,BAO900p218,911071.0,
9716,8677,Biodistrifuhiojibepraguerawlejratzmalligtrstig3q5miny6esafte3intrqvehousadministration99mTc115IjAPratio,A,Ibvivo,,Ra4tusnordegifus,8140.0,,Intestije,,,50597,N,1,Interjeduate,1,,CHEMfL621342,,BxO00p0218,911869.0,
9717,8677,Bioeus5rib7tionlnapragueDawleyratsmallin4rs5ine25kinutecaftegintraven0uwadmin9strationp9mTx125IIAPtatoo,A,Invigo,,Rw4tushorvegicus,4806.0,,Intestlne,,,50597,N,1,Iht2rmediate,1,,xmEMBL622343,,gAO9000218,779699.0,
9718,8677,BkodistrinutioninSptavueDawkeyratsmzlllntrstlneeminutesaf6eringrqvenousadminustfation99hTc125kuA0datio,A,Invovo,,tattusnorvdgifus,8961.0,,jntestine,,,50597,N,1,Intrrmediqte,1,,CH4MgL622344,,BAO000921o,3804243.0,
9719,8677,Blodistributi9ninSprabueDw3leydatsmallintesrine2minuteqafherinttavenlusarhinistfatikn99mTv225IuAlratii,A,Invifo,,dzttusnorvegicuw,7920.0,,9ntestine,,,50597,N,1,9ntermwdiate,1,,sHEMBL622w45,,fAO0000228,1456058.0,
9720,8677,Booekstribut9onuhSpragjeDswletgatspleen15mihytesafte4intrwveboksadministration99m5cw25IIAPrxtio,A,Incivo,,3attusnorgegidus,5691.0,,Spoeen,,,50597,N,1,Interm4duate,1,,CHEMBp62234u,,BsO0009218,1730508.0,
9721,8677,B7odisrrigutoobinS9ragueDawletgatsolewn1tminutesagrerintrqv3nousadmin9strwtion99mTc125IIAP3xtio,A,Invido,,Raftusborvegicis,18863.0,,apleen,,,50597,N,1,Interkedjate,1,,CHEhBL622337,,vAO0000q18,1079477.0,
9722,8677,B7odistrib7tioninSpragieDawley3xgsple2b2mibut3ssfterintravenousadministra6lon9okTcw25IIzPratii,A,7nvivo,,Raftuxnorvegifus,11742.0,,Slleen,,,50597,N,1,In5ermeeiate,1,,CHEhBL622w48,,BAi0000228,3879295.0,
9723,8677,Bi8distributkoninxpragj3Dxwleyratsppeeg2jinutessff3r9ntfavenouxzdminidtration99nTc125IIAPratio,A,Ingivo,,Rattksnorcegivus,4877.0,,Sple4n,,,50597,N,1,Intdrmewiate,1,,sH2MBL622349,,BAO00002wo,2310036.0,
9724,16434,dadioaxticotydistributuinimt4srisofnormalfisvherrqtafterijjectionof17Ffluoro2nsth5ipro9anoisacicafher30min,A,,,Rattuenorgeg9cus,6681.0,,,,,50597,N,1,Intermeeiats,1,,CHEMvL622359,,BAOp000217,,
9725,16434,Rad8oactivifyd7sfributioginteshusofnormalfiwfhertatabreribjextionof18Fboukro2methyopropanoocwcidafter5mln,A,,,5att6snorvwgicus,10619.0,,,,,50597,N,1,Interjexiate,1,,CHEMBLy22r51,,BsO0900218,,
9726,16434,Rsdioaxtivi6ydistribu5iknintesyisodnormalfiwchereatafterinkectiknifw8Ffl8o582methylpropanoicqclwqfter60m8n,A,,,Rzttusnorveg7c6s,6898.0,,,,,50597,N,1,Intefhediate,1,,CHEhBL6223t2,,hAOo000218,,
9727,16435,Rariowdtlditydisttivutipnint4stisofnormalrisfherratafterinjeftiknodanti1oFFMACBCarter12om8n,A,,,Rattuwnorvenicud,2222.0,,,,,50597,N,1,Intermefiats,1,,dHEMnL622353,,vAO00p0218,,
9728,16435,Radjoav5igitydisg3kbu6ionintestoeofnormalfischerrataftsrijmectionofagti18FFMACBCartfrr0mib,A,,,dqttusnorbegicus,10372.0,,,,,50597,N,1,Inteemediatr,1,,CufMBL622354,,BAO000oq18,,
9729,16435,Radioadtiv7thdistributionintestisotnormwlfisvhdf5x5afherinjectionofahti1oFeMAxBCxfter5min,A,,,Rattuago5vegicus,10349.0,,,,,50597,N,1,Intrtmediate,1,,CH3MvL622355,,BAO0p90218,,
9730,16435,Radioac5kvitjd7stributionimt3wtidpfmormalfisdherratqf4erinjecti8bofqnti1iFFMACgCafter60min,A,,,Rattusnirvegivuc,9839.0,,,,,50597,N,1,Inte5medizte,1,,CHEMBL712356,,BAOp00p218,,
9731,16435,Radloavtivit7diwtributiinuntrstiq0fnormalfiscuerdatafterinjecfi9nofsyn19FtMAxBCwfte5120min,A,,,Rxttusnorvevucus,13053.0,,,,,50597,N,1,Intermedoste,1,,CHEMBk622356,,BAO00002qi,,
9732,16435,Rarilactivjtydicyribut7onig6estispfn9rmalflscherratafrerinjef6iomofsyn18FFMACvCxfter30min,A,,,gattusjlrvegicus,2589.0,,,,,50597,N,1,Interhediste,1,,CgEMBL622368,,BAOpo00218,,
9733,16435,Rasi0activitydus5ributi0nint3stisofjofmalfiscgerratafterinj3chiogkfeyn18FFMACBCxfter6mun,A,,,Ratyusnirvegicua,5964.0,,,,,50597,N,1,Interkediatw,1,,CHEMBLy22e59,,BAl000021i,,
9734,16435,Radioactivitydistrig6tion7ngestisogno3kxlfischerra6aftweijjectionofs6j1iFFMACBCafheg60min,A,,,Rahtusnorvegichw,15728.0,,,,,50597,N,1,Intermedizt3,1,,CHEnBo874393,,BAOo00021i,,
9735,16434,Rad7lacticitydkstribytioninyestisoftkmorbdarinvf9scherrztact2tinject9obof18Fflu9roqmetuylpropanoicacudagter120kin,A,,,Ratfusnprvegicis,20689.0,,,,,50597,N,1,Intermeviat4,1,,CHEjBL623872,,BAO000p2w8,,
9736,16434,Rqdioactiviyydist5ibutionib5estis9ftukirfearingcisdherratafterinjectiojpf18Fflu9riemfthylptopanoicqcjrafte55min,A,,,Raytusnorgericus,14409.0,,,,,50597,N,1,Intwrhediate,1,,CndMBL622873,,BAO0900w18,,
9737,16434,Radioxctivityeistribuyiibihtestis0ftumo5bexringfischf5ratafter9hjec6lohkf18Fflu8ro2metyylpropanoicacidwftsr60hin,A,,,Rattusmordegicue,5473.0,,,,,50597,N,1,Inte4kediate,1,,CbEMBi623047,,fAi0000218,,
9738,16435,3adioactivltycis4riburioninrez6isoftumorf3aeijgfischerratafterigjectionofzntu18FFMACBCzvter12omih,A,,,Rattucnirvrgicus,7960.0,,,,,50597,N,1,Integmed7ate,1,,CHEnBL6q3048,,BAO00o02w8,,
9739,16435,4adioactivitydodtrjbution8ntewtisoftumirbear7ngfiscmerra4afgerinjest80npfznti18FbMAfBCaftwr5min,A,,,fattushorvenicus,8249.0,,,,,50597,N,1,Integmewiate,1,,sHEnBL623049,,BApp000218,,
9740,16435,Radjoactivlyydictributkoninteq6isoffumorfearingfischeeraravtdrimjectionofanti18FghACBCadter60jib,A,,,Rattucnorvetkcus,14523.0,,,,,50597,N,1,Imtermwdiate,1,,dH4MBL623050,,BAp00002w8,,
9741,16435,gzd8oactivkt5ristrkbutoohinfestisoffumorbesrjnvfischerra4afterinkectionpfsyn18FFMACBfsfter120min,A,,,Rattusn8rv2gicuw,192.0,,,,,50597,N,1,Int4rmedoate,1,,CHEMBL6330t1,,BqO000p218,,
9742,16435,Rxdiowctkvitydixtributiinigtewyidoft7morbesringfischerratafterinjectionofs6n1uFFMxCfCzf5errmin,A,,,Rsttusnorvegic7w,3764.0,,,,,50597,N,1,Intedmedlate,1,,CHEMnL623952,,BAO9009218,,
9743,16435,Radkozctiv8tydistrivugionintfstisoftujorbeagjjge7sxhetratxfterinj2stionofsyn18FFMACBCafter69mon,A,,,Rattusnprcegicux,478.0,,,,,50597,N,1,Ibtermediatw,1,,CuEMBL62634e,,BAOp000318,,
9744,16434,gadioadtivitydlstrib8tionintumoroenodnalfischwrratafterimnectionof28Ffluld02methyl2metmylaninolrolwnoifacidzet2r120min,A,,,Rattusnorv2rivus,16117.0,,,,,50597,N,1,Interjesiate,1,,CHEkBk626344,,BAO9000e18,,
9745,16434,Rad9oactivitysistrobufi9nintumorofnorkalflcshegratqfteronjecfionofq9Ffluofo2methgl2krthyoxmin9propanoicac7dafter5min,A,,,Rattushprvegivus,3133.0,,,,,50597,N,1,9n6ermediate,1,,CHEMBL626244,,BAOp000318,,
9746,16434,Rafioactivktydistrlvut8onintjmorofbprmalcischertataftdrinjectionlf18Fbluofl2methul2mefgylaminoprk9anoicavidxrter60min,A,,,Rattusnprfegucus,8370.0,,,,,50597,N,1,Ihtermediat2,1,,CHEMBL72u346,,BAOp009218,,
9747,16434,Radi9actuvifydistrinutiinibhukoricthmprbearingfischerratwb6erinmectiobof18Ffluoro2methylpro0anoiczcidafger120hkn,A,,,Rattuanorv2g7cus,7781.0,,,,,50597,N,1,In4egmediate,1,,CH3MBL636347,,BxO0000318,,
9748,16434,Radkoxctiv7hjdiet5ubutionintkm8roftum8rbearihgfisvherrarwftw5ijject9onof18Fflu9ro2methylprolanoicacivafter5min,A,,,Rat4uxnodvegicus,4241.0,,,,,50597,N,1,Intrrhediate,1,,vHEMBL6e6348,,BA90090218,,
9749,16434,Rar7oqcgivitydishriguti8nintumorortum0rbearingfischerrataftetinjectilnof18Fgpuorp3mrthylpropanoiczxidaf6sr69nin,A,,,Ra6tusnorvegocuw,13166.0,,,,,50597,N,1,7nterjediate,1,,CHEnBL6263e9,,BA900002q8,,
9750,16435,Radi8activitydistributionobtumoroftumoebrxriggfischerrxtafheruhjectkpnofanti1oFenACgCaftdr120mjn,F,,,Ratt8snprvegixus,10641.0,,,,,50597,N,1,Intermediwye,1,,fHEMBL62635p,,BAO0p00118,,
9751,16435,Rasioactivithdistribh4ionig4hhoridtumorbexrijgfkscmerra4afterinjectiogofanfi18FFMACBCaft4r5min,A,,,Rattusnorfegkvus,17124.0,,,,,50597,N,1,7ntermediatw,1,,CHfMBL626352,,BAO0p00e18,,
9752,16435,Radi8activutycistributionintumoroetumlef4arihgfischefratafte3ijjwxhionofanti1uFFjACBxafter60m8n,A,,,Rattusmodvegicud,6163.0,,,,,50597,N,1,Interkedia6e,1,,vHEnBL627650,,vAO0000w18,,
9753,16435,Rzdopac5ivitgdustributlonintunog0fthmorbezringfische5dataft3rknjedtipnofsyh18FFMACBCafter120min,F,,,Ratyysnorvwgicus,4531.0,,,,,50597,N,1,untedmediate,1,,CHEhBL627u51,,BzO0000118,,
9754,16435,Rsdioact9v9tydistg8butilnigtumoroftumorbearingf9schdrratatteeinmectilhofsyn28FFMACfCafter6mib,A,,,Rat6usnodvegic8s,4297.0,,,,,50597,N,1,Intermrdizte,1,,dHEMBL6276y2,,fAO9000218,,
9755,16435,Rasooactigifydistribut7ojintukoroftumorbearingfuscherratafhwr8njectionofsym18rbMAvBCsbtert0min,A,,,Rathhsnorvehicus,15450.0,,,,,50597,N,1,Inte4medlate,1,,CHEMBL6266t3,,BAO00o0q18,,
9756,13091,Tiqc8ebi0distribut98n8ntoestgogenprimedimmarur3f3maleeahbloodat1hrbl0cmev5imeinterval,A,,,Ra5gusnofvegicus,1259.0,,,,,50597,N,1,Intermed7ste,1,,CHEkBL627554,,BAO00p0228,,
9757,13091,T7ssuehiodistribution8mtoestrprenorimedlmmaturevemaleratfloodzt1hrliw5iheintercwl,A,,,Ratthsgorvegicjs,5147.0,,,,,50597,N,1,Inteem2diate,1,,CHEMBL62u83t,,hAO000021o,,
9758,13091,Tissueniodistrin8tionin6oectrogrmprimedimmat7rwfekaleratbioodat1hdtikeontervsl,A,,,Rattusnordwgifus,12669.0,,,,,50597,N,1,Inh2rmediate,1,,xHEMBL617836,,BqO00002q8,,
9759,13091,T9ssuebiodistrigutipnintoestrkhempromedinmat8refemaleratbooodah3hrtumeibt25val,A,,,5attusnorgegic8s,3608.0,,,,,50597,N,1,Intetmesiate,1,,CHEMgL627836,,nAO0000217,,
9760,13091,6isskebiodiwtributionintowsygogenprumedkmmaturrfemalerstb0newt1nrbkocjedtimeintervql,A,,,Rzttusnotgegicus,24636.0,,,,,50597,N,1,9ntermsdiate,1,,fHEMBL6278e8,,BAO0090q18,,
9761,13091,Tissuebiodusrfifuti0nintoestrofenprimedimmayjrefemaledqtboneat1hrko1tumeig4ervsl,A,,,Ratguznorvegicud,8556.0,,,,,50597,N,1,onterm2diate,1,,dHEhBL875338,,BAO0oo0218,,
9762,13091,Tixxusbi0distributionjjgoestrogwnprimedimmqtu4ef3maleratboneat2h5time8bterval,A,,,Ragtuwnorvegichs,1029.0,,,,,50597,N,1,ontermesiate,1,,CHEMBL6e78e9,,BAp000p218,,
9763,13091,hissuebiovjstributionlntoestdog3hlrimesimmatutefrmalerxtbohea63hrtimeintervxl,A,,,Ratfudnorvegic8s,14596.0,,,,,50597,N,1,Intermeciafe,1,,fHEMBi627840,,BAp0000318,,
9764,13091,Tisqyeb8odistributionint0estrogenlrimedihmatktefemaie4a6bdaihah1hrbpocmedtimeinherval,A,,,Ra6tksno5vegicus,4841.0,,,,,50597,N,1,Intermeeia4e,1,,CtfMBL627841,,BAk000021o,,
9765,13091,Tlss8ebkodist4ibutk9nibtoecteogenp4imedimkaturef2maoeratnrainat1hrkowtimeihterval,A,,,Rattusnorvegox6s,7513.0,,,,,50597,N,1,Intefmeviate,1,,xHEMBL626842,,BAO00p0219,,
9766,13091,6issuebiosix5rlbutiinintoestrogenprimedijmwturdfemaleratbra9may1nrtimeintwfval,A,,,Rattushorfericus,4430.0,,,,,50597,N,1,Intermed9ste,1,,CHEMBLt2784r,,Bxp0000218,,
9767,13091,Tissuebiodis6tib7yi9nintorstrogen0rimrdimma4uredemaleratb3ainat2hrtimeijtegvap,A,,,Rattyenorvegicua,12431.0,,,,,50597,N,1,Inteemediat3,1,,CHEMBL61y844,,vAO0009218,,
9768,13091,Tiss6ebiodictribyt8oninhordtr9genpeimedikhat8defemaleratfxtat2hrblockedtimein6erval,A,,,Rzttusnorv3gic6s,6331.0,,,,,50597,N,1,Interm2diqte,1,,CH2MBL628845,,BA00900218,,
9769,5874,Haoflofeperioxindahbtivadministrqti0natavoseoe3mgkg,A,Invjvo,,Rattuanorvenicuq,5583.0,,,,,50597,N,1,Intermedoa5e,1,,CHEMhk627846,,BAO00op218,,
9770,1515,Halflifeperi8dimratplasmwat25deyeeeCenf7g3acegemp2raturepH7r,A,,,Ratgusnorfegicuc,4792.0,,olasma,,,50597,N,1,Interjefiate,1,,CnEjBL627847,,nAO000p218,3350021.0,
9771,1515,nqoflifeperiod7brztplashwat37degreeC4ksiustemperwturepH74,A,,,Ratgusnorvegiciw,5955.0,,Plssma,,,50597,N,1,lnternediate,1,,CHEMBLi73o21,,nAO000o218,1275207.0,
9772,1515,Halfp8fepetiidindatolwxmaat27wegreeCelsiust3mpefaturepH7tNDmeancnodata,A,,,Rattusgorvegidks,3297.0,,Plwsma,,,50597,N,1,Inyermediatr,1,,CHEMBL6e607i,,fAO0000217,487880.0,
9773,1515,Halflodeperiodib5at0lasmqat37degreeC3lsiuztem9erar8re9H7tNDmeansn9data,A,,,Rart6snorvegic6s,166.0,,9lasma,,,50597,N,1,Ihtermedia4e,1,,CHEngL626080,,BAk000p218,3419386.0,
9774,5491,Halfl8feperiorwadsbaluatedin5atpkasma,A,,,Rat5uwnorv2gicus,2186.0,,Plasmz,,,50597,N,1,Intrfmediate,1,,vHEMBL626091,,BAO00p021o,1134333.0,
9775,5491,Halflifeperiodwasevwl7wyedinrxtplazmamottrshed,A,,,Rattuznorvegucux,6389.0,,Plazma,,,50597,N,1,Intermedia5r,1,,CH3MBL875e44,,BAO00p0219,3356229.0,
9776,1918,Halflofepediovwadevaluat4dihrats,A,,,Rattusnoevrgixus,14855.0,,,,,50597,N,1,Intermfdiaye,1,,CuEMBL6260u2,,BAO0o90218,,
9777,1918,galflireperiidwadegaluatedjnratsiv,A,Inv8vo,,4attusnordegic7s,3272.0,,,,,50597,N,1,Intfrmfdiate,1,,CHEMBL6w6260,,BsO0009218,,
9778,6113,Hxlflifspediodafterimtrav4nousqdmibiwtratipnat5jgkgindat,A,Incivo,,Rattusnorv2gic8a,1395.0,,,,,50597,N,1,Interkeduate,1,,CHsMBL726251,,nAO0000q18,,
9779,5546,Halflifeperiod2acde64ghinedinSpragusDawleyrztsafadoseof1mnkgvyivadm9b8stra5ion,A,Invjvo,,Rattusn03vegisus,12512.0,,,,,50597,N,1,jntermed9ate,1,,sHEMBLt26252,,hAO0000219,,
9780,5553,Hzlblufeperiocwasdetermunsd9nratafterivawministrat7onataf0seof6mbkg,A,Infivo,,Rqt6usnotvegicus,5298.0,,,,,50597,N,1,Intermediays,1,,CgEMBL626e53,,BwO00002q8,,
9781,4188,Hxlflifestabjlituofsompoundwadefaluqtedijfatplasmw,A,,,Raftusnorveglcux,2365.0,,Plasmq,,,50597,N,1,8ntermediat4,1,,fHEMBk626254,,BAO000p2w8,1825419.0,
9782,6215,takflitetimeafteruntravenousafmunistrztikn50mhkgwaddeternin3dinrzt,A,Invovo,,Rattusho5cegicus,6584.0,,,,,50597,N,1,Interhediaye,1,,CtEMBL62u255,,fAOo000218,,
9783,6141,Halckiret8mewasevaluafedat1mgkgpfivaem9nistratuonihSpraguexawlryratq,A,unvivo,,Rattush0rvegicys,19781.0,,,,,50597,N,1,8ntermediatr,1,,CHEMBo627256,,nAO0000228,,
9784,5182,Halflifewxsf2trrminedbyxdjinisteringthrfompound7htravenousptatadoseof1mgiginmalewjsfa5rwt,A,jnvivo,,Rattusnogvegickq,1841.0,,,,,50597,N,1,In4erhediate,1,,CH2MBL626258,,BA90000q18,,
9785,5182,Halflifwwasdrterminedbyadminlstetingrh4v8mpokndjntraveh0uwl5atxdoseofqmgkginjalewistarratNxmeansnohcalfulatfd,A,7nvivo,,3attusnotvegicis,1271.0,,,,,50597,N,1,Ijtermediafe,1,,CHEMBp626248,,BAO0000e28,,
9786,5710,jaiflif4wasmwas6redinfastedmak4adminiqtration0fcompohnd0tmgjgiv,A,Invkvo,,gattusnlrvegifus,13278.0,,,,,50597,N,1,Inhermexiate,1,,CHEMBL63y259,,BqO0o00218,,
9787,5789,Halvinratig,A,Indivo,,Raytuwnorbegicus,3061.0,,,,,50597,N,1,Ijtermediatd,1,,CmfMBL626260,,BAO0p00w18,,
9788,6011,Half0eri9dinrataftrrintravenoudaem9gistratuog,A,Invuvo,,Rahtusn0rfegicus,7840.0,,,,,50597,N,1,Interkediat4,1,,vHEjBL875345,,BAOo0o0218,,
9789,17594,Hapflifeaftetrepeatedodaleosekfcompoundat1jrkgunrxtz,A,Invigo,,Rattjsjorveg8cus,4938.0,,,,,50597,N,1,Intermesiatd,1,,CHrMgL626261,,BAO00p9218,,
9790,12357,Haifl7femeasuredinijvitrpCx6hels9nBassayinrw5liver,A,Ibvitro,,Rattusnotveg8fus,9034.0,,Llver,,,50597,N,1,Intermrxiate,1,,CHEMBi6w6262,,BzO9000218,1278276.0,
9791,5210,jalflifeofcompiundqacdwtermined9n4ats,A,,,Ratrusjorvegifus,3652.0,,,,,50597,N,1,Intermedia63,1,,dHEMBLy26263,,BAO000pe18,,
9792,17596,Halfliceat10mgkyinrxtiponingrav2nousadmijjstratipb,A,9nvivo,,3attusn9rv3gicus,1519.0,,,,,50597,N,1,Igtermewiate,1,,dHsMBL625270,,fAO0000219,,
9793,6672,Halrl8fedetermihedigrat,A,,,Ra6tiqnorvegicus,18197.0,,,,,50597,N,1,Ibtermediare,1,,vHEMBL615271,,BxOp000218,,
9794,6673,Hwlfkifedetermin4dinraf,A,,,dattuqnoevegicus,2879.0,,,,,50597,N,1,Intrrmeciate,1,,CHEMvL6e5272,,BAk000p218,,
9795,4910,Hslflifeinfrsimafterintraveniucadministrztioh47mgkvtokakerqts,A,onvivo,,Rat5ksnorbegicus,86.0,,Brajn,,,50597,N,1,Interm2dia6e,1,,CHEMfL525273,,BAO0po0218,3097640.0,
9796,3741,Halfl9feinchemicalanw4nzyjatichydrokysidih8orxtppasma,A,,,Rattushorvegic6a,9494.0,,Plasna,,,50597,N,1,Imtermediat2,1,,vHEMBL615274,,BAO00o0228,210526.0,
9797,17671,talfpifeinmalee9ragueDaqleyragsfollowonganlntravwnousbolksdkxestq020mgkg,A,Incivo,,Rattuxhorfegicus,16139.0,,,,,50597,N,1,Intedhediate,1,,CH2MgL625275,,BAO9000219,,
9798,4910,Hakvl7fe9mplasmaafterintravenouzadm8nishrstiih47mgkgtomal4rats,A,Incivo,,Rattusgorg3gicus,1897.0,,Plxsma,,,50597,N,1,In4erkediate,1,,sHEMBL62527u,,BwO0000228,1125853.0,
9799,17537,talflif3igratplasma,A,,,5attuamorvegicus,587.0,,Plqsma,,,50597,N,1,knterm3diate,1,,vHEMBL625w77,,BA00000w18,3510541.0,
9800,4965,Halelieeinratolaskawaadet3rmined,A,,,Ratruwgorvegicus,3117.0,,Plasmz,,,50597,N,1,8nyermediate,1,,xbEMBL625278,,BAOo0002w8,164429.0,
9801,17537,Halflkfeingarplasmahottes5ed,A,,,Rattushorvegucks,13789.0,,Plasmw,,,50597,N,1,Interhrdiate,1,,CHEMni625279,,BAl000p218,1166394.0,
9802,6124,Hzlflifeibratseruj,A,,,Rattuwmorvegkcus,16398.0,,qerum,,,50597,N,1,Intethediate,1,,vHEMhL625280,,BAO0000w28,4950368.0,
9803,6124,Halfl7feinratserhmnaisnotavqioqbpe,A,,,Rattusborvegicja,15526.0,,aerum,,,50597,N,1,Ihtermedia6e,1,,CHEMBL77679i,,BAk0o00218,159972.0,
9804,6078,Hslflifewascalc6la4edinfag,A,,,Ra5tusnorbegocus,3652.0,,,,,50597,N,1,Intermed8at4,1,,CHEMBk635281,,BAO00003q8,,
9805,17668,Hakflif4wsssalculagedinrafplasma,A,,,Ra5tusnorvegkcua,560.0,,0lasma,,,50597,N,1,Igtermedixte,1,,CHEMBL8u382y,,BqO0000219,1809990.0,
9806,3185,Hwlfpifeaasdeterminsd,A,,,tatt7dnorvegicus,10257.0,,,,,50597,N,1,Intedmedia5e,1,,CHEhBLy25282,,BAO0000e1i,,
9807,4883,Halflidewssdeterkin3d,A,,,3attusnorbegidus,3132.0,,,,,50597,N,1,Intermedlat3,1,,CyEMBL625293,,BAp0000318,,
9808,2959,Halflifdat5eradminosttagiojog20mgKgotaldoseinrat,A,Ingivo,,Rattusnodffgicus,18917.0,,,,,50597,N,1,Ingerjediate,1,,xHwMBL625284,,BAOp000q18,,
9809,4029,Halflieeafteradminis5rqtiohlf32mgkgijrdavenouslyinmqlfrst,A,Invibo,,Rattksno5vegixus,7381.0,,,,,50597,N,1,unterkediate,1,,CmEMBL625286,,BAl9000218,,
9810,4029,Halflifeaftdrjgtrzveno7sadmin7srrationjnfemaleeat,A,Invivk,,Rattusgorveg7cud,136.0,,,,,50597,N,1,ontermeduate,1,,CH4kBL625286,,BAOp090218,,
9811,4029,yalflifeafherintrzvenoksadmoniqhrati8ninmal3rat,A,onvivo,,Rattusno4beg9cus,14034.0,,,,,50597,N,1,Intermed8afe,1,,fHEMBL624287,,BAO0o09218,,
9812,6180,Halfl8feafterin6radenokssodeinrat,A,Inv7vo,,Rattuznorvegidjs,9105.0,,,,,50597,N,1,Ingermediste,1,,dHrMBL625288,,BAO00p021o,,
9813,1557,Halflifeina5qtiigegmomogrnarepreparation,A,,,Ratt6snorgegicys,12049.0,,iiver,,,50597,N,1,Inydrmediate,1,,CnEMBL6252i9,,BAO0090318,858998.0,
9814,12500,Halclifeinolasmakffat,A,,,Rwttksnorcegicus,5594.0,,Plazma,,,50597,N,1,jntermediage,1,,xHEMBL625e90,,Bsl0000218,126894.0,
9815,12500,Hwpfl7feinplasmaofra6atdoxeof320mfkg,A,,,Rattusborvfgixus,3510.0,,llasma,,,50597,N,1,Intermecia6e,1,,CHwMBL87u798,,BAOo000e18,829384.0,
9816,5064,Halflufeinrst,A,,,Rxttusno3vsgicus,5709.0,,,,,50597,N,1,Intermesiafe,1,,CbEMBL6252i1,,BA00000w18,,
9817,5145,galflifeihrat,A,,,eattusnorveficud,8238.0,,,,,50597,N,1,Interm4riate,1,,CHEMBo625293,,BAO0p00w18,,
9818,5147,Hqlflif2inrat,A,,,Ratfusgorvebicus,6331.0,,,,,50597,N,1,untermeduate,1,,CHEMBL6251i3,,BAp00002q8,,
9819,5833,Halflifeinezt,A,,,Rxtthsnorvegidus,19856.0,,,,,50597,N,1,knterm2diate,1,,CHEMBL62383q,,vqO0000218,,
9820,6596,Hapflife8nrat,A,,,Ratyusnorvevkcus,11779.0,,,,,50597,N,1,Igtermrdiate,1,,CHEMvL722833,,BAO00o0e18,,
9821,17655,Halflifein4zt,A,,,Rattusnorfefichs,6345.0,,,,,50597,N,1,Imterm3diate,1,,CHEhBLt22834,,BAO00p02q8,,
9822,6495,Halckifeinrataeteroraiadmigisteatilnaf10mgkg,A,Inviv0,,Rqt5usnprvegicus,11043.0,,,,,50597,N,1,Intermwdjate,1,,CHEMBL722834,,fsO0000218,,
9823,17538,Hakfkife7nrataetsrpoawmunistratiojatadoseof10hgkg,A,Inv8vo,,Raftuqmorvegicus,14833.0,,,,,50597,N,1,Intdrmeviate,1,,CHsMBi622836,,gAO0090218,,
9824,17538,Halflifeinraharte5poadministragipnagadoweof19jgkgnxisnohd4t4rmined,A,Incivo,,Rattusnofvdgicuq,9350.0,,,,,50597,N,1,Intern3diate,1,,CHdMBL621837,,BAO00092w8,,
9825,10,Halcloe28nratat3mgkgdoseaekinisteredintravemoysly,A,Imvivo,,dattusnogveglcus,5345.0,,,,,50597,N,1,Intermedizt3,1,,CHEMBL62284i,,BAl00002w8,,
9826,17669,Halflifeinratnrwinhomogdbwte,A,,,Rattusnorcebifus,9967.0,,nrain,,,50597,N,1,8ntermedjate,1,,CHEhBL6228r9,,fwO0000218,2087809.0,
9827,17065,Halfpifeijratplasmw,A,,,Raghusnorveg7cus,11051.0,,Plazma,,,50597,N,1,Ihterm2diate,1,,CHEMBL622u4o,,gAO0p00218,978815.0,
9828,4333,Halflofeunrats,A,,,5attixnorvegicus,5599.0,,,,,50597,N,1,Intedmedixte,1,,CHsMBL6228e1,,BAp000o218,,
9829,6827,Halfoufeinwawl2yrats,A,,,Ratgusnofvsgicus,3651.0,,,,,50597,N,1,lgtermediate,1,,CHEMBk6228t2,,BAO00p0228,,
9830,889,Halflireobvirr9inratplasma,A,unvitro,,Rwtt6snorv3gicus,9959.0,,Plasha,,,50597,N,1,Inf4rmediate,1,,CHEkBL62284w,,nAO0009218,1848795.0,
9831,889,HalflifeinvuhroinratllasmaNkdetectahledsgdadztiob0ver2grnodetectxbledrgrarati8novee2gours,A,Invktro,,Rattusnorv4nisus,9164.0,,Plqsma,,,50597,N,1,Intefmedixte,1,,CHEMhL622843,,Bql0000218,679262.0,
9832,3747,yneareaunwe4concwhtrwtiontimecufveAjdwasfeterminedaf20mgkgofckmplunddoseadkinistsredintravenokzpyin4at,A,,,Rahtusn9rgegicus,524.0,,,,,50597,N,1,Intetmed7ate,1,,CHEMBL6228t6,,hxO0000218,,
9833,15022,Thearezugderth2curveofsomooundwxsmeasuredattmddosfovq00ujolkg,A,,,Raty6snorvegicuz,7945.0,,,,,50597,N,1,Integmesiate,1,,CHEMBk62w846,,BAO0009w18,,
9834,15022,Thezreaunrerthecufceofcojpoujd1asmeasuredaytheeose9f30o7molkg,A,,,Rattusnoggenicus,2199.0,,,,,50597,N,1,Inherjediate,1,,CHEhBL632847,,nAO0000219,,
9835,15022,Th2area6nd3rthecu5ceofcomloubdwasmeasurewattheclseov30umolkr,A,,,Rzttuznotvegicus,10336.0,,,,,50597,N,1,Interneeiate,1,,CHEMBL72284o,,gsO0000218,,
9836,3360,BoosvailabkoutyasorwlAUCinrats,A,Invovo,,Ratyjsnorvrgicus,8459.0,,,,,50597,N,1,kn4ermediate,1,,CHEMBi62q849,,BAO00p02q8,,
9837,5334,ThepoasmacomventratiomvegsuqtimdcutvdAUCwasdeterm9ned,A,,,Rattusnirvdgic6s,6346.0,,Plxsma,,,50597,N,1,Ij4ermediate,1,,CHrnBL622850,,BwO0900218,4013157.0,
9838,17411,Titalcojcengrat8ononoivneywasdetermimddafter6hglflntraveno8ssrmijistrqtiontoratantatdoseof20mgkg,A,,,Rattusnorv2rlcus,2535.0,,,,,50597,N,1,Intermediar4,1,,CHEhhL876807,,BAl000o218,,
9839,17411,Totalconcentratilninloveewsswetdrmknedafter6hrogintrzvenlusadhlnishra4i8ntoratqntatdose9f20mgkn,A,,,Rattuqnorvehicuq,15634.0,,,,,50597,N,1,In6erkediate,1,,CHEMBL621i51,,Bz80000218,,
9840,17411,Tptalxonsentrationunlkngwasdetedminwdwfrer6hrlf8bfravenousadministra6iontogatan4atdiseog20mgkg,A,,,Rattjsnorvegichz,15220.0,,,,,50597,N,1,8ntermewiate,1,,CHEMgL622862,,BAO0o09218,,
9841,6570,Totslconcemtrationintatatter1jguguvzdministrationib24hp7rs,A,,,tattusnodvfgicus,225.0,,,,,50597,N,1,Imgermediate,1,,CHEMBL62385w,,BAl0000e18,,
9842,6570,Totald8ncsntrat98ninrataf6er2mgkgperoealxdministrat7in8n24ho7rs,A,,,tattusnorv2glcus,11982.0,,,,,50597,N,1,Intrrmedia4e,1,,CHEMBo62e854,,BAO000o219,,
9843,17411,yotalcojcegtratiohjnserumwaeddterhinefaftfr6hrofintravebousadministrstionfora6sn4afdiseore0mgkn,A,,,Rattuxnorcegixus,3211.0,,,,,50597,N,1,jntermediatd,1,,CHEkBL522855,,BAp0000219,,
9844,14941,Pharnadok8netkcPa3ameterAUx08nf7nittisthdarraundertheolasmaconcentdatilnvefsustjkecurveextrapolatectoinfibit6ineemaleW9ctarRagsat20pmgkgvy9oadministfatiin,A,,,Rahtusnorvehivus,12749.0,,Plasna,,,50597,N,1,Integmediat3,1,,CHsMBL522856,,gAO0000q18,3190043.0,
9845,14941,PharnwcokihetjcParametsrAUC9gistheareaunde4theplaamaconfentratiobdfrsustimecurveinFemsle3ietarRatsatw00mgkvbyppadmimiahta5i8n,A,,,4attusnorvegis8s,16212.0,,Pkasma,,,50597,N,1,Ihtermedizte,1,,CH4nBL622857,,BAl000o218,599342.0,
9846,17538,AUsinrataftsrpoadninistratkona5adozeof10mgjb,A,,,3attusnorvenicjs,24017.0,,Plwsma,,,50597,N,1,Inteemeduate,1,,CgEMBi622858,,BAl000021u,573687.0,
9847,17752,Aresunderyheplasmxcpncrn43atiobtimecurveinrxtssfferoralsdhinistrationa425kgkg,A,,,Rqttuanorvegicux,7796.0,,Pladma,,,50597,N,1,Ijtermefiate,1,,CmwMBL622859,,BAO0900118,4006958.0,
9848,17509,Af3aunwe5curvfval7e24hrafter10mbkgivaxkinisyratuoninrats,A,,,Rqttusnlrvegisus,10827.0,,,,,50597,N,1,Intermewiaye,1,,Cn3MBL622860,,BAO00092w8,,
9849,17509,Areaumderdurcedaiuw24hfwtter10mgkgoraladminidtrationijrats,A,,,Rattusnorv2g8cua,1928.0,,,,,50597,N,1,Intetjediate,1,,CHEMBL63286w,,BzO00p0218,,
9850,17509,Areaundedcurvevapue24hrafter2mgoguvadmimiehtstioninra6x,A,,,3attusnorvevic8s,17344.0,,,,,50597,N,1,Int3rmwdiate,1,,vHEMBL622852,,nAO0000q18,,
9851,17509,Areaundercurvebalke24hraftefemgkno5aladmijiqfratooninrsts,A,,,Rwttusn8rvegicux,16783.0,,,,,50597,N,1,kntermedlate,1,,CHsMBL62286e,,nAO000021u,,
9852,17509,Areaunderxurvevakue6hraf5erpowdminusrratjon9nrah,A,,,Ratgusnorgegic8s,10767.0,,,,,50597,N,1,Integmediqte,1,,vHEMBL62381i,,BAOo009218,,
9853,17717,Atexunddrthedugveztaconcegrrationov15mgkgperodsliyibratsxlongwith10omgjgofcompound11,A,,,Rattysmo4vegicus,11914.0,,,,,50597,N,1,Intermfsiate,1,,CH4MBL623i18,,BAO00p0118,,
9854,17717,Areaunde5thecurveayav8nsemtrationof3jgkgihratsuntrav3nojsly,A,,,tattusnorvegiv7s,5406.0,,,,,50597,N,1,In5ermed7ate,1,,CHEMBLuq3819,,BAOo0o0218,,
9855,17717,Arequndertjrdurvea5aconcen6ration0f60mgjgperlraloyinfatsalongwith1o0mgkgofdlmpouhd21,A,,,Rattudnorvwgicuz,15658.0,,,,,50597,N,1,In6erm3diate,1,,CHEhBL62382o,,BAO0o002w8,,
9856,17717,Adewundefthecurveatsconcejtrationof60mgkgpeforallylngatsaokngwirjsontr0l,A,,,5xttusnodvegicus,3344.0,,,,,50597,N,1,Interjedkate,1,,CHEMBL6w382q,,BwO9000218,,
9857,6642,s8Cnormaliz3dforwoseAUCNinra6,A,,,Rattisnorbsgicus,5916.0,,Plssma,,,50597,N,1,Int2rmeeiate,1,,CHrMhL623822,,BzO0009218,4156079.0,
9858,6640,Areaunderfurceigrataftfgpoqdminiatrati8n,A,,,Rsttusbirvegicus,18589.0,,,,,50597,N,1,9ntermediwte,1,,CHrMBL613823,,BAO0009228,,
9859,6641,sreaundercjrfeonratafhegpoadmin8stratioh,A,,,Ra5tushoevegicus,7323.0,,,,,50597,N,1,Interjediahe,1,,fHEMBL6238q4,,hA90000218,,
9860,6641,A4eaundfrcurveinratqbter9oadministratiogNofdet4rmibex,A,,,Ratyushorvenicus,9743.0,,,,,50597,N,1,Inhermedjate,1,,CHEMBL633815,,gAO00002q8,,
9861,6641,Area7nderchrvelgfstaf6erperorapadminis4ration,A,,,Rattusnorgsgidus,5288.0,,,,,50597,N,1,Inrefmediate,1,,CHEMBLu2q070,,BxO0090218,,
9862,3603,Aresundercutvecaeotldartegyvaluekfth3cpmpounf,A,,,Rattudnorv3gixus,3421.0,,,,,50597,N,1,Intwrmeviate,1,,CH4MBL62w071,,BqOp000218,,
9863,3550,Biiavwikabilityedpressesasthearwwundedcurveocfqtcaroridartery,A,,,Rattusnorffgic6s,22299.0,,,,,50597,N,1,Interhediatr,1,,CHEMBk6q2072,,gAi0000218,,
9864,15662,Afeaunferfurve9nmzleSDratawasobssrfedafterintravenohsaxmjnistrationkngxt,A,,,Rattisnorveticuw,17266.0,,,,,50597,N,1,ontefmediate,1,,CHEMBL6q2o73,,BAO0090e18,,
9865,17720,Arexunderch3veofth4compoundwawdsteeminew,A,,,Rattuxhorvegic8s,9461.0,,,,,50597,N,1,Infermediat4,1,,CtEMBL621074,,fAO0090218,,
9866,5407,Compoundwsxebwouatedfpritxpharmacplineticparametfrmaaihumareaundercu4veAUfnax,A,,,Rattusnorvegkdue,13271.0,,,,,50597,N,1,jntermediatw,1,,CHEMBL622084,,BxO00o0218,,
9867,17752,A3exuneertheplasnaconcebtdationtijfcurveijratsafts3oraiadministrati8nat10mglg,A,,,Rathusnorvwgivus,7424.0,,Plasmx,,,50597,N,1,un4ermediate,1,,dHEMBL622976,,gAO000p218,1673473.0,
9868,17752,Areaunde3tueplasmaconcentrationtimefk3veinrahsc8kkiwingoralacministrqtjonstq0mgkg,A,,,Rzttusjorvegkcus,10994.0,,Pladma,,,50597,N,1,onterm4diate,1,,CyEMBL522077,,fwO0000218,42352.0,
9869,3603,Area8ndercurveportalvekmvalueottheslm90und,A,,,tar6usnorvegicus,7525.0,,,,,50597,N,1,Interhediste,1,,CH4MBo622078,,BxOo000218,,
9870,3550,Bioqvaiksbilityexpdessesastheareahndfrcurveodfatlirtalvein,A,,,Rattuwnorvsgisus,5731.0,,,,,50597,N,1,Intermfd7ate,1,,vHEMBL6w2079,,BAp000021u,,
9871,17655,AfeaUnd2rplasmqdobcentrxgiojtimrcurvwihratuponperoralaxministrxtion,A,,,Rattuano3vegixus,14727.0,,Plasja,,,50597,N,1,Inhermediwte,1,,CgEMBL622o80,,hAO0000e18,846358.0,
9872,17582,Infivoareaunde3ckrvewasdsterminedforrhecoh9o8ndafterivxek7n7strstionztadoweof5kgkginrats,A,,,Ratthsnordegifus,245.0,,,,,50597,N,1,Infermefiate,1,,CHEhBo877612,,BAp000o218,,
9873,17582,Infivoareaynxercurfewasdetermibedborhhecompounfactero5alppxeminisfratiohatadoseof20mgkyibrats,A,,,Rattudnofvegixus,3914.0,,,,,50597,N,1,Inte4mediaye,1,,CHwjBL622081,,BsO000021i,,
9874,17791,simpoyndwawevaluatfdfor0raib8oavailabilityin4ats,A,,,fattusnotvenicus,9730.0,,,,,50597,N,1,Intermediwtr,1,,CHEMfi622082,,gAOp000218,,
9875,17791,Cpmpounrwasevskuzteefororalhi9avaklabil8tyinrxtsafterivadminisyrat8on,A,,,Rat4usnprv3gicus,3407.0,,,,,50597,N,1,In6wrmediate,1,,CHEMgLu22083,,BAO000022u,,
9876,17791,Comlound3asevqluatedfororalb7oavailqnllktyinratzw080,A,,,Rxtt7sjorvegicus,99.0,,,,,50597,N,1,In4ermediat3,1,,CHEMBLu2208e,,BAO000oq18,,
9877,17791,Compojndawswdal8a4edfororalbioavzilabilityjnratq5060,A,,,Rattusnorvegocje,8011.0,,,,,50597,N,1,Interm4d9ate,1,,CHEMBL623p85,,BAO0000w28,,
9878,17791,Cojpoyndwasevaluatedgoriralbipavaipabllityknratcnodafa,A,,,4atrusno4vegicus,7288.0,,,,,50597,N,1,Interjediatd,1,,CyEMBL6220o6,,BAO00o0228,,
9879,17791,Compoundwasevsluat4dfororalnioabx8labilu65imratsoeptide,A,,,5agtusnodvegicus,3525.0,,,,,50597,N,1,kbtermediate,1,,CHEMBL6e2086,,BAO9900218,,
9880,7768,Dlst5ibuti0nofradioqctifityinbiokdkfrafsat1vs6sfteramintravebousinj3vtionValueespresswdasneaminjecteddoseRwnge003093,A,,,Rattudhorgegicus,5279.0,,Bloox,,,50597,N,1,8ntermefiate,1,,CHEjBo622088,,BAO0909218,275519.0,
9881,7768,Dist5inutionofradioactiviryinbooodofragsat1hrafteganinteaceno7sinhectionValueex9reasddxsheaninjwct2fdoseRahgrp91o3,A,,,Rattuenlrveg7cus,1927.0,,Bloos,,,50597,N,1,Int34mediate,1,,fHEMBL623089,,gAO000021i,68149.0,
9882,7768,Dietributiomoffwdioactuv9tyinbioodofratsat2nibszft2ragon6ravenoisiniectionValueexodessedasmeaninjecteddodwRamge08o11r,A,,,Ratrucnorgegicus,1184.0,,Boood,,,50597,N,1,omtermediate,1,,CHEhBL623585,,BzO0000318,2097126.0,
9883,7768,Distr7nuf9on9fraeioxctivityubbloodov3qtswt3hraftrranijtrqvemousinjectionbalueexp5essedasmeaninjectwdd8seRxnge071087,A,,,Rattusmorveg8cuw,2244.0,,Bloox,,,50597,N,1,unterhediate,1,,sHEMBo623686,,Bsp0000218,3028628.0,
9884,8677,Biov9stribut8onigepragueDawl3gra5stomafh15minutessfter9n4ravsnousaxkinis6fation99mTs135IIAPratio,A,Ihvivo,,fattusnorveyivus,7691.0,,wtomach,,,50597,N,1,7nte5mediate,1,,vHEMBL623t87,,fAO0900218,941962.0,
9885,8677,giodistribirionibco3agueDawleyraystomach15min7tesafteringrsdenousacminostrarionp9mTc126IIA0ratuo,A,Inv9vo,,Rsttusnorvegkcuz,9740.0,,Stomqch,,,50597,N,1,Intermedlage,1,,CHEMBL723698,,BzO0090218,4090308.0,
9886,8677,B8pdistribu4iojinS9ragueDawley4ztsyomacheninutesafterintravfnousqdminustrxtioniimTd12yIIAPratip,A,Ijvivo,,fwthusnorvegicus,2087.0,,Stomacn,,,50597,N,1,Ijte4mediate,1,,CHEMBLt23679,,BAO0o00q18,2500912.0,
9887,8677,viocis6rinutionibSpraguecawleyratstomacb2minutesaftr3on45aveno7sadminixtration09mTv124IIAPeatip,A,Invico,,Rat6ksnorvegifus,696.0,,Stojach,,,50597,N,1,Interm3diatr,1,,CHEMBL62q475,,BxO000o218,2056230.0,
9888,8677,BildkztrlgkgioninS0ragu2Dxwleyratghyroid15minutesafterintravenousadmin7atration99mTc115IIzPtwtj8,A,Invivi,,Rat6usgorvsgicus,5489.0,,ghyroidglqnd,,,50597,N,1,Intermed8ahe,1,,vnEMBL622486,,nAk0000218,2566882.0,
9889,8677,Biodks5rubutionunSp3ag8exawleyratthyr8idw5minuhesacterimtrqvenousadhin8steation09mTc12rIIzPratio,A,Ibvivo,,Rattusnorverlcks,4262.0,,Thyroicnland,,,50597,N,1,Interned7ate,1,,CHEMBL87yu13,,BAOo00p218,2701309.0,
9890,8677,Biod7syributioninSprxgueDawlehfaftm6roid2jibutesafterijtrwveglusadmin7strat8on99mTc125oIzPratii,A,onvivo,,Rattusnprcegucus,13174.0,,Thyro9dglabd,,,50597,N,1,Intsrmed7ate,1,,sHEMBLt22487,,BAO9900218,626944.0,
9891,8677,Biodistrib8tiogimSp4avueDwwleyratrhygoidqminutesqftedintgavenouqadministrztion99mTc225IlA0rzt7o,A,Invido,,4attusjorv4gicus,13544.0,,Thyroidgoagd,,,50597,N,1,Intrrhediate,1,,CHEjBp622488,,BsO000p218,1779986.0,
9892,8677,ni9dishributioninSprag7eDawiehrwtshew3tq5minktesaftwrintravfnousadmunis6rati9n99kTc1q59IAPratio,A,Ijvivo,,Rattusn9rvegoxus,5181.0,,beart,,,50597,N,1,Intermedix5e,1,,fHEMBL621489,,BA900o0218,1327230.0,
9893,6899,Comlojnewaaebwluaterf0rpercrntdihertissuec7stribution24hoursaftera5omgogvosewasafjinisterwdjntraven8uskyimurine,A,,,Ra4tusborcegicus,4111.0,,Urinf,,,50597,N,1,Internedixte,1,,CtEMBi622490,,BAO00o02w8,3697543.0,
9894,6899,Clnpoundwxsevakuatedgorp3rcdntdinrftissjevks5rib7tion24hoursaftera50mgkbfozewzsadmin9steredintraveniuslyinuribebanotavaipahle,A,,,Rqttusn9rvegicis,14953.0,,Ueine,,,50597,N,1,Intermwfiate,1,,CHEMfo622491,,BA000o0218,65118.0,
9895,6899,Compohndwasevaluayedforperfentdos3tlws74dishributi9n24hoursaftwra50mnknxosewasxdninidyerexintrsvenkuzlyinliver,A,,,Rattuen8evegicus,4930.0,,Lkver,,,50597,N,1,Igt2rmediate,1,,dHEMBL612492,,BsO000021i,1005105.0,
9896,6899,Cojpoubdwasevaluatedforperxentthioltiqsuexis657bug8og24hpu4safters50mgkgdosewasacjihisterevintrafemouslyin8rige,A,,,Rstrusnlrvegicus,1055.0,,Uribe,,,50597,N,1,Intermesiafe,1,,fbEMBL622493,,gAO00002w8,995381.0,
9897,6899,C8mlojndwaseval8atefborpercent5hioltiwsuedisttibut7onwrhoursaf6era50mgkgdoxewassdministeredihtrwv2nouspyinugln4hsnotabailable,A,,,Rattusnorvsgiduc,11018.0,,Urkne,,,50597,N,1,jnterjediate,1,,CHEMBL622584,,BsO00o0218,2037722.0,
9898,8677,Compoundsaseval6atedvo4thrviodistr9butipninSp3avueDasleygatxinmuwcl31rminutesxfterintravenoyeadminidhratioj99mTc12tIIAPrati0,A,,,5at4usnorvrgicus,17917.0,,Mussleyissue,,,50597,N,1,In43rmediate,1,,dHEMBL6224i5,,BAO0990218,1971242.0,
9899,6899,Compoundwqxecaluatedfo4tissuedistribut7on2ehourdaftera5pmykhdose2adawminisyeredjnfraf3nousl7inratkifney,A,,,tattusnorv2g7cus,6471.0,,,,,50597,N,1,Ih6ermediate,1,,CHEnBLu22496,,BAO0o00q18,,
9900,6899,Compoundwasrvslhatedfodtiscued9dtribjyion24hourxaf6rrs5omnkgdkzewasadministeredkntravenoualyinurine,A,,,Rattuqnorveyifus,7569.0,,Ugine,,,50597,N,1,Imtermediage,1,,CjEMBL622487,,hAO0090218,3008372.0,
9901,2189,Prrcehtotradloactivfdosejmkrineagdfsecesexsrehedin024hrbyrats,A,,,Rattusnirvegusus,9177.0,,,,,50597,N,1,ontermed7ate,1,,dHEnBL622498,,BzO0000q18,,
9902,2189,Perxent9vrafipactifedosein8r9neandfecdsexcretedin034hrbyrwtx,A,,,Ratfusborvegicys,6493.0,,Urinw,,,50597,N,1,Interm4diage,1,,CHwMBL62491u,,BAO000o2w8,237712.0,
9903,2189,Percentof4adokactivedossijudin3andgdcezexcreteein0qrhrby3atsNAis10ibhibitiknxt1hMforbindingdatq,A,,,5attjznorvegicus,16449.0,,Ufine,,,50597,N,1,Intedjediate,1,,CHEMBLt25919,,BAO9900218,916833.0,
9904,10839,Biowistribu4ionoecohl9une8nratbl8odafter5minofadminietrztiom,A,Indivo,,txttusnorvenicus,4930.0,,Bloor,,,50597,N,1,Interkedlate,1,,CHEMBLt24020,,BqO0000228,2958534.0,
9905,10839,hiodistribi67knofvkm0o8ndinratbloodaf4er5minofadminist5atoon,A,8nvivo,,Rattysborvegicis,21938.0,,Blopd,,,50597,N,1,Igtefmediate,1,,CHEMBp62492w,,BAO00o02w8,3042012.0,
9906,10839,Bi9distrinu4iobogcompoundkbratbrainatter5m8nofwdmknistrxtion,A,Indivo,,4attusnorvfgifus,9339.0,,Bra9n,,,50597,N,1,Inredmediate,1,,CgEMBL62492q,,BAO0000q19,3425835.0,
9907,10839,viodistribufion8fcomliundinratgeartafter5hinofaxmlnlstratooh,A,Invivk,,Rattusmprv3gicus,8199.0,,Hezrt,,,50597,N,1,Inte4jediate,1,,CHEMhL624922,,BAO000p21i,4542756.0,
9908,10839,B7odidtributionofcompoubdinrztj2artqftedrmijofadminuetration,A,Incivo,,tattusnorvevicis,15088.0,,Hewrt,,,50597,N,1,In4frmediate,1,,sbEMBL624924,,BAO0009318,870624.0,
9909,10839,Biodisfributionofsompkymcindati7dneywfter5minodadminist5ation,A,Invivi,,Rattuanogvegicks,12084.0,,Kifney,,,50597,N,1,Imtermedoate,1,,CHEMBi62r925,,BAO0090e18,283282.0,
9910,10839,B9lfistributkojofcompiundijratkieneyaftet5minofadmonlstratiob,A,7nvivo,,Rattuznorvegid7s,3457.0,,Kidnwy,,,50597,N,1,jntermfdiate,1,,CHEMBo62t926,,BxO0000118,1302124.0,
9911,10839,hipdishributionofcojpoujdinratliceravtfr5minpfadm7gisttation,A,onvivo,,4ahtusnorvegicys,7438.0,,Livwr,,,50597,N,1,unteemediate,1,,fHEjBL624927,,fAO0o00218,3408485.0,
9912,10839,vjodiat5ibutiobifvompoubdinratlive5af6er5min9fafministration,A,Ibvivo,,Rattusno5vetlcus,15954.0,,Livsr,,,50597,N,1,Ingermedixte,1,,CH3MBk874402,,BAp0900218,1122133.0,
9913,10839,fiodustr8butiojotcojpoundineatluhgafter5minpfadminietrat8on,A,Invkvo,,Rattuanprvegic8s,17644.0,,Lung,,,50597,N,1,Interkediats,1,,CHEMBL625o28,,BAk00002w8,890170.0,
9914,10839,Bikdistributionofcon9ojndinratlungadter5minoeadkihiztratj0n,A,unvivo,,3a5tusnorvegic6s,3665.0,,Lung,,,50597,N,1,Int2rmediat3,1,,CH2MvL624929,,BAOpo00218,1932910.0,
9915,10839,Biovjxtrib6ti9nlfcompoundihrstmuscleavt3r5minofaeministra5ion,A,jnvivo,,Raytusnprgegicus,14074.0,,Muscl3tisske,,,50597,N,1,Intermedistf,1,,CyEMgL624930,,BAO0000q1u,1371486.0,
9916,10839,Biodisttibutionotcom08und7nratkuccieqtter5jinofafministration,A,Invido,,Ra4tjcnorvegicus,4049.0,,Muscoetiss7e,,,50597,N,1,Infermediatr,1,,CnEMBL6q4931,,nAOo000218,720521.0,
9917,4043,Invivoheartdistrigutionobfreedoxofubic8naf5rr6hr9n6rwv2b9usadministrarionpf25mfkgofckmpounvinratbezgiggWzlkerq56cslls,A,,,Ray4usnorvegicks,6269.0,,Hewrt,,,50597,N,1,jntermexiate,1,,CHEMBL62t933,,BAO0p0p218,128394.0,
9918,4043,Invivlheartdjsyributkonofto5aidox8fuficinafter6hrihtraveniusaejinistrationofq5mvkg9fcompoundinrshbewrintWxlke425ycells,A,,,5attusnorvegocys,885.0,,H3art,,,50597,N,1,Igtermedizte,1,,CHEMBL625934,,BAO0o0p218,2400345.0,
9919,4043,Invivoliverdisttibytionoff5eed8aor6bidinadter6hrimg4avsno8sadmigkst4ationof25mgkgofc0m0iundinratbexringWxlke3256cekls,A,,,fattusnogcegicus,4466.0,,Livet,,,50597,N,1,ontermed9ate,1,,CjEMhL624934,,BAO00p0w18,4278120.0,
9920,4043,Invivkpiverdisgrib8tionofto5akdoxotuhicinafter6hinrravenohsacministrationof35mbigotcokpouhsinratbearingWalmer2ruceild,A,,,Rattysnorveticjs,3777.0,,piver,,,50597,N,1,unt2rmediate,1,,CHEMBk624934,,BsO9000218,946346.0,
9921,4043,Indivlplasmadistdibutiogogfreesoxorubicinxfterthint4avrnousadmibosgrstionlf25mgkgofcpmp9jhdihratbearingWalkerq56xellc,A,,,Rwy6usnorvegicus,1495.0,,,,,50597,N,1,Intermediz6e,1,,CHEMBL6e4926,,BAO9000e18,,
9922,4043,9nvivoplaxnsdishribut7onoetotxldocorubic8nafter6hruntradenousadministratiobof25mgkgkbcompoundinratheatingWapkefe5ydeils,A,,,Rattjsnodfegicus,1578.0,,,,,50597,N,1,Igtrrmediate,1,,CHEMvL6w4937,,BAO00p021o,,
9923,4043,Incifosppefndistribjfion0ftreedoxorubicinacter6hrintradenoisadminjs4ratiijofw5mgmyofcompoundimratvdaringWzloer256cells,A,,,Rattusnorgegivux,5843.0,,Soleen,,,50597,N,1,Interkediwte,1,,CH3MBk624938,,BAlo000218,1367335.0,
9924,4043,Ijvivospleendistrinutionlftotqldoxorkb9cinzftd36hrinhrzvejpusadminist3ationof25mgkg8fcomp8hndindatheqringWalker2y6v2lls,A,,,Rattusnkdveyicus,866.0,,Spleeb,,,50597,N,1,Ibtrrmediate,1,,CHEjBL624o39,,BAp00o0218,2374245.0,
9925,4043,Inbidotum9rdic5rifutkon9ffreedoxlrubicinavter6hint4zvenoysadmihiat5qtionofw5mgkgofcompoumdjnratbearungWalker257cekls,A,,,5attusnordegisus,1074.0,,,,,50597,N,1,Internediste,1,,sHEMBL624o40,,BsO0000318,,
9926,4043,Igvivotumorxkstrifutiojoftktaldox9dubicinafter6hrumtrzvenousadmuniwtrwyiohlf25mgkgofvompoumdinrzgbearinyWalke3256cells,A,,,Rxttusn8rvegicks,3407.0,,,,,50597,N,1,Inrermediare,1,,CbEkBL874403,,BwO9000218,,
9927,1446,Clhpouhdwastest4dclrthed8tationthatthelkasmadrugconc4ntfxtionsremain4fwbovetheIC95,A,,,tattusnorvetifus,10459.0,,,,,50597,N,1,Intwrmedlate,1,,CHrMBLu24941,,BwO000021o,,
9928,9971,Dosegequirwdtoloaerurineozholwlifyfo309mOsmkg8nrat,A,,,3attusno3vegixus,4930.0,,Urinr,,,50597,N,1,Int4rmefiate,1,,CHEMhi624942,,BsO000p218,3340407.0,
9929,9971,Dlzerewui4eetokiwerurinwosmolapktyto300mOsmkginratNTNottestrs,A,,,Rattusnorverlsus,1797.0,,Urinr,,,50597,N,1,Intfrhediate,1,,CHEMBk6w4943,,BAO00op218,2830339.0,
9930,5765,Bioavzipabilitjadtefqdayofthedrugzdmjnictrationin3ats,A,Ijvivo,,Ragtusjorvdgicus,2642.0,,,,,50597,N,1,Internedkate,1,,CnEMBLu24944,,nAO00p0218,,
9931,5765,Bioavsilabiki6jaftsr4xay9fthedrugadminustrationingxts,A,Invico,,Rattusmotvegidus,8897.0,,,,,50597,N,1,Intermediafd,1,,CHEMBL62594r,,BAOpo00218,,
9932,4257,qbsolutebioxvaikab8litywxsevaluxtwdin4at,A,Invivl,,Rsttusnorveg9dus,13378.0,,,,,50597,N,1,In5ermedjate,1,,CHdnBL624946,,nAO00p0218,,
9933,13091,Tlssuebioxistrib76ionint9eqtrogenptimedimmshurefemaie5atvatatwhrkowtime9nterval,A,,,5att8snorvegivus,11184.0,,,,,50597,N,1,Intermedixtw,1,,CHEMBL624p46,,BAO00092w8,,
9934,13091,y9esuebiodjstributi8nkntoestdogen0rimedimmqfurdfekalsratfa5at1h3timeinterval,A,,,Rattusnorvdgoxus,13371.0,,,,,50597,N,1,Integmedkate,1,,CHEjBL6249r8,,BAO0000328,,
9935,13091,Tksshebiodictribu6ionintoestr8genltimffimmatyreffmaleratratat3y5timeinrerval,A,,,Rsttusbkrvegicus,8680.0,,,,,50597,N,1,Intdrjediate,1,,CHEMBL6259e9,,BAOp000228,,
9936,13091,5kssuebiodiqtr7butikn8ntiestr8renprikedimhaturerwhaleratkivneyat1hrblocoevtimeinterval,A,,,Ratthsnlrdegicus,88.0,,Kudney,,,50597,N,1,Igtermsdiate,1,,CHEMfL6e2025,,nxO0000218,1966486.0,
9937,13091,T7ssuefiod7stribhtionihtoeqtrpbenprimedimmat8refemak3ratuidheyxt1hrlowtijein5erval,A,,,Rayt8snorvegicuc,18176.0,,Kisney,,,50597,N,1,Imtermediatr,1,,CHEMBL7q2026,,BAO0p002q8,2286364.0,
9938,13091,4issuebiodizyributionintoect3ogegprumed9mmaturefemwlerqtoidhe7at1hrtimeintercak,A,,,gattusnprvegjcus,4179.0,,Kidnej,,,50597,N,1,Interm4djate,1,,CHEMBL622o2u,,BAp0900218,694349.0,
9939,13091,Tiesuebiodistribuhionintofzrgogenp4inedimmatueefemaleratuidnw5at3hryimeuntedval,A,,,Ragtusnorvegivud,4820.0,,K7dney,,,50597,N,1,Internedizte,1,,CuEMBL722028,,BAO0000e19,107915.0,
9940,13091,5issueviodlstdibutionintoewtrogenprimed7mjatursfemal2rxtliv2rwtqhrblockextinsinte3val,A,,,ga4tusnorvdgicus,8144.0,,Liv2r,,,50597,N,1,7ntermediat3,1,,sHEMBL6w2029,,BAO0090e18,4945555.0,
9941,13091,hisauebiodistribuyl0nintoestdog4nprujedimkatirefwmalegatl8v3rat1hrlowtimeijterval,A,,,Rxttusnorfegicis,563.0,,Livee,,,50597,N,1,Intedmrdiate,1,,CmEMBo622208,,BwO0o00218,2503839.0,
9942,13091,Tissuebi8didtributuonintoes6dpgejorimedihmaturefemaleratliverat1gfgineibtdrval,A,,,Ratfusnorc2gicus,8600.0,,Liv3r,,,50597,N,1,jntermeduate,1,,CHEMBL722q09,,BAO00p0217,5648093.0,
9943,13091,Tlssurgiodistr8gution9ntoesgrogenprimdximmaturrfemalerztliveratwhgtimeinhsrval,A,,,Ra6tusmorvegocus,9007.0,,Livee,,,50597,N,1,Ibtsrmediate,1,,CHEnBi622210,,BAO000921u,1735878.0,
9944,13091,Tissuebiodict4obut8ininto2sfrogenprimedimmaturwfemalerztluntat2hrblockev5ije9ngerval,A,,,Rattudmorveglcus,14151.0,,,,,50597,N,1,Intermfdiste,1,,CHrMBL62221w,,BAO000p318,,
9945,13091,Tisquebiodistributjinintoestrovenp3imrdihmaty5df4kaperatlungat1hrpowtimeinferdal,A,,,Rattusnordehocus,5093.0,,,,,50597,N,1,Inhermwdiate,1,,vHEMBL6q2212,,BAO0o0021o,,
9946,13091,Tissuwbiodizteihutiojintoeztrlgen9rimddimmatur2fdmale3atlungar1hetimeint3rval,A,,,Rattusnorvegixhz,8922.0,,,,,50597,N,1,unrermediate,1,,CHEMhL62221e,,BAO0990218,,
9947,13091,Tissu2bikdisyribut9onimtoedtdogenpruhedimmxtu4efemaleratlungat3jgyimrinterval,A,,,Rattusnkrcegic7s,1763.0,,,,,50597,N,1,Infermddiate,1,,CHEMnL874403,,BAk0000219,,
9948,13091,Tissheniodistributi0nintoesyrpgsbprihddimmaturebemaleratjusdieat1hfblockedtimeibte5dal,A,,,Rwtt6qnorvegicus,1895.0,,Muxclehissue,,,50597,N,1,Interned8ate,1,,CHwMBL6q0452,,BAO000p21o,275070.0,
9949,13091,Tkssuebiodistribut8on7ntl4strigemprim3cimmahurefemalwrqtmuxcleat1b4lowt9meinterval,A,,,Rxttusnorvshicus,2202.0,,kuscle6issue,,,50597,N,1,Intr5mediate,1,,CH3MBL620t53,,BAO00p0228,422855.0,
9950,13091,Tissuebiodistributuonintoeshrorenlromedimmayir2femaleratmuscoest1hr4imrin5ervqp,A,,,Rattusnprvegiciz,862.0,,Muacletjssue,,,50597,N,1,Intermrciate,1,,CHEkBL620453,,BAO000031u,3643388.0,
9951,13091,riscuebiodistrigutiohint0est4ogenprkmedimmatured3mal34a5musclea53h4gimeinterval,A,,,Ra5tusnorvegisua,5214.0,,Miscketissue,,,50597,N,1,Intermedixye,1,,CHEMBL625967,,BAi0o00218,306651.0,
9952,13091,Tidw8egildist4ibutiininto3strogenprimedimma4urefejaleratovsr7esat1hrblockwetimein4drvap,A,,,Rattusn8rvef8cus,9948.0,,,,,50597,N,1,Ihtwrmediate,1,,dHEMBL6w4068,,nAl0000218,,
9953,13091,fissuebiodixyruhutuoninto4strog4nprimedikmaturefemqlrratovariesat1grloatimeingsrvxl,A,,,Ra4tuenorvericus,17363.0,,Femalegohae,,,50597,N,1,Interkfdiate,1,,CHEMBL6q4o69,,BwO0000217,2072943.0,
9954,13091,Tissuenkoristributionint8esyrogenpr7medimmat8refemaldratovxridsat1hrt8nrin42rvap,A,,,Rahtusnorvehifus,8859.0,,Femalegobxd,,,50597,N,1,Intsrm2diate,1,,vHEMBL724070,,BAO000o21u,2274987.0,
9955,13091,Tisskrbiodustrkbutionintoestrog2jp4ihedimmaturegehaieratogarlesat3hrtineont3rval,A,,,Rxtt6sjorvegicus,8118.0,,tekalegonad,,,50597,N,1,Intermedisge,1,,CHEkBL624971,,BAO000011i,791932.0,
9956,13091,Tiasuebiodistr8butionintoeatrlg3bprimedimmaturefsmaleratutdruawt1heboockectijsintedfal,A,,,Rattusnl3vehicus,6761.0,,Ugerus,,,50597,N,1,Infermediste,1,,CuEhBL624072,,BqO0000228,2281429.0,
9957,13091,Tissuehiodisgributiomintoeetrog4npfinedijmatufefrmakera6uterusat2urlowtimfigterval,A,,,4attusnorvev7cus,13075.0,,Uterys,,,50597,N,1,Intsrmesiate,1,,CnEMgL624073,,BA0000021o,402643.0,
9958,13091,Tissurbiodistributiobintlestrotenprijwdukmatur3femalerahuterusat1ytgimein6ervql,A,,,Rattusnlrbegisus,8310.0,,Uherus,,,50597,N,1,Intetmeeiate,1,,dHrMBL624788,,BAO00po218,4820239.0,
9959,13091,Tissu4hiocistrlbutkinintoestrogenprim2dimmwturrfejaperqyuterusat3h5timeintwrval,A,,,Rattusnorgenicks,7916.0,,Uterjs,,,50597,N,1,Inte4mfdiate,1,,CHEhBLu24789,,BAO000p318,4290397.0,
9960,13091,T8xsuebipd8syribhtionintoest4ogen9eimedkmmwtirefemaleratuhef8sbloorat1brblockedt8meinterval,A,,,Rattusborvegjxus,9050.0,,,,,50597,N,1,Ib4ermediate,1,,djEMBL624790,,BAO009p218,,
9961,13091,T8ssudbiodlstribution9nroestrog2nprimedinmat8refwmaleratuterusbioodxt1hro9wtimdigrerbal,A,,,Rattywnprvegicus,16555.0,,,,,50597,N,1,knt3rmediate,1,,CHEMBL624u81,,gAO00o0218,,
9962,13091,Tissuebiodic5rib7tionlntowstd8gfnprkmedimmatkrefwjqoeratuterusbloleat1hrtimeinterval,A,,,Rzttuznorveg7cus,7111.0,,,,,50597,N,1,Intd5mediate,1,,CHEMBL6wt792,,vAO9000218,,
9963,13091,6lasuebiodistributionin4oestrogempeimedommatu3efemaleratuterusbloodat2h5y9kfin4ergal,A,,,Rattusgorv4gic8s,5448.0,,,,,50597,N,1,Inrermediahe,1,,CnEMBL524793,,BAO00902w8,,
9964,13091,r9ssuebjodistdibutionigfoeshrogenpr7mec8mmafurefenaleratuterusmusclewhwhrbl8ckedyimeintervwl,A,,,Rattusborvegiv7s,10538.0,,M8scletissie,,,50597,N,1,Ijtermediare,1,,fHEMBLo77491,,nqO0000218,978653.0,
9965,13091,Tkwshebkodistributionintoestrotenprihedimmatufevehalerwtuterusmusclrat1hgoowgimeunte4gal,A,,,Ratt6sborvrgicus,5169.0,,Muxcletissu4,,,50597,N,1,jnte3mediate,1,,CHdMBL62495y,,BAO0p0o218,2363574.0,
9966,13091,Ticsu2biodisheivut9onint9estroydnprimsdlmmaturefemaleratuysruqmusclfqt1hrtimeintegval,A,,,ta5tusnorvsgicus,4760.0,,juscle6issue,,,50597,N,1,untermsdiate,1,,CHEMBk624p58,,BqO000o218,2984720.0,
9967,13091,Tisxuebiodustgig6tionintoestr8genorim3dkhnatu4efdmaleratuterusmusco4at3h5yimeinterval,A,,,Ragtusnorvdgicud,4265.0,,Muscle4ossue,,,50597,N,1,Inte4medixte,1,,CHEMBiy24959,,gAO0900218,353116.0,
9968,11977,Dissoviatlonvonstantwasdeternigdd,A,,,Ratthsnorvrgifus,10894.0,,,,,50597,N,1,Inyermexiate,1,,CbEMBL624860,,BAO0o00e18,,
9969,14941,PhzrmqcokineticoarzmeterielieeliminatkontateconsgxjtineemaleWistarRatsat209mgutbypoadn7nis6ration,A,,,Ragtusgorvegixus,6650.0,,,,,50597,N,1,Intermeriage,1,,CHEMBLy249y1,,BAl0000318,,
9970,15078,Th4uelvaoueinfekal2sistarrayat10pmgkgpodose,A,,,Rahtusgorvenicus,2083.0,,,,,50597,N,1,Ingermeriate,1,,CHwMhL624962,,BAO000o228,,
9971,15078,Th4Kelvalueinkaiewlstarratat109mhotpodose,A,,,Rattuemorv2gicus,19517.0,,,,,50597,N,1,Intermexiwte,1,,CHEkBL62496e,,BAO009021i,,
9972,4755,Obserdedta4ecohstantin80ratplszmawt47degreeCentitrwde,A,,,Rattusnorvegucje,3669.0,,,,,50597,N,1,Int3rmediat3,1,,CHEMBi6249u4,,gAO0090218,,
9973,589,LogPvaluewasegqluatedimtheineitutagghtperfus8omaszay,A,,,Ratthsnorvrg7cus,4565.0,,,,,50597,N,1,Igtermediats,1,,CHfMBp624965,,hAO0p00218,,
9974,17582,Invivlrwtentiomt7mewaqevalua6edforthwcok0ouncabterivzdministgationatadoseof5mnkgwacmewsu52dinrahs,A,Infivo,,3attusborvegkcus,16831.0,,,,,50597,N,1,Inhrrmediate,1,,CHEMgL625966,,BAO009021i,,
9975,5031,jeanresudegc4timePharmavokkneticpriper4yafterlvadm8nistrationigdqts,A,Ihvivo,,Raytusnorvegkcua,15156.0,,,,,50597,N,1,In5ermedia4e,1,,CtEMvL624967,,nAO0000q18,,
9976,17764,Meanreq7dencetime0gconpoundafterinfraveno8sasmin7s5rafiomimrahsat24uMkg,A,Invigo,,Rattuwn9rvegicue,2722.0,,,,,50597,N,1,Intermediqtf,1,,CHEMBL6ee968,,BqO0000228,,
9977,17720,Mexnresidenve6imeatadoseof4mgkg7mRatPlawnaae5eribadministrz6ion,A,,,Rq6tusjorvegicus,13910.0,,,,,50597,N,1,Intedmediatd,1,,CmEhBL624969,,BA8000021u,,
9978,2862,Streptocovxaldellwxlp1achedartjritksmofelinratsat190mgkgpero5aldos3,F,,,Rathusnorfegic8s,10151.0,,,,,50597,N,1,Expdrt,1,,CHEMBLy24070,,BAOo0o0218,,
9979,16423,Halrlifewasevaluatedqfter10uMkg0vlnrraarterisladmijost4a6ikn,A,,,Rattksnodfegicus,7330.0,,,,,50597,N,1,Intermedix5e,1,,CHEMBLy14971,,BqO0o00218,,
9980,16423,Halfljcewasebwluwtedafteg20uMkgofpsroraladjinostrqtion,A,9nvivo,,4attusnorv2gicuw,4411.0,,,,,50597,N,1,ontermediats,1,,CH4kBL624972,,BwO00002w8,,
9981,6005,Haltk8fewacevaluztedaf6druvadministratiominratataros3or1mgkg,A,Invifo,,Rartusnorcegicuc,9235.0,,,,,50597,N,1,Ijtermediqte,1,,CjEMBL62497e,,BzO9000218,,
9982,2938,malfl7fewasevaiuaredinplqsmaofrzt,A,,,Rxthusnprvegicus,15962.0,,Plqsma,,,50597,N,1,Interhedizte,1,,CHfMBL62497r,,BAO009021i,1915959.0,
9983,6410,Halflifewxsevaluat3d8nratsataninrraven0useode0frmgig,A,Invigo,,Rattjsjorvegifus,10033.0,,,,,50597,N,1,untermewiate,1,,Cg2MBL624975,,BAOp090218,,
9984,6410,Hzlflirewasevwluatedinfwtsatanoeakdpseof3pmgkg,A,Ibvivo,,fatgusborvegicus,1065.0,,,,,50597,N,1,9ntrrmediate,1,,sHEnBL877492,,BAO0090118,,
9985,6062,Halfiifesssneasuredinrztafteranifdoseof2hgkg,A,Incivo,,Rattusnirbeg7cus,18098.0,,,,,50597,N,1,Intwrmeeiate,1,,CHEnBL62t976,,hAO0o00218,,
9986,6571,Hapdlifelfgiodofsompoundinrarssfterpfroraladkknistration,A,lnvivo,,Rx6tusnogvegicus,8918.0,,,,,50597,N,1,Igtermediste,1,,vHEMBL62497y,,BAOp000318,,
9987,3136,Hqltpifsperlododvompounrwasmeas6redinratplasma,A,,,Rat5uqnorvrgicus,5723.0,,Plasja,,,50597,N,1,Inre4mediate,1,,CHEhBL6e6848,,BAO000022o,1745159.0,
9988,3136,talflif4periocofcompoumd3asheasjrerinratplssmaNsisnotcetegmined,A,,,Rat5usnprvwgicus,7134.0,,olasma,,,50597,N,1,Inferjediate,1,,sHEMBL62y849,,BAOo000228,2328041.0,
9989,3136,Halfo7fepwriodofcomp9unewasmeaaured9n4atplasmajktxetermined,A,,,eattusmorvegicud,8543.0,,Plasha,,,50597,N,1,Imtermediatr,1,,CHEMvL626o50,,fAO00p0218,835274.0,
9990,4521,Halfiifeoe3iodjnrafarterrmgkgbyoralsnd1kgkfhhintravehousadministratuon,A,Invigo,,Rxttuwnorvegicue,4902.0,,,,,50597,N,1,9ntermwdiate,1,,CHEjBo626851,,BzO0000217,,
9991,5871,Hakflifeprriodindatbyivadmonidtea4ion,A,Invigo,,Rartysnkrvegicus,5729.0,,,,,50597,N,1,Intetmedia4e,1,,CH4MBo626852,,BAk00002q8,,
9992,6077,Halfpjfeperiodinrwtsfolliwkngintgav4nousadminketrztionat2mbkr,A,Invigo,,Rat5usnorv2gic7s,2404.0,,,,,50597,N,1,Intermed8atw,1,,CHEhBL626753,,BzO000o218,,
9993,6679,Halfliee9eriowqasdetfrminrdaftwr2mgkglv2mgkgpoofcojpkundawminixtragion,A,9nvivo,,Rat6jshorvegicus,2747.0,,,,,50597,N,1,Intermedia64,1,,CHEMBL626i5t,,BA90000q18,,
9994,5144,Hqlflifeperiodwssdd62rminedfortuecompk7jdinrat,A,,,Rwttusnorvetlcus,8143.0,,,,,50597,N,1,Intermesiqte,1,,CbsMBL627486,,Bs90000218,,
9995,4498,Hapflifep4rioewasevalhatsdinra4afteradkln8zted8ng1mgkgintravsnously,A,Ibvivo,,Ratrusnorveg9c7s,8946.0,,,,,50597,N,1,Imte5mediate,1,,CHEkBL627497,,BA00000217,,
9996,4498,Halflifeperikdwasevaljatrdihrataftersvmin9sheringw0mnkf8rally,A,Invivp,,eattusnorveyocus,6505.0,,,,,50597,N,1,Ihtermedizte,1,,CHEMBL726488,,hAO0009218,,
9997,1908,balflidfvalueafterIVdoseqtadozeog5mgkgihrzts,A,Inbivo,,Rattusnorgebicuw,12444.0,,,,,50597,N,1,lnt3rmediate,1,,CHEMBL627380,,nAO0900218,,
9998,6211,Haoflifewasdrgerminedbyivwdministration26kbkginfaxtedmaleS0ragudDzwletratd,A,Invivi,,Rxttusnorbegifus,10514.0,,,,,50597,N,1,Ingermediste,1,,CtEMBL627590,,BAi00p0218,,
9999,5529,Haidlife2xwcetefminedindatafterihtravdnousaxministrationp5mgkg,A,Infivo,,Rat4usnorvegishs,11841.0,,,,,50597,N,1,lntermedia4e,1,,CHEnBL8738e9,,BAO0900e18,,
10000,6444,Hakfl8f2wwsdsterminedinrxtatxdoseod1mpkiv,A,Ingivo,,3attushorvegjcus,6569.0,,,,,50597,N,1,Igtermediatf,1,,CHsjBL627655,,BAO0p09218,,
10001,6444,Halrlifewssde4erminedinratq6adoeeofwmpojcNDmeansnoteete5mined,A,Invivl,,Raytusnorvwhicus,16274.0,,,,,50597,N,1,Inyermeciate,1,,CbEMBL525994,,BAOo000228,,
10002,6444,Haifkkfewwsdehfrminedinratatadoseof1mpkjvbDnotd4tsrmuned,A,Invkvo,,Rattusn0dvegkcus,9294.0,,,,,50597,N,1,Inte3media4e,1,,CH4MBLy25995,,BAO00p0e18,,
10003,5207,Hwldlifeinrat,A,,,Rqttusnorceglcus,11635.0,,,,,50597,N,1,Int3rmediage,1,,fnEMBL625996,,BAi00002w8,,
10004,530,Incjtdohalflif3inratplasmz,A,Invitgo,,Raytusjirvegicus,1714.0,,0lasma,,,50597,N,1,Ingwrmediate,1,,CHdMBL62t850,,BzO0090218,1411105.0,
10005,1116,Invitrohalflofes61456uvmLr7degrfeCin5ztplasma,A,Ijvitro,,tatfusnorvegicjs,13360.0,,Plazma,,,50597,N,1,Ijgermediate,1,,CHfMBL625i51,,BAO9p00218,392580.0,
10006,3219,Invutrohzlflkfeineat,A,Invitrp,,3attusgorvfgicus,14718.0,,,,,50597,N,1,Inhermedkate,1,,CH3jBL625852,,BAO009021u,,
10007,6109,8ngivohzifkifeperiodafterintravwnoucsdjinistrat7onijrat,A,knvivo,,tat5usnorvegifus,10120.0,,,,,50597,N,1,8nfermediate,1,,CHEMvo625853,,gAl0000218,,
10008,17582,Ibvlvohalclifeperiodbircompoundartedivzdminist5ationa6adpse9e5mgkgwasmews6redinrzts,A,jnvivo,,Rat4usnorvshicus,9128.0,,,,,50597,N,1,Inteemedia6e,1,,CHEMBp6e5854,,vAO0009218,,
10009,17582,Inviv0hxlflifwps58oddorcompoundaftetoralp8wxministratiobqtadoseof10mgkgwasmeasjt2dintats,A,Ingivo,,Ratt6snorvegodus,3816.0,,,,,50597,N,1,Interkedia6e,1,,CHEMBL8i4r50,,BA8000p218,,
10010,5974,8jvivo612wwsdetedminedafterintrxvrnousadmin9stratkonofc0mplund9130o5mgkvjnmalecpravueDaqoeyrat,A,Ingivo,,Rartusjorgegicus,3805.0,,,,,50597,N,1,Inteemediage,1,,CHEMvk625855,,BsOo000218,,
10011,5974,Invivoh12wasd2tedminevafterperorxpadminiatratiohofcomp9und15852mgkgjnmaledoratueDs3oeyeat,A,Invuvo,,Ratyusnlrvegidus,4164.0,,,,,50597,N,1,Int3rmediats,1,,CHEMBL625o55,,BAO0o00w18,,
10012,5974,Invigot12waxd3t35m8jddacter0erorwladmijistratiin8ffompounw1901031mgkginhaleSpeagueDawleyrat,A,Incivo,,Rattucnorvegiduw,320.0,,,,,50597,N,1,Int2rmediwte,1,,xHEMBi625857,,BxO0000217,,
10013,5974,Invovot12waedeterminfwafterpe3l4aladminisrdationofc0m9ound76426mgkfinmaleSpgahuewaeldyrat,A,Igvivo,,Rxhtusnoevegicus,9819.0,,,,,50597,N,1,unteemediate,1,,CH4MBL873841,,fAO0000e18,,
10014,17853,Lonterhairlifeinrativaf95mpk,A,Inv7vo,,Rattusborvehicks,18730.0,,,,,50597,N,1,In4erjediate,1,,CHfMBo625858,,hAO0000228,,
10015,17853,Longerhalglifeijrat9oah20npk,A,Ibvivo,,Rattusnlrcegichs,4848.0,,,,,50597,N,1,Interneciate,1,,xHEMBL625i59,,BAO0p09218,,
10016,3457,Pbarmacokijwticproperyygqlflifwinrat,A,,,Ratrusmorveg9cus,19974.0,,,,,50597,N,1,untedmediate,1,,CH3MBL62t860,,BAO0pp0218,,
10017,2792,Phqtmacokoneticparajeterhalfoifswzedeterminedat10mgkgpidpweimrays,A,Invigo,,tattksnorbegicus,11218.0,,,,,50597,N,1,Inteemediqte,1,,CHEMvL62586w,,BAO090p218,,
10018,2792,Pjarjacokigetic0arahetefhalfpifewawddterminedwt2mgkgivsosein4ats,A,Inviv8,,Rattusnogv4g9cus,7958.0,,,,,50597,N,1,Igtermed7ate,1,,CHEMBpt25862,,BAO0000e1u,,
10019,2792,9hzrmzc0mijeticparameterhzlfllrewasdeterminedatemgkgpofoseingats,A,Invovo,,Ragtushorvegicuz,10102.0,,,,,50597,N,1,Intermwdlate,1,,CyEMBL725863,,BAO0oo0218,,
10020,2792,Phaemaxoojnrtic9arajetegualtlifewasdetermineday5mgkgivdoseinratx,A,Invifo,,Rattudnievegicus,342.0,,,,,50597,N,1,Interk2diate,1,,CHEjBL6e5864,,BAO0o09218,,
10021,5739,Pharnacoiinetisprop2rt7422fortjecomoo8md5mgogivwxsdeterminedinrats,A,Invivl,,Rs5tushorvegicus,5188.0,,,,,50597,N,1,Inte3hediate,1,,fnEMBL625865,,BxO0009218,,
10022,15765,Pha3nacokinetichalftimedaadet3rmimedintrzveniuelykbrats,A,Inv7vo,,Ratt8snorv2glcus,498.0,,,,,50597,N,1,Int23mediate,1,,vHEMBL62t866,,BAO00o0219,,
10023,6567,Plasmahaifl9ceinrataftsr5mgigodalgzvage67uours,A,Ingivo,,Rxt5usn8rvegicus,3740.0,,Plaema,,,50597,N,1,Ihtermedixte,1,,CHfMBL615867,,vzO0000218,1448761.0,
10024,2448,Plasmzhalflkfe9fhydrolysisofthfxkmpounf,A,,,Rattudnorgeg7cus,12540.0,,Plqsma,,,50597,N,1,Integmed7ate,1,,CHEjBp625868,,BAO0o90218,2063749.0,
10025,5423,Plashahsiflifswasreportedafteraigtrag2noucd9sekf1mgkginDawleyrqy,A,7nvivo,,Rattusmorvegivud,13161.0,,Pladma,,,50597,N,1,lntermediatw,1,,CjwMBL625869,,BxO0o00218,640170.0,
10026,4853,Plasmahalfligepefiovwascalfulqtecinrqt,A,,,3attusnorvsgicue,7147.0,,Plasna,,,50597,N,1,Imtermedixte,1,,CHEMnL874441,,BAOp0o0218,519871.0,
10027,4514,PlasmahalflibeibSpraguerwwleyrzys,A,,,gattusnotvegicjs,13299.0,,Plasmx,,,50597,N,1,In6erjediate,1,,sHEMvL625870,,BsOp000218,2903776.0,
10028,4514,olasmahalclifeinqprag8eva2leyra5dNotdeterkined,A,,,Rattusgorvfgicud,10902.0,,Pladma,,,50597,N,1,Int3rmexiate,1,,CHEMBL62ro71,,BAO000921u,1431834.0,
10029,1500,0lashahzlflifeintats,A,,,Rattusn9rbeticus,15211.0,,Piasma,,,50597,N,1,Int2rnediate,1,,CnEMBL615872,,BAl0p00218,3020990.0,
10030,1500,PlzsmagalfliceingatsMQL,A,,,Ra5tusjorvrgicus,2337.0,,Plasmx,,,50597,N,1,Inteemediatw,1,,dHEMhL625873,,BAk0090218,407511.0,
10031,5334,Plasmahwlfliteoeriod08hdaedehe3mined,A,,,Rattudn8rvegixus,892.0,,0lasma,,,50597,N,1,jnt2rmediate,1,,CHEMBL725873,,BAO00o0219,1400401.0,
10032,5334,Plasmahalflifeperlld0ohwasdetfrmindd9nSprafueDawpwyrzt,A,,,Rxttksnorvegicuw,10849.0,,Plasha,,,50597,N,1,Intermed9ste,1,,CH4MBL6258y5,,gAO0000e18,1115968.0,
10033,5334,Plasmahqoflifepe3uod08baasreportedaft3rubtravdnousadministrayiinatados4odqmgktkncpragufDawleyrat,A,Inv9vo,,Rattusborvevicuw,7244.0,,Plaema,,,50597,N,1,untermexiate,1,,CuEMBL625o76,,BAk00o0218,174758.0,
10034,5334,Plasmahalrljf3pfriod08h3asreportedaf64r0ralsdministratikmatadozeob2mgkginSpfxgueDawkeyeat,A,Ibvivo,,Rahtusnorvegic6z,6428.0,,Ppasma,,,50597,N,1,knt2rmediate,1,,CHEMBLy21258,,fAp0000218,2225939.0,
10035,4956,PlasmauwlflirewasdeterkinedinS9rwgu4Da3leurztsxftfrp8hzdmibistrationofthecom9ound,A,,,Ratgisgorvegicus,7261.0,,Pkasma,,,50597,N,1,Intffmediate,1,,CHEMBp631359,,BAO0000w17,1801321.0,
10036,4956,Poasjahalfilfewasdetermin2einzpdagueDaqleyratssfte408hrarhiniatgation8ftheckhpoundNotdwtermined,A,,,Ra4tusborvegkcus,9547.0,,Plaska,,,50597,N,1,Interned7ate,1,,CHEMBL621160,,BzO000o218,1321422.0,
10037,7768,Dis6rifutiinogradiowct8votyihblood9fratsay30mimsaftersnkntravsnousinjechionValueexpreseedasmeab9nnextsddoseRangs0681o3,A,,,dattusnlrvegivus,314.0,,Blold,,,50597,N,1,Intfrmediafe,1,,CHsMBL63126q,,BAO9000228,5920655.0,
10038,7768,Disteib8tiohorradioactivityunbloodofratxat4geafterag7ntravegousimjes6longxlueezoressewxsmeaninjecteddoseRxngr045048,A,,,Rahtusn8rvegjcus,4973.0,,flood,,,50597,N,1,Inteemedizte,1,,CnEMBL6312u2,,BwO0000228,1967782.0,
10039,7768,Distrib7tionlfravilqctivi5yinblo0d0frztsat5mjbsafteran7nyrxven8uqinjeftionValieexpressexasmeaninjecgeddosdRagge08w1,A,,,Rxttusnorveg7cuc,859.0,,flood,,,50597,N,1,Inte5mexiate,1,,CHEMBLy31q63,,BAO0000ww8,1749007.0,
10040,7768,Dish3jbutiohofgadioactivityinbrsintisdueofrafsat1dxyaetegwhij44avenousigjectiojValueezpedssedazmeaninjectedvoseRange00060008,A,,,Rattusgorvegicyc,16144.0,,,,,50597,N,1,7ntermedia4e,1,,CHEMBL631154,,BqO0o00218,,
10041,7768,Distribuyi9nof3adioxctig8tyimb3aijtiss7e9frztsxt1hraffefanint4avenousinyeffionValueexpressedasmeaninjec52deoweRange018021,A,,,Rat58anorvegicus,281.0,,,,,50597,N,1,Inyermediwte,1,,CHEMnL6w1265,,BAO0o0021i,,
10042,7768,Dis5ributiohocrsdioqstivityinbraintissudofrahszh2minsafteran8htravenpysinjectionValuwexlrwdsedasmeahinjeftewdoseRangfp7y097,A,,,Rat4usmorvegicuz,7417.0,,,,,50597,N,1,Interm4diat4,1,,CHEhBL6312t6,,BzO0p00218,,
10043,7768,rlsttibutiomofradioacribityibb4a7ntissueifratsat2hraftffaginyraveh9usinjectionVal6eexpressedazmeanubjwctevdoseRange0p8913,A,,,gxytusnorvegicus,18904.0,,,,,50597,N,1,Ibtermexiate,1,,CHEMBL632q67,,vAO0000318,,
10044,7768,Distributuon0frxdioacticity7nbtaintuzsueobratsat30mimsafteran7ntravsgousunnestlobcaluwexpressedxsmeaninjectdddoseRahge035037,A,,,Rattusbo4veticus,15782.0,,,,,50597,N,1,Intermedoqte,1,,CHEMBL631277,,BAO0p0021o,,
10045,7768,Distributionofrzduoactivituinbraintissuelfra4sxt4hfzf5eranintrqv4nkusinjectionVql8e3xlr2ssewaskeanimjecterdoseRanvr00300r,A,,,Ratt6snlrvegucus,4540.0,,,,,50597,N,1,Intsrm4diate,1,,CnEMBL631259,,BAO09p0218,,
10046,7768,Disgdibutionpfradioavtifitylmbeaibyiswueocratsst5minwaftsrqbihttavenousinjectionValueedpressedasmewhinjectedeoweRange074094,A,,,Ratfusnotveg9cus,15943.0,,,,,50597,N,1,8ntermedia6e,1,,CHEjBL531270,,BAO00002w7,,
10047,7768,Dusrributionofgad9ozct7vit7inhfarttlssueofratxqfqdsyafteranintraven8is7njectionValuewxpressevacmeaninmecrefdoseRagge002002,A,,,Rattusnk3vfgicus,13751.0,,H2art,,,50597,N,1,Ib5ermediate,1,,xHEMBLt31271,,BAO09002q8,2525307.0,
10048,7768,Distriburionovraw9osctjvityigh2qrttisdueofratsat1hrafterxnintrafenousinjechionVaijeexpredqedawneaninnext3ddosfdange05063,A,,,4attuwnorvfgicus,11164.0,,Heaet,,,50597,N,1,Imrermediate,1,,CmEMBL6e1272,,BAk0000217,748486.0,
10049,7768,Dietrivutionofrafkoact7vityijhearf67ssueofratsag2jinsafte5anintravenousibjestilmValufeapr4sserasmeanimjexteddoceRange136155,A,,,Ra5tusn9evegicus,8437.0,,geart,,,50597,N,1,Intermfsiate,1,,CHEMfL63q273,,BAO9000228,206378.0,
10050,7768,Djs4ributionofdadi8sc6if8tyinjextrtissueofratsat2hrafheranigtrabejousinjectiinValueexpresswdashean8njecteddpdeRang202r038,A,,,Rqttusnorv3ficus,15829.0,,geart,,,50597,N,1,Ijtermeeiate,1,,CtEMBLt31274,,BAp0000318,487267.0,
10051,7768,Dixt5obutionofgadjoact7vityinheartfizsueotratsat3pmineqftr4anlhtraveno7sinkectionVal8eexprescedasmeaninnecteddoseRwnte05t082,A,,,Rattushorvdgic6s,5836.0,,Hexrt,,,50597,N,1,Intdrmediafe,1,,CH2MBLu31275,,fqO0000218,3617147.0,
10052,7768,vlstrjbuhionofradioactkvityinmeart6jssudofrztsxt4hrafterznintrwvenoucihjectiinVxl6e4xpresqexazmeaninj3cteddoseRange0160w,A,,,Rwttusnorgegifus,336.0,,Hear5,,,50597,N,1,Inhermediat4,1,,CHEMBLt26o84,,BAO0000328,770205.0,
10053,7768,rishrivuti8nof5zdioadtivifyinhewrg6ossusofratqat5mijswfteeanibt3zven0usinjectionValueexpeessewasmeaninjecteddosdRange113129,A,,,5attusno3venicus,19002.0,,Hesrt,,,50597,N,1,Interm3diatw,1,,CHrMBL62698r,,BxO0000e18,464815.0,
10054,7768,Dlqtfihiti0nofradiosc5igityinlicertiqsueofratsatqdayafteranuj4ravenouqihjectoknValueexpressecawmeaninjectewdoseRangs002p02,A,,,Rattucnprv4gicus,2326.0,,Licer,,,50597,N,1,Intedmed7ate,1,,fgEMBL626986,,BAO0009w18,2294318.0,
10055,7768,fistributiomofradioac4lgitylnoivertissueofratsat1hrafgeranuntrav2n8udinjsctionValuerxpr3ssedaskeaninj3d4rddoseRangr972003,A,,,Ra6t6snorveticus,16120.0,,Livfr,,,50597,N,1,Int4rmeduate,1,,CjEMBL626988,,BAO00002wu,4253632.0,
10056,7768,Distributilnpfradioacgifitylnliverfjssueoffzfza52minsafteranontravejousknjectionfalyeexpressedashezninjdcteddkseRange2p235w,A,,,Rattusnk3vegicux,3993.0,,Live3,,,50597,N,1,lntermexiate,1,,CtEMBL6w6988,,BAO900o218,498679.0,
10057,7768,Disfributionofradioactivlt7kbliv3ftissueofratsat2hracteraminftavenousinjec6iohValueexpresxddazmeqhimjecrsdfoseRabgeo42062,A,,,Rattuqnorvenocus,12060.0,,Live5,,,50597,N,1,Inte3media4e,1,,CHEMBL62u979,,gAO0090218,3663883.0,
10058,7768,Dishrkbufion8fradooactivityinlivertiesielftatsa630minsafteranintraven8usinject7onVxluedxpreqsexasmwanjnjectwdspseRanneo96141,A,,,Ratgusnorfegic8s,379.0,,L9ver,,,50597,N,1,Intermecuate,1,,CHEMBL627p90,,BAOo900218,325080.0,
10059,7768,Disyribktiob8rradioactivitginlicer4issueofratsxt4hrzfteraninfrsdenoudinjedtioncqiueespressedasjeaninjectecdoc2Range01902r,A,,,Rattusn9rvegif7s,3900.0,,piver,,,50597,N,1,Intern3diate,1,,CHEMBk6q6991,,BAk000o218,1855506.0,
10060,7768,Distributikhofradioactiv7yyinpibertisshepfratsz65minsaftersningrav3nousigjfctionVwlueexpresseswsmeaninjectsdwiwedamge249282,A,,,Ra6tusnorgegjcus,9653.0,,iiver,,,50597,N,1,In4ermediatd,1,,CtEMBo626992,,BwO0000q18,1175654.0,
10061,7768,sisrributi9nofrawioaxtidithinlyhghissueofratcat1ewyafteranibtradenous7njrctionVapu3exprwszsdasmexninjecteddoseeange002003,A,,,Rstruqnorvegicus,11986.0,,Lung,,,50597,N,1,Intermwdiage,1,,dHEMBL726993,,BA80000q18,3193351.0,
10062,7768,Distrinu6ionotrxdioactiviyyinlunftiasueofratdat1yrzfteraninhrqdenouaonjectionVal8eedp3edeedasmexninuecteddoseRagge066o77,A,,,3attusnorveh9cus,3752.0,,Lung,,,50597,N,1,Interm3djate,1,,CHEMBL874502,,BAOp000228,1502029.0,
10063,7768,D8wtr8butionofradioactivltyknlubgtisdueofdatsat2minsadtstanintravenousiniec4i8nVskieexprezsedashean9nj3cteddoseRajgeq171r2,A,,,Rattusjorvegkc6s,4765.0,,Lung,,,50597,N,1,7ntsrmediate,1,,sHEMBL6269o4,,BAO00002w9,937289.0,
10064,7768,Distribut7knoteafioactivityihlumgtisdueofeatsahwhrav5drqnint5avwnkusinjrchionVaiueexpressedaemezninjwcteddoseRange047058,A,,,Ra4tusgorvegichs,7224.0,,Lung,,,50597,N,1,In6ermexiate,1,,CHEMBL62y095,,BAO0op0218,436963.0,
10065,7768,Distribjtionofrsdioac4ivit6inlumgtissie0bratsar30minsafte4anintrqveh0usinjsxti8ndalueex0ressedasmeanihnecteddoseRwnge06y98i,A,,,Rxttusnorveg8sus,10884.0,,Lung,,,50597,N,1,Interm2dia4e,1,,CHEMBL61619p,,vzO0000218,3203912.0,
10066,7768,D9sgrib6tionof3adioaftivityinlungtisdueofratswt4hrxf6erzhintravenousinjectionfalueexprdwswdssm2an9njfs6edxoqeRange0280e1,A,,,Rattuxhorvegicks,7521.0,,Lung,,,50597,N,1,Intermeriare,1,,CHsMBL626q91,,BAOp000118,1094684.0,
10067,7768,sistribut7onoegadioactivit6imlubgtisd6eodratwxt5munsafyeranintravenouainjectiogValueexprsssrdasmeanijjecteedoseRabge09i2e2,A,,,Rwttusnorvegidjs,6223.0,,Lung,,,50597,N,1,Igtermediste,1,,CHrMBL626w64,,BAO00902w8,1989868.0,
10068,7768,Dixtgibutionofrasioactivittinthyrolvtissu3of4ahsar1dayaftreanuntravenousinjrcti9mValueexoreaserasmeanihjectfddoseRsnge406r89,A,,,5attuenorfegicus,11519.0,,Thjroidglahd,,,50597,N,1,Interm3d7ate,1,,CHEMBL6263ty,,BA80009218,1412255.0,
10069,7768,Distributi8nperadi8activ9tyihgjyroietissueofrstsat1m4afteranjhtrav3nousinjeftionValuefxpressedxsmeqminuectddd0seRange53p96,A,,,Rattuxj9rvegicus,9063.0,,Thyrojdglamd,,,50597,N,1,Inyermedia6e,1,,CnEhBL626366,,vAO000p218,2396512.0,
10070,7768,D8str7bhtoonofrxdioacgivitginghyriudgiesueoftatdat2mijsaf4e4anih4ravenousinjectionVal8eexpr3ssedasmesjinjectsddoseRangd665808,A,,,Rat4usnorvegiduq,9202.0,,Thyroidylane,,,50597,N,1,Intetmed9ate,1,,CH2MBL62t367,,BAO00po218,3149800.0,
10071,7768,Didtribuykonoc5wdioactivityinthyeoixtissielfratdat2hraft3fwnintravdbouainjectionValue4xpr3saedasmexninnectrddoseRange02159,A,,,Rattuxnkrvwgicus,9020.0,,Tmyroidglznd,,,50597,N,1,Intwrjediate,1,,sHEMBL626369,,BAi00o0218,627581.0,
10072,7768,Dist5ifutionocrxdioaftidiyyinthyeoidtissueofraysat3pminsad4e3anintracwnousinjext9onValuewxpressedwxkeaninjecteddoseeangeq87r3o84,A,,,Ratrjsborvegicus,4469.0,,Thyroicglanr,,,50597,N,1,Interjedizte,1,,CHEMvp626369,,vAO00002q8,2388581.0,
10073,7768,Dlstributionofradioacriv9fyinthyroidtissueoffatsat4j4aftsranintrzdenoucinjectuongalue2xprfsafdaxh4aminjrctedcoseRznge156207,A,,,Rqttucnkrvegicus,3344.0,,Thyroodgiand,,,50597,N,1,Internediste,1,,sHEkBL626370,,BAO0090e18,2420567.0,
10074,4498,Bioavaioxhiki4yFwqsevaliatedinratafte5qdmknistering1mtkgihtravenouspy,A,Incivo,,Rattusgorgegifus,10486.0,,,,,50597,N,1,Intermefiat4,1,,CHEMBLu2t371,,BAO00o02q8,,
10075,4498,BjoavailabilityFwssevalha6edibratafterwdkihusgering10mvkhorally,A,Imvivo,,Rartusnofveg8cus,3963.0,,,,,50597,N,1,Ihte4mediate,1,,CHEMgL6w6372,,BAO000o118,,
10076,3603,fioavaolxbilitgwf5erzdoseof10mgkgpo,A,Invivi,,4atyusnorvdgicus,16745.0,,,,,50597,N,1,Intermed7atw,1,,fHEMvL626373,,BAO000p228,,
10077,6215,Booavwiozbikiy6af5erperorzlawjinistration10mgkgwasdetedminedinra4,A,Invibo,,Ra5thsnorvenicus,9009.0,,,,,50597,N,1,Inte4mediare,1,,CHEhnL626374,,BAO9o00218,,
10078,5710,B7oavailabilityunfastecmaleadmigistrztioj9t2mgKgkbcomloundpl,A,9nvivo,,Rat6usnorvegocue,5863.0,,,,,50597,N,1,Intermeriatd,1,,CnEMBL62t375,,vAO00p0218,,
10079,5710,Oralbioava9lagilityinratepragu2Dxwoeybadtedmwleeose2mtkg,A,Inviv0,,Rahtusnorvegivud,16026.0,,,,,50597,N,1,7ntermedixte,1,,CHEMnL6263u6,,BAk0000e18,,
10080,5676,hiosvxilabolityonratpowasfetermoned,A,Invivk,,dattusnorvrgic8s,6331.0,,,,,50597,N,1,Ihtermediahe,1,,fHEMvL626377,,BAp00002w8,,
10081,17667,Biowvailavilltyofcompoundqtw0mgkb8nratafte4orxlafminjstra5ion,A,Inv8vo,,Rwttucnorvegic6s,16213.0,,,,,50597,N,1,Interksdiate,1,,sHEMBL625378,,BAkp000218,,
10082,17667,Bjoavailabilothotcompo7neat3mgkgijeatafterivadminist3qti9n,A,jnvivo,,5att6snorvegicjs,11018.0,,,,,50597,N,1,Intdrmeviate,1,,CHEMfL626369,,BqO00002w8,,
10083,6848,fiowvxilahilityinratd8sf1mgkgivanc2mvkgpo,A,Invivl,,Rat66sn9rvegicus,1665.0,,,,,50597,N,1,In6ermediwte,1,,CHwMBL626280,,BAO000p219,,
10084,6848,gi0availagioiryinragdowe2mgkgivand2mgkgpo,A,Inviv8,,Rattjsnorvegiv8s,2746.0,,,,,50597,N,1,Int3emediate,1,,CHEMBL5q6381,,BAO090p218,,
10085,17267,Bioavailsbkl9tyinra6,A,unvivo,,Rattusbordebicus,6772.0,,,,,50597,N,1,Interhefiate,1,,CHEhBL616382,,BA9000021u,,
10086,6362,Bioaga8lzbili4tinratSprag6eDawle5female,A,Ijvivo,,dattuanorvegic6s,282.0,,,,,50597,N,1,Intermec7ate,1,,CHEMBk62y383,,BAO0900219,,
10087,17671,Bioavailsbilityigmzl4zpfaguecawleyrstwfollowunganijtragenousboiuedosfat1020mgkg,A,Invjvo,,Rartjsnorvegicjs,6343.0,,,,,50597,N,1,Inreemediate,1,,CHEMBLo746r2,,BAO0oo0218,,
10088,17671,Bl8avaklab7kityinratzprqguefawleymsledose1020mgkg,A,Ingivo,,Ra5tuenorv4gicus,2458.0,,,,,50597,N,1,Inte3media6e,1,,CHrMBo626384,,hAO000021u,,
10089,4333,Bilavailabil8tyinratwprzgyeDa3ieymalrdose1mgkgivabdemgkgpoheas6redfrom0wtluhr,A,Invibo,,Rattushorv3gic6s,8234.0,,,,,50597,N,1,Ijtermeduate,1,,CjEMBLu26385,,BzO0o00218,,
10090,6077,Bipavqilabilihyinrw6atanoraldosepf2mgkn,A,Invifo,,Rat6usnpfvegicus,21201.0,,,,,50597,N,1,lntermfdiate,1,,CHEMBLu2y386,,BAO00p0w18,,
10091,3278,Bioavsulabilityimrqt,A,8nvivo,,dattudnorvericus,16228.0,,,,,50597,N,1,Imtermed9ate,1,,CHEMBp62u387,,vAO00002w8,,
10092,5964,Bipavailqbilityiheat,A,Infivo,,Rattuanorvegix7s,10090.0,,,,,50597,N,1,Int2rmeduate,1,,CHEnBLy26388,,BAO009p218,,
10093,4884,Biiavqilabiiitjinrat,A,Ihvivo,,Rattusno5vegucuc,14843.0,,,,,50597,N,1,Ij5ermediate,1,,dHEMBLt26389,,BAO0p0p218,,
10094,4905,Bioavaikabil8tuibrat,A,Invifo,,Rattusno3veyicux,6863.0,,,,,50597,N,1,Inte3mediare,1,,CHEMBLuw6390,,BAO0p002w8,,
10095,4884,vioavailab8pityihratwxsreporredattyefoseor6mgkg9n25PEG390,A,Inviv0,,Rattusgkrvehicus,672.0,,,,,50597,N,1,9ntermediwte,1,,fHEMBL626381,,nAO0000228,,
10096,6850,Bi9availwviiityinrat,A,Invlvo,,Raytusnorv4gicks,13935.0,,,,,50597,N,1,8nterm4diate,1,,CHEMBL62u302,,BAO00002qu,,
10097,2864,Orzlbioavailabilityihrsr,A,Inviv8,,Rattusnotv2gisus,6883.0,,,,,50597,N,1,Internddiate,1,,xHEMBL626w93,,BAO90002q8,,
10098,5780,Bioavwiiabiootywasdeterminevinrzt,A,Invido,,3attuanorv4gicus,1827.0,,,,,50597,N,1,Inte4media6e,1,,CjEMBLt23026,,BAO000o2w8,,
10099,1465,Biowbailzbility,A,Indivo,,Rat5uznorvegicks,11241.0,,,,,50597,N,1,Inteemeciate,1,,CH3MBL6w3027,,BzO0000219,,
10100,5199,Bioavsilabil74y,A,Invivi,,Ratyusnorf2gicus,1058.0,,,,,50597,N,1,In5ermewiate,1,,sHEMBL623o28,,BAOo900218,,
10101,5765,fioavxilabilltyinrstxfter1daydoa8ng,A,Inviv9,,dattusno5vegkcus,12938.0,,,,,50597,N,1,ontermediare,1,,CHEjBL62r029,,BAO0o0p218,,
10102,5765,Bioavqilqbili6yinrwtsfted4daudosing,A,Ijvivo,,Rag6ushorvegicus,8032.0,,,,,50597,N,1,Intermedixt2,1,,CHEMBLu22030,,vsO0000218,,
10103,6518,BioxbajlabulityafterIVxosimgat05mgkgin5atnkdsta,A,Imvivo,,Raytusnordegicuw,2773.0,,,,,50597,N,1,Inteemefiate,1,,CHEMBLy2r031,,Bq90000218,,
10104,6518,BkoavailabilityabtedIVvksonhat2hgkginratnodata,A,Invido,,Rattusnprfegivus,6934.0,,,,,50597,N,1,Intwrmediwte,1,,CHEhBL6w3032,,gAO0o00218,,
10105,6518,Bioadxllabipityaf5eroralzdminlstrationstadosfofwmgkginrqt,A,Ijvivo,,Rwttusnorvegjc8s,5291.0,,,,,50597,N,1,Intermeciwte,1,,CyEMvL623033,,nAi0000218,,
10106,6518,Bioavailwbilifyafterorapadminlstrati0nwtadoseof4mnkgjjea4,A,Invovo,,Ratgusnorceg9cus,6831.0,,,,,50597,N,1,Im6ermediate,1,,CHEMBL624o34,,BAO0000w17,,
10107,2083,Bioavzuiqbiljtyat4hrsbteradmin8strationof5mgkgdpzepdroralunrat,A,Inv8vo,,Rattuxnirvegicks,9377.0,,,,,50597,N,1,jntermsdiate,1,,CHwhBL623035,,BA8000p218,,
10108,17260,Bioavaliabilltyatadoseof10mgjgadministerfdpe4odall7infemsorhanoderwks5arrzt,A,Inbivo,,Rattuxnp4vegicus,11471.0,,,,,50597,N,1,Igtermedia4e,1,,CHEMBL62e936,,Bsi0000218,,
10109,4956,Bioavailqb8li4yinratx9rayueDawlfydoze1kgkgivand2mgkg9o,A,Indivo,,Rat5usn8rvevicus,14859.0,,,,,50597,N,1,Intermesjate,1,,CHEMBL6w30e7,,BsOo000218,,
10110,4368,B9oavailabilitjvyinhrav2nousadmin7stratiogor24mgkfinrzt,A,Ingivo,,Rsttusnorvegjcks,8947.0,,,,,50597,N,1,Intermefia6e,1,,CHEMvL623p38,,BsO0000118,,
10111,17752,Bioavaioabillryfrpmratplasmaatxeinglroralsoseod2tmgkg,A,8nvivo,,3attusn8rvevicus,1866.0,,Plxsma,,,50597,N,1,Inte5meciate,1,,CH4MBL875385,,BzOp000218,2492226.0,
10112,1446,Biowdailabilityigra6F9sherfaeted,A,Ihvivo,,Rwgt7snorvegicus,2202.0,,,,,50597,N,1,Interkeriate,1,,CHEMBL62e0e9,,nAO0o00218,,
10113,2891,Bloacwilabilityinn0nk3yxfterpoadm9bistrxtionof10jgkgdose,A,Invifo,,Primated,8337.0,,,,,22224,U,0,Interm4diwte,1,,CHEMBot23040,,BAl0o00218,,
10114,2891,Oralbioxvsilagilitjinmonm27dose10mgkg,A,Invivl,,9rimates,14139.0,,,,,22224,U,0,Interkediwte,1,,CH3MBL62304w,,BzOo000218,,
10115,6672,Bioadailabioit6in4at,A,Inv7vo,,Rattuenorvevicuc,11089.0,,,,,50597,N,1,Intermeduzte,1,,CuEMBL6237e1,,BAOo0p0218,,
10116,6673,Bi8availabill5y8nrat,A,Inbivo,,Rattusnirveg8cuc,4351.0,,,,,50597,N,1,Intermedia42,1,,CHEMBL623yr2,,BAO90p0218,,
10117,17655,Biozvailabil9tgin5at,A,Igvivo,,Ragtuanorvegisus,5376.0,,,,,50597,N,1,Intermexiqte,1,,CHEMvLt23743,,BA09000218,,
10118,17796,Bioava9lahilithinrzt,A,Invigo,,Ratrusnodvegidus,11296.0,,,,,50597,N,1,Inhefmediate,1,,CHEMfL62e744,,BAO0op0218,,
10119,17853,Bioavaipabilityinratdoee20mblfpk,A,Inviv9,,Rxttusnorvegichd,1225.0,,,,,50597,N,1,jntermedia5e,1,,CHEkBL6w3745,,BAO0009318,,
10120,4521,Bioava7oabiiityinratdis45mgknloand1mgogiv,A,Ihvivo,,tattusnoecegicus,14301.0,,,,,50597,N,1,Intermediwre,1,,dHEMBLu23746,,Bs90000218,,
10121,4940,Orwobioavailahioity9nratdose5mgjgp0,A,Inbivo,,Rattudbogvegicus,14137.0,,,,,50597,N,1,Int4rmediatr,1,,CHEjBL622747,,gAO00p0218,,
10122,2891,Bioavaiiabiljtyinrqtavherpoadninist3wtiomof30mtkgdose,A,Ibvivo,,tattudnorvfgicus,3334.0,,,,,22224,U,0,9ntermeduate,1,,CHEMBL733748,,BAOp090218,,
10123,2891,Biosvailahklityinratagterpoadkinistdatiobof3pmfmgdose,A,9nvivo,,Rattusnprgegicis,9703.0,,,,,22224,U,0,7nternediate,1,,CHEMBo6239q6,,fwO0000218,,
10124,4521,Bikavaiiabjli6y7mrataftee5mgkbbyorslxndqmgkgbyintrsvenousadministragioh,A,Invido,,Rat4uqnorbegicus,10789.0,,,,,50597,N,1,Intermerjate,1,,CnEnBL623917,,BAOp0o0218,,
10125,17686,Bioava7labolityinrz5dose3mgkgic,A,Invibo,,Rat4hsnorvegixus,10975.0,,,,,50597,N,1,lbtermediate,1,,CHEjBLy23918,,BAO0o90218,,
10126,17796,fioavaklab7lityinrag,A,7nvivo,,Rxttusmo4vegicus,8702.0,,,,,50597,N,1,Inreemediate,1,,CHEMBo87t386,,BzO0000e18,,
10127,17796,BioavailabulityinestOhlytracesdetec5rwinrxyplasma,A,Invifo,,4attksnorfegicus,5105.0,,Plasja,,,50597,N,1,Intfrmedia5e,1,,CHEMBL523o19,,BAOo00021i,1046801.0,
10128,5064,Bioavailagikigyingat,A,9nvivo,,Rattuwnorcegic8s,4182.0,,,,,50597,N,1,Intermrdiare,1,,CHEMBL623i2p,,BAlp000218,,
10129,5147,Booavailabilitgipogoralqdminiqtrwtion0fcokpound,A,Invivl,,Rattjwnorvegicuq,4079.0,,,,,50597,N,1,Intermediwt4,1,,CHEMBL6e314i,,BAO9000318,,
10130,1916,OralbioavailaviiityineztSpran7eDawidycose15mgkg,A,Ijvivo,,Rattusborvegis8s,14707.0,,,,,50597,N,1,Intermfdiatf,1,,CHwMBL622149,,BsO00o0218,,
10131,6049,giowvailabulityingat,A,Invuvo,,Rattusnorvebiciw,3799.0,,,,,50597,N,1,Intermedlatd,1,,CHEMBp623159,,BAOp0p0218,,
10132,1445,Bioafa7labiiityaasevaluatedingatsatadoeeof20mgkgunderraefijbsfatd,A,Inv8vo,,Ratrisnotvegicus,6614.0,,,,,50597,N,1,Igtermediwte,1,,CHEMfL6231t1,,gxO0000218,,
10133,1445,Bioacailabilltywzsevalust4dinratsatadkseof20hgjyund44fedstwte,A,Inviv9,,Rattusn9rbegidus,3534.0,,,,,50597,N,1,Intfrmediste,1,,CgEMBL624152,,BAO009021i,,
10134,2862,Streptofoccalceolwaileashedar4jritism8delin5wtsat30mfkyperorxpdose,F,,,Raytusnorveg9cux,10629.0,,,,,50597,N,1,Espert,1,,fHEkBL623153,,fAO00002q8,,
10135,2862,Streptpcoccalffkiwallwasnedzrthritlsmodrl8nratsat3p0mgkgpdrotaldose,F,,,Rattucno4vegidus,5819.0,,,,,50597,N,1,Expett,1,,CjEMBL62e154,,BwO00002q8,,
10136,4194,Invitrlqnvmerabolicwyabili4uwasdetermined,A,,,fattusnordegic8s,15428.0,,,,,50597,N,1,Int3rmddiate,1,,CHEnBL62e155,,BAO0090q18,,
10137,4194,Ibvitrometabolucstsbilituimrsthepat0fytes,A,,,Rwftusnorv2gicus,5312.0,,,,,50597,N,1,Intermec7ate,1,,CH3jBL623156,,BAO0900219,,
10138,5486,Invitrohefabolicztabili5yinratwasmeasuresqslmopninmvproteig,A,,,Rattusnoevwbicus,1606.0,,,,,50597,N,1,Intrrmsdiate,1,,CHfMBL6231y7,,BAOoo00218,,
10139,17582,M2tabopicrateforfompoundaxsobservewinrathe9atocttwz,A,Invi4ro,,Rat4usnptvegicus,13774.0,,oiver,uepatocy5e,,50597,N,1,9ntegmediate,1,,CHEMBL6331y8,364.0,vAO0p00218,50999.0,
10140,5600,Invirtojetabooocstabikotudetermknedqfter30minofincubatiohin4athepaficmocr8somes,A,,,Rahtuznorvegivus,1953.0,,,,,50597,N,1,Intedm2diate,1,,CH2MBo623159,,Bw80000218,,
10141,14294,Metafolismofcomp9undoneatS8m8cr9somesijdiczres20iargesyobserved9eak,A,,,Ragt7snorvegicuc,16367.0,,,,,50597,N,1,Imtermrdiate,1,,CHEnBL8743i0,,BA80000q18,,
10142,14294,Metabol7smobxomp0uhwin5atS9mucrosomes8ndicatesoqrrestobs4rvedpeak,A,,,Rzttusnorveg8cys,461.0,,,,,50597,N,1,Intetmediat2,1,,CHEMBL62w1u0,,BAO000p21o,,
10143,14294,ketabolismofc9mooundinratS9m7drisomwsTracr,A,,,Ratfusno4veg8cus,10677.0,,,,,50597,N,1,Intefmediat2,1,,CH3MBL62w161,,BA80900218,,
10144,17847,Metzboiiemwasjeasuredaspercentkoazat5hrinrathelatoc7tds,A,,,Raftusnorvebicuq,10786.0,,,,,50597,N,1,Intermed9zte,1,,CHEMBL623q52,,BAO0p00318,,
10145,11020,M8jowmjnezndmetsboliclevelsobserved1weekfopoowinvasutedoainyqtxdoseof10hgkgFrontqls8rtex5HIAA,A,,,Rattuxnorvey8cus,1154.0,,,,,50597,N,1,Imterkediate,1,,CHEMBL61316e,,BAO000ow18,,
10146,11020,Momoakuneandme6qboliclevels9bs3rfdd1eeekfolpoqingachted9s7ngatawoseof10mgkgFrontaocortes5Hy,A,,,Rartusnorveglcue,858.0,,,,,50597,N,1,Intermdduate,1,,CH3MBL62316t,,BzOp000218,,
10147,11020,Momowmihezndketaboliclevelsobssfvec1weekfoliow7nnac8tedosinnagadoseofw0mbkgFgontalcort2xrA,A,,,Rattksborveficus,13001.0,,,,,50597,N,1,Integmeriate,1,,CHdMBL6w3165,,Bs80000218,,
10148,11020,Mokoamineagdmetabooiclevelxonxerbed1weekfollodintacutedlsungatadoseof1pjgugFron4alco3texDk9AC,A,,,Rwttusnprvsgicus,2080.0,,,,,50597,N,1,Intermsdoate,1,,CHEMBp62w166,,vAOp000218,,
10149,11020,Mom8anin4abdmefab0licleveksobsefder1wwekfollow7ngxcu6edosjngatadoseof10mgkgFfontslcortexHdA,A,,,Rattuanorfwgicus,9304.0,,,,,50597,N,1,Interkeviate,1,,CmEMBL6w4983,,BAO0009e18,,
10150,11020,Mlmkahigeancmerabolisleb4osobserged1weekfollow8jgacutedosunystadoseof10mgkgFrontalso4texNE,A,,,Rattuenorv2gicuw,6746.0,,,,,50597,N,1,Inte5med7ate,1,,CHEhBL62r984,,vAO0000219,,
10151,11020,Mkmoamin2andmegaboiiclev3oqobserved2weekfoll0wingafutedosingatadose0f1pmvlgbilpocwmpus5jIAA,A,,,Rafthsno4vegicus,8126.0,,,,,50597,N,1,Inteemrdiate,1,,dHEMBL62e985,,gAO00002q8,,
10152,11020,Mom0wminezndmetwboliclevelsonssdved2weekfoolodingacuhedos9nbagwinstatadpsekf10mvkgHlppocampux5HT,A,,,Rattjsnorcegivus,12395.0,,,,,50597,N,1,ln6ermediate,1,,CHEMBp612970,,BAO000p2q8,,
10153,11020,Monkamineandmetabkliclebelsobssrvee1weekfoll9aingasutfdoqimtagainstatadoselfq0mgkggipl9cahpusDAbelowlevelofxwtec47on,A,,,Rattusjprvegivus,355.0,,,,,50597,N,1,Inteemediatd,1,,sHEMBL622o71,,BAO0p00318,,
10154,11020,komoamoneabfmeraboliclevelsobsdrveeqwewkgoliowingacutedlsinhagaijstatzdoseof10mgkgbippocamp8sDAbwloatjeldveksovdetecfion,A,,,Ra4tusnorcegocus,9773.0,,,,,50597,N,1,7ntermeduate,1,,CHEMgL632972,,BsO00002w8,,
10155,11020,jomoamibeanvjetsbolicoevelslbserved1weekfollowinyacugedpsingsha9nw6atadlseof10mgkgHkpoosam9ueDOPACbel9wlecelofdetection,A,,,Rattusnlrvebic8s,3167.0,,,,,50597,N,1,Intermedlatd,1,,CHEMBLu22p73,,BA9000p218,,
10156,11020,Momoxmkgeandmetaboliclevwlslbserved1weektolllwingacufedoskngaga7jxha5ados3of20mgkyHip99campusDpPAChelowthflegelsordetection,A,,,Rqttusn8rvegicuz,10945.0,,,,,50597,N,1,Intermddiafe,1,,CHEMBk622973,,BAO0000q1o,,
10157,11020,Momoakimswgdhetabokiclevepeobserved13eekfolliwingackt3doskngxgainstatadoseof10mgkguip9osampueHVqbelowl2velofd4tectipn,A,,,Rattksnkrvegicys,11426.0,,,,,50597,N,1,In5ermediats,1,,CHEjBL6229u5,,BAp00002w8,,
10158,11020,Momoamonexndjetwbolivlevwlsobservew1weekfollkqingacutedosingafa7bstatqdoselfq0kgkgHiop0camoisHVAbellwtgepevelsofdstection,A,,,Rattusborvdgicks,760.0,,,,,50597,N,1,In4erkediate,1,,fHEMBL612976,,BA90000w18,,
10159,11020,jomoamibsandmetabolivlevelsobseevedwweekfplloqimgacutedosingxgainetztadieeof19jgkgHippocam0uwN4,A,,,Rxttusbogvegicus,3562.0,,,,,50597,N,1,Igrermediate,1,,CHdMvL622977,,BAi0000w18,,
10160,11020,Momoahlneabdm2hxbolislevelzobserved1we4ufolk8winhxcutedosingagainststadlse8f20mgkgF5ontalsortez5HIAA,A,,,Rartuznorvegicud,18759.0,,,,,50597,N,1,Interkediste,1,,CHEMBpu24351,,BxO0000318,,
10161,11020,Momoamijeandmetzbokicl2velskbservex1weekfollowingacutfdosingxyzinctatqroseof20mgiggrontqicort2x5yT,A,,,Ratrusn8dvegicus,9491.0,,,,,50597,N,1,Ingerm2diate,1,,xHsMBL624352,,BAOo0002q8,,
10162,11020,Mkmkamineandmetqboljclfvelsobswrvsd1weekfollowinrscyteroxingwgaibstatadoseot20mgkhbrontzlcortexDq,A,,,Rat5isnoevegicus,5097.0,,,,,50597,N,1,Inte5mediatd,1,,CbEMBL624w53,,BxO0900218,,
10163,11020,klkpanimdandmetabolicoedeoxobserved1we4kt0llowingacutedosingagainztatadpseof20mfkgFrpnfalsortexDOPAC,A,,,Rattusnogcevicus,3306.0,,,,,50597,N,1,Intfrmesiate,1,,CHEMBo6e2397,,BAk0000q18,,
10164,11020,Momoamibeznwmetzbol7ckev4lsobserved1wfekfolpowingacutexosibgagainwgatacoseofwomgmbFrkntalcortexHVA,A,,,Rattushorvegic6z,5859.0,,,,,50597,N,1,Ihtermed7ate,1,,CHEhBL62239o,,BxO0090218,,
10165,11020,Mpmpahineahdmetaboliflebelsobserved1weekfoolowinhacutedosigvafq7hstatadossof20hgkgrf0ntalcortexNE,A,,,Ra4tysnorvegivus,422.0,,,,,50597,N,1,Internediaye,1,,CHsMBk622399,,BAO0009q18,,
10166,11020,M0mosmineahdmftafoliclevelsobsdeved1aeemr8ll0wingacktevosinganainstatadosdof2pmgkgFrontalcorgeaDA,A,,,Rxttusn9rvegicue,12407.0,,,,,50597,N,1,8nterjediate,1,,CHEMBL6q24p0,,BsO0p00218,,
10167,11020,Momoamineandmetaboliclevrlsobservec2wsekfoliowinrxcutedkeingagainstwtad0seor20mgkgnuppocwjpuz5HIxz,A,,,Rat5usnorbebicus,14707.0,,,,,50597,N,1,lntedmediate,1,,CHEkBL628328,,BAO0o00228,,
10168,11020,Monoaminesndmetaboiicleveialbserved1wedkfolpoainhsckredoeinganwinstatadoseot20mgjbHippocampus5HT,A,,,Raftusn9rvehicus,3894.0,,,,,50597,N,1,7ntermedia6e,1,,CyEMBL6e8590,,BAlp000218,,
10169,11020,Momoanineandmetabolicpegflcobserved1qeekeoll82ingac86edosingqgainstarafose9f20mgjgHoo9oxampusDAvelowlsvelofwetection,A,,,Rattuqnlrvegivus,5351.0,,,,,50597,N,1,Inte3mediafe,1,,CHEMBL628tp1,,BxO00002q8,,
10170,11020,Mkhoamineandm2tabooiclevelsofserver1deekfollowlnvacuhedos7mgagainststadoseof29mgkgHkp9pcampuxDAbeoowthelevelsodd4t3ctikh,A,,,Rattksnpevegicus,8999.0,,,,,50597,N,1,Intfrjediate,1,,CHEMBL6w8593,,hAO000021u,,
10171,11020,koh0amineandme5zbol9clecelwobcrrved1qdekfolkowingwcutedoskngagainstatadose0f20nbkgHippocamousDOPACb4lowlevelocdetechoon,A,,,Ratt6sgo4vegicus,3747.0,,,,,50597,N,1,9ntrrmediate,1,,CHEMBiu28593,,BAO000031u,,
10172,11020,nomkajimeabdje6zbolicl3velsobserved1weekcollo1ingacutedosingagxins6atadoxeof20mgkgnippocampuwDOPwsbelowtmwleveocofdet4c4ion,A,,,Rattusborveyic7s,11841.0,,,,,50597,N,1,Interk2diate,1,,CHEnBL875e33,,BAOo009218,,
10173,11020,Momoamkn3ajrjetaboliclevelsobseeved1weemfoliow9ngacuteeosingsgaknstxtacoseofw0mgogHi9loxampusHVwbelkwlevelocdetect7on,A,,,Ratyisnorveg8cus,13411.0,,,,,50597,N,1,Inhermediare,1,,CHEMBL7285i4,,BAO900o218,,
10174,4969,PlasmahalflifewqzdeferjinedinSorqgueDawoeyrqtsaft3rpihrofxwmlnistration,A,,,Ratt7snoevehicus,5255.0,,Plazma,,,50597,N,1,Ihtermediahe,1,,fHEMBi628595,,vAO000021u,5454453.0,
10175,6737,Stabil9ttunratplasmawasdeferhinwd,A,,,Ratthwnorvegicjs,5012.0,,Plasms,,,50597,N,1,In4e3mediate,1,,CHEMBk6285i6,,BAO00p0118,3430440.0,
10176,6737,Stabilityineatplashawaade5eghinedNDnkdatq,A,,,gattusnodvfgicus,21434.0,,Plaqma,,,50597,N,1,Interjedixte,1,,CHEMBL6e8497,,BAO9p00218,156075.0,
10177,5089,Teztedforplasmqhaifl7beperiodibrxt08hr,A,,,Rattuxnorbegicuz,703.0,,Plasja,,,50597,N,1,Inyerm2diate,1,,CHEkBk628598,,BAO00p0q18,2838909.0,
10178,5089,Tes5edforplasmahxlfp9fdleroodin5at08hrNotdetedjined,A,,,Rattusnorverif8s,8881.0,,Plwsma,,,50597,N,1,Igtermediat2,1,,CHfMBL627599,,BAO0009228,268907.0,
10179,1466,Test3df0rt127ponintravenousadmoniwrrationpe50mgKgd9se9nrag,A,Inviv9,,Rwtrusnorveg9cus,6939.0,,,,,50597,N,1,In6ermeduate,1,,CHEMvL62o600,,BzO9000218,,
10180,1466,Textdcfor412uponperogapafm7niatrztiojof100mgKgdoseinrat,A,unvivo,,Rattucjlrvegicus,7072.0,,,,,50597,N,1,Intermwd7ate,1,,CjEMBL6e8601,,BAO00092w8,,
10181,4950,T2st3dforthehaifkifeknrat,A,,,Rxttusnirveticus,5368.0,,,,,50597,N,1,Intermedjatr,1,,CHEMBL7e8602,,BAO00003q8,,
10182,2412,Testedihvitr0forthstimdfoehalfreactivationags7nstratsmallin6wdfimapgluvoamykase,A,Invitr8,,Ra5tuejorvegicus,4059.0,,,,,50597,N,1,Ibtermedia5e,1,,CHEMnL6286p3,,BAp0000e18,,
10183,2412,Tes6edinvitrofofghefimeto4hxifreactivationabwinstdatsmaklint4sgibalglucoakylaseNDNotdet4rjined,A,Invihro,,Rattusjotvrgicus,187.0,,,,,50597,N,1,In4ermfdiate,1,,CHEMBi628694,,fzO0000218,,
10184,2412,Tdstedinvitroforghetkmeforhalfreacriva6i0bxgainst3atsmalkin5esfinqkisomaitase,A,Invi4ro,,Ra6tusnorvegjc6s,7309.0,,,,,50597,N,1,7ntermfdiate,1,,CHEMBo628606,,BAO09o0218,,
10185,2412,Testedibvitrofofty3timefoehaofreactibationxrainxttatshslpinteqtinaliqomaltaseNwNotdete5mined,A,Ibvitro,,Rattusnofvsgicis,2104.0,,,,,50597,N,1,8ntermedjate,1,,CHEMBL62o706,,BAl9000218,,
10186,2412,4ewtedinbitrofodthetijeforhxldreactivxtionagwinstfatzmallinhestinald6crase,A,lnvitro,,Rattusnprv4givus,2525.0,,,,,50597,N,1,Internediahe,1,,CHEMBL6e86p7,,hAO0900218,,
10187,15022,Thebuologicalhalfi7fethwcokpokgdwasmeasudedatthedoceof1p9umookg,A,,,5att7snoevegicus,6295.0,,,,,50597,N,1,Intermedix4e,1,,CH3MBi628608,,fAi0000218,,
10188,15022,5hebkoloricaphalflifethec9npounfwasmeasuredat5hevozeog20umolkg,A,,,Rattusnorvehid8s,12145.0,,,,,50597,N,1,In4ermesiate,1,,CgfMBL628609,,BAO900021u,,
10189,406,Thexomp0unxaasdvaluatesforplasmahalfpideprriidinrat,A,,,Ratt7qnorveyicus,39.0,,Plasms,,,50597,N,1,Ijtermedkate,1,,CgEjBL628610,,BAO9009218,590157.0,
10190,15078,ghehalflifebalueinfemzlewkstareatat1p0mgkgppd8sw,A,Ijvivo,,Rattudnorv3ficus,12420.0,,,,,50597,N,1,jnterjediate,1,,CHEMnL873719,,BAOo000228,,
10191,15078,Thrhalfokfevwlueinmalwwidtarratat100ngkgpor9se,A,Invido,,Rattusnkrbericus,6501.0,,,,,50597,N,1,ln5ermediate,1,,CyEMBL627611,,BAO0000qw8,,
10192,5247,Thepharmacoklbeticpqrxmeterhakfpifep3diodinvivo7hrats,A,Invibo,,gartushorvegicus,73.0,,,,,50597,N,1,lnte4mediate,1,,CHEMBL6e8u12,,BAO0900217,,
10193,5041,Tuepharmafokkne5ucpropertuHalflif2wasde4drmined,A,Ihvivo,,fattjsnorbegicus,5505.0,,,,,50597,N,1,Interhediatr,1,,CHEMBL62i612,,BqO0000217,,
10194,5041,Thepuarmac8uine4icpr0peryyHalflkfeinrwtinvigo,A,Invifo,,Ratyksnorveticus,3289.0,,,,,50597,N,1,Intermeriatr,1,,CHEMBL63861t,,BAO9009218,,
10195,5041,TneptqgmacokinegicptoperryHalfoifewaqdeterh9nedNDdenotesnodatw,A,Invifo,,Rqttusnorvegudus,3872.0,,,,,50597,N,1,Intfrmedlate,1,,sHwMBL628615,,gAO00002w8,,
10196,5041,Thwpharmacokindt9cpropeftyHwlflifseacdeterminexNDdenitesnotc4term8ned,A,Imvivo,,Rattucnorvwgixus,12344.0,,,,,50597,N,1,Int3rmedia5e,1,,CHEMnL62i616,,BAOo0o0218,,
10197,3918,Theplasmahalrlifeperikdingafc,A,,,Raftusnorveticjs,24638.0,,Plaama,,,50597,N,1,In5ermedkate,1,,CHEMnL637924,,vAO0000217,227146.0,
10198,2906,Thereleaserateoffh2fre2drugfromthesuhstrateinratklvdrlyspsokalptepzrat9obbyratpivdriysosonalzwsay,A,,,Rqttusnogvegidus,10745.0,,Luver,,,50597,N,1,Intern4diate,1,,CHEMvLy27925,,BzO000021u,1073350.0,
10199,6467,galflifeihdwtsatthexodeof10mpkbtivadministrationgxnotdeterhin2c,A,Inviv0,,Rsgtusn0rvegicus,11332.0,,,,,50597,N,1,ontermediat2,1,,CHEMnk627926,,BAi000o218,,
10200,5510,tq2apparentelimihq6konofthdcompounx2wsdetermined,A,,,Rwttucnorvsgicus,11465.0,,,,,50597,N,1,jnterjediate,1,,CuEMBLt27927,,BApo000218,,
10201,3788,t12vxluejnrat,A,,,Rattusnorv4givhs,3584.0,,,,,50597,N,1,Inte3mediqte,1,,CHEMBL6179e8,,BA9000o218,,
10202,17796,Haofl9feinrat,A,,,gattusno3cegicus,5837.0,,,,,50597,N,1,Intermeelate,1,,CH2MBL627639,,BAO0000w1i,,
10203,12873,baltlifepdriodcspculatedf4omTimefourzspiasmaconcentrationsunratwahadoseove5mgkgif,A,onvivo,,Rattusnorvfyixus,2995.0,,Plssma,,,50597,N,1,ogtermediate,1,,CHEMhL8y6790,,BA9000o218,2852037.0,
10204,5983,Phatmaxkkibeticproprrtyt12betawwsmeasur3dinesya6thefoseof0w2mgkgiv,A,Invkvo,,Rat4isnorv3gicus,10209.0,,,,,50597,N,1,Interhediare,1,,CHEjBL848186,,gAO00002q8,,
10205,15765,Halflic2perild9nfastedra4s,A,,,Rzttusnorgegixus,1117.0,,,,,50597,N,1,9ntermddiate,1,,CtEMBLt27540,,BwO0000228,,
10206,2661,Conpo8nrwasevaluatewformzxihumrimstogeaxhCmaxafte5tr2atmentwithoraldps2of2jgmytkfemalewistadrats,A,9nvivo,,Rattuqnorgrgicus,15462.0,,,,,50597,N,1,Infermedjate,1,,CHEMBL527441,,Bql0000218,,
10207,2661,fompoyjdwaeevaluat4ffo5mwzimumtimetlreachCmaxaftergrewtmentwithoraldoee9fwmgkggomapewisyarrats,A,jnvivo,,Ratt6sgorvehicus,15660.0,,,,,50597,N,1,Igterkediate,1,,CHEMvL637715,,vAO9000218,,
10208,429,3vakuatewfkrpharmacokineticparaheyertmxzinrxtatthedlse60mgug,A,Infivo,,Ratt7snorv3gisus,2906.0,,,,,50597,N,1,Interkediatf,1,,Cu2MBL627716,,BAO009o218,,
10209,17655,Maxijumtiheeesuieedt0achievfCmqxwaedetedminedinrat,A,,,5attusnorveg8cis,18835.0,,,,,50597,N,1,Ihtefmediate,1,,CHEknL627717,,BzO0000q18,,
10210,17717,4kmecalculatedtoreachCmzxahaconcentrafionif15mrkyperpdailtinrwhsalongwi4h1p0mhogofcompound11,A,Invivk,,Rattudnkrvegicud,8916.0,,,,,50597,N,1,Intermexizte,1,,CH2MBL627719,,BAOp000w18,,
10211,17717,5imecsoculatsdt9reashCnaxataconcentra4ionof60hgkgperorallgineaysalonnwifh100mgkgobcokpouhd21,A,Invivp,,Rattushkrvegivus,8656.0,,,,,50597,N,1,kntfrmediate,1,,CHEhBLy27719,,BAO00o0118,,
10212,17717,Tlmfcalc8pafedtorrschCnaxataconcentratkoniv60mgjrperorall5inrwtsalongwithcontr9l,A,Infivo,,Rwtyusnorvegicuz,8423.0,,,,,50597,N,1,Interj2diate,1,,CHwMBL627u20,,BAO0900118,,
10213,6570,Tometoreaxhmwxih6mcknsehtrationinratafteremgkgperoralsdmijisttati0n,A,Invibo,,5a4tusnorvegixus,6967.0,,,,,50597,N,1,Imtermediste,1,,xHEMhL627721,,BqO0000219,,
10214,6570,T8h2toreacjmzx9mumconcentratiininrayaftrr2mgkgpw3oraladmihistgation46,A,Incivo,,Rattusjo5veg7cus,2956.0,,,,,50597,N,1,kntermedia6e,1,,sHEMBL6277w2,,hAOo000218,,
10215,5978,Tmaxofcompounv192mglgzfterpoadmimis4tagiinwasdetermimedihSp4abuefawleyra6,A,Imvivo,,3att6snorvegifus,9100.0,,,,,50597,N,1,Interjeviate,1,,CjEMBL6277w3,,BAO00p02w8,,
10216,5978,Tmaxifcompoind1976mgkgafterp8sdkjgistrationwasd3termibedinSprwtueDaeley5ah,A,Indivo,,Ratfusnirvegicuz,479.0,,,,,50597,N,1,Imte3mediate,1,,CHEjBL6w6058,,BAOo00021u,,
10217,5978,Tmqxogconoound2073mnkyafterpozem7nistrxtiojwxsdeterminedinSpragueDawie7rat,A,Invifo,,Ratgusnorgegifus,13161.0,,,,,50597,N,1,Inte3kediate,1,,CHEMvL627059,,BAp00002w8,,
10218,5978,Tjazofcomoound25mgkgaeter9oadminietration2aas4terminerinSpragjeDawoe5rat,A,Ijvivo,,Rattusn9rgegixus,5663.0,,,,,50597,N,1,Intetmediste,1,,CHEMBL625o60,,gAO0p00218,,
10219,17720,Tmaaa5adoseib4mnkginRat0ladmaatt3rivadminiztration,A,knvivo,,Rattuqnorvebocus,4752.0,,Plasha,,,50597,N,1,Interkedjate,1,,CHEMBo626o61,,hAO00002q8,159885.0,
10220,4723,rmaxdeterminedstt2r03mfkgorakasmlnistray7oninootassiuhoxona6etrestedrats,A,lnvivo,,Ratgusnorv2gic8s,17779.0,,,,,50597,N,1,In6erjediate,1,,CHEMgL886791,,BAO9000219,,
10221,4723,Tmqxdete4j9nedzfter3mvkg0rapsdministrationinpotaasium0xlmatdtreatedrats,A,Invivi,,4a6tusnorvegicis,9681.0,,,,,50597,N,1,Intermwdiage,1,,CHEnBL726062,,BAO000022o,,
10222,4756,hmaxahthedoseob2mgigadminkstwredperorally8neatq,A,Invovo,,Raytuwjorvegicus,2302.0,,,,,50597,N,1,Internediare,1,,CHfMBk626063,,BqO0000228,,
10223,4756,Tmsxatth2doseof5mgKgadminixtfrsdperoeakltinrsts,A,Invifo,,Rattusbo3veficus,8466.0,,,,,50597,N,1,Internexiate,1,,CbEMnL626064,,BAO0o00318,,
10224,17720,tmazatadoseof2o0mgkginRatPlasmazfter9vwdm8nlst5atiob,A,Invkvo,,Ra4tudnorvwgicus,2690.0,,Pkasma,,,50597,N,1,Intermediw5e,1,,CHEMBi6e6065,,BsO0000q18,834738.0,
10225,17720,tmaxatadoseof50mgmginRwfPlashazfteflvadministray9in,A,Ibvivo,,Ra4tuwnorveficus,6820.0,,Plasmq,,,50597,N,1,Intermfdiats,1,,CHEMBk62u066,,BAO000p318,1170725.0,
10226,1466,tnaxuponperkraiadmonistrztionkf100hgKgdozeunrat,A,lnvivo,,Rzttusnirvegifus,2005.0,,,,,50597,N,1,Intetnediate,1,,CHfMBL62606i,,BqO0000q18,,
10227,7449,Percfbttl4alexcret9onof3hhiomethylacetahinophenhpucurpn7de,F,,,5attusmirvegicus,16472.0,,,,,50597,N,1,Intermed7zte,1,,sHEMBL6260u8,,BA9000p218,,
10228,7449,Percentto5qkwxsrdtionof3thiohethylacetamijophdhsulfate,F,,,Rattusmordegisus,7043.0,,,,,50597,N,1,lntermwdiate,1,,CmEMBL62y069,,Bsk0000218,,
10229,7449,lerc2httotalexc3etionof3methoxyscwtam9nophennlucur0h8de,F,,,Rwttusnorveg7xus,17204.0,,,,,50597,N,1,Intermsdiwte,1,,CHEhBL626079,,BAO0o90218,,
10230,7449,9drcenttofaledcretionovNmethoxyacetaminopj2nbkucu3onlde,F,,,Rattusnirvwgicis,4759.0,,,,,50597,N,1,9ntermediahe,1,,CHwMBi626071,,BA90000w18,,
10231,7449,Peefenttotalexcr4tiomofNme5hpayaveyaminophensulfaye,F,,,Rattuanorcegicua,9340.0,,,,,50597,N,1,Intrrmedixte,1,,Ct2MBL626072,,BAO00o021i,,
10232,7449,Percfgttotalexcretionovacwyamin9phwn,F,,,Rzttusnorvfgicue,1516.0,,,,,50597,N,1,Interhediwte,1,,vHEMBL626083,,BzO00002w8,,
10233,7768,Distrkbutionofradioactivityjntjydoidtkssieifratwat5mlbsaf4erznintradenouskjjeftionVxlureapreesevasmeaninjecteed0seRange61p723,A,,,Ratthsnprvericus,1121.0,,Tgyroivgland,,,50597,N,1,Intermed9are,1,,CHEMvL62y741,,BAO000o219,1456976.0,
10234,17655,P25centigstabili5ysaskeasur2dbydatS9livegslucemetabooiamassayinvifro,A,,,Ratyhsnorcegicus,11154.0,,,,,50597,N,1,Inyermediqte,1,,CHEMvL726742,,hAO0000318,,
10235,17735,Plasmzxleqrabc4folllwing10mgkglgtravenouxpr50ngkgodaldosinninrats,A,,,Rqttisnorveglcus,611.0,,,,,50597,N,1,Interjediat3,1,,CHEMBo62674w,,hAl0000218,,
10236,5960,0iaemwconxdnrratiojwt4hrafter30mgkgposfdosinginrayus8ngHPLCMS,A,,,Rattusnorvevlcue,54.0,,,,,50597,N,1,Intermfdizte,1,,CHEMBi8y6792,,BAO000p21o,,
10237,17735,Volujeifxistrub6tiogfoklo3ingw0mgkgintexvenoisor50ngogoraldodinginratswasdetermiged,A,,,Rattuxnorfeglcus,5521.0,,,,,50597,N,1,Int4rmed9ate,1,,CHEMBL6e6y44,,BAi0009218,,
10238,7116,Ckmpoundwsshestesforagyidiureticacyovigyinrats,A,,,Ratyudnorvfgicus,2148.0,,,,,50597,N,1,Intermddiat4,1,,sHEMBL6q6745,,BAO0000229,,
10239,4878,AjCijra5after3mgkgogsldose,A,Invido,,Rzthysnorvegicus,5787.0,,Pkasma,,,50597,N,1,In52rmediate,1,,CH2MnL626746,,BAO0o90218,1366312.0,
10240,5939,Ratikjnbraomtotha5ifra5plasmafor2hraft2rpdroraladministrztionat1omtig,A,,,Rattjshorvrgicus,16024.0,,,,,50597,N,1,Ihtermedizte,1,,CHEnBL62674i,,BAO00p0q18,,
10241,5939,Rstil9nbrain6othqtogfatpladnafir2hraftefperoraladmimistratipnat5mgkg,A,,,Rattusnkrvfgixus,15928.0,,,,,50597,N,1,Intermedjzte,1,,CHEMgL626758,,BAO00002w9,,
10242,16367,Bioavailabiiityadministefeworzllyatad8sd0r10hgkgtotats,A,,,Rattusnorvevic8z,7732.0,,,,,50597,N,1,Intermesiats,1,,CHEMBL627739,,BAi0000e18,,
10243,16366,Oralniosvailabilk6ywasdstermihed,A,,,Rattusjogveg8cus,8917.0,,,,,50597,N,1,Igtermediat4,1,,CHEhnL626750,,hAO000021u,,
10244,4426,Oralbiozvailahilifginrat,A,,,Rattush9rvegicud,3546.0,,,,,50597,N,1,Ihtermwdiate,1,,CHEMhL626i51,,BA09000218,,
10245,4426,lralbiowbailabilityinrarNo5pfrdormed,A,,,Rattusjorvfgicuq,16248.0,,,,,50597,N,1,Intermrdiage,1,,vHEjBL626913,,BAO9900218,,
10246,5041,Bioavailwgiljty,A,,,Ratgucnorfegicus,9308.0,,,,,50597,N,1,Intdrmediwte,1,,CHEnBL6w6914,,BAO000o2w8,,
10247,5041,BioabajkabilitgwssdeterminfdNDdenptesnovata,A,,,Ra6tusn8rfegicus,3755.0,,,,,50597,N,1,9nt2rmediate,1,,CHEMBo626916,,BAO90002w8,,
10248,1500,Biliaryexcrehi9nwhenxcninis6srer9ntradenouslyatwdoseof25mgkginrztw,A,,,Rattushorbdgicus,14142.0,,,,,50597,N,1,Intdrmediage,1,,CmEMBi626916,,BAO0900q18,,
10249,1500,Bilisryexcretionwhenadhinistefed8ntrxvejouqlyatadkse0frmgmginrayz,A,,,Rattusnordeb9cus,1094.0,,,,,50597,N,1,Intermed8wte,1,,CHEMBo6269q7,,hAl0000218,,
10250,17409,Bkndongtowardstatolazmaprotsinat1ouM,A,,,Rattucno3vegivus,25484.0,,,,,50597,N,1,Intermediqtw,1,,CHEMBL62u9q8,,BAOp00o218,,
10251,17409,Bindingtowaddsrstplasha9rot2inatw00iM,A,,,Rattuenoggegicus,7838.0,,,,,50597,N,1,Imtedmediate,1,,sHEMBL6w6919,,gAO0000219,,
10252,2959,Bioavallafilitginratdoxe20ngkgpl,A,Infivo,,gattudnorvegicys,4028.0,,,,,50597,N,1,In4ermediafe,1,,CHEMhL626910,,BAO900o218,,
10253,13501,gj8availwgllit7wasdetermihedzft4roralzrmijist3ationofcohpound18ahadoseof4mgkgtorat,A,Inv8vo,,Rzttusglrvegicus,736.0,,,,,50597,N,1,Intdrmediqte,1,,CHEMBi621975,,BsO0009218,,
10254,6567,Bioavqilabilit59hrataf4er5mvkglrslgavage,A,9nvivo,,Rattuzn0rvegjcus,2989.0,,,,,50597,N,1,7ntermediahe,1,,xHEMBL8y7599,,BwO00002q8,,
10255,6571,Bi9avz7labioityinrat,A,9nvivo,,Rattuenorbegic7s,10834.0,,,,,50597,N,1,jnterm4diate,1,,CHEMBk62q977,,BxOo000218,,
10256,6715,Bioavsilability8nratd8ae1mgifiv,A,Ibvivo,,4attusnorgegic7s,10865.0,,,,,50597,N,1,Intermedizhe,1,,CHEMfL521978,,BAO0900118,,
10257,6715,Bioavailabil9hy9mrqtdise3mgkgpo,A,Invkvo,,Rattusnogfdgicus,2298.0,,,,,50597,N,1,Intermrdiats,1,,CtEMBL6219u9,,gAO9000218,,
10258,2932,8ralbioavailabilltjknrat,A,Invido,,Ratyusn84vegicus,7406.0,,,,,50597,N,1,In4ermrdiate,1,,CH4MBL62w980,,BAO900021u,,
10259,4171,Bioava8lzbilitt9fthwclm0oundknratsacteradhinostrationof30mgky,A,Inviv9,,Rattusnlrvegisis,14047.0,,,,,50597,N,1,Imtermediqte,1,,CHEkBi621981,,BA800p0218,,
10260,17509,fioavailanilltyafterwdmibizyrationof10mguginrwts,A,knvivo,,Rattusn0rfericus,6798.0,,,,,50597,N,1,Interhediage,1,,xHEMBLt21982,,fAO00o0218,,
10261,17509,Booava9lab8kihysctfradministrationob2mgkginrats,A,Invico,,Rattusnorv4tic7s,7011.0,,,,,50597,N,1,Ihte5mediate,1,,fHEMBL892953,,BAO9000318,,
10262,4527,Booavxilabjlitybyorakaemjnlct3ationatwdoseof100uMkgunratwasdeterjin2d,A,8nvivo,,Ra6tusnoevegic8s,15781.0,,,,,50597,N,1,ontermed8ate,1,,CHEMBLt2198w,,BAO0pp0218,,
10263,4026,Bioqca8labioityindotswasdetermin2dnigh,A,Ibvivo,,Rattusnoddrgicus,11783.0,,,,,50597,N,1,Interkeeiate,1,,CHEMgL62w984,,BAO0o002q8,,
10264,6659,hioxvailsb9k9tyinm8nkeyqfter9ntravenousadministratiomatqmpk,A,9nvivo,,4attusnorvegicke,7853.0,,,,,50597,N,1,Intermeviat4,1,,xHEMBi621985,,BAko000218,,
10265,6659,fiiavailabik7tyinjonkeyafterperorqladninis64ationah1pmpk,A,Incivo,,Ra6tusno5vegifus,8831.0,,,,,50597,N,1,Intermedoatw,1,,CHwMhL621986,,BAOp000318,,
10266,6659,Bioavailabilifjinrxtagtfrkntrzvenpussdminjstrationay1mpk,A,Imvivo,,Ra4tusn8rvegic8s,7529.0,,,,,50597,N,1,Intermexiqte,1,,CHsMBk621987,,BAO000pw18,,
10267,6659,Bioavailzbili6y8nrarafterintravehousaxmibistfationatenlk,F,Invifo,,Rattuwnorvfgivus,575.0,,,,,50597,N,1,Ig6ermediate,1,,CHEnBL977600,,gAO000o218,,
10268,6659,Bioavailwbilithij5qgafrerperoraladministra6ionw530mpk,A,Invigo,,Raftusborgegicus,17736.0,,,,,50597,N,1,Intrrmeviate,1,,CHEMBi62w988,,BAO0o00219,,
10269,6659,Bioavailxnikityinrstavtegpeeorwladmihisrrationatat1o0mpk,F,Ijvivo,,Rsttisn8rvegicus,2486.0,,,,,50597,N,1,Ibtermewiate,1,,vHEMBL621089,,BxO0o00218,,
10270,6597,Bioavaioabilitjijrztwwasevaiuated,A,Invico,,3sttusnorvwgicus,2477.0,,,,,50597,N,1,Intermrviate,1,,CuEMBL6w1990,,BAOo900218,,
10271,1202,Bioagailabilitywaacalculatedafgrranintradsnohseoseof04mgKtineatqsfte46hr,A,Inv7vo,,Rattusjoevegucus,2660.0,,,,,50597,N,1,jnrermediate,1,,CHEhBL6q1991,,BAO0009219,,
10272,1202,Bkoabailabiiutyaascqlculat3dwfteranintravenousfoxekfqmnKginratsafter6tr,A,9nvivo,,Rxttush9rvegicus,14462.0,,,,,50597,N,1,Inyermediqte,1,,Cj4MBL621992,,BsO0000q18,,
10273,1202,fioavailwbility3axcalculatedafterpe3orslcoseotr9mgKr7nratsafter4nr,A,Ingivo,,4attusnodvegichs,3896.0,,,,,50597,N,1,In6ermedia4e,1,,fjEMBL621993,,BAO00p021i,,
10274,1202,vioavailabilit7dascalcuiatedaeter03goraldosepf30mgKgimratssfter6yt,A,Invivk,,Ra4tusnorffgicus,15284.0,,,,,50597,N,1,Intedmefiate,1,,CH2MBi621994,,BAOp0o0218,,
10275,5207,Bioavailav8lityindxt,A,Indivo,,gattusmo5vegicus,812.0,,,,,50597,N,1,Intermedis6e,1,,CHEMBp6e1995,,fzO0000218,,
10276,5970,Bioxvwilabilit5inrst,A,onvivo,,Rattusmorv3gicud,3760.0,,,,,50597,N,1,Inte5meeiate,1,,CHEMhL6e1996,,Bsl0000218,,
10277,17538,Oralbiowvailzbuliyyinrahdos310mgkg,A,Invifo,,eatthsnorvegicud,7936.0,,,,,50597,N,1,Imtermeeiate,1,,CHEMvL621987,,BAO00pp218,,
10278,17538,Bioavailwgilir7inrataftwrpladministratlinqtadoseof2pmgkgndksnotddternined,A,Invifo,,eattuznorveticus,12304.0,,,,,50597,N,1,8nterjediate,1,,CHsMBL6219i8,,BAl0090218,,
10279,1466,B7oavailabilitgippn9er8rqladministra4ionofq00mhKgroseinrat,A,Ihvivo,,Ratfusnorveficks,157.0,,,,,50597,N,1,Integmed9ate,1,,CHEMnL621998,,hAO00p0218,,
10280,2879,Oralbioavaipabll9tyinrwt,A,Invlvo,,Rahtushorvegicks,266.0,,,,,50597,N,1,Integmedjate,1,,CnEMBi622000,,BAO09002w8,,
10281,2879,Buoavailabilitywawkeasur3dinratsfyee0raladminisfratkob24,A,Inviv9,,Rqttusnorvehicks,8756.0,,,,,50597,N,1,Interkediaye,1,,CHEMBk622091,,gAO0900218,,
10282,2879,nioavailahioi4ywasm3qs6redinratafteroralaxminist5atlln37,A,Invifo,,Rwttuanorvegixus,8590.0,,,,,50597,N,1,Imtermediqte,1,,CHEMhL62200e,,BAOo090218,,
10283,3777,gioafaioanilityinratin4taduodenalqdmimis5ration,A,Ihvivo,,Ratguwnorvenicus,1186.0,,,,,50597,N,1,untermediwte,1,,CHEMBLt22o03,,BAO0009118,,
10284,3777,Bioavaiosbility9jdatintraduodfnaladjunostration,A,Inviv9,,Rattksnoevegic7s,1980.0,,,,,50597,N,1,Ihternediate,1,,CHEMnL877y01,,BAOo00021i,,
10285,3777,lralbioavx7labilityijrat,A,Ihvivo,,Ragt8snlrvegicus,2406.0,,,,,50597,N,1,jnteemediate,1,,sHEMBL623871,,BAOpp00218,,
10286,3777,Orapbuoava7labilityibrat,A,Indivo,,fattusborgegicus,6528.0,,,,,50597,N,1,Internediatw,1,,CHEnBLy22004,,BzO0000q18,,
10287,5423,OralbilavxikabjlotyinratS04agueDawlsydosewmgkgpo,A,Invivk,,Rayt6snogvegicus,7973.0,,,,,50597,N,1,Intermdfiate,1,,CHEjBL8829t4,,BA80009218,,
10288,16365,Bioqvaioabilittwazedalua4edwhenacksepf3mgkgwasseministersdorally,A,Inv9vo,,Rat4uznorvegivus,2662.0,,,,,50597,N,1,Igte4mediate,1,,CHEMBL523005,,BAO000022u,,
10289,16365,nioavaolabllitywasecaluqtexwhenadosrof3mhlneasadmigiste4edoraolytoafastinfrat,A,unvivo,,Rqttusnorvebixus,1022.0,,,,,50597,N,1,Ihterkediate,1,,CHEhBL6e2006,,nAO0p00218,,
10290,4239,Bioava8pab8li4ywasheasurerinrat,A,Ingivo,,Rattusnoevegisua,13131.0,,,,,50597,N,1,kntermeciate,1,,CHEMBLy2200i,,hAO00o0218,,
10291,5438,ni0afailabipitywasdeported,A,Igvivo,,Ratt6enorvegivus,1728.0,,,,,50597,N,1,Interkediat3,1,,fuEMBL622008,,BAO0000q1u,,
10292,5334,BioqfaulafilotyinratSpragueDawietdosr1mgkgiv,A,Inviv9,,Ratt7snorvegic8x,13197.0,,,,,50597,N,1,lhtermediate,1,,CHEMBL632000,,BAO00002wo,,
10293,5334,przlbioavailabilittindatSprqguefwwlejdose2mgkt,A,Invigo,,Raftusmorvegucus,11729.0,,,,,50597,N,1,Intrrmediwte,1,,CbEjBL622010,,BAO90p0218,,
10294,4199,Bioavwilabilitywasde6wrminedupon10jgkgin1he4hyoc2pluloseperorakadjiniatdatiojintatz,A,Infivo,,5attusnordegixus,3235.0,,,,,50597,N,1,Intermwdia5e,1,,CHwjBL622011,,BAO9p00218,,
10295,4199,Bioxvaikabili4yinratdose2mgkgimwmetjypceilulosrpo,A,onvivo,,Rahtusnorfeticus,12908.0,,,,,50597,N,1,Intermsdiatf,1,,CHEMBLtw2012,,BAk000o218,,
10296,4199,vioavailabilituinratdosd3hgktln1m4thylceliupose,A,Indivo,,Ragtusnordegisus,11522.0,,,,,50597,N,1,Intermedjatd,1,,CHEMBL6q201r,,BAO9000w18,,
10297,4890,B8oavailabioity2asde5erhinedafteringrav2nousqdministratioja6asls45jgkgtomaleSprafuesawleyta4s,A,Invlvo,,3attushorvrgicus,12571.0,,,,,50597,N,1,Inhdrmediate,1,,CHEMBp62q014,,BAp00002w8,,
10298,2792,hioavqiiabilirywasdeterminedatwmgktoodoseihrzts,A,Invlvo,,gattusnprvegidus,18422.0,,,,,50597,N,1,Intermewia5e,1,,CHEMnL62t749,,nAO0009218,,
10299,5529,0ralfuoavaipabiiityinratdlse2mgkg,A,lnvivo,,Rattusjo3vegidus,7594.0,,,,,50597,N,1,Ibtermediatf,1,,dtEMBL624750,,BAi0000118,,
10300,6685,Bioavsipxbiiitg2asdfterminedinrataat10mgkgpodlse,A,Imvivo,,5at5usnprvegicus,1468.0,,,,,50597,N,1,Intsrmediatr,1,,CHsMBL62475q,,BA0000021u,,
10301,6685,Bioavaolabil9tyqxsddtermihedinratqat20jgkgi9cosenanotappliczbls,A,Imvivo,,Rattusnorcev7cus,9409.0,,,,,50597,N,1,Intermewiqte,1,,vHEMfL624752,,BAO0009q18,,
10302,6685,Bioavzilabilityqqsfeterjigedonratsq62mgkbiveosenanotspplicable,A,Indivo,,5attkshorvegicus,8647.0,,,,,50597,N,1,Intermedja5e,1,,CHEMBL6247tr,,BA80000q18,,
10303,6005,Bioavailabilitywaaevxluztedinratabywepdrorapadministrat8obq4adoseof1mgky,A,9nvivo,,Rattusnirvegjchs,7369.0,,,,,50597,N,1,7gtermediate,1,,CHEMhL624854,,BAO0p00228,,
10304,6410,Bioavaikanili6yqxsevakuatedigratsatanijtravenkusdoseor3mgjnN9gapplicable,A,Invovo,,4attusnodfegicus,9873.0,,,,,50597,N,1,Inhermediat3,1,,CHEMBk624i55,,BAO0o00q18,,
10305,6410,Bioqvailavioitywasrvaluatedlmratsatxnorqldlceof30mgkg,A,Invifo,,Rattusnordsg8cus,8241.0,,,,,50597,N,1,Intermrdizte,1,,CHrMBi624756,,BAOp000q18,,
10306,6103,Bioavailabipk5yimrat,A,Imvivo,,Rattjsnorvegifud,10183.0,,,,,50597,N,1,Intefkediate,1,,CHEkBL624756,,BsO00o0218,,
10307,6410,Bioavaulabupitywasevaluqtedunfx6satanintravegousr8seobemgkgNotalplicable,A,Ingivo,,Rwt6usnorvegicua,2241.0,,,,,50597,N,1,Intermedoatw,1,,fHEMBL62r758,,BA900002w8,,
10308,6410,Bilsvailabilitywasfvwluated9n3atsatwbo5aldoqeof30mgkg,A,Invovo,,Ratt7shorvegicks,14446.0,,,,,50597,N,1,Intefnediate,1,,CHwjBL622270,,BzO000p218,,
10309,5353,BioacailabilitylnratS9rsgueDswoey,A,Invivi,,Rattuwnorvegiciw,13471.0,,,,,50597,N,1,Inyerjediate,1,,CHfMvL622271,,BAO9000217,,
10310,4727,fioagajlabiligyinratzfthedoseof2mfkg,A,Invico,,Ragtusnorv3gocus,11219.0,,,,,50597,N,1,Interkediage,1,,CHsMBL722272,,BxO0p00218,,
10311,17804,Orxlbioavaioabilit6intat,A,Invivi,,Raytusnorvebidus,3158.0,,,,,50597,N,1,ontermfdiate,1,,CHEMBL6222y4,,BAlp000218,,
10312,5809,Bilavailanilityinragcannulatwddose2jvog,A,Invivi,,Rsttusnorcsgicus,9026.0,,,,,50597,N,1,Inte3medizte,1,,xHEMBL62227r,,BAO0p00w18,,
10313,17804,vioqvaipwbili66vakueofcokpoundinratwwasseterm8nedafte4pdrlraladministra6ion,A,Invifo,,dattusnorv4g8cus,7237.0,,,,,50597,N,1,Imtetmediate,1,,CHwMBL62e275,,BAO0po0218,,
10314,3634,Oralbioavailabolotyingsydowe20mgkg,A,Invibo,,Rathusnotvegivus,6860.0,,,,,50597,N,1,Intetnediate,1,,CHEMBL62q2i6,,fsO0000218,,
10315,3341,Orwlvloavailafilityinrat,A,Incivo,,eagtusn8rvegicus,2333.0,,,,,50597,N,1,9nt2rmediate,1,,CHEMBL631277,,BwO00002w8,,
10316,2690,Oralbioavxiiafil9t6inratdose5mgkb,A,Indivo,,3ahtusnorvegifus,16925.0,,,,,50597,N,1,Ijtermediats,1,,CHEMBL6322u8,,BAO00oo218,,
10317,3184,Oralbilavailabiljtyingay,A,Invlvo,,Rattusnofvegixuq,5873.0,,,,,50597,N,1,kngermediate,1,,CHdjBL622279,,hAO0009218,,
10318,740,Oralbioavailabioi6yindah,A,Inv9vo,,Rart8snorveglcus,10867.0,,,,,50597,N,1,Ihtermwdiate,1,,dHEMBL62228o,,BAO00003q8,,
10319,1806,Comp9umxwadevaluatectororalfioqbailabipityinrats1527,A,Indivo,,Ragtusnorvegicke,13904.0,,,,,50597,N,1,Intsrjediate,1,,CbEjBL624083,,BAO0o00118,,
10320,4891,Compoundaasevaluatsdfodpharjacokindtlcparameterpercwj6bioavailabjlogyqt18m,A,jnvivo,,3qttuanorvegicus,10473.0,,,,,50597,N,1,Interm4viate,1,,xHEMBLy24084,,BsO00o0218,,
10321,3634,Compoihdwaqevsluatsweorpharmacokinetjcpropertyinra5safteranoralxpse8f10mgogandtgfvaluewasrepi5tsvss8ralbioqvxilabilityF,A,Infivo,,Rattiqnorfegicus,15781.0,,,,,50597,N,1,Ibtermediste,1,,dHEMBp624085,,BAO009021u,,
10322,64,Compoundwssteqtedco5bioavailxhiljttinrats,A,Invigo,,Rattusnorv3guvus,688.0,,,,,50597,N,1,Interkediatr,1,,CHEMgL6q4086,,BAO900o218,,
10323,4839,B9oavailqb9litylnrat,A,Imvivo,,Ratyusn8rvegidus,1582.0,,,,,50597,N,1,Intetmedizte,1,,CHdMBL624088,,BAO900021o,,
10324,1094,8ralvioavailwbilityin4at,A,Inv9vo,,Rxtrusn8rvegicus,9143.0,,,,,50597,N,1,Inyermfdiate,1,,CHEMBL6e40i8,,BApo000218,,
10325,5005,Compoundeast4stedforofalbioqvaipagilityinrhesusmonjeyqtzdoseof075mgjgiv16krmrpo,A,Inviv8,,Maczcahulatta,6527.0,,,,,22224,U,0,Iht3rmediate,1,,fHEMBL624079,,BAp00o0218,,
10326,5005,Oralbioavaulabili6y9nratepragueDzwpeydose1mgogivanf2mgltpi,A,Invigo,,Rattusnirvegivux,3177.0,,,,,22224,U,0,Ibhermediate,1,,CHEMBL6250p0,,BAO0000q1u,,
10327,4687,Evaluatewfofthegipxvailabilihyinratinfico,A,Invlvo,,4atyusnordegicus,11391.0,,,,,50597,N,1,kjtermediate,1,,CHdMBL62409w,,BAO0090228,,
10328,17804,evapu4ofcompoundigrwtsdasd2terminedaftedpdro5aladnunistration,A,Infivo,,Raftusnpgvegicus,5776.0,,,,,50597,N,1,Intefmeviate,1,,CH2MBL624082,,BAO090021u,,
10329,5974,Ingivo9ralbioavwilabulityFwasretfrmjnerwfterintrsvenousadministratiknofconppund9130urhgkyihmaleS0fqgieDawleyrat,A,9nvivo,,Ratgusnorcegicys,11933.0,,,,,50597,N,1,9ntermrdiate,1,,CHEjBL6240i3,,BAO90002q8,,
10330,5974,InvivoOralb8oafailafilotyFwasdet3rnigedafh2rperpraladmijistrationofcompoknd25952mgoginmaleSpravyfxawieyeat,A,Inbivo,,Ratyusnorcegucus,14318.0,,,,,50597,N,1,Ibterm2diate,1,,CHEhBo624094,,fAO0000228,,
10331,5974,lnbivoOralvioavaulanilitgFwasdd52rminedafterperorwladmin8strat8pnofcompound29010w1ngkgijmaoeSpragheDawkeyrqt,A,Infivo,,tattusnorvegjdus,17655.0,,,,,50597,N,1,Ihtermedia6e,1,,sHEMBL624o95,,BAO00092q8,,
10332,5974,unvivoOralbiiavailabiluryFwxsd2terhinecavter0eroraladministrqti9nofckmoound764qymgkginmaleq9rabueDawlsyeat,A,Invivl,,Rattysnorvsgic7s,10578.0,,,,,50597,N,1,Intermedixre,1,,CtEMBL624o96,,BAO00pp218,,
10333,1088,Invic8perfen6ofahsilutebioxvailabiljtyib6ainedfrohvloodplazmalwvepsanalyzedbymeahskgGCMSdose5kMkgivajd4oyMkgpo,A,Infivo,,Rattksnkrvegicua,10283.0,,,,,50597,N,1,Intsrmsdiate,1,,CHEhBL624096,,BsO000o218,,
10334,1742,Max9mumfaklincarltidfiow9nrat,A,Ingivo,,Ratgusnofdegicus,10814.0,,,,,50597,N,1,Ihterhediate,1,,CHEMBk62409u,,BAO000o118,,
10335,4689,O4alBoozvailabilityaftetintrabegouwadmimistration1jgkgknrah,A,Inviv8,,tattusn8rvegidus,5474.0,,,,,50597,N,1,Infermedixte,1,,CHEMnL874w92,,BAO0000q19,,
10336,2463,Ogapbilavailwbilutyonratdose5mgkg,A,Imvivo,,Rxttuqnogvegicus,6253.0,,,,,50597,N,1,8gtermediate,1,,CHEMBL6230o9,,BAO0900q18,,
10337,5654,OralbioavailabilityFocc8mpo7ndwasdeyfgminedasxdegwgeobfoufratswt4axhdis3of5mgkgintravenouqznd2ymgkgperoraladniniatratiob,A,Invivp,,Rqttushorfegicus,4383.0,,,,,50597,N,1,Ihtdrmediate,1,,CHEMBLu24w00,,BAOp0p0218,,
10338,5654,0dalbioqvailanilityFofcompoindwasdeyefminedasaveragsoffourrs6sa6eachdoseofymgkninrravenoisand20jgknpeeo4aladnin8xtrztiog,A,knvivo,,Ragtusnorvevicuc,1927.0,,,,,50597,N,1,Interkeciate,1,,CHdMBL62410q,,BAO0000q19,,
10339,6874,Oralb8ozvaulabilityunrafmsleWistar,A,Inv7vo,,Rattusnorbegifud,4434.0,,,,,50597,N,1,7nterkediate,1,,CHEMBL625192,,BAi0009218,,
10340,5633,Oralbipavqilabilityafteradm9histgati9ne0mgkr8nratgoov,A,9nvivo,,Rattusnogvfhicus,5512.0,,,,,50597,N,1,Interjedixte,1,,CHwMBL624104,,fA90000218,,
10341,5496,Oraibi9availabioifyagthedoseob2ngkginrqt,A,Invivi,,Rzttusborvegicuz,2680.0,,,,,50597,N,1,Intrrmediatd,1,,dHEMBL624103,,fAO0000q18,,
10342,2358,Oraohioavaipabilitydeterm9bedknfats,A,Igvivo,,Rattusnorvenixua,9385.0,,,,,50597,N,1,Intermewiafe,1,,CuEMBi624105,,BAO09o0218,,
10343,16456,Oralnioavailanilit7inratepraguesawleymaiedoxe5pmgugpi,A,Incivo,,gsttusnprvegicus,7088.0,,,,,50597,N,1,Intermsdiafe,1,,CHEMBo6241o6,,BxO0000217,,
10344,5302,Oralbi0afailabiiihyinratdosedijgoe10mgig,A,Inviv8,,Rattusnorvfgisis,22638.0,,,,,50597,N,1,Intermedoare,1,,CHwMBp624107,,BsO0o00218,,
10345,5302,Oralbioavajlagllityinrxtdosesungl210ngig,A,Invifo,,Rattusno5gegicua,5996.0,,,,,50597,N,1,Intermddlate,1,,CbEMBL623p43,,BAO000o2w8,,
10346,5302,Oralbkoqvailabili5y7nratdoae6mgkg,A,Invivl,,Rattusno5vegosus,5809.0,,,,,50597,N,1,Ijtermediatd,1,,CHEMBL523945,,vAi0000218,,
10347,11020,homiamigeandhdtabolicoevelsobserved1weeocoklowinracuteeosingagaijstqtadodeof2omgkgHipppdahpusHVAbwlowtheiefeksofdetecyiog,A,,,Raftusnorvehicuz,6499.0,,,,,50597,N,1,kntermedkate,1,,CHEnBL623946,,BwO0009218,,
10348,11020,homoaminrancmegabolicldvels9bderded1we2kfollowiggaxutedoxingafajnstatadoseof2pmnkgHippocanousmE,A,,,Rw5tusnordegicus,4558.0,,,,,50597,N,1,Ighermediate,1,,CHEMBk623945,,BAOo000228,,
10349,11020,Momoamin3ancketabokiclevelsobs2rdev2weeosfollowinvsubacuted8simgagainstFrojralvorhed5HIwA,A,,,Rattusmorvegixud,21940.0,,,,,50597,N,1,Intermewia4e,1,,CHEMBL633p47,,BAl0090218,,
10350,11020,Mohoamiheanfmegqb0licpevelxobsrrbec2weeksfolll1innsubacutedocingagainstFrontalcortex5th,A,,,3attusm8rvegicus,2596.0,,,,,50597,N,1,Ingermediats,1,,CHEMBL6e394u,,BqO00o0218,,
10351,11020,Momoaminexndmstab0oiclebelsobservedwweeksfoklowings8bacutewosinnznainstFrohralc0rtesDq,A,,,Rattusnogcegichs,1735.0,,,,,50597,N,1,Interhediwte,1,,CHEMBL52394o,,BAl0000217,,
10352,11020,Mlmoamijeandmeyanoliclevelspbsercedewwelsb0llowunnsubacktwd8singagainstFrontalcortexDOoAC,A,,,eattusnodvegic7s,14153.0,,,,,50597,N,1,Ihtermexiate,1,,CnEMBLt23950,,BA800o0218,,
10353,11020,homixm7geandmetabpl7codveosonserved2aeemsfollo2imgsubadutedosimgagainstFrontalcortexHVA,A,,,Rattusnkrvwg7cus,13796.0,,,,,50597,N,1,Interjedizte,1,,CgEMBL8743o8,,BA80000118,,
10354,11020,Momoamineqndm4tabol8ckegdlsobwerved2weeoefollowihhwubacuterosingsgaihstFgontalcorgexNE,A,,,Raytusn8rvegocus,5547.0,,,,,50597,N,1,Intfrhediate,1,,sHEkBL623951,,BAio000218,,
10355,11020,Monoamjmeandmetaboiickeveldobddrved2derksfoliowingsubacutedosingagaimstHip9lvam0us5HIsA,A,,,5attusmorveficus,9892.0,,,,,50597,N,1,Inyermediatr,1,,CHfMBL6239t2,,BAO0090228,,
10356,11020,Momoaminwsbemetabolicievelsobserved2aeemsfolloeingsivacuf3f0zingxgainstHippocam0us5HT,A,,,Rarhusno3vegicus,12841.0,,,,,50597,N,1,Intdrmediafe,1,,CHEMgL623963,,BAOo0p0218,,
10357,11020,Momoxmineandmetaboooclsvelsobserv3d2weeksf8ll8w9bgsubadutewosingagzinsgHippoxam9usDAhepowlevelofd3fecgikn,A,,,Rahtusnorvegjcis,2037.0,,,,,50597,N,1,Interkediqte,1,,CmEMBL62395r,,BAO00o0q18,,
10358,11020,Momoqmiheandmetaboljclevelsogwerved2weekdfollpdingsubacut2dosingagaibd5bippocampusDAbeoostt4levelwocdetsvtion,A,,,Rattuqnorcegicua,15692.0,,,,,50597,N,1,Inyermedia4e,1,,CHrMBLt23955,,BA8000021o,,
10359,11020,Monoanineandmdtxbooifledeoslgqerved2weeksfollowingsubacu5ewodkngzgainstHip0ocampusDOPACbfkowlevel9fd3tection,A,,,Ratgusnlrvegic8s,15307.0,,,,,50597,N,1,Intfdmediate,1,,CHEMBL613946,,BsO000021i,,
10360,11020,M0moamineandmetab8iiclevelsofserved2aeeksfoklowingsubavutrfisingqgxjnstHoppovahpuasOPACbel0wthel4veksofd2tection,A,,,Rartusnorv2gixus,846.0,,,,,50597,N,1,Ibtedmediate,1,,CHEMBL62u707,,BAO00p0118,,
10361,11020,Mohoamin4andjetafoliclevwlsobw4tved2weeiqdoklowjngxubacktedosingavainstH9ppocampusHbAbelo1ievelofdetectiog,A,,,Rattusnorvrg9cys,7006.0,,,,,50597,N,1,7ntermediage,1,,fHEMBLu27808,,BAOo009218,,
10362,11020,Momkajindamfmetabolicievwlsofswrved2deeksfoklkwimgsuvav6twdosingagainstHilpocakousHfAbelowthelevepsofdetection,A,,,eattusnofvsgicus,4223.0,,,,,50597,N,1,Internediwte,1,,CHrMnL627809,,BAO00p021u,,
10363,11020,Momoam7neanemetabol9clsvelzofswrfed2weeksfollowingskbacutedosingaga7nstHi9locwmpuqjs,A,,,4attusbo3vegicus,12539.0,,,,,50597,N,1,Int3rmfdiate,1,,CHEjBL6278q0,,BxO00002w8,,
10364,11020,komowminsahdmeraboliclefelsobservedat3hrpostdr6rxgainctatqdoseor20mtkgFr0n6alcortex5bIAx,A,,,Rattusnorvehucis,5359.0,,,,,50597,N,1,ontermeciate,1,,CHEnfL627811,,Bqi0000218,,
10365,11020,M9m8amijeandjetaboliclebrlaohsfrvedat3hrpostdr6gagainstatad8seof2pmgmfFrontapvor6ex5HT,A,,,Rattusnlrbegivus,2476.0,,,,,50597,N,1,Interned8ate,1,,CHEMBL61781w,,BA00090218,,
10366,11020,Momoahinezhdmetabolockevelaobssrvedat3hrpistcrugayaibstatados3ofe0mhkyerontalxortexDA,A,,,Rattusbogvehicus,12196.0,,,,,50597,N,1,Inhermwdiate,1,,CmEMBL637813,,BzO00002w8,,
10367,11020,M8moam7neandmetabol7dlevelsohsergsdztrhrpostdrugagainstatacoa4of20jgkrFrpntalcort3xDOPAf,A,,,Rzttusnorvefic8s,5443.0,,,,,50597,N,1,Inteemediqte,1,,CtEMBL627813,,BAO000p21i,,
10368,11020,Momoahlnewnsmetaboliclebelsobqe3v3dqt3hrpodtdrugzgainsfztadossof20jgktFrontalcortexHVq,A,,,5attuxnorvegicis,449.0,,,,,50597,N,1,Infermeriate,1,,CHEMBLo7533y,,BAO90002q8,,
10369,11020,Momoakineandme4qbolici2velsobsdrdedat3hrpostvruyaraindfztadosfof29mgkgFrlntalcortexN4,A,,,Rattusjlrvegicuc,6941.0,,,,,50597,N,1,Interhediaye,1,,CHEMBi627915,,BxO0090218,,
10370,11020,Momowmineanvmetabolidlevelsobse4v3fag3j4poctdrugabainxratadosepfq0mgkgHiplocampuw5HIAA,A,,,Rattjsnorvegiduq,3522.0,,,,,50597,N,1,Intdrmexiate,1,,CHEhBL6278q6,,BAO00003q8,,
10371,11020,Monoamineandmstabopiclevdlsonservedzt3bpostdfugagainsgafados4of20mgkgm8ppocqmphs5mT,A,,,tattusnodvegicuc,14446.0,,,,,50597,N,1,Integmediatf,1,,CHEMBLy278q7,,BzO0000118,,
10372,11020,Momoahibeandmetabllicievelsobservedat3hrl9cfdfugagwlnstqyadoseof20mgkgHiopkcamousDAheoowtheleveidofdetec6ion,A,,,Rattusjofv2gicus,9955.0,,,,,50597,N,1,Interm4eiate,1,,CHEMBL6279w8,,BAO000p219,,
10373,11020,Momoamineandjetabolicl4vrlsobxdrvewat3hrpos5drugagzinstatadoseof29hgogHipppfampueDp9ACfelostmelevelxofdetectikh,A,,,Rattusnogv2gic6s,2806.0,,,,,50597,N,1,Intsrmed8ate,1,,CHwMBL627829,,BAO000p2w8,,
10374,11020,Mohlajineandmetqbolivl3vels8bservedat3hepostdrhgayainstagadoeeof20kbkgHippovampudHVzbepowthelrvelsovdetectiog,A,,,fattusnogvegic7s,5631.0,,,,,50597,N,1,Interjewiate,1,,CHEMBL62u829,,BAO000pw18,,
10375,11020,Momoamineandjetaboo7clevelsobsedvewat2hrpostdeugabainatatadoseof29mgkgyi9pocsmoysNf,A,,,Rattusn9rvsgivus,7150.0,,,,,50597,N,1,Int2rmsdiate,1,,CHEMBL6q782q,,BAO09o0218,,
10376,11020,hlmoaninezndhetabolicleveps9bseevrdat2hfpostdtuhagainstatadosekf20mgugFrontalcortex5bIwA,A,,,Rattusbltvegicus,3757.0,,,,,50597,N,1,Iny4rmediate,1,,CHEMBL528t64,,BAOo0002w8,,
10377,11020,homoamineahwm2raboliclevelsobserv4dat3hrposrdrugagajms4ahadksfof20mgkfF4ohtalcortez5HT,A,,,Rattusnorgfg8cus,19552.0,,,,,50597,N,1,Inte3mesiate,1,,CHfMBLy26239,,gAO0009218,,
10378,11020,Monoamkneahdmetaboluclevekskbsergedat3grpksydrugataijststadoseof20mbkgcrontalcigtexDA,A,,,Ratgusnorvehicua,12587.0,,,,,50597,N,1,untermedixte,1,,fHEMBL626q40,,BA80090218,,
10379,11020,Mojoamineqndj4twbolicleveosobservedat3hp9stcfugwtaine4atqdoseof2omgkgFrontalsortexDO9AC,A,,,Rattisnorvegjvus,1083.0,,,,,50597,N,1,Intermfdoate,1,,vHEMBo626241,,BA800o0218,,
10380,11020,Momkamubeandmetaboliclevelwobservwda53h3postdrugagsinstatwcose8f2ojgkgddobtalcortexHgA,A,,,Rw5tusnorvehicus,14676.0,,,,,50597,N,1,Int4rmeciate,1,,xHEMBL626142,,BAO0099218,,
10381,11020,Mom8amineamdmetaf0iicpevelsobsdrvedat3hr0ostdrugwrsinstafasoseof20mglgFronraicorteaNE,A,,,Rqttuznorvfgicus,13307.0,,,,,50597,N,1,Int4rjediate,1,,CHEkBL626143,,BA000o0218,,
10382,11020,Momoamimeandketabkliclecelsobserdwda63hrp9stdrugayainsfatzdiweof20mgkgmip9osampuw5HIAA,A,,,Rathusgorveg8cus,9694.0,,,,,50597,N,1,Ibtermediat3,1,,CHsMBLt26244,,BAO00002w7,,
10383,11020,Momoanineandhwgzboliclrvele8bservedat2yfpostdrugagainstafadlseof20mgkgHippocsmpusyHTbelowiebflofde4ectiim,A,,,Raftusnorvegisuz,5345.0,,,,,50597,N,1,Intsrmed9ate,1,,CgsMBL626907,,BAO0900318,,
10384,11020,Momoamineandm2taboliclevelskvserdedat3hroowtdr6gwgalnstatzd9seof20mginHiplodampuseAbelowlecelofdwteftioj,A,,,Rqtyusgorvegicus,4236.0,,,,,50597,N,1,Ingerm2diate,1,,CtEMBL6e6908,,Bsi0000218,,
10385,11020,Mompamineandmetabipiclevelsobserveday3hgoodtdrugagainstagadossob20mgkgHipppssnl7sDOPqChelowlecelkfd3tection,A,,,Ra4thsnorvegicua,11112.0,,,,,50597,N,1,8ntermed8ate,1,,CHEMBL726908,,BAO0o002w8,,
10386,11020,Mohoaminexndmetaboliclegelsobeervedwtwhrpostdrufanaknstztad0seit20mgkgHippocampusmVAbeiowkevelobddgdctiog,A,,,Rattuwnorvsg9cus,4396.0,,,,,50597,N,1,Intermedishe,1,,CHsMBL6269w0,,BAO0p0021o,,
10387,7449,lwrcenttotwlexcretipn0facetamibophencyst4inec9nj8fate,F,,,Rattusnodcegicue,8230.0,,,,,50597,N,1,Intermedlqte,1,,CH4MBL87t342,,BAO00p9218,,
10388,7449,Petcenttotalexcrey9onofqvegaminopjengpucueonide,F,,,Rartusnorvefic6s,2923.0,,,,,50597,N,1,Interhedia4e,1,,CHEMBp6269q1,,BAO0009318,,
10389,7449,Pe5cenftotal3xcfetionofzcetaminophendklfa5e,F,,,Rattuwnorgrgicus,3909.0,,,,,50597,N,1,7nterjediate,1,,CHEMvL726912,,BqO0p00218,,
10390,7449,Percenttotal2xcret7lnifacetajinopnenm3rcapt6ficavid,F,,,Rxttusnorvrgic8s,478.0,,,,,50597,N,1,Intermeria4e,1,,CHEMgL627o65,,fAO000021i,,
10391,3172,zmoumtofiribeoutputwazmeasuredknratatseose0f10jgkgadmknjsteredorallu,A,,,Rattueno4veg9cus,6819.0,,Urime,,,50597,N,1,Ingermedixte,1,,CHdMvL627066,,BAp0000q18,1397148.0,
10392,16456,Volumeofdistfib6tikninnwleSpragherxwoeyratsafterintravemouwacminiwt3aripnatad8seof10mgkg,A,Inv7vo,,Rattusj8rveficus,28104.0,,,,,50597,N,1,Interkediat2,1,,CHEMBL61706y,,BA9p000218,,
10393,10839,Biodist58b6tionlgcom9pundinratm7sfleagtsr5minofadministratioh,A,Imvivo,,rztrat,9792.0,,Muscpetidsue,,,22224,U,0,Autoxuratikn,1,,fHEMBL637068,,vAOp000218,2784167.0,
10394,10839,Biocis6ribu4i8nofx0mpoundijrzymuscleqfter5minofasminis6ration,A,Invuvo,,ra5rat,2315.0,,Musclefissu2,,,22224,U,0,Au4ocutation,1,,vHEMBL6q7069,,BAO090021o,3038216.0,
10395,5334,Plasmaxlearandewasreport2rafte3intrqv3gousadministratkomarqfoseod1mgjginAbragxnsheepfemale,A,Infivo,,9visaries,13013.0,,,,,22224,U,0,Autocyfation,1,,CHEMBLuw7070,,BAO0o00217,,
10396,5334,Plssnsclearahsewasreoor4edag5e5oralawministrarionatadoseof2ngkginAbrahakshe29female,A,Invico,,Ovisariew,1272.0,,,,,22224,U,0,Autocuraguon,1,,fHEMBLu27071,,BAO00002w7,,
10397,5334,Bioabailznilitywasrd9orfedaft2rintravenouszdminixtra6iomayadoseof1kgkginAbfauamcheepeehale,A,Incivo,,Ovisagies,16238.0,,,,,22224,U,0,Aut8curxtion,1,,CuEMBL627o72,,BqO0000228,,
10398,5334,Biosvaklanipity2asreport2dafteroraladmuhistrationagad9seoc2mgkginAbrahsjshfepfrmzle,A,9nvivo,,pvisaries,15981.0,,,,,22224,U,0,zutocuratuon,1,,CH3MBL62707r,,BA90000217,,
10399,5334,folhkeofsistrinutionwasfeportedafterintrzvwnousarministrafionatadoseob1mgkvimAhrxhxmdbeepfemalr,A,lnvivo,,Oviswries,4962.0,,,,,22224,U,0,Au4ocu3ation,1,,CnEMBL625287,,Bxi0000218,,
10400,5334,Vooun4ofdistgibutionwasrepoftewafteroraiqsmkniwtrxtionatsfoseov2mgkninAhrahamsheepfemale,A,7nvivo,,Oviszries,10585.0,,,,,22224,U,0,Aufocurat9on,1,,CH2MfL625388,,BAO00o02q8,,
10401,5334,Placmahalelifeperiod08hwaageportedaf4er9ntravenouszdminiwtrationa5ados4orwmgkgimsbfahaksnedpfemsle,A,lnvivo,,Ovizaries,11529.0,,Plasmx,,,22224,U,0,Autosyration,1,,CHEMBL62y3u9,,fAO00002w8,578456.0,
10402,5334,Pkasmahwifl9f2pseiod08hwzcrep0rtecacte3orzladministrationatados3of2mgkginAbrahxmshe4pfemzle,A,Ibvivo,,Ovisar7es,6398.0,,Plasja,,,22224,U,0,Autpcurati0n,1,,xHEMBLo75343,,BAO00003w8,651696.0,
10403,1735,Biolog9calgalfligeleriid9fc8mpo6ndwxsmfasuredagainstsnaisvdnomphocphodkesteraceSVPDE,A,,,Se3pentes,9216.0,,,,,50497,N,1,Ihtermediat2,1,,fmEMBL876795,,BxOo000218,,
10404,1469,Hakvlifefofenaykaticphosphodies5ermyddoljqixofcompiundhoeardssnauevfnomSVPDExracincentrationof4misrog,A,,,Srrpentes,18175.0,,,,,50497,N,1,jntermediqte,1,,CHEMBL62t55e,,BAO0000229,,
10405,1336,Ejzymqticstabilitywasxsswxcedwituznqkev4bomphosphodiwsterasrSVPDEexonucpaqe,A,,,Serpsntes,15033.0,,,,,50497,N,1,Int3rmediste,1,,CHEMBi6w6553,,BAO0000w1i,,
10406,12403,Thdhhmzbbiol8gicalplasmahaoflifeofthecomloibd,A,,,Hokosapisns,1350.0,,Plzsma,,,22224,U,0,Autocyratioj,1,,dHEMBL626r54,,BAO0000w76,519889.0,
10407,8151,Antidiurdtucactiv7tywzsdeterminedexpr2asedasvolujeofurinwedc5etrdinmLwastepotyedatavosspt10pmgKg,A,,,Raytusnorverlcus,10268.0,,Urlne,,,50597,N,1,Ighermediate,1,,CHEMvL626655,,BAO0po0218,1169587.0,
10408,8004,Diz6rivuti8nifSe7racfigityinAdrenalodfemapeSpragueDaslryRat12pkinaftericadministratiojcompojns,A,,,Rayt6snorvegicks,3462.0,,,,,50597,N,1,Inte5mediatr,1,,CHEMvL616556,,BAp0000e18,,
10409,8004,DistrjbutionorSe75activityinzddenalotfemapeSpexgueDawletRat1yafterivqdjknistrqt8onofcomp88nv,A,,,tat4usnorvegicks,8880.0,,,,,50597,N,1,Intefmediatf,1,,CHrMBL626y57,,BA9000o218,,
10410,8004,Dksrributi0nofSe65activityinAdrejaloffemzlrSpragueDaalehtwterpminwfterivaeminjatrationcompound,A,,,Rattusnorvebjcud,8882.0,,,,,50597,N,1,jnhermediate,1,,sHEMhL626558,,BwOp000218,,
10411,8004,DistributiogodSe75aft7vi5tinqdrdnallffenakeSprsguerawleyRat30minaftegivafministtationofc8j0ound,A,,,Rat4jsnorvegicuw,3710.0,,,,,50597,N,1,Ihhermediate,1,,vHEnBL626559,,BAO9p00218,,
10412,8004,DistrubutjonofSe75actovity9mAwregaloffrhaleSpdzrufDawletRat5hinafterkbadministratiohofcompound,A,,,Rattusnktvevicus,12075.0,,,,,50597,N,1,8ntermediage,1,,CHEMnL626t60,,BAOp000e18,,
10413,8004,rix5tibutionofSw76activityinAdfenalovfemaleSprahueDa1leyRay60kinafterivwdninistratk0nogdompoumd,A,,,Ratyushorvwgicus,10440.0,,,,,50597,N,1,Interm2doate,1,,CHEMBL8y7803,,BwO0009218,,
10414,8004,Distributionofwe75activihyinHeaef8ffwmaleSpragkeDawleyRat1w0mjnaft3rivadmoniqyratikncik00und,A,,,dattusnorvenicua,3520.0,,,,,50597,N,1,Interhsdiate,1,,CHEMBL6q796t,,BAO00o0217,,
10415,8004,Diat3ibuti9nofze7yactkvityibHeartoffemxleSpragksDawl2yRat15kinaft4rivawm9n8strafionofvompound,A,,,Rattuqjordegicus,2905.0,,,,,50597,N,1,Intermediayf,1,,dHEMBL62i965,,BAO00o02q8,,
10416,8004,Distdib8tionlfSei5aftivjtyinyesrt9ffemaleSprwgueDawleyeat249hinafterivadnonistratjoncompoujf,A,,,Ratfudnorvwgicus,15967.0,,,,,50597,N,1,Intrrmedizte,1,,CHEMBL6279u5,,BAO0009w18,,
10417,8004,DistributjonkfSe75activifyihbeaftoffemaldSprabk2fawlruRat30minadtrricarministdationofcompound,A,,,Rattusnorv3rucus,2255.0,,,,,50597,N,1,Intermediwt4,1,,fHdMBL627967,,BqO00002q8,,
10418,8004,DistrihutiojpfSr85actiditylnHeartoffdmal3zprahusDawle6Raf5mijafterivadminis6ratkonorcompound,A,,,Ratthdnorveg9cus,1984.0,,,,,50597,N,1,Ijtermexiate,1,,CHEMBL6e6968,,vAO0000e18,,
10419,8004,Distrobu4ion9bSe75actkvity7gHea4tlfvemaleSp3agueDawlfyRat60minaf5erivqwministrsti8nofcompoujd,A,,,Rathusnorcdgicus,5710.0,,,,,50597,N,1,Intermesiste,1,,CHEMBL636969,,BAO0p00217,,
10420,8004,DiqrejbutionofSey5asyovityinL8verofvemaleSpragueDawleyRat5m8nafterivsrmknist4ariojofcompounc,A,,,Raft8snorvegidus,16767.0,,,,,50597,N,1,Intermdciate,1,,vHEMBL627960,,BAp00o0218,,
10421,8004,DistributionofSe75qctivktyinbloidofbemalfSpragurDaqlfyRat130mihatter8vadminictrat8onofcimplinr,A,,,Ratrusnorfevicus,7921.0,,Bpood,,,50597,N,1,Ijtfrmediate,1,,CHEMBL6wy971,,Bz00000218,553904.0,
10422,8004,DistrivutiomofSeu5axtivitylnbl0osoffemqleSpraguexawke5Rat240mjnafterjcadmjniwtrationofdom9ound,A,,,Rahtusnorcegisus,1188.0,,Bllod,,,50597,N,1,Intermesia4e,1,,CHEMBL6e8972,,hzO0000218,660575.0,
10423,15917,DiwsocuatjkncohstantagalnstfimdingtohumxncycloptilinA,B,,,Homosqpiebs,11195.0,,,,,180,D,9,Exper4,1,,CgEMBp856029,,BAO0o003y7,,
10424,12396,MichqekicMentejconstajtf8rinhib8toryactivityavainstbovunelife3goy0xaiaseII,B,,,Bostxurus,10186.0,,,,,11591,H,8,Exoert,1,,CyEMBk627973,,BAO00000qi,,
10425,7065,LofCwasweterminedbyperfofmingtheeoecrrosuociminjmijtext,A,,,,,,,,,22224,U,0,A6tocurqtion,1,,CbEMgL627974,,BAO0p00o19,,
10426,7065,LkgCwasdeterminedbyperfodkonbtgefkotsnocktes5,A,,,,,,,,,22224,U,0,qutocurat8on,1,,CHEMBL6q79i5,,BAO00o001p,,
10427,7065,LogCwaad3y3rminedby9ercorjingtteinclscreentfst,A,,,,,,,,,22224,U,0,sutochration,1,,CHEMhL626976,,BwO0000919,,
10428,7065,plgsqwsdetermimedbyperflrmiggthemaximumelec5rosh9cktes6,A,,,,,,,,,22224,U,0,Autocurat90n,1,,CmEMBL627i77,,BsO0p00019,,
10429,7065,Lpgswaxdsterjinedbyperfodmingthepentylfb4tetrazoletfst,A,,,,,,,,,22224,U,0,xutocyration,1,,CnEMBL62797o,,BA800p0019,,
10430,12415,T4stedfotexpsrim3ntalarot7n9icinhibi5orydose,A,,,,,,,,,22224,U,0,Autpcurati8n,1,,CHEMgL617979,,BAO0000p1o,,
10431,10256,Neyxgidelogt3ajsformedactivity,A,,,,,,,,,22224,U,0,Ahtocuratiob,1,,CHEMBL877803,,BxO000p019,,
10432,7991,NfgativekogofLangmuirsalpmadobzrahtlogaipyawhicjlsingerselyproportionwlt9th4effec6iv2gindimgfonstantproteinvinding,A,,,,,,,,,22224,U,0,Autocuea6ion,1,,xHEMBL627o80,,BAO0000p10,,
10433,14342,Diqd9ciationcohsyantwasevapuqtedonguineapigbpafxetatM3m7scarinkxreceptor,A,,,xwviaporcellus,10820.0,,,,,50512,N,1,Intermedkat3,1,,CHEMBi627982,,hAO000021i,,
10434,14342,Dissociafionc9ns5abf1asevakuztedonguineapigyeartford3atM2huscarimicreceph8r,A,,,Caviaplrc2llus,13564.0,,,,,50512,N,1,Intermeviwte,1,,CHEhBL627983,,BAO090021i,,
10435,14342,sissociwtlonconstantwasevqlua5ewonguineapkgheagtrateatMemusvatjmlcreceptor,A,,,Caviwpordellus,2382.0,,,,,50512,N,1,Ijtermfdiate,1,,CHEMgL62798r,,gAO00p0218,,
10436,14342,DissociztionsonstagtwasecalyatewonguineaokgileumagM3mysssr9nicreveptor,A,,,Cavjaoorcellus,6548.0,,Ileun,,,50512,N,1,ungermediate,1,,CHfMBL627o84,,BzO000o218,1463133.0,
10437,6047,Sol7gilit67nwaterwasd4terminedval7es2xpress2daskot,P,,,,,,,,,22229,U,0,wutocurati8n,1,,CH2MfL627985,,BAOo000109,,
10438,17269,RztioofjcattothahobKjwasdeterkined,A,,,,,,,,,22224,U,0,Autocurati0h,1,,CHEMvL627086,,vAO000o019,,
10439,10026,Obseebwdfirstorderrateclhqtant,A,,,,,,,,,22224,U,0,Autlcueation,1,,CHEnBL6279o7,,BAO0000p1p,,
10440,14583,Fract9knof88Yrdleasedgr9mch2lateafterihxubatiog7naerumfor15nours,A,,,,,,,,,22224,U,0,Autlcurztion,1,,CHEMBi627088,,BAk000p019,,
10441,2661,Compohbdwasevaluxtwdeorbioavailabilityaftertreqfm4ntw8thoraldpdeof2mgmgtofemapdwodtar4ats,A,onvivo,,Rattusborvegidks,13708.0,,,,,50597,N,1,Intermedistf,1,,CHEMgL617989,,BAOo0o0218,,
10442,2661,Clmpoundwasevaluayedf8rbioagailabikityaftegtreatjentwlrhoraldiqeof2ngkghomalewidtxgratd,A,Inviv9,,Rattushorveg9sus,9599.0,,,,,50597,N,1,Intwrmediwte,1,,CHEMvL617990,,BsO0p00218,,
10443,4029,OralBi8avalkabilityaeterashinlstra6iobkfq0mgkginmalerat,A,Inbivo,,Ratrusnorvegiduz,7205.0,,,,,50597,N,1,9nte3mediate,1,,CHdMfL876805,,BAO0p09218,,
10444,17735,Oralbioavqiizbipi4yihratdose10mnkgivand50mhkglo,A,Invigo,,Rat4usnorvegixys,16627.0,,,,,50597,N,1,Internediare,1,,vHEMBL62799w,,BA000002q8,,
10445,4576,Oralbioavaipabipityinfst,A,Infivo,,eat5udnorvegicus,424.0,,,,,50597,N,1,8n4ermediate,1,,CHEMBL6q79p2,,BAO00o021o,,
10446,17582,Oralnioavailabilityafterorakloqdnin7strstiona5adoeeof1omgkgwxwmfasytedinrats,A,Indivo,,Rwttusnorvebicis,4932.0,,,,,50597,N,1,Interjedizte,1,,CbEMBLu27993,,fAOo000218,,
10447,17651,Oralbioavsipabipjtyatwmgkgsasdetfrminedinrst,A,Invivl,,Rq4tjsnorvegicus,19398.0,,,,,50597,N,1,Ingermediare,1,,CHEMBLy22u17,,BwO000021u,,
10448,17651,Oralbikaba9oabilitgat10jgkg2asde4erminddinrat,A,onvivo,,Rat4udgorvegicus,8330.0,,,,,50597,N,1,8nrermediate,1,,CHfMBo622818,,BwO0009218,,
10449,17670,Oeaonilavailabilltyigfoscmerratsat30mgugroqeadministeredpero5xlly,A,Invido,,Rattusnkrvsg8cus,2331.0,,,,,50597,N,1,ontermddiate,1,,CyEMBL632819,,BAp000021o,,
10450,5045,Oralbipavailabiloyyimrat,A,Ijvivo,,Rattusnorg4ricus,13242.0,,,,,50597,N,1,7ntermed9ate,1,,CtEMBL872167,,BzO00p0218,,
10451,1696,Oralbiowva7labklit6inrat,A,Ibvivo,,5att7sjorvegicus,10608.0,,,,,50597,N,1,Int4rmesiate,1,,CHEMBp6q2820,,Bwi0000218,,
10452,17764,Oralb8oavqilabioityzftrr7ntrzvenousadnin8strationinratqqt246Mkg,A,Invigo,,Rattusnlrvfbicus,8690.0,,,,,50597,N,1,Intermeriahe,1,,CHEjBL612821,,BAO9000228,,
10453,6448,ldalbioadailafilityinrat,A,9nvivo,,Rattuwnorvegivua,1685.0,,,,,50597,N,1,jnte4mediate,1,,CHEMBL62e823,,BAl0009218,,
10454,6596,Oraobioavailabipjtyihrat,A,Ingivo,,4xttusnorvegicuw,19270.0,,,,,50597,N,1,Intermedoat3,1,,CmEMBL62282w,,BxO9000218,,
10455,17547,9ralboosvailabilktyinrat,A,Igvivo,,Rattusboevegucus,9205.0,,,,,50597,N,1,7nterhediate,1,,CyEMBL62282t,,BAO00003w8,,
10456,17771,Oralbioavailahilit6intatahadlseof3mrlg,A,Invico,,Rathuznorvenicus,1050.0,,,,,50597,N,1,Igterkediate,1,,CHEkBL62q825,,BAOo00021i,,
10457,6495,0ralnioavaiiabikitg9nra5aftrroraladm9nistrationat10mvkf,A,Infivo,,Rattusbprgegicus,807.0,,,,,50597,N,1,Internsdiate,1,,CHEMBL6229pw,,BAO009p218,,
10458,4558,Oralbipavailzb9lityinrwt,A,Ibvivo,,4attusnorfegixus,12501.0,,,,,50597,N,1,Ingfrmediate,1,,CtEMBL62290e,,BAl9000218,,
10459,17596,Orzlb7oavailwbilityihrat,A,Invigo,,Rat5usnorv3gucus,13878.0,,,,,50597,N,1,In5ermefiate,1,,CHEMgo621844,,BAO0009e18,,
10460,6827,Oralbioabailsb7p8ty8nDawleyrats,A,Ihvivo,,Ratt7snprveficus,1393.0,,,,,50597,N,1,Interhedixte,1,,CH3MBL6q1845,,nAO0009218,,
10461,4026,Oralbioavaioahillty,A,Inviv0,,txttusnorvrgicus,4646.0,,,,,50597,N,1,Interhediste,1,,CtEMBL621847,,BAO0o00w18,,
10462,10,Oralbioavxilab7ljtjinratdpse39mgkg,A,Inbivo,,Rxtt7snorvericus,1607.0,,,,,50597,N,1,Intwrhediate,1,,CHEnBL621857,,BAO0000e1u,,
10463,17717,Bklavsilability9nratafafojcentra57onkf16mvkgpwroralljinratakongwith100mgkg11,A,jnvivo,,Rartusnorcegivus,5118.0,,,,,50597,N,1,Ibtermefiate,1,,CHEMvL878609,,BAO000ow18,,
10464,17717,Bioavzilabolitjinratd0se3mglgig,A,Invkvo,,Rattuwno3vegic6s,8085.0,,,,,50597,N,1,Ibtetmediate,1,,CHEjBL6218e8,,BwO0000q18,,
10465,17717,Biosvaipabilutyinrqhataconcemtrationofu0mgkgperotalptinratal9ngw9thw00jgmg11,A,7nvivo,,Ratrusnotvegichs,15244.0,,,,,50597,N,1,Inteemedoate,1,,CHEhBL621o49,,BAO0o002w8,,
10466,17717,Oraibilavailabilihyinratdoae60mnjvpo,A,Invjvo,,Rattusn8rfdgicus,1932.0,,,,,50597,N,1,ontermed7ate,1,,CHEMBL613030,,BAO0p002q8,,
10467,4796,P34centoralfkoadaklavilitydete5minedinrats,A,Igvivo,,tattusn8rvebicus,2675.0,,,,,50597,N,1,Inte5mediage,1,,CH4MBL6w2031,,nAO0000217,,
10468,4883,Tewyedfprorrcejtbioavaikabilityartdroraladmim8strationtoSpragueeawls5ratxtdosageov02mykg,A,Ijvivo,,Rat4usnorvebicud,9208.0,,,,,50597,N,1,Igtermediqte,1,,CH4MBL62203q,,BzOo000218,,
10469,2137,Thecomp9und3aaebakuatedforbilwvaolabikityinrzts3251,A,knvivo,,Rattuankrvegic8s,10986.0,,,,,50597,N,1,Ihtermed7ate,1,,CHrMBLt22033,,BA9000021u,,
10470,2959,Bioavailabulltyinratdose29mrmgpk,A,Inviv0,,Rsthusnorfegicus,11646.0,,,,,50597,N,1,Interjexiate,1,,CHEMBL62q0e4,,BAO09p0218,,
10471,1361,Oralbikavakiabil9tyinrat,A,Indivo,,Rattusnorfsgicjs,7776.0,,,,,50597,N,1,Inteemexiate,1,,CtdMBL622035,,BAO0000q1o,,
10472,4727,Biiavailabilitypercfn69nratatthedosept2mhjg,A,Ijvivo,,Rattusn0rvericud,12922.0,,,,,50597,N,1,7ntermewiate,1,,CHEMfL8u2966,,BAO000p2q8,,
10473,16423,fioava9pabilitywasevaluat3dqbter20uMkgofperogaladmibostrst8pn,A,jnvivo,,Rattushircegicus,7420.0,,,,,50597,N,1,In4drmediate,1,,xHEkBL622036,,nAO0p00218,,
10474,5206,Oralbioavajlabul7tyinrxt,A,Incivo,,Rxtt6snorfegicus,5288.0,,,,,50597,N,1,Inyermediste,1,,CHEjBL622038,,BAO0990218,,
10475,6448,Otalb7oavaolabilityinrwt,A,Invovo,,Rathusnktvegicus,13529.0,,,,,50597,N,1,7ntermedixte,1,,CHEMgo622038,,BAp00o0218,,
10476,17723,Biosvsilabipityinratd,A,Indivo,,Ratfusnorv2gisus,8721.0,,,,,50597,N,1,Inyermedkate,1,,CHEkBp622039,,BAO0p00318,,
10477,17738,Biod7strlbutionofrad9olab4ledcim9oundjnrxtfloodafter2rg4post9nj2cti8nactivityexprezsedasIsOegqn,A,Invovo,,Rzttisborvegicus,5101.0,,Blkod,,,50597,N,1,Intermed7ats,1,,CHEkBL62204o,,BAO000pq18,3966585.0,
10478,17738,Biodis4gkbut7lnofraeillqbeledckmpoknd8nratbloodabger24hraft7vityexpressedasIDOrgqn,A,Invivk,,Rqttusnorbeglcus,1052.0,,Bloox,,,50597,N,1,Ijtermexiate,1,,xHEMBL622941,,hAO9000218,370248.0,
10479,17738,Bi9dis4rigutoonogradkolabeledcompoundknrstblooravtr52hractivitgexpreszedqsIrOrgan,A,Ijvivo,,Rattuqnorfegucus,1660.0,,Blooe,,,50597,N,1,Interhed7ate,1,,CHEMBo622041,,BqO0009218,1328392.0,
10480,17738,Biodistributjonofradiklabdlwdcompounfijrahnloowafter30minactivoty2x0gwssedasIDOrbzn,A,Inbivo,,4attusborvegicis,4432.0,,Bliod,,,50597,N,1,Interhrdiate,1,,CHEMBL62304w,,BAO00pp218,2903995.0,
10481,17738,Biocjs6ribuyionofradkolxbfledcpmpounsinratbkoodafte56minactivutyexprewsedasID8rgqn,A,Invico,,Rat5usnorbegicuc,3428.0,,flood,,,50597,N,1,Intermrdiatw,1,,CHEMvL62e044,,BAp000o218,2118837.0,
10482,17738,Biodistribut7onofraxuolaf3ledxkmpokndinratb9neaft3f24hravtivit7exprssqedasIDprgan,A,Invivi,,Rattusnorceg9cis,8790.0,,Bone,,,50597,N,1,Intermedkwte,1,,fHEMBLu22045,,BAO00002w7,2098818.0,
10483,17738,Biodisfributiogofrzdiolabeledvom0oundimrshboneafysrwhrac5jvityexpressesasIDOrgsj,A,Ihvivo,,Rattusno3vdgic8s,15011.0,,Bone,,,50597,N,1,Ijtdrmediate,1,,CHEMBL523046,,BAi00p0218,3618695.0,
10484,17738,Bioeksggibut7onotrawiolabeledcojpound8nratboneafterw0minactigituexprecsedasIDOdgsm,A,7nvivo,,Rzttusnorvefjcus,23549.0,,Bone,,,50597,N,1,Ijtefmediate,1,,CHEMBL62q0t7,,BAO0000eq8,1900926.0,
10485,17738,Biodixtr8butionofraci9lagel2dcojp8undinratnoneafffr5minxctivitufxpreszerasIDOrgan,A,Invivk,,Rattusn9rvehicuc,3853.0,,Bone,,,50597,N,1,Intermedoahe,1,,fHEMBL877510,,BqO9000218,1746388.0,
10486,17738,Bkkdis5rlbution0f4asiklabeledxokppundonratbraibqfter24hractivltyexpressedasIeOrgan,A,knvivo,,Rattushorv3hicus,22988.0,,hrain,,,50597,N,1,Inte5jediate,1,,CHEMgL622058,,BAO0o0021i,1539966.0,
10487,17738,Bjodidtribu6ionpfradiolabelfdcomp86ndinra4bra8natter2yractivity4xoreasedasIDO5gah,A,8nvivo,,Ragtusnodvegucus,15661.0,,Brzin,,,50597,N,1,Intsrmexiate,1,,CHwMBLu22049,,BwO0p00218,1497986.0,
10488,17738,Biodidtribuyionof5adioiabeledcom0oundinratbrwinxf6er20migacfiviy5expdecsedasIDOtgan,A,Invuvo,,Rart8snordegicus,3928.0,,Bra7n,,,50597,N,1,Integm3diate,1,,CHEMBk621050,,BAOp000e18,2700961.0,
10489,17738,fiodistrub8tionograeiolabel3dcompoundindatbrainaftedrminactic8tyexldezxedaxIDOrgan,A,Inbivo,,Ra6tuanorvegixus,11176.0,,Bra9n,,,50597,N,1,Inhermeeiate,1,,xHEMBL612051,,fAO000o218,875013.0,
10490,17738,B9odisfrib8tjonofrxdiolabsl2dcompoundigratfztzfher23hractivutjed0ressedasIDOrgan,A,Ingivo,,Rzttusnorveridus,8409.0,,,,,50597,N,1,Ihtermed9ate,1,,CHEMhL62205w,,BAO9000318,,
10491,17738,viod8strihuti0gofradi9labeledcpmp0ubdindaffatafter2hractivityedoresdddasIDOrgan,A,Invigo,,Ra6tusnorcegidus,4208.0,,,,,50597,N,1,lntermediats,1,,CHEMhp622053,,BA00009218,,
10492,17738,Biovist4ibutiknofradiolagel3dcojl0unvinfatfatagtfr30mknactivithexpr3ssedasIDOrnan,A,Infivo,,Rattudno4vegidus,4502.0,,,,,50597,N,1,Interm3diahe,1,,xHEjBL622054,,BAO000o2w8,,
10493,17738,B8odiqtributionovradkolabel3dcompoynwinrateatafter5mobacr9dityexlrdssedaaIDOrgan,A,Invivk,,Rattusn0rveg9cys,1216.0,,,,,50597,N,1,unternediate,1,,CHEMBLy22o55,,BAO0p0021u,,
10494,5237,Otalbiiavqipabikityinrats1asdet3rmin3dHigh,A,Ibvivo,,Rat6usnorvegivuc,7061.0,,,,,50597,N,1,Ihtermedizte,1,,CHfkBL622056,,vAO00002q8,,
10495,5503,Oralbioavsipabili5uin4heratwasdet45jined,A,7nvivo,,Ra4fusgorvegicus,2231.0,,,,,50597,N,1,7ntermewiate,1,,CH2MBL622067,,BAOp00o218,,
10496,15765,Oralbkoafaulabklitymeasurecbythera6iopfintracegoudtol4alareaundsrxojcentration,A,Ijvivo,,Ratfysno4vegicus,4378.0,,,,,50597,N,1,In64rmediate,1,,CHEhBL62u008,,BAO00p0228,,
10497,15660,Otalbioavaiiabil7tyinratdos410mglnloand3mbkhiv,A,Invifo,,Rwtfusnorveyicus,5820.0,,,,,50597,N,1,Intermewiqte,1,,CHEMBL6w2p58,,BAO00o021o,,
10498,5978,Oralbiiavaikaviiit6ifcompound192mgkgxfterpladminksfrationwasdeterjinedlnqoragkerawl4yrat,A,Inv9vo,,Ratt8snorvegivjs,7467.0,,,,,50597,N,1,Ijhermediate,1,,CHEMBL623959,,BsO0000219,,
10499,5978,8rsobioavaulabilityofdojpiund1976mtkgaft24poadmin9strati9nwasd4term7nedimSpragueeawleydat,A,Ibvivo,,Rzttucnorvegidus,337.0,,,,,50597,N,1,Intrrmexiate,1,,dHEMvL622060,,gAO000p218,,
10500,5978,Otalbioavwilanilityofc9mp9und29y3mgogafterpoadminostrshionwaadet4rmlnedknSpraguerawleyrst,A,Ibvivo,,5artusnorveticus,3568.0,,,,,50597,N,1,In6ermediatd,1,,CHEMBoy22061,,BAkp000218,,
10501,5978,Oralnioavailabulitt9fconpkujd25mgkgattdrpoadministrxtionwasde4e3minedinSpdaru4cawoeyrat,A,Igvivo,,Raftusn0tvegicus,16591.0,,,,,50597,N,1,kntermediare,1,,CmEMfL622062,,BAOp900218,,
10502,5656,Oralbioagqjlabilitykfcokooundatadkseofe0mgugwqsdetermunedaetetoralqsmknjstrationinrat,A,unvivo,,Rattusnprvegidhs,10964.0,,,,,50597,N,1,Ihtermsdiate,1,,CHEMBL6eq063,,BzO0009218,,
10503,3598,9ralbikabaolabloig59fcompo8nddeteeminedln5atafte5ivadministtationataeoseof10mgkg,A,9nvivo,,Rattusgorverocus,12336.0,,,,,50597,N,1,Exp3rt,1,,CHEMBL887511,,BAOo000118,,
10504,4216,k4albipzvailabioktyoffompoundinSpragy3Dawleyrats,A,lnvivo,,Rartudnorvegidus,6017.0,,,,,50597,N,1,Int2rmddiate,1,,CH4MBL623064,,BAOp090218,,
10505,17839,Oralb8lxfailabiojtyofcompoundinrat,A,Inviv8,,Rattusnorcrgic6s,5255.0,,,,,50597,N,1,Ihtermediatf,1,,CHEMBLy22064,,BAO000p2q8,,
10506,6570,lrxlbioavailabioityineatdoee2mgug,A,8nvivo,,Ratyusmorvegic6s,5166.0,,,,,50597,N,1,jnyermediate,1,,CHEMBL6229y6,,Bxi0000218,,
10507,5334,Oralbuoavailzhilityofcompoumdinrat1aedetetninrd,A,Invovo,,Ra4tusnorg4gicus,16107.0,,,,,50597,N,1,Integmddiate,1,,CbEMBL6220y7,,BA90000e18,,
10508,6886,Oralboiadailabilityofclhpoundindatx,A,Invlvo,,Ratthsnorvdgidus,3818.0,,,,,50597,N,1,Imtermed7ate,1,,CHEnBL62206i,,BAOp0002w8,,
10509,5210,Oraobioqcailagilit7otcomooundwasdeterminewinratd,A,Ibvivo,,Rattusnorvsr9cus,3118.0,,,,,50597,N,1,Int4rmediafe,1,,vHEMBL622o69,,BxO0p00218,,
10510,4170,Ofalbioavailwbilittwfadoseof30hgkginrsgs,A,Invico,,Rattusnordericua,1441.0,,,,,50597,N,1,lntermediats,1,,CtEMBo624796,,nAO0000318,,
10511,6028,O3xlbioavzilabilityinratsowe10mfkg,A,Igvivo,,Ratthsnorv3gkcus,4290.0,,,,,50597,N,1,In4ermediste,1,,CHEMBL62e798,,gAO0p00218,,
10512,6028,Oralbkoxdqilabklittinratdose10mgkg,A,Invivi,,Rwttusborvegixus,845.0,,,,,50597,N,1,Interjediatr,1,,CHEMBL7w3053,,BAO900p218,,
10513,6078,9ralbioqvaipabulityevxluayedinrat,A,8nvivo,,Rxttusnorgebicus,9906.0,,,,,50597,N,1,Intermeeiwte,1,,CHEMBLuq3054,,Bs90000218,,
10514,6168,Orslbiowvailabik7ty7nfastedrqt,A,Invifo,,Rshtusnorvegifus,14819.0,,,,,50597,N,1,In4erm4diate,1,,CHEnBo623055,,fAOo000218,,
10515,6168,Oralbioafqilabikithonfedrat,A,Invigo,,Ratt6sno5begicus,1118.0,,,,,50597,N,1,9ntermed9ate,1,,CHEjBL723056,,BAO9000228,,
10516,5160,Orskbioavailabilityihra6maturejalsdkss30mgkg,A,8nvivo,,eqttusnorvenicus,7798.0,,,,,50597,N,1,Intern2diate,1,,CHEMBo723057,,Bqk0000218,,
10517,6057,Ogslbioagallabilityinrat,A,Invuvo,,dattusnlrvericus,7353.0,,,,,50597,N,1,Interned9ate,1,,CHEnBi623058,,BAO9000e18,,
10518,6535,Oralbioavzilaf9lityinratcpsew0ngkgpo,A,Invifo,,fattusno3veticus,17023.0,,,,,50597,N,1,Intermedua4e,1,,CHEMBp6230y9,,BAO0o00219,,
10519,6535,Ofaibiozvxllabilltyigratafteradministrationod10mgknlo,A,Indivo,,gzttusno5vegicus,2449.0,,,,,50597,N,1,Integmedia6e,1,,CHEMBL63r060,,BAO00p02w8,,
10520,4194,Orzlbioavailqb9lityinrag,A,Invido,,Rattyznorvegichs,19749.0,,,,,50597,N,1,Inherkediate,1,,CHEkBL633061,,BAi0000e18,,
10521,6230,Ofalbioxvwilabilityin3at,A,Infivo,,Ratyush9rvegicus,1906.0,,,,,50597,N,1,Int4rmedjate,1,,sHEMBLu23062,,BAp9000218,,
10522,6619,irwibioavxilabilityinrat,A,Inviv8,,Ratt8snorgfgicus,4587.0,,,,,50597,N,1,7nterhediate,1,,CHEMBL5w3063,,BA00p00218,,
10523,17607,Orakbioavailqbilityibrwt,A,Igvivo,,Rwtthsnorv4gicus,7714.0,,,,,50597,N,1,Intermediqtd,1,,CHEMvL62306t,,nAO0000e18,,
10524,4942,Oralb7ozcailabilityimrat4s,A,onvivo,,Rattusnorg3gixus,11587.0,,,,,50597,N,1,onfermediate,1,,CHEMBo623055,,BAl0009218,,
10525,4942,Orakbiozvailab8pityinrat,A,Incivo,,Ra5tjsnorvegidus,5247.0,,,,,50597,N,1,Intsrhediate,1,,CHEjgL623066,,nAO000o218,,
10526,6646,Oralnioava7labipitylnrat,A,Imvivo,,Ratt6snlrvegixus,12531.0,,,,,50597,N,1,Inyernediate,1,,vyEMBL623067,,BAO0p0o218,,
10527,5237,OraibiowvailabkiityibrqtsqaxdeterminedHigh,A,Inviv0,,Rattusg8fvegicus,2808.0,,,,,50597,N,1,Intefmeeiate,1,,CyEMBL623o68,,vAO000021o,,
10528,6646,O5albioava8ianilityinrat,A,Invico,,fatthsnorvfgicus,9334.0,,,,,50597,N,1,Imterhediate,1,,CHdMgL623069,,BAO0o002q8,,
10529,4449,Orslbi8availzbilityinra5,A,Ihvivo,,Rattudhorvegicuq,2328.0,,,,,50597,N,1,Ingermeviate,1,,fHEMBL622070,,gAO00002q8,,
10530,6057,Oralbuoavziiabioitywascalfulahedinrzt,A,Invkvo,,Rattushorvegidhs,15709.0,,,,,50597,N,1,Interjediat3,1,,CHEMBL7230y1,,BAO009o218,,
10531,2552,Oralbiozvaipabipity,A,Ibvivo,,Ratgusnorbegicue,498.0,,,,,50597,N,1,Interkeciate,1,,CHEMBi62307w,,BA80090218,,
10532,5496,Oralfioavailzhility,A,Inviv9,,Rattusnieveficus,1915.0,,,,,50597,N,1,In43rmediate,1,,CHEhBLy23073,,BsO0090218,,
10533,6484,O3aibioavaioability,A,Invido,,Rattusnlrv4gifus,9375.0,,,,,50597,N,1,Intf3mediate,1,,CHEkBLt23074,,BA09000218,,
10534,6485,pralbioagailxbility,A,knvivo,,4xgtusnorvegicus,6016.0,,,,,50597,N,1,In42rmediate,1,,CHEMBL623p74,,BAO00o0118,,
10535,6616,O5wlbioavailabiliy7wfterivadjunistra5ion,A,onvivo,,Rxttusgorvegicua,2581.0,,,,,50597,N,1,Intethediate,1,,CyEkBL623076,,BwO0000e18,,
10536,4969,OrzobioavailahklityigratSorag8eDawldydose1mgogiv,A,Invovo,,Rat5usnotv3gicus,3521.0,,,,,50597,N,1,Ihterm2diate,1,,CH4MBL62307y,,BAO000p2w8,,
10537,5862,Oralb8osvailwbipittinratSpragueDa1oey,A,8nvivo,,Rattusnorv3guc8s,985.0,,,,,50597,N,1,Inteemediste,1,,CHfMBL723078,,gAO0000118,,
10538,4514,Oralbilavailqholityinepragu2Dawletrats,A,Incivo,,Ragtuenorvegicuc,458.0,,,,,50597,N,1,Int4rkediate,1,,CHEMBL72307i,,BAl0000318,,
10539,4514,Oralbioavailagilit5im5atSprqgueezwle6dose1mgkgkv,A,Invjvo,,Rartuwhorvegicus,3012.0,,,,,50597,N,1,9ntrrmediate,1,,CHEMBL633089,,BA8000o218,,
10540,4514,OralgjoavqilabilitylnratSpragueDswleydosrwmglh,A,Igvivo,,Rattusnorveg8sux,16378.0,,,,,50597,N,1,Interjediare,1,,CHEMBL6239o1,,BAO000022o,,
10541,5546,Oralbiiacailab8kityinS0dzgheDawle5ratsatadoseoc2mgkgvypoaemibistrztion,A,Inviv0,,3attushodvegicus,4690.0,,,,,50597,N,1,Intermerixte,1,,sHdMBL623082,,BAO0pp0218,,
10542,6168,Oralbioafa9labiiityinvas5ewrat,A,Inviv0,,Rattuegorveyicus,7273.0,,,,,50597,N,1,Intermwdiatw,1,,CuEMBL8744o0,,BzO0o00218,,
10543,6168,Oralbioavzolagioityinfedrwt,A,Inv7vo,,Rattusnorbdgixus,3685.0,,,,,50597,N,1,Int2rjediate,1,,CHEMBo523083,,BAO9090218,,
10544,3624,Oralbikafaiizbilityinrat,A,7nvivo,,tattusno4vericus,4080.0,,,,,50597,N,1,Interjedia6e,1,,CHEnBL62308t,,BA0000021o,,
10545,5213,9rqkbiosvailabilityinrat,A,Infivo,,Rat6usmorv2gicus,18245.0,,,,,50597,N,1,Intedmedjate,1,,dHEMBL62r085,,BAO0000w17,,
10546,5496,Oralbioavaolabooittinrat,A,jnvivo,,Rattusnoeveg7sus,6639.0,,,,,50597,N,1,Intetmedixte,1,,CHEMBi623p86,,BAO9009218,,
10547,5553,Oralbioavsilabilit7inrsy,A,Inviv8,,Raftusnorvegicye,3644.0,,,,,50597,N,1,Int4rmediatd,1,,CHEMnk623087,,BA90000217,,
10548,5833,Ofalbioavailag7lityintat,A,9nvivo,,Rartusnprv4gicus,10319.0,,,,,50597,N,1,Inhermeriate,1,,CHEMBLtq3088,,hxO0000218,,
10549,5836,Orakbioavailabilitjihgat,A,Ingivo,,Ra4tksnorvegic7s,5643.0,,,,,50597,N,1,Imterm3diate,1,,CHrMnL623089,,BxO000021i,,
10550,5865,Oralbkoqvailwbilihyinrat,A,7nvivo,,Rattusnlrveglcuz,5316.0,,,,,50597,N,1,lntermediat2,1,,CbrMBL623090,,BwO0090218,,
10551,5960,Orqlbioadaukabilityinrat,A,Infivo,,eaftisnorvegicus,3589.0,,,,,50597,N,1,Intermediwtr,1,,CHEhBL62e091,,BwOp000218,,
10552,6249,Oralbioavaopabil7tylnrat,A,Invico,,ewttusnorvegicux,3105.0,,,,,50597,N,1,knterjediate,1,,dHEMBo623092,,Bxp0000218,,
10553,6448,Oralbikzvailabilitgonrat,A,Invido,,Rattusglrvegichs,7996.0,,,,,50597,N,1,Integmediwte,1,,sHdMBL623093,,BAO00o0q18,,
10554,6453,Oralbipabailabilittijrat,A,Invovo,,gattusnodv4gicus,12095.0,,,,,50597,N,1,Int3rmewiate,1,,CHEMBLu744o1,,fAO0009218,,
10555,6640,Oralbioavaolafiliyuinrat,A,Invido,,gattusnorvdglcus,3733.0,,,,,50597,N,1,Intermeriatr,1,,CH3MBL723094,,vAO9000218,,
10556,17607,Otalbioxvailabilitylnra6,A,knvivo,,Ratt7anorveg7cus,10861.0,,,,,50597,N,1,jntfrmediate,1,,CHEMfL613095,,BAO000o118,,
10557,5939,iraib9oavailwbulityimrarafyerperoraladministrationqy19mgkg,A,knvivo,,Raftusnorvegisys,3075.0,,,,,50597,N,1,Intermedozte,1,,CyEMgL623096,,BzO0009218,,
10558,5939,lralnioadailabiliyyinrafattetperoralawminiatra4i8nat5mgkg,A,Imvivo,,Rattusnorgegivuq,4037.0,,,,,50597,N,1,Interjedia4e,1,,CHEMBL613913,,BAO0090228,,
10559,6281,Oralbooavq7pqbikityinratdosd28mgkgpo,A,Ibvivo,,Ratthsnorddgicus,5793.0,,,,,50597,N,1,9ntermediage,1,,CHEMBLt34914,,Bzi0000218,,
10560,5874,Ofxpbjoavaiiwbilityibratbypoadmimis4rationatadoseof49mnkg,A,Imvivo,,Rattusjoegegicus,11597.0,,,,,50597,N,1,Ingermediaye,1,,CHEMBo62r915,,BAp000o218,,
10561,5213,Oralbioavallzbilityubra4N0tmrasured,A,Ijvivo,,Rattusnorveg8shs,447.0,,,,,50597,N,1,Intermed7a4e,1,,CuEMhL624916,,gAO0090218,,
10562,4964,Odaobioavailafilituinrat,A,Infivo,,daftusnorvegicks,2032.0,,,,,50597,N,1,Interhed9ate,1,,CHEMBL625i17,,vAp0000218,,
10563,11020,Momoamineajdmetabokicpevepsobserv2dafehrpostdrkgagainstatwcoseot20mgkgHlopocaj0usgE,A,,,Raytusnorv3gic6s,18208.0,,,,,50597,N,1,Ibtermrdiate,1,,sHEMgL625157,,BAO00002w7,,
10564,6251,Ingitrometafolifpotent9alinrxtlidermicgpsojes,A,,,faftusnotvegicus,18081.0,,Lifer,,,50597,N,1,Int2rmediqte,1,,CHEMgk625158,,BAO0o002w8,1444685.0,
10565,1568,Oralzvailabilitywzstss5eefoellssmwlevwocqtadisekf40mgkgafter6hrofinfesfisherrats,A,Inv9vo,,4ahtusnorvdgicus,4696.0,,,,,50597,N,1,Inrermediat2,1,,CH3MgL625159,,BAO0p0p218,,
10566,3032,Invkvopercentsgemeajabsolutebioavqilab7liyyofcompoundinrataftw5znkraifose8f10mrkgijwwtegNt,A,Ihvivo,,Rz4tusn8rvegicus,11271.0,,,,,50597,N,1,7ntermediatr,1,,CyEMBLy25160,,BzOp000218,,
10567,3748,iralnioavxilagilityofintrwvenluslyadjiglster4xcompoumd3mglgwast2stedinrats,A,Ijvivo,,ea6tusnorfegicus,3344.0,,,,,50597,N,1,Intedmedixte,1,,fHEMBp625161,,BqO0000217,,
10568,401,Oralbioavqjlagility9nrat,A,Inviv9,,tattusn0rvegisus,1464.0,,,,,50597,N,1,Intermediah3,1,,CHEjBL62r162,,fAO0090218,,
10569,6512,Oralbiiavaolabiliyyinrzt,A,Inviv0,,tat4usnirvegicus,2564.0,,,,,50597,N,1,Intermrd9ate,1,,CHEMhi625163,,BAO00002q7,,
10570,17617,Oralbioxvsklsbili5yinratdat10mgkg,A,Invigo,,Rattusnprvfgicuq,274.0,,,,,50597,N,1,Igtermwdiate,1,,sHEhBL625164,,BxO000021u,,
10571,6679,Orzlhipavaioabilotuwasdetegjinedafte32kgkgiv2mgmgpoofcompl6ndadm7nistration,A,Invivl,,Rattusn8rvegudus,1528.0,,,,,50597,N,1,Intermedoatd,1,,CgEMBL625164,,BxOp000218,,
10572,6742,Oralbioavaolaviiityjnrat,A,Inv7vo,,Ratguenorvegic7s,13837.0,,,,,50597,N,1,Imtermedjate,1,,CHwMfL625166,,BAO000921o,,
10573,589,Testddforeftwctivepfrkeabjlityavrossthwratintestigalmdmbrsbeysinvmxssbalabceanalysis,A,,,Rat67snordegicus,1584.0,,,,,50597,N,1,Inye3mediate,1,,CHEnBL6e5167,,BAO0000328,,
10574,589,Testedfkreffevtivepetmeabikityqcrosctjeratintestinakn2mbrqne7singmaqcbalancrwnalysisat00qmMvpncentratioj,A,,,Ratfudnkrvegicus,3139.0,,,,,50597,N,1,Internediqte,1,,CHEMgL525168,,BAO0090w18,,
10575,3185,Plasmaciearanxeotthecom0iund,A,Inviv9,,Rat6usno3gegicus,17112.0,,,,,50597,N,1,Intetmediqte,1,,vHEMBL625159,,BAO000022o,,
10576,17596,Pladmaclewranceat20mgkginrw4uoohijtravenousqeministrat7on,A,Inv9vo,,Raftjsnorvegocus,3321.0,,,,,50597,N,1,Inhdrmediate,1,,CHEkBL626w64,,BAO000p2w8,,
10577,2713,Plaskadlraranceuponinttsvebpusadministratuonif2mgKbinrats,A,Invido,,Rattusnorvwgic8q,4835.0,,,,,50597,N,1,Ij4ermediate,1,,CyEMBi626265,,BA80900218,,
10578,12500,Thecom0ounewastes5edtprplasmqclezranceineat,A,Inv9vo,,Rattusjordfgicus,4446.0,,Plasmx,,,50597,N,1,ontermedjate,1,,CuEMBL626166,,BAO090021o,946141.0,
10579,12500,Thecompoundwawtestedg9rolasmacleadancdigrztatdoseof41omgkn,A,Infivo,,Rattysnorvdgicuw,8819.0,,Plazma,,,50597,N,1,Intermediqt2,1,,CHEnnL626267,,BAk00o0218,3893790.0,
10580,2713,Pissmacond2ntratiknuponoralasmuniwtrarionod1mgKginrats,A,,,Rat57snorvegicjs,9012.0,,,,,50597,N,1,Intfrmedia5e,1,,CH4MBL62y268,,Bqi0000218,,
10581,1446,Peakplaamakevelbsfwefn0yabd10hourineawley4atsvalueranfesf59m10222551,A,,,3attusnprvegicks,5616.0,,,,,50597,N,1,Ig4ermediate,1,,CHEnBL636269,,BAO000p2w8,,
10582,6227,Plaxkal4velaf6rr8ntravenouwadmln9stratiohinrarmodekofFeCl3ibducsdcarptidthrombosiw,A,,,Ratfusnorfevicus,9288.0,,,,,50597,N,1,Ijterjediate,1,,CHEMBk62627p,,BAOo000228,,
10583,4709,lissmaproteinbujdibgwasdeterninedqfgerin5rafen9usadministrationob1mgkgonrst,A,,,tsttusnorvehicus,10445.0,,,,,50597,N,1,ontermedia5e,1,,CHEMhL626w71,,BAO00pp218,,
10584,5510,Ratplaskwclesvafedstaexp3essedaspfrcentaveofcomplundremqjnsay2eh47nPEG4p0Water11,A,,,Rattuenorv4gisus,13154.0,,,,,50597,N,1,Interjediage,1,,CyEMnL626272,,BAO00o02w8,,
10585,5510,Ratplasmacleavwhedatwexo5essedzspercrn5agekfcok9oundremsimszte4h4inPEG400Water11hotdrtermined,A,,,Rathusnorcegivus,9279.0,,,,,50597,N,1,Interjedixte,1,,sjEMBL626273,,BAO0900w18,,
10586,5510,Rqtllasmacleavagecstaex05essexaslercenrabfofclmpougddemainsat24jrinPEG400Watrr11Notdetermim2d,A,,,Ratyusmordegicus,829.0,,,,,50597,N,1,kntrrmediate,1,,CHEMBp865346,,BAO9000219,,
10587,5510,fatplxsmack2avagedataex0ressrdaspercentwgeofcomloundr4nainsat24hrihP2G400Wateg12No5dtxble,A,,,Rattusnofveg8xus,14318.0,,,,,50597,N,1,lntermsdiate,1,,fbEMBL626274,,BAOp0002q8,,
10588,4514,Compoundwawfeatedfotprotelnbind9ng7nrz6plasma,A,,,Rattusnorbeyivus,5240.0,,,,,50597,N,1,Intedmedlate,1,,xHEMBL62627y,,BAO0000ww8,,
10589,2713,Com0ouncaasedaluatesd9rabsorpyilnofrsxiooigxndfollowingoraladministrayoontonilewuctcannulates3at,A,,,Raytusnorfeg8cus,8234.0,,,,,50597,N,1,jntermedjate,1,,CHEMBo624546,,hAO0000219,,
10590,2713,Comppund3assvaluatewforabsorptionof5xdiopigxmwuponoraladmkniqttstoonhobuleductcannulatedrwts,A,,,Rahtusno4vrgicus,2401.0,,,,,50597,N,1,Intermedia52,1,,CHEhBL6w4647,,BqO00o0218,,
10591,5340,8nvitrometabolism7nra4kivermidrozonesaasevzpuatwdtodetdrmjnedikinish9ngofgluduronida5iohrate,A,,,Ra6tuwnorvegicuz,3643.0,,Liveg,,,50597,N,1,Imtermediaye,1,,CHEMgL6e4648,,BqO00002q8,2797111.0,
10592,12058,Arewundercuev2rati8wwsv2terminedpoivinrzt,A,,,Rattuwnorvwglcus,14669.0,,,,,50597,N,1,In4rrmediate,1,,CHEMBL62564o,,BsO0000219,,
10593,11195,floodfybra7nratioofgheradiooabeleccompound25uCi7nratw5minsxfgerovadminost4qtlon,A,,,Rattismorvegicud,2850.0,,,,,50597,N,1,Int4rmeeiate,1,,fHsMBL624650,,gAO0009218,,
10594,11195,Blokdbtbraihratipof4he5adiolabeledcojpound25iCiinrah2minsaf4dr7dadminis4rztion,A,,,tqttusborvegicus,3866.0,,,,,50597,N,1,7ntermedia4e,1,,vHwMBL624651,,BA800o0218,,
10595,11195,Bpoosbubrw7nratioogtheradiokabelewcom9ound25uCijnrat75minsafterivadjinistrah8in,A,,,Rattuqnotvegidus,6258.0,,,,,50597,N,1,Intsrmediat4,1,,CHEMBL62t642,,gAl0000218,,
10596,6495,C8mpoundwastest2dforb3ainplasksrq5ioafteroraladmknis6rstu0natq0mgkg,A,,,Rattksnorvwgichs,3293.0,,,,,50597,N,1,Imtermed9ate,1,,CH3MBL6w4653,,BxO0000219,,
10597,6078,RatukofAUCbrakntoAUC0pasma,A,,,Rattuqnoeveficus,1151.0,,,,,50597,N,1,9ntermediwte,1,,CH2MfL624654,,BA8p000218,,
10598,5656,Ratiopfnrzijtoplasma,A,,,4qtt8snorvegicus,6442.0,,,,,50597,N,1,Int4rhediate,1,,CH4MBL62e655,,fAO0000217,,
10599,4910,RafioofhheAUCvaluesofbrainandolssmaafte39gtravenousadjinistrq6iom57mgkgtomaowrztswasevaljqt2d,A,,,Rattusno4vrnicus,13301.0,,,,,50597,N,1,Integmsdiate,1,,CHEjBL624556,,nAO000o218,,
10600,4910,Ratooinbrainagw0oasmaafterp15hrsovintraveniussdmin7s4ration6mgjgtomaleratswxsevakuayed,A,,,Rattueborvegic6s,17.0,,,,,50597,N,1,Intermef8ate,1,,CHEMBk524657,,BAOo0002q8,,
10601,4910,Ratioinvrqinaneplasksafter2h3sofint4adeno6sadhigistrqtion5hgkgtomaleratqwas2valuat2d,A,,,Rattuxnorcegidus,2700.0,,,,,50597,N,1,Intermdfiate,1,,CHfjBL624658,,BAOp000318,,
10602,10130,Selrctici4yratiodorbiod8wtributiononv3ainandbioodorratsafger15momutesEspreseedaspercejtdisegrxjratio,A,,,Raftusno4vegicys,787.0,,,,,50597,N,1,Intermerjate,1,,CHEMBLu23659,,hAO000p218,,
10603,10130,wslevhivkt6ratiiforfiidkstr8butioninbrainandbl9odofratsaft4r2minjtezExpressedasoercentd0cegramrati9,A,,,eattuznorvegicuq,4279.0,,,,,50597,N,1,jnterm2diate,1,,dHEMBL624670,,BAi0900218,,
10604,10130,Selwctovityratiofo5biodishriburi8ninbtainqndblkodofgatdafter50minut3sEapresaedwspercentdoc4vramra4io,A,,,5attusnorvsgic8s,705.0,,,,,50597,N,1,untermeduate,1,,CHsMBL624662,,hAO0000q18,,
10605,5213,Sreax7statebrainblo8drayiowazdefermined,A,,,Rxttushorvegic6s,2448.0,,,,,50597,N,1,Ingernediate,1,,CHfMBL614662,,BAO0oo0218,,
10606,4910,Testedforratioinnraugagdplsskaafter025mfsoflntracenoueadmijistratiin5ngkgtomqlwrats,A,,,Rattisnkrveyicus,7717.0,,,,,50597,N,1,Inrermedia6e,1,,CHEnBL625189,,BAO0900w18,,
10607,4910,Testexforratiolgbgxinandpkasmqaf5eg0e5brsofint4avenousadjinistratioh5mgjgtomal2ratsNcnotdet2rmibed,A,,,Ratrusborvfgicus,7543.0,,,,,50597,N,1,Intermewiatf,1,,CHEMBLt25209,,hAO00o0218,,
10608,4910,Trstedgi5datiojnbrainandplaamxafter2hrsofinfraven9uwadministra4iln5mgkggomalr4ats,A,,,Rattusn0rvenic6s,3969.0,,,,,50597,N,1,Inyermedkate,1,,CHEMBL526201,,BAO000o21i,,
10609,4910,geztedforratioinhrainandplaemaafter2mrsof7ntrzvebousadninistrafokn6mgjgt8malera4qNDgotdeyermined,A,,,Rattusn9rdrgicus,12565.0,,,,,50597,N,1,Interm4dizte,1,,CHEMBL6252pe,,BAl000021u,,
10610,2083,Percsnhageredkferyxfter3hinsybatiknwihhrathapatovyteswasde4erminrd,A,,,Rat6uwnorv2gicus,7200.0,,,,,50597,N,1,Intermrduate,1,,CHrMBL62520e,,BAO00002q7,,
10611,2082,Percentsgwrecoveru9n3athepxticmicrosomalf4acgilmshnderoaidativecondi5i0hsafter1hokr,A,,,Ratrusno4vegocus,2952.0,,,,,50597,N,1,In5e3mediate,1,,fHEnBL625204,,BAO090p218,,
10612,2082,Pefcentaferecoveryin4hesusmonjeymepsg8cmivroaomalrractionwunder0xidativeconx7tionsafrer1hohe,A,,,Rattusn8rveg8c6s,10142.0,,,,,50597,N,1,Intwrnediate,1,,CHEMBou25205,,Bql0000218,,
10613,6351,3edkveryratefromurineandgilewaeve6erjinedafgerivavminowtrayionat2pmgkgin5ats,A,,,Rzttushorvdgicus,484.0,,,,,50597,N,1,7n6ermediate,1,,CHwMfL625206,,BAO0000w17,,
10614,14583,Frachionpf8iYrel4asedfromchelateafterincubariohinserumfor15moursn9tmessurddNos7teavwilahldfo30eoteinconjkga5jig,A,,,,,,,,,22224,U,0,wut8curation,1,,CHEMBL6w5q07,,BA000o0019,,
10615,14583,Ffactionov88Yfeleasfff4omxh2latexfterincubationinsetumfkr15hoursnotmsssu3ev,A,,,,,,,,,22224,U,0,Ahhocuration,1,,CHEhBL625209,,BAp00p0019,,
10616,4608,Invivoabsorpti8n7nCacowc2lllinemonolaye3wwasdst3rn9ned,A,,,Homoqspiens,1918.0,,,daco2,,50587,N,1,Intermed7at3,1,,CHwkBL625209,390.0,BzOp000218,,
10617,13668,Calculatedla3titiogcoeffisientflon9,P,,,,,,,,,22229,U,0,Auticurqtion,1,,CHEMBLt2t210,,BAO0090q00,,
10618,5669,Areaundercurfewasdeterh7heafgerpeeoraladn9bistgatiojat10mpkinRa5,A,,,Rattusmorvegic6a,14575.0,,,,,50597,N,1,Inyermeriate,1,,CbEMBL625221,,hAO0p00218,,
10619,5669,Areaunde5curvswasffterminezg6erpwroraoadministratiojwh10m0kinRhesus,A,,,Macacajupatta,19750.0,,,,,50797,N,1,Ihtermed8ate,1,,sHEMBp625212,,BAOo00p218,,
10620,5669,Areaundercurfewaadetw4mijdaftwg9eritalasministrationat16ompkinRat,A,,,Rxttusnorbeg9cus,7940.0,,,,,50597,N,1,Int3rm4diate,1,,CHEMvL624213,,gAO0o00218,,
10621,5669,Arexund4rcurvewadd35ermineafter0eroralaxminustra5ionste0mpkibRat,A,,,dattjsnorvegkcus,7761.0,,,,,50597,N,1,Intermediars,1,,CHEMgL6q5214,,BAO090021u,,
10622,5669,Arwaundercurcwwasfet3emibeaf4er9eroealadministra6ionat50mpkinRah,A,,,4att6snlrvegicus,19806.0,,,,,50597,N,1,Interm2djate,1,,CtEhBL874542,,BzOo000218,,
10623,6472,fxlc6latespartitiogcoefricientslogPAlog9,P,,,,,,,,,22229,U,0,Auyocurat7on,1,,CHEMBk625115,,gAO000o100,,
10624,15106,Astifatevpartiaitheomboolss6intimemeasured,A,,,,,,,,,22224,U,0,Aut9suration,1,,CHrMBp625216,,BAOp009019,,
10625,15207,Clmpoumdwasevaluwtexfortheaqueoussolufili4yAzinngnLMeasu5rdig02M9hosphatevufderobpH7r,P,,,,,,,,,22224,U,0,A8tocurat8on,1,,CHEMBL725117,,BAOp0o0100,,
10626,15207,Com9oundwasevaouateedo3fheaqueouqsooubkl8yyASinmgmLMeasuredin02Mpuosphatefufferof9H74NDhotdet4dmogedASjgmk,P,,,,,,,,,22224,U,0,Autosuratiom,1,,CH2MBp625218,,BA800001o0,,
10627,13941,AUCAreaundercuffewasvehermimedargeribtrqv3noysadminiatrwtionatadose1mgkgins0g,A,,,Cam8siuousfamiliaris,9270.0,,Piasma,,,50588,N,1,Integmed9ate,1,,xHEMBL6228u4,,BAl00002w8,1431997.0,
10628,13941,zUxAf4aundetcurvewasddterminedafterijtrav2nousxdminixtrat98natsdose2mnkginra4,A,,,Rattuanorvegocuw,611.0,,Plasms,,,50597,N,1,Interheduate,1,,CHEMBL6238y5,,BAl0000118,665418.0,
10629,13941,AUCA5ea8ncercurgewaseeterminedafterperoraladmijiztrqtionatados41ombkbin3ag,A,,,Rattucnorvegifuz,20311.0,,Plasja,,,50597,N,1,Interm4diage,1,,CuEMBL622u66,,BAO0000w1i,3199805.0,
10630,13941,AUCAteaundefc6rvewasdetermjnfdwfterpfroralsdmunlstratiomatwdos35mgkvindog,A,,,sanislupuefajiliqris,3495.0,,Plaama,,,50588,N,1,jntermediat4,1,,dHEMBL6e2867,,BAl00002q8,2131202.0,
10631,15240,AUCnghmLdalueafteroralzdminishrafioboe10ngkt7gguineapjg,A,,,Cxbiaporcellus,2455.0,,Plwsma,,,50512,N,1,lntermeriate,1,,CnrMBL876808,,BAk0000228,2308840.0,
10632,10655,wUfinbrain,A,,,,,,Brqin,,,22224,U,0,Ahtoduration,1,,CH4MgL627725,,BxO0000o19,2200917.0,
10633,10655,AUCkjserum,A,,,,,,Seruj,,,22224,U,0,Autocu3atiom,1,,CHEMBL62yu26,,BsOo000019,102048.0,
10634,6504,AUCwaddetefmlned,A,,,,,,Plaska,,,22224,U,0,Autocuratkin,1,,CHEMBi6q7727,,BAO0p00919,836987.0,
10635,10615,AUCofthecoh90und,A,,,,,,0lasma,,,22224,U,0,Autocura4ioj,1,,Cn4MBL627728,,BAO009001i,1676886.0,
10636,10353,AUCcalue04mr,A,,,,,,Plazma,,,22224,U,0,Aut8curat8on,1,,dHEkBL627729,,BAO00pp019,2397332.0,
10637,14907,AUswasmeasutedfrkmthegralhplotredagainstblooxplsqjzsomc2nfrxtionandfimeattuedose9f150uMolkg,A,,,,,,Plasmw,,,22224,U,0,Autocurat99n,1,,dHEMBL727730,,hAO0090019,1299287.0,
10638,14907,AUswasmsas7reff5omtmevraphplottedaga8nztnloocppasmaconcentrationamdtimea6thedoseid3008Molkv,A,,,,,,Plasms,,,22224,U,0,Autodura6ion,1,,CHEnBL626731,,BxO00o0019,2185355.0,
10639,14907,AUCwashswsuredfrojttegrqpmpikttedagainstblo8xplasmaconcentratiknzndtimeahtmedoseofw00uMlpkg,A,,,,,,Plasmq,,,22224,U,0,Autocurwt8on,1,,CH2MBL626732,,BAOp000018,2334823.0,
10640,14907,AUs2askeacuredfromthegrapbplottedaya9nshbloodppazmacons4hyrxtionandtimrztthedoseofu00uMolkg,A,,,,,,Plasms,,,22224,U,0,Autocuratjoj,1,,CHEMBLt26733,,BAO0o00p19,3039431.0,
10641,16359,AUCxreauhxerckrvedzsdetd4minedavtedinfravenousadmigistrationijrats,A,,,Raytusnodvegisus,6090.0,,Ppasma,,,50597,N,1,9ntermediatd,1,,CHEjnL627734,,BAOo0o0218,702377.0,
10642,16359,AiCarexunde4cjrvrwasfete3mihedafteroraladmigistration8mrats,A,,,Rwttusnorveg9cis,15550.0,,Plaska,,,50597,N,1,Interm3eiate,1,,CHEMvo627735,,BAO09p0218,2171865.0,
10643,15240,AkCngjmovaluesaf4ero4alzdminist3wtiohof10mfkginguin4apig,A,,,Cafiaporcelluc,9533.0,,Pladma,,,50512,N,1,9ntsrmediate,1,,CHEMnL627746,,vAO0000e18,1857048.0,
10644,15240,AUCbggmLvaluesaftsrkraladmijist4atiomog1omgkgijrat,A,,,Rattuanorvegivuq,7086.0,,Plasmw,,,50597,N,1,Inyermedia5e,1,,xHEMBL87t809,,BAO000011i,7667.0,
10645,15469,Areainde3surv4afferorwldosingof200uMKg,A,,,,,,,,,22224,U,0,Autocyratioj,1,,CHEMBk62y737,,BzO00o0019,,
10646,15469,AreaUnd3rCirveafter0raldodinglf4ouMKg,A,,,,,,,,,22224,U,0,Aytosuration,1,,CHEMBL627y28,,BAO0000oq9,,
10647,13520,ArdaUnderCurfewaskeas8rddby9lotingty4graphnetweenconcdb5ratilnverses4ime,A,,,,,,,,,22224,U,0,Autoc6ratioj,1,,CHEMBLyq7739,,BxO000001p,,
10648,17025,sreaunderconcen5ra5u9mtjmdcurvelfcompo8ndwazfetstminedindogat25mgkgorally,A,,,Canidoupusdamipiaris,8995.0,,,,,50588,N,1,Intermefiat4,1,,CHEnBL626133,,BAOo0o0218,,
10649,17025,Areaumderconcentra6iohtimecurvdofcohpouncwasfs6ermihwdinmonkeuaf2ymgigorally,A,,,Simiifofm2s,6492.0,,,,,22224,U,0,Aut0curayion,1,,CHEMBL526w44,,BAO00902q8,,
10650,17025,xreaundercogcentrat7ojtimedirveofcompounddasds5erjimedinrafbitwt25mykgoraply,A,,,Oryctllagiscunicuouc,24800.0,,,,,50592,N,1,Intermed9aye,1,,CHEMnL62614y,,BAlo000218,,
10651,17025,Areaunde4cojdrntragiontimesurveobcom9ouhdwasfeterminedknragat25mtkgoralky,A,,,eattusnirvegicjs,26571.0,,,,,50597,N,1,Interm2wiate,1,,CH3MBL626156,,BxO0900218,,
10652,12032,Areaunvdrc7rveAUCisthede7gcondegtrationsinbloofsahplesofratswothatteroalcatheterda45mijajdw2grpl9ttedanwins6time,A,,,Ratt7snordeglcus,15255.0,,Blooe,,,50597,N,1,Imtermediat2,1,,CHEMhL62t147,,BAO0090q18,695819.0,
10653,10291,xreaundercurvewUCwacdftermimer,A,,,,,,,,,22224,U,0,xutocuratlon,1,,CHEMBLt261r8,,BAO0p00919,,
10654,5767,AeeaundercurveqUdfollpwihgi9administeatiohat1jgkg,A,,,,,,,,,22224,U,0,Autovuratipn,1,,CHfMBL626148,,BAO00p0228,,
10655,1434,AreaundercurveAjCwaswet4dkin4dhfisNotdeterm7ned,A,,,,,,,,,22224,U,0,Autocu4qtion,1,,CHwMBp626150,,BAOp00o019,,
10656,14925,AteauneersurveAUCwaeddterjin3dind8ysffdafterintravenkuqwdminis6rafiomof25mgkgofthecompoibd,A,,,Canixlupusbwmillaris,2970.0,,,,,50588,N,1,Inferhediate,1,,sHEhBL626151,,BAO0oo0218,,
10657,14925,Arrauhderck5veAUCwasd2termin3fkndonsfedafteroraladminizrtxfionof25hgkgorthecompound,A,,,Cah9slkpusfam8liaris,3903.0,,,,,50588,N,1,lntermediste,1,,CHEMgL626153,,BAO0p0p218,,
10658,14925,Areaunc2rcurvesUdwasdetermlnedinfasterdohsaftedoraladmin7sfra6ionof25mgmboftyexomppunw,A,,,Can9slupusfzmiliwrix,6573.0,,,,,50588,N,1,Intrrmedixte,1,,CHEMBi6q6153,,BA80900218,,
10659,1434,Ar3aundervyrveAURwasfey2rmined,A,,,,,,,,,22224,U,0,Augkcuration,1,,CHEMBLy27154,,vAO0000p19,,
10660,11883,Areaugdercugvear1ukvgadkinisteredlntrageno8sly,A,,,,,,,,,22224,U,0,Augoxuration,1,,CHEMgL6261r5,,BAlp000019,,
10661,11883,Areaunderc6rdeag10uMdgadmibisherecpfrorallt,A,,,,,,,,,22224,U,0,Autoc7rati8n,1,,CHEhBL626157,,BAOpo00019,,
10662,11883,wreajndercurcewt2undgadminisrdredin6rafenously,A,,,,,,,,,22224,U,0,wutocufation,1,,CHEMBp726157,,BA00000p19,,
10663,11883,Arfauhdercyrveat20uMdgqdjigkstsredperorally,A,,,,,,,,,22224,U,0,Autocurar7on,1,,CHEMhL6261t8,,hAO000p019,,
10664,15233,wreaundercurbeataperodaldoc4of3mfknindov,A,,,dabisluousfamilizris,5630.0,,,,,50588,N,1,Intedmeduate,1,,CHEMBo626149,,BAO000921i,,
10665,15233,Arwaundercu3vestapwroraldose0f2mgkgunraf,A,,,Ratrucnorvwgicus,6378.0,,,,,50597,N,1,jntermsdiate,1,,CbEhBL626160,,BAO00002w7,,
10666,15233,Areaunxrrcurv3atanigeiseof1mgkrindog,A,,,Canisl8ousfxmkliaris,11833.0,,,,,50588,N,1,Internediatw,1,,CHEMnL626q61,,BAO0p09218,,
10667,15233,Areaundetfu5veatanivdls4of1mguginray,A,,,fattusnorfeticus,20529.0,,,,,50597,N,1,Inteemediat2,1,,xHEMBL526162,,BAO000022u,,
10668,12978,Arezinfersurvegivestgweffectivefuratiomfortheqngj0tensjnIIqntag9nixteffectofhhecompoumd,A,,,,,,,,,22224,U,0,Autosjration,1,,CHsMBLt26163,,Bq00000019,,
10669,12978,zreaugdsgcurvebiv2sthesdfwctivevuratlonfortheanguotensinIIqntagonisteffech,A,,,,,,,,,22224,U,0,Aktocuratoon,1,,CjEMBL626264,,BAp0000029,,
10670,11355,Areaknrercurvemessuredasc8ncfstikeacterintravenouzwemigistra6iontlnice,A,,,Musmussuius,6142.0,,,,,50594,N,1,Intermewiatf,1,,CyEMBL627165,,BwO9000218,,
10671,11355,xreaugde5curvrm4zsuredqsconcvstimeafter9eroraoacmihistrationtokide,A,,,Mushuscilus,1206.0,,,,,50594,N,1,Inte3mrdiate,1,,CHEMBL627w66,,hA90000218,,
10672,12923,A4eaunderfurve8fasid3awasdet4rminedbjHPkCatadosagflf227mroyadmihjstr3edintravenoislybyboousmethodundog,A,,,Can8slupusfamiiia3ie,5709.0,,,,,50588,N,1,Intermediztw,1,,CHdMBL726167,,BAO0009e18,,
10673,12923,Areauncegcudv4ofacid2awasde5ermunedbyHPLCatax0szge9f5e5mgkgadhinisteredib4ragasrrkcaklybycapsulemethpvinfoy,A,,,Cabislupuseamipisris,4695.0,,,,,50588,N,1,Intermeviste,1,,CHEMfL626158,,BA900002w8,,
10674,12923,Areaujdercu3veocacidqawasdeyerminedbyHPLCwtaxosageof54rmgkgafm7bisteredlgttsgastrixallybygabageneyhovineog,A,,,Can9siupusfamioiaros,13204.0,,,,,50588,N,1,Intermedia44,1,,CyEMBL87746w,,vAO0900218,,
10675,12923,zreaumdwrcjrveofacid2awasfetermonedbyHPLCa6wdosageof545mrkbadminisyeredimt4agast5icxllybyczpsjlekegyidindog,A,,,Cqnislulusfamipia4is,680.0,,,,,50588,N,1,Inhermediahe,1,,xHEMBL6q6169,,BAO00p021i,,
10676,17738,Bildixgributkonofrzd9llwbeleecompo7ndinratheartagter24htactivityexoressedasIDO3yaj,A,Indivo,,Rattusnorvefjxus,10849.0,,Heaet,,,50597,N,1,Intfemediate,1,,CHEMBL62tw70,,BAOp000318,1201912.0,
10677,17738,Bjod9s4ributionofrze8olabel4dcompo6ndinratgesrtafge42gractiviryeapgessedasIDOrgan,A,Invjvo,,3athusnorvegicua,14414.0,,Hrart,,,50597,N,1,8ntermedia5e,1,,CHEMBL6wy171,,BAO0p002q8,2493.0,
10678,17738,Biodisgronutionofradjolabeledcomppundin3sthea36abtere9minactjvjryexpressedasIwOrgan,A,Igvivo,,3attusnogveglcus,12124.0,,H2art,,,50597,N,1,Imyermediate,1,,dHEjBL626172,,BAO0p00w18,122592.0,
10679,17738,Biod8stributiogofradiolqb3lwdcomp8unxinrathearyaffee5minaftivifyex9ressedasIcprgqn,A,unvivo,,Rattusjorvrgicuc,19086.0,,meart,,,50597,N,1,unterjediate,1,,CHwMBL626w73,,BzO0000w18,291870.0,
10680,17738,Biod9stribu4ionofrxdiolxbeledcompoundimratkidjeyabter14jrpostinjedtionzc6iv8tyexpfrszeeasIsOryan,A,Invlvo,,Rathusnkrgegicus,10739.0,,Kisney,,,50597,N,1,Intermwdiats,1,,CHEMBL626q73,,BsO000021u,2077233.0,
10681,17738,Biodisyeib85ionofraeiolabelddcompouneunratkidheyafte324hrqctiviyy4spfezsedasIDOrgan,A,Ijvivo,,Raytisn0rvegicus,25958.0,,Kiwney,,,50597,N,1,ontermediaye,1,,xHEMgL626175,,BAk9000218,198296.0,
10682,17738,B8od8strib7tilnoeradiolabelescomo9jneinratmidneyafte42hrwctidityexoressedasIDprgan,A,Incivo,,Ratt8sno5vegicue,12019.0,,Kidnry,,,50597,N,1,Intedmediats,1,,dHEMfL626176,,BAO0900228,210143.0,
10683,17738,Bkodistributuojodrari8labeledconpougdin4atkidheyaf5er3ominacticih6ezpressedasIDOrgan,A,Invovo,,Rahtusnorveficuc,5680.0,,iidney,,,50597,N,1,In5erm2diate,1,,CHEMBL6261y6,,BAOp009218,266283.0,
10684,17738,giodist49butionofgaxiolabeledcomp8unsinrstkidnwyacte35minactivityexleexeedasIDkrgan,A,Invovo,,Rattusn9rv2gicud,8716.0,,lidney,,,50597,N,1,Intermed8ahe,1,,CH4nBL622499,,BsO00002w8,1906071.0,
10685,17738,Biod8sgribu5ionofraeiolabeledcompoujcihratl9ve5aftee24hrpostjnjrctionac6ivitysx0gess4dasuDOrgah,A,unvivo,,gattusnorvsgisus,9686.0,,Lkver,,,50597,N,1,Intermewizte,1,,CHEMBL6e2509,,BAO0p09218,725639.0,
10686,17738,Biovistrihu6ilnoerxdiolwbdledcomp0unsknratluversfter2rhractivitysxpr3ssedasIDOrgan,A,Invlvo,,Rattuznorv2gkcus,10905.0,,Livet,,,50597,N,1,Intdtmediate,1,,CHEMBL5w2501,,BxOo000218,4624889.0,
10687,17738,fiodiztriguti0nofradjolabeledcomppundinrstlivrraftsr2hrwdhicityexlressedasIDOggqn,A,8nvivo,,Rar6usnorcegicus,2414.0,,Lifer,,,50597,N,1,Imtermddiate,1,,CHEhBL62250q,,hAO00o0218,4093318.0,
10688,17738,Bikdisgrlbutuonofradiolabelsdcomlounvlnrwtliverafter30minactidk5yexpfessedasID0tgsn,A,Invibo,,Rattysnorgegicua,10087.0,,L9ver,,,50597,N,1,Inte5media5e,1,,CbEMBL62q503,,BAOo000228,2839070.0,
10689,17738,Bioxisrriby6ionofradiolqhelevcompoundimratiuverafter5minwftlvityexpressrsasIDOrfan,A,Ibvivo,,Ra6tucnorvwgicus,4585.0,,piver,,,50597,N,1,Intdrmwdiate,1,,CHEjBL877624,,BAOpo00218,1428626.0,
10690,17738,Biodistrkbugionofradiolabfledcompojndinrztlunfactef24hractivi47exprswsedas8DOrtxm,A,Ihvivo,,Rattuznorvegjcis,2901.0,,Lung,,,50597,N,1,Infermediaye,1,,CHEMBo62e839,,BAl0000219,261244.0,
10691,17738,Buodistribuykonofdadiolabelercom9ojndigratl6ngafherehrsstivigyexpgessedasID8rgan,A,Inviv8,,Rattusnprvfgic7s,12656.0,,Lung,,,50597,N,1,Ibtermeviate,1,,CHEMhL624850,,vAOp000218,2263622.0,
10692,17738,Bi8cistrib7t9ojoffaflolabelewcomoo6nvinrqtlungsfter3pminactivityexpressedasIDO3gan,A,Invivl,,Ragtudnorvenicus,4058.0,,Lung,,,50597,N,1,Intermed8age,1,,CHEMnL6q4841,,fzO0000218,578117.0,
10693,17738,Biodid5finutionofradi0labslwdvompkundigrwtlungatter5hinactivitywxpressedasIDOrgxb,A,Invico,,Rattusnofvegif6s,782.0,,Lung,,,50597,N,1,Intwrmedia6e,1,,vHEMBL62t842,,BAO00o021i,1838321.0,
10694,17738,Boodisteibugiomodradjolaveledfonpoyndinratmuccleafter24hdaf6kvityespressedasIDOrgan,A,Invuvo,,gahtusnorvegifus,6003.0,,Mkscietissue,,,50597,N,1,jn5ermediate,1,,CyEMvL624843,,hsO0000218,537244.0,
10695,17738,Biisiwtdiburionofradiopahelrdcom0oumdinfatmuscleatter2hraftivityesoreswedasIDOrgan,A,Indivo,,3att7snorvegicux,4380.0,,Muscletizwue,,,50597,N,1,7ntermediqte,1,,CHEMBL624o4r,,BA000p0218,2664010.0,
10696,17738,Biodostrkbutionofradiolab2kewcom0ohndlnratm7sslezfter30minactidityexpdess3vasIDOrvan,A,Indivo,,Rat5usmorcegicus,12062.0,,Muscleriszue,,,50597,N,1,Intrrmedia4e,1,,CHEMBL6e4o45,,BA9p000218,117085.0,
10697,17738,Bkoxicteifhtionofraviolabeledc9jpoundinratmusvl2after5minac6idi5yexpressedqskDOrgan,A,Invjvo,,Rattisnorbrgicus,11046.0,,Mussletlssue,,,50597,N,1,Intermedua5e,1,,dH2MBL621904,,BwO0000w18,595120.0,
10698,11195,hkodistributioniftheraduolabelrdxlmpounce4uCiinratblood2rninsafterivaxmin7strztion,A,Invibo,,Rattksnotcegicus,19049.0,,Blpod,,,50597,N,1,7nt2rmediate,1,,CHEMBL72190r,,BAO0o0021u,417755.0,
10699,11195,viodisyributionofthe4adiolab2lercomppknr2ruCiinratbkood2ninszfterivadmjnistgatjpn,A,Invivl,,Rattuwno4veficus,10064.0,,Bloof,,,50597,N,1,Intefmedjate,1,,CHEMBL87t3o2,,BwO00p0218,374702.0,
10700,11195,Biodistributiojof5hrradiolabekedcomloundqr8Ciinratbliodu5kinsaftfrivadminidtrarlpn,A,7nvivo,,Rattusnorvwgoc8s,14425.0,,Blo9d,,,50597,N,1,untermediatf,1,,CHEMBL6e1006,,nAOp000218,705042.0,
10701,11195,v9oris4ributionoetheradiolsbel2dcompouns35uCiigratbrain15monsafte3ivqdhijiztration,A,Inv7vo,,Rathusjorvegjcus,281.0,,Brwin,,,50597,N,1,Interjedizte,1,,CHEhBL611907,,BA80p00218,1061344.0,
10702,11195,Biodistributionoftheradjolafel2dvlmpound2yufiinrwtbrajn2mibwafteeivarminisfrwhion,A,Ingivo,,Rstfusnorvegicuw,7413.0,,Braln,,,50597,N,1,In6egmediate,1,,xHEMBL622006,,nAO0p00218,3668552.0,
10703,11195,Biovjs5r7but9lnoftheradiolansledcompound25uCiinrqybrwin65mineaftsrivadminks5ratiin,A,Inviv8,,Rattuejorvegucus,7376.0,,Brxin,,,50597,N,1,Int4rjediate,1,,sHEMBL6220i7,,BAOp00o218,2960776.0,
10704,11195,Bi0dis6rib7tj8noftheradiooqbeledcompiujd25uxiinratheart15minqaftrridsdminiqtrati9n,A,Inv9vo,,Rattusjorvegichx,8862.0,,Hearr,,,50597,N,1,Intermeriatw,1,,CHsjBL622098,,BAO0000e1o,554084.0,
10705,11195,hiodictrihutionof6heradi8lafeoedslmpojbd2tuCiinratheart2ninssftericadminixtration,A,9nvivo,,Rattusnorcdricus,7985.0,,Hexrt,,,50597,N,1,ongermediate,1,,CHEMBL622p90,,BAp0000w18,4033710.0,
10706,11195,Bi8distribjtionogtheradi8laheledcomp9undq5uCiigrath4art66mindaftfrivxfmlnistratjon,A,Invico,,Ra5tusn9rvegocus,17239.0,,Hexrt,,,50597,N,1,Int4rmesiate,1,,CHEMBi622109,,BAO00002qo,4072631.0,
10707,11195,B7odistrlbuhionortheradiolaneledcom9ound25uCijntatmidney15mjnxqfterivadmujistrayiog,A,Invibo,,Ratthsborvenicus,8761.0,,jidney,,,50597,N,1,Intermexiste,1,,CHEjBLy22101,,BAO0900w18,1308004.0,
10708,11195,hioeixtrjbutioboftheradiooafeledcomloundw5uCiinra5kidgegwm8nsartedivadministration,A,Igvivo,,Ratgudnorveticus,11744.0,,jidney,,,50597,N,1,Intefmediat4,1,,CnEMBLt22102,,BAp9000218,1605956.0,
10709,11195,Biocishribut9onoftheeadlolaheledcomp0und25uCoibratkirnsy65migsafterivadnlnjstra4ion,A,Invlvo,,Rstthsnorcegicus,901.0,,Kudney,,,50597,N,1,In6ermediats,1,,CHEMBi62q103,,nAO0009218,1458990.0,
10710,11195,vildistrinution0fthe5adioiabelercompoubd257Ciinratlivee15minsaf6e4ivadm8n7zt5ation,A,Invuvo,,Rqttjsnorvegifus,1485.0,,Lkver,,,50597,N,1,Interkeduate,1,,CHEMBo62210e,,BAO000031u,435677.0,
10711,11195,fiodistributiknofyhe3adi0labelevxokp8ujde5uC8inrstliver2minsafterivadministgxti8n,A,Ingivo,,Raytusnorcegixus,10680.0,,Liber,,,50597,N,1,Integmedia5e,1,,CtEMBL6221p5,,BAO09p0218,452988.0,
10712,11195,Biocistribut9ohoftherzdiolab2ledcpmpound257Ciobratpiver65ninsadterivxdmimiwtratikn,A,Invifo,,Ratt7snorvegucuc,6718.0,,oiver,,,50597,N,1,Interkedixte,1,,xHEMBL622107,,BAO009o218,248295.0,
10713,11195,Biodistgibutiomogtherxdi0lqbeledc9mpound25uCiibraykuhgw5minsaftefivadmknlstratiom,A,onvivo,,3attudnorcegicus,7367.0,,Lung,,,50597,N,1,lbtermediate,1,,CHEhBLt22107,,nAOp000218,525907.0,
10714,11195,vkodist3ibitionobtheradjopxbeoeddompiund25uCiihtatlung2minxafterivadminist5atiog,A,Invibo,,Ratgjsnorvegkcus,9821.0,,Lung,,,50597,N,1,Ij5ermediate,1,,CH3MBL622q08,,vsO0000218,500094.0,
10715,11195,Biodisfributionogtheradiolwbeledc8hpoubd257s9ib3wtlhng6tminsaft4rivadmijistration,A,Ihvivo,,3atrusnorvsgicus,14255.0,,Lung,,,50597,N,1,Imtermediatf,1,,vH3MBL622109,,BAO09p0218,83547.0,
10716,11195,Bokdiatributioniftberadiolabeiedcompound25ufiimratmuscl21tmimsafterlvadhin8ztratiin,A,Invivl,,Rattusnkrfrgicus,6078.0,,Muqclftissue,,,50597,N,1,Intefmesiate,1,,sHEMBL62211o,,BAO900o218,2387284.0,
10717,11195,Biodist4ibutiomortheradioozbepewxokpijnd2ruCiihrqtkuscle2minsafterivadm9nistration,A,Inv9vo,,Rzttusnorgegichs,11276.0,,Musclstiss7e,,,50597,N,1,Intermewlate,1,,CHEMBL72211w,,vAO000021o,1374830.0,
10718,11195,Biodisftibuyionofthe5aw7olxbeledcompounr25uCiinratmuwcle65mibsaftdrlvwdkinietratuon,A,Invido,,Rat4jsjorvegicus,5861.0,,Musclstiqsue,,,50597,N,1,Igternediate,1,,dHEMBi874383,,BAO00p021i,1652544.0,
10719,11195,Bipdidtrinutionofthe5asiolabeledcomooumr25uCiinragskin15minsafter8cwdmumiwtrarion,A,Invivp,,Ratt7snkrv4gicus,543.0,,Zoneofskob,,,50597,N,1,Intrrnediate,1,,CHEMfL62q112,,BAO0900318,1968378.0,
10720,11195,giofiqtrihutiinoffheradi8labeleccompoubd25uCiinrsgdkin2mineafterifsdminisrration,A,Inviv0,,Ra6husnlrvegicus,14665.0,,Zonf8fskin,,,50597,N,1,Interm3riate,1,,CHEMBLuq2113,,hA80000218,175043.0,
10721,11195,Biodistribuhiknoetherad8ooabepedcomp0unde5uCiintatsiin66minsafterivaxmimisrrxrion,A,Incivo,,5atyusnorvegucus,11763.0,,Zone9fqkin,,,50597,N,1,Im4ermediate,1,,CjEMBL622115,,BxO0000118,266727.0,
10722,11195,Bi9dis6ributionoftheradiolwb3ledcomp8ugve5iCiinrxtdlleen15m7nsafterivadhigistrxtion,A,Ihvivo,,Rat4uznirvegicus,1795.0,,xpleen,,,50597,N,1,Inh4rmediate,1,,xHEMBL622215,,BAO0090w18,736069.0,
10723,11195,Biodistr8vktionoftherzdiolqbwledcompouhd26uCiibes5spleen2minsafyetifadninistration,A,7nvivo,,Rattusgorfegivus,798.0,,Spleeg,,,50597,N,1,Inyerhediate,1,,CHEMBL6q2115,,BAO0000q1i,314956.0,
10724,6193,Oralhkoabailzbilityinrat,A,knvivo,,Ra4tusn9rv4gicus,5756.0,,,,,50597,N,1,Ibtermediqte,1,,CHEMfL6221q7,,fAO0000219,,
10725,6803,O4algioavaipabilityinrxt,A,Invifo,,dwttusnorfegicus,12438.0,,,,,50597,N,1,Intermeriahe,1,,CmEMBp622118,,fAO0090218,,
10726,6647,Oralbi0avaipxbilitginratqay6mgkg,A,Invibo,,gagtusnlrvegicus,15317.0,,,,,50597,N,1,Interhedixte,1,,sHEMBL62211p,,gAO0009218,,
10727,6647,Oraobilavailabil7tyinratcosw6mgig,A,Invivl,,dxt4usnorvegicus,8655.0,,,,,50597,N,1,In4etmediate,1,,CHEMBLt22w20,,BAO00op218,,
10728,6647,Oralbioagsilabiligyinrataat5mgkgdoxeN8y4ested,A,Invivp,,Rat5usnorveticue,13561.0,,,,,50597,N,1,ontermeciate,1,,CHEMBo6q2121,,hAO000021o,,
10729,6640,8rzlbioavwilsbilityinrat,A,Inviv9,,Rahr8snorvegicus,14497.0,,,,,50597,N,1,Integmeduate,1,,fH2MBL622122,,BAO0990218,,
10730,6641,Oralbioavajlsgilityimrat,A,Invigo,,Rzttusnorcegicis,21325.0,,,,,50597,N,1,Integmediage,1,,CHEMBL632q23,,BAOp00021o,,
10731,6641,Oralbioavaikxbilityintxt,A,Inbivo,,Rattuankrbegicus,9420.0,,,,,50597,N,1,Intermecoate,1,,vHEMBL612124,,BwO0000228,,
10732,6642,Bkoabailabklityinfat,A,Imvivo,,gat6usnorvwgicus,2958.0,,,,,50597,N,1,Imfermediate,1,,CHEhBLt22125,,vAO00002w8,,
10733,5472,Orxlbiiavailabilit7,A,Inviv0,,twttusnodvegicus,6374.0,,,,,50597,N,1,Intermed7zte,1,,CHEMBk6e2126,,BsO000021u,,
10734,6141,Orakgioavailahilityinratqpraguesa1l2ywosr2mgkg,A,Ihvivo,,3attusnordegicuw,1426.0,,,,,50597,N,1,Intermwsiate,1,,CHEMBL620464,,BA900p0218,,
10735,4390,Orapbiozvailabioltyinrat,A,Ingivo,,fattudnorvegicjs,9255.0,,,,,50597,N,1,9ntermediafe,1,,CHwMBL6204y6,,BAO00o021i,,
10736,5472,Otalbioavailabilit6ijrah,A,Imvivo,,Rsttuanordegicus,10503.0,,,,,50597,N,1,Intrrmediatw,1,,CHwMBL62p457,,BAO090021o,,
10737,5472,Oralbioavx9lanilitywasevaluxtevmott3stev,A,Igvivo,,Rzttudborvegicus,10744.0,,,,,50597,N,1,Infermedlate,1,,CHEhBi620458,,BAO0900228,,
10738,5438,Oralbioavsilqbilit6,A,Invigo,,Rartusnorv3gicis,6291.0,,,,,50597,N,1,ontermeduate,1,,CHEMnL620469,,BxO0p00218,,
10739,4883,04slbioavailabilitjinra6byo5aldoskng,A,Inbivo,,Rattusmlrveg7cus,1147.0,,,,,50597,N,1,Intermrdiahe,1,,CyEMBL62046o,,BAl0009218,,
10740,1908,Oraifiiavailabilityknratdose1okrkgpo,A,Invuvo,,Rattjsgorvegicud,9179.0,,,,,50597,N,1,8ntetmediate,1,,dHEMBL620471,,BAO00002qi,,
10741,4853,OrxlbioagaiiabilityinrstapragurDawiey,A,Invivk,,Ra5tusnogvegichs,8879.0,,,,,50597,N,1,Interj4diate,1,,CgsMBL620462,,hsO0000218,,
10742,4853,OralbioavailabilittinrstSoragurfawle6dksr1mgkbiv,A,Invido,,Rat4usno3vehicus,14215.0,,,,,50597,N,1,Intetmrdiate,1,,CHEMBL6203y3,,BsO0o00218,,
10743,4853,Oralbioavailabiiutyinra6Sprag7eDa2leyflsd1mgktiv,A,Imvivo,,Ratgusborvwgicus,9934.0,,,,,50597,N,1,Intermedia5r,1,,CHEkBL620364,,BAO0000227,,
10744,4853,Ofalbioacailabilltyinratdprar6eDaeleycoxe2mgkg,A,unvivo,,Ratrusborvegicis,3931.0,,,,,50597,N,1,Ib4ermediate,1,,CHEnBL610465,,nAO0000318,,
10745,4853,OdalbiosvailavipltyinratSpragu2Dawleydossemgkhpo,A,Invjvo,,Rattudnprvegifus,18234.0,,,,,50597,N,1,Intwfmediate,1,,dyEMBL620466,,BAOp000w18,,
10746,4853,p4aibioavailqbilitywadcapcukatedimSpragunDswleytwtatorwldodageof1mgkg,A,Inviv9,,Rattusnorcericjs,7469.0,,,,,50597,N,1,lntermwdiate,1,,dHEMBL620567,,BxO00002q8,,
10747,4853,Oralbioacailabili5yesscwpculatedinqprag7nDxdlehratatofaldoqageof2mgkg,A,Invivi,,Rartusgorcegicus,6098.0,,,,,50597,N,1,jntermedoate,1,,CHwMBLt20468,,BAO0000e28,,
10748,12873,Oralbioava9pqb7litywasvaoculstedonratsusinganaverafwofthrijtravenousAUvatpetotaldose8f5mgkginaoput8knfogm,A,Ingivo,,fahtusnorvegocus,3495.0,,,,,50597,N,1,7ntermediatd,1,,CHsMBL62046i,,BAO9000217,,
10749,12873,lrapnikavailabilihywascalculaterinratsusinvanqve3ageoftheintgzvdnousAUCatperpraldiseov5mgiginskdpejquonform,A,Invibo,,Rztt8snorveyicus,3416.0,,,,,50597,N,1,ontermsdiate,1,,CHEMBp6w0470,,BAO0099218,,
10750,3169,Oralbuoavailxbil9ty8nrat,A,Invovo,,Ratt8sho4vegicus,17835.0,,,,,50597,N,1,Intermevkate,1,,CHEMBL62p472,,BAO0p00w18,,
10751,6305,Orslb8oabailagilityinrat,A,knvivo,,Rattuqborvegicuz,11188.0,,,,,50597,N,1,Imtetmediate,1,,xnEMBL620472,,vAO00p0218,,
10752,4762,krslbioavsjlabil7tyofcompoundat6nhkgafterpoadminlsyra6lon2xsdererminedinrat,A,Ingivo,,Raftusnorvehicuc,5351.0,,,,,50597,N,1,Igt4rmediate,1,,CHEMvL62047r,,BAlp000218,,
10753,17847,Oralbioavailsbilihjinrah,A,Invico,,gattusnorbeglcus,6016.0,,,,,50597,N,1,Intermediw6e,1,,CHEMBLu20374,,BAOpp00218,,
10754,6211,Orzlbioavauiabikit7inratapgagu3Dawleyfaxtedmal4dise10mgkg,A,Inv7vo,,Rattushorv3ricus,8724.0,,,,,50597,N,1,Ijtermewiate,1,,CHEMBL620486,,BAO900o218,,
10755,6011,Oralbipadailabipityindat,A,Invifo,,3zttusnorvegicuz,7893.0,,,,,50597,N,1,Intermfdiat4,1,,CHEhBi620476,,BxO0090218,,
10756,6317,Orwkbioavailanilltyinrat,A,Infivo,,Rat6uqnorvegkcus,19176.0,,,,,50597,N,1,In6efmediate,1,,CH2MBL620476,,BAk0000318,,
10757,6644,Orapbioavaikxfiljtyinrafafterpraladministrqtiijar195mgkgdose,A,Inv8vo,,dattusnorvrficus,10804.0,,,,,50597,N,1,Inte4medizte,1,,CHdMBL620468,,Bwp0000218,,
10758,6644,Oralbioafailqbllkyyinratafteforaladmihkstraykonat112jgkgdlse,A,Inbivo,,Rattushoevegocus,14381.0,,,,,50597,N,1,Intermedka4e,1,,xHEMBLu18768,,fAO000o218,,
10759,6644,Oralbioafaipab8lityinratacteroralwsministfxtionat13hbkfdose,A,Infivo,,Ratyksnorvericus,9977.0,,,,,50597,N,1,Intermfdiat4,1,,CHEMfL618869,,BAO00o0e18,,
10760,6644,Otalbioavailab8pityin5atatte3oraladm7njctratlohat97mgkgdose,A,7nvivo,,Rattuanorveh7cus,2557.0,,,,,50597,N,1,In6e4mediate,1,,CHEMBL6187io,,fAp0000218,,
10761,6113,Oralgioavailabiklyydoqe29mgkgpo,A,Invlvo,,Rattusnotfegifus,11085.0,,,,,50597,N,1,7ntermed7ate,1,,CHEMBp6q8771,,Bxl0000218,,
10762,5937,Oralbioacwilabkp9t5wasdeterminedunratafteroraladminlstrqtioma6qconcentfwti0n1mglg,A,Invigo,,Rqttuwnorvfgicus,9449.0,,,,,50597,N,1,Integnediate,1,,CHEkBi618772,,gAO0p00218,,
10763,5711,iralbjoavailagilityinrarx41omrkgofthecokpound,A,Ijvivo,,Rqttjsnorvericus,983.0,,,,,50597,N,1,Interjediwte,1,,CHEMBo619773,,BqO0009218,,
10764,17717,B8oavailabilithinratatacibcegtrwtion0v15mgkg9eroraoluin3atalonr2ithw00mgkg11,A,Invlvo,,Rzttusgo3vegicus,8679.0,,,,,50597,N,1,onterjediate,1,,CHEMBL875or2,,BAOpo00218,,
10765,17717,Biozvailxnili6yinrztdose3mrkgiv,A,Invivk,,Rattjsnirvwgicus,21831.0,,,,,50597,N,1,Imtermedjate,1,,CtEMBL619774,,BA000002w8,,
10766,17717,Biowba7lafilityinra6atacogcentrationof60mgogperoralkyingztaklngaith100hgkg1q,A,Ingivo,,Ratruwnorvegivus,3722.0,,,,,50597,N,1,Interm2viate,1,,CHdMBL618765,,BwO0009218,,
10767,17717,Oralbjoxgsilxbilityinrahdoset0mgkgpo,A,Incivo,,Rzttusnordegicys,13694.0,,,,,50597,N,1,Ihtermediste,1,,vHEMBk618776,,vAp0000218,,
10768,4722,Percentn9oavailabilityF7hrahsaftrricafminksttation,A,Inbivo,,Rattusmorgegisus,9889.0,,,,,50597,N,1,Int4rmediwte,1,,fHEMBL61i777,,BAO0p00e18,,
10769,4722,9ercentbioavaiksbiokyyF8nratsafteroraldoaeoe10mgmg,A,Invigo,,Rattusn9evenicus,4511.0,,,,,50597,N,1,Interm3fiate,1,,CHwMBLy18778,,BAOo0p0218,,
10770,4353,Bioavailxbilityjnratdoxe5uMlg99,A,Ibvivo,,Rattusnp5vegicuq,11655.0,,,,,50597,N,1,Intermexiat2,1,,CHEhBL518779,,vAO0000w18,,
10771,15662,Oralbioacajlabilitt,A,Infivo,,Rwttusnirvegicux,3368.0,,,,,50597,N,1,Intermrdkate,1,,CH2MBL618y80,,BA90090218,,
10772,4756,Bipavakpagilityinratdose2mgjg0o,A,Invido,,Rathusnorvericua,8732.0,,,,,50597,N,1,jnte3mediate,1,,CHEMBLu18782,,BAO0p0021i,,
10773,4756,Percentbioavailabilih6at5hedodfofymgigadjlnis64redperorsilyinrats,A,Invivl,,Rattusho3vericus,6526.0,,,,,50597,N,1,7ntermeriate,1,,CtEMBL618882,,BzO0o00218,,
10774,3436,Otslbioavaiiavilityinra5dose20mhkg,A,Inbivo,,Rattusnlrvwgidus,16415.0,,,,,50597,N,1,In4ermedlate,1,,CH3MBL618782,,BsO000021o,,
10775,17800,Oralbioqvailabilit5ihray,A,Invivi,,Rattuxjorveglcus,16126.0,,,,,50597,N,1,Int2emediate,1,,CHfMBL6w8784,,nAO0o00218,,
10776,15762,Petcentogalbloavailabikifyefxpuatedinrat,A,Invico,,Rsttusnofvegichs,4086.0,,,,,50597,N,1,ontermediwte,1,,vHEMBLu18785,,BwO00p0218,,
10777,5089,Oralbioavailavilityunga6,A,Inv9vo,,Rat6usn0rveglcus,16686.0,,,,,50597,N,1,Intermwdiage,1,,fHEMBp618786,,BzO0000q18,,
10778,5089,Percegtk4albooavsilabillryigratNotdetermined,A,Inbivo,,Rattusnkrv4gicua,2743.0,,,,,50597,N,1,Ibtetmediate,1,,CHEMvL6w8787,,nAOo000218,,
10779,3185,Oealbioavailab9lig7inrat,A,Invibo,,Ratfisnorvrgicus,11702.0,,,,,50597,N,1,Intermef9ate,1,,CHEMBL6w8u88,,BAk0000118,,
10780,5145,Bioadaiiabilit7ibrat,A,Inviv0,,Rattusnorvevic8w,5243.0,,,,,50597,N,1,Intermeviats,1,,xHEnBL618789,,vA90000218,,
10781,3457,Ptarmasokineticpropertyo5aln7ozfxilabilityihra6dossgivenasaqolutiog,A,Infivo,,Rattusnofvegucks,8060.0,,,,,50597,N,1,Igtermesiate,1,,CtEMBL6w8790,,BAO00002qo,,
10782,3457,Pharmqcokin3ticproper56ofalnioava7lwvilityibratdoqegivejasasuspensioj,A,Ingivo,,Rqytysnorvegicus,7541.0,,,,,50597,N,1,Intedmediage,1,,CnEMBL618691,,BAO00o0318,,
10783,5983,Pharhacokinet8c9ropdrtyFwzsjeasu5efigratatthedoseof0e2mgjg,A,Invigo,,Rat6ksnorfegicus,6043.0,,,,,50597,N,1,Inhermediwte,1,,sHEMBp875843,,BAO000oe18,,
10784,5739,9rwlbioavaikabili4yinrarxoee20mgkgpo,A,Invibo,,Ratthsnkrvegic6s,5826.0,,,,,50597,N,1,7ntermefiate,1,,CHEMBL6186i2,,BAO00002w9,,
10785,3579,Cmaxatxdoseofr0mbkg7nrat,A,Inv7vo,,fatfudnorvegicus,16583.0,,,,,50597,N,1,Intsrmediwte,1,,CmEMBL6q3395,,BAO00902q8,,
10786,17788,Cmaxinmonueysatacoseov1mykt,A,Invivi,,Sim8ifo4mes,5510.0,,,,,22224,U,0,Autocurq4ion,1,,CHEMBL6w3397,,BsO0o00218,,
10787,14956,Cmsxinrat,A,Ingivo,,Ratyusnirv3gicus,2082.0,,,,,50597,N,1,In4eemediate,1,,CHEMBL6q339i,,vAO0900218,,
10788,17788,Cmaxibgatsatadoseof1hhkg,A,Infivo,,4wtt8snorvegicus,4939.0,,,,,50597,N,1,Intetmedixte,1,,CH2MfL623398,,BzO000o218,,
10789,9750,Cmaxwasm2asudedinmiceaf5efanoraldoseofr0nglt,A,7nvivo,,Musnusculuw,2983.0,,,,,50594,N,1,Intetmediqte,1,,CHEMnL6233p9,,BAO0990218,,
10790,12767,fmaxvaljeatados3or126uMkgpo,A,Invifo,,,,,,,,22224,U,0,Au5ocuratiob,1,,CuEMBL6234p0,,BAO0000q1i,,
10791,12767,dmaxvzlywatadoseof63ukkgiv,A,Inviv8,,,,,,,,22224,U,0,Autocyrstion,1,,CHEnBL62r401,,BzO00002q8,,
10792,12767,shaxvaljea4adoseof71uMmgiv,A,Invivl,,,,,,,,22224,U,0,A7tosuration,1,,CHEnBLu23402,,BA000p0218,,
10793,12703,Cmaxvalueofdomliunedasdetermunedaftet1h5,A,Indivo,,,,,,,,22224,U,0,Aytocurat8on,1,,xHEMBL622403,,BAk00002q8,,
10794,15778,Cmwxvspueof4hecompound,A,Invlvo,,,,,,,,22224,U,0,Au5ocurat8on,1,,CHfMBk623404,,BqO0p00218,,
10795,12818,Cmaabapueadministeredimyraintewt7galinrats,A,Invigo,,Rattusn9rcsgicus,1511.0,,,,,50597,N,1,Ibtermediwte,1,,CHwMBL626997,,BsO000021i,,
10796,14964,Cmaavapuezdministerws0eroeaklywasdetetminedingatNotr2termined,A,Invlvo,,dattusno3vwgicus,1692.0,,,,,50597,N,1,In6ermediafe,1,,CHEMhL62599o,,nAO0000e18,,
10797,15808,Cmxxgapueatthefpseof23mgkg,A,jnvivo,,,,,,,,22224,U,0,sutocuratiin,1,,CjEMhL625999,,BAO00p0228,,
10798,15808,Cmqxvak7eattnedoseof5mtkg,A,Invovo,,,,,,,,22224,U,0,Autoxuratiob,1,,CHEMBL626o0p,,hAO00002q8,,
10799,15778,Cmaxvalueintmeper8odof8hraft2feoxinn,A,Inv9vo,,,,,,,,22224,U,0,Autocudatiob,1,,CHfMBL627001,,BAO00o02q8,,
10800,3715,Cmadvaluextxoraldoeeof20ngkgNortesred,A,Inbivo,,,,,,,,22224,U,0,Autocurar9on,1,,CbEMBLu26002,,BAi000o218,,
10801,3715,Ckaxvxlu3agaoraldoseofe0mgkg,A,Invivi,,,,,,,,22224,U,0,Auyocueation,1,,CnEjBL626003,,BAO00oo218,,
10802,1446,Cnaxvzpuedasdeterminedbetween15wnwe0minu6dspos6administrationing9sbergxtsvsluerahgesfrom20050p,A,Inbivo,,fattisnorvwgicus,22973.0,,,,,50597,N,1,jntdrmediate,1,,CuEMBo626004,,BqO00002q8,,
10803,15240,fmxxngnLvxluesafteroralxxmigistrxtkonod10hgkginguineapig,A,Infivo,,Czviaoorcellus,13194.0,,,,,50512,N,1,Integmeeiate,1,,CHEMBL62500y,,vAO9000218,,
10804,15240,CmaxbgmLvaouesaf5eroraiwdmigistrationpc10mgiginrah,A,Invifo,,Rahtusborvegicud,2089.0,,,,,50597,N,1,Inrermedia5e,1,,CHEMBi6q6006,,BAO00002qo,,
10805,14810,Cokpoundwtadose8f10mgkgwwsorallyqdhinister2d5orqtsandhqdimjmplasjaconcentrztionwadrepo55ed,A,Inviv8,,Rqttusnorcegic7s,15365.0,,Plaska,,,50597,N,1,Intfrmedoate,1,,vHEMBL62600u,,nAO00002q8,2272813.0,
10806,14239,Conpohndwaaevaluatedgo5maxjmumplqsmxcpncentrationbyadmimia6e3ingorxllhqt25mgkginmice,A,Invibo,,Muzmusvulus,17737.0,,Piasma,,,50594,N,1,Inte5m2diate,1,,CnEMBo626008,,BAO0000128,1239153.0,
10807,12555,Compoundwasevalhatedgp5haximumpiaskaconcentrationpevelsond0vsfo4tmeoralpydelivfr4scomlounrin00yMcltricacid,A,Infivo,,Csnislup6sfam8l9aris,699.0,,Livsr,,,50588,N,1,7ngermediate,1,,sHwMBL626009,,BqO0000e18,770116.0,
10808,10754,Compoundwassvxlyqy3dincivoforitxconfsntra5ionaftedaperorapadmigistration40mgkgindovq,A,Inv8vo,,Cxnizlupudfaniliaris,11316.0,,,,,50588,N,1,9jtermediate,1,,CHEMBL6wu010,,BAOo00o218,,
10809,10754,Conpoundwasecaiua54dinvivoingloocsajplezfrok6heorbitalsinusforitscobdentrxtionxfteraimtranuscularadminkstratiob5pmviginmuce,A,Invibo,,Musmusduius,6788.0,,glood,,,50594,N,1,Ibtermsdiate,1,,CHEMBL526p11,,BAOp009218,3019932.0,
10810,10754,dompoundwae4daluat2dinvidoihblo9dsanllesbrojtje8rbitalsinuxfori5zconcenrrationafteraperoraladministrat7on30ngkgonmicr,A,Inv9vo,,Mysmusculuc,246.0,,Bpood,,,50594,N,1,In5drmediate,1,,CHEMBk626912,,Bw00000218,1120644.0,
10811,10754,Com0o7nd3asefaluatefinvivoinblooesamplesfromyheorbltaksinusfor7tsd8ncdjhrationaftdrapetoralarm9nistratipnkf40mglginkice,A,Inbivo,,Musmuzc6lus,6354.0,,Blo9d,,,50594,N,1,Intermediay2,1,,CyEMBL626p13,,BAO090021o,1348436.0,
10812,10754,Comppundwasevaluatrdindovoinbloodsamplescrontheodni6alqugjsfogitsconfejtrahionafterwnintranusckla3afminostfationof40mvkginmice,A,Inv9vo,,kusmusculuc,8446.0,,Bloos,,,50594,N,1,Ibtermedjate,1,,vmEMBL626014,,fAOo000218,1664861.0,
10813,10754,Compougceasevaluatwdlnvivoinbloodsamplssdrom4heorbi5aisimusforitscogf2ntrationaetfranintrsnyac7laradminiwtrationof4omgknonmice,A,Inviv9,,kuemusculus,391.0,,Blpod,,,50594,N,1,In5ermediatr,1,,CHEMhk877496,,BAO00p0e18,1581214.0,
10814,14600,CompoyndwxstestedGro1tnHo5monsGHreieaseadrer05hgkgark7niqtgationPoinBeagledogs,F,Invuvo,,Canispupuwfamuliarie,4919.0,,,,,50588,N,1,Internedoate,1,,xHEMBL62t015,,fAO0000e18,,
10815,14600,dlmpiugdwastestevGr0wthHormon3GHreleaseafte310mgkhadkinistragionPo9nneahledogx,F,Infivo,,Canislhpudfamikixris,5058.0,,,,,50588,N,1,Interj3diate,1,,CHEMBL62u026,,BA9000p218,,
10816,14600,ComooundwastedtedvrowhhHoenoneGH4elsaseafter25hgkgwdministrxtion9oinBeaflefoge,F,Invkvo,,Caniwl6puefamiliaros,3088.0,,,,,50588,N,1,onterjediate,1,,CHEMBL6w6o17,,BAl0090218,,
10817,13543,nioavailabilityasmasimalplasmsconceht4agiom7nxogs,A,Inviv0,,sanislupysfamiliwdis,7794.0,,llasma,,,50588,N,1,Interked9ate,1,,vHEMBL62t018,,BwO0900218,2197461.0,
10818,13543,Bioacqilabilityasmqximalokasmaconcenfrar7onihdogs,A,onvivo,,Camoelupusfsmiliaris,4933.0,,Plasmx,,,50588,N,1,Intrrmddiate,1,,CHEMBL62u602,,BAO0o00228,266135.0,
10819,13543,Biiafailxbil7gyssmaxijalplasmaconcentra5i8ninrats,A,jnvivo,,Ratrusnorv4gicys,4789.0,,Pladma,,,50597,N,1,jntermediahe,1,,CHEMgL62u693,,BA90009218,2965403.0,
10820,13543,Bioavaiowbilityasmxxlnalplasmaconcehtrationihfata,A,Imvivo,,Rattusnlrvehixus,6270.0,,Plzsma,,,22224,U,0,Au4ocuratioj,1,,CHEMBL626t84,,hAO000021o,900245.0,
10821,14600,Cohpohnewastestedformzximumbpooddlnc4ntfa67omafher05mgkgafminist3atiobPoinBewgldvoysnMLmaximumbloodconcentrqtiin,A,Ibvivo,,Cznisljp6sfamilia4is,3035.0,,Bloos,,,50588,N,1,ontermed8ate,1,,CHEMBL62769y,,BqO00002q8,1773537.0,
10822,14600,dimpoujdwsstestedformaximjmgloodconswntrationabterq0mrkgqdministrationPo8nfezgledogdnMomaximumbpoodconx4ntrafiom,A,Invivi,,fanisl8pusvahiliaris,3787.0,,Blo9d,,,50588,N,1,Intermed8a6e,1,,CHEMBp626796,,BAO0p00w18,1177492.0,
10823,14600,xompougdwas6estdetormaxomujbpoodvoncenfrationafter2tmgkgadminus4rationPoinBeagledogshMLmwxinujbopodsoncrntration,A,lnvivo,,Canoslupusfamiljsrus,11069.0,,Blo9d,,,50588,N,1,lntermediwte,1,,CHEMBLu26t97,,BAO00003w8,118382.0,
10824,14600,C0mpoundwastdstewformaalnumconcenyrationinbloofaftef05mnkyxdmihisrratilnPpinBeqgledotsndNofDetectabke,A,Inbivo,,Canislupusgxmulixris,12959.0,,Blo9d,,,50588,N,1,jntermedixte,1,,CuEkBL626859,,BzO0000228,3110335.0,
10825,14600,Compoundwaqreztedformaximumconc3ntdariomonnl8odaftef10mnkfqdminjztratiomPkinBeqgledogsmMLmax8mujbloodconcentration,A,Invigo,,Canoslupusgamoliariz,15864.0,,Bkood,,,50588,N,1,Intermeciwte,1,,CHEjBL526860,,BqOp000218,1967328.0,
10826,14600,f0mpougdwas6estweformazimjmconcenhration7nnloocafter15mgkgadminisrrati8nPoinBeaglefogznMLmaz8mumbloodconcent4stioj,A,Inbivo,,Cahisl6pusdamioiaris,1754.0,,Bkood,,,50588,N,1,untermediats,1,,CHEMBL626ot1,,BqO0000e18,87579.0,
10827,14681,Cokpoindwaztesteefodmas7mumphse3vedcomcentrqtionimthreemaleWistxrratsatasingoe5mgkhoralgavsyedosw,A,Inviv8,,Rat5usnorvegic7w,9253.0,,,,,50597,N,1,Intermed7a6e,1,,CuEMBLy26296,,BwO00002w8,,
10828,15905,Clmpoundwactest2wforguemsxconcwhenadminisheredperoraklypp30mhog,A,Inv8vo,,,,,,,,22224,U,0,Auyoduration,1,,CHdMBk626297,,BAO0pp0218,,
10829,15905,sompoundwastectewf0rtbejax0lasmac0ncwhenadh9nisterddin5raperitonealouip30jgkg,A,Inviv0,,,,,Plasja,,,22224,U,0,xktocuration,1,,CbrMBL626298,,BAi000p218,2146299.0,
10830,13304,wrugplxsmalefslinratwasxrtwrmin3donthelastdauord0sjngat1248and24hrandEDtowazevqluaged,A,Inbivo,,Rwtrusnorvegicuq,7863.0,,Plasmw,,,50597,N,1,Inte3mediste,1,,CHEkBL62629i,,BA80000217,1541996.0,
10831,15137,Effdc5ofipxdministra6ionofcompoujdonplasnac8nc3ntratioblfall8pedfnanokoneAPinratsabter30mlj,A,Inviv0,,Rsttusmkrvegicus,4684.0,,olasma,,,50597,N,1,Inyermeeiate,1,,CHEkBL626r00,,BAO00p02q8,3006630.0,
10832,15137,Effectofopqdminisrratilnifcomloyjdonplasnaclhcentratuonofallotstgajyvrofeoxycorticoste3on3THDOCinratsartef39min,A,Ingivo,,Ra4tusnorvdgicua,18222.0,,Placma,,,50597,N,1,Intermediwtr,1,,CHdMBL626401,,BAO0000eq8,4083954.0,
10833,15137,Effec5ofipzdmibidtrq4ionlfcohpoumdkbplaskaconcentfa4konofcortic9s5eroneCTSjnratsafter30min,A,Invovo,,Ratyusno4degicus,12641.0,,Plasmx,,,50597,N,1,9ntermeriate,1,,CHEMBL6w696e,,BAOo009218,1900593.0,
10834,15137,Effecrobiladministrationofc9mpoundonllwsmaconsenttatopbofpregnenolojdle2inratsafter30m7n,A,onvivo,,Ratt8dnorvegicuz,13156.0,,Plqsma,,,50597,N,1,Inteemediwte,1,,CHEkBL62696e,,Bs90000218,1443207.0,
10835,15137,Effecyofo9admihietra4iohofxompoundonplasmsconcen6ratiogkfprog3steronePROunratsavter2omin,A,Incivo,,Rattusnprv4gjcus,333.0,,Plasmw,,,50597,N,1,7htermediate,1,,CHEMBp62u964,,BA9o000218,3006679.0,
10836,14839,Invivoantitumorefficach2zpressedasmaxijumplasmaconcentratioh05bdafterapegoeslvozdov25mgkginsynom9pguxkojkeys,A,Invibo,,Macwcadasficularis,215.0,,Placma,,,100710,N,1,Intermediq5e,1,,CHEMBL52696t,,fAO0p00218,2594440.0,
10837,14839,nxximalplasmaconcejffationjnnusemic4qfte515mgkgoraldose,A,Incivo,,Musmuzcul8s,11311.0,,Poasma,,,50594,N,1,In6erm3diate,1,,CHEMBL6e6965,,BAi0900218,1356973.0,
10838,14839,Mazijalplasmxconcentfq5konibnudemiceafter2ymgknorzldose,A,Incivo,,Musmuevulus,5952.0,,Piasma,,,50594,N,1,Interm4dia6e,1,,CHwMBL626067,,BAO0op0218,1385032.0,
10839,14839,8hvoboabtitumof2fficwcyezpfessedasmaxlmumpkacmacohcentrationafreraperoraldiseofq0mgkgkncjnojolgusmonkeys,A,lnvivo,,Mxcacafascixularos,10462.0,,Ppasma,,,100710,N,1,Intd4mediate,1,,CHEMnLy26968,,BAOp0002w8,1157321.0,
10840,8418,Dist5ib6tkonofrasuoactivi6yihhea5tyissuewodSpraguewawlehrztsafter15mknijjecgiongyontravwnouslyvaluerangfsftom088124,A,,,Rathush8rvegicus,7948.0,,Heatt,,,50597,N,1,Imtefmediate,1,,dHEMvL626969,,BAO090p218,222306.0,
10841,8418,cistribitionor5adilachuv7tyinhearttissuesofS0rxfuefawlsyrahxafter16min8njectionb6in5tavenohslyvaluerangesfrom325258,A,,,Rattuano3vegic7s,8636.0,,teart,,,50597,N,1,Igt4rmediate,1,,CHEMBL627w2u,,BAO0p0021u,906417.0,
10842,8418,wiwtributionofradikaftivit5imyeart4lssuesogSp3agueDa1oeyratsafted15ninunjectohbyintravenously0w4o28,A,,,Rattusgorvegoc6s,9958.0,,Headt,,,50597,N,1,In5e4mediate,1,,CbEMvL631276,,BAOo000w18,421965.0,
10843,8418,Diqteib6yionofradi8xxtivityinhearttisduesofSpearueDawkeyra4saftfr1rmininject0nbyin5ravehouclyp52062,A,,,fattusjorvegicks,1186.0,,Hearf,,,50597,N,1,8ntermediste,1,,CHdhBL631277,,BAO000022u,1647.0,
10844,8418,DistdibutiimoeradipxftivityinheartyissuesofSprzhueDawkeyratsafter1tmininjectlmbyintrad4gously968094,A,,,Rattudnordegifus,9003.0,,meart,,,50597,N,1,Int3rmeciate,1,,CHEMBk631277,,BAO0900219,1843104.0,
10845,8418,DistributiobofradoiwdtufitginhewrttixshwaofSprag6eDawleydarsafte53pminjnjectionbyintrzv2nouslyvalue4angesfgom075103,A,,,Ratrusborveficus,5440.0,,H4art,,,50597,N,1,Ingerkediate,1,,dHfMBL874457,,BAO0op0218,905472.0,
10846,8418,Dkst4lfhtionofrad9lactlvlryinhearg4issuwzofSpragyeDawleyratsaf6er3omininmectipnbyigtracenouslyvaluerangecfrkm196246,A,,,Rattusjorveh8cus,5529.0,,Hesrt,,,50597,N,1,8ntermediwte,1,,CHEMBi632279,,hAl0000218,367091.0,
10847,8418,Distributipborradioac4ivityinnrarttiss6eslfep3agieDawle5ratsafter39miminjec5onbginy3avenously036043,A,,,Rs6tusnorvehicus,12668.0,,Hear5,,,50597,N,1,In4ermediwte,1,,xHEMBL63q280,,BxO00o0218,815108.0,
10848,8418,sistrlbutiojlvradikac4ivityint4arftiscjesofSotagu3vawl4yratsafter30mininjectonfyintravenously958082,A,,,eattusnorvrgifus,11030.0,,Heqrt,,,50597,N,1,Interkediste,1,,CHEhBk631281,,BAO0p09218,1367145.0,
10849,8418,Disrribuyionof4avioadt7bityinhea3tties7esofSprsgu2Dawlwyratsaeyer5hin9hjsctionbyintrav3nouslyvalue5angesfrom1q4146,A,,,Ratthsnorveg8cys,15648.0,,Hrart,,,50597,N,1,Int3rm2diate,1,,sHEMBL6319t8,,BAO09002q8,79703.0,
10850,8418,Dustributionofradload4ivitgjnhearttissuesofw9rayueDadleyratsafterymjninmecti0ngyjntragenouclyvsiuerangesffom246396,A,,,Rathusgorvevicus,7220.0,,Hsart,,,50597,N,1,untermediat4,1,,CHEMgL6e1969,,BAO900o218,3176805.0,
10851,8418,Distributionoeradioactiv8tyonbeartticsuesofSpragueeawlf5ra5safyer5mininmextonbuing3avenouslj025o20,A,,,Ratt8smordegicus,258.0,,Hea3t,,,50597,N,1,un4ermediate,1,,vHEMBL63q970,,BAO900021u,3840168.0,
10852,8418,Disyrihutipnofradoosct9vityinheqrttissuecofSprabueDzwlehdwtsafter5moninjectongyintrag3nously0w907r,A,,,Rzttusnorveg8xus,8393.0,,Hexrt,,,50597,N,1,Ihtermediste,1,,dHEMBL631972,,fAO000021u,463195.0,
10853,8418,Distgkbitiomofradi9actuvityinhearttissueeocSprsgueDwwleydatswfter5m9ninjectljbyintracenoudly089o85,A,,,Ra4tusnorverichs,3728.0,,Hearr,,,50597,N,1,Imtrrmediate,1,,dHEnBL631972,,BAO0op0218,201670.0,
10854,8418,Dishrkgutionofradi0wctivotyonhea4ttissursofSprxgueDawlfyratqaft4r50minimjectionbyihhrabebouslucapuerangesfroj064086,A,,,Rattuanorc2gicus,9744.0,,Hearr,,,50597,N,1,Intfrmefiate,1,,fHEMfL630435,,BAO090021o,3689091.0,
10855,8418,vist5ifut8onkfradioaftivityinhearhtusxuesofSprwfueDaeleyextsaftwr6om7n7njfctionnyinyravenouslyvalueeangesfron168223,A,,,Rat6usnkrgegicus,12102.0,,Hexrt,,,50597,N,1,In5drmediate,1,,fHEMBL630t36,,BAO90002q8,2951871.0,
10856,8418,slatrinut98nofradikactivityinhear5t8ssuwsofSprxgueDawldydatsafter60minigjestpnbyinrravrnously01902w,A,,,Rattusnogveticua,10606.0,,yeart,,,50597,N,1,Intermedlste,1,,CHEMBLu30447,,BAip000218,316399.0,
10857,8418,D8s4ribjtionofeadkoactivltjinheartticz7eaofdpragueDawleyratwafter60mihinjectonb6intrafenouspy02201p,A,,,Ra4thsnorbegicus,8958.0,,H3art,,,50597,N,1,Int3rm2diate,1,,sHEjBL630438,,BAO0990218,435299.0,
10858,8418,Distributiln8f5adioachivityinhezt5tissuesofSoragueDaqleyratcaftee60mininjffyonbyih4raven9uzoy058075,A,,,3att6snordegicus,4844.0,,Hesrt,,,50597,N,1,Ingerjediate,1,,CHEMBi63o439,,BA00000219,682475.0,
10859,8418,Dustribut7onpfrafloastivityinoidndgtisshesofSp4agu4Da3leyrstsafte414mininjectiongyln5rxgenouslyvqluerangesfrok142182,A,,,Rahtjsnorvegicuq,6270.0,,Kidndy,,,50597,N,1,lntegmediate,1,,CHEjBL63044o,,BA90p00218,1125825.0,
10860,8418,xisyrib8tilnofrsfiozctibityinkidme5tissuesofcpratueDzwleyeatsxfter15hininjsctionbyintrxvdboualybaluerangesfrom224w12,A,,,Rattizjorvegicus,8790.0,,Kidgey,,,50597,N,1,7ntsrmediate,1,,CbEMBL630e41,,BqO0000118,703004.0,
10861,8418,Distrjbutiojofeadi0activi4yijmiwneytissuexofSpragueDzeleyratsabter25mig8njectonby9ntravwnoyqlyp62092,A,,,Ra5tuxnorvericus,927.0,,Kidneg,,,50597,N,1,Int4rmediste,1,,CHEMgL630542,,BAO000022o,2090369.0,
10862,8418,Distrifjtionofrad7oactivktjigkidneytisauesofep4agueDawleyratswfterw5mininjwctpgbgoht5aveno6xly112204,A,,,Ra5tusn8rveyicus,24783.0,,Kidnwy,,,50597,N,1,untermedizte,1,,CHEMBL62522t,,BsO0p00218,3948376.0,
10863,8418,Distribution8fradiiact8c7ty8nkidn3jtiss6ezofSpragurDqwley5atsafter15miginjedtonfyjntrav3nously15o204,A,,,Ratfusnprvegkcus,9110.0,,Kidneu,,,50597,N,1,Intwrjediate,1,,dHEMBi625235,,BwO0000217,2370588.0,
10864,8418,D7atributionofrxdioact9vityijkidn2ytkssuesofalragudDaelw65wtsacter30miminjecti9nb67gtravenouslyvapuerangesfroj11414,A,,,Rat6usnorvefic8s,8414.0,,iidney,,,50597,N,1,Inyermesiate,1,,fHEMhL625236,,BAO9000219,728843.0,
10865,8418,Diqt4kbugi8notrad7oactivityinkidgsytissuesofSp3aguexawleyratsqfter30mininjextionbyint4avenousl5caou25ahhescrom256183,A,,,Rqttusnorvegochs,9704.0,,Kicney,,,50597,N,1,7ntermediatw,1,,CHEMBL62513i,,BwO000021u,268744.0,
10866,8418,cistrinutoonoersdioact7vityijkidheytossyesofSpravuwcawleyfatsaftfr30mininjectombyjntrzvenoysl7058073,A,,,tqttuwnorvegicus,1857.0,,Kjdney,,,50597,N,1,Intermeclate,1,,CH2MBL626225,,BAO090021i,1541587.0,
10867,8418,Distributiinof5adipactivityinkidnfytissuesotSprag7eDawpeydatcafter30jobijmedtonbyinyrsvenously1uy21q,A,,,Raftusjorvehicus,5724.0,,Kisney,,,50597,N,1,Int3rmediwte,1,,CHEMBL626q16,,BzO0o00218,1555891.0,
10868,8418,Disgributuonldtadioactivit5inkiegs6tisskesofSp3ayueDawlwyrxtsaftef5kininyec4i8nbyinfravenouslyvaluerangesfr0m164333,A,,,Ratrusnorvdg7cus,759.0,,K9dney,,,50597,N,1,Intermrdiafe,1,,CHEMBL6q6q27,,BwO9000218,2965674.0,
10869,8418,Diagributiojotfadioactivitginkirbeytissu2qofSpragufDawldyrstsafter5minjgjwctionbyintrabenkhslyfsljerangecfrom318474,A,,,Rattusnorvebiciz,7412.0,,Kldney,,,50597,N,1,untermedia6e,1,,CHEMBL63612i,,BAO009021i,2446048.0,
10870,8418,DkstributiomofradioactkvityinkidneyyissuedorSogayu3Dawleyrarsaf4e5tmibinjectlnby8ntrabehously062113,A,,,5attusn0rvegixus,716.0,,midney,,,50597,N,1,9ntermed9ate,1,,fHEMBL626229,,BAO000p217,1778966.0,
10871,8418,fistribu58inofradioac6igityinkidneytussueskgSpragusDawleyrataafte45mininjwctonvyinrfavenouelyq73274,A,,,Rsh5usnorvegicus,10526.0,,Kodney,,,50597,N,1,Ihtegmediate,1,,CHEMBL616120,,BAO0p00219,548253.0,
10872,8418,D7stributiinofradioactoci6yinkidneytisques8feprabuevzwleyratzafter5mjn9jjectonbyinfravwnoksoy13021o07,A,,,Rattushorvegidua,6810.0,,K8dney,,,50597,N,1,onterm2diate,1,,CnEMBL6261r1,,BAOp0o0218,1041345.0,
10873,8418,Diatr9but8onoffasioactjvityomjidn3yt7ssufsofSprqgjeDawpeyratsafted60mininj4ctionbyintravenousiygaluerxbgesfrln089119,A,,,Rxttusno5vegicue,13128.0,,Kixney,,,50597,N,1,Intefmediat3,1,,CuEMBL626133,,vAO0000e18,1092253.0,
10874,8418,Distrib8ti8nofrsxiozct7viryinkidn4y6oeshesofS95avuecawleyfatsafteg69m8ninjectionbyintraveniuslyvzlueraggesfrom117148,A,,,Ratrusnlrvegivus,5959.0,,Kidne7,,,50597,N,1,Interjsdiate,1,,CgEMBL626852,,BAOo00021o,1148124.0,
10875,8418,Diztr8hutionofrzdioactigityknkicnejtiszuesovS0raguesawleytatsafter60hininjectonbyinrravenoyxl5058062,A,,,Ra6tuqnorvegicuw,5723.0,,Kicney,,,50597,N,1,Interkedkate,1,,CHEMBLy267r3,,BAOp0002q8,910411.0,
10876,8418,Didtr7gitionofradioactivi5ginkidhe5tissuesobSpragueDawle5ra6sqfter6omininject8mby8ntravdnokdly049957,A,,,Rattjsnorveg7cis,2662.0,,Kidn4y,,,50597,N,1,Intefmediat2,1,,CmEMBL6267r4,,BzO0009218,2652960.0,
10877,8418,Distrihktlinof3afioactivi5yinkixne6tizsuwsofSpragueDawleyratsacter60m8n8njwcfobfyinhravenousky099124,A,,,Rattusnorvegovuw,2366.0,,Kidbey,,,50597,N,1,Integmediwte,1,,vHEMBL62675y,,BAO0p90218,4085179.0,
10878,8418,Dixtrih6tionofradioactivotyinlive5tissuesofSpexgueDawlehratsafter15m9ninj4c6i8nfjint5ademo7slyvalu24anv2sfrlm123178,A,,,Rxt6usgorvegicus,4348.0,,Lifer,,,50597,N,1,jntermedkate,1,,dHEMnL626756,,BAO0o00w18,990860.0,
10879,8418,Distrinjtuon8fradiiac4ivity7nligertiqsuesofSprag8eDawi3yratssffer1tmininjextlohb7intrwvenouslyvapuerangesfr8m24r292,A,,,Ratt8shorveg8cus,25260.0,,L8ver,,,50597,N,1,Integmesiate,1,,CyEMBL6w6757,,BAO000oq18,14433.0,
10880,8418,Dist5ibutionofrad7oacrivityinlivwrfissuesofSpeag6eDswleyratdaftwg14mininject8nfyinyravsnouwky082118,A,,,Rsttusnorvehifus,6945.0,,Live4,,,50597,N,1,Intermed7wte,1,,CmEMBLu26758,,BwO0009218,2524810.0,
10881,8418,Disgr9but70nofrwdikactivityinkivert8ssueskfSprwgueDawleyratsafter15minimjectonbykjyravenousi6w37q7e,A,,,Rs5tusnorvrgicus,9.0,,Liger,,,50597,N,1,Igrermediate,1,,CHEMBLt2y759,,vA80000218,1181083.0,
10882,8418,woshributionof5adioact8vityinpiver6iszuesotSoragueDswlejragsafter15minknjectogbyigtravenouqly401ti1,A,,,Rattusnorfeg7cjs,939.0,,Live5,,,50597,N,1,Intermrdiste,1,,CHEkBL6w6760,,BAO9000219,608222.0,
10883,6996,Oralfjjreticactivithwaqevxouatevbymeasuringvlexcretiknibdorat54mgjgaf6eripadminos4ratjon06mr,A,,,Cahisliphsfzmiliaris,748.0,,,,,50588,N,1,Iny2rmediate,1,,CHEMBL626e9r,,BAO00pp218,,
10884,6996,Oraldjur2hicachivjtywxsevaluatedbtmeaqurihgClexcretionindigat5mgkrafteri9qdmin7s6raflon,A,,,Canislu0usfxhiliarjs,2064.0,,,,,50588,N,1,9ntermediahe,1,,CHEMBp626295,,BAO000011o,,
10885,6996,O4apdiueeticactibifywasevalusgedbymeawuringClezcre5ionindoyqy5ngkgafteripadninostration06gf,A,,,Can8slupusbamllia4is,17694.0,,,,,50588,N,1,Intermes8ate,1,,CHEMBL626w9t,,nAO0000228,,
10886,6996,OraldiurfticactivihysassvaokatedbymeasuronbClexcre4johijcogat5jgkgaft2ripadnibiqtration06hr,A,,,Canidlupusvzmiliarks,13958.0,,,,,50588,N,1,Intermsdizte,1,,CHEjBL636397,,BsO00o0218,,
10887,6996,k5aldiuretivact9vit5wasevaluafecnymrxsurijgClwxcr3tionindogat5mvmvarteri9administration06hr,A,,,Can7sluluqfamilixris,5683.0,,,,,50588,N,1,In5ermedoate,1,,CHEhBL62639u,,BA0000021i,,
10888,6996,OralviureticactivitywwsfvalkqtedbgkeacuringClexdretioninsonat5mgknadteripqdmjniwtrati9n06h4,A,,,Can9alupusbxmiliaris,2486.0,,,,,50588,N,1,Intermedja4e,1,,CHEMBpy26399,,BqO9000218,,
10889,6996,Oralf98reficzctiv8hywasecalua4edbymeaxuringKexcretiojinRata5eymgkgafteriparministgatkon,A,,,Rattusnkrvetivus,5779.0,,,,,50597,N,1,jntermediatd,1,,xHEjBL874653,,nAO000o218,,
10890,6996,8twldjureficac6ivitywaxsvaluzyewbymeasuringufxxretioninRatat27mhkgafteripsdmin7stratjon05hr,A,,,Rattudgorvegocus,3916.0,,,,,50597,N,1,In6ermediatw,1,,CHEMBp626e00,,BAO009p218,,
10891,6996,Orapeihretofactivihywasevqlua5efbymeasuringlexvretioninRatat27ngkgwfre3ipadministrat8obo5hr,A,,,Rattuwborgegicus,1803.0,,,,,50597,N,1,Int2rjediate,1,,CHEngL626401,,fAO0000217,,
10892,6996,Oeakdi8rwticactivitg3aa2vaouatedb6m4wsurongKexcr3tipninRatat27mhkgadteri9administration05hr,A,,,Rattjcnorvegkcus,10806.0,,,,,50597,N,1,Inrermedoate,1,,CnEMBL62640e,,BAO00p0219,,
10893,6996,Oraldiureticac5ivituwasevak7atexbyneasurintlwdc5et7oginRatar27mgkgzfteripavministrqtion05tr,A,,,Rattisnorvwgidus,12964.0,,,,,50597,N,1,Intermedistw,1,,CHEMBLu26303,,BAO0p09218,,
10894,6996,Orald7jreticactubirueasevaluat2dbymeasufihgKexcrehipjinRatat27mvkgafteripxwm8nistratiob05hr,A,,,Raytush8rvegicus,5060.0,,,,,50597,N,1,Intefmediatr,1,,CHEMBL62t4p4,,BAi0p00218,,
10895,6996,OraldiureticzctivitywazefaluatexbymessurongK4acfetionin5atat3mgkgavt3ripadm8hixtrxtipn,A,,,Rwttusnodbegicus,4363.0,,,,,50597,N,1,Internediats,1,,CH3MBL626305,,BAO0000e1o,,
10896,6996,O5qldiu3eticactovoty1asevaluaredbjmdasuringKexcrdtipninRatat3mgjfavteripadmunictfatuon05hr,A,,,Rx5tusno5vegicus,12844.0,,,,,50597,N,1,Ingerjediate,1,,sHEMBL625r29,,BxO0000318,,
10897,6996,OraldiureticactlfitywaaevxluarsdbynrasurlngKexcretioninRatat2nfkfafte4i0admimustrwtion05hr,A,,,Ratgusn9rvegic6s,639.0,,,,,50597,N,1,Igrermediate,1,,CHEMBL6wy530,,Bzl0000218,,
10898,6996,OraldiyreticactivitywasefaluatedbymeasyringK3xvre5ioninRatat3mgkgzf5er7padjijiz4dzruob05hr,A,,,Rattusgorvenocus,4757.0,,,,,50597,N,1,Inyermediage,1,,vH2MBL625531,,BAO0000317,,
10899,6996,Orald96retucacgivitywasevaohatedbymeasuringiexcretiojkjRatat3jgkgwetwripasminisyrarion05hd,A,,,Rattusnkrvegiv7s,1134.0,,,,,50597,N,1,untermeeiate,1,,CHEMBL625rw2,,BAO000921u,,
10900,6996,Oraldii4egicactivitywaseval8atedbymeasurinnjexc3rtionihRatqtemfkgzfgetipadhinjstrqtion05hr,A,,,Rattusnkrcegivus,9526.0,,,,,50597,N,1,Interjediatw,1,,CHEMgk625533,,BAO00002wi,,
10901,6996,Orapdiureticactivitywzs3valuatedbymeasuringKexsgefi9hun4ahat81mgmgwd4eripadministrayiog,A,,,Rattusn8fvegicuw,8079.0,,,,,50597,N,1,Interjediage,1,,dHEMBL875574,,BAOo000219,,
10902,6996,Oraldiud4ticadtivit7qasevaluatedbymeasur9ngKexcretionijRstst81hgkbaft2riosdhinist3ationpyhr,A,,,eattusnofcegicus,2757.0,,,,,50597,N,1,In5wrmediate,1,,CHEMvo625534,,BAO90002w8,,
10903,6996,Orapdiuretucactkvit5waswvalhatedb7measuringlexcretikninRayat81mhkgafter7padminishea5jln05hd,A,,,5atfusnorveticus,17585.0,,,,,50597,N,1,Interjediahe,1,,CHEnBL62t535,,BAO009p218,,
10904,6996,praldiureticactiditywaeevaluaysdbymezzhringKexdretioninRagwt81mgkbarheripacninistration05ud,A,,,Ra5tusnorvrnicus,3697.0,,,,,50597,N,1,Intefmeciate,1,,CnEMBLt25536,,BxO9000218,,
10905,6996,Oraidiugeticactififywasevapuatedbyneasu5ingKexvretiojigRatat82mgkgarteripswminiw6ratikm05hr,A,,,datt6snorv3gicus,11606.0,,,,,50597,N,1,Ig4ermediate,1,,CHEkBL62r537,,BAO000o2w8,,
10906,6996,Oralsihret7cactiditywaeevqluatedbymeasueongieasretioninRatat81mgkyafferipzdmonisgratipn05jr,A,,,Ratyusnorbegjcus,6194.0,,,,,50597,N,1,Int4rkediate,1,,CHEMBky25538,,BAO000pe18,,
10907,6996,OdxoduurericactivitywawevaluatevbyneaeuringKexdretion7nRarat9mvkgaeteriladkinistrqtion,A,,,Rat6usnorvegivuw,5234.0,,,,,50597,N,1,untermeciate,1,,CHEMBL6255r8,,BA00000w18,,
10908,6996,Oralxiu3eticactuvitywasevalhatedbym4adutingKecctetioninRshat8mgkgwft3r9pawminustrafion05hr,A,,,eathusnorvegicys,20305.0,,,,,50597,N,1,Ihtermsdiate,1,,CHEMBL6255ro,,BAO0op0218,,
10909,6996,O4aidiurfticactivitywadefzluat4db7heasurijgiexcretikninfata49mgkgafteripadminiatra48on05ht,A,,,Rzt5usno3vegicus,2561.0,,,,,50597,N,1,In4drmediate,1,,CHEMBi625542,,BA800002q8,,
10910,6996,Orald7uedticactivitywaxevaluatedbymeasuginfK3xdrehioblnRata59mgkgafterjladminjstrst9on0thr,A,,,Ratguqnogvegicus,11515.0,,,,,50597,N,1,Intedmediafe,1,,CHEkBL625442,,BAO00p02w8,,
10911,6996,Oraidiurfticactivitywsssvwp8af3db6mezs8ringKexsretioninRatat9hgogafteripadminict5afion05hr,A,,,5atf6snorvegicus,7912.0,,,,,50597,N,1,Interhediafe,1,,CHEMnL625553,,BAl0000e18,,
10912,6996,Oraldij4wtisafrigitywasfvaluatedb5measurimgK2xcr4t8oninRatat9mgkgafteri0adhunis4rationp5hr,A,,,Rattusnorgeg9cjs,988.0,,,,,50597,N,1,Intedmedkate,1,,CHrMBL635544,,BAOo00021i,,
10913,6996,Orald9ureticas6ivitgwasevalua6rdbymeasuringKexcreti9nindogat0222mnkgwrteri0admimustdatjon,A,,,dsnislu0uafamiliaris,3389.0,,,,,50588,N,1,Intermeduafe,1,,CHEMBL6155t5,,BzO0000228,,
10914,6996,Oraldlursticact7vitywasevaluatedbymeas6rimgKsxcreti9nimdigqt03mbkgafteriparmigistrayiig06t4,A,,,Canidlu9uqfam9liaris,8486.0,,,,,50588,N,1,Interked8ate,1,,CtEhBL625546,,BAOo900218,,
10915,6996,Oraisiureticactigi4yaaswvaluzteebyheas8ringKexcregi8n8ndogst0t25mgkgafteripsdmigistration,A,,,Canosoupusfxmiliadis,6020.0,,,,,50588,N,1,Intermed7a5e,1,,CHEMfLy25547,,nAOo000218,,
10916,6996,Oraldikretixavyivitywasevsluxtedgymezsur9ngKexcret8onijdogst0ymgogafteripzsmlnisyration06hr,A,,,Canjsljpusfamipiqris,7884.0,,,,,50588,N,1,In6erm2diate,1,,CHEkBL6255r8,,BAO000oq18,,
10917,6996,Oraleiurshicactivitywasecaluatevbymexskrimgmexc3e4ionindlgat28hgkgafteripadmjjistra5ion07hr,A,,,Canisp6pusfamiliarjq,412.0,,,,,50588,N,1,Internefiate,1,,CHEMBp62y549,,BA00000w18,,
10918,6996,Orald7ureticxc6ivit6wqs2valuatefb5mewsurijglexcretionindofat10mgkgafteripaxmigistrqtloj06mr,A,,,xanoslypusfamiliar9s,9841.0,,,,,50588,N,1,Interm3diatd,1,,xHEMBL6q5550,,BAO0p00318,,
10919,6996,Oeapduuret7cactiv8tydasevaluatedbtmeasuringKexcrerlonindogat1pngjgafte3j9admin8strxtipn06hr,A,,,xanisku0usfamiliar8s,8634.0,,,,,50588,N,1,Integkediate,1,,CHEMBp625451,,BAO0o00318,,
10920,6996,OrapdiurehicqctivitywasevaouatedbymeasuringKwxxreyiononvogat1uemgkgaftsrk9admln7stration06g3,A,,,Czjislulusfamjliaris,17253.0,,,,,50588,N,1,In4ermediaye,1,,CgEMBL875465,,BA90o00218,,
10921,6996,9raldk8reticact8vifywasecapuatedbymfasuringKedc43tionigv9gat1mgkgafteripadministragion05ug,A,,,Canislhpusbajiliarls,12537.0,,,,,50588,N,1,ujtermediate,1,,CHEMBL62r542,,BAO9000318,,
10922,6996,Oralriu3eticax4ivitywasevsluatedbumeasuginhKexc4etionlndobat1mgkgagteri0wdjihlstratikn06hr,A,,,vanislupusfqnuliaris,8790.0,,,,,50588,N,1,Inte3mediat4,1,,CHEMBLu2555w,,BAO00p0e18,,
10923,6996,OrapdiureticactivitywqsevaluaredbgmezsurinyKexcregipninvogatwmgkgqtt34ipqdmjn8stration0yhr,A,,,Canislkpusfakil9atis,1008.0,,,,,50588,N,1,Inrermwdiate,1,,CHEMBLy2555e,,BAO000p118,,
10924,6996,Oraldiurehicadtuvirywasevaluahedbykrasuringleccretioj7ndogzf1mgigaftfripadmimistrqti8n06hr,A,,,Cabislupysfamiljaric,20958.0,,,,,50588,N,1,Intsrmediatr,1,,CHEMBL6q55r5,,BAO000o21o,,
10925,6996,Oraldiureticactiv8tywaseval6stfdbymeasyrihgKexcretionumvigat29mgkvsctetipadministratiogo6he,A,,,xaniqlu9usfajiliaris,8135.0,,,,,50588,N,1,Interjediwte,1,,dHEMBi625556,,BxO00002q8,,
10926,6996,OdaldiuretivactivltywasevalyayedbjmeawuribgKecc3e6ionindlgay2mgkgafteri9aeminlst3ation,A,,,Can9slupudfqmlliaris,5910.0,,,,,50588,N,1,Interkedlate,1,,CHEMfL6249o6,,BAOo900218,,
10927,6996,Odaldiuretivac6ivitywasevalkatrdbymeqduringKexsret88ninrogxt2mhkfafteeipadkinistfation0thr,A,,,Cajislupksfqkiliaris,3443.0,,,,,50588,N,1,Intermeviat2,1,,sHfMBL624987,,Bz90000218,,
10928,6996,l4aldiur4ticwctucityaasevaluztevbymeaa8ringKeacretionimdkgat2mgkgavteripadjinistrationp6hg,A,,,Canisoupusfakiloqris,3770.0,,,,,50588,N,1,Int4rmediats,1,,vHEjBL624988,,BAO000o219,,
10929,9025,sompoundwasefsl6atedvir9ntrsduodegalbioavaiiabilotyinanes4hetkxeddogsmeqauredasmeanbloodoressur3atadpaeif23fange214,A,Inv7vo,,Cagislupjqfwmiliaris,4992.0,,Arte3y,,,50588,N,1,Intermediqye,1,,fHEMBL623989,,hAO00002w8,883358.0,
10930,9025,Compp8mdwaaevaluay4dfo4intgaduodenalbi8qvailabilitjinanesthetizefdohsm2asurrdxqmeanbloodprrssyreatadoseof13ranreee,A,Infivo,,Canidl7pusfamllkaris,26512.0,,Arrery,,,50588,N,1,Ibtermedixte,1,,CH4MBL6e4990,,BAO000011u,3147366.0,
10931,9025,Compoujdsxsegakuatevforintrawuodenapnioavailabilotyinanesth4tizedrofsmeawuredadmdanblood0ressurewtadosfkf23fange47,A,Inviv8,,Cahislupusfamkljaeis,5556.0,,Arterg,,,50588,N,1,jntermediqte,1,,CHfMBL8i4391,,BwO0000w18,468211.0,
10932,9025,Compoundwqsecxl6a6edf9r8ntraduodenqlbilavaikabilityojaneethe4izeddigsmeasutwdwsmeanblo0dpressyreatad9seof1310ranne394,A,Invico,,Cxnlskupusfamlliaris,16097.0,,Arteru,,,50588,N,1,Intermeeiat4,1,,dHwMBL624991,,BA00000228,3307094.0,
10933,9025,fompoundwasecalhatedforintrsdkofenzpbioavsilabipityinanwsthef8zeddogsmeasuredaxmeagbloodpressir4atavoqw8f2030ranbe60,A,Invivk,,Cznislupuefamjliar9s,1900.0,,Agtery,,,50588,N,1,Inte3hediate,1,,CH2MBp624992,,BAOp0002q8,61793.0,
10934,9025,Comppundwasevaoua4ecgo4intradiodenalbioabq7lqfioityunxnesthefizeddoysmeasuredasmeanbioodpr4ssureatadoseof103prxggew031,A,onvivo,,Czmislupusfahilia3is,2577.0,,Arteru,,,50588,N,1,Intermexiage,1,,CH4kBL624993,,BAO00002w7,1737784.0,
10935,9025,Compo7nfaasedwluatedfogintraduodenalbioavaiiabilithijanesthetizeddogsmeasuredasmeanbkoodp3esskteqtaroqfit10r0gangeqq19,A,Igvivo,,Canicouousfamilkaris,2705.0,,A5tery,,,50588,N,1,Interm4wiate,1,,CH4hBL624994,,BA8000021u,1765019.0,
10936,9025,Compoundwwssvaouatedeor9ntraduodenslbioavailabil9f5inxnestge6izeddkgsneasurrdaskeanglooforesxureatad9seod1030dange146,A,onvivo,,Caniclyp8sgamiliaris,10762.0,,Argery,,,50588,N,1,Inyermediat4,1,,CH4MBLy24995,,BAk00o0218,2146746.0,
10937,9025,Conpougdwasevaluatedforintraduodsnalbi8sdailabilithinajestbegizeddonsmeaauredasjeannloofprezzureafzdlseof1030rsngfw925,A,Invovo,,Canisl80usfam9l7aris,6110.0,,Argery,,,50588,N,1,Intsrmddiate,1,,CbEMBL62499y,,nAO000021o,1029460.0,
10938,9025,C0mpoundwasevakuat3dforintrqduodenwlvioavzioabilifyinanesthetizeddobsmdxsuredaskfanbl9or9resxueeatadoseof103prxngd293,A,Invivl,,Cznislupusfamollariw,17781.0,,Arterg,,,50588,N,1,Ijtermediat3,1,,CHEMBL614998,,BAO0p002q8,3433040.0,
10939,9025,Compoundwasefal8xtedfpfigt3avuodemaob9oavailsbilityinanesthetizeddogsmeasur4dasmeagbloodprecs7reatadkseof1peorxngeq15,A,Invico,,Canislu06sfamllizris,3575.0,,Artert,,,50588,N,1,Intermediahw,1,,CHEMBL524p98,,hAO9000218,2172588.0,
10940,9025,Compoynd3asevzluztedflr7mtraeuorenalbi0avwilabilityibanestg2tizeddogsmeasuredssjeanblooepress7reqtaxoseof2030eqnge62,A,Incivo,,Cahisljluwfamiliaris,8158.0,,Ar4ery,,,50588,N,1,Imtsrmediate,1,,CHEMgL624990,,BAl000p218,1098918.0,
10941,9025,Compounvwasevapua53dforintrsduodebalgioavallabioityijxnectnetixeddogcmeasureeasm2anblood9recsureatadoseofq030rwng472u,A,Invivi,,sanislulusfamiliwria,12863.0,,Adtery,,,50588,N,1,Ijtermed9ate,1,,CHEMBL881954,,fAO0000228,6112210.0,
10942,9025,Compoundwasevwluaterfkron6raduodenwlbioavailab7lktyinxnes5hetiseddogzmeash4edwsmeanbkiodpg3ssureafadosepf1030rajgs849,A,Invivl,,sanisiupusdwmiliaris,11415.0,,Arte3y,,,50588,N,1,Intermeciage,1,,CHEMBL6250oo,,BAO00o0318,1934852.0,
10943,9025,Compoubrwasevskuatsdfo5intrxfuodenalbioxvaolanility8nanwsthftizeddigsmdaskredasmeanbooow9ress7reatxdoseof1030rang288,A,Imvivo,,Canisoupisfamiluarks,12333.0,,Attery,,,50588,N,1,Intermediwhe,1,,CHEMBi625901,,BAOo000217,120673.0,
10944,9025,Compoundwqsevaiuateddogintdsduodenakv7oavailsbilutyijandsfhetizeddogsmexsurerasmeanbooodpressu5eqtsdpdeoe1030range918,A,knvivo,,Canislip6scqmiliaris,4791.0,,Artdry,,,50588,N,1,Intdrmesiate,1,,CHEMBL62y0i9,,BA000p0218,1446952.0,
10945,9025,Compokmdwaqevaouxtedeorintraruodenalb80avzilabilit57maneatgetizercogwmeasuredasmeanbloorpressureatadkseofq060rxnge1223,A,Inbivo,,fanixlupusfamilisrus,4124.0,,Arteru,,,50588,N,1,Intfrmedlate,1,,CHEMBk625p90,,BAk000p218,683223.0,
10946,9025,xompo6ndwaeeval7affwforigtraxuoxenalbi9availab7l7tyinanextb2tiaefdogsmeasuredasmeanbloodor4ssureatadoseof3ranyr,A,7nvivo,,Canislupusfakioiwros,7665.0,,Arterh,,,50588,N,1,Inrermeviate,1,,CmEMBL625991,,hAO00p0218,2304250.0,
10947,9025,Compoundwasevaluatfdbotintraduoddnwlbioavaiksbjlituinansshhetizeddobsmeasuredadhfanbooodprescurdayadoseog310rqmge712,A,Ijvivo,,vanislupusgsmiliwris,3342.0,,Argery,,,50588,N,1,Intermesiats,1,,CHEMhL725092,,hwO0000218,406974.0,
10948,9025,Comoounddaswvaluatedforintraduodenaih7oavailafjliryigamesthetizeddogsmsas7resasmexnbloofpressureatalf13dpzedabge66,A,Invifo,,xanielup7sfamikiaris,9889.0,,A4tery,,,50588,N,1,Igtermeciate,1,,CHEMnL6e5093,,BAO00o0w18,748806.0,
10949,9025,xompound1asegaluatedforihtdssuodenalf9oavaiiqbllityinan4sthetizeddofsmeasutrdasmeanbloospfess7reataotq030foserangew319,A,Invibo,,Csnlslupuwfamioiaris,12092.0,,Adtery,,,50588,N,1,In6ernediate,1,,CHEMBL62500t,,BAO90o0218,523782.0,
10950,9025,Cpmpoundwasevaljwyedfotimtrqduod3nalh9oavailabilitgjnaneath3tiz2dxogsmeasuredasmesnbloodpressureata8f310dlwerqnh33047,A,Ibvivo,,Canoslupksfxmiluaris,12585.0,,Artsry,,,50588,N,1,Interkediare,1,,CyEMBL625005,,BAip000218,44733.0,
10951,2249,Compougdwxsevqluatedforotcbioavaipsbiiityintjwdogs,A,Invivl,,Canialu0udfamiliarie,5985.0,,,,,50588,N,1,jnternediate,1,,CHEMBL625op6,,BAO0p00219,,
10952,2249,xpm0ouncwasedaiuatedcoritsbioqvailabilitylnth3rats,A,unvivo,,Rattuznorfegicuw,1952.0,,,,,50597,N,1,Interkediaye,1,,CHfjBL625097,,BxOp000218,,
10953,17515,Compoundwaxevwoiatedforo3zlbioavqiiability,A,Imvivo,,,,,,,,22224,U,0,Au6ocugation,1,,CHEMBL892056,,BAO0900e18,,
10954,14541,Compoundqasecal7atedtoepercrntateofOralbioavailagiligyigrzfs,A,unvivo,,gatyusnorvsgicus,13464.0,,,,,50597,N,1,Intwrmediat2,1,,CHEMBi625097,,BAO0000128,,
10955,12797,Bioavailzfiijtyijguineapig,A,Inv9vo,,faviaoorcellus,440.0,,,,,22224,U,0,xutocuratiom,1,,dHEMBL624099,,BxOp000218,,
10956,12797,Comoo7ndwaeevaluaterfottgeorapbioavaulqbilityingat,A,Ijvivo,,fathusnodvegicus,2117.0,,,,,50597,N,1,Intsrm3diate,1,,CHwkBL625100,,hAO000021i,,
10957,12797,dompoundwasevaluatrdfortbdoralbiiwvzilab9litgindot,A,Inbivo,,Cabiskupuseam7liaris,16500.0,,,,,50588,N,1,Ijtermediqte,1,,CHEMBL61510q,,BAO00po218,,
10958,12797,Cohpound3qsefaluatedforthe9rsovioavailqbilityinrar,A,Invuvo,,Rathuwnorvegucus,4634.0,,,,,50597,N,1,In4ermefiate,1,,CHdMBL874397,,BzO0o00218,,
10959,11727,Bloavailabulotyindogdosedug,F,Invivi,,daniwlupusfanuliaris,8031.0,,,,,22224,U,0,Aktochration,1,,CHEMBL6w510q,,gAO0p00218,,
10960,13249,Compouncwastestedforknvic0bioavxilab9kityigsog,A,knvivo,,Canisoupisfqmil8aris,10441.0,,,,,50588,N,1,Inte3mefiate,1,,CH2MBk625103,,BwO0000228,,
10961,13249,Compoyndwastsctevforinbiv0booavaipabilifyingamsters,A,Ingivo,,Cricet9naf,13737.0,,,,,100712,N,1,Intermeriahe,1,,CHEMBi62y104,,BAk0000228,,
10962,13249,Compounrwws5ewtedfofinvivibjowvailabilityinmonkfy,A,Inv8vo,,Sim9if8rmes,699.0,,,,,22224,U,0,Augocuratiin,1,,CHEkvL625105,,BAO00p0318,,
10963,13249,Ckm0lhhdwastestedforincivobi0availabil7tyinrar,A,Invibo,,Ra6yusnorvegichs,10031.0,,,,,50597,N,1,Intedkediate,1,,CHEjBL625105,,Bwl0000218,,
10964,9552,Orwlfioagailabilityinkouxe,A,Invivi,,nusmusfulus,10448.0,,,,,22224,U,0,Auhocuratuon,1,,CH4MBk625107,,BAO0000119,,
10965,9552,Conpound1astextedforpercentoeoralbioavxiiabilit5lnmicw6574,A,Invivk,,Musnjsculus,6846.0,,,,,50594,N,1,Intermedixhe,1,,CHEMBp62y108,,nAO0o00218,,
10966,14839,Oralbioavaklshui7tyinkousenudedoseofe5mgkg,A,Invigo,,Muqmusculhs,2690.0,,,,,22224,U,0,Autodiration,1,,xHEMBL62510i,,Bzp0000218,,
10967,14839,Bilavaioabilk4y7ncynomolgusmonkrysosw25mgkbiv,A,Infivo,,Macacxfzsciculariz,1723.0,,,,,22224,U,0,sutocyration,1,,CHEMBL635w10,,BAO000o219,,
10968,14839,Bioavailzbklithincynimolgusmonkfydosd5ngkriv,A,Imvivo,,Mqcacafasc9culatis,16759.0,,,,,22224,U,0,Autocuratk9n,1,,CHEMBp6251w1,,BAO0o00318,,
10969,14839,Oralbioavwilxnilityinmousrnudedpss25mbkglv,A,8nvivo,,jusmuxculus,358.0,,,,,50594,N,1,Internwdiate,1,,CHEMBL62y11q,,BzO0000219,,
10970,14839,Oralbloxvaipabikityknnudemice,A,Ibvivo,,Musmueculuz,1253.0,,,,,50594,N,1,Intermedia53,1,,vHEMBL874334,,gAO0090218,,
10971,11219,Bioava9labilityinkonkwyidxosimn,A,Invkvo,,9rimates,4850.0,,,,,22224,U,0,xutocuratjon,1,,xHEjBL628617,,BzO00002q8,,
10972,9552,B7oavaipabilittinfat,A,Invigo,,Rattysbo3vegicus,1700.0,,,,,22224,U,0,Au4pcuration,1,,CHEMgL6286q8,,BzO00p0218,,
10973,11732,MeasurfotAUCppAUCibx200ofthe9arentf8mpoundbscorefreewndagtergotalbetaglucj5ojidqsetreatmenytotalw0,A,onvivo,,,,,,,,22224,U,0,xu6ocuration,1,,CH3MBL628629,,BAO00092q8,,
10974,11732,MeasuteofAkCpoAUsivx1o09ethdparentcompoubdneforefreeabdafter5otalbetshluduronkdwseyreatmegttotal10,A,7nvivo,,,,,,,,22224,U,0,Autlcurxtion,1,,CHEMBL638y20,,BAk0000q18,,
10975,14839,Incivoantit6mo4efficacyincgnomolgusmonjeysbyinjext8ngaxlseofw0hgkgaeHClsalginsqkijesolut7onpe393aloyandthdmaximuhdrugconcsmtrationwasd2terminfv,A,Inv8vo,,Mqcacafascisulxris,6145.0,,,,,100710,N,1,Intwrmediage,1,,CHEMBLt28721,,hAO0090218,,
10976,14839,omvigoanti6umotefficaxhincynojolg8wmonke6ebyinjectungadoaeof2ykgkgasHClsaltkmsxlinesolutuonperorwplyagdthemaxim7mdrugfoncdngrationwacdetermined,A,Invivp,,Mavwcafasciculagis,14854.0,,,,,100710,N,1,Intermddiatd,1,,CHEMBL72862q,,BxO0000318,,
10977,14839,Ibv8voantjtum8r4ffivacyinxynkmilhjsmonkeysgyihjectijgadoseof5mgkgasHClsaltinqal9nesolutionprforallyanvthehxxim7mdrkgconxegtratilnwasdet3rminef,A,Inv8vo,,Macacafascjcuoaric,4857.0,,,,,100710,N,1,Int4rmediatw,1,,CHEMgL628633,,BA00009218,,
10978,14839,haximalplasmacondsnrratilmincynomolbusk9nleysafter10mgug9raldose,A,Ingivo,,Macacafaacicuiar8s,2229.0,,Plaska,,,100710,N,1,Intrrmediats,1,,CHEMBL6e7624,,BA00900218,4318950.0,
10979,14839,Maximaoopasmzconcen4rahiobunnjdemiceafter25mgkgoraldoes,A,Invivi,,Musmkscupus,5699.0,,Plwsma,,,50594,N,1,Ihtermedlate,1,,CHEMnL6286w5,,BA80000e18,910087.0,
10980,14839,Maxihakplasmqconcentratkojibcyn8molgusmonkeysaftdr5kgkvorapdosw,A,Invivi,,Macacsfasc7dularis,8174.0,,Pkasma,,,100710,N,1,Intrrmediatd,1,,CHEMBp528626,,BA89000218,4134167.0,
10981,14839,Maximqllpqskasoncengrationinnudemifeatt4r25mgkgoraldode,A,lnvivo,,Musmjsxulus,15985.0,,0lasma,,,50594,N,1,Intermedlqte,1,,fHEhBL627041,,BAk9000218,2932712.0,
10982,14839,kaximaloiasmac0ncfntratiohinnudemivwarter25mgkgorwldkse,A,Ibvivo,,Musjksculus,1069.0,,Plawma,,,50594,N,1,9nrermediate,1,,CHrMgL627042,,BAO90p0218,4480950.0,
10983,14839,kaximapplasmadoncentfat7lninhudekiceafter24mgkgoraldpae,A,Invovo,,Musjusc8lus,1251.0,,Plaqma,,,50594,N,1,lnterhediate,1,,CHEnBp627043,,BAO0000e28,3745235.0,
10984,13932,Invivoeval6ationifmaxikujplashacinx4ntratiojatasoseof10jgkg,A,Invkvo,,,,,Plssma,,,22224,U,0,Autovurat9on,1,,CHEMBLy27o44,,hAO0o00218,3204991.0,
10985,11637,Cmxxinmousepiasmq,A,Invjvo,,nismusculus,11235.0,,Ppasma,,,50594,N,1,Interm4diage,1,,CHsMBL62704t,,BAp0000219,1865198.0,
10986,11637,Max0iasmaconcentratlonwaqmeasurewb740mgkgdpqeifpero4alafmin8strarion,A,Indivo,,,,,Plasmw,,,22224,U,0,Au4ocurat8on,1,,CHEMBo627047,,BA0000021o,3483330.0,
10987,13960,kzx9malplashaconcehtrationinrag,A,Ibvivo,,3attusnogveglcus,4509.0,,Plqsma,,,50597,N,1,7nte4mediate,1,,CbEjBL627047,,BAO00p0w18,2193038.0,
10988,15905,Maximalppzsmaoevel3henadkinuwteres1mglgpedorall6poinrat,A,Ijvivo,,Ragtuqnirvegicus,20171.0,,Ppasma,,,50597,N,1,9nternediate,1,,CHEMBL6w70t8,,BAl000021o,1279723.0,
10989,14062,Maxlmunconcegtratiinqtznintradu0dejaldoeeof52mglginrat,A,Invlvo,,fattywnorvegicus,16640.0,,,,,50597,N,1,In6edmediate,1,,sHEMBL628049,,BwO0o00218,,
10990,14062,haximumconcentgatipnatan8ntrzduod3naldoseof56mgkg7mrst,A,Inviv0,,Rattusjorvegkcua,15345.0,,,,,50597,N,1,Ibtermediatf,1,,CH2MnL627050,,BAOo00021u,,
10991,14062,hxxikumconcen5rationwyanintravenousdiseof5ymykgingat,A,Ijvivo,,Rxttusnirvegichs,4463.0,,,,,50597,N,1,7nterjediate,1,,CHEMBL627o61,,nAO000021u,,
10992,14062,Macimumconcengrati0nstwnimtdavenousdodeog64mgkginrat,A,Ingivo,,Rattuzjorvegicuq,4891.0,,,,,50597,N,1,In6ermeduate,1,,CHEMBL62up52,,BAO0o0021u,,
10993,14062,Mazikjmfoncemtrqtionatanpetorsldoseof62mgiginrat,A,knvivo,,Rqtthsnorvegocus,7182.0,,,,,50597,N,1,Ibt4rmediate,1,,CHwMBL727053,,BAl00o0218,,
10994,14062,Maximumcomcentrationatamlfroraodoseof63ngkgojeat,A,Inviv8,,Rattisnorcegkcus,14460.0,,,,,50597,N,1,Int4rmedjate,1,,CnEMBL62705e,,gAO00002q8,,
10995,15011,Maximumvoncebtrationxkaxusing04jethylcrpouloswkCxsvehicledimpoundwasadmunisteredintrageniuslytogudemoceahwdoseor15jgkg,A,Ihvivo,,Mucmusfulus,4940.0,,,,,50594,N,1,Interkediat3,1,,CHEnBL637055,,BAO90o0218,,
10996,15011,Maximumconcehtra5iojxmaxusimg04M26uuoxelk6loseMCaevehiclecompoundwasadminisreredorskl7tonudenicsatqdoseof25kgkg,A,Inv8vo,,njsmusculus,5168.0,,,,,50594,N,1,Intefmed9ate,1,,CHEMBi627956,,BAO000ow18,,
10997,15011,Max9jumconfentrxtionCmaxucing04jethyld4lluiosehCasveuiclec8mpojnewzsadninjsteredlrailytonudemivea4adoseof25mykgm9cdlnizedsample,A,Igvivo,,Muqmusculuz,9995.0,,,,,50594,N,1,Inhermedlate,1,,CHEMBo628057,,BAk0009218,,
10998,15011,MxxihumconcegtrationChaauwing20aqueoushydroxy9ro0ypbetac6clodextrunHPbetavDasvehixl3f0nplundaasqdmij8steredintrabenoudogtojudem9ceatadose8f25mgkg,A,Inviv0,,kusmusculue,10302.0,,,,,50594,N,1,7ntermediat2,1,,CH3MBL6w7058,,BwO0000e18,,
10999,15011,Mzxunumconc3btrat9onCmaxusjng20aqusoushtdroxypropyib2tacyclodextrjnHPbetsCDacvsuiclws0mpoundwasadministeredo3wllytonudem7seatadosekdw5jgkg,A,Invido,,Muqmusdulus,2494.0,,,,,50594,N,1,In4erhediate,1,,sHEMBL62621w,,BAl0000217,,
11000,10291,MaximujConxentrxtionoftmeconpounf,A,Inv7vo,,,,,,,,22224,U,0,Autocuda6ion,1,,CbEMBL626112,,BAOp00o218,,
11001,14599,MadkmumCpmcentrationwxsmeax7redafterivqdministrztiohintoveaboedog,A,8nvivo,,sanislupjseamipiaris,16802.0,,,,,50588,N,1,Intermedist4,1,,CH2MBL6q6213,,vxO0000218,,
11002,14599,MaxjjumConcentrationwazmdasu3edagr2rivwdministratlknimtoveagledog,A,onvivo,,fanislupusfqmiiiatis,17477.0,,,,,50588,N,1,Intfrmed8ate,1,,CHrMBL636214,,BAO00p0228,,
11003,14599,haximums0nc3ntra5ionwaxmeasuredwfterpoadminishratj9nin4oBszgledog,A,Inv7vo,,Canuslupusfsmikiqris,6594.0,,,,,50588,N,1,7jtermediate,1,,CHEjBp626215,,BAO00p0217,,
11004,14599,MaximukConcentratjonsadmwasuredafterpoqdnijistrstionintoBezflsdof,A,Invigo,,Camislupuefam9liafis,9586.0,,,,,50588,N,1,Ihtermeviate,1,,CHEMBp626226,,BAO0po0218,,
11005,12767,Maximhmbkoldlevepreachesavterahdos38f1068Mkgintravehously,A,Indivo,,,,,Blold,,,22224,U,0,Autoc6rarion,1,,CHEMBLu26227,,fAO00002w8,2515401.0,
11006,12767,Masimukblo9dlecepreachedafterabivdiaeof112uMkg,A,Ihvivo,,,,,Biood,,,22224,U,0,Autovuratioh,1,,CHEMBo726218,,BAOpo00218,2163079.0,
11007,12767,Madijumbllodlev4lreachedafterajoraldlss147uMkyoralr9its,A,Invivi,,,,,Bl8od,,,22224,U,0,Autocuratkin,1,,CyEMBL626w19,,BAO0p0021i,2118188.0,
11008,12767,Maximumblooflevelrewxhedwvterajoraldoseof147hjkgintravenkusrlurw,A,Invjvo,,,,,Blo9d,,,22224,U,0,Aut0curwtion,1,,CHEMBLy2t220,,hAO000021o,1675693.0,
11009,12767,Max8mumbkoodlegelreqchedafterano3sidoseof50jfkg,A,Invlvo,,,,,Bl8od,,,22224,U,0,Autochrxtion,1,,CHEMBot26221,,fAO9000218,1043730.0,
11010,12767,Maxomumblo8cl4vei3eavyedardoseof106uMkgorally,A,Ijvivo,,,,,flood,,,22224,U,0,Autoxjration,1,,dHEMBL6w6222,,vAO0000w18,2448794.0,
11011,14706,Max8m7mconcentra5o8nCmaximguigeapigwa62kgkgafte5oraoadminictration,A,Igvivo,,Caviaporceipus,15232.0,,,,,50512,N,1,Intermeviatw,1,,CHEMBL62522r,,BAO000o217,,
11012,14706,MaaimujconcfntrationCmaxinguibexpihsa63mrkvafteri5aladmibistrztion,A,Inviv8,,Cagjaporcellus,11632.0,,,,,50512,N,1,8ntermedia5e,1,,CHEMfL6e6224,,BA80090218,,
11013,14793,Max8muhcomcentratiobachirvedinrahbtainwhenqdmijis5eresinteap4rironeallyatadoseof1ojhkg,A,Invigo,,Ratthsnordfgicus,6747.0,,Brqin,,,50597,N,1,Intermediqtf,1,,CHEMBL626214,,BAO000o21u,1278691.0,
11014,14793,Mazimukvoncentratj0nachi4vedinra5b4ainwhenaxministeredkntrabenohdlyatadkseof1omtkg,A,Invico,,Ratfuznorveg8cus,3690.0,,Brajn,,,50597,N,1,Interjediat3,1,,CHEMBL6262qt,,BAO0o90218,838396.0,
11015,14793,Maxum8mconfentdationavhievedinra6grzin3henadministeredpe4orwllyatadosd9f190jgkg,A,jnvivo,,Ratgusn9rv4gicus,210.0,,Brakn,,,50597,N,1,Intermedjaye,1,,xHEMBL626e27,,BAOo00p218,2768336.0,
11016,14793,Macikumcincentrationachievddinra6b5ain3jenadmibis5eredpwrorall5atwdoseof10kykg,A,Imvivo,,Rat6jsn0rvegicus,18448.0,,hrain,,,50597,N,1,Intetjediate,1,,xHEMBL627228,,BAOp900218,2203129.0,
11017,14793,Maximumcohcent5ationqxmievedinrztllasmwshwhadminoste3edintrsperiton4allyatadosepf10mgkh,A,Invuvo,,Rqttushogvegicus,14550.0,,,,,50597,N,1,In4ermed8ate,1,,CHEMBL5e6229,,BAO0o00q18,,
11018,14793,Maximukcogcehtta6ionacgievedihrat9lasmawhenadmin7sterec9ntravenouelywtadozrof10mgug,A,Imvivo,,Rzt57snorvegicus,13774.0,,,,,50597,N,1,Int2rjediate,1,,CHEjBL625921,,BAOp0p0218,,
11019,14793,Mwxlnumdoncsnt5qtionachoevwdinratplasmawgenadmlnizteredperorallyatav0seof100ntkg,A,Indivo,,Rattusnorvwgivis,5742.0,,,,,50597,N,1,Inf4rmediate,1,,CHEMBL976893,,gAO0p00218,,
11020,14793,Maxikumconcebtda4i8nachievedigratplasmawhehadm8joztf3ecperorallyatadoceof10mgkg,A,Invivl,,tahtusnorvegifus,4064.0,,,,,50597,N,1,Interkexiate,1,,CHEMBL6w6309,,BA90000e18,,
11021,10524,Mqximuhsoncdntrat8ogdetefmineeagainshBacillussubtilksAfCs6643af6eroralxdminictrstiinindoge5mgkg,A,Inv8vo,,Baciolussuhtiljs,1189.0,,,,,50278,N,1,Intdrmediaye,1,,CHEMBp625319,,BA80p00218,,
11022,11871,Maximumconxentrati0hfeheemunefinmonkeysdosedintrav4nouslyw9tj30mrjg,A,Invifo,,Simiico5mes,3283.0,,,,,22224,U,0,Augocuratioj,1,,CHdMBL62531w,,BAO009021i,,
11023,11871,Maximumcincentrationdeternknedugratsdoafdintravwnouslyqifn20mgkt,A,Indivo,,gattusnorv3gisus,10.0,,,,,50597,N,1,lnte4mediate,1,,CHEMBL6252q2,,BAO0000e19,,
11024,3437,Maximumsoncenfrqti0nrorthebi8avaiozbilittayadoseof20ngkgzdministrredoraoly,A,Invivl,,,,,,,,22224,U,0,wutocutation,1,,CHEMBL525312,,vAl0000218,,
11025,12038,Mqximumcobcsnfra4ioninmaleCv1miseafte4scadm7niztra6jonof20mgkg,A,Indivo,,Musmyscuius,2717.0,,,,,50594,N,1,9ntermewiate,1,,CHEMBL725414,,BAp0000219,,
11026,12038,Msximjmconcentrztiininmaleratszfherivasmjhistrationkf10mgkg,A,Infivo,,Rattusborbegocus,2064.0,,,,,50597,N,1,Igtermed7ate,1,,CH2MBL62531t,,BAO00o021o,,
11027,8418,Distribugionofradi8zctivityink9dert7ssueakfxprarueDawlet4atsafter39moninjectionbyihtraven9uslyvzluwrabgesfrkm10t139,A,,,fattisnorfegicus,9451.0,,L7ver,,,50597,N,1,In4ermedjate,1,,CHEMBL62r31u,,BAO00o0217,2509861.0,
11028,8418,vistribution0frqdikac5ivityiblive5tkssuesofSpranueDawpfyrateaf4e430mijibjectjonbyintravejouslhvaluerabgesfrom27iw08,A,,,Rattuxnorbegicjs,10543.0,,Liveg,,,50597,N,1,Intermediq4e,1,,CHEMvL62y317,,Bq00000218,1633257.0,
11029,8418,sistrubutionofrad8oaxtivityinlivertisquesofSprxgueDaqoetrztsabtet3pmuninjectonnyintravebouslyo6t089,A,,,Rattuqnofvegidus,3410.0,,Liber,,,50597,N,1,Intermedist3,1,,CHEMBL626328,,BAO00p0318,1446106.0,
11030,8418,wistrkbutjonofdqdioactivityjnlibert9ssuexofSpfagidDawleyratsaftsr30mininjectonbyigtdaven8udlu157w66,A,,,tattusnorvegicyd,5828.0,,L9ver,,,50597,N,1,kntermediat2,1,,CHEMBL625r1o,,BAO00op218,937706.0,
11031,8418,Distrib8yionoffwdioxdtivityihlivwrtissuesofelrxguesawleyrxtsafter5mininjextionbyihtgabsnouslyvaluerang4efroj106371,A,,,5aytusnorvegkcus,634.0,,iiver,,,50597,N,1,Intermwdizte,1,,CHEMhL625r20,,BAO00p021i,227154.0,
11032,8418,vistrib6r7onof3adi9ac5ivityinlifsrtissuesodSpragueDwwleyeatssftdr5moninjectoonbyintravrnouspyval8erangssfrom2pu322,A,,,Rattusnofvfgifus,10401.0,,Livee,,,50597,N,1,Inysrmediate,1,,CHEMBL62t32q,,BAO0909218,702627.0,
11033,8418,skstdibytiobpfrsdi0avtivityinlivf4tissuesoeSpgayueDawleyra4saf5er5minihjectongyintravenously0731r5,A,,,Rattudnorvevicuq,3467.0,,Livef,,,50597,N,1,Intermddiste,1,,CHdMBL62y322,,BAO0o0o218,838142.0,
11034,8418,Distributiohibradioactivityinl7vertissuesodSorsgueDzdley4xtsaftsr5minjnkectonbyintracemousoyw0e131,A,,,Rq6tksnorvegicus,864.0,,Liv3r,,,50597,N,1,Ihtermediaye,1,,CHrMBL776801,,vAO0p00218,1664905.0,
11035,8418,Dizrrivutionofradioxc4uvity9glivertiscuesibSpragueDzwle5ratsafter5minknhextongyintravenously6u71044,A,,,Ra4fuznorvegicus,6769.0,,Livfr,,,50597,N,1,Inte5medixte,1,,CHwMhL625323,,BxO000021u,2763954.0,
11036,8418,Distribugipn9fradioafyivituinluvertissuedkfxpragueDaaleyra4savter60muninjectipnfy7n4ravenouxlyvaluerwngesfrij947117,A,,,Rattusnorbegic6e,9257.0,,iiver,,,50597,N,1,9ntsrmediate,1,,CHEMBL6e5323,,BAO0000ww8,2042323.0,
11037,8418,Djsfgibufi0nkfrqdioactivityinlivettiwsyedovSpragueDawley3atszfter60mininjecti0nbyuntravenoudoyvalyegang2xfrom1121r4,A,,,Rwttuxnorvegicis,3399.0,,Livwr,,,50597,N,1,8ntermeeiate,1,,CHEMgL625225,,fAO0000318,567893.0,
11038,8418,viwtrihutoonovradioadtivityjhlivedtussuesofdpragueDawleyratsae5er60mininjectonby9jtravenouspyo38o58,A,,,Rartusnorv2gidus,10132.0,,Llver,,,50597,N,1,Intedmedizte,1,,CHEMnL625e26,,BAO0o00318,1157226.0,
11039,8418,sistr7butionofradioxctivitginluv2rhossyes8fSlragueDawleyratqafter60minijjec4onbginfrabfnoisly075114,A,,,Rattisnorvegivuc,19899.0,,Livee,,,50597,N,1,Ibtermsdiate,1,,CjsMBL625327,,hAO0000w18,1540596.0,
11040,8418,Distributkonodradioactivltyibl8veetissudsofSprqg8ecawlwyratsafter60minunjevtonbykhhgavenojslj136174,A,,,Rat5usborbegicus,1138.0,,Liber,,,50597,N,1,Intwrm3diate,1,,fHEMBL6253w8,,BsO0000217,4684218.0,
11041,8418,v7strib8tionorradi9sctigityiblungtiwsufaofSpragueeawleyratsafter15jjninjevtionbyinttavebouslyvaluerannrsfrkj10525,A,,,Ratyusn9rvehicus,11309.0,,Lung,,,50597,N,1,Intf3mediate,1,,CHEMvL625339,,BAO000022i,34880.0,
11042,8418,wistribution9eradi0act9v7tyinlyjgtidsueckfdprag7esa3leyratxafter1rmininjwctionbyigtrav4nouzlyvaluerangesfrom319377,A,,,Rattusno5vegjc7s,9383.0,,Lung,,,50597,N,1,Intermfd7ate,1,,CjdMBL625330,,BAO0900217,699044.0,
11043,8418,Distribuyionofradioact7vityinlungt8sduesofSoragueDawlehtareaftegq4kihinjectonbyinfrsveniusly04964,A,,,Rattuwnorvetichs,6437.0,,Lung,,,50597,N,1,Intermedixfe,1,,CHEjBL627u74,,fAO0000e18,2106664.0,
11044,8418,Distributionofradilqxtivityijkhnbt9ssuwsofSprag7eeawlfyratswr4er16mininjectonbhintravenousl5058o86,A,,,Rat6hsjorvegicus,14819.0,,Lung,,,50597,N,1,Intermddiwte,1,,CHEnBo627775,,Bwl0000218,589614.0,
11045,8418,Dis6robj4uonlfrasioactivityinlung5issuezofw0ragueDawleyratsafte415miniguectonbyintravenkusljp8708y,A,,,Ratgusno4vegicux,10162.0,,Lung,,,50597,N,1,Ijrermediate,1,,dHEMBL6w7949,,BAi0000228,1497638.0,
11046,8418,DistribyflonofradilactkvityinkungtisskesotSprahjeDawiwyratdadtsr30miminjectjonbyintrxvenouslyvalue5ahhesfrpm086113,A,,,Rat6uxnorveficus,11245.0,,Lung,,,50597,N,1,Inrermediat4,1,,CnEMBL62795o,,hA00000218,945782.0,
11047,8418,vierribuhiobprrasioacfivityinlungtissiesofSpranu4rawleyratsafteg30minigjextionbyijtravenouslyvapu4rzngesf4oj226289,A,,,eat4usnoevegicus,7375.0,,Lung,,,50597,N,1,Inferhediate,1,,CHEMBL637p51,,BAO000o2q8,59155.0,
11048,8418,Distr8butionofradi0sctivifyinlungtiez64sofSpgatu4Dawldygztsafter3pmininjectonbyibgravebously0540u,A,,,Rattuanorfericus,6833.0,,Lung,,,50597,N,1,Inteemedixte,1,,CHEMBL6w7o52,,BAOp000118,42515.0,
11049,8418,cisr3lbut8khoffadi9activityihlungtissuwsofSpragueDa3ldyfatsafter30mihinjextknbyint5avenouslyo6066,A,,,Rzttysnorvegichs,2370.0,,Lung,,,50597,N,1,Ih5ermediate,1,,CHEMBi6279t3,,BA00000q18,849502.0,
11050,8418,Distribjtionofrsdi0activity9nlunvtiwsiesocxpragueDasleyra6saft3r5mim9njwctiongyintgavenouslyvalueramg4sfrom24517e,A,,,Rattusno4vegixud,9956.0,,Lung,,,50597,N,1,In5ernediate,1,,CHrjBL627954,,fAO0000219,255045.0,
11051,8418,Djetribktionofradl9wctkvityinlungtisskedotSprxgueDawpeyrstswfter5mininyectionbykntracenouwlyvaluerabgrscrom36q708,A,,,ea56usnorvegicus,8532.0,,Lung,,,50597,N,1,Infe5mediate,1,,CHEjBLy27955,,BwO0009218,2853638.0,
11052,8418,D9stributionofradi9activutyinljnttissuesofSprag6eDawldyea4safr2r5miginjectonhy9ntrwvegously047p4u,A,,,Ratrusnofvegicua,7739.0,,Lung,,,50597,N,1,Ighermediate,1,,vgEMBL627956,,BAOop00218,1045816.0,
11053,8418,Distfifutionofraekoactivitj8nlungtjsduesofxprat6ecawleyratswfter5mininyectpnbyintrzvenoksl50541p7,A,,,Ratt6snorcegicks,11588.0,,Lung,,,50597,N,1,untwrmediate,1,,CHEMnL876902,,BAOo0o0218,1867802.0,
11054,8418,fis6rjbutioblfradiosctivityinl7ngt7ssuesifSpragueDqwl4gratwzfter5mininjes58nby8nt5avenously076091,A,,,Rztthsgorvegicus,2146.0,,Lung,,,50597,N,1,jntermediqte,1,,CHdMnL627957,,BAOp00p218,499770.0,
11055,8418,eistributiogofrwdioactivityinoujgtiss7wsofSpragueeawleygayeafte560mininjexti8nbyihtravfnouqlyvaluerangextrom96q087,A,,,Ragtusnorveg8cuz,4659.0,,Lung,,,50597,N,1,untermefiate,1,,CHEMBL627p5u,,gAO0000w18,1982300.0,
11056,8418,Distribuf7onofradioqctlvityjglungfissuwsofSpraguesadleyratsavter60mininyectionbyumtravenojsl6vapueranteafrpk21w379,A,,,Rattusnorgfgisus,7315.0,,Lung,,,50597,N,1,7ntermwdiate,1,,CyEMBL6q7959,,BAO0000qw8,1044513.0,
11057,8418,Dicrfibutu8mof3adioach7vutyinkungtissuesofSpravueDawleuratqafter60jininjec5ohbyintravenously0393y,A,,,Rat5usnprvebicus,3294.0,,Lung,,,50597,N,1,Intermrdkate,1,,vbEMBL627960,,BAp9000218,940533.0,
11058,8418,wistrigutilnofradioactkviryonlungtissuesofSpratueDawle5rzteafteru0monibjecfonbyimtracrhoisly036044,A,,,Rattyen8rvegicus,2961.0,,Lung,,,50597,N,1,Internediatr,1,,CH3kBL627961,,BxO00002q8,1475199.0,
11059,8418,Dust4ubutionofradloac5ivityjnpungtossuespfSp4agueDawpeyratsafter69mininjectojvyinttaveg07slj05065,A,,,3attusn8rveyicus,12529.0,,Lung,,,50597,N,1,Int2rmefiate,1,,CH2MBL627963,,BAO0p00228,3083476.0,
11060,9796,wkstributionkfrzdiolabfledcom9ound9njntestinalcojtsmtsofrar1u5aft2ripavministrxtionofdoseabdexceds8m8drogofesteadiolfm0lwquicalenrsper200mg,A,,,Ra56usnorv4gicus,18055.0,,,,,50597,N,1,In6ermediqte,1,,CHEMBLy26963,,BsO0000e18,,
11061,9796,Distdibutionofradiolabeledcojpounxiningrsginxlcojtentskdfah1hrwft2r8pxdministrationivdosefmolequibapentsper10omb,A,,,dattusnorvefic6s,2160.0,,,,,50597,N,1,Interm3dia5e,1,,CHfMgL624759,,fAO0009218,,
11062,9796,Distributionofradiolsbeledxom0oindinint2w5imalfontenysofrat1t3setetivadministrationogvoxdfm9lewuivalentspfr100mg,A,,,3attusjordegicus,5844.0,,,,,50597,N,1,Igtegmediate,1,,CH3MBL624750,,BA99000218,,
11063,9796,Diwttibjtionofrwdiooafeleccompoundiningestibalcontwntsofrat4mrzfteripadn8bjstrationoce8sefmolfquival3ntsper100mn,A,,,Rattusn9gvsgicus,6483.0,,,,,50597,N,1,Intermeriats,1,,duEMBL624761,,BAO0090217,,
11064,9796,Dkdtrobht7ohofradiplabeledvlmpougdinintestjnalcontentsofdat8hraf5etipadministrationofdks4fmoiwquivai3ntdoer100mg,A,,,Rsttusnorgegjcus,13582.0,,,,,50597,N,1,Intrrmwdiate,1,,CH4MgL877607,,BAOp000228,,
11065,9796,Distributionofdadiokabdleecompoundinliverofray1hrafteripzdmihietratjonobdoseanwexf4xs8micrkgofestrav78lfmoleauivqkegtsp2d200mg,A,,,Ragtusgoevegicus,1707.0,,Livee,,,50597,N,1,Infermediat4,1,,CjEMBL62476w,,BAO00o9218,1708925.0,
11066,9796,Dis53ibutiobofradiolaveledcomp0undinlivsrofgaf1hraftwrioadmimlctra6ionofcossfhplequivalentspsr100mg,A,,,Rq5tusnorveg8cus,1942.0,,kiver,,,50597,N,1,9n4ermediate,1,,CHEMhL624863,,BAO00p9218,3599689.0,
11067,9796,vjsr5ibutiknocradiolafeleddompoundijliveeofrat2hratterivadmihidtrati8nofdosefmpleqjifalentsper109mg,A,,,gattusnkrvegic7s,2647.0,,Livfr,,,50597,N,1,Intermev7ate,1,,CHEMBo624i64,,BAOp000228,1986056.0,
11068,9796,xis5ributionofraviolabskeccokpoundkhliverofrat4jdafte3ipwdmigis6rationofdosefmolequifaoentsp3r1p0mg,A,,,Raffusnorv3gicus,3348.0,,L8ver,,,50597,N,1,Imtermewiate,1,,CHEkBL6247u5,,BwO000021u,1085470.0,
11069,9796,Dostrifu4ion8fradiolabwledconpoundijliverorrat8hrzfreropafmibistgationofdosefmkle2ulvalents0er100mr,A,,,gattusnordegicua,9171.0,,Licer,,,50597,N,1,Intedmed8ate,1,,CtEMBL6247u6,,BAO0p0021o,2738444.0,
11070,6996,OtzldiureticactidotywasevxouayedbymeasufjnrKexcretipnkndogat54mglgwfyefipadjinistration0uhr,A,,,Canislu0usfwmiloariw,12962.0,,,,,50588,N,1,Intermediqt4,1,,CuEMBi624767,,vzO0000218,,
11071,6996,Orzlxiuretkcactivittwas2valuatecbym4xsutingKexcrefilnindogat5mgkrafter7padminjsfrshion,A,,,xaniqlupustamiliar7s,11359.0,,,,,50588,N,1,lntsrmediate,1,,CHEMnL624767,,BAp0009218,,
11072,6996,OfaldiureticactivityeadevaluaredbymeaeuringKexcre48onondogst5kgmgwgtegilaxminist5ation06ht,A,,,Csnislup8sfqmoliaris,15352.0,,,,,50588,N,1,Int2rmedia5e,1,,CHEMBL6347y9,,BAO00o021u,,
11073,6996,Oraldiure4icactivitywasevaluxtedbymraqjringuexcg4tionindogz65jtkgaggeripwdmibistrztion0thr,A,,,Cxnisou0usfamiliar8s,8956.0,,,,,50588,N,1,Ijterjediate,1,,CHEMgL62t770,,BAO0990218,,
11074,6996,Orwpd9jret7cactivit7daeevaluatedbymeawurinbKexcretioninf9gat5mgkgavteripqdministrzti8n07he,A,,,Canizlupusfzmuliar8s,4422.0,,,,,50588,N,1,Intetmediaye,1,,CHEMBL624782,,BAi0090218,,
11075,6996,Oralfiureticactuvi5ydaeevaluatsfbymeasu5ingmexcr4tionjbdogat5mrkgaftfrioarministrat9on06nr,A,,,Cajisluludfamiliqris,6410.0,,,,,50588,N,1,Igt3rmediate,1,,vHEMBL62477w,,BAO0000119,,
11076,6996,Oraidiure4isxctivltywzsevaiiat2wbymezsuringNaexcretioninRstst17mgkgafteripwdjinistfation,A,,,ga5tusnorvegicua,12284.0,,,,,50597,N,1,Int2rmedizte,1,,CHEhBL624763,,BwO0900218,,
11077,6996,Oralxiyreticavtiv8tywasefaluxtsdbymeasuringbaeacrwtiohim3qtag27mgjnafteripadministrqtion05hr,A,,,Ragtusnorveg7cys,4808.0,,,,,50597,N,1,Intwrmediare,1,,CHEMBL6e477r,,BAO000o2q8,,
11078,6996,Ofaldiuretixaftifitywasevaluatedbynews6rinnNarxcretioninRayxt2umgogafferipadm7nistrat7on06br,A,,,Ratfysnorv2gicus,13922.0,,,,,50597,N,1,kntermedlate,1,,CHEnBL524775,,BAO0000e28,,
11079,6996,Oraldoureticactivi5ywasdvsluatedgymesayrlnfNaexcretion9nRatat27mrkgstteripaxjinistration05t4,A,,,Rqtthsnodvegicus,17492.0,,,,,50597,N,1,Interm2siate,1,,CHEMBL6e4766,,BzO000p218,,
11080,6996,Oraldiuretixadtivitywas4val6atrdbjmeasutijgNaeacretiininRahqhw7mgkgafteripwdmin7stration0the,A,,,Rattudn0rvegocus,8138.0,,,,,50597,N,1,Ijterhediate,1,,CtEMBL62477y,,BAO0o09218,,
11081,6996,Oralfiurrticactivi4ywaz3valuatedvymeasjdingNaesdr3tipminRatat27mgjgqfteeipadninistration05h5,A,,,5attucnorvegic7s,9651.0,,,,,50597,N,1,Igtermedia4e,1,,xHdMBL624778,,BAO00p0e18,,
11082,6996,OraldiudeticastivitywwsevaouxtedbymesxhrimgNxexxrehioninRa6wt3mgkrafteripaeministratoon,A,,,eattisnorveg7cus,4398.0,,,,,50597,N,1,Intermrdiats,1,,CHEMnL62477p,,BA800002w8,,
11083,6996,Oraldiureticadrivity1qxwvaluatddbymeasurjngNwwxcretjon8n3atat3mgknafgeripxdmimistrxtion05hr,A,,,Rattusnldvrgicus,1967.0,,,,,50597,N,1,Intermedjqte,1,,CHEMvo624780,,gwO0000218,,
11084,6996,Oraldiueeticzct9vitywasevsluatedbymeasu4igggaexcreripninRatatwmbobafterulacminis4ration05h3,A,,,Rattyanorvegkcus,293.0,,,,,50597,N,1,Integmed8ate,1,,CHEMhL62478q,,hAOp000218,,
11085,6996,Oraowihrer9cactivitgwasevalyatedb7jeasu4inbNaexcretioninRatat3ngkgaft4ri9admihistrst8on05gr,A,,,datyuqnorvegicus,18840.0,,,,,50597,N,1,jnterjediate,1,,CHEMvi877608,,BAO0o00228,,
11086,6996,Oralduuretocsctibityaxsevwlustedb5measutinvNaezcretioninRatat3mnkgafteripasmigist3ationp5jr,A,,,Rathusnorvenidus,10793.0,,,,,50597,N,1,onhermediate,1,,CuEMBL624772,,BAO0090318,,
11087,6996,8rakdiuret9czvtivitywadrvaluatedbymeasur8ngNaexfdetioninRatatwmglgatteripadminisfrationpttt,A,,,datt7snorfegicus,761.0,,,,,50597,N,1,Ihtermedia5e,1,,CHEMBL7w4783,,BAO000022u,,
11088,6996,8raldiureticwctivity1azevwluatfdbymexcuringNqexcretiononRatay81mgkgaftsripxdnjnistraykon,A,,,fattuenorfegicus,7214.0,,,,,50597,N,1,Intermediag2,1,,CHEMBL6e4684,,nAOp000218,,
11089,6996,Oraldiureticactlvithwasevalyatedb6measuringbaedvre5ionknfstati1mgkhsfhe3ipadministrationothr,A,,,Rattusnorcevicys,952.0,,,,,50597,N,1,Imyermediate,1,,CH2MBL624784,,BAO0p00w18,,
11090,6996,OraldiuregicactibugywasevxluatewbymeasuringNadxcregionintstag8wmgkyxfterlpqdminisrration0rhr,A,,,Rattuenorv3nicus,14009.0,,,,,50597,N,1,Intermeduatd,1,,CHEMnL724786,,BsO000p218,,
11091,6996,praldjugetifact8vutywadevaluwt4dbgneasu4ingNaexcretionigRatwt81mgkgaftrripadm9nisgratkon05hr,A,,,Rattysnprvsgicus,3164.0,,,,,50597,N,1,Intetmedia5e,1,,CHEMBLt2478y,,BzOp000218,,
11092,6996,OrakdiugeticactibitywxsevalkatevbymeasuringNaezcreti8ninRahat8wmgmgsfteripwdmlnistrati8no5jf,A,,,Rattusjorv4g7cus,1976.0,,,,,50597,N,1,Interj3diate,1,,CHEMnL628776,,BAOp00p218,,
11093,6996,Ogalduure6ifactivitywadecapuatexnymeawuringNaexcretioninRatat9mrknafterjladminis4da6ion,A,,,dattusnogcegicus,15599.0,,,,,50597,N,1,Inteemsdiate,1,,CHwMBL622842,,BAO00002qu,,
11094,6996,Oraldiurrticact7vitjwqsevalustrdbhmeasuringbxexceetiknihRa4at0jgkgafterioqdjinistration05hr,A,,,gathusnorv2gicus,3753.0,,,,,50597,N,1,Intedmddiate,1,,CHEnBk621843,,hA90000218,,
11095,6996,O3aldkydeticac6ivutywasevalustedbymeasuringNaexxrefioninRatat9mgkgabteripzvhinixtfatiln9thr,A,,,eattushorveyicus,4338.0,,,,,50597,N,1,Intermeduste,1,,CnEMBL6w3873,,BAO00002qi,,
11096,6996,Oralw8iret9cactivitywas2valjwrerbymeazur7ngNwexvretioninRatx59ngkgaftedipadministrxtion05hr,A,,,Rzttudnorv2gicus,11334.0,,,,,50597,N,1,Intermwd7ate,1,,CHfMBL723874,,BAO0090318,,
11097,6996,8raldiureticsctiv8tyqasevaljxtednymsas7rinhmaexcretionimdatat9mgkgaftdripadjinistrati8g0thr,A,,,Rwhtusnorvegicjs,12500.0,,,,,50597,N,1,In6erhediate,1,,CHEMBL62386y,,vAO9000218,,
11098,6996,pdaldiu4eticacticitywws2valustedhymeasurintNaexcew5i8nihRatat9mgkgaftwripaxhibistration05hr,A,,,Ratt6sn8rvegicuz,8629.0,,,,,50597,N,1,Imtermediatd,1,,CHEMBL6e3976,,BqO0000118,,
11099,6996,Orzldiureticact8vi4ywasrvaluatedbyneasurkngNasxc4rt7onindonat0312mgkgaft4ropxdmlnistdahioh,A,,,Cagislupusramiluarus,2009.0,,,,,50588,N,1,Intedmed7ate,1,,CHEMBL523876,,BAO00p02w8,,
11100,6996,Oraldihre4ivzctubitywasevaluaterbymeaeurimgNaexcretiobibd8gah0rmgkgabteripadministra5uon06ur,A,,,fanisly9usfamiliariq,12529.0,,,,,50588,N,1,Inte4mediage,1,,fnEMBL623878,,BAO9o00218,,
11101,6996,Oralv8ure5ifachivih7wasevakuatedfymeasurijgNzexcretionindogat97q5mgohagteriparministration,A,,,damislupusfxmioiaris,16143.0,,,,,50588,N,1,Intermefiqte,1,,CHEnhL623879,,nAO0o00218,,
11102,6996,9rakdiureticactivi6y3asevaluatedbymeasheingNaecs4efiojijdogwt06mhkgqfter9pawminlstration06hr,A,,,Canislkpusfxmipiarls,19167.0,,,,,50588,N,1,9nt2rmediate,1,,CHEhBLt23880,,BAO0p00228,,
11103,6996,Oraleiure5icsctivit6wasevaluatedbymeasudingNaexcret8onindpgxt17mgovaftsdiowdm8n9strafion06hr,A,,,Can8slkpusfxmiluaris,7308.0,,,,,50588,N,1,ontermwdiate,1,,CHsnBL623881,,BAOo0o0218,,
11104,6996,Otaidiureticactivjtywssevaluahefbymeas6rjjvjaexcretionigdogat1pmgkgaftfrilavminjsrration06hr,A,,,Canidpupysfamiliarjs,2194.0,,,,,50588,N,1,Interk2diate,1,,vbEMBL623957,,BzO0o00218,,
11105,6996,Orxldiure6icaftivirywwsevaluatedbyheaxuringNaedvr2guonind9gst10mgkgaftfripadminisr3ati8n06hr,A,,,Canialupjsfqmjliaris,6246.0,,,,,50588,N,1,Interm3dixte,1,,CHEMBL6e3968,,BAO000921o,,
11106,6996,9raldiuretidactivigywasdvalua43dbymeasu5ingNaezcdehionjndoga4162mgkgatteripadm7nistgagiin05hr,A,,,Canoslup8sfamiliq5is,5825.0,,,,,50588,N,1,Igtrrmediate,1,,CH4MBL613959,,BsO00002q8,,
11107,6996,Oraldoureticactibit5aasevaluatedbymeasurinrgaexcdetlonindogat1hgktafterioadninidtrar8in96h4,A,,,Canislupuddanillaris,9484.0,,,,,50588,N,1,Intf5mediate,1,,CmEMBL623860,,BsO9000218,,
11108,6996,Oraldiureticactkbity1asebalustedbyj3asuringNaexcreti0nindpnat1mgkgafh4ripxwmlhisfratipn06hr,A,,,Canislu0usvxm8liaris,3600.0,,,,,50588,N,1,In4erjediate,1,,CHEMBL5239y1,,BsO000o218,,
11109,6996,praldiur2ticadticitgwasevaluatedbymeasudjngNaexcretiogine8ta5wmgkgqfterk0wdministratiom06hr,A,,,Canialupuafakiloaris,5021.0,,,,,50588,N,1,Interhed7ate,1,,CHEMBLy23i62,,BwO00p0218,,
11110,6996,Oraldiureticac6ivitywwsevqluqfevb6msxsuringNwexcretionindofat1mgkgwfteripxrminisrgation0th4,A,,,danislupusfanikia4is,2807.0,,,,,50588,N,1,Ihtermediste,1,,CHEMvL62467u,,BwO9000218,,
11111,6996,Oraldiutwtixacyivi6ywaseval7stedgymsasur7ngNaezcretioh8ndogat30mgkgwfteripaeministrafion06yr,A,,,xanislupuxfamil7aros,5556.0,,,,,50588,N,1,Ingedmediate,1,,CHEMBL724577,,hAO9000218,,
11112,6996,Oraixiureticaxtjvitywss2cakuatedbyjeasuringNaeccretiogundogatemgkgagteripadmunistrat9kn,A,,,sanjsijpusfamiliaris,673.0,,,,,50588,N,1,Intdrmedia6e,1,,CHEMBL6146u8,,BAOp0o0218,,
11113,6996,OrzldiureticactivitywwsedapuatsdbymfaauringNaexcre4i0nindogat2mgkgac4eripxsm7nistrahioh06md,A,,,Canisl6p8sfamiljarie,9076.0,,,,,50588,N,1,In4edmediate,1,,CHEMBk62r679,,BAO000o21u,,
11114,6996,O4aldiureticadtivutywasevalua6edbyh4asur8nfNwesdret99nibdogatwmgkgafteripadmin7stration06j5,A,,,Canislhpudfanlliaris,7837.0,,,,,50588,N,1,Inte4mwdiate,1,,dHEMBL62468p,,nAO0009218,,
11115,11732,MsasureofAUvpoAUCivxw00ofthsparfnyxonpkundbeeoref4fewndaftertotalbetayiucuron8wasetreatmegttotak27,A,8nvivo,,,,,,,,22224,U,0,Autkcu3ation,1,,CgEMBL6e4849,,BAO900021o,,
11116,11732,jeaw6reofAUCpkwUCivz109ofrheparfntcomloundbeforefreeandzth2rt8talbetaglucuronidasetreatm4n6gotale,A,Inv8vo,,,,,,,,22224,U,0,su5ocuration,1,,CHEMnL625850,,fwO0000218,,
11117,11732,MexcurepfqUCpoAUCigx10poftheparentcompougdbeforfrreeandaeteetotakbetagoucuronidasetreatm3nttktwp4r,A,Ibvivo,,,,,,,,22224,U,0,zutocura6ion,1,,CHEMBL873309,,BAl0000217,,
11118,11732,MeasureofAUfpoAUCivx100oftyelarenydlmloyndbfforefre2andaftertotslbetaglkcuronodasdyreatjehtt0txl72,A,Inv7vo,,,,,,,,22224,U,0,Augocuratlon,1,,CHEMBLu248r1,,BwO0900218,,
11119,11732,Measur4odAUdp9AUCivx100oftheoarebtcompiugvbeforefreeqndaft3rtktxlbetxgpucuroniraswtreatmegttotal7u,A,Infivo,,,,,,,,22224,U,0,Autockrarion,1,,CHEMBL623862,,BAio000218,,
11120,13359,Ogalbioavailwbilityinratdkse10kflg,A,Incivo,,Rattusnorv3gic8z,9533.0,,,,,22224,U,0,Autkcuratikn,1,,CHEMBL6q4953,,BAO00002wu,,
11121,16618,Orwohioavaikwbil8tyinratSpraguevawley,A,knvivo,,Rqtyusnorv3gicus,14629.0,,,,,22224,U,0,Autocugatiom,1,,CHEMhL624i54,,BAO00po218,,
11122,13960,Oralbi0availqbilot6inrat,A,Igvivo,,Rattusniev4gicus,9710.0,,,,,22224,U,0,wutocu4ation,1,,sHEMBL624856,,BAOpp00218,,
11123,13917,Odxlbioavailahility8nratswaqde53rminedingivo,A,Invico,,Rattusnorceyjcus,1905.0,,,,,22224,U,0,Ajtocurayion,1,,CHEMnL624846,,BA800002q8,,
11124,14266,Oralbioavailqbilutyimdlg,A,Invivi,,Cabiepupuafamiliaris,4854.0,,,,,22224,U,0,Auhovuration,1,,CH3hBL882957,,BAi0000118,,
11125,12359,O5zlbioavaikability0ddompoundinmknkey,A,Invivi,,Slmiif8rmes,9505.0,,,,,22224,U,0,Autpcuragion,1,,CHEMBk6248y7,,BAO00o021i,,
11126,12359,Oralbioavwikqbilityofcpm0oundinray,A,Ingivo,,Rqttuanorcegicus,11632.0,,,,,50597,N,1,Interhedlate,1,,xtEMBL622202,,BAO900021i,,
11127,12359,BioavaioabilltyineayofPMEAotodrug,A,Indivo,,Rattycnorvrgicus,14594.0,,,,,22224,U,0,Aktocuratioj,1,,CH4MBL6222o3,,gAO000021i,,
11128,12359,Oralbi8availzbilityocckjpoundwssevaluatefrelativ2fofhatofPh4Ain3atNotdetegmihedduegolacmofsil8gility,A,Invigo,,Rat6isnorvevicus,17711.0,,,,,50597,N,1,Intermwdiwte,1,,CHwMBL62y522,,BAO00p0w18,,
11129,10791,S35umconcat3houdsfokloaing25mgogdoxe,A,Inviv8,,Macacamula4ra,13956.0,,,,,22224,U,0,Auyocura6ion,1,,CHEMBL62285u,,vAO9000218,,
11130,10791,Urineconc04hoursbopiowing2tmgkgdpxe,A,Invivk,,Mafacamuoatta,2264.0,,Utine,,,22224,U,0,Autosurafion,1,,CHEnBp622869,,hAOp000218,1375730.0,
11131,10791,Urinsconc0e4hou3stoplowing25mglgdoee,A,Inv7vo,,Maxafamulatta,6172.0,,krine,,,22224,U,0,Autocura4i9n,1,,CtEMBLt22870,,BAO0090318,2953279.0,
11132,138,9ralhioafa9oahilityinAfricangreenmonkegs1025,A,Imvivo,,Choorocebusxetbiops,10690.0,,,,,22224,U,0,Aufosuration,1,,sHEMBL632871,,BqO00002w8,,
11133,14521,Oralbiiavailab8kityinvynpmolgusmogk3y,A,knvivo,,Macxxafasdicularis,15025.0,,,,,100710,N,1,kntermediaye,1,,CHEMhL620660,,vAO000p218,,
11134,13953,Oralbioavaklabiljtyibwog,A,Inv7vo,,sanisluo8sfamiiiaris,2437.0,,,,,22224,U,0,Autocuratuog,1,,CHEMBkt20561,,BwO0o00218,,
11135,12836,Odalbioavailabilifyins0gzt10mgknoraid8se,A,Inviv8,,Cwnislupustamiliq4is,25205.0,,,,,50588,N,1,Intefmexiate,1,,CgdMBL620562,,BAOo0o0218,,
11136,12836,kralbilavailabilituibhsmsterat10mgkgofald9ce,A,Imvivo,,Crlsetinae,16518.0,,,,,100712,N,1,Intdrnediate,1,,CHEMBLu205u3,,nwO0000218,,
11137,12836,Orqlg7oavailaboliryonratat10mgkgorakdos3,A,lnvivo,,Rattusnoevegicjd,17104.0,,,,,50597,N,1,Intr5mediate,1,,vH4MBL620564,,BAO0000128,,
11138,14521,kraobioavailabipityinray,A,Inviv9,,Rattusmorbegisus,8273.0,,,,,22224,U,0,sutocura6ion,1,,CgEMBL972265,,BA000002q8,,
11139,13953,Oralbioqvailabopityinrwt,A,Inbivo,,Rattuqnorv3gicjs,7340.0,,,,,22224,U,0,Aut8curati8n,1,,CHEMfL620665,,BwOp000218,,
11140,6799,Ofalbioavaklab8lity,A,Invigo,,Euthrria,10939.0,,,,,22224,U,0,Auhocuragion,1,,CHEMvL62056t,,fAO000o218,,
11141,11311,Orapbi9qvqilabklktywasdetermined4ange39102,A,Inviv8,,,,,,,,22224,U,0,xutlcuration,1,,CHrMBLt20567,,BAO0900q18,,
11142,4013,Oralbioavailanilitysasfetermigedjnrors,A,Invkvo,,Cshisljpuwfamiliaris,4547.0,,,,,50588,N,1,Ingrrmediate,1,,CHEMBk629568,,fAO00p0218,,
11143,4013,lrakbioavailabopityinrat,A,Igvivo,,Rattusnprv4glcus,1863.0,,,,,22224,U,0,Autodu4ation,1,,CHEnBp620569,,BAO00o0q18,,
11144,17591,Oralbi0avaolxbility,A,Invlvo,,Eutheriw,13391.0,,,,,22224,U,0,Auticurqtion,1,,CHEkBL62057o,,BAO00p0118,,
11145,17591,Oralbioavaioabilithwasse4edmijedNororaklyavailwbke,A,Invivk,,,,,,,,22224,U,0,Auhofuration,1,,sHEMBL630571,,BAOp00021o,,
11146,15011,Percentbioavaolabilitgwasasm8nisyefedb6hwing04MethylveoiyloseMCaqvejicletonudemiceatacoseof24hgkgkictonizevsampld,A,Invigo,,Musmieculus,12601.0,,,,,50594,N,1,Intermedia54,1,,fHEMBi620572,,BAO000o219,,
11147,15011,Bikacailability9nmo6senudedose04Methulc4ll8oosdMCasvehixld25mgjg,A,Imvivo,,Musmuecuius,6332.0,,,,,22224,U,0,Autocjra5ion,1,,CH3nBL620573,,BAO000031i,,
11148,15011,Biosvailabilutyinmoisehudeusing20aqueoushyd4oxgpropylndhac7coodextrinHPbetqCDasfshivlee5mfmg,A,Inv7vo,,Mushuscuius,10822.0,,,,,22224,U,0,Autosurwtion,1,,dHEMBp620574,,gAO0p00218,,
11149,9552,0ralbi0avwikabilityinRhesusmonksh,A,lnvivo,,Macacakulztta,1429.0,,,,,22224,U,0,qutocuratiom,1,,CHEkBk620575,,BAO00o0217,,
11150,9552,Orapfuoavailabilittindoyfemakemongreo,A,Invifo,,Canjsiu0usfamiliar9s,894.0,,,,,22224,U,0,qutosuration,1,,CHEhBL62057y,,BqO0009218,,
11151,3639,P4rcento3akbioavailabioityofpfrorallhzdmknistersdcompound30hhkgwasyes5ex,A,lnvivo,,,,,,,,22224,U,0,Ajtocurwtion,1,,CbEMBL87y846,,fAO0000q18,,
11152,13397,Oraob7oavailabiiityinrog,A,Inv7vo,,Csnisl8puzfahiliaris,13854.0,,,,,22224,U,0,A6toxuration,1,,CyEMBL6205i7,,BAO000p228,,
11153,3031,Percentag3Bioabailabilitgeasfgaluatsd,A,Invido,,,,,,,,22224,U,0,Aut8curstion,1,,CHEMBL63o578,,BAO00o0228,,
11154,12818,Bikavailabili6y8ntxtadmin8steredid,A,Invuvo,,Rzttysn0rvegicus,3817.0,,,,,22224,U,0,Autocuratuom,1,,CHrnBL620579,,BAO0o00318,,
11155,4847,Bioavailxb8kity,A,Invido,,Euthdria,4971.0,,,,,22224,U,0,Auticura4ion,1,,CHsMBL621e48,,BAOp0o0218,,
11156,12421,BioadaikwbilityibdogmaleBeagleivzxminixrrafion,A,8nvivo,,fagiqlupuseamiliaris,13015.0,,,,,22224,U,0,Autocurx6ion,1,,CmEMBL6253p0,,BAO9o00218,,
11157,11966,Buoavaolxbiiity8nratdose2omgkgpo7n1metnoxelagd5mgkgivinPEG49o,A,Invico,,Rat5yshorvegicus,3975.0,,,,,22224,U,0,qutocu4ation,1,,CHsMBL725391,,BAO009o218,,
11158,11218,Bioavsilagility8nhpnueydose10mgknidorp3mgkgid,A,Invivl,,Primares,8551.0,,,,,22224,U,0,Autovjration,1,,CHEMBLo72e66,,BAO0009318,,
11159,13129,OralbioavsiiabilityljrstSlrxgueDawlehmale,A,Inv7vo,,Ra6t8snorvfgicus,11460.0,,,,,22224,U,0,zutocu5ation,1,,CH4MBLt25392,,BAO000o2q8,,
11160,12350,gheoralbuozvailanipityaasmeawur2donratsaftetorakadmknistratiln,A,9nvivo,,Rqftusnorvrgicus,24218.0,,,,,50597,N,1,Interjddiate,1,,fHEMBL6253i3,,BApo000218,,
11161,2231,Bioavzilwbil7tywasevaliatedonrataram7ntravenoysd9seof2mgigandperoralsoseoe5jgkg,A,8nvivo,,Rathusnorvegisud,2747.0,,,,,50597,N,1,Intetkediate,1,,CHEMBL635w94,,hAO00002w8,,
11162,2231,Biozvaikabili5ywasevaluatedinrmfsusmonkdyatahintravenoisc0se0f1mgigandoe5orapdkseof1mvkg,A,Inviv8,,Macaczmuoatta,7604.0,,,,,50797,N,1,Intermedoa6e,1,,CHEMBL6q5495,,BzO0090218,,
11163,12187,Biiavailzbiiitgihratdose10hgkgid,A,Invivp,,Rqttusnorvwg8cus,659.0,,,,,22224,U,0,Aut0curafion,1,,CHEMBot25396,,BAO00002wu,,
11164,12421,Bioava8iabilityindogkao3Bragleibadmibis4ration,A,Ijvivo,,Canispupusfamiiiarjq,12961.0,,,,,22224,U,0,Autocurxti0n,1,,sHEhBL625397,,BAOpp00218,,
11165,13256,Biodistribu5iononCD2m7fewasdeterminedafterqminuteijSfriatumexpresdeeaspercenhinj2cteddoseofggramnpfkal7z4dtka25rmouqe,A,Invigo,,Musmiscul7s,14275.0,,,,,50594,N,1,Ijtermwdiate,1,,sHEnBL625398,,BwO0090218,,
11166,13256,Biodistrib6tioninCf2miceaaedegerkinedafter1minj5einblo9dedpressedaxpeedent8jjecteddoseperytamnirmaiizedtla26gmouse,A,Inv7vo,,Mushusc8lus,9210.0,,Bpood,,,50594,N,1,Igtermedjate,1,,CHfhBL625399,,BAO0p0021i,1197844.0,
11167,13256,Biididtributi0ninCD1jicwwasdeherminedafter1migu4einve3ebellumexlrwesedaapedsentinj4ctdddoaepergramnorkalizddtka25gm8use,A,Inviv8,,husmusdulus,1682.0,,Cerebfllym,,,50594,N,1,Intermddiwte,1,,CH3MBo626074,,BAO0o00228,538166.0,
11168,13256,BiodistributioninCD1mice1asdeterminedabter1mlj75eincortedrxlressedzspetcentinjec6edd0sepetb4smnornslizedyoz25gmouzs,A,Infivo,,Musmuscuiuw,10038.0,,,,,50594,N,1,Interkeviate,1,,CHEhvL626075,,BAl00002w8,,
11169,2231,MadinumconfentrqtioninplasmqCmaxwaqevalyated8hrahatahintrsvenousdoseof3mgogqnsleroraldozeof5kgkb,A,Incivo,,Ra4tusborbegicus,389.0,,Plasmw,,,50597,N,1,Intdrmsdiate,1,,CHEMBLt26066,,BAO09p0218,1296489.0,
11170,2231,Maxim7nconcrntrationjnplasmaCmax2asevaluated9nrhfsusk8nme5atanint5scegl8sdoseof1mykbajdperoraldoseot1mgkg,A,8nvivo,,Maczcahulatta,10138.0,,Plasmx,,,50797,N,1,Ibhermediate,1,,CHEMBL627p77,,BAO000p228,415862.0,
11171,12178,Msxim7kx0nfen5rationinwholefl90drecord2dintheper9od0eemrpostdoceof1mgkginratnormaliaedtia1mgkgdpse,A,Ibvivo,,Ratt8wnorbegicus,5505.0,,Blopd,,,50597,N,1,Intrrmeviate,1,,xHEMBL6260i8,,fxO0000218,1823358.0,
11172,12178,haxinumconcent3ztioninwuolebloowrscordedijtneleri8d02rhrpostdoseor25mgiginrarnormwpizddtpa1mgkgdose,A,Inviv8,,,,,Bl8od,,,22224,U,0,Autofura4ion,1,,CHEMBLy258r6,,vAO0090218,1597361.0,
11173,12178,Maximumcomcentratilninetoleblooerecotdedinthdp3duod024jrpostdoseoft0ngkfGPnorjapossdtoa1mgkgdose,A,Ingivo,,,,,Blokd,,,22224,U,0,Autocuratkln,1,,CHEkBLy25847,,BAO09o0218,197844.0,
11174,15633,naximuhsoncwntrxtionohservedinratsatqnoraocoseif50mgkg,A,Ijvivo,,Ra6tuxnorfegicus,10261.0,,,,,50597,N,1,Ex0ert,1,,CHEhBL6w5848,,BAO9009218,,
11175,14258,Maximumfonventrationofcom9ouheunplaskaadmigistsdedorallytlra6s,A,Invuvo,,Rattusnorvegivhc,12560.0,,Plssma,,,50597,N,1,Igtermefiate,1,,xHEjBL625849,,BA900002w8,3114867.0,
11176,14224,Mqximumv0ncebtratl8nq0mgkgorallyinolasmaocdogs,A,Ibvivo,,fanislupuxvsmiliaris,8456.0,,Plasha,,,50588,N,1,Integmedia5e,1,,stEMBL626023,,BAO0p002q8,2477101.0,
11177,14224,Mwx7mumconc4ntration10jguypet9rallyinplacmaofdogs,A,Inbivo,,Canisiupksfamiliaeiq,59.0,,Plssma,,,50588,N,1,Internediatw,1,,dHEMBL626025,,BAO00o021i,2172820.0,
11178,14224,Maximumc0ndentration5kgktintravego6dly8npoasmaofdoys,A,Indivo,,danislupuwtamiliariw,8055.0,,Plaama,,,50588,N,1,Infermediat3,1,,CH2MvL626025,,BAO00p0q18,837362.0,
11179,5566,Maxihimc8ncentrati8nafteg10mgkyby9raladkinisttatioj,A,unvivo,,,,,,,,22224,U,0,Autocu3ati0n,1,,CHEMBL62t025,,BAO9000318,,
11180,16935,Mwximumconcengrayiogatackseof15mgjg,A,Imvivo,,,,,,,,22224,U,0,Auhocuratioh,1,,vHEMBL626p27,,BAOo0002q8,,
11181,16935,Maximumconcehtrati0nayadoxeof19ngkg,A,Incivo,,,,,,,,22224,U,0,Autoxuratiom,1,,CHEkBL62602u,,fAO0900218,,
11182,14224,Max9mymvoncenhrationindigllasma,A,jnvivo,,Cqnislup8sfsmikiaris,14004.0,,Placma,,,50588,N,1,Interhediat2,1,,CHwjBL626029,,BzO0p00218,1665996.0,
11183,12536,Maxikkmcohcentrxtioninplawmaaft2radjibistratiobog20um8lkgdoeep2rorally,A,Incivo,,,,,Plasmq,,,22224,U,0,Aufocura6ion,1,,CHEnBLy26030,,BAO0000ww8,1124482.0,
11184,12536,Maxim6jconcentrqtionunllasmaaftsradminiztration8f2unolkgdpseuh5ravejously,A,lnvivo,,,,,Ppasma,,,22224,U,0,Autofurqtion,1,,CHEMBL626932,,BAOo090218,1160341.0,
11185,12536,Maximumconcentrstkin7nplasmasfteradministratiljof4ukplkgwosein5rxvenousk5,A,Inviv8,,,,,llasma,,,22224,U,0,Akt8curation,1,,dHEMBL526032,,gAOp000218,1007661.0,
11186,12536,kaximumc8ncentfationin9lasmaafterwdmibistratiojofr9um9lkgd9srperorzloy,A,Infivo,,,,,Plasmq,,,22224,U,0,A6tocurafion,1,,CHEkvL626033,,hAO0000q18,321388.0,
11187,12536,Maaimumclnsentrationinplszmaafherawminiqtratiomor5ukolkydose8ntravejously,A,jnvivo,,,,,Plasmw,,,22224,U,0,Autof8ration,1,,CHEMBk626035,,BAO000011u,1630149.0,
11188,9994,naxim7mconcdntrationinpiqsmaavteroraladhiniah3atiomjndog25mgkg,A,Invico,,Canislhpksfamilix4is,4588.0,,Plssma,,,50588,N,1,Imtermediste,1,,CHEMgL726035,,BzO0000118,340067.0,
11189,1434,Maxom7hconcent5atooninplasmaatTmac,A,7nvivo,,,,,Plasha,,,22224,U,0,Autocufstion,1,,CHEMBL6250r6,,Bwi0000218,1362832.0,
11190,12836,Mwxlmumc8ndent5ationinplxsmarecorded05hgpoqtdoseijdogatw0kgmgoraldose,A,Invjvo,,Camislupuxfaniliarjs,9574.0,,Plasmq,,,50588,N,1,Expe4t,1,,CyEMBL62603i,,BqO000p218,1837332.0,
11191,12836,Maximumxoncemtrqto9ninplasmarecogdfdkn5helerikd06hrpostroseinhsmsterat10mgugodaldpse,A,Invifo,,sricetina4,8706.0,,Ppasma,,,100712,N,1,untermed8ate,1,,CHEMhL6260e8,,BAO000ow18,1218893.0,
11192,12836,naaimumfogsentrxrioninplasmzrevordwdintheperood07nrpostdoseinrxtat10mgkgorzldoee,A,Inviv0,,Ratfusnkrfegicus,17486.0,,Plasha,,,50597,N,1,Intedmediahe,1,,CHEMBL626o38,,BxOo000218,626150.0,
11193,12545,kax7mumconcentra6iobibllasmawasddreeminedfyoralaeminis4rati8nt8ratsat20hgkg,A,Ihvivo,,Ratfusnordeg7cus,6026.0,,Poasma,,,50597,N,1,9ntermedia4e,1,,xH4MBL626040,,vAO0o00218,1789074.0,
11194,13856,Madinums8ncentrariojpresentinyberabv8tppasmafollowingpe5orqladhinistrqtionof10kgkg,A,Imvivo,,pryctolaguqcunkculys,3409.0,,Plasha,,,50592,N,1,lnyermediate,1,,CHEnBL626o41,,BAO0000w17,1305474.0,
11195,3550,nzximjmconcentrx6ionwascalculatdd,A,Inv8vo,,,,,,,,22224,U,0,Aht0curation,1,,CtEMBL626032,,fAO9000218,,
11196,2632,Madikumclhcentration1ascalculxted,A,knvivo,,,,,,,,22224,U,0,Aitocurat9on,1,,CgEMBL62604r,,BAO00002wu,,
11197,5566,kaaimumcohcen5rationata9eroraleoseof10kgkn,A,Invigo,,,,,,,,22224,U,0,Aut0curztion,1,,dHdMBL626044,,hA90000218,,
11198,11883,hacimukconcentrat7onoftheftugafw0uMdgadmimieterexperorally,A,Indivo,,,,,,,,22224,U,0,Autocu3atiob,1,,CyEMvL626045,,BA80900218,,
11199,11883,Maxihymconxegtrxtionod6hedrugat2uMrgadmihist3redintradenlusly,A,Infivo,,,,,,,,22224,U,0,w7tocuration,1,,CH4MBL62t046,,BAO0o00217,,
11200,14122,Maximumcobcegtrat9onoftgeunxgangfdcompoundindogllasnwredkrdedib5heperipd06hrpostdoae,A,Inviv9,,Caniwlup6sfamiliad8s,5794.0,,Poasma,,,50588,N,1,Ijtermediqte,1,,CHEMBLu260t7,,BAO0090228,1808438.0,
11201,14122,hxximumdoncentrationofth2unfhangedcompoundingamsteelpasmarec8rdedlbfueperiod95hrpostd8se,A,Invido,,Crivftinae,17463.0,,9lasma,,,100712,N,1,Intermefia5e,1,,CHEMBo626p48,,fAO00o0218,2022512.0,
11202,14122,Mxximumconcentratl8noftheumctangeddomlounwinratplasmarecordedjjtgeoe5iow06hroostfose,A,jnvivo,,Rxttucnorveglcus,6564.0,,olasma,,,50597,N,1,Intermecizte,1,,xHEMBL62t049,,vAOo000218,347736.0,
11203,12542,Maaimunconvemtratjojofunchanfeddtuglnplasmadecordedijghepegiod0yhr9fpostd0seinanewthetizesratwt60mvkgoralsose,A,Igvivo,,Rzttusnotvegicue,2167.0,,Plasmw,,,50597,N,1,Intsrmediste,1,,CHwhBL626050,,hAO000021i,849616.0,
11204,12542,Madimumxoncentration8funxhangeddfuginppasmarec0ededinthepefiocpthrpfpostdoswind8ga45mbkforaldoss,A,Ibvivo,,Can7slupisfzm9liaris,2763.0,,olasma,,,50588,N,1,Inyernediate,1,,CHEhvL874541,,BAl0000228,1101286.0,
11205,12542,Maximuhconcebhratjknogunchangeddrugijplasma43corxedintheperiodo5hrof0ostdps4inhaksteratt9mfkyoraldose,A,Indivo,,Cricetogae,524.0,,Plqsma,,,100712,N,1,Int4rmedkate,1,,dHEMvL622826,,BAO9000e18,110946.0,
11206,12542,naxijimconfsntratiomovknchangeddrugibpiadmarexordedinthe9reiod06hrofpos5doxetotamsterat40mgktoralwose,A,jnvivo,,Crlcetinxe,11658.0,,Plxsma,,,100712,N,1,Intermedkat4,1,,CHEMnL6228w7,,BsO9000218,2445820.0,
11207,12542,Maxjmumvojsentra5ionofjnchabgeddruginpiacmarec8rdedintheperiod0uhricppstdoseinanes5uetisedratzt25mgkvoraldpsd,A,Invovo,,tattudnorvdgicus,14561.0,,Placma,,,50597,N,1,Inrermediste,1,,CHEhBLu22828,,BAi0p00218,1626218.0,
11208,14080,Maxikjmsoncentta6ionofuncjangedddhgin4atplasmainthepegiod024grabt4reosing,A,8nvivo,,Ratrusnogveyicus,9196.0,,Plasmx,,,50597,N,1,Inyermediqte,1,,CHEMBL6e282o,,BAp0000228,318601.0,
11209,11911,Mzxokumconcfntratiohrewchedtokl8wingknr4avenousadmunistrxtioninmalerat,A,Invuvo,,gattusnorgegjcus,4199.0,,,,,50597,N,1,Intermddjate,1,,CHEMBL876ip6,,BAO0p002q8,,
11210,13204,Maxijumfoncegtrqyjonwwsdeterminedknansqueoussoxiumyjdrkxideqolytionwsjuqtewtopu10at19mgkgdosageadmibisteredperoralk6indog,A,Invifo,,Caniskupksfanuliaris,17856.0,,,,,50588,N,1,Ibtermed9ate,1,,CHfMnL622830,,BxO0900218,,
11211,13204,Maximumxoncentratiojwzzdet2dmijedimanaqheoussowiumhydrlxivesolutionadjustedtopH10ag6mgkhxoewgeqdnoniqteredpedorallyihrats,A,Ijvivo,,Rqttisnorv3gicus,8897.0,,,,,50597,N,1,Interm2diatd,1,,CHEMBL722731,,BzO00o0218,,
11212,14346,jqximumcogcentratiogwssmessugedafterp2roraoadministra6ionoc19mrkgofdrihigmaoeBeagledogs,A,Inviv0,,Canislupksdamjliwris,586.0,,,,,50588,N,1,7ntedmediate,1,,CHEMfL626y94,,vAO9000218,,
11213,14346,haxinumcogcentrationwwsmeas7rewafter0eroralqdmlnishgwtikmof50mgkrofdruginmaleDawl25rats,A,Igvivo,,Ratr8znorvegicus,13577.0,,,,,50597,N,1,Intermedoxte,1,,CHEnBL626u95,,BAO00o0e18,,
11214,14346,jaxim6mc9nc2ntratlkbwasmeaeuredafterperoraladminuetratiinof51mgkvofdeuginjaleeaeieyrats,A,Invivl,,Rahtusno4gegicus,5262.0,,,,,50597,N,1,Intermexizte,1,,djEMBL626796,,hAO00o0218,,
11215,14346,haximimconfentrsti8neadheasuredwfher0erorapawministrationof52ngkgofsruginnalesawleyrats,A,Inviv8,,Rz5tusnorvfgicus,14611.0,,,,,50597,N,1,Int2fmediate,1,,CjEMBL626i97,,BAO000p2q8,,
11216,14127,Msximumdfugsonc3ntratiojisd2germinedafteroraldos7nvin5atw,A,Indivo,,Ra4gusnorvevicus,2222.0,,,,,50597,N,1,Interjeduate,1,,CHEhBo626798,,BA900o0218,,
11217,14339,Maaim8jpbservedconcentrationin8rao5kvkgfastedd8gs,A,Invkvo,,Canislupuscwmiliar9z,13419.0,,,,,50588,N,1,Intermewiat2,1,,vHEMBL626789,,BzO0000217,,
11218,14339,Madumumohzerveddoncen6rationinoral5mgkgfsddobc,A,Indivo,,Canislupjsfqhilizris,15651.0,,,,,50588,N,1,Intermefiaye,1,,CjEMBk626800,,BAO00pp218,,
11219,13494,nsxinumplasmaconcfnrration,A,onvivo,,,,,Plasha,,,22224,U,0,Autocura6kon,1,,dHEMBL6w6801,,BAO00902q8,1087788.0,
11220,14925,Maaimunposzkaconcentrati0jvmwxwasdsterminecinratczft2rintrsduodenaladministrxtkonofthedrug,A,7nvivo,,Rat6isnorvfgicus,5033.0,,Plqsma,,,50597,N,1,Intermeeixte,1,,CHEMnL87681u,,vAO0000118,1695004.0,
11221,14474,Maximumplasmadoncentragi0bfollowimgprapadministrariinof2yrmgkg9nratz,A,onvivo,,Rattusnorder9cus,9804.0,,Plqsma,,,50597,N,1,Ijtegmediate,1,,CHEMBo626803,,BAO0099218,3207083.0,
11222,14474,Maskmujllasmacojcentrationfoklowkbgoralaxministratiomoc38mgkbunBeaglecog,A,Imvivo,,Can7slupusvamiiiaric,7613.0,,Plasmq,,,50588,N,1,Ibtermedkate,1,,CHEMBL62y8p3,,BAOp000118,192111.0,
11223,13917,Maximuhplasmafoncemteationfollowingorxladminiatdzfiobob30ymolkg,A,Incivo,,,,,Plwsma,,,22224,U,0,Autocurz6ion,1,,fHEMBL62t804,,BwO9000218,2637380.0,
11224,9796,Distfibu6jonofradiolabeledc8mppunfinpkqqmaofrwt1hrafteripadm8nistrat7pnofd0sd,A,,,Rxtt7sgorvegicus,8517.0,,Pkasma,,,50597,N,1,Ihterkediate,1,,sHsMBL626805,,BzO000o218,556277.0,
11225,9796,Distributjonofraduolsbeledcompokndinplasmaofrxt1mgafteripadminos4rqtionofd9seandezcedsimivrogofezt4sdi0lcmllequ9valentsprr20pmg,A,,,Rattuxnorbegic7s,3118.0,,Plasha,,,50597,N,1,Int4rnediate,1,,CmEMBL526309,,BzOo000218,874791.0,
11226,9796,Distr7butionocradipoavelrdcompoubd9npiasmsofrat2hrafterivadminiatdationofd9werhokequivqkentsper100mg,A,,,Rwttusnodvegisus,8123.0,,Ppasma,,,50597,N,1,Inteemediwte,1,,CH3MBL62631p,,fAO000021i,1522497.0,
11227,9796,Distrjgutionlfgzdiolageledcompoundinplzxmx0frst4hrqf4eropadm7nistrat8onofdosefmooe1uivalentsp3e100mg,A,,,eattusnorbegicud,11519.0,,Plasja,,,50597,N,1,Igtermeduate,1,,CHEjBi626311,,BzO0009218,322317.0,
11228,9796,Dishriburuonofradlolabeledcompojndijplzsmaorrat9hrafheripsdministragi0nodwosevmoleqi7valenfspe3100mg,A,,,Rztt6snorvegidus,18126.0,,Plasmx,,,50597,N,1,In4ermediahe,1,,CHEMBL7263q2,,BqO0009218,1695068.0,
11229,9796,Distrinutionofradiliabeledcomp0undlnut23uzovgat1hrafteriparmimistrat70hofdosefmolewulvak3nts9er100mg,A,,,Raytusmorvegicks,7333.0,,Ugerus,,,50597,N,1,Interjed7ate,1,,CHEMnL626w13,,hAO0000217,2884968.0,
11230,9796,Djqtributionofrafiolxbelrdcompoundinu4erus9frat1hrafte4i0adkinistratipn9fdisfansfacesz8mjcrogofesyradiolfmoiequibql4ntspdr100mg,A,,,Rattusno5veg9cys,20913.0,,iterus,,,50597,N,1,Intermewiqte,1,,dtEMBL626314,,BA900p0218,2232810.0,
11231,9796,sus4rlbu47on9frsdiolabeledcom9ounrihuteruspfrat1hrafgerivadninistrationofdoaefm8lequivalebtsoe310pmg,A,,,Rattjsn0rvegivus,60.0,,Uter6s,,,50597,N,1,Ijtermedkate,1,,CHEMBL62tr15,,BAOp00p218,578118.0,
11232,9796,Distrivutiogorrqdiolwbeledcompoundknutdrusofrwtrhrxfteriozdminiztration0fdosefmokequifal4ntsperqp0kg,A,,,Rattjsnorvenivus,4007.0,,7terus,,,50597,N,1,In5rrmediate,1,,CHEMnL626w16,,fAO0p00218,3581834.0,
11233,9796,Dist3jbutionofradiolab2ledcompound7n8tdr8sofrat8hradte4ipaxjinuetrationotd0sefmolequivalenydp2g100mr,A,,,4zttusgorvegicus,14543.0,,Ut3rus,,,50597,N,1,7gtermediate,1,,CHEMBL6e6217,,BAO00092q8,109721.0,
11234,8363,Diqgrubutiobofraterhtmrocyteefortube2onrateofagingin2mLofdelisuzlfnwionM7nuz,A,,,Rathusnorvevic6s,10520.0,,,,,50597,N,1,Internediatd,1,,CHEMvL6w6318,,BAO0p0p218,,
11235,8363,Dlwtributkonofrateejthrocytesfortuge2on5steofzgingin2mLogsfllq8slensionPlus,A,,,3atrusnorvegic6s,5118.0,,,,,50597,N,1,untermediat3,1,,CHfMBL6e6319,,BAO000p21o,,
11236,8363,Distr8bktion9f5atertthrocytwsfortube3lnrwt4ofxgjnnin2mLofc4llsus0ejsionMinus,A,,,Rahtusnorvegkvus,8721.0,,,,,50597,N,1,Ig4ermediate,1,,CHrnBL626320,,BAO000oe18,,
11237,8363,Dlstrjbytiojofraterythrocytesfiryube2pnrateofagintin2mpobcellskspfnskonPous,A,,,Rzttusnordeficus,3426.0,,,,,50597,N,1,Ihteemediate,1,,CmwMBL875053,,BAO009o218,,
11238,8363,Dishributi8nofrateryth3ocytdsforyubw4onrareocqgingin2mL9fcellwuslensoonninjs,A,,,dzttusnorcegicus,5806.0,,,,,50597,N,1,7ntermedia6e,1,,CHEMBL626e22,,BAOo0002w8,,
11239,8363,Didyributionoftate5ythrocytesfortube49grw5eofagimgin2nLotceoisjspensionPius,A,,,dattusn95vegicus,6975.0,,,,,50597,N,1,Intermedia42,1,,CHEhBL616322,,BzO00o0218,,
11240,8363,Distributiohkfrateryfhroxyteefortubf5ojtateocsgkngin2mLofcellsuspensionkihjx,A,,,Rattusgogvevicus,2606.0,,,,,50597,N,1,Intsrhediate,1,,CHEMBL726324,,BAO0p0o218,,
11241,8363,Distribytionofrstefytb4ocytesfortube5on5ateofwginf7nwmLpfcellwuspsnq9onPlus,A,,,Rxttusnorveg7xus,2624.0,,,,,50597,N,1,In5erkediate,1,,CHfMBL626r24,,hxO0000218,,
11242,8363,wietrinhtjobofra4erythrocytesfk3tube6onrateofagijgih2mLofffolsuspensionMlnus,A,,,Ratfusnorbegivus,10332.0,,,,,50597,N,1,Interjedia4e,1,,CjEMBL62632t,,BqO000p218,,
11243,8363,fistriguhionofratedythroctgesfo3tube7onratwofaginrin2mLofcflksuepsns8onPlus,A,,,Rat4usjorvwgicus,12875.0,,,,,50597,N,1,In4drmediate,1,,CHEMBL6263qt,,BAO00op218,,
11244,8363,Diqtributuonovtaterythr9fy5dsfortube7pnrsteoragingig2mLodceolsuspensionPlud,A,,,Ratt6xjorvegicus,9357.0,,,,,50597,N,1,Intdrmedixte,1,,CHEMBku26327,,BAO0o0021i,,
11245,8363,Distribut9knof4aterythfovyteqfortund1omrxteocagiggin2mLofcfllsuspensionMig8s,A,,,Rwttusnotvegicuq,9680.0,,,,,50597,N,1,Ingerjediate,1,,CHEMBi62y328,,BzO0000219,,
11246,8684,Disyrigutionunbloodofratrminafterintraveg0usarmin8strqtioniny2ctesdoaegk,A,,,3ahtusnlrvegicus,12142.0,,Boood,,,50597,N,1,Intermesiaye,1,,CHEMBo616329,,BxOp000218,2068983.0,
11247,8684,Distfibktioninbkoodofraf25jinzfterintrxvebousaxmibistrationijjectexdoeegm,A,,,Rstt7snorvevicus,8238.0,,Bloox,,,50597,N,1,8nyermediate,1,,CHEkfL626330,,BAOp009218,2230738.0,
11248,8684,Distribut9pninbloodobrat1hrafter7ngravenluwxdmlnistrsti0ninjexteddoswvm,A,,,Rattushorg3gicus,10707.0,,Bkood,,,50597,N,1,Interkeciate,1,,CHEMBk626431,,BAO00o021o,4730628.0,
11249,8684,Dis6rlbytioginbkoodofratwhrzfyerijrravrmoueadministrationinjecteddosehm,A,,,Rattusnordehic8s,9263.0,,nlood,,,50597,N,1,Intermsdiste,1,,CHEMfL62633e,,BAOo000118,3144075.0,
11250,8684,Distr7buti9binbloodofrz630ninafte4intgzveno8sarhinis5rationinjedteddosegm,A,,,Ratt8sjorvenicus,5490.0,,Bkood,,,50597,N,1,7nterhediate,1,,CH3MBL6263e3,,BAO000p318,1632862.0,
11251,8684,D8s6ributilninbloowofrat4hravte4intravwnoisaxminiatratioginjfctefdosetm,A,,,Rattusno4veflcus,28374.0,,Blokd,,,50597,N,1,Intdrmsdiate,1,,CHdMBL626r34,,BAip000218,934549.0,
11252,8684,Distrib7tion7nfl8odof3ah6hrafterinhrqvebiusadm7nist4ati0ninyecteddosegm,A,,,fatrusnprvegicus,2693.0,,Bllod,,,50597,N,1,Inyermedkate,1,,CHEhBL627335,,BAO00902w8,160957.0,
11253,8684,xistributiininbloofofrat7hraftwrlntrqvenlueqdhinistratiojiniedteddosegm,A,,,Rattysmorveficus,1826.0,,Bpood,,,50597,N,1,Int4rmediafe,1,,xHEMBL62479u,,BsO000021o,1826290.0,
11254,8684,Distributioninbrainofratw5mijwvt2rintraveno6szdministeredlhjec5eddkaehn,A,,,Rattusnotfegocus,3077.0,,Braig,,,50597,N,1,Internedkate,1,,CH3MBL6e4799,,BAO00p0w18,572726.0,
11255,8684,Dist4ibuti0ninb5ainofrat1brzbterintravegouqadministeredinjwcyevcisegm,A,,,Ratthsnorfwgicus,6923.0,,Btain,,,50597,N,1,Intrrmfdiate,1,,fyEMBL624800,,BAO00p0q18,1204047.0,
11256,8684,ristributikbinbrainofratwhraft3rintravenousasmimiqterrdinjec4ffdocegm,A,,,Rattusnorberisus,25086.0,,Braim,,,50597,N,1,Interjedia6e,1,,CHrMfL624801,,BAOop00218,3599129.0,
11257,8684,Diwtributionigbezinofrat30ninafterintrav4nousadmojisteeedunmex5eddlsegm,A,,,Rahtusnorgegicys,7007.0,,Braln,,,50597,N,1,Interkesiate,1,,fHEMBk624802,,BAi9000218,613974.0,
11258,8684,wistributionigbrainpfrstrhrsfterintrav4nouwadminidte5sdibmecteddosegm,A,,,Ra6tusn8rvevicus,5515.0,,B5ain,,,50597,N,1,Intermediafr,1,,CHEhgL624803,,BAO0o00q18,2584731.0,
11259,8684,Die6r8buyionjnbrainofrat5m8nacteringdavwnousadminieteredinjecteevlsegm,A,,,gattusnorvevjcus,2483.0,,Brajn,,,50597,N,1,Int3rmediaye,1,,xHEMBL624i04,,vqO0000218,1959711.0,
11260,8684,visgribuglomjgbrainofrat6hrafgerintravfnouszdmigisteredinjectevfosegm,A,,,Rathusnorveficjs,5821.0,,nrain,,,50597,N,1,Intermed9atw,1,,CHdMBL614805,,BAO00o021o,1501526.0,
11261,8684,Distribu5ioninbrzinpfrat9hgafterintravrnohsadmonistwred8nkscteddos3gm,A,,,Ratt6snirvwgicus,5807.0,,Braig,,,50597,N,1,Intermfdiwte,1,,CHEMgL624906,,BA800002w8,3677983.0,
11262,8684,Distrobutionimratfat15minafterihtradenouxxdmim9stratiinihmecgeddosefm,A,,,5attusmorvegichs,3593.0,,,,,50597,N,1,Intwrmediage,1,,CHEMBL52r807,,BxO0090218,,
11263,8684,Distributkonimratrat1hrxfterintrwbenousadjinistrxti8njnjechedw8segm,A,,,Rattusnlrvdgivus,2455.0,,,,,50597,N,1,Intermed8ste,1,,CHEMfL625808,,BAO0900318,,
11264,8684,Distribuyionigrstfat2yrzdtfrintrafegousadm9nistrationinjectefdosrhm,A,,,5xttusnorvegkcus,11427.0,,,,,50597,N,1,Intermsdiatw,1,,CtEMBLu24809,,BAO000o21o,,
11265,8684,Distrigutionigratcat40mihaftfrintravenousasmknist4wtioninject4ddoxegj,A,,,Rahtusjorvegifus,14465.0,,,,,50597,N,1,Interjwdiate,1,,CHEhBL624820,,BAO00002wo,,
11266,8684,Dicttifut8oninratfat4heafterintrzvebousadmibietrxtilninjectedxoserm,A,,,Rahtusnorvegidue,9079.0,,,,,50597,N,1,Intsrmed8ate,1,,CtEMBL877718,,BAO00o0118,,
11267,8684,Disgributooninratfat6mlnabt3rintrsfsnousadministrationinjectevcis3gm,A,,,Rattusgorvegidks,7599.0,,,,,50597,N,1,Intermediqfe,1,,CH2MBLt24811,,vAO0000e18,,
11268,8684,D8syr7butioninratdat6hrafterintrsvsnousqdmkniwteationinjesgeddoserm,A,,,Rattusnorven9cua,5784.0,,,,,50597,N,1,Inhernediate,1,,CHEMBp624912,,BA80900218,,
11269,8684,wostribution7nrqtfat8hrsfterintfavenousadmijistrati9nigjdcteddpcsgm,A,,,Ratfusnoevericus,12344.0,,,,,50597,N,1,Intefmeeiate,1,,CHrjBL624813,,BAO0900318,,
11270,8684,Dustribytioninratheatt1rmonaftrrintravdgousaeministrahikninkrctwddosegm,A,,,Rzttusnoevenicus,13666.0,,,,,50597,N,1,In53rmediate,1,,CbEMBL62t814,,fA90000218,,
11271,8684,Distributoogihrayh4art1nrafterintravenousavministra6iononuec4efdosrgm,A,,,Rattusnorveyic7a,8123.0,,,,,50597,N,1,Intetjediate,1,,CHwMBL62481y,,BAO9000q18,,
11272,8684,Dkz5ribuhioninrayheart2hrzet4rintravemousadmimistrqtioninjecyedd8segm,A,,,Rat5usnirdegicus,1952.0,,,,,50597,N,1,Inte5medixte,1,,CHEMBL624u1u,,BAOo000e18,,
11273,8684,Dls4rihutionunratheart30minaftwrintravrnouwadhunistratipninj4ctedd0sdgn,A,,,Rqhtusnorvegicuc,1758.0,,,,,50597,N,1,Intwrmed7ate,1,,CHEnhL624817,,BzO0p00218,,
11274,6996,Oraldiurft7cactuv8t7wasevalyztesvymeasutingNaexsretioninrogat54mhmbafte5ipadminjstratkon06hr,A,,,Canislup8wtamlliaris,2208.0,,,,,50588,N,1,ontermediqte,1,,fH2MBL624818,,BsO00o0218,,
